<SEC-DOCUMENT>0001047469-16-010308.txt : 20160223
<SEC-HEADER>0001047469-16-010308.hdr.sgml : 20160223
<ACCEPTANCE-DATETIME>20160223101348
ACCESSION NUMBER:		0001047469-16-010308
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160223
DATE AS OF CHANGE:		20160223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		161447134

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>a2226904z10-k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg72301_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM 10-K  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><B>(Mark one)</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(D) OF THE SECURITIES<BR>
EXCHANGE ACT OF&nbsp;1934</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><B> For the fiscal year ended December&nbsp;31, 2015</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><B> or</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Commission File Number&nbsp;000-15006  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2>(Exact name of registrant as specified in its charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Delaware</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> 13-3191702</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>(I.R.S. Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, New Jersey 08827</B></FONT><FONT SIZE=2><BR>
(Address of principal executive offices) (Zip Code) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Registrant's
telephone number, including area code: </FONT><FONT SIZE=2><B>(908)&nbsp;200-7500</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Securities
registered pursuant to Section&nbsp;12(b) of the Act: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Title of Class: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Name of Each Exchange on Which Registered: </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Common Stock, par value $.001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>NASDAQ Global Market</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Securities
registered pursuant to Section&nbsp;12(g) of the Act: </FONT><FONT SIZE=2><B>None</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities
Act.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
Act.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the
past 90&nbsp;days.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to
be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&sect;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the
registrant was required to submit and post such files).&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K (&sect;229.405 of this Chapter) is not
contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K
or any amendment to this Form&nbsp;10-K.&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See
definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="134pt" style="font-family:times;"></TD>
<TD WIDTH="4%" style="font-family:times;"></TD>
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="4%" style="font-family:times;"></TD>
<TD WIDTH="144pt" style="font-family:times;"></TD>
<TD WIDTH="4%" style="font-family:times;"></TD>
<TD WIDTH="163pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Large accelerated filer <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Accelerated filer <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Non-accelerated filer <FONT FACE="WINGDINGS">&#111;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Smaller Reporting Company <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Act).&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate market value of the registrant's common stock held by non-affiliates as of June&nbsp;30, 2015 was $2.5&nbsp;billion. Exclusion of shares held by
any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the actions of the management or policies of the registrant, or that such
person is controlled by or under common control with the registrant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of common stock outstanding at February&nbsp;16, 2016 was 98,703,484 shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>DOCUMENTS INCORPORATED BY REFERENCE</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Portions
of the definitive Proxy Statement for our 2016 Annual Meeting of Stockholders are incorporated by reference into Part&nbsp;III of this Report. </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=323807,FOLIO='blank',FILE='DISK133:[15ZCW1.15ZCW72301]BA72301A.;4',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg72301_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG72301A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg72301_celldex_therapeutics,_inc._ann__cel02573"> </A>
<BR></FONT><FONT SIZE=2><B>  CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  ANNUAL REPORT ON FORM 10-K<BR>  YEAR ENDED DECEMBER 31, 2015    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg72301_table_of_contents"> </A></FONT> <FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG72301_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc72301_part_i"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Part&nbsp;I</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc72301_item_1._business"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;1.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dc72301_item_1._business"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc72301_item_1._business"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg72301_item_1a._risk_factors"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;1A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dg72301_item_1a._risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg72301_item_1a._risk_factors"><FONT SIZE=2>31</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dk72301_item_1b._unresolved_staff_comments"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;1B.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk72301_item_1b._unresolved_staff_comments"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unresolved Staff Comments</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk72301_item_1b._unresolved_staff_comments"><FONT SIZE=2>57</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dk72301_item_2._properties"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;2.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk72301_item_2._properties"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Properties</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk72301_item_2._properties"><FONT SIZE=2>57</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dk72301_item_3._legal_proceedings"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;3.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk72301_item_3._legal_proceedings"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Proceedings</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk72301_item_3._legal_proceedings"><FONT SIZE=2>58</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dk72301_item_4._mine_safety_disclosures"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;4.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dk72301_item_4._mine_safety_disclosures"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mine Safety Disclosures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk72301_item_4._mine_safety_disclosures"><FONT SIZE=2>58</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm72301_part_ii"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Part&nbsp;II</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm72301_item_5._market_for_registrant___ite04666"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;5.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dm72301_item_5._market_for_registrant___ite04666"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm72301_item_5._market_for_registrant___ite04666"><FONT SIZE=2>59</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm72301_item_6._selected_financial_data"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;6.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dm72301_item_6._selected_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm72301_item_6._selected_financial_data"><FONT SIZE=2>60</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#do72301_item_7._management_s_discussio__ite03668"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;7.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#do72301_item_7._management_s_discussio__ite03668"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#do72301_item_7._management_s_discussio__ite03668"><FONT SIZE=2>62</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ds72301_item_7a._quantitative_and_qual__ite02669"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;7A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ds72301_item_7a._quantitative_and_qual__ite02669"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ds72301_item_7a._quantitative_and_qual__ite02669"><FONT SIZE=2>84</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fa72301_item_8._financial_statements_and_supplementary_data"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;8.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fa72301_item_8._financial_statements_and_supplementary_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial Statements and Supplementary Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fa72301_item_8._financial_statements_and_supplementary_data"><FONT SIZE=2>85</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_item_9._changes_in_and_disagre__ite03576"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;9.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fs72301_item_9._changes_in_and_disagre__ite03576"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fs72301_item_9._changes_in_and_disagre__ite03576"><FONT SIZE=2>113</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_item_9a._controls_and_procedures"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;9A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fs72301_item_9a._controls_and_procedures"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Controls and Procedures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fs72301_item_9a._controls_and_procedures"><FONT SIZE=2>113</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_item_9b._other_information"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;9B.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fs72301_item_9b._other_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fs72301_item_9b._other_information"><FONT SIZE=2>114</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_part_iii"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Part&nbsp;III</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_item_10._directors,_executive___ite02336"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;10.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fs72301_item_10._directors,_executive___ite02336"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Directors, Executive Officers and Corporate Governance</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fs72301_item_10._directors,_executive___ite02336"><FONT SIZE=2>114</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_item_11._executive_compensation"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;11.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fs72301_item_11._executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fs72301_item_11._executive_compensation"><FONT SIZE=2>114</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_item_12._security_ownership_of__ite04004"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;12.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fs72301_item_12._security_ownership_of__ite04004"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fs72301_item_12._security_ownership_of__ite04004"><FONT SIZE=2>114</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_item_13._certain_relationships__ite03067"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;13.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fs72301_item_13._certain_relationships__ite03067"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Transactions, and Director Independence</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fs72301_item_13._certain_relationships__ite03067"><FONT SIZE=2>114</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fs72301_item_14._principal_accounting_fees_and_services"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;14.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fs72301_item_14._principal_accounting_fees_and_services"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Accountant Fees and Services</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fs72301_item_14._principal_accounting_fees_and_services"><FONT SIZE=2>115</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja72301_part_iv"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Part&nbsp;IV</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja72301_item_15._exhibits,_financial_statement_schedules"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Item&nbsp;15.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ja72301_item_15._exhibits,_financial_statement_schedules"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exhibits, Financial Statement Schedules</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ja72301_item_15._exhibits,_financial_statement_schedules"><FONT SIZE=2>116</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><A HREF="#jc72301_signatures"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Signatures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#jc72301_signatures"><FONT SIZE=2>121</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=530732,FOLIO='i',FILE='DISK133:[15ZCW1.15ZCW72301]BG72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da72301_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Annual Report on Form&nbsp;10-K contains
forward-looking
statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section&nbsp;27A of the Securities Act of 1933, as amended, and
Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations,
assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual
results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than
statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "will," "can,"
"anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target,"
"potential" and other similar words and expressions of the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include,
but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to successfully complete research and further development, including animal, preclinical and clinical studies, and, if we
obtain regulatory approval, commercialization of Rintega&reg; (also referred to as rindopepimut and CDX-110), glembatumumab vedotin (also referred to as CDX-011) and other drug candidates and
the growth of the markets for those drug candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to raise sufficient capital to fund our clinical studies and to meet our long-term liquidity needs, on terms acceptable to
us, or at all. If we are unable to raise the funds necessary to meet our long-term liquidity needs, we may have to delay or discontinue the development of one or more programs, discontinue or delay
on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or part of our business; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to manage multiple clinical trials for a variety of drug candidates at different stages of development, including ACT IV
and ReACT for Rintega and METRIC for glembatumumab vedotin; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost, timing, scope and results of ongoing safety and efficacy trials of Rintega, glembatumumab vedotin, and other preclinical and
clinical testing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost, timing, and uncertainty of obtaining regulatory approvals for our drug candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to fund and complete the development and, if we obtain regulatory approval, to commercialize Rintega in North America and
Europe ourselves; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the availability, cost, delivery and quality of clinical management services provided by our clinical research organization partners; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or
supplied by contract manufacturers, suppliers and partners, who may be the sole source of supply; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to develop and commercialize products before competitors that are superior to the alternatives developed by such
competitors; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=117963,FOLIO='ii',FILE='DISK133:[15ZCW1.15ZCW72301]DA72301A.;4',USER='CHE108062',CD='19-FEB-2016;19:13' -->
<A NAME="page_da72301_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to negotiate strategic partnerships, where appropriate, for our programs, which may include, Rintega outside of North
America and Europe, glembatumumab vedotin and varlilumab (also referred to as CDX-1127); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to develop technological capabilities, including identification of novel and clinically important targets, exploiting our
existing technology platforms to develop new product candidates and expand our focus to broader markets for our existing targeted immunotherapeutics; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to adapt our proprietary antibody-targeted technology, or APC Targeting Technology&#153;, to develop new, safe and
effective therapeutics for oncology and infectious disease indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to protect our intellectual property rights, including the ability to successfully defend patent oppositions filed against
a European patent related to technology we use in varlilumab, and our ability to avoid intellectual property litigation, which can be costly and divert management time and attention; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the factors listed under "Risk Factors" in this Annual Report on Form&nbsp;10-K. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which
speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or
correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith, and we
believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>iii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=588475,FOLIO='iii',FILE='DISK133:[15ZCW1.15ZCW72301]DA72301A.;4',USER='CHE108062',CD='19-FEB-2016;19:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc72301_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc72301_part_i"> </A>
<A NAME="toc_dc72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART I    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="dc72301_item_1._business"> </A>
<A NAME="toc_dc72301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex Therapeutics,&nbsp;Inc., which we refer to as "Celldex," "we," "us," "our" or the "Company," is a biopharmaceutical company
focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Our drug candidates are derived from a broad
set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are using these technologies to develop targeted
immunotherapeutics comprised of protein-based molecules such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
latest stage drug candidate, Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that
express a specific cancer marker known as EGFRvIII. In February 2015, the U.S. Food and Drug Administration, or FDA, granted Rintega Breakthrough Therapy Designation for the treatment of adult
patients with EGFRvIII-positive glioblastoma. We completed enrollment in December 2014 in ACT IV, a pivotal Phase&nbsp;3 study in front-line glioblastoma. ACT IV completed its first interim analysis
at 50% of events (deaths) in June 2015, and an independent Data Safety and Monitoring Board recommended that the study continue as planned. The required number of events to perform the second interim
analysis of ACT IV were reached in late 2015 and the analysis is expected to occur in March 2016. Final data from ACT IV are expected by the end of 2016, although our expectations regarding the timing
for the final data read out may change based on event rates.We have also completed a Phase&nbsp;2 study in patients with recurrent EGFRvIII-positive glioblastoma. Updated results from this
randomized study comparing Rintega added to the standard of care, or SOC, compared to SOC alone were presented in November 2015. A statistically significant overall survival benefit and the emergence
of a long-term survival benefit were observed. The primary endpoint of the study, progression-free survival at six months, or PFS6, was met. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glembatumumab
vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase&nbsp;2b study for the treatment of triple negative breast cancer and a
Phase&nbsp;2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response
against their cancer. We established proof of concept in a Phase&nbsp;1 study with varlilumab, which has allowed several combination studies to begin in various indications. We also have a number of
earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells, or APC, for cancer indications and CDX-301, an immune cell
mobilizing agent and dendritic cell growth factor. Our drug candidates address market opportunities for which we believe current therapies are inadequate or non-existent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are building a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Our program assets provide us with
the strategic options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach allows us to
maximize
the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=849871,FOLIO='1',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table includes the programs that we currently believe are significant to our business: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="281pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:62pt;"><FONT SIZE=1><B>Product (generic)

<!-- COMMAND=ADD_SCROPPEDRULE,62pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication/Field </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Partner </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Status </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Rintega</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Front-line glioblastoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;3</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Glembatumumab vedotin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Metastatic breast cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2b</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Rintega</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Recurrent glioblastoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Glembatumumab vedotin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Metastatic melanoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Varlilumab</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1/2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-1401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Allogeneic hematopoietic stem cell transplantation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Renal cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
future success depends upon many factors, including our ability, and that of any licensees and collaborators that we may have, to successfully develop, obtain regulatory approval for
and commercialize our drug candidates, as well as any related companion diagnostic tests. We have had no commercial revenues from sales of our drug candidates, and we have had a history of operating
losses. It is possible that we may not be able to successfully develop, obtain regulatory approval for, or commercialize, our drug candidates, and we are subject to a number of risks that you should
be aware of before investing in us. These risks are described more fully in "Item&nbsp;1A. Risk Factors." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Development Programs  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rintega  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rintega is an epidermal growth factor receptor variant III, or EGFRvIII, specific vaccine for glioblastoma, or GBM. EGFRvIII is a
mutated form of the epidermal growth factor receptor, or EGFR, that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. EGFRvIII is expressed
in approximately 30% of GBM tumors, the most common and aggressive form of brain cancer. Rintega is composed of the EGFRvIII peptide linked to a carrier protein called Keyhole Limpet Hemocyanin, or
KLH, and administered together with the adjuvant GM-CSF. The FDA and the European Medicines Agency, or EMA, have both granted Orphan Drug Designation for Rintega for the treatment of EGFRvIII
expressing GBM. The FDA has also granted Fast Track designation. In February 2015, the FDA granted Rintega Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive
glioblastoma. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase&nbsp;2a study of Rintega referred to as ACTIVATE was led by collaborating investigators at the Brain Tumor Center at Duke Cancer Institute in Durham, North Carolina and at
M.D. Anderson Cancer Center in Houston, Texas and enrolled 18 evaluable GBM patients. An extension of the Phase&nbsp;2a study referred to as ACT II evaluated 22 additional GBM patients treated in
combination with the current standard of care, maintenance temozolomide, or TMZ, at the same two institutions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase&nbsp;2b study of Rintega referred to as ACT III combined Rintega with standard of care, TMZ, in patients with newly diagnosed GBM. The ACT III study provided for a
multi-center, non-randomized dataset for Rintega in 65 patients at over 30 sites throughout the United States, or U.S. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2013, we announced the four- and five-year survival data from the 105 patients enrolled in the three Phase&nbsp;2 Rintega clinical studies (ACTIVATE, ACT II and ACT
III)&nbsp;in EGFRvIII-positive GBM. Across these three Phase&nbsp;2 studies of Rintega, survival data remains consistent and suggests a continuing survival benefit in comparison to independent
control datasets (see chart below) at the median and at all other time points evaluated. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=351548,FOLIO='2',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc72301_phase_2_front-line_lon__dc702268"> </A>
<A NAME="toc_dc72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Phase&nbsp;2 Front-line Long-term Overall Survival Assessments    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Median, Years<BR>
(95% CI) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2-year<BR>
rate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>3-year<BR>
rate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>4-year<BR>
rate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>5-year<BR>
rate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Phase&nbsp;2 Rintega studies (n=105)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.1 (1.8, 2.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matched historical control (n=17)(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.3 (0.9, 1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(1)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Patients treated at M.D. Anderson contemporaneously to ACTIVATE, matched for major eligibility requirements, including
EGFRvIII-positive GBM, gross total resection and no disease progression through chemoradiation treatment.</I></FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pooled overall long-term survival results continue to be consistent with the ACT III Phase&nbsp;2 study (18% for 4-years and 14% for 5-years). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we initiated ACT IV, a pivotal, randomized, double-blind, controlled Phase&nbsp;3 study of Rintega in patients with surgically resected, EGFRvIII-positive GBM.
Patients were randomized after the completion of surgery and standard chemoradiation treatment. The treatment regimen includes a Rintega priming phase post-radiation followed by an adjuvant phase
where Rintega is dosed along with TMZ and a Rintega maintenance therapy phase. Patients are treated until disease progression or intolerance to therapy. The primary objective of the study is to
determine whether Rintega plus adjuvant GM-CSF improves the overall survival of patients with newly diagnosed EGFRvIII-positive GBM with minimal residual disease post resection and traditional
chemoradiation when compared to treatment with TMZ and a control injection of KLH. KLH is a component of Rintega and was selected due to its ability to generate a similar injection site reaction to
that observed with Rintega. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2014, enrollment was completed in the ACT IV study. In total, over 4,800 tissue samples from GBM patients were submitted for EGFRvIII evaluation from more than 200 clinical
trial sites across 22 countries and, consistent with prior studies, 30% were positive for the EGFRvIII mutation. The study enrolled 745 patients to reach the required 374 patients with minimal
residual disease (assessed by central review) needed for analysis of the primary overall survival endpoint. All patients, including patients with disease that exceed this threshold, will be included
in a secondary analysis of overall survival as well as analyses of progression-free survival, safety and tolerability, and quality of life. The timing of the overall survival primary endpoint data is
event-driven. The study design requires interim analyses to be conducted by an independent Data Safety and Monitoring Board (DSMB) at 50% and 75% of events (deaths). The first interim analysis
occurred in June 2015, and the DSMB recommended continuation of the study as planned. The required number of events to perform the second interim analysis of ACT IV were reached in late 2015, and the
analysis is expected to occur in March 2016. Final data from ACT IV are expected by the end of 2016, although our expectations regarding the timing for the final data read out may change based on
event rates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we also initiated ReACT, a Phase&nbsp;2 study of Rintega in combination with Avastin&reg; in patients with recurrent EGFRvIII-positive GBM. This study
completed enrollment in 2014 and includes 3 groups. Group 1 consists of 73 patients who had not previously received Avastin and were randomized to receive either Rintega and Avastin or a control
injection of KLH and Avastin in a blinded fashion. Group 2 includes 25 patients who are refractory to Avastin having received Avastin in either the frontline or recurrent setting with subsequent
progression and who received Rintega plus Avastin in a single treatment arm. In August 2013, we announced the addition of an expansion cohort of up to 75 patients, called Group 2C, to better
characterize the potential activity of Rintega in this refractory patient population. This decision was based on early evidence of anti-tumor activity, including stable disease, tumor shrinkage and
investigator-reported response. In total, Group 2C enrolled 28 patients. The primary endpoint is six month progression-free survival rate (PFS-6) for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=971908,FOLIO='3',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>groups
1 and 2 and objective response rate (ORR) for group 2C. Other study endpoints include PFS-6, ORR, PFS, overall survival, or OS and safety and tolerability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2015, we reported the following mature data from Group 1 of the ReACT study. Tumor responses were evaluated in accordance with Response Assessment in Neuro-Oncology (RANO)
criteria by an independent expert review committee blinded to treatment group assignment. Data for this long-term update included study results through September&nbsp;1, 2015. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> PFS6:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;As previously reported in May 2015, the primary endpoint of the study, PFS6,
was met. In the intent to treat (ITT) population, 28% of patients on the Rintega arm were progression free at six months compared to 16% of patients on the control arm (p=0.1163). </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Survival:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Mature overall survival (OS) data continue to show a marked benefit
[hazard ratio&nbsp;=&nbsp;0.53 (0.32, 0.88); p=0.0137] with a long-term survival benefit observed in the Rintega arm. Consistent with previous studies of Rintega and the
published data observed for immune-mediated therapeutics, this survival benefit includes multiple patients exceeding what is customary survival for EGFRvIII-positive glioblastoma, also referred to as
a tail on the survival curve. At two years, the survival rate for Rintega patients in the ITT population is 25% versus 0% for control patients. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc72301_overall_survival_(os),__dc702063"> </A>
<A NAME="toc_dc72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Overall Survival (OS), Intent to Treat (ITT) Population    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Hazard Ratio (HR)<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=10 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><B> HR&nbsp;= 0.53 (0.32, 0.88); p=0.0137<BR> </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1><B> </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Median (95% CI)</B></FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OS 12&nbsp;months</B></FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OS 18&nbsp;months</B></FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OS 24&nbsp;months</B></FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Rintega +&nbsp;BV</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.3 (9.9, 16.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Control +&nbsp;BV</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.3 (7.1, 11.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Objective Response Rate
(ORR):</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Nine out of 30 evaluable ITT patients (30%) on the Rintega arm experienced a confirmed objective response versus six out of 34
evaluable patients (18%) on the control arm. Five patients on the Rintega arm experienced durable responses greater than six months, and three of these patients experienced durable responses greater
than 18&nbsp;months (range of 18.6+ to 22.2&nbsp;months). In contrast, only two patients on the control arm experienced a durable response greater than six months, and none experienced a response
greater than 7.4&nbsp;months.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Steroid
Use:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Further emphasizing the level of disease control, 50% of the 18 patients on the Rintega arm who were on steroids at the start of
treatment were able to stop steroids for at least two months during treatment versus only 26% of the 19 patients on the control arm who were on steroids at the start of treatment. 33% of patients on
the Rintega arm were able to stop steroids for more than six months, and, of these, three were able to stop for more than one year versus none on the control arm for either time point. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Immune
Response:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Prolonged survival was associated with high anti-EGFRvIII humoral responses. Recent </FONT><FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> experiments have shown those immune responses had tumor killing function through antibody dependent cellular cytotoxicity (ADCC) of EGFRvIII-expressing tumor cells. This
biologic effector function is rarely proven for immune therapies. Importantly, rapid generation of anti-EGFRvIII humoral response correlated with longer survival; however, even those with slower
development of immune responses benefitted. No patient in the control arm had detectable EGFRvIII specific antibody response. This effect is consistent with Rintega's proposed mechanism of action as a
targeted immunotherapeutic vaccine.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Other:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Multiple subgroup and adjusted analyses have concluded that the consistent
survival benefit observed in the study was not influenced by potential imbalances in patient demographics. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=748525,FOLIO='4',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Safety:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Rintega was very well tolerated without unexpected additive toxicity to
Avastin. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
studies of Rintega are currently planned including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;2 study of Rintega prior to and concurrent with chemoradiation and maintenance temozolomide in patients with newly
diagnosed EGFRvIII-positive glioblastoma. Prior studies of Rintega in the newly diagnosed setting have initiated Rintega dosing upon completion of chemoradiation concurrent with maintenance
temozolomide. This single-cohort, open label study is designed to explore the feasibility of dosing at an earlier timepoint (after surgery but prior to and concurrent with chemoradiation). The primary
objective of the study is to evaluate the EGFRvIII peptide-specific immune response obtained with this dosing regimen. Secondary objectives include evaluation of anti-tumor activity, including PFS,
OS, ORR and duration of response, assessment of health-related quality of life outcomes, and safety and tolerability. This study is expected to open to enrollment in the second half of 2016. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;2 single-arm study of Rintega with adjuvant imiquimod, a topically administered immune response modifier, in
combination with Avastin in patients with recurrent EGFRvIII-positive glioblastoma. Previous studies of Rintega have utilized the immune response modifier GM-CSF. Imiquimod has broad commercial
availability and could potentially serve as a second source of adjuvant if needed, especially outside the United States where GM-CSF is currently available through specialty distribution channels. The
primary objective of this study is to evaluate EGFRvIII-specific immune responses. Secondary objectives include evaluation of measures of anti-tumor activity, including ORR, duration of response, PFS,
and OS, and to characterize the safety and tolerability profile of this combination approach. This study is expected to open to enrollment in March of 2016. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with our Rintega clinical development program, we are collaborating with Laboratory Corporation of America (LabCorp) in the U.S. and Qiagen in the European Union, or EU, for
the potential commercialization of a companion diagnostic to enable identification of the EGFRvIII mutation in patients with glioblastoma. The LabCorp diagnostic has been developed in parallel with
the clinical development of Rintega and was utilized to screen patients for the Phase&nbsp;3 ACT IV study and the Phase&nbsp;2 ReACT study. In the U.S., we are working with LabCorp to file the
diagnostic for FDA approval concurrently with Celldex's potential BLA submission, pending successful completion of the ACT IV study. In the EU, Qiagen will seek CE marking of the diagnostic and
anticipates completing this certification in the second half of 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Glembatumumab Vedotin  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glembatumumab vedotin is an antibody-drug conjugate, or ADC, that consists of a fully human monoclonal antibody, CR011, linked to a
potent cell-killing drug, monomethyl-auristatin E, or MMAE. The CR011 antibody specifically targets glycoprotein NMB, referred to as gpNMB, that is over-expressed in a variety of cancers including
breast cancer and melanoma. The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics,&nbsp;Inc. and is the same as that used in
the marketed product Adcetris&reg;. The ADC is designed to be stable in the bloodstream. Following intravenous administration, glembatumumab vedotin targets and binds to gpNMB, and upon
internalization into the targeted cell, glembatumumab vedotin is designed to release MMAE from CR011 to produce a cell-killing effect. The FDA has granted Fast Track designation to glembatumumab
vedotin for the treatment of advanced, refractory/resistant gpNMB-expressing breast cancer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Breast Cancer:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Phase&nbsp;1/2 study of glembatumumab vedotin administered intravenously once every three weeks
evaluated patients
with locally advanced or metastatic breast cancer who had
received prior therapy (median of seven prior regimens). The study began with a bridging phase to confirm the maximum tolerated dose, or MTD, and then expanded into a Phase&nbsp;2 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1008274,FOLIO='5',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>open-label,
multi-center study. The study confirmed the safety of glembatumumab vedotin at the pre-defined maximum dose level (1.88&nbsp;mg/kg) in 6 patients. An additional 28 patients were enrolled
in an expanded Phase&nbsp;2 cohort (for a total of 34 treated patients at 1.88&nbsp;mg/kg, the Phase&nbsp;2 dose) to evaluate the PFS rate at 12&nbsp;weeks. The 1.88&nbsp;mg/kg dose was well
tolerated in this patient population with the most common adverse events of rash, alopecia and fatigue. The primary activity endpoint, which called for at least 5 of 25 (20%) patients in the
Phase&nbsp;2 study portion to be progression-free at 12&nbsp;weeks, was met as 9 of 26 (35%) evaluable patients were progression-free at 12&nbsp;weeks. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
all patients treated at the maximum dose level, tumor shrinkage was seen in 62% (16/26) and median PFS was 9.1&nbsp;weeks. A subset of 10 patients had "triple negative disease," a
more aggressive breast cancer subtype that carries a high risk of relapse and reduced survival as well as limited therapeutic options due to lack of over-expression of HER2/neu, estrogen and
progesterone receptors. In these patients, 78% (7/9) had some tumor shrinkage, 12-week PFS rate was 70% (7/10), and median PFS was 17.9&nbsp;weeks. Tumor samples from a subset of patients across all
dose groups were analyzed for gpNMB expression. The tumor samples from most patients showed evidence of stromal and/or tumor cell expression of gpNMB. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2012, we announced final results from the EMERGE study, a randomized, multi-center Phase&nbsp;2b study of glembatumumab vedotin in 122 patients with heavily pre-treated,
advanced, gpNMB-positive breast cancer. Patients were randomized (2:1) to receive either glembatumumab vedotin or single-agent Investigator's Choice, or IC, chemotherapy. Patients randomized to
receive IC were allowed to cross over to receive glembatumumab vedotin following disease progression. Activity endpoints included response rate, PFS and OS. The final results, as shown below,
suggested that glembatumumab vedotin induces significant response rates compared to currently available therapies in patient subsets with advanced, refractory breast cancers with gpNMB over-expression
(expression in at least 25% of tumor cells) and in patients with triple negative breast cancer. The OS and PFS of patients treated with glembatumumab vedotin was also observed to be greatest in
patients with triple negative breast cancer who also over-express gpNMB and all patients with gpNMB over-expression. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc72301_emerge__overall_respon__dc702190"> </A>
<A NAME="toc_dc72301_5"> </A>
<BR></FONT><FONT SIZE=2><B>  EMERGE: Overall Response Rate and Disease Control Data    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>gpNMB Over-Expression </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Triple Negative and<BR>
gpNMB Over-Expression </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>glembatumumab<BR>
vedotin </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Investigator<BR>
Choice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>glembatumumab<BR>
vedotin </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Investigator<BR>
Choice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(n=25) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(n=8) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(n=12) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(n=4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Response</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Disease Control Rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=2><I>Responses per RECIST 1.1; IC&nbsp;= Investigator's Choice; glembatumumab vedotin arm includes 15 patients who crossed over to receive glembatumumab vedotin treatment after
progression on IC. Analysis of best response excludes patients who discontinued from study without evaluable post-baseline radiographic imaging (n=15 for glembatumumab vedotin arm; n=5 for IC
arm).</I></FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=914278,FOLIO='6',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc72301_emerge__progression_free_survi__eme02633"> </A>
<A NAME="toc_dc72301_6"> </A>
<BR></FONT><FONT SIZE=2><B>  EMERGE: Progression Free Survival (PFS) and Overall Survival (OS) Data    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>gpNMB Over-Expression </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Triple Negative and<BR>
gpNMB Over-Expression </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>glembatumumab<BR>
vedotin </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Investigator<BR>
Choice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>glembatumumab<BR>
vedotin </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Investigator<BR>
Choice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Median PFS (months)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>p=0.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>p=0.008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Median OS (months)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>p=0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>p=0.003</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=2><I>When cross over patients are removed, median OS in patients with gpNMB over-expression is 10.0&nbsp;months for glembatumumab vedotin vs 5.2&nbsp;months for
IC (p=0.05), and median OS in triple negative patients with gpNMB over-expression is 10.0&nbsp;months for glembatumumab vedotin vs 5.2&nbsp;months for IC
(p=0.009).</I></FONT></P>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2013, we initiated METRIC, a randomized, controlled Phase&nbsp;2b study of glembatumumab vedotin in patients with triple negative breast cancer that over-express gpNMB.
Clinical trial sites are open to enrollment across the U.S., Canada and Australia, and trial expansion into the EU is underway with enrollment planned to open in the first quarter of 2016. The METRIC
protocol was amended in late 2014 based on feedback from clinical investigators conducting the study that the eligibility criteria for study entry were limiting their ability to enroll patients they
felt were clinically appropriate. In addition, we had spoken to country-specific members of the European Medicines Agency, or EMA, and believed a significant opportunity existed to expand the study
into the EU. The amendment expanded patient entry criteria to position it for full marketing approval with global regulators, including the EMA, and to support improved enrollment in the study. The
primary endpoint of the study is PFS as PFS is an established endpoint for full approval registration studies in this patient population in both the U.S. and the EU. The sample size (n=300) and the
secondary endpoint of OS remained unchanged. We implemented these changes in parallel to regulatory discussions to maintain momentum at open clinical trial sites. Since implementation, both the FDA
and central European regulatory authorities have reviewed the protocol design, and we believe the METRIC study could support marketing approval in both the U.S. and Europe dependent upon data review.
Based on current projections, we believe enrollment will be completed in the second half of 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Metastatic Melanoma:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Phase&nbsp;1/2 open-label, multi-center, dose escalation study evaluated the safety, tolerability
and
pharmacokinetics of glembatumumab vedotin in 117 patients with un-resectable Stage&nbsp;III or Stage&nbsp;IV melanoma who had failed no more than one prior line of cytotoxic therapy. The MTD was
determined to be 1.88 mg/kg administered intravenously once every three weeks. The study achieved its primary activity objective with an ORR in the Phase&nbsp;2 cohort of 15% (5/34). Median PFS was
3.9&nbsp;months. Glembatumumab vedotin was generally well tolerated, with the most frequent treatment-related adverse events being rash, fatigue, hair loss, pruritus, diarrhea and neuropathy. In the
subset of patients with tumor biopsies, high levels of tumor expression of gpNMB appeared to correlate with favorable outcome. In the seven patients whose tumors were found to express high amounts of
gpNMB, and who were treated at the maximum tolerated doses across all dosing schedules, median PFS was 4.9&nbsp;months. The development of rash, which may be associated with the presence of gpNMB in
the skin, also seemed to correlate with greater PFS. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2014, we initiated a single arm, open-label Phase&nbsp;2 study of glembatumumab vedotin in patients with unresectable Stage&nbsp;III or IV melanoma. The study includes
approximately 10 sites in the United States and will enroll approximately 60 patients. The primary objective is to evaluate the anticancer activity of glembatumumab vedotin in advanced melanoma as
measured by the ORR. Secondary endpoints include analyses of PFS, duration of response, OS, retrospective investigation of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=842200,FOLIO='7',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>whether
the anticancer activity of glembatumumab vedotin is dependent upon the degree of gpNMB expression in tumor tissue and safety. Based on current projections, we believe enrollment will be
completed in the second quarter of 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into a collaborative relationship with PrECOG under which they will conduct a Phase&nbsp;2 study in squamous cell lung cancer. This study is expected to open to
enrollment in the first half of 2016. We have also entered into a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, under which NCI is sponsoring
two studies of glembatumumab vedotin&#151;one in uveal melanoma and one in pediatric osteosarcoma. Both studies are currently open to enrollment. The uveal melanoma study is a single arm, open
label study in patients with locally recurrent or metastatic uveal melanoma. The primary outcome measure is ORR. Secondary outcome measures include change in gpNMB expression on tumor tissue via
immunohistochemistry, safety, OS and PFS. The osteosarcoma study is a single arm, open label, evaluation of adolescent and adult patients with recurrent or refractory osteosarcoma. The co-primary
objectives are to determine whether glembatumumab vedotin therapy either increases the disease control rate at 4&nbsp;months in patients with recurrent measurable osteosarcoma as compared to
historical experience and/or whether glembatumumab vedotin therapy produces an objective response rate greater than 20% in patients without previous eribulin (eribulin mesylate) treatment. Secondary
outcome measures include safety, pharmacokinetics and the relation of gpNMB expression as measured by immunohistochemistry to clinical response. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Varlilumab  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Varlilumab, a fully human monoclonal agonist antibody, binds and activates CD27, a critical co-stimulatory molecule in the immune
activation cascade, primarily by stimulating T&nbsp;cells to attack cancer cells. Restricted expression and regulation of CD27 enables varlilumab specifically to activate T&nbsp;cells, resulting
in an enhanced immune response with a favorable safety profile. Varlilumab has also been shown to directly kill or inhibit the growth of CD27 expressing lymphomas and leukemias </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT
SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>. We have entered into license agreements with the University of Southampton, UK for
intellectual property to use anti-CD27 antibodies and with Medarex (now a subsidiary of the Bristol-Myers Squibb Company, or BMS) for access to the UltiMab technology to develop and commercialize
human antibodies to CD27. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient
treatment is complete in the open label Phase&nbsp;1 study of varlilumab in patients with selected malignant solid tumors or hematologic cancers at multiple clinical sites in
the U.S. Initial dose escalation cohorts were conducted to determine an optimal dose for future study, and no maximum tolerated dose was reached. The lymphoid malignancies dose escalation arm
completed enrollment (n=24), and a new cohort was added to include evaluation of T cell malignancies. An expansion cohort was also added at 0.3&nbsp;mg/kg dosed once every three weeks in patients
with Hodgkin lymphoma
(n=&nbsp;up&nbsp;to&nbsp;15). The solid tumor arm, which included patients with various solid tumors, completed dose escalation in 2013. Two expansion cohorts were subsequently added at 3 mg/kg
dosed weekly in metastatic melanoma (n=16) and renal cell carcinoma, or RCC, (n=15) to better characterize clinical activity and further define the safety profile in preparation for combination
studies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
presented updated data from this Phase&nbsp;1 study in November 2014. Varlilumab was very well tolerated and induced immunologic activity in patients that is consistent with both
its mechanism of action and preclinical models. A total of 86 patients have been dosed in the study. 55 patients have been dosed in dose escalation cohorts (various solid and hematologic B-cell
tumors), and 31 patients have been dosed in the expansion cohorts (melanoma and RCC) at 3&nbsp;mg/kg. In both the solid tumor and hematologic dose-escalations, the pre-specified maximum dose level
(10 mg/kg) was reached without identification of a maximum tolerated dose. The majority of adverse events, or AEs, related to treatment have been mild to moderate (Grade&nbsp;1/2) in severity, with
only three serious AEs related to treatment reported. No significant immune-mediated adverse events (colitis, hepatitis, etc.) typically </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=12,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=51417,FOLIO='8',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>associated
with checkpoint blockade have been observed. Two patients experienced objective responses including a complete response in Hodgkin lymphoma and a partial response in renal cell carcinoma.
Thirteen patients experienced stable disease with a range of 3-36.2+ months (as of November 2015) to-date. Based on the results observed in hematologic malignancies, an expansion cohort in up to 15
patients with Hodgkin lymphoma, and an abbreviated dose escalation in T cell hematologic malignancies were added and are now closed to enrollment. Any incremental data updates from this study will be
included in future scientific presentations/publications. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2014, we entered into a clinical trial collaboration with BMS to evaluate the safety, tolerability and preliminary efficacy of varlilumab and Opdivo&reg;, BMS' PD-1 immune
checkpoint inhibitor, in a Phase&nbsp;1/2 study. Under the terms of this clinical trial collaboration, BMS made a one-time payment to us of $5.0&nbsp;million, and the companies amended the terms
of our existing license agreement with Medarex (a subsidiary of BMS) related to our CD27 program whereby certain future milestone payments were waived and future royalty rates were reduced that may
have been due from us to Medarex. In return, BMS was granted a time-limited right of first negotiation if we wish to out-license varlilumab. The companies also agreed to work exclusively with each
other to explore anti-PD-1 antagonist antibody and anti-CD27 agonist antibody combination regimens. The clinical trial collaboration provides that the companies will share development costs and that
we will be responsible for conducting the Phase&nbsp;1/2 study. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase&nbsp;1/2 study was initiated in January 2015 and is being conducted in adult patients with multiple solid tumors to assess the safety and tolerability of varlilumab at
varying doses when administered with Opdivo followed by a Phase&nbsp;2 expansion to evaluate the activity of the combination in disease specific cohorts. We completed enrollment of the dose
escalation portion of the study without identification of a maximum tolerated dose, and a varlilumab dose has been identified for study in Phase&nbsp;2 (3&nbsp;mg/kg). We
anticipate that the Phase&nbsp;2 portion of the study will open to enrollment in the second quarter of 2016. The protocol originally included five disease cohorts in the Phase&nbsp;2 portion of
the study&#151;advanced non-small cell lung cancer, colorectal cancer, ovarian cancer, head and neck squamous cell carcinoma, and metastatic melanoma. Based on the evolving treatment paradigm
for the combination of Opdivo and Yervoy&reg; in metastatic melanoma, a decision has been made not to enroll patients in this disease setting at this time. The protocol is also being amended
to include additional cohorts in renal cell carcinoma, where varlilumab has demonstrated single-agent clinical activity, and glioblastoma, an area of focus for both Celldex and BMS. The primary
objective of the Phase&nbsp;2 cohorts will be ORR. Secondary objectives include pharmacokinetics assessments, determining the immunogenicity of varlilumab when given in combination with Opdivo and
further assessing the anti-tumor activity of combination treatment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2015, we entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab and atezolizumab (anti-PDL1), Roche's
investigational cancer immunotherapy, in a Phase&nbsp;1/2 study. The Phase&nbsp;1 portion of the study is being conducted in multiple tumor types, and the primary outcome is safety and
tolerability. The Phase&nbsp;2 portion of the study will be conducted in RCC, and the primary outcome is ORR. Secondary outcome measures include safety and tolerability, pharmacokinetics,
immunogenicity and further assessment of anti-tumor activity across a broad range of endpoints. Under the terms of this agreement, Roche will provide study drug, and we will be responsible for
conducting and funding the study, which opened to enrollment in December 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2015, we initiated a Phase&nbsp;1/2 safety pilot and expansion study examining the combination of varlilumab and Yervoy in patients with Stage&nbsp;III or IV metastatic
melanoma. In the Phase&nbsp;2 portion of the study, patients with tumors that express NY-ESO-1 will also receive CDX-1401. The Phase&nbsp;1 portion of the study will assess the safety and
tolerability of varlilumab at varying doses when administered with Yervoy to identify a recommended dose for the Phase&nbsp;2 portion of the study. The Phase&nbsp;2 study will include two
cohorts&#151;one comprised of patients who are NY-ESO-1 positive and one </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=13,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=377455,FOLIO='9',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<A NAME="page_dc72301_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>comprised
of patients who are NY-ESO-1 negative. Patients who are NY-ESO-1 positive will also receive CDX-1401 (with poly-ICLC at 2 mg given as an adjuvant) in addition to varlilumab and Yervoy. The
primary objective for both cohorts is objective response rate up to 24&nbsp;weeks. Secondary objectives for the Phase&nbsp;2 study include safety and tolerability, immunogenicity, pharmacokinetics
and further assessment of anti-tumor activity across a broad range of endpoints. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2015, we initiated a Phase&nbsp;1/2 safety and tolerability study examining the combination of varlilumab and sunitinib (Sutent&reg;) in patients with metastatic clear
cell renal cell carcinoma. The Phase&nbsp;1 portion of the study will assess the safety and tolerability of varlilumab at varying doses when administered with sunitinib to identify a recommended
dose for the Phase&nbsp;2 portion of the study. The primary objective of the Phase&nbsp;2 portion of the study is to assess the preliminary
anti-tumor efficacy of the varlilumab/sunitinib combination measured by the overall response rate. Secondary objectives include safety and tolerability, pharmacokinetics, immunogenicity and further
assessment of anti-tumor activity across a broad range of endpoints. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our sponsored studies and clinical trial collaborations, we anticipate that varlilumab's potential activity will also be explored in investigator sponsored studies at
various academic institutions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CDX-1401  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1401, developed from our APC Targeting Technology, is an antibody-based NY-ESO-1-specific therapeutic vaccine for multiple solid
tumors. The vaccine, which is administered with an adjuvant, is composed of the cancer-specific antigen NY-ESO-1 fused to a fully human antibody that binds to DEC-205 for efficient delivery to
dendritic cells. Delivery of tumor-specific proteins directly to dendritic cells </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> elicits potent, broad, anti-tumor immune responses across
populations with different genetic backgrounds. In humans, NY-ESO-1 has been detected in 20% to 30% of all melanoma, lung, esophageal, liver, gastric, prostate, ovarian and bladder cancers, thus
representing a broad opportunity. We are developing CDX-1401 for the treatment of malignant melanoma and a variety of solid tumors which express the proprietary cancer antigen NY-ESO-1, which we
licensed from the Ludwig Institute for Cancer Research in 2006. Preclinical studies have shown that CDX-1401 is effective for activation of human T cell responses against NY-ESO-1. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have completed a Phase&nbsp;1 study of CDX-1401 which assessed the safety, immunogenicity and clinical activity of escalating doses of CDX-1401 with TLR agonists (resiquimod and/or
Poly ICLC) in 45 patients with advanced malignancies refractory to all available therapies. Sixty percent of patients had confirmed NY-ESO expression in archived tumor sample. Thirteen patients
maintained stable disease for up to 13.4&nbsp;months with a median of 6.7&nbsp;months. Treatment was well tolerated, and there were no dose limiting toxicities. Humoral responses were elicited in
both NY-ESO-1 positive and negative patients. NY-ESO-1-specific T cell responses were absent or low at baseline, but increased post-vaccination in 53% of evaluable patients, including both CD4 and/or
CD8 T cell responses. Robust immune responses were observed with CDX-1401 with resiquimod and Poly ICLC alone and in combination. Long-term patient follow up suggested that treatment with CDX-1401 may
predispose patients to better outcomes on subsequent therapy with checkpoint inhibitors. Of the 45 patients in the Phase&nbsp;1 study, eight went on to receive subsequent therapy of either Yervoy or
an investigational checkpoint inhibitor, and six of these patients had objective tumor regression. Six patients with melanoma received Yervoy within three months of treatment with CDX-1401, and four
(67%) had objective tumor responses, including one complete response, which compares favorably to the overall response rate of 11% previously reported in metastatic melanoma patients treated with
single-agent Yervoy. In addition, two patients with non-small cell lung cancer received an investigational checkpoint blockade within two months of completing treatment with CDX-1401, and both
achieved partial responses. We are currently developing a follow on program that will better assess the impact of CDX-1401 activity on response to subsequent checkpoint inhibitor therapy in these
diseases. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=14,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=615644,FOLIO='10',FILE='DISK133:[15ZCW1.15ZCW72301]DC72301A.;27',USER='VSTEFAN',CD='20-FEB-2016;02:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de72301_1_11"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Phase&nbsp;1 study identified a well-tolerated and immunogenic regimen to take forward into future studies. As described above, in April 2015, we initiated
a Phase&nbsp;1/2 safety pilot and expansion study examining the combination of varlilumab and Yervoy in patients with Stage&nbsp;III or IV metastatic melanoma. In the Phase&nbsp;2 portion of the
study, patients with tumors that express NY-ESO-1 will also receive CDX-1401. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our sponsored studies, CDX-1401's potential activity is also being explored in investigator sponsored and collaborative studies. A Phase&nbsp;2 study of CDX-1401 in
combination with CDX-301 is being conducted in metastatic melanoma by the Cancer Immunotherapy Trials Network under a CRADA with the Cancer Therapy Evaluation Program of the NCI. This study will
determine if CDX-1401 works better with or without CDX-301 in melanoma. The primary outcome measure of the study is immune response to NY-ESO-1. Secondary outcome measures include analysis and
characterization of peripheral blood mononuclear cells (dendritic cells, T&nbsp;cells, natural killer cells, etc.), additional immune monitoring, safety and clinical outcomes (survival and time to
tumor recurrence). Enrollment is now complete. Based on results to date, plans for additional studies are being considered by NCI. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
a Phase&nbsp;1/2b multi-arm study of the IDO1 inhibitor INCB024360 in combination with CDX-1401 and Hiltonol&reg; is being conducted in patients in remission with
ovarian, fallopian tube or primary peritoneal cancer by the Roswell Park Cancer Institute. Celldex is providing CDX-1401 and Hiltonol in support of this study. Patients' tumors must have expressed
NY-ESO-1 or the LAGE-1 antigen to be eligible for the study. Primary outcome measures include identifying a maximum tolerated dose determined by the incidence of dose limiting toxicities and
progression free survival. Secondary outcome measures include additional safety analyses and immune monitoring. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CDX-301  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-301, a recombinant FMS-like tyrosine kinase 3 ligand, or Flt3L, is a potent hematopoietic cytokine that uniquely expands dendritic
cells and hematopoietic stem cells in combination with other agents to potentiate the anti-tumor response. Depending on the setting, cells expanded by CDX-301 promote either enhanced or permissive
immunity. CDX-301 is in clinical development for multiple cancers, in combination with vaccines, adjuvants and other treatments that release tumor antigens. We licensed CDX-301 from Amgen&nbsp;Inc.
in March 2009 and believe CDX-301 may hold significant opportunity for synergistic development in combination with other proprietary molecules in our portfolio. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2013, we announced final results from our dose-escalating Phase&nbsp;1 study of CDX-301 in 30 healthy subjects in collaboration with Rockefeller University. The
Phase&nbsp;1 study evaluated seven different dosing regimens of CDX-301 to determine the appropriate dose for further development based on safety, tolerability and biological activity. The data from
the study were consistent with previous clinical experience and demonstrated that CDX-301 was well tolerated and can effectively mobilize hematopoietic stem cell populations in healthy volunteers. In
December 2013, we announced data from a preclinical combination study of CDX-301and Mozobil&reg; (Plerixafor injection, formerly AMD3100) demonstrating that the combination of these agents
significantly increases hematopoietic stem cell mobilization in mice. The data demonstrate a novel potent cell mobilization regimen combining CDX-301 and Mozobil&reg;, which may have
significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation. Based on the safety profile and the clinical and preclinical data to date, we initiated a pilot
clinical study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell
transplantation. Related donors of patients with hematological malignancies requiring hematopoietic stem cell transplant are administered CDX-301 for 5 or 7&nbsp;days alone or in combination with
Mozobil to mobilize CD34+ stem cells. The primary efficacy endpoint of the study is determine if treatment of the donor results in the collection of <FONT FACE="SYMBOL">&#179;</FONT>
2&nbsp;million CD34+ </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=228132,FOLIO='11',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<A NAME="page_de72301_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>HSCs/kg
recipient body weight in <FONT FACE="SYMBOL">&#163;</FONT> 2 leukopoiesis collections. Other key endpoints are the safety of the treatment regimen in the donor and clinical outcomes
in the recipient, including stem cell engraftment, graft-versus-host disease, immune reconstitution and relapse. Preliminary results from this study were presented at the annual meeting of the
American Society for Blood and Marrow Transplantation in February 2016. These preliminary data from three donor/patient pairs showed that CDX-301 given as a single agent was well tolerated and
effective at mobilizing hematopoietic stem cells in healthy donors. The stem cell graft contained notable increases in na&iuml;ve lymphocytes and plasmacytoid dendritic cells consistent with
preclinical data suggesting a possible better outcome. Recipients experienced successful engraftment in an expected time frame. Additional subjects are being accrued to assess the potential synergy of
combining CDX-301 with Mozobil in this setting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our sponsored studies and clinical trial collaborations, CDX-301's potential activity is also being explored in investigator sponsored studies at various academic
institutions. This includes a Phase&nbsp;1/2 study of CDX-301 and Hiltonol in combination with low-dose radiotherapy in patients with low-grade B-cell lymphomas conducted by the Icahn School of
Medicine at Mount Sinai. The primary outcome of the study is objective response rate. Secondary outcome measures include safety and tumor specific immune response. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CDX-014  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-014 is a fully-human monoclonal ADC that targets T cell immunoglobulin and mucin domain&nbsp;1, or TIM-1, a molecule that is
upregulated in several cancers, including renal cell and ovarian carcinomas. TIM-1 is associated with kidney injury, and the shedding of its ectodomain is a predictive biomarker for tumor progression.
TIM-1 has very restricted expression in healthy tissues, making it a promising target for antibody mediated therapy. The TIM-1 antibody is linked to MMAE using Seattle Genetics' proprietary
technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into TIM-1-expressing tumor cells, resulting in a targeted cell-killing effect. CDX-014 has
shown potent activity in preclinical models of ovarian and renal cancer. The Investigative New Drug (IND) Application is active, and we expect to initiate a Phase&nbsp;1 clinical study in renal cell
carcinoma in 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Development Strategy  </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Immunotherapy Platform:  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe there is untapped potential in immunotherapy that can be captured through the right combination and/or sequence of
therapeutic agents. Immunotherapy approaches have encountered difficulties when following standard drug development. The mechanisms of action are complex, activity is generally not dependent on
highest tolerated dose and patient response is highly variable. Our understanding of the immune system, cancer's effect on immune mediated mechanisms, and the impact of conventional therapies on the
immune system provide a new rationale for combining therapies that may lead to significant clinical benefit for patients with cancer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
intent is to leverage this knowledge and the availability of good, tested products that may not have optimal clinical activity as a monotherapy, but which we believe may be very
effective in combination approaches. Our goal is to design and develop targeted products that maximize the efficacy of immunotherapy regimens through combinations of therapeutic agents in significant
and growing markets. We establish governmental and corporate alliances to fund development when appropriate and intend to commercialize our products either through our own direct selling efforts or,
for products which we cannot develop ourselves through to commercialization, through corporate partners. This approach allows us to maximize the overall value of our technology and product portfolios
while best ensuring the expeditious development of each individual product. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=6748,FOLIO='12',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<A NAME="page_de72301_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Factors
that may significantly harm our commercial success, and ultimately the market price of our common stock, include but are not limited to, announcements of technological
innovations or new commercial products by our competitors, disclosure of unsuccessful results of clinical testing or regulatory proceedings and governmental approvals, adverse developments in patent
or other proprietary rights, public concern about the safety of products developed by us and general economic and market conditions. See "Item&nbsp;1A. Risk Factors." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Partnerships  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to commercialize our lead drug candidate Rintega ourselves in North America and Europe. We may enter into co-development and
commercialization partnerships for any of our programs where appropriate, including Rintega for commercialization outside of North America and Europe, glembatumumab vedotin and varlilumab. In the
past, we have entered into collaborative partnership agreements with pharmaceutical and other companies and organizations that provided financial and other resources, including capabilities in
research, development, manufacturing, and sales and marketing, to support our research and development programs and may enter into more of them in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Partnership
agreements may terminate without benefit to us if the underlying products are not fully developed. If we fail to meet our obligations under these agreements, they could
terminate and we might need to enter into relationships with other collaborators and to spend additional time, money, and other valuable resources in the process. We cannot predict whether our
collaborators will continue their development efforts or, if they do, whether their efforts will achieve success. Many of our collaborators face the same kinds of risks and uncertainties in their
business that we face. A delay or setback to a partner will, at a minimum, delay the commercialization of any affected products, and may ultimately prevent it. Moreover, any partner could breach its
agreement with us or otherwise not use best efforts to promote our products. A partner may choose to pursue alternative technologies or products that compete with our technologies or products. In
either case, if a partner failed to successfully develop one of our products, we would need to find another partner. Our ability to do so would depend upon our legal right to do so at the time and
whether the product remained commercially viable. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research Collaboration and License Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into license agreements whereby we have received licenses or options to license technology, specified patents and/or
patent applications. These license and collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing
patent prosecution costs and potential future milestone payments to third parties upon the achievement of certain development, regulatory and/or commercial milestones. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Medarex,&nbsp;Inc., a subsidiary of Bristol-Myers Squibb (Medarex)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and Medarex have entered into an assignment and license agreement, as amended, that provides for the assignment of certain patent
and other intellectual property rights and a license to certain Medarex technology related to the Company's APC Targeting Technology&#153; and an anti-mannose receptor product. Under the terms
of the agreement, we may be required to pay royalties in the low-single digits on any net product sale of a Licensed Royalty-Bearing Product or Anti-Mannose Product to Medarex until the later of
(i)&nbsp;the expiration of the last to expire applicable patent and (ii)&nbsp;the tenth anniversary of the first commercial sale of such licensed product. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and Medarex have also entered into a research and commercialization agreement, as amended, that provides that we may be required to pay Medarex milestones of up to $7.0&nbsp;million
upon obtaining first approval for commercial sale in a first indication of a product containing a licensed antibody and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=92512,FOLIO='13',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<A NAME="page_de72301_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>royalty
payments in the low-to-mid single digits on any net product sales with respect to the development of any products containing such licensed antibodies until the later of (i)&nbsp;the
expiration of the last to expire applicable patent and (ii)&nbsp;the tenth anniversary of the first commercial sale of such licensed product. In September 2010, we exercised an option under our
research and commercialization agreement, whereby we licensed from Medarex access to the UltiMab technology to develop and commercialize human antibodies to CD27, including varlilumab. In connection
with the clinical trial collaboration we entered into with BMS in May 2014, we and BMS agreed to waive certain future milestone payments and to reduce future royalty rates that we may have owed
Medarex in connection with any CD27 program. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rockefeller University (Rockefeller)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2005, we and Rockefeller entered into a license agreement for the exclusive worldwide rights to human DEC-205 receptor,
with the right to sublicense the technology. The license grant is exclusive except that Rockefeller may use and permit other nonprofit organizations to use the human DEC-205 receptor patent rights for
educational and research purposes. We may be required to pay Rockefeller milestones of up to $3.8&nbsp;million upon obtaining first approval
for commercial sale in a first indication of a product targeting the licensed receptor and royalty payments in the low-to-mid single digits on any net product sales with respect to development and
commercialization of the human DEC-205 receptor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Duke University Brain Tumor Cancer Center (Duke)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2006, we and Duke entered into a license agreement that gave us access and reference to the clinical data generated by
Duke and its collaborators in order for us to generate our own filing with the FDA relating to Rintega. We may be required to pay Duke milestones of up to $0.7&nbsp;million upon obtaining first
approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of Rintega. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ludwig Institute for Cancer Research (Ludwig)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2006, we and Ludwig entered into an agreement for the nonexclusive rights to certain cancer tumor targets for use in
combination with our APC Targeting Technology. We may be required to pay Ludwig milestones of up to $1.0&nbsp;million upon obtaining first approval for commercial sale in a first indication and
royalty payments in the low-single digits on any net product sales with respect to development and commercialization of the technology licensed from Ludwig. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Alteris Therapeutics,&nbsp;Inc. (Alteris)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2005, we completed the acquisition of the assets of Alteris, including the EGFRvIII molecule. We may be required to pay
Alteris up to $5.0&nbsp;million upon obtaining the first approval for commercial sale of a product containing EGFRvIII, including Rintega. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


University of Southampton, UK (Southampton)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2008, we entered into a license agreement with Southampton to develop human antibodies towards CD27, a potentially
important target for immunotherapy of various cancers. We may be required to pay Southampton milestones of up to approximately $1.4&nbsp;million upon obtaining first approval for commercial sale in
a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of varlilumab. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=744234,FOLIO='14',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<A NAME="page_de72301_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amgen&nbsp;Inc. (Amgen)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2009, we entered into a license agreement with Amgen to acquire the exclusive rights to CDX-301 and CD40 ligand, or CD40L.
CDX-301 and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. We may be required to pay Amgen milestones of up to
$0.9&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and
commercialization of the technology licensed from Amgen, including CDX-301. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amgen Fremont (formerly Abgenix)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our acquisition of CuraGen Corporation in 2009, we assumed the license agreement between CuraGen and Amgen Fremont
(successor in-interest to Abgenix) to develop fully-human monoclonal antibody therapeutics. In May 2009, an amendment to the license agreement was entered into related to CuraGen's exclusive rights to
develop and commercialize glembatumumab vedotin, CDX-014 and antibodies to 10 other licensed antigens. Under the amendment, CuraGen and Amgen Fremont agreed to modify the terms of their existing
cross-license of antigens whereby our amended license is fully paid-up and royalty-free. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Seattle Genetics,&nbsp;Inc. (Seattle Genetics)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our acquisition of CuraGen, we assumed the license agreement between CuraGen and Seattle Genetics whereby CuraGen
acquired the rights to proprietary ADC technology, with the right to sublicense, for use with its proprietary antibodies for the potential treatment of cancer. Under the terms of the agreement, we
have the responsibility of using commercially reasonable efforts to develop, commercialize and market such treatment. In furtherance of these responsibilities, technical assistance from Seattle
Genetics is available to us as necessary. We may be required to pay Seattle Genetics milestones of up to $5.0&nbsp;million and $9.0&nbsp;million for glembatumumab vedotin and CDX-014,
respectively, upon obtaining first approval for commercial sale in a first indication and royalty payments in the mid-single digits on any net product sales with respect to development and
commercialization of these product candidates. The term of the agreement varies country to country and may be until the later of the expiration of the last relevant patent or the
10<SUP>th</SUP>&nbsp;anniversary of the first commercial sale. The agreement allows us to terminate with prior written notice, with both parties being able to terminate the agreement for an
uncured material breach or insolvency of the other party. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology and pharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Many
of the products that we are attempting to develop and commercialize will be competing with existing therapies. Other companies are pursuing the development of new therapies that target the same
diseases and conditions that we are targeting and may compete directly with our drug candidates. We face competition from companies, major universities and research institutions in the United States
and abroad, including a number of large pharmaceutical companies, as well as firms specialized in the development and production of vaccines, adjuvants and immunotherapeutic delivery systems. Some of
our competitors possess substantially greater financial, technical and human resources than we possess. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors
that we are aware of that have initiated a Phase&nbsp;3 study or have obtained marketing approval for a potential competitive drug/device for Rintega in the treatment of
glioblastoma and/or glembatumumab vedotin in the treatment of breast cancer include AbbVie, Arbor Pharmaceutics,&nbsp;Inc., AstraZeneca&nbsp;PLC, Bayer, Bristol-Myers Squibb, Celgene Corporation,
Eisai&nbsp;Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics,&nbsp;Inc., Novartis, Novocure, Pfizer&nbsp;Inc., and Roche. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=19,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=299138,FOLIO='15',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<A NAME="page_de72301_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
competitors may utilize discovery technologies and techniques or partner with collaborators in order to develop products more rapidly or successfully than us or our collaborators are
able to. In addition, some competitors have significantly greater experience than we have in conducting preclinical and nonclinical testing and human clinical trials of drug candidates, scaling up
manufacturing operations and obtaining regulatory approvals of drugs and manufacturing facilities. Accordingly, our competitors may succeed in obtaining regulatory approval for drugs more rapidly than
we do. If we obtain regulatory approval and commence commercial sales of our drug candidates, we also will compete with respect to manufacturing efficiency and sales and marketing capabilities, areas
in which we currently have limited experience. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive
products or technologies and may establish exclusive collaborative or licensing relationships with our competitors. Moreover, technology controlled by third parties that may be advantageous to our
business may be acquired or licensed by our competitors, thereby preventing us from obtaining technology on commercially reasonable terms, if at all. We will also compete for the services of third
parties that may have already developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies to target the diseases on which we have
focused both in the U.S. and outside of the U.S. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also face competition in recruiting and retaining highly qualified scientific personnel and consultants and in the development and acquisition of technologies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
competitive position will depend upon our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes and
secure sufficient capital resources for the often lengthy period between technological conception and commercial sales. We will require substantial capital resources to complete development of some or
all of our products, obtain the necessary regulatory approvals and successfully manufacture and market our products. In order to secure capital resources, we anticipate having to sell additional
capital stock, which would dilute existing stockholders. We may also attempt to obtain funds through research grants and agreements with commercial collaborators. However, these types of funding are
uncertain because they are at the discretion of the organizations and companies that control the funds. As a result, we may not receive any funds from grants or collaborations. Alternatively, we may
borrow funds from commercial lenders, likely at high interest rates, which would increase the risk of any investment in us. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have limited experience in commercial manufacturing. Our ability to conduct late-stage clinical trials, manufacture and
commercialize our drug candidates will depend on the ability of such third parties to manufacture our drug candidates on a large scale at a competitive cost and in accordance with current Good
Manufacturing Practices, or cGMP, and foreign regulatory requirements, if applicable. We rely on contract manufacturing organizations, or CMOs, to manufacture drug substance and drug product for our
late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. We also rely on CMOs for filling and packaging, labeling, storage and shipping of drug
product. In order for us to establish our own commercial manufacturing facility, we would require substantial additional funds and would need to hire and retain significant additional personnel and
comply with extensive cGMP regulations applicable to such a facility. The commercial manufacturing facility would also need to be licensed for the production of our drug candidates by the FDA. We work
with CMOs under established manufacturing arrangements that comply with the FDA's requirements and other regulatory standards, although there is no assurance that the manufacturing will be successful. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=20,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=507254,FOLIO='16',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<A NAME="page_de72301_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have recently initiated use of Rintega drug product manufactured by MilliporeSigma (formerly SAFC, a division of the Sigma Aldrich Corporation) and Patheon Ferentino, in the ACT IV
and ReACT clinical studies as well as in compassionate use. We have also established a relationship with Cook Pharmica to fill Rintega for commercial supply. We rely on Biosyn and Ambiopharm for
supplying suitable quantities of cGMP starting materials for the manufacture of Rintega. We also rely on Sanofi to supply suitable quantities of commercial quality GM-CSF which is co-administered with
Rintega. Any manufacturing failures or delays by our Rintega contract manufacturers or suppliers of critical materials could cause delays in ACT IV and/or the commercial launch of Rintega. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, we have utilized contract manufacturing organizations for the manufacture of clinical trial supplies of glembatumumab vedotin. We have established relationships with Lonza
Biologics to manufacture the glembatumumab vedotin antibody and Piramal Healthcare UK&nbsp;Ltd. to manufacture the antibody drug conjugate with the MMAE toxin. The drug substance is then filled and
packaged at contract manufacturers. We rely on MilliporeSigma for sourcing of suitable quantities of vcMMAE. Any manufacturing failures or delays by our glembatumumab vedotin contract manufacturers or
suppliers of materials could cause delays in our glembatumumab vedotin clinical studies including the METRIC study and/or the commercial launch of glembatumumab vedotin. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have established a relationship with Patheon Biologics to scale up and manufacture varlilumab drug substance for global clinical trials and potential commercialization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
operate our own cGMP manufacturing facility in Fall River, Massachusetts, to produce drug substance for our current and planned early-stage clinical trials. Our Fall River
manufacturing facility has 250L and 1000L bioreactor capacity and is able to manufacture in compliance with FDA regulations, allowing us to distribute potential products to clinical sites in the U.S.
for early clinical trials. We manufacture CDX-1401, CDX-301 and CDX-014 drug substance in our Fall River facility for our current and planned Phase&nbsp;1 and Phase&nbsp;2 clinical trials. The
products are then filled and packaged at contract manufacturers. Any manufacturing failures or compliance issues at contract manufacturers could cause delays in our Phase&nbsp;1 and Phase&nbsp;2
clinical studies for these product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
manufacturing processes for our drug candidates and immunotherapeutic delivery systems utilize known technologies. We believe that the products we currently have under development
can be scaled up to permit manufacture in commercial quantities. However, there can be no assurance that we will not encounter difficulties in scaling up the manufacturing processes. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we believe that there is currently sufficient capacity worldwide for the production of our potential products through contract manufacturers, establishing long-term relationships
with contract manufacturers and securing multiple sources for the necessary quantities of clinical and commercial materials required can be a challenge. Qualifying the initial source of clinical and
ultimately commercial material is a time consuming and expensive process due to the highly regulated nature of the pharmaceutical/biotech industry. These costs may be mitigated by the economies of
scale realized in commercial manufacture and product sale. The key difficulty in qualifying more than one source for each product is the duplicated time and expense in doing so without the potential
to mitigate these costs if the secondary source is never utilized. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of third party manufacturers limits our control over and ability to monitor the manufacturing process. As a result, we may not be able to detect a variety of problems that may arise
and may face additional costs in the process of interfacing with and monitoring the progress of our contract manufacturers. If third party manufacturers fail to meet our manufacturing needs in an
acceptable manner, we would face delays and additional costs while we develop internal manufacturing capabilities or find alternate third party manufacturers. It may not be possible to have multiple
third party manufacturers ready to supply us with needed material at all or without incurring significant costs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=21,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=455905,FOLIO='17',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<A NAME="page_de72301_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Commercial Organization  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our strategy is to build a fully integrated, commercial stage biopharmaceutical company that would give us the opportunity to retain
marketing rights to our product candidates and commercialize such products ourselves where we deem appropriate or pursue strategic partnerships to develop, sell, market and distribute our product
candidates where we deem appropriate. We currently plan to commercialize Rintega in the United States and Europe ourselves, if regulatory approval is obtained, and to seek strategic partnerships to
commercialize Rintega in other geographies. We may enter into strategic partnerships to develop, sell, market and distribute our other product candidates, including glembatumumab vedotin and
varlilumab. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Over
the past few years, we have begun to assemble key components of a commercial organization with a focus on preparation for the potential commercial launch of Rintega, if regulatory
approval is obtained. We are assembling a focused commercial team with broad experience in marketing, sales, distribution and product reimbursement. We have also developed the capability to provide
current and future market insights to our research and development organization regarding glembatumumab vedotin, varlilumab and our earlier-stage product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have been expanding our understanding of the glioblastoma market, developing our commercial strategy for the potential commercial launch of Rintega, and planning the infrastructure
necessary to support future commercial activities. Our understanding of the glioblastoma market in the United States and Europe incorporates information regarding the current standard of care as well
as patient, health care provider and payor attitudes toward current and potential future therapies. Based on this information and the data obtained from our Phase&nbsp;2 clinical trials of Rintega,
we have begun developing our go- to-market strategy for Rintega, which we intend to update and refine as we obtain additional information regarding the potential commercial profile for Rintega. In
particular, we plan to incorporate the information we obtain regarding the efficacy and safety of Rintega from our registration program into our marketing strategy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
we continue to prepare for a potential Rintega commercial launch in the United States and Europe, we plan to expand our commercial organization over the next six to twelve months.
This expansion will include implementation of internal systems and infrastructure in order to support commercial sales, incorporation of appropriate compliance policies and procedures, establishment
of patient-focused programs and hiring and training a marketing and sales force to promote Rintega, if regulatory approval is obtained, to health care providers. There can be no assurance that we will
be able to accomplish any of these activities or hire and train an effective marketing and sales force. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patents, Licenses and Proprietary Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, our intellectual property strategy is to protect our technology by filing patent applications and obtaining patent rights
covering our own technology, both in the United States and in foreign countries that we consider important to our business. In addition, we have acquired and will seek to acquire as needed or desired,
exclusive rights of others through assignment or license to complement our portfolio of patent rights. We also rely on trade secrets, unpatented know-how and technological expertise and innovation to
develop and maintain our competitive position. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patents  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The successful development and marketing of products by us will depend in part on our ability to create and maintain intellectual
property, including patent rights. We are the owner or exclusive licensee to proprietary patent positions in the areas of immunotherapy technologies, vaccine technologies, antibody technologies and
complement inhibitor technology. Although we continue to pursue patent protection for our products, no assurance can be given that any pending application will issue as a patent, that any issued
patent will have a scope that will be of commercial benefit or that we </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=22,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=70227,FOLIO='18',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<A NAME="page_de72301_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>will
be able to successfully enforce our patent position against infringers. We routinely review our patent portfolio and adjust our strategies for prosecution and maintenance of individual cases
according to a number of factors including program priorities, stage of development and patent term. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
own or license rights under more than 300 granted patents and national and regional patent applications in the U.S. and in major international territories covering inventions relating
to our business. The key patents and patent applications owned by us or licensed to us that we consider important to our business include the following (the indicated and estimated patent expiry dates
do not include any possible patent term extensions or supplementary protection certificates, if these may be secured in due course):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have licensed rights from Duke University under an issued European patent, a patent application in the U.S. and patents and patent
applications in other major international territories relating to uses of Rintega. If and where issued and maintained to full term in a form which covers commercial use of Rintega, the filings could
potentially provide patent protection for the relevant use in the relevant territories to 2026. We also have patent applications in the U.S. and major international territories relating to methods of
manufacture and formulation of Rintega, which, if issued in a form which covers manufacture and/or formulation of Rintega and maintained to full term in due course, would have estimated patent expiry
dates in 2030. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our patent portfolio for glembatumumab vedotin includes issued patents in the U.S., Europe, Japan and Australia and a pending patent
application in Canada. If and where issued and maintained to full term in due course, these would have estimated patent expiry dates in 2025. In addition, patent rights relating to the toxin and
conjugation technology used in glembatumumab vedotin have been licensed from Seattle Genetics. The patent rights from Seattle Genetics include issued patents and pending applications in Australia,
Canada, Europe, the U.S. and Japan which include composition of matter claims relating to the toxin and conjugation technology. If maintained to full term in due course, the main Seattle Genetics
patent rights would have estimated patent expiry dates ranging from 2023 in Europe to 2026 in the U.S. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have licensed rights from the University of Southampton under issued U.S. and European patents and under pending patent
applications in Japan and Canada relating to the technology used in varlilumab. If and where issued and maintained to full term in due course, these would have estimated patent expiry dates in 2027.
In July 2013, the United States Patent and Trademark Office issued a patent to the University of Southampton, that we have exclusive license to under our license agreement, which broadly supports
varlilumab. The patent includes 18 claims covering various methods of treating cancer using agonistic anti-human CD27 antibodies and relates, among other things, directly to our CD27 antibody program
and therapeutic uses of varlilumab. In September 2014, two European patent oppositions were filed against the University of Southampton European patent. We intend to defend the European patent
vigorously in cooperation with the University of Southampton. We also have an issued U.S. patent which covers varlilumab as a composition of matter. If maintained to full term this patent would have
an estimated patent expiry date in 2034 (including additional term due to Patent Term Adjustment). We also have corresponding patent applications in the major international territories which, if
issued and maintained to full term in due course, would have estimated patent expiry dates in 2031. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=23,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=965004,FOLIO='19',FILE='DISK133:[15ZCW1.15ZCW72301]DE72301A.;10',USER='CHE108069',CD='19-FEB-2016;19:39' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg72301_1_20"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have issued U.S. patents relating to the technology used in CDX-1401 which have estimated patent expiry dates in at least 2028 (not
including increases of term due to Patent Term Adjustment). We have a corresponding issued European patent and further patents and pending patent applications in other international territories
relating to the technology used in CDX-1401 which, if and where issued and maintained to full term in due course, would have estimated patent expiry dates in 2028. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Patents for the technology used in CDX-301 have current expiration dates that range from 2016 in the major European territories to
2020 in the U.S. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our patent portfolio for CDX-014 includes rights under issued U.S. and European patents and further pending patent applications in the
U.S., Europe, Australia, Canada and Japan. If issued and maintained to full term in due course, these filings would have estimated patent expiry dates in at least 2024 (not including increases of term
due to Patent Term Adjustment in the U.S.). In addition, patent rights relating to toxin and conjugation technology have been licensed from Seattle Genetics. The patent rights from Seattle Genetics
include issued patents and pending patent applications in Australia, Canada, Europe, the U.S. and Japan which include composition of matter claims relating to the toxin and conjugation technology. If
maintained to full term in due course, the main Seattle Genetics patent rights would have estimated patent expiry dates ranging from 2023 in Europe to 2026 in the U.S. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurance that patent applications owned by or licensed to us will result in granted patents or that, if granted, the resultant patents will afford protection against
competitors with similar technology. It is also possible that third parties may obtain patents or other proprietary rights that may be necessary or useful to us. In cases where third parties are first
to invent a particular product or technology, it is possible that those parties will obtain patents that will be sufficiently broad to prevent us from using important technology or from further
developing or commercializing important drug candidates and immunotherapeutic systems. If licenses from third parties are necessary but cannot be obtained, commercialization of the covered products
might be delayed or prevented. Even if these licenses can be obtained, they would probably require us to pay ongoing royalties and other costs, which could be substantial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
a patent has a statutory presumption of validity in the United States, the issuance of a patent is not conclusive as to validity or as to the enforceable scope of the patent
claims. The validity or enforceability of a patent after its issuance by the Patent and Trademark Office can be challenged in litigation. As a business that uses a substantial amount of intellectual
property, we face a heightened risk of intellectual property litigation. If the outcome of the litigation is adverse to the owner of the patent, third parties may then be able to use the invention
covered by the patent without authorization or payment. There can be no assurance that our issued patents or any patents subsequently issued to or licensed by us will not be successfully challenged in
the future. In addition, there can be no assurance that our patents will not be infringed or that the coverage of our patents will not be successfully avoided by competitors through design innovation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are aware that others, including universities and companies, have filed patent applications and have been granted patents in the United States and other countries which claim subject
matter potentially useful or necessary to the commercialization of our products. The ultimate scope and validity of existing or future patents which have been or may be granted to third parties, and
the availability and cost of acquiring rights in those patents necessary to the manufacture, use or sale of our products presently cannot be determined by us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=893006,FOLIO='20',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
parties may have or may obtain valid and enforceable patents or proprietary rights that could block us from developing products using our technology,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain patents and applications in the United States and Europe owned by Sanofi, which relate to antibody-antigen conjugates and
methods of their use for eliciting an immune response against the antigen; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain patents and applications in the United States and foreign countries covering particular antigens and antigenic fragments
targeted by our current drug candidates, including CDX-1401; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain patents and pending applications related to particular receptors and other molecules on dendritic cells and macrophages that
may be useful for generating monoclonal antibodies and can be employed in our APC Targeting Technology; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> two United States patents and related foreign patents and applications covering methods of diagnosing gliomas by detecting the
presence of the EGFRvIII (tumor specific splice variant) protein; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a United States patent relating to certain uses of GM-CSF; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a United States patent owned by Genentech,&nbsp;Inc., relating to the production of recombinant antibodies in host cells; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a United States patent owned by GlaxoSmithKline&nbsp;plc related to methods of culturing cells under certain conditions; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain patents held by third parties relating to antibody expression in particular types of host cells. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the patents referred to in the previous paragraphs, there may be other patent applications and issued patents belonging to competitors that may require us to alter our
drug candidates and immunotherapeutic delivery systems, pay licensing fees or cease some of our activities. If our drug candidates conflict with patents that have been or may be granted to
competitors, universities or others, the patent owners could bring legal action against us claiming damages and seeking to enjoin manufacturing and marketing of the patented products. If any of these
actions is successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture or market the affected products. There can be no
assurance that we would prevail in any such action or that any license required under any such third party patent would be made available on acceptable terms or at all. We believe that there may be
significant litigation in the biotechnology industry regarding patent and other intellectual property rights. If we become involved in that litigation, we could consume substantial resources. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Licenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into several significant license agreements relating to technologies that are being developed by us. In general, these
institutions have granted us an exclusive worldwide license (with right to sublicense) to make, use and sell products embodying the licensed technology, subject to the reservation by the licensor of a
non-exclusive right to use the technologies for non-commercial research purposes. Generally, the term of each license is through the expiration of the last of the patents issued with respect to the
technologies covered by the license. We have generally agreed to use reasonable efforts to develop and commercialize licensed products and to achieve specified milestones and pay license fees,
milestone payments and royalties based on the net sales of the licensed products or to pay a percentage of sublicense income. If we breach our obligations, the licensor has the right to terminate the
license, and, in some cases, convert the license to a non-exclusive license. Generally, we control and are responsible for the cost of defending the patent rights of the technologies that we license. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=25,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=861790,FOLIO='21',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Proprietary Rights  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also rely on unpatented technology, trade secrets and confidential information, and no assurance can be given that others will not
independently develop substantially equivalent information and techniques or otherwise gain access to our know-how and information, or that we can meaningfully protect our rights in such unpatented
technology, trade secrets and information. We require each of our employees, consultants and advisors to execute a confidentiality agreement at the commencement of an employment or consulting
relationship with us. The agreements generally provide that all inventions conceived by the individual in the course of employment or in providing services to us and all confidential information
developed by, or made known to, the individual during the term of the relationship shall be the exclusive property of us and shall be kept confidential and not disclosed to third parties except in
limited specified circumstances. There can be no assurance, however, that these agreements will provide meaningful protection for our information in the event of unauthorized use or disclosure of such
confidential information. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our activities and products are significantly regulated by a number of governmental entities, including the FDA in the United States
and by comparable authorities in other countries. These entities regulate, among other things, the manufacture, testing, safety, effectiveness, labeling, documentation, advertising and sale of our
products. We must obtain regulatory approval from FDA and comparable authorities in other countries, as applicable, for our drug candidates before we can commercialize such drugs in the U.S. and
foreign jurisdictions. Product development within this regulatory framework takes a number of years and involves the expenditure of substantial resources. Many products that initially appear promising
ultimately do not reach the market because they are found to be unsafe or ineffective when tested. Our inability to commercialize a product would impair our ability to earn future revenues. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FDA Approval Process  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA regulates drugs and biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, the
Public Health Service Act, or PHSA, and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign
statutes and regulations requires the
expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after
approval may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA's refusal to approve pending applications, withdrawal of an approval, imposition of a clinical
hold, issuance of untitled or warning letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts,
restitution, disgorgement of profits, civil penalties and criminal prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
process required by the FDA before a drug or biological product may be marketed in the United States generally involves the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA's good laboratory
practice, or GLP, regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an IND, which must become effective before human clinical trials may begin; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=26,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=931246,FOLIO='22',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the
safety and efficacy of the proposed drug or biological product for each indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an NDA or BLA, as applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of an FDA advisory committee review, if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess
compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FDA review and approval of the NDA or BLA. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that all of our clinical product candidates will be subject to review as biological products under BLA standards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Data
obtained at any stage of testing is susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. Moreover, during the regulatory process, new or
changed drug approval policies may cause unanticipated delays or rejection of our product. We may not obtain necessary regulatory approvals within a reasonable period of time, if at all, or avoid
delays or other problems in testing our products. Moreover, even if we received regulatory approval for a product, the approval may require limitations on use, which could restrict the size of the
potential market for the product. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Trials  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA provides that human clinical trials may begin thirty (30)&nbsp;days after receipt and review of an IND application, unless
the FDA requests additional information or changes to the study protocol within that period. An IND must be sponsored and filed for each of our proposed products. Authorization to conduct a clinical
trial in no way assures that the FDA will ultimately approve the product. Clinical trials are generally conducted in three sequential phases. In a
Phase&nbsp;1 trial, the product is given to a small number of healthy volunteers to test for safety (adverse effects). Phase&nbsp;2 trials are conducted on a limited group of the target patient
population; safety, optimal dosage and efficacy are studied. A Phase&nbsp;3 trial is performed in a large patient population, generally over a wide geographic area to provide evidence for the safety
and efficacy of the product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
product's safety and effectiveness in one clinical trial is not necessarily indicative of its safety and effectiveness in another clinical trial. Moreover, we may not discover all
potential problems with a product even after completing clinical trials on it. Some of our products and technologies have undergone only preclinical testing. As a result, we do not know whether they
are safe or effective for humans. Also, regulatory authorities may decide, contrary to our findings, that a product is unsafe or not as effective in actual use as its clinical trial results indicated.
This could prevent the product's widespread use, require its withdrawal from the market or expose us to liability. The FDA or the sponsor may suspend or terminate a clinical trial at any time on
various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its
institution if the clinical trial is not being conducted in accordance with the IRB's requirements or if the drug has been associated with unexpected serious harm to patients. Any such action could
materially harm us. Clinical trials are critical to the success of our products but are subject to unforeseen and uncontrollable delay, including delay in enrollment of patients. Any delay in clinical
trials could delay our commercialization of a product. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=27,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=443887,FOLIO='23',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Marketing Approval  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with
detailed information relating to the product's pharmacology chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA or BLA requesting
approval to market the product for one or more indications. FDA approval of the NDA or BLA is required before marketing of the product may begin in the United States. Under federal law, the submission
of most NDAs and BLAs is additionally subject to a substantial application user fee, currently exceeding $2,374,200, and the sponsor of an approved NDA or BLA is also subject to annual product and
establishment user fees, currently exceeding $114,450 per product and $585,200 per establishment. These fees are typically increased annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA conducts a preliminary review of all NDAs and BLAs within the first 60&nbsp;days after receipt before accepting them for filing based on the agency's threshold determination
that they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional
information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The
FDA has agreed to specified performance goals in the review of NDAs and BLAs. Most such applications for non-priority products are reviewed within ten to twelve months after filing, and most
applications for priority review products, that is, drugs and biologics that the FDA determines represent a significant improvement over existing therapy, are reviewed in six to eight months after
filing. The review process may be extended by the FDA for three additional months to consider certain late-submitted information or clarification regarding information already provided in the
submission. The FDA may also refer applications for novel drugs or biological products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel
that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines
that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before
approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP and integrity of the clinical data submitted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
testing and approval process requires substantial time, effort and financial resources, and each may take many years to complete. Data obtained from clinical activities are not
always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may
encounter difficulties or unanticipated costs in our efforts to develop our product candidates and secure necessary governmental approvals, which could delay or preclude us from marketing our
products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the FDA's evaluation of the NDA or BLA and inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter
authorizes commercial marketing of the drug or biological product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the
submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's
satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information
included. Even with </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=28,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=733946,FOLIO='24',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>submission
of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product
labeling, require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess a drug's safety after approval, require testing and surveillance programs to
monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, which can materially affect the potential market and
profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, some types of changes to
the approved product, such as changes in indications, manufacturing changes and labeling, are subject to further testing requirements and FDA review and approval. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Special Regulatory Procedures  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fast track designation</I></FONT><FONT SIZE=2>&#151;The FDA is required to facilitate the development and expedite the review of drugs and biologics that are intended for the
treatment of a serious or life-threatening disease or condition and which demonstrate the potential to address unmet medical needs for the condition. Under the fast track program, the sponsor of a new
drug or biologic candidate may request the FDA to designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the product candidate. A
drug that receives Fast Track designation is eligible for some or all of the following: (i)&nbsp;more frequent meetings with FDA to discuss the drug's development plan and ensure collection of
appropriate data needed to support drug approval; (ii)&nbsp;more frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers;
(iii)&nbsp;eligibility for Accelerated Approval and Priority Review, if relevant criteria are met; and (iv)&nbsp;Rolling Review, which means that a drug company can submit completed sections of
its BLA or NDA for review by FDA, rather than waiting until every section of the NDA or BLA is completed before the entire application can be reviewed. This rolling review is available if the
applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA's time period goal for reviewing a fast
track application does not begin until the last section of the NDA or BLA is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is
no longer supported by data emerging in the clinical trial process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Priority review</I></FONT><FONT SIZE=2>&#151;Under FDA policies, a product candidate may be eligible for priority review, or review within a six to eight month time frame from the
time a complete application is accepted for filing. Products regulated by the FDA's Center for Drug Evaluation and Research, or CDER, are eligible for priority review if they provide a significant
improvement compared to marketed products in the treatment, diagnosis or prevention of a disease. Products regulated by the FDA's Center for Biologics Evaluation and Research, or CBER, are eligible
for priority review if they provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious or life-threatening disease. A fast track designated
product candidate could be eligible for priority review if supported by clinical data at the time of the BLA or NDA submission. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accelerated approval</I></FONT><FONT SIZE=2>&#151;Under the FDA's accelerated approval regulations, the FDA may approve a drug or biologic for a serious or life-threatening
illness that provides meaningful therapeutic benefit to patients over existing treatments based on a surrogate endpoint that is reasonably likely to predict clinical benefit. Surrogate endpoints can
often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the
completion of Phase&nbsp;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=29,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=442656,FOLIO='25',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>during
post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are
subject to prior review by the FDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Breakthrough therapy designation</I></FONT><FONT SIZE=2>&#151;The FDA is also required to expedite the development and review of the application for approval of drugs that are
intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one
or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as
a breakthrough therapy concurrent with, or after, the filing of the IND for the drug candidate. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Orphan drug designation</I></FONT><FONT SIZE=2>&#151;Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or
condition, which is generally defined as a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation does not convey any advantage in, or shorten
the duration of, the regulatory review and approval process. The first NDA or BLA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan
drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve
any other applications to market the same drug or biologic for the same orphan indication, except in limited circumstances. Among the other benefits of orphan drug designation are tax credits for
certain research and a waiver of the NDA or BLA application user fee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pediatric information  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Pediatric Research Equity Act of 2003, an NDA, BLA or supplement to an NDA or BLA must contain data that are adequate to
assess the safety and effectiveness of the drug or biological product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Under the Food and Drug Administration Safety and Innovation Act, or FDASIA, the FDA
has additional authority to take action against manufacturers not adhering to pediatric study requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to
products with orphan drug designation. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post Approval  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any drug or biological products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing
regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse
experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may impose a number of post-approval requirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase&nbsp;4
clinical trials, and surveillance to further assess and monitor the product's safety and effectiveness after
commercialization. Regulatory approval of oncology products often requires that patients in clinical trials be followed for long periods to determine the overall survival benefit of the drug or
biologic. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=30,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=93994,FOLIO='26',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_27"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, drug and biologic manufacturers and other entities involved in the manufacture and distribution of approved drugs and biological products are required to register their
establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. The FDA was also granted
new inspection authorities under FDASIA. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require
investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain cGMP compliance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches
the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition
of distribution or other restrictions under a Risk Evaluation and Mitigation Strategy program. Other potential consequences include, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines, untitled and warning letters or holds on post-approval clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product
license approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product seizure or detention, or refusal to permit the import or export of products; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> consent decrees, injunctions or the imposition of civil or criminal prosecution. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications
and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses, and a company that is
found to have improperly promoted off label uses may be subject to significant liability. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Biosimilars Law  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Biologics Price Competition and Innovation Act of 2009, or BPCIA, amended the PHSA to provide for an abbreviated approval pathway
for biological products that demonstrate biosimilarity to a previously-approved biological product. The BPCI Act establishes criteria for determining that a product is biosimilar to an
already-licensed biologic, or reference product, and establishes a process by which an abbreviated BLA for a biosimilar product is submitted, reviewed and approved. The BPCI Act provides periods of
exclusivity that protect a reference product from biosimilars competition. Under the BPCI Act, the FDA may not accept a biosimilar application for review until four years after the date of first
licensure of the reference product, and the biosimilar may not be licensed until 12&nbsp;years after the reference product's approval. Additionally, the BPCI Act establishes procedures by which the
biosimilar applicant must provide information about its application and product to the reference product sponsor, and by which information about potentially relevant patents is shared and litigation
over patents may proceed in advance of approval. The BPCI Act also provides a period of exclusivity for the first biosimilar to be determined by the FDA to be interchangeable with the reference
product. The BPCIA may be applied to our drug candidates in the future and could be applied to allow approval of biosimilars to our products. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=31,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=166812,FOLIO='27',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA has not yet issued proposed regulations setting forth its interpretation of the BPCIA's provisions but has issued guidance documents related to BPCIA implementation. Because the
BPCI Act is a relatively new law, we anticipate that its contours will be defined as the statute is implemented over a period of years. This likely will be accomplished by a variety of means,
including FDA issuance of guidance documents, proposed regulations and decisions in the course of considering specific applications. Such evolution may significantly affect the impact of the BPCI Act
on both reference product and biosimilar sponsors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Companion Diagnostic Review and Approval  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that some of our drug candidates, including Rintega, will rely on the use of a companion diagnostic. Companion diagnostics
are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate clearance or approval prior to their commercialization. Based on the guidance
published by the FDA in July 2014 and the FDA's past treatment of companion diagnostics, we believe that the FDA will likely require one or more of our </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> companion diagnostics to obtain Premarket Approval Application, or PMA, in conjunction with approval of the related drug candidate. The receipt and timing of PMA approval
may have a significant effect on the receipt and timing of commercial approval for such drug candidates. Currently we rely on third party collaborators to develop companion diagnostics for our drug
candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
PMA process is costly, lengthy and uncertain. PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical,
preclinical, clinical and manufacturing data, to demonstrate to the FDA's satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data
regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance
with the Quality System Regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. If the FDA evaluations of both the
PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in
order to secure the final approval of the PMA. If the FDA's evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter.
A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional
clinical trials are necessary, in which case the PMA approval may be delayed while the trials are conducted and then the data submitted in an amendment to the PMA. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
even after PMA approval is obtained, numerous regulatory requirements apply to the manufacturer of the companion diagnostic. The FDA enforces these requirements by
inspection and market surveillance. These requirements include: the QSR, labeling regulations, the FDA's general prohibition against promoting products for unapproved or "off label" uses, the medical
device reporting regulation, and the reports of corrections and removals regulation. If the FDA finds a violation, it can institute a wide variety of enforcement actions, ranging from a public warning
letter to more severe sanctions such as: fines, injunctions and civil penalties; recall or seizure of products; operating restrictions, partial suspension or total shutdown of production; refusing
requests for PMA of new products; and withdrawing PMAs already granted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal and State Fraud and Abuse, Data Privacy and Security and Transparency Laws  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to FDA restrictions on marketing and promotion of pharmaceutical products, several other types of federal and state laws
have been applied to restrict certain marketing business practices in the biopharmaceutical and medical device industries in recent years. These laws include, without limitation, state and federal
anti-kickback statutes and false claims statutes and false claims laws, data </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=32,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=392037,FOLIO='28',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>privacy
and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. Applicable state law may be broader in scope than federal law and
may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. If our operations are found to be in violation of any of the health regulatory laws
described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines, disgorgement,
imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the
curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold
in a foreign country, we may be subject to similar foreign laws, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and
implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the United States Foreign Corrupt Practices Act, or FCPA, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to
influence a person
working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any official of another country, government staff member, political party or
political candidate in an attempt to obtain or retain business or to otherwise influence a person working in that capacity. In many countries, the healthcare professionals we may interact with may
meet the FCPA's definition of a foreign government official. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Regulation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market any therapeutic or diagnostic product outside of the United States, we need to comply with numerous and varying
regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products.
Whether or not we obtain FDA approval for a product, we need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or
marketing of the product in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time
required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in
another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the EU regulatory system, we will submit most of our marketing authorization applications under the centralized procedure. The centralized procedure is compulsory for medicines
produced by biotechnology, or are for the treatment of cancer, or officially designated as 'orphan medicines'. The centralized procedure provides for the grant of a single marketing authorization that
is valid for all EU member states. As in the United States, we may apply for designation of our products as orphan drug for the treatment of a specific indication in the EU before the application for
marketing authorization is made. The EMA grants orphan medicinal product designation to promote the development of products that may offer therapeutic benefits for life-threatening or chronically
debilitating conditions affecting not more than five in 10,000 people in the EU. Orphan drugs in Europe enjoy economic and marketing benefits, including a 10-year market exclusivity period for the
approved indication, but not for the same product, unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=33,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=368023,FOLIO='29',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Regulatory Processes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions
governing the testing, approval, manufacturing and marketing of products regulated by the FDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is
impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations changed or what the effect of such changes, if any, may be. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Third-Party Payor Coverage and Reimbursement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory
approval. Sales of any of our drug candidates, if approved, will depend, in part, on the extent to which the costs of the drugs will be covered by third-party payors, including government health
programs such as Medicare and Medicaid, as well as commercial health insurers, such as managed care organizations. The process for determining reimbursement rates is separate from the payor coverage
decision. Therefore, despite obtaining coverage, reimbursement rates may be lower than expected, which can result in larger out-of-pocket payments for the patient. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to secure coverage and reimbursement for any drug that might be approved for sale, we need to conduct analyses and pharmaco-economic studies in order to demonstrate the
incremental medical benefit over and above the generally-accepted standard of care and cost-effectiveness of the drug. Our drug candidates may not be considered medically necessary, provide
insufficient incremental medical benefit, or may not be deemed cost-effective. A payor's decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be
approved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are
increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety
and efficacy. If these third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their
plans or, if they do, the level of reimbursement and/or restrictions in formulary placement may be such that they would significantly
limit projected sales volumes. In addition to third party payors, we will also need to negotiate formulary placement with hospitals, health systems and certain independent delivery networks. Such
negotiations may be more protracted than anticipated and may be compromised because of similar considerations, relating to insufficient incremental medical benefit and/or cost-effectiveness. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pricing
and reimbursement schemes vary widely from country to country. For example, certain EU member states may approve a specific price and volume for a drug product after which
incremental revenues or profits need to be paid back by way of rebates. They may also institutionalize utilization restrictions, curb physicians' drug budgets, provide conditional reimbursement
schemes that require additional evidence to be generated post-marketing authorization, etc. The downward pressure on healthcare costs in general, particularly prescription drugs, has been particularly
evident in EU markets, for some time, with evidence pointing to increasing pressures on the horizon. As a result, increasingly high barriers are being erected to the pricing and reimbursement of new
drugs, despite regulatory efforts to bring drugs to market sooner. In addition, cross-border trade has existed for some time in the EU, allowing pharmacies in one country to import, at a lower price,
drug from another country, further exerting pricing pressures across the EU. There can be no assurance that any country that has price controls or reimbursement limitations for drug products will
allow favorable reimbursement and pricing arrangements for any of our drugs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=34,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=196597,FOLIO='30',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_31"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
marketability of any drugs for which we receive regulatory approval for commercial sale may suffer if third-party payors and/or hospital administrators fail to provide adequate
coverage, reimbursement or formulary placement. Coverage policies, third-party reimbursement rates and drug pricing regulations may change in the future. In particular, uncertainty within, and over
the long-term, of the Patient Protection and Affordable Care Act, or PPACA, in the U.S., may mean that coverage, reimbursement and pricing structures available today may be different in the future. In
addition, the States may continue to consider legislation of their own which could further restrict the ability to freely price drugs and/or curb utilization in the U.S. Even if favorable coverage and
reimbursement status is attained for one or more drugs for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2015, we employed 199 employees (196 full-time, 1 part-time and 2 interns), 36 of whom have Ph.D. and/or M.D.
degrees. Of these employees, 162 were engaged in or directly support research and development activities. We believe that our employee relations are good. We believe that our future success will
depend in large part on our ability to attract and retain experienced and skilled employees. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate and Available Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are incorporated in Delaware. In February 2016, we formed a wholly-owned subsidiary, Celldex Therapeutics Europe&nbsp;GmbH, in
Zug, Switzerland, to operate as Celldex' European headquarters when European operations commence, pursuant to intercompany agreements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
website is located at </FONT><FONT SIZE=2><I>http://www.celldex.com.</I></FONT><FONT SIZE=2> On our website, investors can obtain, free of charge, a copy of our Annual Report on
Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, other reports and any amendments thereto filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of
the Exchange Act of 1934, as amended, as soon as reasonably practicable after we file such material electronically with, or furnish it to, the Securities and Exchange Commission, or SEC. None of the
information posted on our website is incorporated by reference into this Annual Report.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dg72301_item_1a._risk_factors"> </A>
<A NAME="toc_dg72301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should consider carefully these risk factors together with all of the information included or incorporated by reference in this
Annual Report in addition to our financial statements and the notes to our financial statements. This section includes forward-looking statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following is a discussion of the risk factors that we believe are material to us at this time. These risks and uncertainties are not the only ones facing us and there may be
additional matters that we are unaware of or that we currently consider immaterial. All of these could adversely affect our business, results of operations, financial condition and cash flows. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to our Financial Condition and Capital Requirements  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently have no product revenue and will need to raise capital to operate our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have generated no product revenue and cannot predict when and if we will generate product revenue. We had an accumulated
deficit of $591.0&nbsp;million as of December&nbsp;31, 2015. Until, and unless, we complete clinical trials and further development, and receive approval from the FDA and other regulatory
authorities, for Rintega and our other drug candidates, we cannot sell our drugs and will not have product revenue. We expect to spend substantial funds to continue the research, development and
testing of our products that are in the preclinical and clinical testing stages of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=35,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=999681,FOLIO='31',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<A NAME="page_dg72301_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>development
and to prepare to commercialize products in anticipation of FDA approval. Therefore, for the foreseeable future, we will have to fund all of our operations and development expenditures
from cash on hand, equity or debt financings, licensing fees and grants. Additional financing will be required to meet our long term liquidity needs. If we do not succeed in raising additional funds
on acceptable terms, we might not be able to complete planned preclinical and clinical trials or obtain approval of any drug candidates from the FDA and other regulatory authorities. In addition, we
could be forced to discontinue product development, reduce or forego sales and marketing efforts, forego attractive business opportunities or curtail operations. Any additional sources of financing
could involve the issuance of our equity securities, which would have a dilutive effect on our stockholders. No assurance can be given that additional financing will be available to us when needed on
acceptable terms, or at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that we will achieve or sustain profitability in the future. Failure to achieve profitability could diminish our ability to sustain operations, pay dividends on our
common stock, obtain additional required funds and make required payments on our present or future indebtedness. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We expect to incur future losses and we may never become profitable.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred operating losses of $129.5&nbsp;million, $122.4&nbsp;million and $81.4&nbsp;million during 2015, 2014 and 2013,
respectively, and expect to incur an operating loss in 2016. We believe that operating losses will continue in 2016 because we are planning to incur significant costs associated with the clinical
development, manufacturing of commercial supply and building a commercial organization to prepare for the potential commercial launch of Rintega and
glembatumumab vedotin if regulatory approval is obtained. During the years ended December&nbsp;31, 2015, 2014 and 2013, we incurred $36.3&nbsp;million, $45.6&nbsp;million and
$32.3&nbsp;million in clinical trial expense and $14.8&nbsp;million, $21.2&nbsp;million and $6.6&nbsp;million in contract manufacturing expense. We anticipate clinical trial and contract
manufacturing expense to increase over the next twelve months related to our Rintega, glembatumumab vedotin and varlilumab programs. In addition, we are planning to incur additional costs in the
clinical development of CDX-1401 and CDX-301. Our net losses have had and will continue to have an adverse effect on, among other things, our stockholders' equity, total assets and working capital. We
expect that losses will fluctuate from quarter to quarter and year to year, and that such fluctuations may be substantial. We cannot predict when we will become profitable, if at all. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need additional capital to fund our operations, including the development, manufacture and
potential commercialization of our drug candidates. If we do not have or cannot raise additional capital when needed, we may be unable to develop and ultimately commercialize our drug candidates
successfully.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to incur significant costs as we develop our drug candidates. In particular, the continuing development and commercialization
of Rintega, glembatumumab vedotin and our other drug candidates requires additional capital beyond our current resources. As of December&nbsp;31, 2015, we had cash, cash equivalents and marketable
securities of $289.9&nbsp;million. During the next twelve months, we may take further steps to raise additional capital to fund our long-term liquidity needs. Our capital raising activities may
include, but may not be limited to, one or more of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> licensing of drug candidates with existing or new collaborative partners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> possible business combinations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issuance of debt; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issuance of common stock or other securities via private placements or public offerings. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=36,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=451076,FOLIO='32',FILE='DISK133:[15ZCW1.15ZCW72301]DG72301A.;7',USER='CHE108057',CD='19-FEB-2016;19:34' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di72301_1_33"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we may continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at
all, and our negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that we will be able to enter into further collaborative
relationships. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability
to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce our economic potential from products under development. If we are unable to
raise the funds necessary to meet our long-term liquidity needs, we may have to delay or discontinue the development of one or more programs, discontinue or delay the build-out of our commercial
infrastructure and our commercial planning and preparation activities, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at
significant discount or on other unfavorable terms, if at all, or sell all or part of our business. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Development and Regulatory Approval of Drug Candidates  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our long term success depends heavily on our ability to fund and complete the research and
development activities and obtain regulatory approval for our program assets, including our lead drug candidates, Rintega and glembatumumab vedotin.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are particularly dependent on the future success of Rintega and glembatumumab vedotin because they are our most advanced drug
candidates. Our management team lacks significant experience in completing Phase&nbsp;3 clinical trials and obtaining regulatory approval for a drug candidate. Only a small minority of all research
and development programs ultimately result in commercially successful drugs. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive
results, and we may decide, or regulators may require us, to conduct additional clinical or preclinical trials. In addition, data obtained from trials are susceptible to varying interpretations, and
regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Success in preclinical testing and early clinical trials does not ensure that later
clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a drug candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we face delays, difficulties or unanticipated costs in completing the development of Rintega or glembatumumab vedotin, we will need substantial additional financing. Further, even if
we complete the development of Rintega or glembatumumab vedotin and gain marketing approvals from the FDA and comparable foreign regulatory authorities in a timely manner, we cannot be sure that
Rintega or glembatumumab vedotin will be commercially successful in the pharmaceutical market. If the results of clinical trials, the anticipated or actual timing of marketing approvals, or the market
acceptance of Rintega or glembatumumab vedotin, if approved, do not meet the expectations of investors or public market analysts, the market price of our common stock would likely decline. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may enter into collaboration agreements for the licensing, development and ultimate
commercialization of some of our drug candidates including, where appropriate, for our lead drug candidates. In such cases, we will depend greatly on our third-party collaborators to license, develop
and commercialize such drug candidates, and they may not meet our expectations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may enter into co-development and commercialization partnerships for certain products, including Rintega for commercialization
outside of North America and Europe,
glembatumumab vedotin and varlilumab. The process of identifying collaborators and negotiating collaboration agreements for the licensing, development and ultimate commercialization of some of our
drug candidates may cause delays and increased costs. We may not be able to enter into collaboration agreements on terms favorable to us or at all. Furthermore some of those agreements may give
substantial responsibility over our drug candidates to the collaborator. Some collaborators may be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=37,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=907827,FOLIO='33',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>unable
or unwilling to devote sufficient resources to develop our drug candidates as their agreements require. They often face business risks similar to ours, and this could interfere with their
efforts. Also, collaborators may choose to devote their resources to products that compete with ours. If a collaborator does not successfully develop any one of our products, we will need to find
another collaborator to do so. The success of our search for a new collaborator will depend on our legal right to do so at the time and whether the product remains commercially viable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we enter into collaboration agreements for one or more of our lead drug candidates, the success of such drug candidates will depend in great part upon our and our collaborators'
success in promoting them as superior to other treatment alternatives. We believe that our drug candidates can be proven to offer disease prevention and treatment with notable advantages over drugs in
terms of patient compliance and effectiveness. However, there can be no assurance that we will be able to prove these advantages or that the advantages will be sufficient to support the successful
commercialization of our drug candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our drug candidates are subject to extensive regulatory scrutiny.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our drug candidates are at various stages of development and our activities and drug candidates are significantly regulated by a
number of governmental entities, including the FDA in the United States and by comparable authorities in other countries. These entities regulate, among other things, the manufacture, testing, safety,
effectiveness, labeling, documentation, advertising and sale of drugs and drug candidates. We or our partners must obtain regulatory approval for a drug candidate in all of these areas before we can
commercialize any of our drug candidates. Product development within this regulatory framework takes a number of years and involves the expenditure of substantial resources. This process typically
requires extensive preclinical and clinical testing, which may take longer or cost more than we anticipate, and may prove unsuccessful due to numerous factors. Many drug candidates that initially
appear promising ultimately do not reach the market because they are found to be unsafe or ineffective when tested. Companies in the pharmaceutical, biotechnology and immunotherapeutic drug industries
have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. Our inability to commercialize a drug candidate would impair our ability to
earn future revenues. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our drug candidates do not pass required tests for safety and effectiveness, we will not be able
to obtain regulatory approval and derive commercial revenue from them.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to succeed, we will need to obtain regulatory approval for our drug candidates. The FDA has not approved our lead drug
candidates, Rintega or glembatumumab vedotin, or any of our other products for sale to date. Our drug candidates are in various stages of preclinical and clinical testing. Preclinical tests are
performed at an early stage of a product's development and provide information about a product's safety and effectiveness on laboratory animals. Preclinical tests can last years. If a product passes
its preclinical tests satisfactorily, and we determine that further development is warranted, we would file an IND application for the product with the FDA, and if the FDA gives its approval we would
begin Phase&nbsp;1 clinical tests. Phase&nbsp;1 testing generally lasts between 6 and 24&nbsp;months. If Phase&nbsp;1 test results are satisfactory and the FDA gives its approval, we can begin
Phase&nbsp;2 clinical tests. Phase&nbsp;2 testing generally lasts between 6 and 36&nbsp;months. If Phase&nbsp;2 test results are satisfactory and the FDA gives its approval, we can begin
Phase&nbsp;3 pivotal studies. Phase&nbsp;3 studies generally last between 12 and 48&nbsp;months. Once clinical testing is completed and a BLA or NDA is filed with the FDA, it may take more than
a year to receive FDA approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
all cases we must show that a pharmaceutical product is both safe and effective before the FDA, or drug approval agencies of other countries where we intend to sell the product, will
approve it for sale. Our research and testing programs must comply with drug approval requirements both in the United States and in other countries, since we are developing our lead products with the
intention to, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=38,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=391308,FOLIO='34',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>or
could later decide to, commercialize them both in the U.S. and abroad. A product may fail for safety or effectiveness at any stage of the testing process. A major risk we face is the possibility
that none of our products under development will come through the testing process to final approval for sale, with the result that we cannot derive any commercial revenue from them after investing
significant amounts of capital in multiple stages of preclinical and clinical testing. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be unable to manage multiple late stage clinical trials for a variety of drug candidates
simultaneously.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our current clinical trials progress, we may need to manage multiple late stage clinical trials simultaneously in order to continue
developing all of our current products. Our management team does not have significant experience in completing late stage clinical trials and the
management of late stage clinical trials is more complex and time consuming than early stage trials. Typically, early stage trials involve several hundred patients in no more than 10-30 clinical
sites. Late stage (Phase&nbsp;3) trials may involve up to several thousand patients in up to several hundred clinical sites and may require facilities in several countries. Therefore, the project
management required to supervise and control such an extensive program is substantially larger than early stage programs. As the need for these resources is not known until some months before the
trials begin, it is necessary to recruit large numbers of experienced and talented individuals very quickly. If the labor market does not allow this team to be recruited quickly, the sponsor is faced
with a decision to delay the program or to initiate it with inadequate management resources. This may result in recruitment of inappropriate patients, inadequate monitoring of clinical investigators
and inappropriate handling of data or data analysis. Consequently it is possible that conclusions of efficacy or safety may not be acceptable to permit filing of a BLA or NDA for any one of the above
reasons or a combination of several. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Product testing is critical to the success of our products but subject to delay or cancellation if
we have difficulty enrolling patients.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our portfolio of drug candidates moves from preclinical testing to clinical testing, and then through progressively larger and more
complex clinical trials, we will need to enroll an increasing number of patients with the appropriate characteristics. At times we have experienced difficulty enrolling patients and we may experience
more difficulty as the scale of our clinical testing program increases. The factors that affect our ability to enroll patients are largely uncontrollable and include principally the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the nature of the clinical test; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the size of the patient population; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patients' willingness to receive a placebo or less effective treatment on the control arm of a clinical study; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the distance between patients and clinical test sites; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the eligibility criteria for the trial. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we cannot enroll patients as needed, our costs may increase or we may be forced to delay or terminate testing for a product. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may have delays in completing our clinical trials and we may not complete them at all.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not completed the clinical trials necessary to obtain FDA approval to market Rintega, glembatumumab vedotin or any of our other
products in development. Other than ACT IV and METRIC which is designed for approval, we have not initiated Phase&nbsp;3 studies for any of our other products in development. Our management lacks
significant experience in completing Phase&nbsp;3 trials and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=39,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=651413,FOLIO='35',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>bringing
a drug through commercialization. ACT IV and METRIC and clinical trials for other products in development may be delayed or terminated as a result of many factors, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> difficulty in enrolling patients in our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patients failing to complete clinical trials due to dissatisfaction with the treatment, side effects or other reasons; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure by regulators to authorize us to commence a clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension or termination by regulators of clinical research for many reasons, including concerns about patient safety or failure of
our contract manufacturers to comply with cGMP requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays or failure to obtain clinical supply for our products necessary to conduct clinical trials from contract manufacturers,
including commercial grade clinical supply for our Phase&nbsp;3 clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> treatment candidates demonstrating a lack of efficacy during clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> inability to continue to fund clinical trials or to find a partner to fund the clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> competition with ongoing clinical trials and scheduling conflicts with participating clinicians; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delays in completing data collection and analysis for clinical trials. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
delay or failure to complete clinical trials and obtain FDA approval for our drug candidates could have a material adverse effect on our cost to develop and commercialize, and our
ability to generate revenue from, a particular drug candidate. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics
for certain of our drug candidates, including our lead drug candidate Rintega, could harm our drug development strategy and operational results.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an element of our clinical development approach, we may seek to screen and identify subsets of patients that express a certain
biomarker or that have a certain genetic alteration who may derive meaningful benefit from our development drug candidates. To achieve this, one or more of our drug development programs may be
dependent on the development and commercialization of a companion diagnostic by us or by third party collaborators. For example, we have engaged a third party collaborator to develop a companion
diagnostic test to identify patients with EGRFvIII for use with our lead drug candidate Rintega and such companion diagnostic requires separate approval by the FDA, for which we must rely on our third
party collaborator to obtain. Companion diagnostics are developed in conjunction with clinical programs for the associated drug candidate. Companion diagnostics are subject to regulation as medical
devices and must themselves be approved for marketing by the FDA or certain other foreign regulatory agencies before the related drug candidate may be commercialized. The approval of a companion
diagnostic as part of the product label will limit the use of the drug candidate to only those patients who express the specific genetic alteration it was developed to detect. We or our third party
collaborators may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners or negotiating insurance
reimbursement for such companion diagnostic, all of which may prevent us from completing our clinical trials or commercializing our drugs on a timely or profitable basis, if at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, the FDA has required premarket approval of all companion diagnostics for cancer therapies. We and our third-party collaborators may encounter difficulties in developing and
obtaining approval for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent
approval of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=40,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=620699,FOLIO='36',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>our
related drug candidates or, if regulatory approval is obtained, delay or limit our ability to commercialize our related drug candidates. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any delay in obtaining regulatory approval would have an adverse impact on our ability to earn
future revenues.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is possible that none of the drug candidates that we develop will obtain the regulatory approvals necessary for us to begin
commercializing them. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the nature of the drug
candidate. Any analysis we perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval.
Rintega has been granted Breakthrough Therapy designation for the treatment of adult patients with EGFRvIII-positive glioblastoma and Fast Track designation by the FDA. Glembatumumab vedotin has been
granted Fast Track designation by the FDA. Breakthrough Therapy and Fast Track designation do not change the standards for approval but may expedite the development or approval process. Such
designations do not guaranteed a faster review time as compared to other drugs and do not ensure that the drug will ultimately obtain marketing approval. In addition, the FDA may withdraw these
designations at any time. Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular drug candidate including,
but not limited to, loss of patent term during the approval period. Furthermore, if we, or our partners, do not reach the market with our products before our competitors offer products for the same or
similar uses, or if we, or our partners, are not effective in marketing our products, our revenues from product sales, if any, will be reduced. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large pharmaceutical companies,
firms specialized in the development and production of vaccines, adjuvants and vaccine and immunotherapeutic delivery systems and major universities and research institutions. Competitors that we are
aware of that have initiated a Phase&nbsp;3 study or have obtained marketing approval for a potential competitive drug/device for Rintega in the treatment of glioblastoma and/or glembatumumab
vedotin in the treatment of breast cancer include AbbVie, Arbor Pharmaceutics,&nbsp;Inc., AstraZeneca&nbsp;PLC, Bayer, Bristol-Myers Squibb, Celgene Corporation, Eisai&nbsp;Inc., Eli Lilly and
Company, Medigene AG, Northwest Biotherapeutics,&nbsp;Inc., Novartis, Novocure, Pfizer&nbsp;Inc., and Roche. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Most
of our competitors have substantially greater resources, more extensive experience in conducting preclinical studies and clinical testing and obtaining regulatory approvals for
their products, greater operating experience, greater research and development and marketing capabilities and greater production capabilities than those of ours. These companies might succeed in
obtaining regulatory approval for competitive products more rapidly than we can for our products, especially if we experience any delay in obtaining required regulatory approvals. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A fast track designation or grant of priority review status by the FDA may not actually lead to a
faster development or regulatory review or approval process.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, Rintega and glembatumumab vedotin have received fast track designation and may be eligible for priority review
status. If a drug is intended for the treatment of a serious or life-threatening disease or condition and the drug demonstrates the potential to address unmet medical needs for this disease or
condition, the drug sponsor may apply for FDA fast track designation. If a drug offers major advances in treatment, the drug sponsor may apply for FDA priority review status. The FDA has broad
discretion whether or not to grant fast track designation or priority review status, so even if we believe a particular drug candidate is eligible for such designation or status, the FDA could decide
not to grant it. Even though Rintega and glembatumumab vedotin have received fast track designation and may be eligible for priority review status, we may not experience a faster development </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=41,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=818222,FOLIO='37',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_38"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>process,
review or approval compared to conventional FDA procedures. Furthermore, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from
our clinical development program. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have many competitors in our field and they may develop technologies that make ours obsolete.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biotechnology, pharmaceuticals and therapeutics are rapidly evolving fields in which scientific and technological developments are
expected to continue at a rapid pace. We have many competitors in the U.S. and abroad. Competitors that we are aware of that have initiated a Phase&nbsp;3 study or have obtained marketing approval
for a potential competitive drug/device for Rintega in the treatment of glioblastoma and/or glembatumumab vedotin in the treatment of breast cancer include AbbVie, Arbor Pharmaceutics,&nbsp;Inc.,
AstraZeneca&nbsp;PLC, Bayer, Bristol-Myers Squibb, Celgene Corporation, Eisai&nbsp;Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics,&nbsp;Inc., Novartis, Novocure,
Pfizer&nbsp;Inc., and Roche. Our success depends upon our ability to develop and maintain a competitive position in the product categories and technologies on which we focus. Many of our competitors
have greater capabilities, experience and financial resources than we do. Competition is intense and is expected to increase as new products enter the market and new technologies become available. Our
competitors may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> develop technologies and products that are more effective than ours, making ours obsolete or otherwise noncompetitive; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain regulatory approval for products more rapidly or effectively than us; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain patent protection or other intellectual property rights that would block our ability to develop competitive products. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Commercialization of Our Drug Candidates  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may face delays, difficulties or unanticipated costs in establishing sales and distribution
capabilities for the commercialization of Rintega, if regulatory approval is obtained, or any other of our drug candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are in the process of building a commercial organization which we believe will provide us with the strategic options to either
retain full economic rights to our drug candidates or seek favorable economic terms through advantageous commercial partnerships. We plan to commercialize our lead drug candidate Rintega ourselves in
North America and Europe. As a result, we may have full responsibility for commercialization of Rintega and our other drug candidates if and when they are approved for sale. We currently lack
sufficient marketing, sales and distribution capabilities to carry out this strategy. If any of our drug candidates are approved by the FDA, we will need a drug sales force with technical expertise
prior to the commercialization of any of our drug candidates. We have recently established a core commercial team with experience in commercialization of immune-modulating and oncology products in
preparation for a potential commercial launch of Rintega. Although our core commercial team has engaged qualified external consultants and vendors to help establish sales and distribution capabilities
for Rintega, we may not succeed in developing such sales and distribution capabilities, the cost of establishing such sales and distribution capabilities may exceed any product revenue, or our direct
marketing and sales efforts may be unsuccessful. We may find it necessary to enter into strategic partnerships, co-promotion or other licensing arrangements and to the extent we enter into such
strategic partnerships, co-promotion or other licensing arrangements, our product revenues are likely to be lower than if we directly marketed and sold such drugs, and some
or all of the revenues we receive will depend upon the efforts of third parties, which may not be successful and may not be within our control. If we are unable to enter into such strategic
partnerships, co-promotion or other licensing arrangements on acceptable terms or at all, we may not be able to successfully commercialize our existing and future drug candidates. If we are not
successful in commercializing Rintega or any of our other drug candidates, either on our own or through collaborations with one or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=42,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=748671,FOLIO='38',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>more
third parties, our future product revenue will suffer and we may never achieve profitability or become unable to continue the operation of our business. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to effectively recruit and train a sales force, our ability to successfully
commercialize Rintega will be harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If regulatory approval is obtained, we need to recruit and train a sales force prior to commercial launch. Rintega will be a
newly-marketed drug with a specific patient population. As a result, we will be required to expend significant time and resources to recruit and train a specialty sales force to be credible and
effective in marketing Rintega for use in front-line glioblastoma in patients that express a specific cancer marker known as EGFRvIII. If we are unable to effectively train a specialty sales force and
equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits of Rintega, we may not be able to successfully
commercialize Rintega. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If Rintega or any other drug candidates for which we obtain regulatory approval do not achieve broad
acceptance from physicians, patients and third-party payors, we may be unable to generate significant revenues, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we obtain regulatory approval for our drug candidates, our approved drugs may not gain market acceptance among physicians and
patients. We believe that effectively marketing Rintega, if it is approved, and our other drug candidates, if any of them are approved, will require substantial efforts, both prior to commercial
launch and after approval. Physicians may elect not to prescribe our drugs, and patients may elect not to request or take them, for a variety of reasons
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitations or warnings contained in a drug's FDA-approved labeling; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the standard of care or the availability of alternative drugs for the targeted indications for any of our drug candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitations in the approved indications for our drug candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approval, availability, market acceptance and reimbursement for the companion diagnostic, where applicable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> demonstrated clinical safety and efficacy compared to other drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> significant adverse side effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> effectiveness of education, sales, marketing and distribution support; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> timing of market introduction and perceived effectiveness of competitive drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cost-effectiveness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> adverse publicity about our drug candidates or favorable publicity about competitive drugs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> convenience and ease of administration of our drug candidates; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> willingness of third-party payors to reimburse for the cost of our drug candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our future drugs fail to achieve market acceptance, we will not be able to generate significant revenues and may never achieve profitability. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=43,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=210486,FOLIO='39',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if our lead drug candidate Rintega or any of our other drug candidates receives FDA approval,
the terms of the approval may limit such drug's commercial potential. Additionally, even after receipt of FDA approval, such drug would be subject to substantial, ongoing regulatory requirements.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA has complete discretion over the approval of our lead drug candidate Rintega and our other drug candidates. If the FDA grants
approval, the scope of the approval may limit our ability to commercialize such drug, and in turn, limit our ability to generate substantial product revenue. For example, the FDA may grant approval
contingent on the performance of costly post-approval clinical trials or subject to warnings or contraindications. Additionally, even after granting approval, the manufacturing processes, labeling,
packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for such drug will be subject to extensive and ongoing regulatory requirements. In addition,
manufacturers of our drug products are required to comply with cGMP regulations, which include requirements related to quality control and quality assurance as well as the corresponding maintenance of
records and documentation. Further, regulatory authorities must inspect and approve these manufacturing facilities before they can be used to manufacture our drug products, and these facilities are
subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If we or a third party discover previously unknown problems with
a drug, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug is manufactured, a regulatory authority may impose restrictions on that product, the
manufacturer or us, including requiring withdrawal of the drug from the market or suspension of manufacturing. If we, our drug candidates or the manufacturing facilities for our drug candidates fail
to comply with regulatory requirements of the FDA and/or other non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> warning letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> civil or criminal penalties and fines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> consent decrees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension or withdrawal of regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension of any ongoing clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voluntary or mandatory product recalls and publicity requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to accept or approve applications for marketing approval of new drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on operations, including costly new manufacturing requirements; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seizure or detention of drugs or import bans. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
regulatory requirements and policies may change and additional government regulations may be enacted for which we may also be required to comply. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we are not able to maintain regulatory
compliance, we may not be permitted to market our future products and our business may suffer. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Reimbursement decisions by third-party payors may have an adverse effect on pricing and market
acceptance of Rintega or any of our other drug candidates. If there is not sufficient reimbursement for our future drugs, it is less likely that such drugs will be widely used.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market acceptance and sales of Rintega, if regulatory approval is obtained, or any other drug candidates for which we obtain regulatory
approval will depend on reimbursement policies and may be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=44,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=654039,FOLIO='40',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>affected
by future healthcare reform measures in both the United States and foreign jurisdictions. Government authorities and third-party payors, such as private health insurers and health maintenance
organizations, decide which drugs they will cover and establish payment levels. In addition, government authorities and these third-party payors are increasingly attempting to contain health care
costs by demanding price discounts or rebates and limiting both the types and variety of drugs that they will cover and the amounts that they will pay for these drugs. In addition, we might need to
conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future drugs to such payors' satisfaction. Such studies might require us to commit a significant amount of
management time and financial and other resources. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reimbursement
rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower-cost products that are already
reimbursed, may be incorporated into existing payments for other products or services, and may reflect budgetary constraints and/or imperfections in Medicare or Medicaid data used to calculate these
rates. Net prices for drugs may be reduced by mandatory discounts or rebates required by government health care programs. Such legislation, or similar regulatory changes or relaxation of laws that
restrict imports of drugs from other countries, could reduce the net price we receive for any future marketed drugs. As a result, our future drugs might not ultimately be considered cost-effective. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that reimbursement will be available for Rintega or any other drug candidates that we develop. Also, we cannot be certain that reimbursement policies will not reduce
the demand for, or the price paid for, any future drugs. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize Rintega or any other
drug candidates that we develop. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Other factors could affect the demand for and sales and profitability of any drug candidates that we
may commercialize in the future.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, other factors that could affect the demand for and sales and profitability of our future drugs include, but are not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of regulatory approval, if any, of competitive drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our or any other of our partners' pricing decisions, as applicable, including a decision to increase or decrease the price of a drug,
and the pricing decisions of our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> government and third-party payor reimbursement and coverage decisions that affect the utilization of our future drugs and competing
drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> negative safety or efficacy data from new clinical studies conducted either in the U.S. or internationally by any party could cause
the sales of our future drugs to decrease or a future drug to be recalled; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the degree of patent protection afforded our future drugs by patents granted to or licensed by us and by the outcome of litigation
involving our or any of our licensor's patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the outcome of litigation involving patents of other companies concerning our future drugs or processes related to production and
formulation of those drugs or uses of those drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the increasing use and development of alternate therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate of market penetration by competing drugs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the termination of, or change in, existing arrangements with our partners. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on the sales of any drug candidates that we may commercialize in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=45,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=934676,FOLIO='41',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to obtain regulatory approvals in foreign jurisdictions will prevent us from marketing our
products internationally.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to seek approval for Rintega in Europe and may seek approval of our other drug candidates outside the United States and may
market future products in international markets. In order to market our future products in the European Economic Area, or EEA, and many other foreign jurisdictions, we must obtain separate regulatory
approvals. Specifically, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
granting the MA, the European Medicines Agency or the competent authorities of the member states of the EEA make an assessment of the risk-benefit balance of the product on the
basis of scientific criteria concerning its quality, safety and efficacy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval.
For example, previous studies of Rintega have utilized the immune response modifier GM-CSF, which is available in the United States, but is currently only available through specialty distribution
channels outside the United States. We are planning to initiate a Phase&nbsp;2 study of Rintega with adjuvant imiquimod, which could potentially serve as an alternative to GM-CSF, if needed,
particularly outside the United States. Clinical studies conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by
regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA.
However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of
the risks associated with obtaining FDA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file
we may not receive necessary approvals to commercialize our products in any market. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we obtain approval to commercialize any approved products outside of the United States, a variety
of risks associated with international operations could materially adversely affect our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to commercialize our lead drug candidate Rintega ourselves in Europe, if regulatory approval is obtained. If our other drug
candidates are approved for commercialization outside of the United States, we may enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions.
We expect that we will be subject to additional risks related to international operations and entering into international business relationships,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> different regulatory requirements for drug approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced protection for intellectual property rights, including trade secret and patent rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unexpected changes in tariffs, trade barriers and regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> economic weakness, including inflation, or political instability in particular foreign economies and markets; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> foreign taxes, including withholding of payroll taxes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident
to doing business in another country; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> workforce uncertainty in countries where employment regulations are different than, and labor unrest is more common than, in the
United States; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=46,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=839891,FOLIO='42',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes,
hurricanes, floods and fires; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> difficulty in importing and exporting clinical trial materials and study samples. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Reliance on Third Parties  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties to plan, conduct and monitor our clinical tests, and their failure to
perform as required would interfere with our product development.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third parties to conduct a significant portion of our clinical development activities. These activities include clinical
patient recruitment and observation, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. We conduct project management and medical and safety
monitoring in-house for some of our programs and rely on third parties for the remainder of our clinical development activities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
significant third parties who we currently rely on for clinical development activities include Novella Clinical, a Quintiles company, for our ACT IV study and PPD
Development,&nbsp;LLC for clinical studies including our METRIC study. If Novella or PPD Development is unable to perform in a quality and timely manner, and at a feasible cost, our clinical studies
will face delays. Further, if any of these third parties fails to perform as we expect or if their work fails to meet regulatory standards, our testing could be delayed, cancelled or rendered
ineffective. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on contract manufacturers over whom we have limited control. Should the cost, delivery and
quality of clinical and commercial grade materials manufactured by us in our Fall River facility or supplied by contract manufacturers vary to our disadvantage, our business operations could suffer
significant harm.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have limited experience in commercial manufacturing. We rely on CMOs, to manufacture drug substance and drug product for our
late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. Our ability to conduct late-stage clinical trials, manufacture and commercialize our drug
candidates, if regulatory approval is obtained, depends on the ability of such third parties to manufacture our drug candidates on a large scale at a competitive cost and in accordance with cGMP and
foreign regulatory requirements, if applicable. We also rely on CMOs for filling, packaging, storage and shipping of drug product. In order for us to establish our own commercial manufacturing
facility, we would require substantial additional funds and would need to hire and retain significant additional personnel and comply with extensive cGMP regulations applicable to such a facility. The
commercial manufacturing facility would also need to be licensed for the production of our drug candidates by the FDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
our most advanced programs, we are working with CMOs under established manufacturing arrangements that comply with the FDA's requirements and other regulatory standards, although
there is no assurance that the manufacturing will be successful. Prior to approval of Rintega or any other drug candidate, the FDA must review and approve validation studies for drug product. The
manufacturing processes for our drug candidates and immunotherapeutic delivery systems utilize known technologies. We believe that the products we currently have under development can be scaled up to
permit manufacture in commercial quantities. However, there can be no assurance that we will not encounter difficulties in scaling up the manufacturing processes. Significant scale-up of manufacturing
may result in unanticipated technical challenges and may require additional validation studies that the FDA must review and approve. CMOs may encounter difficulties in scaling up production, including
problems involving raw material suppliers, production yields, technical difficulties, scaled-up product characteristics, quality control and assurance, shortage of qualified personnel, capacity
constraints, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=47,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1027950,FOLIO='43',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>changing
priorities within the CMOs, compliance with FDA and foreign regulations, environmental compliance, production costs and development of advanced manufacturing techniques and process controls.
Any of these difficulties, if they occur, and are not overcome to the satisfaction of the FDA or other regulatory agency, could lead to significant delays and possibly the termination of the
development program for such drug candidate. These risks become more acute as we scale up for commercial quantities, where a reliable source of drug product becomes critical to commercial success. The
commercial viability of Rintega, if approved, will depend on the ability of our contract manufacturers to produce drug product on a large scale. Failure to achieve this level of supply can jeopardize
and prevent the successful commercialization of the drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have recently initiated use of Rintega drug product manufactured by MilliporeSigma (formerly SAFC, a division of the Sigma Aldrich Corporation) and Patheon Ferentino, in the ACT IV
and ReACT clinical studies as well as in compassionate use. We have also established relationship with Cook Pharmica to fill Rintega for commercial supply. We rely on Biosyn and Ambiopharm for
supplying suitable quantities of cGMP starting materials for the manufacture of Rintega. We also rely on Sanofi to supply suitable quantities of commercial quality GM-CSF which is co-administered with
Rintega. Any manufacturing failures or delays by our Rintega contract manufacturers or suppliers of critical materials could cause delays in ACT IV and/or the commercial launch of Rintega. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, we have utilized contract manufacturing organizations for the manufacture of clinical trial supplies of glembatumumab vedotin. We have established relationships with Lonza
Biologics to manufacture the glembatumumab vedotin antibody and Piramal Healthcare UK&nbsp;Ltd. to manufacture the antibody drug conjugate with the MMAE toxin. The drug substance is then filled and
packaged at contract manufacturers. We rely on MilliporeSigma for sourcing of suitable quantities of vcMMAE. Any manufacturing failures or delays by our glembatumumab vedotin contract manufacturers or
suppliers of materials could cause delays in our glembatumumab vedotin clinical studies including the METRIC study and/or the commercial launch of glembatumumab vedotin. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have established a relationship with Patheon Biologics to scale up and manufacture varlilumab drug substance for global clinical trials and potential commercialization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
operate our own cGMP manufacturing facility in Fall River, Massachusetts, to produce drug substance for our current and planned early-stage clinical trials. Our Fall River
manufacturing facility has 250L and 1000L bioreactor capacity and is able to manufacture in compliance with FDA regulations, allowing us to distribute potential products to clinical sites in the U.S.
for early clinical trials. We manufacture CDX-1401, CDX-301 and CDX-014 drug substance in our Fall River facility for our current and planned Phase&nbsp;1 and Phase&nbsp;2 clinical trials. The
products are then filled and packaged at contract manufacturers. Any manufacturing failures or compliance issues at contract manufacturers could cause delays in our Phase&nbsp;1 and Phase&nbsp;2
clinical studies for these product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
leading drug candidates require specialized manufacturing capabilities and processes. We may face difficulty in securing commitments from U.S. and foreign contract manufacturers as
these manufacturers could be unwilling or unable to accommodate our needs. Relying on foreign manufacturers involves peculiar and increased risks, including the risk relating to the difficulty foreign
manufacturers may face in complying with cGMP requirements as a result of language barriers, lack of familiarity with cGMP or the FDA regulatory process or other causes, economic or political
instability in or affecting the home countries of our foreign manufacturers, shipping delays, potential changes in foreign regulatory laws governing the sales of our product supplies, fluctuations in
foreign currency exchange rates and the imposition or application of trade restrictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurances that contract manufacturers will be able to meet our timetable and requirements. Further, contract manufacturers must operate in compliance with cGMP and
failure to
do so could result in, among other things, the disruption of product supplies. As noted above, non-U.S. contract manufacturers may face special challenges in complying with cGMP requirements, and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=48,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=258644,FOLIO='44',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>although
we are not currently dependent on non-U.S. collaborators or contract manufacturers, we may choose or be required to rely on non-U.S. sources in the future as we seek to develop stable
supplies of increasing quantities of materials for ongoing clinical trials of larger scale. Our dependence upon third parties for the manufacture of our products may adversely affect our profit
margins and our ability to develop, manufacture, sell and deliver products on a timely and competitive basis. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently rely on sole suppliers for key components of our drug candidates. Any production
problems with our suppliers or other disruptions in the supply of such components could adversely affect us  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently rely on sole suppliers for key components of our drug candidates, including Hiltonol, vcMMAE, KLH, APi1036, and GM-CSF.
While we work with the suppliers of these key components to ensure continuity of supply, no assurance can be given that these efforts will be successful. In addition, due to regulatory requirements
relating to the qualification of suppliers, we may not be able to establish additional or replacement sources on a timely basis or without excessive cost. If our suppliers were to terminate our
arrangements or fail to meet our supply needs we might be forced to delay our development programs or we could face disruptions in the distribution and sale of any drugs for which we obtain regulatory
approval. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently rely on third party collaborators to develop and commercialize companion diagnostic
tests for certain of our drug candidates, including our lead drug candidate Rintega.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have experience or capabilities in developing, administering, obtaining regulatory approval for, or commercializing companion
diagnostic tests and will need to rely in large part on third party collaborators to perform these functions. Companion diagnostic tests are subject to regulation by the FDA and similar regulatory
authorities outside of the United States as medical devices and require separate regulatory approval prior to commercialization. We are dependent on such third party collaborators to obtain regulatory
approval and commercialize such companion diagnostic tests. Such third party collaborators:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may not perform its obligations as expected or as required under our collaboration agreement; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may encounter production difficulties that could constrain the supply of the companion diagnostic test; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may have difficulties gaining acceptance of the use of the companion diagnostic test in the clinical community; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may not pursue commercialization of the companion diagnostic test even if they receive any required regulatory approvals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may elect not to continue the development or commercialization of the companion diagnostic test based on changes in the third parties'
strategic focus or available funding, or external factors such as an acquisition, that divert resources or create competing priorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may not commit sufficient resources to the marketing and distribution of the companion diagnostic test; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may terminate their relationship with us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
such third party collaborators fail to develop, obtain regulatory approval or commercialize the companion diagnostic test, we may not be able to enter into arrangements with another
diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development
and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=49,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=525020,FOLIO='45',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our reliance on third parties requires us to share our trade secrets, which increases the
possibility that a competitor will discover them.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we rely on third parties to develop our products, we must share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements
with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically restrict the ability of our collaborators,
advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in
advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively
by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs which may require us to share trade secrets under the terms of
research and development partnership or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements,
independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor's
discovery of our trade secrets would impair our competitive position. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Business Operations  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We depend greatly on the intellectual capabilities and experience of our key executives, commercial
personnel and scientists and the loss of any of them could affect our ability to develop our products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The loss of Anthony S. Marucci, our President and Chief Executive Officer, or other key members of our staff, including Avery W.
Catlin, our Chief Financial Officer, Dr.&nbsp;Thomas Davis, our Chief Medical Officer, Dr.&nbsp;Tibor Keler, our Chief Scientific Officer, Dr.&nbsp;Ronald Pepin, our Chief Business Officer and
Dr.&nbsp;Richard Wright, our Chief Commercial Officer, could harm us. We entered into employment agreements with Messrs.&nbsp;Marucci, Catlin, Davis, Keler, Pepin and Wright although an employment
agreement as a practical matter does not guarantee retention of an employee. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside commitments that may
limit their availability to us. In addition, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled scientific, managerial and marketing
personnel, particularly as we expand our activities in clinical trials, the regulatory approval process and sales and manufacturing. We routinely enter into consulting agreements with our scientific
and clinical collaborators and advisors, key opinion leaders and heads of academic departments in the ordinary course of our business. We also enter into contractual agreements with physicians and
institutions who recruit patients into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for this type of
personnel from other companies, research and academic institutions, government entities and other organizations. We cannot predict our success in hiring or retaining the personnel we require for
continued growth. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We expect to expand our clinical development, regulatory and sales and marketing capabilities, and
as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that if our clinical drug candidates continue to progress in development, we will require significant additional investment
in personnel, management systems and resources, particularly in the build out of our commercial capabilities. In preparation for potential approval of Rintega we are building the commercial
organization that will be responsible for the commercial launch of Rintega in the United States and Europe, if it receives marketing approval in such jurisdictions. To date, we have hired a core
commercial team, which is building our sales and distribution capabilities in preparation for a possible commercial launch of Rintega. Over the next several years, we expect to experience </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=50,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=446632,FOLIO='46',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>significant
growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated
future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due
to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources.
Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees may engage in misconduct or other improper activities, including noncompliance with
regulatory standards and requirements, which could have a material adverse effect on our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply
with FDA regulations, provide accurate information to the FDA, comply with applicable privacy laws, comply with manufacturing standards we have established, comply with federal and state health-care
fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of
information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Ethics, but it is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us,
and we are not successful in defending ourselves or asserting our rights, those actions could have a significant effect on our business and results of operations, including the imposition of
significant fines or other sanctions. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may engage in strategic transactions that could impact our liquidity, increase our expenses and
present significant distractions to our management.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or
in-licensing of products, product candidates or technologies. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs,
strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase
our near and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect
our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> exposure to unknown liabilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disruption of our business and diversion of our management's time and attention in order to develop acquired products, product
candidates or technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> higher than expected acquisition and integration costs; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=51,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=562787,FOLIO='47',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> write-downs of assets or goodwill or impairment charges; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increased amortization expenses; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> inability to retain key employees of any acquired businesses. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete could
have a material adverse effect on our business, results of operations, financial condition and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to successfully integrate our existing technology or to modify our technologies
to create new immunotherapeutic drugs  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we are able to integrate our acquired and licensed assets with our immunotherapy technologies, we believe these assets will give our
immunotherapeutic drugs a competitive advantage. However, if we are unable to successfully integrate licensed assets, or other technologies which we have acquired or may acquire in the future, with
our existing technologies and potential products currently under development, we may be unable to realize any benefit from our acquisition of these assets, or other technologies which we have acquired
or may acquire in the future and may face the loss of our investment of financial resources and time in the integration process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that our immunotherapy technology portfolio may offer opportunities to develop immunotherapeutic drugs that treat a variety of oncology, inflammatory and infectious diseases
by stimulating a patient's immune system against those disease organisms. If our immunotherapy technology portfolio cannot be used to create effective immunotherapeutic drugs against a variety of
disease organisms, we may lose all or portions of our investment in development efforts for new drug candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our internal computer systems, or those of our CROs, CMOs, or other contractors or consultants, may
fail or suffer security breaches, which could result in a material disruption of our drug development programs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite the implementation of security measures, our internal computer systems and those of our CROs, CMOs and other contractors and
consultants are vulnerable to damage from cyberattacks, malicious intrusion, computer viruses, unauthorized access, loss of data privacy, natural disasters, terrorism, war and telecommunication,
electrical failures or other significant disruption. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs
and commercialization efforts. For example, the loss of clinical study data from completed or ongoing clinical studies for any of our drug candidates could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development or commercialization of our drug candidates could be delayed. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business requires us to use hazardous materials, which increases our exposure to dangerous and
costly accidents.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development activities involve the use of hazardous chemicals, biological materials and radioactive compounds.
Although we believe that our safety procedures for handling and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=52,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=864497,FOLIO='48',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>disposing
of hazardous materials comply with the standards prescribed by applicable laws and regulations, we cannot completely eliminate the risk of accidental contamination or injury from these
materials. In the event of an accident, an injured party will likely sue us for any resulting damages with potentially significant liability. The ongoing cost of complying with environmental laws and
regulations is significant and may increase in the future. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face the risk of product liability claims, which could exceed our insurance coverage, and produce
recalls, each of which could deplete our cash resources.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a participant in the pharmaceutical, biotechnology and immunotherapeutic drug industries, we are exposed to the risk of product
liability claims alleging that use of our drug candidates caused an injury or harm. These claims can arise at any point in the development, testing, manufacture, marketing or sale of our drug
candidates and may be made directly by patients involved in clinical trials of our products, by consumers or healthcare providers or by individuals, organizations or companies selling our products.
Product liability claims can be expensive to defend, even if the drug or drug candidate did not actually cause the alleged injury or harm. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance
covering product liability claims becomes increasingly expensive as a drug candidate moves through the development pipeline to commercialization. Under our license agreements,
we are required to maintain clinical trial liability insurance coverage up to $15&nbsp;million. However, there can be no assurance that such insurance coverage is or will continue to be adequate or
available to us at a cost acceptable to us or at all. We may choose or find it necessary under our collaborative agreements to increase our insurance coverage in the future. We may not be able to
secure greater or broader product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any liability for damages resulting from a product liability claim could exceed
the amount of our coverage, require us to pay a substantial monetary award from our own cash resources and have a material adverse effect on our business, financial condition and results of
operations. Moreover, a product recall, if required, could generate substantial negative publicity about our products and business and inhibit or prevent development of our drug candidates and, if
approval is obtained, commercialization of our future drugs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Intellectual Property  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We license technology from other companies to develop products, and those companies could influence
research and development or restrict our use of it. In addition, if we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that
are important to our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Companies that license technologies to us that we use in our research and development programs may require us to achieve milestones or
devote minimum amounts of resources to develop products using those technologies. They may also require us to make significant royalty and
milestone payments, including a percentage of any sublicensing income, as well as payments to reimburse them for patent costs. The number and variety of our research and development programs require
us to establish priorities and to allocate available resources among competing programs. From time to time we may choose to slow down or cease our efforts on particular products. If in doing so we
fail to fully perform our obligations under a license, the licensor can terminate the licenses or permit our competitors to use the technology. Termination of these licenses or reduction or
elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms. Moreover, we may lose our right to market and sell any products based on
the licensed technology. The occurrence of such events could materially harm our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=17,SEQ=53,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=876845,FOLIO='49',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to successfully develop and, if regulatory approval is obtained, commercialize our drug
candidates may be materially adversely affected if we are unable to obtain and maintain effective intellectual property rights for our drug candidates and technologies.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in part on our ability to obtain and maintain patent protection and other intellectual property protection for our
drug candidates and proprietary technology. We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our drug candidates and
technology that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable
cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Our existing
patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies or from developing competing drugs and technologies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biotechnology
patents involve complex legal, scientific and factual questions and are highly uncertain. To date, there is no consistent policy regarding the breadth of claims allowed in
biotechnology patents, particularly in regard to patents for technologies for human uses like those we use in our business. We cannot predict whether the patents we or our licensors seek will issue.
If such patents are issued, a competitor may challenge them and limit their scope. Moreover, our patents may not afford effective protection against competitors with similar technology. A successful
challenge to any one of our patents could result in a third party's ability to use the technology covered by the patent. We also face the risk that others will infringe, avoid or circumvent our
patents. Technology that we license from others is subject to similar risks and this could harm our ability to use that technology. If we, or a company that licenses technology to us, were not the
first creator of an invention that we use, our use of the underlying product or technology will face restrictions, including elimination. For example, in September 2014, two European patent
oppositions were filed against a University of Southampton European patent to which we have exclusive rights and which broadly supports one of our drug candidates, varlilumab. While we plan to defend
the European patent vigorously in cooperation with
the University of Southampton, we may be unsuccessful and the scope of such patent may be limited or the patent may be invalidated. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we must defend against suits brought against us or prosecute suits against others involving intellectual property rights, we will incur substantial costs. In addition to any potential
liability for significant monetary damages, a decision against us may require us to obtain licenses to patents or other intellectual property rights of others on potentially unfavorable terms. If
those licenses from third parties are necessary but we cannot acquire them, we would attempt to design around the relevant technology, which would cause higher development costs and delays, and may
ultimately prove impracticable. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be unable to protect the confidentiality of our trade secrets, thus harming our business and
competitive position.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely upon trade secrets, including unpatented know-how, technology and other proprietary information to develop and maintain our
competitive position, which we seek to protect, in part, by confidentiality agreements with our employees and our collaborators and consultants. We also have agreements with our employees that
obligate them to assign their inventions to us. However, it is possible that technology relevant to our business will be independently developed by a person that is not a party to such an agreement.
Furthermore, if the employees, consultants or collaborators that are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach
or violation, and we could lose our trade secrets through such breaches or violations. Further, our trade secrets could be disclosed, misappropriated or otherwise become known or be independently
discovered by our competitors. In addition, intellectual property laws in foreign countries may not protect our intellectual property to the same extent as the laws of the United </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=18,SEQ=54,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=846120,FOLIO='50',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>States.
If our trade secrets are disclosed or misappropriated, it would harm our ability to protect our rights and have a material adverse effect on our business. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may become involved in lawsuits to protect or enforce our patents, which could be expensive,
time-consuming and unsuccessful.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our patents. To counter infringement or unauthorized use, we may be required to file infringement claims,
which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from
using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of
being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Third parties may initiate legal proceedings alleging that we are infringing their intellectual
property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our drug
candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights or intellectual property of third parties. We may become party to, or
be threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our drug candidates and technology. Third parties may assert infringement claims
against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third-party's intellectual property rights, we could be required to obtain a license
from such third-party to continue developing our drug candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were
able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease developing
the infringing technology or product. In addition, we could be found liable for monetary damages. Claims that we have misappropriated the confidential information or trade secrets of third parties can
have a similar negative impact on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Third parties may assert that our employees or consultants have wrongfully used or disclosed
confidential information or misappropriated trade secrets.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We employ individuals who were previously employed at universities or other diagnostic or biopharmaceutical companies, including our
competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information
or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual
property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result
in substantial costs and be a distraction to management and other employees. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=19,SEQ=55,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=870203,FOLIO='51',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulatory Risks  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our processes and systems are not compliant with regulatory requirements, we could be subject to
delays in submitting BLAs, NDAs or restrictions on marketing of drugs after they have been approved.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently are developing drug candidates for regulatory approval and are in the process of implementing regulated processes and
systems required to obtain and maintain regulatory approval for our drug candidates. Certain of these processes and systems for conducting clinical trials and manufacturing material must be compliant
with regulatory requirements before we can apply for regulatory approval for our drug candidates. These processes and systems will be subject to continual review and periodic inspection by the FDA and
other regulatory bodies. If we are unable to achieve compliance in a timely fashion, or if compliance issues are identified at any point in the development and approval process, we may experience
delays in filing for regulatory approval for our drug candidates, or delays in obtaining regulatory approval after filing. In addition, any later discovery of previously unknown problems or safety
issues with approved drugs or manufacturing processes, or failure to comply with regulatory requirements, may result in restrictions on such drugs or manufacturing processes, withdrawal of drugs from
the market, the imposition of civil or criminal penalties or a refusal by the FDA and/or other regulatory bodies to approve pending applications for marketing approval of new drugs or supplements to
approved applications, any of which could have a material adverse effect on our business. In addition, we are a party to agreements that transfer responsibility for complying with specified regulatory
requirements, such as filing and maintenance of marketing authorizations and safety reporting or compliance with manufacturing requirements, to our collaborators and third-party manufacturers. If our
collaborators or third-party manufacturers do not fulfill these regulatory obligations, any drugs for which we or they obtain approval may be subject to
later restrictions on manufacturing or sale, or may even risk withdrawal, which could have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we receive regulatory approval for a drug candidate, we will be subject to ongoing
regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once regulatory approval has been granted, the approved product and its manufacturer are subject to continual review by the FDA and/or
non-U.S. regulatory authorities. Any regulatory approval that we or our collaboration partners receive for our drug candidates may be subject to limitations on the indicated uses for which the product
may be marketed or contain requirements for potentially costly post-marketing follow-up studies to monitor the safety and efficacy of the product. In addition, if the FDA and/or non-U.S. regulatory
authorities approve any of our drug candidates, we will be subject to extensive and ongoing regulatory requirements by the FDA and other regulatory authorities with regard to the labeling, packaging,
adverse event reporting, storage, advertising, promotion and recordkeeping for our products. In addition, manufacturers of our drug products are required to comply with cGMP regulations, which include
requirements related to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory authorities must inspect and approve these
manufacturing facilities before they can be used to manufacture our drug products, and these facilities are subject to continual review and periodic inspections by the FDA and other regulatory
authorities for compliance with cGMP regulations. If we or a third party discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems
with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the
market or suspension of manufacturing. If we, our drug candidates or the manufacturing facilities for our drug candidates fail to comply with regulatory requirements of the FDA and/or other non-U.S. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=20,SEQ=56,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=915709,FOLIO='52',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<A NAME="page_di72301_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>regulatory
authorities, we could be subject to administrative or judicially imposed sanctions, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> warning letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> civil or criminal penalties and fines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> consent decrees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension or withdrawal of regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension of any ongoing clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voluntary or mandatory product recalls and publicity requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to accept or approve applications for marketing approval of new drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on operations, including costly new manufacturing requirements; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seizure or detention of drugs or import bans. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
regulatory requirements and policies may change and additional government regulations may be enacted for which we may also be required to comply. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we are not able to maintain regulatory
compliance, we may not be permitted to market our future products and our business may suffer. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws,
false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we obtain FDA approval for any of our drug candidates and begin commercializing those products in the United States, our operations
may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False
Claims Act. These laws may affect, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government
and the states in which we conduct our business. The laws that may affect our ability to operate include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving,
offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the
Medicare and Medicaid programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or
entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that
prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing
regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=21,SEQ=57,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=637135,FOLIO='53',FILE='DISK133:[15ZCW1.15ZCW72301]DI72301A.;7',USER='CHE108062',CD='19-FEB-2016;19:25' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk72301_1_54"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal transparency requirements under the Patient Protection and Affordable Care Act of 2010 requires manufacturers of drugs,
devices, biologics and medical supplies to report to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and
investment interests; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> state law and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply
to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which
differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. If our operations are found to
be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and
the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Moreover, achieving and sustaining compliance
with applicable federal and state privacy, security and fraud laws may prove costly. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compliance with laws and regulations pertaining to the privacy and security of health information
may be time consuming, difficult and costly, particularly in light of increased focus on privacy issues in countries around the world, including the U.S. and the EU.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to various domestic and international privacy and security regulations. The confidentiality, collection, use and
disclosure of personal data, including clinical trial patient-specific information, are subject to governmental regulation generally in the country that the personal data were collected or used. In
the United States were are subject to various state and federal privacy and data security regulations, including but not limited to Health Insurance Portability and Accountability Act of 1996, or
HIPAA, and as amended in 2014 by the Health Information Technology for Economic and Clinical Health ("HITECH") Act. HIPAA mandates, among other things, the adoption of uniform standards for the
electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the
adoption of administrative, physical and technical safeguards to protect such information. In the EU personal data includes any information that relates to an identified or identifiable natural person
with health information carrying additional obligations, including obtaining the explicit consent from the individual for collection, use or disclosure of the information. In addition, we are subject
to EU rules with respect to cross-border transfers of such data out of the EU. Furthermore, the legislative and regulatory landscape for privacy and data protection continues to evolve, and there has
been an increasing amount of focus on privacy and data protection issues. The United States and the EU and its member states continue to issue new privacy and data protection rules and regulations
that relate to personal data and health information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with these laws may be time consuming, difficult and costly. If we fail to comply with applicable laws, regulations or duties relating to the use, privacy or security of
personal data we could be subject to the imposition of significant civil and criminal penalties, be forced to alter our business practices and suffer reputational harm. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Health care reform and restrictions on reimbursement may limit our returns on potential products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because our strategy ultimately depends on the commercial success of our products, we assume, among other things, that end users of our
products will be able to pay for them. In the United States and other countries, in most cases, the volume of sales of products like those we are developing depends on the availability of
reimbursement from third-party payors, including national health care </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=58,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=617040,FOLIO='54',FILE='DISK133:[15ZCW1.15ZCW72301]DK72301A.;7',USER='CHE108077',CD='19-FEB-2016;19:38' -->
<A NAME="page_dk72301_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>agencies,
private health insurance plans and health maintenance organizations. Third-party payors increasingly challenge the prices charged for medical products and services. Accordingly, if we
succeed in bringing products to market, and reimbursement is not available or is insufficient, we could be prevented from successfully commercializing our potential products. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
health care industry in the United States and in Europe is undergoing fundamental changes as a result of political, economic and regulatory influences. Reforms proposed from time to
time include mandated basic health care benefits, controls on health care spending, the establishment of governmental controls over the cost of therapies, creation of large medical services and
products purchasing groups and fundamental changes to the health care delivery system. We anticipate ongoing review and assessment of health care delivery systems and methods of payment in the United
States and other countries. We cannot predict whether any particular reform initiatives will result or, if adopted, what their impact on us will be. However, we expect that adoption of any reform
proposed will impair our ability to market products at acceptable prices and that uncertainty concerning future government regulation of consumer healthcare purchasing and insurance may result in
difficulties for drug development companies, like us, in raising capital. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in laws affecting the health care industry could adversely affect our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S., there have been numerous proposals considered at the federal and state levels to reform the health care industry and its
cost, and it is likely that federal and state legislatures and health agencies will continue to focus on health care reform in the future. While additional health care reform may increase the number
of patients who have insurance coverage for our products, it may also include cost containment measures that adversely affect reimbursement for our products. Congress has also considered legislation
to change the Medicare reimbursement system for outpatient drugs, increase the amount of rebates that manufacturers pay for coverage of their drugs
by Medicaid programs and facilitate the importation of lower-cost prescription drugs that are marketed outside the U.S. Some states are also considering legislation that would control the prices of
drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which
supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts
to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger
segment of the population and a corresponding constraint on prices and reimbursement for our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and our collaborators and partners operate in a highly regulated industry. As a result, governmental actions may adversely affect our business, operations or financial condition,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care
availability, method of delivery and payment for health care products and services; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost
market opportunity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product
distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved
products, or otherwise adversely affect the market for our products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> new laws, regulations and judicial decisions affecting pricing or marketing practices; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the tax laws relating to our operations. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=59,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=184039,FOLIO='55',FILE='DISK133:[15ZCW1.15ZCW72301]DK72301A.;7',USER='CHE108077',CD='19-FEB-2016;19:38' -->
<A NAME="page_dk72301_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
enactment in the U.S. of health care reform, possible legislation which could ease the entry of competing follow-on biologics in the marketplace, new legislation or implementation of
existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of previously enacted and
possible future changes in laws that could adversely affect our business. In addition, the Food and Drug Administration Amendments Act of 2007 included new authorization for the FDA to require
post-market safety monitoring, along with an expanded clinical trials registry and clinical trials results database, and expanded authority for the FDA to impose civil monetary penalties on companies
that fail to meet certain commitments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Capital Stock  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our history of losses and uncertainty of future profitability make our common stock a highly
speculative investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have had no commercial revenue to date from sales of our drug candidates. We had an accumulated deficit of $591.0&nbsp;million as
of December&nbsp;31, 2015. We expect to spend substantial funds to continue the research and development testing of our products candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
anticipation of FDA approval of these products, we will need to make substantial investments to establish sales, marketing, quality control, regulatory compliance capabilities and
commercial manufacturing alliances. These investments will increase if and when any of these products receive FDA approval. We cannot predict how quickly our lead products will progress through the
regulatory approval process. As a result, we may continue to lose money for several years. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that we will achieve or sustain profitability in the future. Failure to achieve profitability could diminish our ability to sustain operations, pay dividends on our
common stock, obtain additional required funds and make required payments on our present or future indebtedness. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our share price has been and could remain volatile.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock has historically experienced and may continue to experience significant volatility. From January
2015 through December 2015, the market price of our common stock has fluctuated from a high of $32.82 per share in the first quarter of 2015, to a low of $10.11 per share in the third quarter of 2015.
Our progress in developing and commercializing our products, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by
stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our competitors could cause the market price
of our common stock to fluctuate substantially with significant market losses. If our stockholders sell a substantial number of shares of common stock, especially if those sales are made during a
short period of time, those sales could adversely affect the market price of our common stock and could impair our ability to raise capital. In addition, in recent years, the stock market has
experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and
may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in
substantial costs and diversion of management's attention and resources and could harm our stock price, business, prospects, results of operations and financial condition. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to use our net operating loss carryforwards will be subject to limitation and, under
certain circumstances, may be eliminated.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilization of our net operating loss and research and development credit carryforwards may be subject to substantial annual limitation
due to ownership change limitations that have occurred </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=60,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=210273,FOLIO='56',FILE='DISK133:[15ZCW1.15ZCW72301]DK72301A.;7',USER='CHE108077',CD='19-FEB-2016;19:38' -->
<A NAME="page_dk72301_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>previously
or that could occur in the future provided by Section&nbsp;382 of the Internal Revenue Code of 1986, or Section&nbsp;382, as well as similar state provisions. In general, an ownership
change, as defined by
Section&nbsp;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50&nbsp;percentage points over a three-year
period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2007, June 2009, December 2009 and December 2013, we experienced a change in ownership as defined by Section&nbsp;382 of the Internal Revenue Code. Historically, we have
raised capital through the issuance of capital stock on several occasions which, combined with shareholders' subsequent disposition of those shares, has resulted in three changes of control, as
defined by Section&nbsp;382. As a result of these ownership changes, utilization of our Federal net operating loss carryforwards is subject to an annual limitation. Any unused annual limitation may
be carried over to later years, and the amount of the limitation may, under certain circumstances, be subject to adjustment if the fair value of the our net assets are determined to be below or in
excess of the tax basis of such assets at the time of the ownership change, and such unrealized loss or gain is recognized during the five-year period after the ownership change. Subsequent ownership
changes, as defined in Section&nbsp;382, could further limit the amount of net operating loss carryforwards and research and development credits that can be utilized annually to offset future
taxable income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not undertaken a study to assess whether an ownership change or multiple ownership changes has occurred for (i)&nbsp;AVANT or CuraGen prior to our acquisitions, (ii)&nbsp;the
Company on the state level, (iii)&nbsp;the Company since March 2015, or (iv)&nbsp;research and development credits. If, based on such a study, we were to determine that there has been an ownership
change at any time since its formation, utilization of net operating loss or tax credit carryforwards would be subject to an annual limitation under Section&nbsp;382. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Refer
to Note&nbsp;15, "Income Taxes," in the accompanying notes to the financial statements for additional discussion on income taxes.  </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="dk72301_item_1b._unresolved_staff_comments"> </A>
<A NAME="toc_dk72301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1B.&nbsp;&nbsp;&nbsp;&nbsp;UNRESOLVED STAFF COMMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dk72301_item_2._properties"> </A>
<A NAME="toc_dk72301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;PROPERTIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of February&nbsp;16, 2016 our significant leased properties are described below. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="210pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="106pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:64pt;"><FONT SIZE=1><B>Property Location

<!-- COMMAND=ADD_SCROPPEDRULE,64pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Approximate<BR>
Square Feet </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Use </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Lease Expiration Date </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hampton, New Jersey</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Headquarters, Office and Laboratory</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>July 2020(1)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Needham, Massachusetts</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office and Laboratory</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>July 2020(2)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fall River, Massachusetts</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Manufacturing Facility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>July 2020(3)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Branford, Connecticut</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>December 2019(4)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Lease
includes two renewal options of five years each.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Lease
includes two renewal options of five years each. Lease includes potential for 11,500 square feet of expansion space.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Lease
includes two renewal options of five years each.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Lease
includes two renewal options of three years. Lease also includes provision for early termination with 12&nbsp;months notice. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=61,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=285234,FOLIO='57',FILE='DISK133:[15ZCW1.15ZCW72301]DK72301A.;7',USER='CHE108077',CD='19-FEB-2016;19:38' -->
<A NAME="page_dk72301_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dk72301_item_3._legal_proceedings"> </A>
<A NAME="toc_dk72301_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not currently a party to any material legal proceedings.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dk72301_item_4._mine_safety_disclosures"> </A>
<A NAME="toc_dk72301_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;MINE SAFETY DISCLOSURES    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=62,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=685044,FOLIO='58',FILE='DISK133:[15ZCW1.15ZCW72301]DK72301A.;7',USER='CHE108077',CD='19-FEB-2016;19:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm72301_1_59"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm72301_part_ii"> </A>
<A NAME="toc_dm72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dm72301_item_5._market_for_registrant___ite04666"> </A>
<A NAME="toc_dm72301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock currently trades on the Nasdaq Global Market (NASDAQ) under the symbol "CLDX". The following table sets forth for the
periods indicated the high and low sale prices per share for our common stock, as reported by NASDAQ. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:46pt;"><FONT SIZE=1><B>Fiscal Period

<!-- COMMAND=ADD_SCROPPEDRULE,46pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Year Ended December&nbsp;31, 2015</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28.08</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Year Ended December&nbsp;31, 2014</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33.33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of February&nbsp;16, 2016, there were approximately 335 shareholders of record of our common stock. On February&nbsp;16, 2016 the closing price of our common stock, as reported by
NASDAQ, was $7.69 per share. We have not paid any dividends on our common stock since our inception and do not intend to pay any dividends in the foreseeable future. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation Plan Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information as of December&nbsp;31, 2015 regarding shares of our common stock that may be issued under
our existing equity compensation plans, including our 2008 Stock Option and Incentive Plan (the "2008 Plan") and our 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"). </FONT></P>
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="121pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="131pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity Compensation Plan Information </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon exercise<BR>
of outstanding options<BR>
and rights(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted Average<BR>
exercise price of<BR>
outstanding options<BR>
and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available for<BR>
future issuance under equity<BR>
compensation plan<BR>
(excluding securities<BR>
referenced in column (a)) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,110,239</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,928,280</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include any Restricted Stock as such shares are already reflected in our outstanding shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the 2008 Plan, 2004 ESPP Plan and Celldex Research's 2005 Equity Incentive Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include purchase rights accruing under the 2004 ESPP Plan because the purchase price (and therefore the number of shares to be purchased) will not
be determined until the end of the purchase period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
shares available for future issuance under the 2008 Plan and the 2004 ESPP Plan.  </FONT></DD></DL>
 </DIV>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=63,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=913607,FOLIO='59',FILE='DISK133:[15ZCW1.15ZCW72301]DM72301A.;5',USER='CHE108057',CD='19-FEB-2016;19:37' -->
<A NAME="page_dm72301_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm72301_celldex_theapeutics,_inc.,_nas__cel02591"> </A>
<A NAME="toc_dm72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  CELLDEX THEAPEUTICS,&nbsp;INC., NASDAQ MARKET INDEX&#151;U.S. AND<BR>  PEER GROUP INDICES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The graph below compares the cumulative total stockholder return on the common stock for the period from December&nbsp;31, 2010
through December&nbsp;31, 2015, with the cumulative return on (i)&nbsp;NASDAQ U.S. Benchmark TR Index and (ii)&nbsp;NASDAQ Pharmaceutical (Subsector) Index. The comparison assumes investment of
$100 on December&nbsp;31, 2010 in our common stock and in each of the indices and, in each case, assumes reinvestment of all dividends. The points on the graph are as of December&nbsp;31 of the
year indicated. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g861164.jpg" ALT="GRAPHIC" WIDTH="495" HEIGHT="330">
  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2010 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Celldex Therapeutics,&nbsp;Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>163</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>588</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>443</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>381</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ U.S. Benchmark TR Index</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>117</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>156</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>175</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>176</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ Pharmaceutical (Subsector) Index</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>117</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>222</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>234</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="dm72301_item_6._selected_financial_data"> </A>
<A NAME="toc_dm72301_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following selected financial data are derived from our financial statements. The statement of operations data for the years ended
December&nbsp;31, 2015, 2014 and 2013 and the balance sheet data as of December&nbsp;31, 2015 and 2014 have been derived from our audited financial statements included in Item&nbsp;8 of this
Annual Report on Form&nbsp;10-K. This data should be read in conjunction with our audited financial statements and related notes which are included elsewhere in this Annual Report on
Form&nbsp;10-K, and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in Item&nbsp;7 below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=64,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=36360,FOLIO='60',FILE='DISK133:[15ZCW1.15ZCW72301]DM72301A.;5',USER='CHE108057',CD='19-FEB-2016;19:37' -->
<A NAME="page_dm72301_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> STATEMENTS OF OPERATIONS DATA<BR>
(In thousands, except per share amounts)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>REVENUE:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development and Licensing Agreements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>160</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>146</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts and Grants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,748</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,617</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>281</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Royalties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,119 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,586</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,202</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,265 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OPERATING EXPENSE:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>104,381</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>67,401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>47,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Royalty</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Operating Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,635</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,106 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Operating Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>135,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>85,553</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>69,279</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,664 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(129,541</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(122,430</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(58,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(43,399</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investment and Other Income, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,344</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>819</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>530</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>396</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,576</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,796</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(59,123</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and Diluted Net Loss Per Common Share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Used in Calculating Basic and Diluted Net Loss Per Common Share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>97,051</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,399</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>79,777</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57,713</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,501 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> BALANCE SHEET DATA<BR>
(In thousands)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working Capital</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>264,696</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>180,494</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>284,839</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,429</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>337,584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>248,014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>347,095</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,541</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,994</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-Term Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,239</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,863</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,082</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated Deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(590,956</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(463,759</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(345,679</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(264,129</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(205,006</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Stockholders' Equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>290,105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211,660</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>319,795</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>95,774</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=65,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=783039,FOLIO='61',FILE='DISK133:[15ZCW1.15ZCW72301]DM72301A.;5',USER='CHE108057',CD='19-FEB-2016;19:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do72301_1_62"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="do72301_item_7._management_s_discussio__ite03668"> </A>
<A NAME="toc_do72301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OVERVIEW  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the
treatment of cancer and other difficult-to-treat diseases. Our drug candidates are derived from a broad set of complementary
technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are using these technologies to develop targeted immunotherapeutics comprised
of protein-based molecules such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
latest stage drug candidate, Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that
express a specific cancer marker known as EGFRvIII. In February 2015, the U.S. Food and Drug Administration, or FDA, granted Rintega Breakthrough Therapy Designation for the treatment of adult
patients with EGFRvIII-positive glioblastoma. We completed enrollment in December 2014 in ACT IV, a pivotal Phase&nbsp;3 study in front-line glioblastoma. ACT IV completed its first interim analysis
at 50% of events (deaths) in June 2015, and an independent Data Safety and Monitoring Board recommended that the study continue as planned. The required number of events to perform the second interim
analysis of ACT IV were reached in late 2015 and the analysis is expected to occur in March 2016. Final data from ACT IV are expected by the end of 2016, although our expectations regarding the timing
for the final data read out may change based on event rates.We have also completed a Phase&nbsp;2 study in patients with recurrent EGFRvIII-positive glioblastoma. Updated results from this
randomized study comparing Rintega added to the standard of care, or SOC, compared to SOC alone were presented in November 2015. A statistically significant overall survival benefit and the emergence
of a long-term survival benefit were observed. The primary endpoint of the study, progression-free survival at six months, or PFS6, was met. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glembatumumab
vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase&nbsp;2b study for the treatment of triple negative breast cancer and a
Phase&nbsp;2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response
against their cancer. We established proof of concept in a Phase&nbsp;1 study with varlilumab, which has allowed several combination studies to begin in various indications. We also have a number of
earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells, or APC, for cancer indications and CDX-301, an immune cell
mobilizing agent and dendritic cell growth factor. Our drug candidates address market opportunities for which we believe current therapies are inadequate or non-existent. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are building a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Our program assets provide us with
the strategic options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach allows us to
maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=66,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=950959,FOLIO='62',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table includes the programs that we currently believe are significant to our business: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="271pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:62pt;"><FONT SIZE=1><B>Product (generic)

<!-- COMMAND=ADD_SCROPPEDRULE,62pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication/Field </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Partner </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Status </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Rintega</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Front-line glioblastoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;3</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Glembatumumab vedotin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Metastatic breast cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2b</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Rintega</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Recurrent glioblastoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Glembatumumab vedotin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Metastatic melanoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Varlilumab</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-1401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Allogeneic hematopoietic stem cell transplantation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Renal cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
expenditures that will be necessary to execute our business plan are subject to numerous uncertainties. Completion of clinical trials may take several years or more, and the length
of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate. It is not unusual for the clinical development of these types of product
candidates to each take five years or more, and for total development costs to exceed $100&nbsp;million for each product candidate. We estimate that clinical trials of the type we generally conduct
are typically completed over the following timelines: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:51pt;"><FONT SIZE=1><B>Clinical Phase

<!-- COMMAND=ADD_SCROPPEDRULE,51pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated<BR>
Completion<BR>
Period </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1&nbsp;-&nbsp;2 Years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1&nbsp;-&nbsp;5 Years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Phase&nbsp;3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1&nbsp;-&nbsp;5 Years</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among
others, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of patients that ultimately participate in the trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the duration of patient follow-up that seems appropriate in view of results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of clinical sites included in the trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the length of time required to enroll suitable patient subjects; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the efficacy and safety profile of the product candidate. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
test potential product candidates in numerous preclinical studies for safety, toxicology and immunogenicity. We may then conduct multiple clinical trials for each product candidate.
As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain product candidates in order to focus our resources on more promising product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
element of our business strategy is to pursue the research and development of a broad portfolio of product candidates. This is intended to allow us to diversify the risks associated
with our research and development expenditures. To the extent we are unable to maintain a broad range of product candidates, our dependence on the success of one or a few product candidates increases. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
approval is required before we can market our product candidates as therapeutic products. In order to proceed to subsequent clinical trial stages and to ultimately achieve
regulatory approval, the regulatory agency must conclude that our clinical data is safe and effective. Historically, the results from preclinical testing and early clinical trials (through
Phase&nbsp;2) have often not been predictive of results obtained in later clinical trials. A number of new drugs and biologics have shown </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=67,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=296465,FOLIO='63',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_64"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>promising
results in early clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
our business strategy includes the option of entering into collaborative arrangements with third parties to complete the development and commercialization of our product
candidates. In the event that third parties take over the clinical trial process for one of our product candidates, the estimated completion date would largely be under control of that third party
rather than us. We cannot forecast with any degree of certainty which proprietary products, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements
would affect our development plan or capital requirements. Our programs may also benefit from subsidies, grants, contracts or government or agency-sponsored studies that could reduce our development
costs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of the uncertainties discussed above, among others, it is difficult to accurately estimate the duration and completion costs of our research and development projects or when,
if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our
failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to
seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable
to us, would jeopardize the future success of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the past five years through December&nbsp;31, 2015, we incurred an aggregate of $351.8&nbsp;million in research and development expenses. The following table indicates the
amount incurred for each of our significant research programs and for other identified research and development activities during the years ended December&nbsp;31, 2015, 2014 and 2013. The amounts
disclosed in the following table reflect direct research and development costs, license fees associated with the underlying technology and an allocation of indirect research and development costs to
each program. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rintega</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43,038</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,861</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38,149</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glembatumumab vedotin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,124</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,907</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,284</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Varlilumab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,484</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,376</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1401</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,385</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>612</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,238</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>532</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,724</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>937</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Programs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,511 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total R&amp;D Expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,171</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>104,381</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,401 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Development Programs  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rintega  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rintega is an epidermal growth factor receptor variant III, or EGFRvIII, specific vaccine for glioblastoma, or GBM. EGFRvIII is a
mutated form of the epidermal growth factor receptor, or EGFR, that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. EGFRvIII is expressed
in approximately 30% of GBM tumors, the most common and aggressive form of brain cancer. Rintega is composed of the EGFRvIII peptide linked to a carrier protein called Keyhole Limpet Hemocyanin, or
KLH, and administered together with the adjuvant GM-CSF. The FDA and the European Medicines Agency, or EMA, have both granted Orphan Drug Designation for Rintega for the treatment of EGFRvIII
expressing GBM. The FDA has also granted </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=68,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=742851,FOLIO='64',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_65"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Fast
Track designation. In February 2015, the FDA granted Rintega Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase&nbsp;2a study of Rintega referred to as ACTIVATE was led by collaborating investigators at the Brain Tumor Center at Duke Cancer Institute in Durham, North Carolina and at
M.D. Anderson Cancer Center in Houston, Texas and enrolled 18 evaluable GBM patients. An extension of the Phase&nbsp;2a study referred to as ACT II evaluated 22 additional GBM patients treated in
combination with the current standard of care, maintenance temozolomide, or TMZ, at the same two institutions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase&nbsp;2b study of Rintega referred to as ACT III combined Rintega with standard of care, TMZ, in patients with newly diagnosed GBM. The ACT III study provided for a
multi-center, non-randomized dataset for Rintega in 65 patients at over 30 sites throughout the United States, or U.S. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2013, we announced the four- and five-year survival data from the 105 patients enrolled in the three Phase&nbsp;2 Rintega clinical studies (ACTIVATE, ACT II and ACT
III)&nbsp;in EGFRvIII-positive GBM. Across these three Phase&nbsp;2 studies of Rintega, survival data remains consistent and suggests a continuing survival benefit in comparison to independent
control datasets (see chart below) at the median and at all other time points evaluated. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do72301_phase_2_front-line_lon__do702280"> </A>
<A NAME="toc_do72301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Phase&nbsp;2 Front-line Long-term Overall Survival Assessments    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Median, Years<BR>
(95% CI) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2-year<BR>
rate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>3-year<BR>
rate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>4-year<BR>
rate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>5-year<BR>
rate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Phase&nbsp;2 Rintega studies (n=105)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.1 (1.8, 2.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matched historical control (n=17)(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.3 (0.9, 1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(1)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Patients treated at M.D. Anderson contemporaneously to ACTIVATE, matched for major eligibility requirements, including
EGFRvIII-positive GBM, gross total resection and no disease progression through chemoradiation treatment.</I></FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pooled overall long-term survival results continue to be consistent with the ACT III Phase&nbsp;2 study (18% for 4-years and 14% for 5-years). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we initiated ACT IV, a pivotal, randomized, double-blind, controlled Phase&nbsp;3 study of Rintega in patients with surgically resected, EGFRvIII-positive GBM.
Patients were randomized after the completion of surgery and standard chemoradiation treatment. The treatment regimen includes a Rintega priming phase post-radiation followed by an adjuvant phase
where Rintega is dosed along with TMZ and a Rintega maintenance therapy phase. Patients are treated until disease progression or intolerance to therapy. The primary objective of the study is to
determine whether Rintega plus adjuvant GM-CSF improves the overall survival of patients with newly diagnosed EGFRvIII-positive GBM with minimal residual disease post resection and traditional
chemoradiation when compared to treatment with TMZ and a control injection of KLH. KLH is a component of Rintega and was selected due to its ability to generate a similar injection site reaction to
that observed with Rintega. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2014, enrollment was completed in the ACT IV study. In total, over 4,800 tissue samples from GBM patients were submitted for EGFRvIII evaluation from more than 200 clinical
trial sites across 22 countries and, consistent with prior studies, 30% were positive for the EGFRvIII mutation. The study enrolled 745 patients to reach the required 374 patients with minimal
residual disease (assessed by central review) needed for analysis of the primary overall survival endpoint. All patients, including patients with disease that exceed this threshold, will be included
in a secondary analysis of overall survival as well as analyses of progression-free survival, safety and tolerability, and quality of life. The timing of the overall survival primary endpoint data is
event-driven. The study </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=69,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=521372,FOLIO='65',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_66"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>design
requires interim analyses to be conducted by an independent Data Safety and Monitoring Board (DSMB) at 50% and 75% of events (deaths). The first interim analysis occurred in June 2015, and the
DSMB recommended continuation of the study as planned. The required number of events to perform the second interim analysis of ACT IV were reached in late 2015, and the analysis is expected to occur
in March 2016. Final data from ACT IV are expected by the end of 2016, although our expectations regarding the timing for the final data read out may change based on event rates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we also initiated ReACT, a Phase&nbsp;2 study of Rintega in combination with Avastin&reg; in patients with recurrent EGFRvIII-positive GBM. This study
completed enrollment in 2014 and includes 3 groups. Group 1 consists of 73 patients who had not previously received Avastin and were randomized to receive either Rintega and Avastin or a control
injection of KLH and Avastin in a blinded fashion. Group 2 includes 25 patients who are refractory to Avastin having received Avastin in either the frontline or recurrent setting with subsequent
progression and who received Rintega plus Avastin in a single treatment arm. In August 2013, we announced the addition of an expansion cohort of up to 75 patients, called Group 2C, to better
characterize the
potential activity of Rintega in this refractory patient population. This decision was based on early evidence of anti-tumor activity, including stable disease, tumor shrinkage and
investigator-reported response. In total, Group 2C enrolled 28 patients. The primary endpoint is six month progression-free survival rate (PFS-6) for groups 1 and 2 and objective response rate (ORR)
for group 2C. Other study endpoints include PFS-6, ORR, PFS, overall survival, or OS and safety and tolerability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2015, we reported the following mature data from Group 1 of the ReACT study. Tumor responses were evaluated in accordance with Response Assessment in Neuro-Oncology (RANO)
criteria by an independent expert review committee blinded to treatment group assignment. Data for this long-term update included study results through September&nbsp;1, 2015. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> PFS6:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;As previously reported in May 2015, the primary endpoint of the study, PFS6,
was met. In the intent to treat (ITT) population, 28% of patients on the Rintega arm were progression free at six months compared to 16% of patients on the control arm (p=0.1163). </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Survival:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Mature overall survival (OS) data continue to show a marked benefit
[hazard ratio&nbsp;=&nbsp;0.53 (0.32, 0.88); p=0.0137] with a long-term survival benefit observed in the Rintega arm. Consistent with previous studies of Rintega and the
published data observed for immune-mediated therapeutics, this survival benefit includes multiple patients exceeding what is customary survival for EGFRvIII-positive glioblastoma, also referred to as
a tail on the survival curve. At two years, the survival rate for Rintega patients in the ITT population is 25% versus 0% for control patients. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do72301_overall_survival_(os),__do702075"> </A>
<A NAME="toc_do72301_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Overall Survival (OS), Intent to Treat (ITT) Population    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Hazard Ratio (HR)<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=10 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><B> HR&nbsp;= 0.53 (0.32, 0.88); p=0.0137<BR> </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1><B> </B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Median (95% CI)</B></FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OS 12&nbsp;months</B></FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OS 18&nbsp;months</B></FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OS 24&nbsp;months</B></FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Rintega +&nbsp;BV</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.3 (9.9, 16.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Control +&nbsp;BV</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.3 (7.1, 11.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Objective Response Rate
(ORR):</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Nine out of 30 evaluable ITT patients (30%) on the Rintega arm experienced a confirmed objective response versus six out of 34
evaluable patients (18%) on the control arm. Five patients on the Rintega arm experienced durable responses greater than six months, and three of these patients experienced durable responses greater
than 18&nbsp;months (range of 18.6+ to 22.2&nbsp;months). In contrast, only two patients on the control arm experienced a durable response greater than six months, and none experienced a response
greater than 7.4&nbsp;months. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=70,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=564416,FOLIO='66',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_67"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Steroid
Use:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Further emphasizing the level of disease control, 50% of the 18 patients on the Rintega arm who were on steroids at the start of
treatment were able to stop steroids for at least two months during treatment versus only 26% of the 19 patients on the control arm who were on steroids at the start of treatment. 33% of patients on
the Rintega arm were able to stop steroids for more than six months, and, of these, three were able to stop for more than one year versus none on the control arm for either time point. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Immune
Response:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Prolonged survival was associated with high anti-EGFRvIII humoral responses. Recent </FONT><FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> experiments have shown those immune responses had tumor killing function through antibody dependent cellular cytotoxicity (ADCC) of EGFRvIII-expressing tumor cells. This
biologic effector function is rarely proven for immune therapies. Importantly, rapid generation of anti-EGFRvIII humoral response correlated with longer survival; however, even those with slower
development of immune responses benefitted. No patient in the control arm had detectable EGFRvIII specific antibody response. This effect is consistent with Rintega's proposed mechanism of action as a
targeted immunotherapeutic vaccine.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Other:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Multiple subgroup and adjusted analyses have concluded that the consistent
survival benefit observed in the study was not influenced by potential imbalances in patient demographics.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Safety:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Rintega was very well tolerated without unexpected additive toxicity to
Avastin. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
studies of Rintega are currently planned including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;2 study of Rintega prior to and concurrent with chemoradiation and maintenance temozolomide in patients with newly
diagnosed EGFRvIII-positive glioblastoma. Prior studies of Rintega in the newly diagnosed setting have initiated Rintega dosing upon completion of chemoradiation concurrent with maintenance
temozolomide. This single-cohort, open label study is designed to explore the feasibility of dosing at an earlier timepoint (after surgery but prior to and concurrent with chemoradiation). The primary
objective of the study is to evaluate the EGFRvIII peptide-specific immune response obtained with this dosing regimen. Secondary objectives include evaluation of anti-tumor activity, including PFS,
OS, ORR and duration of response, assessment of health-related quality of life outcomes, and safety and tolerability. This study is expected to open to enrollment in the second half of 2016. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A Phase&nbsp;2 single-arm study of Rintega with adjuvant imiquimod, a topically administered immune response modifier, in
combination with Avastin in patients with recurrent EGFRvIII-positive glioblastoma. Previous studies of Rintega have utilized the immune response modifier GM-CSF. Imiquimod has broad commercial
availability and could potentially serve as a second source of adjuvant if needed, especially outside the United States where GM-CSF is currently available through specialty distribution channels. The
primary objective of this study is to evaluate EGFRvIII-specific immune responses. Secondary objectives include evaluation of measures of anti-tumor activity, including ORR, duration of response, PFS,
and OS, and to characterize the safety and tolerability profile of this combination approach. This study is expected to open to enrollment in March of 2016. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with our Rintega clinical development program, we are collaborating with Laboratory Corporation of America (LabCorp) in the U.S. and Qiagen in the EU for the potential
commercialization of a companion diagnostic to enable identification of the EGFRvIII mutation in patients with glioblastoma. The LabCorp diagnostic has been developed in parallel with the clinical
development of Rintega and was utilized to screen patients for the Phase&nbsp;3 ACT IV study and the Phase&nbsp;2 ReACT study. In the U.S., we are working with LabCorp to file the diagnostic for
FDA approval concurrently with Celldex's potential BLA submission, pending successful completion of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=71,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=51142,FOLIO='67',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_68"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>ACT
IV study. In the EU, Qiagen will seek CE marking of the diagnostic and anticipates completing this certification in the second half of 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Glembatumumab Vedotin  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glembatumumab vedotin is an antibody-drug conjugate, or ADC, that consists of a fully human monoclonal antibody, CR011, linked to a
potent cell-killing drug, monomethyl-auristatin E, or MMAE. The CR011 antibody specifically targets glycoprotein NMB, referred to as gpNMB, that is over-expressed in a variety of cancers including
breast cancer and melanoma. The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics,&nbsp;Inc. and is the same as that used in
the marketed product Adcetris&reg;. The ADC is designed to be stable in the bloodstream. Following intravenous administration, glembatumumab vedotin targets and binds to gpNMB, and upon
internalization into the targeted cell, glembatumumab vedotin is designed to release MMAE from CR011 to produce a cell-killing effect. The FDA has granted Fast Track designation to glembatumumab
vedotin for the treatment of advanced, refractory/resistant gpNMB-expressing breast cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Breast Cancer:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Phase 1/2 study of glembatumumab vedotin administered intravenously once every three weeks evaluated
patients with
locally advanced or metastatic breast cancer who had received prior therapy (median of seven prior regimens). The study began with a bridging phase to confirm the maximum tolerated dose, or MTD, and
then expanded into a Phase&nbsp;2 open-label, multi-center study. The study confirmed the safety of glembatumumab vedotin at the pre-defined maximum dose level (1.88 mg/kg) in 6 patients. An
additional 28 patients were enrolled in an expanded Phase&nbsp;2 cohort (for a total of 34 treated patients at 1.88 mg/kg, the Phase&nbsp;2 dose) to evaluate the PFS rate at 12&nbsp;weeks. The
1.88 mg/kg dose was well tolerated in this patient population with the most common adverse events of rash, alopecia and fatigue. The primary activity endpoint, which called for at least 5 of 25 (20%)
patients in the Phase&nbsp;2 study portion to be progression-free at 12&nbsp;weeks, was met as 9 of 26 (35%) evaluable patients were progression-free at 12&nbsp;weeks. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
all patients treated at the maximum dose level, tumor shrinkage was seen in 62% (16/26) and median PFS was 9.1&nbsp;weeks. A subset of 10 patients had "triple negative disease," a
more aggressive breast cancer subtype that carries a high risk of relapse and reduced survival as well as limited therapeutic options due to lack of over-expression of HER2/neu, estrogen and
progesterone receptors. In these patients, 78% (7/9) had some tumor shrinkage, 12-week PFS rate was 70% (7/10), and median PFS was 17.9&nbsp;weeks. Tumor samples from a subset of patients across all
dose groups were analyzed for
gpNMB expression. The tumor samples from most patients showed evidence of stromal and/or tumor cell expression of gpNMB. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2012, we announced final results from the EMERGE study, a randomized, multi-center Phase&nbsp;2b study of glembatumumab vedotin in 122 patients with heavily pre-treated,
advanced, gpNMB-positive breast cancer. Patients were randomized (2:1) to receive either glembatumumab vedotin or single-agent Investigator's Choice, or IC, chemotherapy. Patients randomized to
receive IC were allowed to cross over to receive glembatumumab vedotin following disease progression. Activity endpoints included response rate, PFS and OS. The final results, as shown below,
suggested that glembatumumab vedotin induces significant response rates compared to currently available therapies in patient subsets with advanced, refractory breast cancers with gpNMB over-expression
(expression in at least 25% of tumor cells) and in patients with triple negative breast cancer. The OS and PFS of patients treated with glembatumumab vedotin was also observed to be greatest in
patients with triple negative breast cancer who also over-express gpNMB and all patients with gpNMB over-expression. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=72,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=377517,FOLIO='68',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_69"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do72301_emerge__overall_respon__do702202"> </A>
<A NAME="toc_do72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  EMERGE: Overall Response Rate and Disease Control Data    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>gpNMB Over-Expression </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Triple Negative<BR>
and gpNMB<BR>
Over-Expression </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>glembatumumab<BR>
vedotin </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Investigator<BR>
Choice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>glembatumumab<BR>
vedotin </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Investigator<BR>
Choice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(n=25) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(n=8) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(n=12) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(n=4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Response</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Disease Control Rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=2><I>Responses per RECIST 1.1; IC&nbsp;= Investigator's Choice; glembatumumab vedotin arm includes 15 patients who crossed over to receive glembatumumab vedotin treatment after
progression on IC. Analysis of best response excludes patients who discontinued from study without evaluable post-baseline radiographic imaging (n=15 for glembatumumab vedotin arm; n=5 for IC
arm).</I></FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do72301_emerge__progression_free_survi__eme02633"> </A>
<A NAME="toc_do72301_5"> </A>
<BR></FONT><FONT SIZE=2><B>  EMERGE: Progression Free Survival (PFS) and Overall Survival (OS) Data    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>gpNMB<BR>
Over-Expression </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Triple Negative<BR>
and gpNMB<BR>
Over-Expression </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>glembatumumab<BR>
vedotin </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Investigator<BR>
Choice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>glembatumumab<BR>
vedotin </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Investigator<BR>
Choice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Median PFS (months)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>p=0.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>p=0.008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Median OS (months)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>p=0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>p=0.003</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=2><I>When cross over patients are removed, median OS in patients with gpNMB over-expression is 10.0&nbsp;months for glembatumumab vedotin vs 5.2&nbsp;months for IC (p=0.05), and
median OS in triple negative patients with gpNMB over-expression is 10.0&nbsp;months for glembatumumab vedotin vs 5.2&nbsp;months for IC
(p=0.009).</I></FONT></P>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2013, we initiated METRIC, a randomized, controlled Phase&nbsp;2b study of glembatumumab vedotin in patients with triple negative breast cancer that over-express gpNMB.
Clinical trial sites are open to enrollment across the U.S., Canada and Australia, and trial expansion into the EU is underway with enrollment planned to open in the first quarter of 2016. The METRIC
protocol was amended in late 2014 based on feedback from clinical investigators conducting the study that the eligibility criteria for study entry were limiting their ability to enroll patients they
felt were clinically appropriate. In addition, we had spoken to country-specific members of the European Medicines Agency, or EMA, and believed a significant opportunity existed to expand the study
into the EU. The amendment expanded patient entry criteria to position it for full marketing approval with global regulators, including the EMA, and to support improved enrollment in the study. The
primary endpoint of the study is PFS as PFS is an established endpoint for full approval registration studies in this patient population in both the U.S. and the EU. The sample size (n=300) and the
secondary endpoint of OS remained unchanged. We implemented these changes in parallel to regulatory discussions to maintain momentum at open clinical trial sites. Since implementation, both the FDA
and central European regulatory authorities have reviewed the protocol design, and we believe the METRIC study could support marketing approval in both the U.S. and Europe dependent upon data review.
Based on current projections, we believe enrollment will be completed in the second half of 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Metastatic Melanoma:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Phase 1/2 open-label, multi-center, dose escalation study evaluated the safety, tolerability and
pharmacokinetics of glembatumumab vedotin in 117 patients with </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=73,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=350961,FOLIO='69',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>un-resectable
Stage&nbsp;III or Stage&nbsp;IV melanoma who had failed no more than one prior line of cytotoxic therapy. The MTD was determined to be 1.88 mg/kg administered intravenously once
every three weeks. The study achieved its primary activity objective with an ORR in the Phase&nbsp;2 cohort of 15% (5/34). Median PFS was 3.9&nbsp;months. Glembatumumab vedotin was generally well
tolerated, with the most frequent treatment-related adverse events being rash, fatigue, hair loss, pruritus, diarrhea and neuropathy. In the subset of patients with tumor biopsies, high levels of
tumor expression of gpNMB appeared to correlate with favorable outcome. In the seven patients whose tumors were found to express high amounts of gpNMB, and who were treated at the maximum tolerated
doses across all dosing schedules, median PFS was 4.9&nbsp;months. The development of rash, which may be associated with the presence of gpNMB in the skin, also seemed to correlate with greater PFS. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2014, we initiated a single arm, open-label Phase&nbsp;2 study of glembatumumab vedotin in patients with unresectable Stage&nbsp;III or IV melanoma. The study includes
approximately 10 sites in the United States and will enroll approximately 60 patients. The primary objective is to evaluate the anticancer activity of glembatumumab vedotin in advanced melanoma as
measured by the ORR. Secondary endpoints include analyses of PFS, duration of response, OS, retrospective investigation of whether the anticancer activity of glembatumumab vedotin is dependent upon
the degree of gpNMB expression in tumor tissue and safety. Based on current projections, we believe enrollment will be completed in the second quarter of 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into a collaborative relationship with PrECOG under which they will conduct a Phase&nbsp;2 study in squamous cell lung cancer. This study is expected to open to
enrollment in the first half of 2016. We have also entered into a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, under which NCI is sponsoring
two studies of glembatumumab vedotin&#151;one in uveal melanoma and one in pediatric osteosarcoma. Both studies are currently open to enrollment. The uveal melanoma study is a single arm, open
label study in patients with locally recurrent or metastatic uveal melanoma. The primary outcome measure is ORR. Secondary outcome measures include change in gpNMB expression on tumor tissue via
immunohistochemistry, safety, OS and PFS. The osteosarcoma study is a single arm, open label, evaluation of adolescent and adult patients with recurrent or refractory osteosarcoma. The co-primary
objectives are to determine whether glembatumumab vedotin therapy either increases the disease control rate at 4&nbsp;months in patients with recurrent measurable osteosarcoma as compared to
historical experience and/or whether glembatumumab vedotin therapy produces an objective response rate greater than 20% in patients without previous eribulin (eribulin mesylate) treatment. Secondary
outcome measures include safety, pharmacokinetics and the relation of gpNMB expression as measured by immunohistochemistry to clinical response. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Varlilumab  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Varlilumab, a fully human monoclonal agonist antibody, binds and activates CD27, a critical co-stimulatory molecule in the immune
activation cascade, primarily by stimulating T cells to attack cancer cells. Restricted expression and regulation of CD27 enables varlilumab specifically to activate T&nbsp;cells, resulting in an
enhanced immune response with a favorable safety profile. Varlilumab has also been shown to directly kill or inhibit the growth of CD27 expressing lymphomas and leukemias </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>. We have entered into license agreements with the University of Southampton, UK for intellectual property to
use anti-CD27 antibodies and with Medarex (now a subsidiary of the Bristol-Myers Squibb Company, or BMS) for access to the UltiMab technology to develop and commercialize human antibodies to CD27. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient
treatment is complete in the open label Phase&nbsp;1 study of varlilumab in patients with selected malignant solid tumors or hematologic cancers at multiple clinical sites in
the U.S. Initial dose escalation cohorts were conducted to determine an optimal dose for future study, and no maximum tolerated dose was reached. The lymphoid malignancies dose escalation arm
completed enrollment </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=74,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=685211,FOLIO='70',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>(n=24),
and a new cohort was added to include evaluation of T cell malignancies. An expansion cohort was also added at 0.3 mg/kg dosed once every three weeks in patients with Hodgkin lymphoma
(n=&nbsp;up&nbsp;to&nbsp;15). The solid tumor arm, which included patients with various solid tumors, completed dose escalation in 2013. Two expansion cohorts were subsequently added at 3 mg/kg
dosed weekly in metastatic melanoma (n=16) and RCC (n=15) to better characterize clinical activity and further define the safety profile in preparation for combination studies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
presented updated data from this Phase&nbsp;1 study in November 2014. Varlilumab was very well tolerated and induced immunologic activity in patients that is consistent with both
its mechanism of action and preclinical models. A total of 86 patients have been dosed in the study. 55 patients have been dosed in dose escalation cohorts (various solid and hematologic B-cell
tumors), and 31 patients have been dosed in the expansion cohorts (melanoma and RCC) at 3 mg/kg. In both the solid tumor and hematologic dose-escalations, the pre-specified maximum dose level (10
mg/kg) was reached without identification of a maximum tolerated dose. The majority of adverse events, or AEs, related to treatment have been mild to moderate (Grade 1/2) in severity, with only three
serious AEs related to treatment reported. No significant immune-mediated adverse events (colitis, hepatitis, etc.) typically associated with checkpoint blockade have been observed. Two patients
experienced objective responses including a complete response in Hodgkin lymphoma and a partial response in renal cell carcinoma. Thirteen patients experienced stable disease with a range of 3-36.2+
months (as of November 2015) to-date. Based on the results observed in hematologic malignancies, an expansion cohort in up to 15&nbsp;patients with Hodgkin lymphoma, and an abbreviated dose
escalation in T cell hematologic
malignancies were added and are now closed to enrollment. Any incremental data updates from this study will be included in future scientific presentations/publications. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2014, we entered into a clinical trial collaboration with BMS to evaluate the safety, tolerability and preliminary efficacy of varlilumab and Opdivo&reg;, BMS' PD-1 immune
checkpoint inhibitor, in a Phase 1/2 study. Under the terms of this clinical trial collaboration, BMS made a one-time payment to us of $5.0&nbsp;million, and the companies amended the terms of our
existing license agreement with Medarex (a subsidiary of BMS) related to our CD27 program whereby certain future milestone payments were waived and future royalty rates were reduced that may have been
due from us to Medarex. In return, BMS was granted a time-limited right of first negotiation if we wish to out-license varlilumab. The companies also agreed to work exclusively with each other to
explore anti-PD-1 antagonist antibody and anti-CD27 agonist antibody combination regimens. The clinical trial collaboration provides that the companies will share development costs and that we will be
responsible for conducting the Phase 1/2 study. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase 1/2 study was initiated in January 2015 and is being conducted in adult patients with multiple solid tumors to assess the safety and tolerability of varlilumab at varying doses
when administered with Opdivo followed by a Phase&nbsp;2 expansion to evaluate the activity of the combination in disease specific cohorts. We completed enrollment of the dose escalation portion of
the study without identification of a maximum tolerated dose, and a varlilumab dose has been identified for study in Phase&nbsp;2 (3 mg/kg). We anticipate that the Phase&nbsp;2 portion of the
study will open to enrollment in the second quarter of 2016. The protocol originally included five disease cohorts in the Phase&nbsp;2 portion of the study&#151;advanced non-small cell lung
cancer, colorectal cancer, ovarian cancer, head and neck squamous cell carcinoma, and metastatic melanoma. Based on the evolving treatment paradigm for the combination of Opdivo and Yervoy in
metastatic melanoma, a decision has been made not to enroll patients in this disease setting at this time. The protocol is also being amended to include additional cohorts in renal cell carcinoma,
where varlilumab has demonstrated single-agent clinical activity, and glioblastoma, an area of focus for both Celldex and BMS. The primary objective of the Phase&nbsp;2 cohorts will be ORR.
Secondary objectives include pharmacokinetics assessments, determining the immunogenicity of varlilumab when given in combination with Opdivo and further assessing the anti-tumor activity of
combination treatment. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=75,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=273777,FOLIO='71',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_72"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2015, we entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab and atezolizumab (anti-PDL1), Roche's
investigational cancer immunotherapy, in a Phase 1/2 study. The Phase&nbsp;1 portion of the study is being conducted in multiple tumor types, and the primary outcome is safety and tolerability. The
Phase&nbsp;2 portion of the study will be conducted in RCC, and the primary outcome is ORR. Secondary outcome measures include safety and tolerability, pharmacokinetics, immunogenicity and further
assessment of anti-tumor activity across a broad range of endpoints. Under the terms of this agreement, Roche will provide study drug, and we will be responsible for conducting and funding the study,
which opened to enrollment in December 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2015, we initiated a Phase 1/2 safety pilot and expansion study examining the combination of varlilumab and Yervoy in patients with Stage&nbsp;III or IV metastatic melanoma.
In the Phase&nbsp;2 portion of the study, patients with tumors that express NY-ESO-1 will also receive CDX-1401. The Phase&nbsp;1 portion of the study will assess the safety and tolerability of
varlilumab at varying doses when administered with Yervoy to identify a recommended dose for the Phase&nbsp;2 portion of the study. The Phase&nbsp;2 study will include two cohorts&#151;one
comprised of patients who are NY-ESO-1 positive and one comprised of patients who are NY-ESO-1 negative. Patients who are NY-ESO-1 positive will also receive CDX-1401 (with poly-ICLC at 2 mg given as
an adjuvant) in addition to varlilumab and Yervoy. The primary objective for both cohorts is objective response rate up to 24&nbsp;weeks. Secondary objectives for the Phase&nbsp;2 study include
safety and tolerability, immunogenicity, pharmacokinetics and further assessment of anti-tumor activity across a broad range of endpoints. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2015, we initiated a Phase 1/2 safety and tolerability study examining the combination of varlilumab and sunitinib (Sutent&reg;) in patients with metastatic clear cell
renal cell carcinoma. The Phase&nbsp;1 portion of the study will assess the safety and tolerability of varlilumab at varying doses when administered with sunitinib to identify a recommended dose for
the Phase&nbsp;2 portion of the study. The primary objective of the Phase&nbsp;2 portion of the study is to assess the preliminary anti-tumor efficacy of the varlilumab/sunitinib combination
measured by the overall response rate. Secondary objectives include safety and tolerability, pharmacokinetics, immunogenicity and further assessment of anti-tumor activity across a broad range of
endpoints. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our sponsored studies and clinical trial collaborations, we anticipate that varlilumab's potential activity will also be explored in investigator sponsored studies at
various academic institutions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CDX-1401  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1401, developed from our APC Targeting Technology, is an antibody-based NY-ESO-1-specific therapeutic vaccine for multiple solid
tumors. The vaccine, which is administered with an adjuvant, is composed of the cancer-specific antigen NY-ESO-1 fused to a fully human antibody that binds to DEC-205 for efficient delivery to
dendritic cells. Delivery of tumor-specific proteins directly to dendritic cells </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> elicits potent, broad, anti-tumor immune responses across
populations with different genetic backgrounds. In humans, NY-ESO-1 has been detected in 20% to 30% of all melanoma, lung, esophageal, liver, gastric, prostate, ovarian and bladder cancers, thus
representing a broad opportunity. We are developing CDX-1401 for the treatment of malignant melanoma and a variety of solid tumors which express the proprietary cancer antigen NY-ESO-1, which we
licensed from the Ludwig Institute for Cancer Research in 2006. Preclinical studies have shown that CDX-1401 is effective for activation of human T cell responses against NY-ESO-1. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have completed a Phase&nbsp;1 study of CDX-1401 which assessed the safety, immunogenicity and clinical activity of escalating doses of CDX-1401 with TLR agonists (resiquimod and/or
Poly ICLC) in 45 patients with advanced malignancies refractory to all available therapies. Sixty percent of patients had confirmed NY-ESO expression in archived tumor sample. Thirteen patients
maintained stable </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=76,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=663207,FOLIO='72',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_73"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>disease
for up to 13.4&nbsp;months with a median of 6.7&nbsp;months. Treatment was well tolerated, and there were no dose limiting toxicities. Humoral responses were elicited in both NY-ESO-1
positive and negative patients. NY-ESO-1-specific T cell responses were absent or low at baseline, but increased post-vaccination in 53% of evaluable patients, including both CD4 and/or CD8 T cell
responses. Robust immune responses were observed with CDX-1401 with resiquimod and Poly ICLC alone and in combination. Long-term patient follow up suggested that treatment with CDX-1401 may predispose
patients to better outcomes on subsequent therapy with checkpoint inhibitors. Of the 45 patients in the Phase&nbsp;1 study, eight went on to receive subsequent therapy of either Yervoy or an
investigational checkpoint inhibitor, and six of these patients had objective tumor regression. Six patients with melanoma received Yervoy within three months of treatment with CDX-1401, and four
(67%) had objective tumor responses, including one complete response, which compares favorably to the overall response rate of 11% previously reported in metastatic melanoma patients treated with
single-agent Yervoy. In addition, two patients with non-small cell lung cancer received an investigational checkpoint blockade within two months of completing treatment with CDX-1401, and both
achieved partial responses. We are currently developing a follow on program that will better assess the impact of CDX-1401 activity on response to subsequent checkpoint inhibitor therapy in these
diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase&nbsp;1 study identified a well-tolerated and immunogenic regimen to take forward into future studies. As described above, in April 2015, we initiated a Phase 1/2 safety pilot
and expansion study examining the combination of varlilumab and Yervoy in patients with Stage&nbsp;III or IV metastatic melanoma. In the Phase&nbsp;2 portion of the study, patients with tumors
that express NY-ESO-1 will also receive CDX-1401. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our sponsored studies, CDX-1401's potential activity is also being explored in investigator sponsored and collaborative studies. A Phase&nbsp;2 study of CDX-1401 in
combination with CDX-301 is being conducted in metastatic melanoma by the Cancer Immunotherapy Trials Network under a CRADA with the Cancer Therapy Evaluation Program of the NCI. This study will
determine if CDX-1401 works better with or without CDX-301 in melanoma. The primary outcome measure of the study is immune response to NY-ESO-1. Secondary outcome measures include analysis and
characterization of peripheral blood mononuclear cells (dendritic cells, T cells, natural killer cells, etc.), additional immune monitoring, safety and clinical outcomes (survival and time to tumor
recurrence). Enrollment is now complete. Based on results to date, plans for additional studies are being considered by NCI. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
a Phase&nbsp;1/2b multi-arm study of the IDO1 inhibitor INCB024360 in combination with CDX-1401 and Hiltonol is being conducted in patients in remission with ovarian,
fallopian tube or primary peritoneal cancer by the Roswell Park Cancer Institute. Celldex is providing CDX-1401 and Hiltonol in support of this study. Patients' tumors must have expressed NY-ESO-1 or
the LAGE-1 antigen to be eligible for the study. Primary outcome measures include identifying a maximum tolerated dose determined by the incidence of dose limiting toxicities and progression free
survival. Secondary outcome measures include additional safety analyses and immune monitoring. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CDX-301  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-301, a recombinant FMS-like tyrosine kinase 3 ligand, or Flt3L, is a potent hematopoietic cytokine that uniquely expands dendritic
cells and hematopoietic stem cells in combination with other agents to potentiate the anti-tumor response. Depending on the setting, cells expanded by CDX-301 promote either enhanced or permissive
immunity. CDX-301 is in clinical development for multiple cancers, in combination with vaccines, adjuvants and other treatments that release tumor antigens. We licensed CDX-301 from Amgen&nbsp;Inc.
in March 2009 and believe CDX-301 may hold significant opportunity for synergistic development in combination with other proprietary molecules in our portfolio. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=77,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=624075,FOLIO='73',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_74"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2013, we announced final results from our dose-escalating Phase&nbsp;1 study of CDX-301 in 30 healthy subjects in collaboration with Rockefeller University. The
Phase&nbsp;1 study evaluated seven different dosing regimens of CDX-301 to determine the appropriate dose for further development based on safety, tolerability and biological activity. The data from
the study were consistent with previous clinical experience and demonstrated that CDX-301 was well tolerated and can effectively mobilize hematopoietic stem cell populations in healthy volunteers. In
December 2013, we announced data from a preclinical combination study of CDX-301and Mozobil&reg; (Plerixafor injection, formerly AMD3100) demonstrating that the combination of these agents
significantly increases hematopoietic stem cell mobilization in mice. The data demonstrate a novel potent cell mobilization regimen combining CDX-301 and Mozobil&reg;, which may have
significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation. Based on the safety profile and the clinical and preclinical data to date, we initiated a pilot
clinical study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell
transplantation. Related donors of patients with hematological malignancies requiring hematopoietic stem cell transplant are administered CDX-301 for 5 or 7&nbsp;days alone or in combination with
Mozobil to mobilize CD34+ stem cells. The primary efficacy endpoint of the study is determine if treatment of the donor results in the collection of <FONT FACE="SYMBOL">&#179;</FONT>
2&nbsp;million CD34+ HSCs/kg recipient body weight in <FONT FACE="SYMBOL">&#163;</FONT> 2 leukopoiesis collections. Other key endpoints are the safety of the treatment regimen in the
donor and clinical outcomes in the
recipient, including stem cell engraftment, graft-versus-host disease, immune reconstitution and relapse. Preliminary results from this study were presented at the annual meeting of the American
Society for Blood and Marrow Transplantation in February 2016. These preliminary data from three donor/patient pairs showed that CDX-301 given as a single agent was well tolerated and effective at
mobilizing hematopoietic stem cells in healthy donors. The stem cell graft contained notable increases in na&iuml;ve lymphocytes and plasmacytoid dendritic cells consistent with preclinical
data suggesting a possible better outcome. Recipients experienced successful engraftment in an expected time frame. Additional subjects are being accrued to assess the potential synergy of combining
CDX-301 with Mozobil in this setting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our sponsored studies and clinical trial collaborations, CDX-301's potential activity is also being explored in investigator sponsored studies at various academic
institutions. This includes a Phase 1/2 study of CDX-301 and Hiltonol in combination with low-dose radiotherapy in patients with low-grade B-cell lymphomas conducted by the Icahn School of Medicine at
Mount Sinai. The primary outcome of the study is objective response rate. Secondary outcome measures include safety and tumor specific immune response. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CDX-014  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-014 is a fully-human monoclonal ADC that targets T cell immunoglobulin and mucin domain&nbsp;1, or TIM-1, a molecule that is
upregulated in several cancers, including renal cell and ovarian carcinomas. TIM-1 is associated with kidney injury, and the shedding of its ectodomain is a predictive biomarker for tumor progression.
TIM-1 has very restricted expression in healthy tissues, making it a promising target for antibody mediated therapy. The TIM-1 antibody is linked to MMAE using Seattle Genetics' proprietary
technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into TIM-1-expressing tumor cells, resulting in a targeted cell-killing effect. CDX-014 has
shown potent activity in preclinical models of ovarian and renal cancer. The Investigative New Drug (IND) Application is active, and we expect to initiate a Phase&nbsp;1 clinical study in renal cell
carcinoma in 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CRITICAL ACCOUNTING POLICIES AND ESTIMATES  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our significant accounting policies are described in Note&nbsp;2 to the financial statements included in Item&nbsp;8 of this
Form&nbsp;10-K. We believe our most critical accounting policies include accounting for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=78,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=821156,FOLIO='74',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_75"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>revenue
recognition, impairment of intangible and long-lived assets, research and development expenses and stock-based compensation expense. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results we report in our financial statements. We evaluate
our estimates and judgments on an on-going basis. We base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Our experience and
assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and
different assumptions or estimates about the future could materially change our reported results. We believe the following accounting policies are the most critical to us in that they are important to
the portrayal of our financial statements and they require our most difficult, subjective or complex judgments in the preparation of our financial statements: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue Recognition  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or
services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic drug
products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product sales
derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of
accounting. In accounting for these transactions, we allocate revenue to the various elements based on their relative fair value. The fair value of a revenue generating element can be based on current
selling prices offered by us or another party for current products or our best estimate of a selling price for future products. Revenue allocated to an individual element is recognized when all other
revenue recognition criteria are met for that element. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of
the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of our involvement in achieving the milestones and whether the amount of the payment is
commensurate to
our performance. If not considered substantive, milestones are initially deferred and recognized over the remaining period of the performance obligation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is
recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or our contractual partner. Payments received in advance that are
related to future performance are deferred and recognized as revenue when the research projects are performed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize our licensed technologies and are recognized when the
amount of and basis for such royalty payments are reported to us in accurate and appropriate form and in accordance with the related license agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Impairment of Intangible and Long-Lived Assets  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We evaluate the recoverability of our long-lived assets, including property and equipment, and finite-lived intangible assets when
circumstances indicate that an event of impairment may have </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=79,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=625888,FOLIO='75',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<A NAME="page_do72301_1_76"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>occurred.
Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows
are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D
assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible assets. These assets are capitalized on our balance
sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the carrying value of the related intangible asset is amortized over the
remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset is
written down to its fair value and an impairment charge is taken in the period in which the impairment occurs. IPR&amp;D assets are tested for impairment on an annual basis during the third quarter, or
earlier if impairment indicators are present.
Discounted cash flow models are typically used in these tests and the models require the use of significant estimates and assumptions including but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> timing and costs to complete the in-process projects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> timing and probability of success of clinical events or regulatory approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> estimated future cash flows from product sales resulting from completed products and in-process projects; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discount rates </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
performed an annual impairment test of the IPR&amp;D assets as of July&nbsp;1, 2015 and concluded that the IPR&amp;D assets were not impaired. Intangible assets acquired in a business
combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a straight-line basis over their estimated useful life. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is recorded to goodwill. Goodwill is evaluated for
impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. We performed an annual impairment test of the goodwill asset as of July&nbsp;1, 2015 and
concluded that goodwill was not impaired. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development
expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other preclinical studies, personnel costs, depreciation, license fees and funding of outside
contracted research. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trial expenses include expenses associated with clinical research organizations, or CRO, services. Contract manufacturing expenses include expenses associated with contract
manufacturing organizations, or CMO, services. The invoicing from CROs and CMOs for services rendered can lag several months. We accrue the cost of services rendered in connection with CRO and CMO
activities based on our estimate of costs incurred. We maintain regular communication with our CROs and CMOs to assess the reasonableness of our estimates. Differences between actual expenses and
estimated expenses recorded have not been material and are adjusted for in the period in which they become known. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=80,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=598675,FOLIO='76',FILE='DISK133:[15ZCW1.15ZCW72301]DO72301A.;21',USER='VSTEFAN',CD='20-FEB-2016;02:16' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq72301_1_77"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We record stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair
values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Our estimates of employee stock option values rely on estimates of
future uncertain events. Significant assumptions include the use of historical volatility to estimate the expected stock price volatility. We also estimate expected term based on historical exercise
patterns. Actual volatility and lives of options may be significantly different from our estimates. Compensation expense for all stock-based awards to employees and directors is recognized using the
straight-line method over the term of vesting or performance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
record stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the vesting term resulting in
periodic adjustments to stock-based compensation expense. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


RESULTS OF OPERATIONS  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Year Ended December&nbsp;31, 2015 compared with Year Ended December&nbsp;31, 2014  </I></B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="21pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenue:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development and Licensing Agreements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>604</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts and Grants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,748</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,290</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,586</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expense:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>104,381</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,210</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and Administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33,837</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,622</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,215</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of Acquired Intangible Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Operating Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>135,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,005</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(129,541</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(122,430</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investment and Other Income, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,344</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,006</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,117</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $9.1&nbsp;million increase in net loss for the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31,
2014 was primarily the result of an increase in general and administrative expenses, partially offset by a decrease in research and development expenses. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $0.6&nbsp;million increase in product development and licensing agreements revenue for the year ended December&nbsp;31, 2015
compared to the year ended December&nbsp;31, 2014 was primarily related to our BMS agreement. In May 2014, we entered into a clinical trial collaboration with BMS whereby BMS made a one-time payment
to us of $5.0&nbsp;million which we are recognizing as revenue along with BMS's 50% share of the clinical trial cost over our estimated performance period of five years. The </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=81,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=143010,FOLIO='77',FILE='DISK133:[15ZCW1.15ZCW72301]DQ72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:33' -->
<A NAME="page_dq72301_1_78"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>$1.3&nbsp;million
increase in contracts and grants revenue for the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31, 2014 was primarily related to our Rockefeller
University agreement pursuant to which we perform research and development services for Rockefeller. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist primarily of (i)&nbsp;personnel expenses, (ii)&nbsp;laboratory supply expenses relating
to the development of our technology, (iii)&nbsp;facility expenses, (iv)&nbsp;license fees and (v)&nbsp;product development expenses associated with our drug candidates as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="21pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,774</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory Supplies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,598</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>757</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Facility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,756</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>694</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>License Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>896</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,254</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,776</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,205</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14,429</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Personnel
expenses primarily include salary, benefits, stock-based compensation and payroll taxes. The $9.1&nbsp;million increase in personnel expenses for the year ended
December&nbsp;31, 2015 compared to the year
ended December&nbsp;31, 2014 was primarily due to increased headcount and higher stock-based compensation of $2.7&nbsp;million. We expect personnel expenses to increase over the next twelve months
as we plan to continue to increase our headcount to support our Rintega, glembatumumab vedotin and varlilumab programs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Laboratory
supply expenses include laboratory materials and supplies, services, and other related expenses incurred in the development of our technology. The $0.8&nbsp;million increase
in laboratory supply expenses for the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31, 2014 was primarily due to higher manufacturing supply purchases. We expect
supply expenses to remain relatively consistent over the next twelve months, although there may be fluctuations on a quarterly basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Facility
expenses include depreciation, amortization, utilities, rent, maintenance, and other related expenses incurred at our facilities. The $0.7&nbsp;million increase in facility
expenses for the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31, 2014 was primarily due to an increase in rent and depreciation and amortization expense. We expect
facility expenses to increase over the next twelve months as a result of us leasing additional space at our facilities in Hampton, NJ, Needham MA, and Fall River MA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License
fee expenses include annual license maintenance fees and milestone payments due upon the achievement of certain development, regulatory and/or commercial milestones. The
$2.3&nbsp;million decrease in license fee expenses for the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31, 2014 was primarily due to the one-time
$2.5&nbsp;million milestone incurred and paid to Seattle Genetics in 2014 as a result of the METRIC study initiation. We expect license fee expense may increase over the next twelve months as our
drug candidates reach achievement of certain development, regulatory and/or commercial milestones, although there may be fluctuations on a quarterly basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product
manufacturing. The $14.4&nbsp;million decrease in product development expenses for the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31, 2014 was primarily due to a
$13.5&nbsp;million decrease in ACT&nbsp;IV costs. Increases in glembatumumab vedotin and varlilumab clinical trial costs of $2.4&nbsp;million and $3.0&nbsp;million, respectively, were offset
by decreases in contract manufacturing costs of $6.4&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=82,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=131429,FOLIO='78',FILE='DISK133:[15ZCW1.15ZCW72301]DQ72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:33' -->
<A NAME="page_dq72301_1_79"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
expect product development expenses to increase over the next twelve months primarily due to increases in our glembatumumab vedotin and varlilumab programs, although there may be fluctuations on a
quarterly basis. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $13.2&nbsp;million increase in general and administrative expenses for the year ended December&nbsp;31, 2015 compared to the
year ended December&nbsp;31, 2014 was primarily due to higher headcount, stock-based compensation of $3.2&nbsp;million and a $6.5&nbsp;million increase in Rintega and glembatumumab vedotin
commercial planning costs as we prepare for potential commercial launches. We expect general and administrative expense to increase over the next twelve months primarily due to increased commercial
planning efforts for Rintega and glembatumumab vedotin. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amortization Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expenses for the year ended December&nbsp;31, 2015 were consistent compared to the year ended December&nbsp;31, 2014.
We expect amortization expense of acquired intangible assets to remain relatively consistent over the next twelve months. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investment and Other Income, Net  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $2.0&nbsp;million decrease in investment and other income, net for the year ended December&nbsp;31, 2015 compared to the year
ended December&nbsp;31, 2014 was primarily due to other income of $3.0&nbsp;million received in 2014 in connection with our TopoTarget agreement. These payments are the last milestone payments we
were owed from TopoTarget. We anticipate investment income to remain relatively consistent over the next twelve months, although there may be fluctuations on a quarterly basis. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Year Ended December&nbsp;31, 2014 compared with Year Ended December&nbsp;31, 2013  </I></B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenue:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development and Licensing Agreements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>160</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>678</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>424</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts and Grants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,748</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,617</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,131</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Royalties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,586</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expense:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>104,381</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>67,401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,980</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Royalty</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and Administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,622</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,805</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,817</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of Acquired Intangible Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Operating Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>85,553</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,463</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(122,430</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,988</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investment and Other Income, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>819</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,531</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>431</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,530</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=83,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=356663,FOLIO='79',FILE='DISK133:[15ZCW1.15ZCW72301]DQ72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:33' -->
<A NAME="page_dq72301_1_80"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $36.5&nbsp;million increase in net loss for the year ended December&nbsp;31, 2014 compared to the year ended
December&nbsp;31, 2013 was primarily the result of an increase in research and development and general and administrative expenses, partially offset by an increase in investment and other income. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $0.7&nbsp;million increase in product development and licensing agreements revenue for the year ended December&nbsp;31, 2014
compared to the year ended December&nbsp;31, 2013 was primarily related to our BMS agreement. The $1.1&nbsp;million increase in contracts and grants revenue for the year ended December&nbsp;31,
2014 compared to the year ended December&nbsp;31, 2013 was primarily related to our Rockefeller University agreement pursuant to which we perform research and development services for Rockefeller.
The $2.3&nbsp;million decrease in product royalty revenue for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013 was due to the termination of our agreement
with GlaxoSmithKline&nbsp;plc which occurred upon the expiration of the last relevant patent right covered by the agreement. The terminated retained interests in Rotarix&reg; net royalties
which were not sold to Paul Royalty Fund II,&nbsp;L.P. had been equal to the amount payable to Cincinnati Children's Hospital Medical Center and recognized as royalty expense by us. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expense  </I></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase/<BR>
(Decrease) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,040</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory Supplies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,598</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,247</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>351</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Facility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,526</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>536</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>License Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,205</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,343</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,862</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
$3.6&nbsp;million increase in personnel expenses for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013 was primarily due to increased
headcount and higher stock-based compensation of $0.8&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
$0.4&nbsp;million increase in laboratory supply expenses for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013 was primarily due to higher
manufacturing supply purchases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
$0.5&nbsp;million increase in facility expenses for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013 was primarily due to an increase in
amortization expense related to the leasehold improvements made at our headquarters facility in Hampton, New Jersey. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
$2.5&nbsp;million increase in license fee expenses for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013 was primarily due to the one-time
$2.5&nbsp;million milestone incurred and paid to Seattle Genetics as a result of the METRIC initiation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
$27.9&nbsp;million increase in product development expenses for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013 was primarily the result
of an increase in clinical trial costs and contract manufacturing of $13.2&nbsp;million and $14.3&nbsp;million, respectively, primarily related to our Rintega and glembatumumab vedotin programs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=84,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=210998,FOLIO='80',FILE='DISK133:[15ZCW1.15ZCW72301]DQ72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:33' -->
<A NAME="page_dq72301_1_81"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Royalty Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $2.3&nbsp;million decrease in royalty expenses for the year ended December&nbsp;31, 2014 compared to the year ended
December&nbsp;31, 2013 was due to the termination of our agreement with GlaxoSmithKline&nbsp;plc which occurred upon the expiration of the last relevant patent right covered by the agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $5.8&nbsp;million increase in general and administrative expenses for the year ended December&nbsp;31, 2014 compared to the
year ended December&nbsp;31, 2013 was primarily due to higher stock-based compensation of $1.5&nbsp;million, increased headcount and Rintega and glembatumumab vedotin commercialization planning
costs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amortization Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expenses for the year ended December&nbsp;31, 2014 were consistent compared to the year ended December&nbsp;31, 2013. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investment and Other Income, Net  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $3.5&nbsp;million increase in investment and other income, net for the year ended December&nbsp;31, 2014 compared to the year
ended December&nbsp;31, 2013 was primarily due to other income in 2014 of $3.0&nbsp;million related to TopoTarget milestone payments. These payments are the last milestone payments we were owed
from TopoTarget. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The $0.9&nbsp;million decrease in interest expense for the year ended December&nbsp;31, 2014 compared to the year ended
December&nbsp;31, 2013 was primarily due to our election in May 2013 to prepay the Term Loan in full, pursuant to the terms of our loan agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


LIQUIDITY AND CAPITAL RESOURCES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our cash equivalents are highly liquid investments with a maturity of three months or less at the date of purchase and consist
primarily of investments in money market mutual funds with commercial banks and financial institutions. We maintain cash balances with financial institutions in excess of insured limits. We do not
anticipate any losses with respect to such cash balances. We invest our excess cash balances in marketable securities including municipal bond securities, U.S. government agency securities, and
high-grade corporate bonds that meet high credit quality standards, as specified in our investment policy. Our investment policy seeks to manage these assets to achieve our goals of preserving
principal and maintaining adequate liquidity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
use of our cash flows for operations has primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices, laboratories and
manufacturing facility, fees paid in connection with preclinical studies, clinical studies, contract manufacturing, laboratory supplies and services, consulting, legal and other professional fees. To
date, the primary sources of cash flows from operations have been payments received from our collaborative partners and from government entities. The timing of any new collaboration agreements,
government contracts or grants and any payments under these agreements, contracts or grants cannot be easily predicted and may vary significantly from quarter to quarter. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=85,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=829170,FOLIO='81',FILE='DISK133:[15ZCW1.15ZCW72301]DQ72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds72301_1_82"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2015, our principal sources of liquidity consisted of cash, cash equivalents and marketable securities of $289.9&nbsp;million. We
incurred a loss of $127.2&nbsp;million for the year ended December&nbsp;31, 2015. Net cash used in operations for the year ended December&nbsp;31, 2015 was $98.9&nbsp;million. We believe that
the cash, cash equivalents and marketable securities at December&nbsp;31, 2015 are sufficient to meet estimated working capital requirements and fund planned operations through 2017, however, this
could be impacted by our clinical data results from our Rintega program and their impact on our pace of commercial manufacturing and the rate of expansion of our commercial operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the next twelve months, we may take further steps to raise additional capital to meet our long-term liquidity needs. Our capital raising activities may include, but may not be
limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common
stock or other securities via private placements or public offerings. While we may seek capital through a number of means, there can be no assurance that additional financing will be available on
acceptable terms, if at all, and our negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that we will be able to enter into further
collaborative relationships. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict
our ability to operate as a business; and licensing
or strategic collaborations may result in royalties or other terms which reduce our economic potential from products under development. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities was $98.9&nbsp;million for the year ended December&nbsp;31, 2015 compared to
$101.5&nbsp;million for the year ended December&nbsp;31, 2014. The decrease in net cash used in operating activities was primarily due to increases in accounts payable and other accrued expenses
of $3.4&nbsp;million and stock-based compensation expense of $5.9&nbsp;million, offset by an increase in net loss of $9.1&nbsp;million. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $101.5&nbsp;million for the year ended December&nbsp;31, 2014 compared to $67.7&nbsp;million for the year ended December&nbsp;31, 2013.
The increase in net cash used in operating activities was primarily due to an increase in net loss of $36.5&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that cash used in operating activities will increase over the next twelve months primarily related to costs incurred on our Rintega, glembatumumab vedotin and varlilumab
programs. We have incurred and will continue to incur significant costs in the area of research and development, including preclinical and clinical trials and clinical drug product manufacturing as
our drug candidates are developed. We plan to spend significant amounts to progress our current drug candidates through the clinical trial and commercialization processes as well as to develop
additional drug candidates. As our drug candidates progress through the clinical trial process, we may be obligated to make significant milestone payments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investing Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities was $50.2&nbsp;million for the year ended December&nbsp;31, 2015 compared to
$41.0&nbsp;million for the year ended December&nbsp;31, 2014. The increase in net cash used in investing activities was primarily due to net purchases of marketable securities for the year ended
December&nbsp;31, 2015 of $45.3&nbsp;million as compared to $39.1&nbsp;million for the year ended December&nbsp;31, 2014. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in investing activities was $41.0&nbsp;million for the year ended December&nbsp;31, 2014 compared to $77.4&nbsp;million for the year ended December&nbsp;31, 2013.
The decrease in net cash used in investing activities was primarily due to net purchases of marketable securities for the year ended </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=86,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=292665,FOLIO='82',FILE='DISK133:[15ZCW1.15ZCW72301]DS72301A.;6',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_ds72301_1_83"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>December&nbsp;31,
2014 of $39.1&nbsp;million as compared to $73.2&nbsp;million for the year ended December&nbsp;31, 2013. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that cash provided by investing activities will increase over the next twelve months as we fund our operations through the net proceeds from the sale and maturity of marketable
securities, cash provided by financing activities and/or new partnerships, although there may be significant fluctuations on a quarterly basis. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financing Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities was $193.2&nbsp;million for the year ended December&nbsp;31, 2015 compared to
$1.2&nbsp;million for the year ended December&nbsp;31, 2014. Net proceeds from stock issuances, including stock issued pursuant to employee benefit plans, were $193.2&nbsp;million during the
year ended December&nbsp;31, 2015 compared to $1.2&nbsp;million for the year ended December&nbsp;31, 2014. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash provided by financing activities was $1.2&nbsp;million for the year ended December&nbsp;31, 2014 compared to $289.6&nbsp;million for the year ended December&nbsp;31,
2013. Net proceeds from stock issuances, including stock issued pursuant to employee benefit plans, were $1.2&nbsp;million during the year ended December&nbsp;31, 2014 compared to
$301.1&nbsp;million for the year ended December&nbsp;31, 2013. We paid $11.0&nbsp;million in principal payments on our Term Loan during the year ended December&nbsp;31, 2013. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Offerings  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2013, we filed an automatic shelf registration statement with the Securities and Exchange Commission to register for sale
any combination of the types of securities described in the shelf registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the years ended December&nbsp;31, 2015 and December&nbsp;31, 2013, we issued 8,337,500 and 21,613,483 shares of our common stock in underwritten public offerings resulting in
net proceeds to us of $188.8&nbsp;million and $278.6&nbsp;million, after deducting underwriting fees and offering expenses, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2013, we issued 2,433,608 shares of our common stock under our controlled equity offering sales agreement with Cantor
Fitzgerald&nbsp;&amp;&nbsp;Co., as amended, resulting in net proceeds to us of $17.1&nbsp;million, after deducting commission and offering expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


AGGREGATE CONTRACTUAL OBLIGATIONS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into license agreements whereby we have received licenses or options to license technology, specified patents and/or
patent applications. These license and collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing
patent prosecution costs and potential future milestone payments to third parties upon the achievement of certain development, regulatory and/or commercial milestones. Because the achievement of these
milestones had not occurred as of December&nbsp;31, 2015 such contingencies have not been recorded in our financial statements. We expect to incur approximately $2.0&nbsp;million of license and
milestone payments in 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes our contractual obligations (not including contingent royalty and milestone payments as described above) at December&nbsp;31, 2015 and the effect such
obligations and commercial commitments are expected to have on our liquidity and cash flow in future years. These </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=87,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=989277,FOLIO='83',FILE='DISK133:[15ZCW1.15ZCW72301]DS72301A.;6',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_ds72301_1_84"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>obligations,
commitments and supporting arrangements represent expected payments based on current operating forecasts, which are subject to change: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017&nbsp;-&nbsp;2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019&nbsp;-&nbsp;2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Thereafter </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contractual obligations:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,239</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,940</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,278</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other contractual obligations(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,039</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total contractual obligations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,678</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,421</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,979</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,278</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Such
amounts primarily consist of payments for our facility leases and do not assume the exercise of renewal terms or early termination provisions. In
February 2016, the Company amended the facility lease in Fall River, MA for additional space and to extend the term from 2017 to 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
enter into agreements in the normal course of business with contract research organizations for clinical trials, contract manufacturing organizations,
vendors for preclinical research studies and other services and products for operating purposes. We have included obligations in the table above if the contracts are not cancelable at any time by us,
generally upon 30&nbsp;days prior written notice to the vendor.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


RECENT ACCOUNTING PRONOUNCEMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Refer to Note&nbsp;2, "Summary of Significant Accounting Policies," in the accompanying notes to the financial statements for a
discussion of recent accounting pronouncements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


OFF-BALANCE SHEET ARRANGEMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ds72301_item_7a._quantitative_and_qual__ite02669"> </A>
<A NAME="toc_ds72301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7A.&nbsp;&nbsp;&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We own financial instruments that are sensitive to market risk as part of our investment portfolio. Our investment portfolio is used to
preserve our capital until it is used to fund operations, including our research and development activities. None of these market-risk sensitive instruments are held for trading purposes. We invest
our cash primarily in money market mutual funds. These investments are evaluated quarterly to determine the fair value of the portfolio. From time to time, we invest our excess cash balances in
marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds that meet high credit quality standards, as specified in our investment
policy. Our investment policy seeks to manage these assets to achieve our goals of preserving principal and maintaining adequate liquidity. Because of the short-term nature of these investments, we do
not believe we have material exposure due to market risk. The impact to our financial position and results of operations from likely changes in interest rates is not material. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not utilize derivative financial instruments. The carrying amounts reflected in the balance sheet of cash and cash equivalents, accounts receivables and accounts payable
approximates fair value at December&nbsp;31, 2015 due to the short-term maturities of these instruments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=88,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=276696,FOLIO='84',FILE='DISK133:[15ZCW1.15ZCW72301]DS72301A.;6',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fa72301_1_85"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="fa72301_item_8._financial_statements_and_supplementary_data"> </A>
<A NAME="toc_fa72301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fa72301_report_of_independent___fa702275"> </A>
<A NAME="toc_fa72301_2"> </A></FONT> <FONT SIZE=2><B>  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To
the Board of Directors and Stockholders of Celldex Therapeutics,&nbsp;Inc. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our opinion, the accompanying balance sheets and the related statements of operations and comprehensive loss, of stockholders' equity, and of cash flows present fairly, in all
material respects, the financial position of Celldex Therapeutics,&nbsp;Inc. at December&nbsp;31, 2015 and December&nbsp;31, 2014 and the results of its operations and its cash flows for each of
the three years in the period ended December&nbsp;31, 2015 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained,
in all material respects, effective internal control over financial reporting as of December&nbsp;31, 2015, based on criteria established in </FONT><FONT SIZE=2><I>Internal
Control&#151;Integrated Framework (2013)</I></FONT><FONT SIZE=2> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible
for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included
in Management's Annual Report on Internal Control over Financial Reporting appearing under Item&nbsp;9A. Our responsibility is to express opinions on these financial statements and on the Company's
internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal
control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal
control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the
design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe
that our audits provide a reasonable basis for our opinions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures
that (i)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&nbsp;provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&nbsp;provide reasonable assurance regarding prevention or
timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers&nbsp;LLP </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Boston,
Massachusetts<BR>
February&nbsp;25, 2016 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=89,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=88834,FOLIO='85',FILE='DISK133:[15ZCW1.15ZCW72301]FA72301A.;4',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fc72301_1_86"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fc72301_celldex_therapeutics,_inc._bal__cel03405"> </A>
<A NAME="toc_fc72301_1"> </A></FONT> <FONT SIZE=2><B><BR>  CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    <BR>    BALANCE SHEETS    <BR>    <BR>    (In thousands, except share and per share amounts)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Consolidated<BR>
December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ASSETS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current Assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and Cash Equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72,108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28,020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>217,781</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>173,023</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts and Other Receivables</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>427</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid and Other Current Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,515 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Current Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>294,936</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>204,985 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and Equipment, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,461</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,535</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Intangible Assets, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,794</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,807</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,428</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,722</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Goodwill</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,965 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>337,584</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>248,014 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>LIABILITIES AND STOCKHOLDERS' EQUITY</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current Liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts Payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,506</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,603</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,296</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current Portion of Long-Term Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,418</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,592 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Current Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,240</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,491 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Long-Term Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,239</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,863 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>47,479</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,354 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and Contingent Liabilities (Notes&nbsp;14 and 16)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' Equity:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible Preferred Stock, $.01 Par Value; 3,000,000 Shares Authorized; No Shares Issued and Outstanding at December&nbsp;31, 2015 and 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common Stock, $.001 Par Value; 297,000,000 Shares Authorized; 98,685,595 and 89,592,779 Shares Issued and Outstanding at December&nbsp;31, 2015 and 2014,
respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional Paid-In Capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>878,655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>672,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated Other Comprehensive Income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,307</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,590</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated Deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(590,956</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(463,759</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Stockholders' Equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>290,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>211,660 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Liabilities and Stockholders' Equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>337,584</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>248,014 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of the financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=90,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=604869,FOLIO='86',FILE='DISK133:[15ZCW1.15ZCW72301]FC72301A.;4',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fe72301_1_87"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fe72301_celldex_therapeutics,_inc._sta__cel04457"> </A>
<A NAME="toc_fe72301_1"> </A></FONT> <FONT SIZE=2><B><BR>  CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    <BR>    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    <BR>    <BR>    (In thousands, except per share amounts)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Consolidated<BR>
Year Ended<BR>
December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Consolidated<BR>
Year Ended<BR>
December&nbsp;31, 2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>REVENUE:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Development and Licensing Agreements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>160</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contracts and Grants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,748</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,617</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Product Royalties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,334 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,586</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,111 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>OPERATING EXPENSE:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>104,381</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>67,401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Royalty</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and Administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33,837</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,622</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,805</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of Acquired Intangible Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Operating Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>135,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>85,553 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(129,541</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(122,430</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investment and Other Income, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,344</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>819</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and Diluted Net Loss Per Common Share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Used in Calculating Basic and Diluted Net Loss per Share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>97,051</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,399</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>79,777 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>COMPREHENSIVE LOSS:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Comprehensive Income (Loss):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign Currency Translation Adjustments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized Loss on Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Comprehensive Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of the financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=91,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=367263,FOLIO='87',FILE='DISK133:[15ZCW1.15ZCW72301]FE72301A.;4',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fg72301_1_88"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> STATEMENTS OF STOCKHOLDERS' EQUITY  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share amounts)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common<BR>
Stock<BR>
Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common<BR>
Stock Par<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Paid-In<BR>
Capital </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Other<BR>
Comprehensive<BR>
Income </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Stockholders'<BR>
Equity </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated Balance at December&nbsp;31, 2012</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 64,359,513</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>64</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>357,094</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>2,745</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(264,129</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>95,774</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued under Stock Option and Employee Stock Purchase Plans</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>840,228</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,402</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,403</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued in Connection with Cantor Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,433,608</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,132</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,134</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued in Underwritten Offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,613,483</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>278,541</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>278,563</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-Based Compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign Currency Translation Adjustments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized Losses on Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated Balance at December&nbsp;31, 2013</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 89,246,832</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>89</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>662,717</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>2,668</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(345,679</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>319,795</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued under Stock Option and Employee Stock Purchase Plans</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>193,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,170</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued in Connection with Supply Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>152,172</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-Based Compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,852</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,852</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign Currency Translation Adjustments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized Losses on Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated Balance at December&nbsp;31, 2014</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 89,592,779</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>90</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>672,739</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>2,590</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(463,759</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>211,660</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued under Stock Option and Employee Stock Purchase Plans</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>755,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,310</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,311</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Issued in Underwritten Offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,337,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>188,832</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>188,840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Share-Based Compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,774</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,774</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign Currency Translation Adjustments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized Losses on Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2015</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> 98,685,595</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>99</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>878,655</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>2,307</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>(590,956</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>290,105</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>
The accompanying notes are an integral part of the financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=92,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=495334,FOLIO='88',FILE='DISK133:[15ZCW1.15ZCW72301]FG72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fi72301_1_89"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fi72301_celldex_therapeutics,_inc._sta__cel02468"> </A>
<A NAME="toc_fi72301_1"> </A></FONT> <FONT SIZE=2><B><BR>  CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    <BR>    STATEMENTS OF CASH FLOWS    <BR>    <BR>    (In thousands)    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Consolidated<BR>
Year Ended<BR>
December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Consolidated<BR>
Year Ended<BR>
December&nbsp;31, 2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash Flows From Operating Activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and Amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,998</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,388</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,932</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of Intangible Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization and Premium of Marketable Securities, Net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>95</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Realized Gain on Sales and Maturities of Marketable
Securities&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss (Gain) on Sale or Disposal of Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-Based Compensation Expense&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,774</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,852</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-Cash Expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>97</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in Operating Assets and Liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts and Other Receivables</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(543</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(445</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid and Other Current Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(653</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,026</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(706</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>276</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts Payable and Accrued Expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,875</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,236</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,202</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,577</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,317 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Cash Used in Operating Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(98,887</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(101,537</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(67,669</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash Flows From Investing Activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sales and Maturities of Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>161,090</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>38,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of Marketable Securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(206,405</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(148,314</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(112,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquisition of Property and Equipment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,876</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,929</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,219</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from Sale or Disposal of Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Cash Used in Investing Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(50,191</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(41,011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(77,422</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash Flows From Financing Activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Proceeds from Stock Issuances</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>188,840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>295,697</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from Issuance of Stock from Employee Benefit Plans</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,311</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,403</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payments of Term Loan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,029</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment of Other Liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(472</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Cash Provided by Financing Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>193,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>289,599 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of Exchange Rate Changes on Cash and Cash Equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Increase (Decrease) in Cash and Cash Equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,088</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(141,382</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144,505</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and Cash Equivalents at Beginning of Period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28,020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>169,402</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,897 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and Cash Equivalents at End of Period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72,108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28,020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>169,402 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Supplemental Disclosure of Cash Flow Information</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash Paid for Interest</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,209</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Non-cash Investing Activities</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued construction in progress</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,027</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of the financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=93,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=56257,FOLIO='89',FILE='DISK133:[15ZCW1.15ZCW72301]FI72301A.;7',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fk72301_1_90"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fk72301_celldex_therapeutics,___fk702214"> </A>
<A NAME="toc_fk72301_1"> </A></FONT> <FONT SIZE=2><B><BR>  CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    <BR>    NOTES TO FINANCIAL STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(1) NATURE OF BUSINESS AND OVERVIEW  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex Therapeutics,&nbsp;Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for
the treatment of cancer and other difficult-to-treat diseases. The Company currently has five drug candidates in clinical development including Rintega (also referred to as rindopepimut and CDX-110),
glembatumumab vedotin (also referred to as CDX-011), varlilumab (also referred to as CDX-1127), CDX-1401 and CDX-301. The Company's latest stage drug candidate, Rintega, is a therapeutic vaccine that
completed enrollment in December 2014 to a pivotal Phase&nbsp;3 study in front-line glioblastoma in patients that express a specific cancer marker known as EGFRvIII. This Phase&nbsp;3 study
completed its first interim analysis in June 2015 and an independent Data Safety and Monitoring Board recommended that the study continue as planned. Updated results from a randomized, Phase&nbsp;2
study of Rintega added to the standard of care for the treatment of recurrent glioblastoma were presented in November 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
December&nbsp;31, 2015, the Company had cash, cash equivalents and marketable securities of $289.9&nbsp;million. The Company incurred a loss of $127.2&nbsp;million for the year
ended December&nbsp;31, 2015. Net cash used in operations for the year ended December&nbsp;31, 2015 was $98.9&nbsp;million. The Company believes that the cash, cash equivalents and marketable
securities at December&nbsp;31, 2015 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising activities may include, but may
not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of
common stock or other securities via private placements or public offerings. While the Company may seek capital through a number of means, there can be no assurance that additional financing will be
available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will
be able to enter into further collaborative relationships. Additional equity financings may be dilutive to the Company's stockholders; debt financing, if available, may involve significant cash
payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the
Company's economic potential from products under development. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of Presentation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;31, 2014, the Company's wholly-owned subsidiary, Celldex Research Corporation, merged into Celldex
Therapeutics,&nbsp;Inc. The statements of operations and comprehensive loss, of stockholders' equity, and of cash flows, are consolidated for the years ended December&nbsp;31, 2014 and 2013. These
consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary prior to the merger. All intercompany balances and transactions have been eliminated in
consolidation. The Company operates in one segment, which is the business of development, manufacturing and commercialization of novel therapeutics for human health care. In February 2016, the Company
formed a wholly-owned subsidiary, Celldex Therapeutics
Europe&nbsp;GmbH, in Zug, Switzerland, to operate as Celldex' European headquarters when European operations commence, pursuant to intercompany agreements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=94,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=798753,FOLIO='90',FILE='DISK133:[15ZCW1.15ZCW72301]FK72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fk72301_1_91"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of Estimates  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America
(U.S.&nbsp;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the
dates of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash and Cash Equivalents  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments purchased with a maturity date of 90&nbsp;days or less at the date of purchase to
be cash equivalents. Cash equivalents consist principally of money market funds and debt securities. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Marketable Securities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company invests its excess cash balances in marketable securities including municipal bond securities, U.S. government agency
securities, and high-grade corporate bonds. The Company classifies all of its marketable securities as current assets on the balance sheets because they are available-for-sale and available to fund
current operations. Marketable securities are stated at fair value with their unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate
component of stockholders' equity, until such
gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss)
to the statements of operations. Realized gains and losses are determined on the specific identification method and are included in investment and other income, net. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Concentration of Credit Risk and of Significant Customers and Suppliers  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash
equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major
financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a
high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue
from Rockefeller and BMS represented 62% and 24% for the year ended December&nbsp;31, 2015, 75% and 20% for the year ended December&nbsp;31, 2014, 35% and 0% for the year
ended December&nbsp;31, 2013, of total Company revenue, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company relies on contract manufacturing organizations (CMO) to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin
as well as for future commercial supplies. The Company also relies on CMOs for supply of raw materials as well as filling, packaging, storage and shipping of drug product. These clinical studies would
be adversely affected by a significant interruption in the supply of Rintega and glembatumumab vedotin. The Company also relies on third-party collaborators to develop companion diagnostic tests for
certain of its drug candidates, including Rintega. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=95,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=736120,FOLIO='91',FILE='DISK133:[15ZCW1.15ZCW72301]FK72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fk72301_1_92"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair Value Measurements  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has certain assets and liabilities that are measured at fair value in the financial statements. The Company seeks to
maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company's assumptions about how market
participants would price assets and liabilities) when measuring the fair value of its assets and liabilities. These assets and liabilities are classified into one of three levels of the following fair
value hierarchy as defined by U.S.&nbsp;GAAP: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1:
Observable inputs such as quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which
transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2:
Observable inputs other than Level&nbsp;1 prices, such as quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or
liabilities in markets that are not active. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3:
Unobservable inputs based on the Company's assessment of the assumptions that market participants would use in pricing the asset or liability. </FONT></P>

</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Property and Equipment  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment is stated at cost and depreciated over the estimated useful lives of the related assets using the straight-line
method. Laboratory equipment and office furniture and equipment are depreciated over five years and computer equipment is depreciated over three years. Manufacturing equipment is amortized over seven
to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the non-cancelable term of the related lease, including any renewals that are reasonably assured of
occurring. Property and equipment under construction is classified as construction in progress and is depreciated or amortized only after the asset is placed in service. Expenditures for maintenance
and repairs are charged to expense whereas the costs of significant improvements which extend the life of the underlying asset are capitalized. Upon retirement or sale, the cost of assets disposed of
and the related accumulated depreciation are eliminated and any resulting gain or loss is reflected in the Company's statements of operations and comprehensive loss. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
treatment of costs to construct property and equipment depends on the nature of the costs and the stage of construction. Costs incurred in the project planning, design, construction
and installation phases are capitalized as part of the cost of the asset. The Company stops capitalizing these costs when the asset is substantially complete and ready for its intended use. For
manufacturing property and equipment, the Company also capitalizes the cost of validating these assets for the underlying manufacturing process. The Company completes the capitalization of validation
costs when the asset is substantially complete and ready for its intended use. Costs capitalized include incremental labor and fringe benefits, and direct consultancy services. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Business Combinations  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records the fair value of the consideration transferred to acquire a business to the tangible assets and identifiable
intangible assets acquired and liabilities assumed on the basis of their </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=96,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=670314,FOLIO='92',FILE='DISK133:[15ZCW1.15ZCW72301]FK72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fk72301_1_93"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>fair
values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets such as in-process research and development (IPR&amp;D), using a variety of methods
including present value models. Each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of IPR&amp;D assets incorporates significant
assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant's assumptions regarding the probability of completing IPR&amp;D projects,
which would require obtaining regulatory approval for marketing of the associated drug candidate; a market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;D
projects; a market participant's estimates of future cash flows from potential product sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs
associated with the transaction are expensed as incurred. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intangible Assets  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible
assets. These assets are capitalized on the Company's balance sheets until either the project underlying them is completed or the assets become
impaired. If a project is completed, the carrying value of the related intangible asset is amortized over the remaining estimated life of the asset beginning in the period in which the project is
completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value and an impairment charge is taken in the period in which
the impairment occurs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D
assets are tested for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. As part of the annual impairment test of the IPR&amp;D
assets as of July&nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed a calculation of the fair value of the asset. The Company concluded that the IPR&amp;D assets were
not impaired. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible
assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a straight-line basis over
their estimated useful life. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Goodwill  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is
allocated to goodwill. Goodwill is evaluated for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. The Company has the option to assess
qualitative factors to determine if it is more likely than not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under
U.S.&nbsp;GAAP. As part of its annual impairment test of the goodwill asset as of July&nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed the two-step impairment
test. The Company concluded that goodwill was not impaired. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Impairment of Intangible and Long-Lived Assets  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluates the recoverability of its long-lived assets, including property and equipment, and intangible assets when
circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=97,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=81361,FOLIO='93',FILE='DISK133:[15ZCW1.15ZCW72301]FK72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fk72301_1_94"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>resulting
from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are
written-down to their estimated fair values. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue Recognition  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has
occurred or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic
drug products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product
sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of
accounting. In accounting for these transactions, the Company allocates revenue to the various elements based on their relative fair value. The fair value of a revenue generating element can be based
on current selling prices offered by the Company or another party for current products or the Company's best estimate of a selling price for future products. Revenue allocated to an individual element
is recognized when all other revenue recognition criteria are met for that element. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of
the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of the Company's involvement in achieving the milestones and whether the amount of the payment
is commensurate to the Company's performance. If not considered substantive, milestones are initially deferred and recognized over the period of the remaining performance obligation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is
recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or the Company's contractual partner. Payments received in advance that
are related to future performance are deferred and recognized as revenue when the research projects are performed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize the Company's licensed technologies and are recognized
when the amount of and basis for such royalty payments are reported to the Company in accurate and appropriate form and in accordance with the related license agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development
expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other preclinical studies, personnel costs, depreciation, license fees and funding of outside
contracted research. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=98,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=886310,FOLIO='94',FILE='DISK133:[15ZCW1.15ZCW72301]FK72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fk72301_1_95"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trial expenses include expenses associated with clinical research organizations, or CRO, services. Contract manufacturing expenses include expenses associated with contract
manufacturing organizations, or CMO, services. The invoicing from CROs and CMOs for services rendered can lag several months. The Company accrues the cost of services rendered in connection with CRO
and CMO activities based on our estimate of costs incurred. The Company maintains regular communication with our CROs and CMOs to assess the reasonableness of its estimates. Differences between actual
expenses and estimated expenses recorded have not been material and are adjusted for in the period in which they become known. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Costs  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent costs are expensed as incurred. Certain patent costs are reimbursed by the Company's product development and licensing partners.
Any reimbursed patent costs are recorded as product development and licensing agreement revenues in the Company's financial statements. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated
fair values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and
directors is recognized using the straight-line method over the term of vesting or performance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the graded vesting
term resulting in periodic adjustments to stock-based compensation expense. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Currency Translation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net unrealized gains and losses resulting from foreign currency translation are included in other comprehensive income (loss). At
December&nbsp;31, 2015 and December&nbsp;31, 2014, accumulated other comprehensive income includes a net unrealized gain related to foreign currency translation of $2.6&nbsp;million. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income Taxes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and
deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax basis. Quarterly, the Company reviews its
deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation
allowances from period to period are included in the Company's tax provision in the period of change. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company records uncertain tax positions in the financial statements only if it is more likely than not that the uncertain tax position will be sustained upon examination by the
taxing authorities. The Company records interest and penalties related to uncertain tax positions in income tax expense. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=99,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=742238,FOLIO='95',FILE='DISK133:[15ZCW1.15ZCW72301]FK72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fk72301_1_96"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comprehensive Loss  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company
includes foreign currency translation adjustments and unrealized gains and losses on marketable securities in other comprehensive loss. The statements of operations and comprehensive loss reflect
total comprehensive loss for the years ended December&nbsp;31, 2015, 2014 and 2013. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss Per Share  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per common share is based upon the weighted-average number of common shares outstanding during the period, excluding
restricted stock that has been issued but is not yet vested. Diluted net loss per common share is based upon the weighted-average number of common shares outstanding during the period plus additional
weighted-average potentially dilutive common shares outstanding during the period when the effect is dilutive. The potentially dilutive common shares that have not been included in the net loss per
common share calculations because the effect would have been anti-dilutive are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,110,239</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,015,350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,770,544</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,129,739</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,022,350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,776,544 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Accounting Pronouncements  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard
setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet
effective will not have a material impact on the Company's financial position or results of operations upon adoption. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2014, the FASB issued a new U.S.&nbsp;GAAP accounting standard that creates modifications to various other revenue accounting standards for specialized transactions and
industries. The new U.S.&nbsp;GAAP accounting standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the
company expects to receive for those goods or services. In August 2015, the FASB deferred the effective date of the new standard from January&nbsp;1, 2017 to January&nbsp;1, 2018. The amendment
allows for two methods of adoption, a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. The Company will further
study the implications of this standard in order to evaluate the expected impact on the financial statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2015, the FASB issued amendments that provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement
includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing
arrangement does not </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=100,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=824673,FOLIO='96',FILE='DISK133:[15ZCW1.15ZCW72301]FK72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fk72301_1_97"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>include
a software license, the customer should account for the arrangement as a service contract. The new guidance does not change the accounting for a customer's accounting for service contracts.
The standard update is effective for fiscal years beginning after December&nbsp;15, 2015 and interim periods within those years. Early adoption is permitted. The standard allows for adoption
retrospectively or prospectively to all arrangements entered into or materially modified after the effective date. The amendment is not expected to have a material impact on our financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2014, the FASB issued a new U.S.&nbsp;GAAP accounting standard that provides guidance about management's responsibility to evaluate whether there is substantial doubt about
an entity's ability to continue as a going concern and to provide related footnote disclosures. The new accounting standard requires management to assess an entity's ability to continue as a going
concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The new accounting standard is effective for the annual period ending after
December&nbsp;15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not expect the adoption of this standard to have a material impact on
the financial statements. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(3) COMPREHENSIVE LOSS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The changes in accumulated other comprehensive income (loss) by component for the years ended December&nbsp;31, 2015, 2014 and 2013 are summarized below. No amounts were reclassified
out of accumulated other comprehensive income during the years ended December&nbsp;31, 2015, 2014 and 2013. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unrealized<BR>
Gain (Loss) on<BR>
Marketable<BR>
Securities </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Foreign<BR>
Currency Items </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2012</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>156</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,589</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,745</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive loss before reclassifications</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts reclassified from other comprehensive income</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net current-period other comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2013</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> 82</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,586</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,668</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive loss before reclassifications</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts reclassified from other comprehensive income</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net current-period other comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2014</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> 9</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,581</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,590</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive loss before reclassifications</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(283</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amounts reclassified from other comprehensive income</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net current-period other comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(283</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance at December&nbsp;31, 2015</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>(289</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,596</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2,307</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=101,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=147212,FOLIO='97',FILE='DISK133:[15ZCW1.15ZCW72301]FK72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fm72301_1_98"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued)  </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(4) FAIR VALUE MEASUREMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables set forth the Company's financial assets subject to fair value measurements: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,677</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,677</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>173,023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>173,023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>191,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>191,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59,831</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59,831</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>217,781</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>217,781</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>277,612</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>277,612</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
have been no transfers of assets or liabilities between the fair value measurement classifications. The Company's financial instruments consist mainly of cash and cash equivalents,
marketable securities, short-term accounts receivable and accounts payable. The Company values its marketable securities utilizing independent pricing services which normally derive security prices
from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include
trade information, broker or dealer quotes, bids, offers or a combination of these data sources. Short-term accounts receivable and accounts payable are reflected in the accompanying financial
statements at cost, which approximates fair value due to the short-term nature of these instruments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=102,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=434146,FOLIO='98',FILE='DISK133:[15ZCW1.15ZCW72301]FM72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:35' -->
<A NAME="page_fm72301_1_99"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(5) MARKETABLE SECURITIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of marketable securities is shown below: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>December&nbsp;31, 2014</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. government and municipal obligations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing in one year or less</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,580</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,604</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,156 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total U.S. government and municipal obligations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,688</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,760 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing in one year or less</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,636</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,605</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,690</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,658 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total corporate debt securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>112,326</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>112,263 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>173,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>88</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>173,023 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>December&nbsp;31, 2015</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. government and municipal obligations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing in one year or less</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,871</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,855</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,940</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(57</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,907 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total U.S. government and municipal obligations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>64,811</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>64,762 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing in one year or less</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>129,327</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(141</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>129,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,932</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,831 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total corporate debt securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>153,259</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>153,019 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>218,070</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(320</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>217,781 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
marketable securities held by the Company were high investment grade and there were no marketable securities that the Company considered to be other-than-temporarily impaired as of
December&nbsp;31, 2015. Marketable securities include $1.5&nbsp;million and $1.4&nbsp;million in accrued interest at December&nbsp;31, 2015 and December&nbsp;31, 2014, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=103,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=628859,FOLIO='99',FILE='DISK133:[15ZCW1.15ZCW72301]FM72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:35' -->
<A NAME="page_fm72301_1_100"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(6) PROPERTY AND EQUIPMENT, NET  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment include the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory Equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,432</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,223</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Manufacturing Equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,178</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Office Furniture and Equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,088</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold Improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,371</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,603</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Construction in Progress</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>451</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,767 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Property and Equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,520</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,755</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less Accumulated Depreciation and Amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(17,059</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,461</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,535 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
and amortization expense related to property and equipment was $3.0&nbsp;million, $2.4&nbsp;million and $1.9&nbsp;million for the years ended December&nbsp;31, 2015,
2014 and 2013, respectively. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(7) INTANGIBLE ASSETS AND GOODWILL  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net of accumulated amortization, and goodwill are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=10 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated<BR>
Life </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Amortization </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Net </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Amortization </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Net </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Intangible Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IPR&amp;D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Indefinite</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amgen Amendment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5,605</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,895</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,708</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Core Technology</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,296</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>99</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,296</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,081</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>215 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Intangible Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,596</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,802</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,794</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,596</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5,789</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,807 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Goodwill</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Indefinite</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,965 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
IPR&amp;D intangible asset was recorded in connection with the acquisition of CuraGen and relates to the development of glembatumumab vedotin. At the date of acquisition and at
December&nbsp;31, 2015, glembatumumab vedotin had not yet reached technological feasibility nor did it have any alternative future use. Glembatumumab vedotin is in a randomized, Phase&nbsp;2b
study for the treatment of triple negative breast cancer and a Phase&nbsp;2 study for the treatment of metastatic melanoma. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization
expense for intangible assets was $1.0&nbsp;million for the years ended December&nbsp;31, 2015, 2014 and 2013. The estimated future amortization expense of intangible
assets for the years ending December&nbsp;31, 2016, 2017, 2018, 2019 and 2020 is $1.0&nbsp;million, $0.9&nbsp;million, $0.9&nbsp;million, $0.9&nbsp;million and $0.9&nbsp;million,
respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=104,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=308502,FOLIO='100',FILE='DISK133:[15ZCW1.15ZCW72301]FM72301A.;8',USER='CHE108062',CD='19-FEB-2016;19:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fo72301_1_101"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(8) ACCRUED EXPENSES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses include the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Payroll and Employee Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,601</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,284</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Research and Development Contract Costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,696</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Professional Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>399</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>490</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Accrued Expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,768</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,826 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,316</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,296 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(9) OTHER LONG-TERM LIABILITIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities include the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Rent</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>409</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>482</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Deferred Tax Liability related to IPR&amp;D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Income from Sale of Tax Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,219</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Revenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,368</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,297 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,657</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,455</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less Current Portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,418</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,592</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-Term Portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,239</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,863 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2015, December 2014, January 2014, January 2013, January 2012 and January 2011, the Company received approval from the New Jersey Economic Development Authority and agreed to
sell New Jersey tax benefits of $9.8&nbsp;million, $1.9&nbsp;million, $1.1&nbsp;million, $0.8&nbsp;million, $0.8&nbsp;million and $0.6&nbsp;million to an independent third party for
$9.2&nbsp;million, $1.8&nbsp;million, $1.0&nbsp;million, $0.8&nbsp;million, $0.7&nbsp;million and $0.5&nbsp;million, respectively. Under the agreement, the Company must maintain a base of
operations in New Jersey for five years or the tax benefits must be paid back on a pro-rata basis based on the number of years completed. During the years ended December&nbsp;31, 2015 and 2014, the
Company recorded $1.0&nbsp;million and $0.4&nbsp;million to other income related to the sale of these tax benefits, respectively. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(10) TERM LOAN  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2010, the Company entered into a loan and security agreement pursuant to which the Company borrowed $10.0&nbsp;million under a term loan. In March 2011, the Company amended
the loan agreement and borrowed an additional $5.0&nbsp;million. In May 2013, the Company elected to prepay the outstanding principal under the term loan in full, pursuant to the terms of its loan
agreement, as amended, and paid $8.8&nbsp;million in principal and $0.7&nbsp;million in interest, prepayment and final payment fees. The Company's obligations under the loan agreement had been
collateralized by a first priority security interest in substantially all of its assets, other than its intellectual property. In connection with the repayment of the term loan and the termination of
the loan agreement, those security interests </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=105,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=4781,FOLIO='101',FILE='DISK133:[15ZCW1.15ZCW72301]FO72301A.;8',USER='HYUNG',CD='22-FEB-2016;11:48' -->
<A NAME="page_fo72301_1_102"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(10) TERM LOAN (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>were
released. Interest expense on the term loan was $0.8&nbsp;million for the year ended December&nbsp;31, 2013. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(11) STOCKHOLDERS' EQUITY  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2013, the Company filed an automatic shelf registration statement with the Securities and Exchange Commission to register
for sale any combination of the types of securities described in the shelf registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the years ended December&nbsp;31, 2015 and December&nbsp;31, 2013, the Company issued 8,337,500 and 21,613,483 shares of its common stock in underwritten public offerings
resulting in net proceeds to the Company of $188.8&nbsp;million and $278.6&nbsp;million, after deducting underwriting fees and offering expenses, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2014, the Company entered into an amended and restated supply agreement with Biosyn Corporation. Under the supply agreement, Biosyn will
manufacture and supply keyhole limpet hemocyanin (KLH) to the Company for use in connection with the development, manufacture or commercial sale of Rintega. In connection with the supply agreement,
the Company issued to Biosyn 152,172 shares of its common stock having a value of $2.0&nbsp;million. The Company is recording the $2.0&nbsp;million to research and development expense through
August 2021, the current term of the supply agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2013, Company issued 2,433,608 shares of its common stock under a controlled equity offering sales agreement with Cantor
Fitzgerald&nbsp;&amp;&nbsp;Co., as amended, resulting in net proceeds to the Company of $17.1&nbsp;million, after deducting commission and offering expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Convertible Preferred Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2015, the Company had authorized 3,000,000 shares of preferred stock all of which have been designated
Class&nbsp;C Preferred Stock including 350,000 shares which have been designated Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock (the "Series&nbsp;C-1 Preferred Stock"). </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(12) STOCK-BASED COMPENSATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has the following stock-based compensation plans: the 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"), the 2008 Stock Option and Incentive Plan (the "2008 Plan") and
Celldex Research's 2005 Equity Incentive Plan (the "Celldex Research 2005 Plan"). There are no shares available for future grant under the Celldex Research 2005 Plan. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee Stock Purchase Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2015, a total of 200,000 shares of common stock are reserved for issuance under the 2004 ESPP Plan. Under the
2004 ESPP Plan, each participating employee may purchase shares of common stock through payroll deductions at a purchase price equal to 85% of the lower of the fair market value of the common stock at
either the beginning of the
offering period or the applicable exercise date. During the years ended December&nbsp;31, 2015 and 2014, the Company issued 15,755 and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=106,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=129083,FOLIO='102',FILE='DISK133:[15ZCW1.15ZCW72301]FO72301A.;8',USER='HYUNG',CD='22-FEB-2016;11:48' -->
<A NAME="page_fo72301_1_103"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(12) STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>10,798
shares under the 2004 ESPP Plan, respectively. At December&nbsp;31, 2015, 137,571 shares were available for issuance under the 2004 ESPP Plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee Stock Option and Incentive Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan permits the granting of incentive stock options (intended to qualify as such under Section&nbsp;422A of the Internal
Revenue Code of 1986, as amended), non-qualified stock options, stock appreciation rights, performance share units, restricted stock and other awards of restricted stock in lieu of cash bonuses to
employees, consultants and non-employee directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
December&nbsp;31, 2015, the 2008 Plan allowed for a maximum of 14,350,000 shares of common stock to be issued for grants of Stock Options and other Awards made prior to
June&nbsp;9, 2025 and grants of Incentive Stock Options made prior to April&nbsp;16, 2025. The Company's board of directors determines the term of each option, option price, and number of shares
for which each option is granted and the rate at which each option vests. Options generally vest over a period not to exceed four years. The term of each option cannot exceed ten years (five years for
options granted to holders of more than 10% of the voting stock of the Company) and the exercise price of stock options cannot be less than the fair market value of the common stock at the date of
grant (110% of fair market value for incentive stock options granted to holders of more than 10% of the voting stock of the Company). Vesting of all employee and non-employee director stock option
awards may accelerate upon a change in control as defined in the 2008 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of stock option activity for the year ended December&nbsp;31, 2015 is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price<BR>
Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Term (In Years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options Outstanding at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,015,350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,865,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(700,561</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Canceled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(69,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.79</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options Outstanding at December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,110,239</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.7 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options Vested and Expected to Vest at December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,065,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.08</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options Exercisable at December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,705,304</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Available for Grant under the 2008 Plan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,790,709</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
total intrinsic value of stock options exercised during the years ended December&nbsp;31, 2015, 2014 and 2013 was $14.4&nbsp;million, $2.7&nbsp;million and
$10.0&nbsp;million, respectively. The weighted average grant-date fair value of stock options granted during the years ended December&nbsp;31, 2015, 2014 and 2013 was $15.25, $8.82 and $10.51,
respectively. The total fair value of stock options vested during the years ended December&nbsp;31, 2015, 2014 and 2013 was $10.0&nbsp;million, $5.7&nbsp;million and $2.4&nbsp;million,
respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate intrinsic value of stock options outstanding at December&nbsp;31, 2015 was $38.6&nbsp;million. The aggregate intrinsic value of stock options vested and expected to
vest at December&nbsp;31, 2015 was $38.6&nbsp;million. As of December&nbsp;31, 2015, total compensation cost related to non-vested employee and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=107,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=409740,FOLIO='103',FILE='DISK133:[15ZCW1.15ZCW72301]FO72301A.;8',USER='HYUNG',CD='22-FEB-2016;11:48' -->
<A NAME="page_fo72301_1_104"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(12) STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>non-employee
director stock options not yet recognized was approximately $36.2&nbsp;million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average
period of 2.6&nbsp;years. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of restricted stock activity under the 2008 Plan for the year ended December&nbsp;31, 2015 is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Grant Date<BR>
Fair Value<BR>
(per share) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding and unvested at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25.41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(26,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22.60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Canceled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding and unvested at December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25.41 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation and Expenses Information  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense for the years ended December&nbsp;31, 2015, 2014 and 2013 was recorded as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,186</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,640</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,588</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,393</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,908 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stock-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,774</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,852</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,548 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair values of employee stock options granted during the years ended December&nbsp;31, 2015, 2014 and 2013 were valued using the Black-Scholes option- pricing model with the
following assumptions: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, 2013 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected stock price volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67&nbsp;-&nbsp;69%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70&nbsp;-&nbsp;72%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71&nbsp;-&nbsp;72%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected option term</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.0 Years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.0 Years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.0 Years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.8&nbsp;-&nbsp;2.2%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.9&nbsp;-&nbsp;2.2%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.2&nbsp;-&nbsp;2.1%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>None</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>None</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>None</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimates expected term based on historical exercise patterns. The Company uses its historical stock price volatility consistent with the expected term of grant as the basis
for its expected volatility assumption. The risk-free interest rate is based upon the yield of U.S. Treasury securities consistent with the expected term of the option. The dividend yield assumption
is based on the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=108,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=155479,FOLIO='104',FILE='DISK133:[15ZCW1.15ZCW72301]FO72301A.;8',USER='HYUNG',CD='22-FEB-2016;11:48' -->
<A NAME="page_fo72301_1_105"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(12) STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Company's
history of zero dividend payouts and expectation that no dividends will be paid in the foreseeable future. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(13) REVENUE  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bristol-Myers Squibb Company (BMS)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, the Company entered into a clinical trial collaboration with BMS to evaluate the safety, tolerability and preliminary
efficacy of varlilumab and Opdivo&reg;, BMS's PD-1 immune checkpoint inhibitor, in a Phase 1/2 study. Under the terms of this clinical trial collaboration, BMS made a one-time payment to the
Company of $5.0&nbsp;million and BMS and the Company amended the terms of the Company's existing license agreement with Medarex (a subsidiary of BMS) related to the Company's CD27 program whereby
certain future milestone payments were waived and future royalty rates were reduced that may have been due from the Company to Medarex. In return, BMS was granted a time-limited right of first
negotiation if the Company wishes to out-license varlilumab. The companies also agreed to work exclusively with each other to explore anti-PD-1 antagonist antibody and anti-CD27 agonist antibody
combination regimens. The clinical trial collaboration provides that the companies will share development costs and that the Company will be responsible for conducting the ongoing Phase 1/2 study. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has determined that its performance obligations under the BMS agreement, which primarily include performing research and development, supplying varlilumab and participating
in the joint development committee, should be accounted for as a single unit of accounting and estimated that its performance period under the BMS agreement would be 5&nbsp;years. Accordingly, the
$5.0&nbsp;million up-front payment was initially recorded as deferred revenue and is being recognized as revenue on a straight-line basis over the estimated 5-year performance period using the
Contingency Adjusted Performance Model ("CAPM"). The BMS agreement also provides for BMS to reimburse the Company for 50% of the external costs incurred by the Company in connection with the clinical
trial. These BMS payments are being recognized as revenue using the CAPM. The Company recorded $1.3&nbsp;million and $0.7&nbsp;million in revenue related to the BMS agreement during the year ended
December&nbsp;31, 2015 and 2014, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rockefeller University (Rockefeller)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2013, the Company entered into an agreement, as amended, with Rockefeller pursuant to which the Company performs research
and development services for Rockefeller. The Company bills Rockefeller quarterly for actual time and direct costs incurred and records those amounts to revenue in the quarter the services are
performed. The Company recorded $3.4&nbsp;million, $2.7&nbsp;million and $1.4&nbsp;million in revenue related to the Rockefeller agreement during the years ended December&nbsp;31, 2015, 2014
and 2013, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


GlaxoSmithKline&nbsp;plc (Glaxo)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1997, the Company licensed its oral rotavirus strain to Glaxo and Glaxo assumed responsibility for all subsequent clinical trials
and all other development activities. The Company's licensed-in the rotavirus strain that was used to develop Glaxo's Rotarix rotavirus vaccine in 1995 and owed a license fee of 30% to Cincinnati
Children's Hospital Medical Center ("CCH") on net royalties received from </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=109,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=789770,FOLIO='105',FILE='DISK133:[15ZCW1.15ZCW72301]FO72301A.;8',USER='HYUNG',CD='22-FEB-2016;11:48' -->
<A NAME="page_fo72301_1_106"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(13) REVENUE (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Glaxo.
In May 2005, the Company entered into an agreement whereby an affiliate of Paul Royalty Fund II,&nbsp;L.P. ("PRF") purchased a 70% interest in the net royalties the Company received on
worldwide sales of Rotarix. In December 2012, the Glaxo agreement expired automatically upon the expiration of the last relevant patent right covered by the Glaxo agreement. The Company's retained
interests in Rotarix net royalties which were not sold to PRF are recorded as product royalty revenue and a corresponding amount that is payable to CCH is recorded as royalty expense. Product royalty
revenue and royalty expense related to the Company's retained interest in Rotarix was $2.3&nbsp;million for the year ended December&nbsp;31, 2013. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(14) COLLABORATION AGREEMENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has entered into license agreements whereby the Company has received licenses or options to license technology, specified patents or patent applications. The Company's
licensing and development collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing patent
prosecution costs and potential future milestone payments to third parties upon the achievement of certain developmental, regulatory and/or commercial milestones. Nonrefundable license fee expense of
$0.9&nbsp;million, $3.2&nbsp;million and $0.7&nbsp;million was recorded to research and development expense for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Medarex,&nbsp;Inc., a subsidiary of Bristol-Myers Squibb (Medarex)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and Medarex have entered into an assignment and license agreement, as amended, that provides for the assignment of certain
patent and other intellectual property rights and a license to certain Medarex technology related to the Company's APC Targeting Technology&#153; and an anti-mannose receptor product. Under the
terms of the agreement, the Company may be required to pay royalties in the low-single digits on any net product sale of a Licensed Royalty-Bearing Product or Anti-Mannose Product to Medarex until the
later of (i)&nbsp;the expiration of the last to expire applicable patent and (ii)&nbsp;the tenth anniversary of the first commercial sale of such licensed product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and Medarex have also entered into a research and commercialization agreement, as amended, that provides that the Company may be required to pay Medarex milestones of up to
$7.0&nbsp;million upon obtaining first approval for commercial sale in a first indication of a product containing a licensed antibody and royalty payments in the low-to-mid single digits on any net
product sales with respect to the development of any products containing such licensed antibodies until the later of (i)&nbsp;the expiration of the last to expire applicable patent and
(ii)&nbsp;the tenth anniversary of the first
commercial sale of such licensed product. In September 2010, the Company exercised an option under the agreement, whereby it licensed from Medarex access to the UltiMab technology to develop and
commercialize human antibodies to CD27, including varlilumab. In connection with the clinical trial collaboration, the Company entered into with BMS in May 2014, certain future milestone payments were
waived and future royalty rates that the Company may have owed Medarex in connection with any CD27 program were reduced. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rockefeller University (Rockefeller)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2005, the Company and Rockefeller entered into a license agreement for the exclusive worldwide rights to human DEC-205
receptor, with the right to sublicense the technology. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=110,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=395589,FOLIO='106',FILE='DISK133:[15ZCW1.15ZCW72301]FO72301A.;8',USER='HYUNG',CD='22-FEB-2016;11:48' -->
<A NAME="page_fo72301_1_107"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(14) COLLABORATION AGREEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
license grant is exclusive except that Rockefeller may use and permit other nonprofit organizations to use the human DEC-205 receptor patent rights for educational and research purposes. The
Company may be required to pay Rockefeller milestones of up to $3.8&nbsp;million upon obtaining first approval for commercial sale in a first indication of a product targeting the licensed receptor
and royalty payments in the low-to-mid single digits on any net product sales with respect to development and commercialization of the human DEC-205 receptor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Duke University Brain Tumor Cancer Center (Duke)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2006, the Company and Duke entered into a license agreement that gave the Company access and reference to the clinical
data generated by Duke and its collaborators in order for the Company to generate its own filing with the FDA relating to Rintega. The Company may be required to pay Duke milestones of up to
$0.7&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and
commercialization of Rintega. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ludwig Institute for Cancer Research (Ludwig)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2006, the Company and Ludwig entered into an agreement for the nonexclusive rights to certain cancer tumor targets for use
in combination with the Company's APC Targeting Technology. The Company may be required to pay Ludwig milestones of up to $1.0&nbsp;million upon obtaining first approval for commercial sale in a
first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of the technology licensed from Ludwig. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Alteris Therapeutics,&nbsp;Inc. (Alteris)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2005, the Company completed the acquisition of the assets of Alteris, including the EGFRvIII molecule. The Company may be
required to pay Alteris up to $5.0&nbsp;million upon obtaining the first approval for commercial sale of a product containing EGFRvIII, including Rintega. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


University of Southampton, UK (Southampton)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2008, the Company entered into a license agreement with Southampton to develop human antibodies towards CD27, a potentially
important target for immunotherapy of various cancers. The Company may be required to pay Southampton milestones of up to approximately $1.4&nbsp;million upon obtaining first approval for commercial
sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of varlilumab. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amgen&nbsp;Inc. (Amgen)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2009, the Company entered into a license agreement with Amgen to acquire the exclusive rights to CDX-301 and CD40 ligand
(CD40L). CDX-301 and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. The Company may be required to pay Amgen milestones of
up to $0.9&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=111,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=715776,FOLIO='107',FILE='DISK133:[15ZCW1.15ZCW72301]FO72301A.;8',USER='HYUNG',CD='22-FEB-2016;11:48' -->
<A NAME="page_fo72301_1_108"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(14) COLLABORATION AGREEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>product
sales with respect to development and commercialization of the technology licensed from Amgen, including CDX-301. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Seattle Genetics,&nbsp;Inc. (Seattle Genetics)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the acquisition of CuraGen, the Company assumed the license agreement between CuraGen and Seattle Genetics whereby
CuraGen acquired the rights to proprietary antibody-drug conjugate (ADC) technology for use with the Company's proprietary antibodies for the potential treatment of cancer. The Company may be required
to pay Seattle Genetics milestones of up to $5.0&nbsp;million and $9.0&nbsp;million for glembatumumab vedotin and CDX-014, respectively, upon obtaining first approval for commercial sale in a
first indication and royalty payments in the mid-single digits on any net product sales with respect to development and commercialization of these product candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(15) INCOME TAXES  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of income tax expense attributable to continuing operations consist of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax benefit (provision):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46,598</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,536</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,962</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,642</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,920</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expiration of Net Operating Losses and Research&nbsp;&amp; Development Tax Credits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(155</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(126</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57,085</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,562</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax valuation allowance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(57,085</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(48,562</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(35,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
reconciliation between the amount of reported income tax and the amount computed using the U.S. Statutory rate of 34% follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pre-tax loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(127,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(118,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss at Statutory Rates</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(43,247</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(40,147</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(27,727</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and Development Credits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,935</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,126</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,261</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State Taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,642</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,920</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,584</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>737</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expiration of Net Operating Losses and Research&nbsp;&amp; Development Tax Credits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>155</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in Valuation Allowance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57,085</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48,562</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,756 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax (benefit) provision</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=112,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=315044,FOLIO='108',FILE='DISK133:[15ZCW1.15ZCW72301]FO72301A.;8',USER='HYUNG',CD='22-FEB-2016;11:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fq72301_1_109"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(15) INCOME TAXES (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future expected enacted
rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
principal components of the deferred tax assets and liabilities at December&nbsp;31, 2015 and 2014, respectively, are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gross Deferred Tax Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Operating Loss Carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>180,777</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>95,577</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Credit Carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,895</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,709</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,608</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85,889</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based Compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,393</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,556</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fixed Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,882</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Revenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,078</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued Expenses and Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>219</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>202 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>277,612</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>220,893</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gross Deferred Tax Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Acquired Intangibles</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,382</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,749</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IPR&amp;D Intangibles</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,043</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Deferred Tax Assets and Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>269,569</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>212,483</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred Tax Assets Valuation Allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(274,230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(217,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Deferred Tax Asset (Liability)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
net deferred tax liability of $4.7&nbsp;million at December&nbsp;31, 2015 and 2014 relates to the temporary differences associated with the IPR&amp;D intangible assets acquired in
the CuraGen acquisition, which are not deductible for tax purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2015, the Company had the following federal net operating loss ("NOL") carryforwards:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Prior to the merger of the Company and AVANT, $33.0&nbsp;million was generated by the Company which expire at various dates starting
in 2023 and going through 2028; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Prior to the merger of the Company and AVANT, $101.2&nbsp;million, net of expirations and utilization, was generated by AVANT which
expire at various dates starting in 2018 and going through 2028; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Following the merger of the Company and AVANT, $392.9&nbsp;million was generated by the combined company which expire at various
dates starting in 2028 and going through 2035; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Prior to its acquisition by the Company, $518.3&nbsp;million was generated by CuraGen. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=113,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=853998,FOLIO='109',FILE='DISK133:[15ZCW1.15ZCW72301]FQ72301A.;6',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fq72301_1_110"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(15) INCOME TAXES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2015, the Company has an additional $17.7&nbsp;million of federal and state net operating losses not reflected above, that are attributable to stock option
exercises which will be recorded as an increase in additional paid in capital on the balance sheet once they are "realized" in accordance with ASC 718. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, an ownership change, as defined by Section&nbsp;382 of the Internal Revenue Code, results from transactions increasing the ownership of certain shareholders or public
groups in the stock of a corporation by more than 50&nbsp;percentage points over a three-year period. Such ownership changes can significantly limit the amount of NOLs that may be utilized in future
periods. The Company currently expects that it is remote that the CuraGen NOLs may be utilized and, as such, no related asset has been recorded for such losses. The Company has not completed an
analysis of losses generated by AVANT, however, the Company believes it is remote that $60.8&nbsp;million of the AVANT NOLs may be utilized in future periods and there may be substantial limitations
on the Company's ability to use the remaining NOLs of $40.4&nbsp;million. Following the merger of the Company and AVANT, the Company experienced changes in ownership as defined by Section&nbsp;382
in June 2009, December 2009 and December 2013. Further, prior to the AVANT merger, the Company as a stand alone company experienced a change in ownership in October 2007. As a result of the ownership
changes in June 2009 and December 2009, there is an annual limitation amount of $6.0&nbsp;million on $67.7&nbsp;million of NOLs generated before that date. As a result of the ownership change in
December 2013, there is an annual limitation amount of $77.0&nbsp;million on $178.7&nbsp;million of NOLs generated before that date. Any unused annual limitation may be carried over to later
years, and the amount of the limitation may, under certain circumstances, be subject to adjustment if the fair value of the Company's net assets are determined to be below or in excess of the tax
basis of such assets at the time of the ownership change, and such unrealized loss or gain is recognized during the five-year period after the ownership change. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similar
to the AVANT and CuraGen NOL carryforwards above, the Company believes that it is not more likely than not that federal and state research and development ("R&amp;D") credits of
$20.8&nbsp;million and $14.4&nbsp;million, respectively, will be utilized in the future periods. Further, the Company's ability to use the state NOLs of approximately $382.3&nbsp;million and the
remaining federal and state R&amp;D credit carryforwards of approximately $28.5&nbsp;million and $11.2&nbsp;million, respectively, may be substantially limited. These state NOLs and federal and state
credits expire at various dates starting in 2016 going through 2035. The Company has not yet completed a study of these credits to substantiate the amounts. Until a study is completed, no amounts are
being presented as an uncertain tax position. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
ownership changes, as defined in Section&nbsp;382, could further limit the amount of net operating loss carryforwards and research and development credits that can be
utilized annually to offset future taxable income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company applies the authoritative guidance on account for and disclosure of uncertainty in income tax positions which requires the Company to determine whether an income tax position
of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. For income
tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced to the largest benefit that has a greater than fifty perfect likelihood of
being realized upon the ultimate settlement with the relevant taxing authority. At December&nbsp;31, 2015 and 2014, we had no unrecognized tax benefits. A full valuation allowance has been provided
against our deferred tax assets and liabilities and, if an adjustment is required, this adjustment would be offset by an adjustment to the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=114,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=428231,FOLIO='110',FILE='DISK133:[15ZCW1.15ZCW72301]FQ72301A.;6',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fq72301_1_111"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(15) INCOME TAXES (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>valuation
allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Massachusetts,
New Jersey and Connecticut are the three states in which the Company primarily operates or has operated and has income tax nexus. The Company is not currently under
examination by these or any other jurisdictions for any tax year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has evaluated the positive and negative evidence bearing upon the realizability of its net deferred tax assets, which are comprised principally of net operating loss
carryforwards, capitalized R&amp;D expenditures and R&amp;D tax credit carryforwards. The Company has determined that it is more likely than not that it will not recognize the benefits of federal and state
deferred tax assets and, as a result, a full valuation allowance was maintained at December&nbsp;31, 2015 against the Company's net deferred tax assets. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(16) COMMITMENTS AND CONTINGENCIES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has facility and equipment leases that expire at various dates through 2020. Certain of these facility leases contain renewal options, early termination provisions, and
provisions that escalate the base rent payments and require the Company to pay common area maintenance costs ("CAM") during the lease term. The following obligations for base rent and CAM costs under
facility and other non-cancelable operating leases as of December&nbsp;31, 2015 do not include the exercise of renewal terms or early termination provisions (in thousands): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,242</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,698</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,754</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,524</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thereafter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total minimum lease payments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,239 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, the Company amended the facility lease in Fall River, MA for additional space and to extend the term from 2017 to 2020. The Company's total rent and CAM expense for all
facility leases was $2.9&nbsp;million, $2.7&nbsp;million and $2.7&nbsp;million for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(17) RETIREMENT SAVINGS PLAN  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains a 401(k) Plan which is available to substantially all employees. Under the terms of the 401(k) Plan, participants may elect to contribute up to 15% of their
compensation, or the statutory prescribed limits. The Company may make 50% matching contributions on up to 4% of a participant's annual salary. Benefit expense for the 401(k) Plan was
$0.4&nbsp;million, $0.3&nbsp;million and $0.3&nbsp;million for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=115,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=187020,FOLIO='111',FILE='DISK133:[15ZCW1.15ZCW72301]FQ72301A.;6',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fq72301_1_112"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CELLDEX THERAPEUTICS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


(18) SELECTED QUARTERLY FINANCIAL DATA (Unaudited)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>2014

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q1 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q2 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q3 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q4 2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands, except per share amounts)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>416</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,477</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,903</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(28,274</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(28,082</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,821</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>2015

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q1 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q2 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q3 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Q4 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands, except per share amounts)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>486</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,026</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,790</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(30,174</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(32,359</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,980</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(32,684</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=116,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=790381,FOLIO='112',FILE='DISK133:[15ZCW1.15ZCW72301]FQ72301A.;6',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fs72301_1_113"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_item_9._changes_in_and_disagre__ite03576"> </A>
<A NAME="toc_fs72301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_item_9a._controls_and_procedures"> </A>
<A NAME="toc_fs72301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9A.&nbsp;&nbsp;&nbsp;&nbsp;CONTROLS AND PROCEDURES    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Evaluation of Disclosure Controls and Procedures  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2015, we evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the
effectiveness of our disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")). Based on that
evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&nbsp;31,
2015. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is
recorded, processed, summarized and reported within time periods specified by the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our
Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Management's Annual Report on Internal Control Over Financial Reporting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control
over financial reporting is defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange Act as the process designed by, or under the supervision of, our Chief Executive Officer and Chief
Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of
our financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures
that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of
assets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorizations of management and directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets
that could have a material effect on our financial statements. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of
our internal control over financial reporting based on the framework provided in </FONT><FONT SIZE=2><I>Internal Control&#151;Integrated Framework (2013)</I></FONT><FONT SIZE=2> issued by the
Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of
December&nbsp;31, 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=117,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=377834,FOLIO='113',FILE='DISK133:[15ZCW1.15ZCW72301]FS72301A.;4',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fs72301_1_114"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
effectiveness of our internal control over financial reporting as of December&nbsp;31, 2015 has been audited by PricewaterhouseCoopers&nbsp;LLP, an independent registered public
accounting firm, as stated in their report, which is included herein. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes in Internal Control Over Financial Reporting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There were no changes in our internal control over financial reporting during the three months ended December&nbsp;31, 2015 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_item_9b._other_information"> </A>
<A NAME="toc_fs72301_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9B.&nbsp;&nbsp;&nbsp;&nbsp;OTHER INFORMATION    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_part_iii"> </A>
<A NAME="toc_fs72301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  PART III    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_item_10._directors,_executive___ite02336"> </A>
<A NAME="toc_fs72301_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;10 will be included in the definitive Proxy Statement for our 2016 Annual Meeting of
Stockholders, or the 2016 Proxy Statement, under "Information Regarding the Current Directors and Executive Officers of Celldex Therapeutic,&nbsp;Inc.," "Section&nbsp;16(a) Beneficial Ownership
Reporting Compliance," "Code of Business Conduct and Ethics" and "The Board of Directors and Its Committees" and is incorporated herein by reference. If the 2016 Proxy Statement is not filed with the
SEC within 120&nbsp;days after the end of our most recent fiscal year, we will provide such information by means of an amendment to this Annual Report on Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_item_11._executive_compensation"> </A>
<A NAME="toc_fs72301_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;11 will be included in the 2016 Proxy Statement under "Executive Compensation," and
"Compensation Committee Interlocks and Insider Participation," and is incorporated herein by reference. If the 2016 Proxy Statement is not filed with the SEC within 120&nbsp;days after the end of
our most recent fiscal year, we will provide such information by means of an amendment to this Annual Report on Form&nbsp;10-K.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_item_12._security_ownership_of__ite04004"> </A>
<A NAME="toc_fs72301_7"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;12 will be included in the 2016 Proxy Statement under "Security Ownership of Certain
Beneficial Owners and Management" and "Equity Compensation Plan Information" and is incorporated herein by reference. If the 2016 Proxy Statement is not filed with the SEC within 120&nbsp;days after
the end of our most recent fiscal year, we will provide such information by means of an amendment to this Annual Report on Form&nbsp;10-K.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_item_13._certain_relationships__ite03067"> </A>
<A NAME="toc_fs72301_8"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;13 will be included in the 2016 Proxy Statement under "Election of Directors" and
"Approval of Related Person Transactions and Transactions with Related Persons" and is incorporated herein by reference. If the 2016 Proxy Statement is not filed with the SEC within 120&nbsp;days
after the end of our most recent fiscal year, we will provide such information by means of an amendment to this Annual Report on Form&nbsp;10-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=118,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=429645,FOLIO='114',FILE='DISK133:[15ZCW1.15ZCW72301]FS72301A.;4',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_fs72301_1_115"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fs72301_item_14._principal_accounting_fees_and_services"> </A>
<A NAME="toc_fs72301_9"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;PRINCIPAL ACCOUNTING FEES AND SERVICES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item&nbsp;14 will be included in the 2016 Proxy Statement under "Independent Registered Public
Accounting Firm" and is incorporated herein by reference. If the 2016 Proxy Statement is not filed with the SEC within 120&nbsp;days after the end of our most recent fiscal year, we will provide
such information by means of an amendment to this Annual Report on Form&nbsp;10-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=119,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=727384,FOLIO='115',FILE='DISK133:[15ZCW1.15ZCW72301]FS72301A.;4',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ja72301_1_116"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja72301_part_iv"> </A>
<A NAME="toc_ja72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART IV    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja72301_item_15._exhibits,_financial_statement_schedules"> </A>
<A NAME="toc_ja72301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS, FINANCIAL STATEMENT SCHEDULES    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(A)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
following documents are filed as part of this Form&nbsp;10-K:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(1)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Financial Statements:</I></FONT></DD></DL>
</DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Financial Statements and Supplementary Data are included in Part&nbsp;II Item&nbsp;8 of this report.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(2)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Financial Statement Schedules:</I></FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedules
are omitted since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required
is included in the Financial Statements or Notes thereto.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(3)</I></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Exhibits:</I></FONT></DD></DL>
</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=9 style="font-family:times;"><FONT SIZE=2><I> Plan of Acquisition, Reorganization, Arrangement, Liquidation or Succession</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated as of October&nbsp;19, 2007, by and among AVANT, Celldex Merger Corporation, and Celldex Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10/22/07</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>2.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Agreement and Plan of Merger, dated as of May&nbsp;28, 2009, by and among Celldex Therapeutics,&nbsp;Inc., CuraGen Corporation and Cottrell Merger Sub,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>5/29/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=9 style="font-family:times;"><BR><FONT SIZE=2><I> Articles of Incorporation and By-Laws</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4<BR>
(333-59215)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7/16/98</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-59215)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>7/16/98</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-59215)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>7/16/98</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Third Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>5/10/02</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Fourth Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/11/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Fifth Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/11/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Sixth Certificate of Amendment of Third Restated Certificate of Incorporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>11/10/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amended and Restated By-Laws, dated April&nbsp;7, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>4/8/14</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=9 style="font-family:times;"><BR><FONT SIZE=2><I> Instruments Defining the Rights of Security Holders</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Specimen of Common Stock Certificate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/24/15</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=120,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=561019,FOLIO='116',FILE='DISK133:[15ZCW1.15ZCW72301]JA72301A.;9',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_ja72301_1_117"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certificate of Designations, Preferences and Rights of a Series of Preferred Stock classifying and designating the Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8-A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11/8/04</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=9 style="font-family:times;"><BR><FONT SIZE=2><I> Material Contracts&#151;Leases</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Commercial Lease Agreement of May&nbsp;1, 1996 between the Company and Fourth Avenue Ventures Limited Partnership</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10-Q/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8/23/96</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Extension of Lease Agreement of May&nbsp;1, 1997 between the Company and DIV Needham 53&nbsp;LLC (successor in interest to Fourth Avenue Ventures Limited Partnership) dated as of August&nbsp;23, 2001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/27/02</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>First Amendment to Lease by and between the Company and DIV Needham 115&nbsp;LLC (successor in interest to Fourth Avenue Ventures Limited Partnership) dated November&nbsp;29, 2005</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/16/06</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Amendment to Lease by and between the Company and DIV Needham 115&nbsp;LLC dated as of August&nbsp;1, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Lease Agreement, by and between the Company and the Massachusetts Development Finance Agency, dated as of December&nbsp;22, 2003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>4/30/04</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>First Amendment to Lease between Massachusetts Development Finance Agency and the Company dated March&nbsp;17, 2005</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Second Amendment to Lease by and between the Company and the Massachusetts Development Finance Agency dated as of November&nbsp;4, 2005</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/16/06</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Third Amendment to Lease between Massachusetts Development Finance Agency and the Company dated December&nbsp;20, 2006</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Fifth Amendment to Lease between Massachusetts Development Finance Agency and the Company dated October&nbsp;3, 2008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Sixth Amendment to Lease between Massachusetts Development Finance Agency and the Company dated August&nbsp;20, 2009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Seventh Amendment to Lease by and between the Company and the Massachusetts Development Finance Agency dated as of June&nbsp;22, 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8/5/10</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=121,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=373118,FOLIO='117',FILE='DISK133:[15ZCW1.15ZCW72301]JA72301A.;9',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_ja72301_1_118"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Eighth Amendment to Lease by and between the Company and the Massachusetts Development Finance Agency dated as of November&nbsp;1, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Lease Agreement dated as of May&nbsp;1, 2013 by and between Crown Perryville,&nbsp;LLC and the Company.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>5/03/13</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>First Amendment to Lease between Company and Crown Perryville,&nbsp;LLC dated as of June&nbsp;17, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8/10/15</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=9 style="font-family:times;"><BR><FONT SIZE=2><I> Material Contracts&#151;License, Collaboration, Supply and Distribution Agreements</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>License Agreement dated as of November&nbsp;1, 2005 by and between The Rockefeller University and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License Agreement dated September&nbsp;1, 2006 by and between Duke University and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment to License Agreement between Duke University and the Company dated April&nbsp;2, 2008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License Agreement between Duke University, The Johns Hopkins University and the Company dated December&nbsp;31, 2003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment to License Agreement between Duke University, The Johns Hopkins University and the Company dated April&nbsp;2, 2008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Assignment and License Agreement, as amended, dated April&nbsp;6, 2004 by and among Medarex,&nbsp;Inc., GenPharm International,&nbsp;Inc. and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Research and Commercialization Agreement, as amended, dated as of April&nbsp;6, 2004 by and among Medarex,&nbsp;Inc., GenPharm International,&nbsp;Inc. and the Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>S-4<BR>
(333-148291)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/18/08</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Research Collaboration and Commercialization Agreement effective October&nbsp;20, 2006 between the Company and the Ludwig Institute for Cancer Research</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/2/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Exclusive Patent and Know-How License Agreement dated as of November&nbsp;5, 2008 between the Company and the University of Southampton</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/2/09</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License and Assignment Agreement, between Amgen&nbsp;Inc. and the Company dated March&nbsp;16, 2009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Collaboration Agreement dated June&nbsp;18, 2004 between Seattle Genetics and CuraGen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=122,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1027467,FOLIO='118',FILE='DISK133:[15ZCW1.15ZCW72301]JA72301A.;9',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_ja72301_1_119"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*10.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Second Restated Collaboration Agreement dated April&nbsp;12, 2004 and amended October&nbsp;19, 2004 between Abgenix&nbsp;Inc. and CuraGen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amgen Letter Agreement, by and between CuraGen and Amgen Fremont,&nbsp;Inc. dated May&nbsp;2, 2009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Transfer and Termination Agreement, dated as of April&nbsp;21, 2008 by and between TopoTarget A/S and CuraGen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>License Agreement between Medarex and Company dated September&nbsp;17, 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q/A<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/23/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Master Services Agreement dated March&nbsp;29, 2010 by and between the Company and Prologue Research International,&nbsp;Inc. (Prologue)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>11/3/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment to Master Services Agreement dated July&nbsp;6, 2011 by and between the Company and Novella Clinical&nbsp;Inc. (formerly known as Prologue)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>11/3/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Master Services Agreement dated May&nbsp;6, 2013 by and between the Company and PPD Development,&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8/6/13</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>*10.33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Third Amended and Restated Supply Agreement dated October&nbsp;15, 2014 between the Company and Biosyn Corporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>11/5/14</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Subscription Agreement dated as of October&nbsp;15, 2014 by and between the Company and Biosyn Corporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10/20/14</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=9 style="font-family:times;"><BR><FONT SIZE=2><I> Material Contracts&#151;Stock Purchase, Financing and Credit Agreements</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sales Agreement, dated January&nbsp;6, 2011, between Celldex Therapeutics,&nbsp;Inc. and Cantor Fitzgerald&nbsp;&amp;&nbsp;Co.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.1.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1/6/11</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>10.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Amendment No.&nbsp;1 to Sales Agreement, dated January&nbsp;6, 2011, between Celldex Therapeutics,&nbsp;Inc. and Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., dated September&nbsp;20, 2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>9/24/12</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=9 style="font-family:times;"><BR><FONT SIZE=2><I> Material Contracts&#151;Management Contracts and Compensatory Plans</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#134;10.37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2008 Stock Option and Incentive Plan, as amended and restated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6/11/15</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>2004 Employee Stock Purchase Plan, as amended and restated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>6/13/13</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Employment Agreement, dated as of January&nbsp;1, 2013, by and between the Company and Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/21/12</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Employment Agreement, dated as of January&nbsp;1, 2013, by and between the Company and Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/21/12</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=123,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1009268,FOLIO='119',FILE='DISK133:[15ZCW1.15ZCW72301]JA72301A.;9',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<A NAME="page_ja72301_1_120"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form and<BR>
SEC File No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SEC<BR>
Filing Date </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#134;10.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Employment Agreement, dated as of January&nbsp;1, 2013, by and between the Company and Thomas Davis, MD</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/12</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.42</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Employment Agreement, dated as of January&nbsp;1, 2013, by and between the Company and Tibor Keler, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/21/12</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Employment Agreement, dated as of January&nbsp;1, 2013, by and between the Company and Ronald A. Pepin, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>12/21/12</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Employment Agreement, dated as of July&nbsp;1, 2015, by and between the Company and Richard Wright, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-Q<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8/10/15</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Stock Option Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>8-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>1/25/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&#134;10.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Form of Restricted Stock Award</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10-K<BR>
(000-15006)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>10.42</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>3/12/10</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>21.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Subsidiaries of Celldex Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Consent of PricewaterhouseCoopers&nbsp;LLP, an Independent Registered Public Accounting Firm</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>31.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certification of President and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>31.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certification of Senior Vice President and Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Section&nbsp;1350 Certifications</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Furnished herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Instance Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Schema Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Label Linkbase Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Filed herewith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Confidential
treatment has been requested for certain provisions of this Exhibit pursuant to Rule&nbsp;24b-2 promulgated under the Securities Exchange Act
of 1934, as amended.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#134;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Indicates
a management contract or compensation plan, contract or arrangement.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=124,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=864037,FOLIO='120',FILE='DISK133:[15ZCW1.15ZCW72301]JA72301A.;9',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_jc72301_1_121"> </A>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg72301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc72301_signatures"> </A>
<A NAME="toc_jc72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> CELLDEX THERAPEUTICS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Date</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I> President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the
dates indicated. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="103pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:34pt;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,34pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer, and Director<BR>
(Principal Executive Officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Senior Vice President, Chief Financial Officer and Treasurer<BR>
(Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;LARRY ELLBERGER<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Larry Ellberger</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director, Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;HERBERT J. CONRAD<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Herbert J. Conrad</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;GEORGE O. ELSTON<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> George O. Elston</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;HARRY H. PENNER, JR.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Harry H. Penner, Jr.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;KAREN L. SHOOS<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Karen L. Shoos</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;RICHARD A. VAN DEN BROEK<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Richard A. van den Broek</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>February&nbsp;25, 2016</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=125,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=603195,FOLIO='121',FILE='DISK133:[15ZCW1.15ZCW72301]JC72301A.;5',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>a2226904zex-10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.4</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECOND AMENDMENT TO LEASE</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Second Amendment to Lease (this &#147;<b>Amendment</b>&#148;) is dated as of August&nbsp;1, 2015, by and between DIV NEEDHAM 115 LLC, a Massachusetts limited liability company (successor-in-interest to Fourth Avenue Ventures Limited Partnership), as landlord (&#147;<b>Landlord</b>&#148;), and CELLDEX THERAPEUTICS,&nbsp;INC., a Delaware corporation (successor-by name-change to T Cell Sciences,&nbsp;Inc. and Avant Immunotherapeutics,&nbsp;Inc.), as tenant (&#147;<b>Tenant</b>&#148;), with respect to that certain Lease dated as of May&nbsp;1, 1996 (the &#147;<b>1996 Lease</b>&#148;), as amended by that certain First Amendment to Lease dated as of November&nbsp;29, 2005 (the &#147;<b>First Amendment</b>&#148;; the 1996 Lease as amended by the First Amendment is referred to herein as the &#147;<b><font style="font-weight:bold;">Original</font> Lease</b>&#148;, and the Original Lease as amended hereby is referred to herein as the &#147;<b>Lease</b>&#148;), by and between Landlord and Tenant, regarding certain premises (the &#147;<b>Existing Premises</b>&#148;) constituting approximately 35,189 rentable square feet on the first (1</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>) floor of the building located at 115-119 Fourth Avenue, Needham, Massachusetts (the &#147;<b>Building</b>&#148;), as more particularly described in the Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Landlord and Tenant desire to enter into this Amendment to modify certain terms and conditions of the Lease, as more particularly set forth herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, for One Dollar ($1.00) and other good and valuable consideration, and in consideration of the mutual covenants and agreements set forth herein, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Defined Terms</u>.&#160; Unless otherwise defined herein, all capitalized terms used in this Amendment shall have the meanings ascribed to them in the Original Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Lease Amendments</u>.&#160; The Original Lease is hereby amended as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Term</u>.&#160; Landlord and Tenant acknowledge and agree that the Lease Term commenced on May&nbsp;1, 1996 and is scheduled to expire on April&nbsp;30, 2017.&#160; Landlord and Tenant hereby extend the Lease Term for the period commencing on May&nbsp;1, 2017 and expiring on July&nbsp;31, 2020 (the &#147;<b>Additional Term</b>&#148;), unless further extended or earlier terminated in accordance with the provisions of the Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Expansion Premises</u>.&#160; Landlord desires to lease to Tenant, and Tenant desires to lease from Landlord, certain space currently leased to Partners Community Healthcare,&nbsp;Inc. (&#147;<b>Partners</b>&#148;), such space consisting of approximately 11,540 rentable square feet on the first (1<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>) floor of the Building as more particularly described on <u>Exhibit&nbsp;A</u> attached hereto (the &#147;<b>Expansion Premises</b>&#148;).&#160; Tenant acknowledges that Partners, under its lease, has the right to occupy the Expansion Premises through and including November&nbsp;30, 2017, with an option to extend its lease term through and including November&nbsp;30, 2022.&#160; Effective as of the date on which Landlord delivers the Expansion Premises to Tenant in the condition required by <u>Section&nbsp;3</u> of this Amendment (the &#147;<b>Expansion Premises Commencement Date</b>&#148;), and continuing for the duration of the Lease Term (as extended by the Additional Term), the Expansion Premises</p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="23423-2-MM-01_PB_1_001541_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=525148,FOLIO='1',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 03:40 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">shall be added to the &#147;Premises&#148; demised under the Lease.&#160; Landlord shall use commercially reasonable efforts to provide written notice to Tenant at least ninety (90) days prior to the date which Landlord reasonably anticipates to be the Expansion Premises Commencement Date, it being acknowledged that Landlord estimates that the Expansion Premises Commencement Date will occur approximately fifteen (15) days after the date on which Partners vacates the Expansion Premises and delivers the Expansion Premises to Landlord.&#160; As of the Expansion Premises Commencement Date, (i)&nbsp;the &#147;Premises&#148; shall be deemed to include both the Existing Premises and the Expansion Premises, (ii)&nbsp;the rentable area of the Premises shall be deemed to equal 46,729 rentable square feet, and (iii)&nbsp;Tenant&#146;s Proportionate Fraction shall be increased from 44.78% to 59.47%.&#160; </font>Except as expressly provided herein, all terms and provisions of the Original Lease shall be applicable to Tenant&#146;s leasing of the </font>Expansion Premises.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Delivery Condition of Expansion Premises</u>.&#160; Landlord shall deliver the Expansion Premises in its &#147;as is&#148; condition as of the Expansion Premises Commencement Date, without any obligation on the part of Landlord to perform any construction therein or to prepare the same for Tenant&#146;s occupancy; provided, however, that Landlord agrees (i)&nbsp;to deliver in good working order those base building systems which exclusively serve the Expansion Premises, and (ii)&nbsp;to deliver the Expansion Premises in compliance with applicable law (except Landlord shall have no obligation to perform upgrades to bring ADA-noncompliant bathrooms into compliance).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Delivery Condition of Existing Premises</u>.&#160; Tenant shall continue in possession of the Existing Premises in its &#147;as is&#148; condition as of the date of this Amendment, without any obligation on the part of Landlord to perform any construction therein or to prepare the same for Tenant&#146;s occupancy.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Second Amendment Allowance</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the terms of this Amendment, Tenant shall be entitled to receive from Landlord an allowance (the &#147;<b>Second Amendment Allowance</b>&#148;) up to and not to exceed $321,617.50 (i.e., calculated at the rate of $7.50 per rentable square foot of the Existing Premises, plus $5.00 per rentable square foot of the Expansion Premises) for tenant improvements within, at Tenant&#146;s sole election, either the Existing Premises or the Expansion Premises (the &#147;<b>Second Amendment Improvements</b>&#148;).&#160; Upon the request of Tenant, Landlord shall provide Tenant with one (1)&nbsp;initial fit plan as well as one (1)&nbsp;revision to the initial fit plan, all at Landlord&#146;s sole cost and without resort to the Second Amendment Allowance; provided, however, that as of December&nbsp;31, 2015, Landlord shall have no further obligation to provide the initial fit plan or to make any revisions thereto.&#160; The Second Amendment Allowance shall be used to contribute toward the payment of documented, out-of-pocket, so-called &#147;hard&#148; construction costs incurred by Tenant in constructing the Second Amendment</p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="23423-2-MM-01_PB_2_001630_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=523,FOLIO='2',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 03:40 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Improvements (the &#147;<b>Second Amendment Work Cost</b>&#148;) consistent with the plans, drawings and specifications (&#147;<b>Second Amendment Plans</b>&#148;) which have been reviewed and approved by Landlord (such approval not to be unreasonably withheld or delayed) prior to the commencement of such Second Amendment Improvements.&#160; Notwithstanding the foregoing, no more than ten percent (10%) of the Second Amendment Allowance (i.e., $32,161.75) shall be eligible for application to so-called &#147;soft costs&#148; incurred by Tenant in designing and constructing the Second Amendment Improvements.&#160; Tenant shall provide Landlord with information as reasonably requested by Landlord to substantiate the complete Second Amendment Work Cost following acceptance of any bids for the Second Amendment Improvements in accordance with the Second Amendment Plans.&#160; At the expiration or earlier termination of the Lease Term, Tenant shall, at Tenant&#146;s sole cost and expense, remove and restore (a)&nbsp;any components of the Second Amendment Improvements for which Landlord requires restoration in writing at the time of Landlord&#146;s approval of the Second Amendment Plans, and (b)&nbsp;any specialty alterations not typically performed under tenancies having general office use, as determined by Landlord in its reasonable discretion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant shall notify Landlord of the parties which Tenant intends to use as architect, engineer and contractor for the Second Amendment Improvements, and such consultants shall be subject to Landlord&#146;s prior written consent (not to be unreasonably withheld, conditioned or delayed).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant shall obtain and furnish to Landlord true and complete copies of all necessary governmental permits and certificates as may be required (a)&nbsp;for the commencement and prosecution of the Second Amendment Improvements and (b)&nbsp;to evidence final approval thereof upon completion.&#160; It shall be the responsibility of Tenant: (i)&nbsp;to submit, at its sole cost and expense, all Second Amendment Plans to any governmental authority requiring the same, and (ii)&nbsp;to secure and pay for all permits or governmental approvals necessary to construct the Second Amendment Improvements and to use and occupy the Premises (including, without limitation, any required certificate of occupancy).&#160; Landlord shall not charge Tenant any oversight or supervisory fee with regard to Tenant&#146;s initial construction of the Second Amendment Improvements.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant shall construct the Second Amendment Improvements in accordance with the Second Amendment Plans, and any material deviations from the Second Amendment Plans shall require resubmission to Landlord, for Landlord&#146;s prior approval, of detailed plans and drawings describing such material deviations.&#160; Tenant shall construct and complete the Second Amendment Improvements in a good and workmanlike manner, using materials of first quality (using no less than building standard materials and finishes) and shall comply with the Landlord&#146;s</p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="23423-2-MM-01_PB_3_001702_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=485826,FOLIO='3',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 03:40 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">construction standards, all applicable requirements of insurance bodies and with the Second Amendment Plans<b>.</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant shall pay all debts incurred and shall satisfy or bond all liens of contractors, subcontractors, mechanics, laborers, and materialmen in respect to construction, alteration and repair in and on the Premises.&#160; If any mechanic&#146;s, laborer&#146;s, or materialman&#146;s lien shall at any time be filed against the Building (or any portion thereof) by reason of any act or omission of Tenant, Tenant shall cause the same to be discharged by payment, deposit, bond or order of a court of competent jurisdiction within twenty (20) days of written notice of Landlord.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Second Amendment Allowance shall be payable by Landlord to Tenant not more than one (1)&nbsp;time per month on a progress payment basis.&#160; In connection with each request for payment, Tenant shall submit to Landlord a detailed requisition request satisfactory to Landlord (each, a &#147;<b>Requisition Request</b>&#148;).&#160; Each disbursement to Tenant shall be made within thirty (30) days after Tenant has delivered to Landlord evidence of the completion of the Second Amendment Improvements (or any portion thereof) pursuant to the Second Amendment Plans and a complete Requisition Request and shall be in an amount equal to the substantiated amount of the expense paid or incurred by Tenant with respect to the Second Amendment Work Cost.&#160; Landlord shall not be obligated to pay any portion of the Second Amendment Allowance during such time that Tenant is in default of any of its obligations under the Lease.&#160; In no event shall Landlord be responsible for any sums in excess of the Second Amendment Allowance, and as a result, after Landlord has disbursed the full amount of the Second Amendment Allowance, Tenant shall be financially responsible for all remaining construction expenses for its Second Amendment Improvements.&#160; Each Requisition Request shall be accompanied by (a)&nbsp;reasonably detailed invoices and billing statements evidencing the completion of the work that is the subject of such Requisition Request, (b)&nbsp;sworn tenant&#146;s and contractor&#146;s statements in customary form in use by Chicago Title Insurance Company reflecting (i)&nbsp;the total cost of the Second Amendment Improvements, provided, however, that line items for work or materials not yet bid or let (e.g., furniture) shall reflect a projected amount and clearly reflect such line items as not yet let; (ii)&nbsp;the progress payments funded to date; (iii)&nbsp;the amount to be funded for the draw being requested; and (iv)&nbsp;the balance to be disbursed, (c)&nbsp;such contractor&#146;s affidavits and partial or final lien waivers as Landlord shall require; (d)&nbsp;with respect to the final draw request, a certificate from Tenant&#146;s architect stating that the Second Amendment Work has been completed in accordance with the Second Amendment Plans and applicable zoning, building, environmental and other laws and final lien waivers, and (e)&nbsp;any other commercially reasonable documentation that may be requested by Landlord.&#160; Tenant</p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="23423-2-MM-01_PB_4_001739_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=111516,FOLIO='4',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 03:40 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shall submit all Requisition Requests no sooner than the Expansion Premises Commencement Date and no later than the day that is six (6)&nbsp;months following the Expansion Premises Commencement Date, unless delayed by Acts of God (as defined in <u>Section&nbsp;14.5</u> of the 1996 Lease), and Landlord shall have no obligation to pay any monies with respect to the Second Amendment Improvements outside of such period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant no longer shall have the right to seek reimbursement from Landlord for Qualified Tenant Improvements.&#160; Accordingly, <u>Section&nbsp;15.3</u> of the 1996 Lease is hereby made void and shall be of no further force and effect.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Annual Fixed Rent</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Effective as of August&nbsp;1, 2015, notwithstanding the Annual Fixed Rent chart set forth in <u>Section&nbsp;5(a)</u>&nbsp;of the First Amendment, Annual Fixed Rent for the Existing Premises shall be payable in the manner set forth in <u>Section&nbsp;4</u> of the 1996 Lease, at the rates set forth below.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.75in;">
<tr>
<td width="60%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:60.18%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Annual&nbsp;Fixed&nbsp;Rent</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Monthly&nbsp;Installment</font></b></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2015 &#150; July&nbsp;31, 2016</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,073,264.50</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">89,438.71</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2016 &#150; July&nbsp;31, 2017</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,102,823.26</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">91,901.94</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2017 &#150; July&nbsp;31, 2018</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,133,085.80</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">94,423.82</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2018 &#150; July&nbsp;31, 2019</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,164,404.01</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">97,033.67</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2019 &#150; July&nbsp;31, 2020</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,196,426.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99,702.17</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Effective as of the Expansion Premises Commencement Date, Annual Fixed Rent for the Expansion Premises shall be payable in the manner set forth in <u>Section&nbsp;4</u> of the 1996 Lease, at the rates set forth below.&#160; For the avoidance of doubt, Landlord and Tenant acknowledge and agree that Tenant shall owe no Annual Fixed Rent in respect of the Expansion Premises for the period prior to the Expansion Premises Commencement Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.75in;">
<tr>
<td width="60%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:60.18%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period*</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Annual&nbsp;Fixed&nbsp;Rent</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Monthly&nbsp;Installment</font></b></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2015 &#150; July&nbsp;31, 2016</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">351,970.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29,330.83</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2016 &#150; July&nbsp;31, 2017</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">361,663.60</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30,138.63</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2017 &#150; July&nbsp;31, 2018</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">371,588.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30,965.67</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2018 &#150; July&nbsp;31, 2019</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">381,858.60</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31,821.55</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="60%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:60.18%;">
<p align="center" style="margin:0in 0in .0001pt 10.1pt;text-align:center;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;1, 2019 &#150; July&nbsp;31, 2020</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">392,360.00</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32,696.67</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="23423-2-MM-01_PB_5_003806_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=475644,FOLIO='5',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 03:40 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">* Notwithstanding the foregoing, provided that no default has occurred beyond applicable notice and cure periods under the Lease, Tenant shall not be obligated to make payments of Annual Fixed Rent in respect of the Expansion Premises for the period commencing on the Expansion Premises Commencement Date and ending on the earlier of (a)&nbsp;the day before the Town of Needham issues a temporary or permanent certificate of occupancy for the Expansion Premises, and (b)&nbsp;the one hundred twentieth (120</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) day following the Expansion Premises Commencement Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Additional Rent</u>.&#160; From the date of this Amendment through and including the Additional Term, Tenant shall continue to pay Additional Rent and all other charges due under the Lease in respect of the Existing Premises.&#160; From and after the Expansion Premises Commencement Date, through and including the Additional Term, Tenant shall pay Additional Rent and all other charges due under the Lease in respect of the Existing Premises.&#160; Landlord represents and warrants that the Expansion Premises will be submetered for electricity as of the Expansion Premises Commencement Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Utilities</u>.&#160; For the period commencing on the date of this Amendment through and including the Additional Term, Tenant shall continue to pay all charges for Tenant&#146;s utilities in respect of the Existing Premises in accordance with <u>Section&nbsp;7.1</u> of the 1996 Lease.&#160; For the period commencing on the Expansion Premises Commencement Date through and including the Additional Term, Tenant shall pay all charges for Tenant&#146;s utilities in respect of the Expansion Premises in accordance with <u>Section&nbsp;7.1</u> of the 1996 Lease.&#160; HVAC shall be available in the Expansion Premises Monday through Friday from 7:30 a.m.&nbsp;to 6:30 p.m.&nbsp;and Saturdays from 9:00 a.m.&nbsp;to 3:00 p.m.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>HVAC Maintenance</u>.&#160; For the period commencing on the date of this Amendment through and including the Additional Term, Tenant shall continue to be solely responsible for the cost of maintenance, replacement and repair of those portions of the HVAC equipment and systems solely serving the Existing Premises, all in accordance with <u>Section&nbsp;13</u> of the First Amendment.&#160; Within the period of sixty (60) days prior to the Expansion Premises Commencement Date, Landlord shall cause the HVAC equipment serving the Expansion Premises to be inspected by a properly qualified technical firm selected by Landlord in its reasonable discretion, which technical firm shall certify that such HVAC equipment is in good working condition. If such HVAC equipment is not then in good working condition, then Landlord shall cause such HVAC equipment to be placed in good working condition at Landlord&#146;s expense prior to the Expansion Premises Commencement Date.&#160; For the period commencing on the Expansion Premises Commencement Date through and including the Additional Term, Landlord shall have control of and shall maintain, repair and replace the HVAC equipment and systems serving the Expansion Premises, all in accordance with <u>Section&nbsp;13</u> of the First Amendment, it being acknowledged and agreed that the</p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="23423-2-MM-01_PB_6_003843_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=706539,FOLIO='6',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 03:40 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">HVAC equipment and systems serving the Expansion Premises are &#147;Common HVAC&#148; under <u>Section&nbsp;13</u> of the First Amendment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Parking</u>.&#160; Effective as of the Expansion Premises Commencement Date, (i)&nbsp;thirteen (13) of the spaces which Tenant is entitled to use under <u>Section&nbsp;1.3</u> of the 1996 Lease, which thirteen (13) parking spaces are shown on <u>Exhibit&nbsp;B</u> attached hereto (the &#147;<b>Reserved Parking Spaces</b>&#148;), will be designated, marked and identified by Landlord as being reserved for the exclusive use of Tenant and its employees and invitees, it being acknowledged, however, that Landlord shall be under no obligation to enforce Tenant&#146;s exclusive parking rights, and (ii)&nbsp;Tenant shall be entitled to use one hundred thirty-seven (137) unreserved parking spaces (the &#147;<b>Unreserved Parking Spaces</b>&#148;), subject to and in accordance with <u>Section&nbsp;1.3</u> of the 1996 Lease.&#160; For the avoidance of doubt, Landlord and Tenant hereby acknowledge and agree that the Unreserved Parking Spaces shall be allocated as follows: 103 unreserved parking spaces on the &#147;Building Parcel&#148; (as designated on <u>Exhibit&nbsp;B</u>) and 34 unreserved parking spaces on the &#147;Parking Parcel&#148; (as designated on <u>Exhibit&nbsp;B</u>).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Extension Terms</u>.&#160; Tenant shall have the right to extend the Lease Term for two (2)&nbsp;periods of five (5)&nbsp;years each, subject to and in accordance with the terms and conditions of <u>Section&nbsp;8</u> of the First Amendment.&#160; Accordingly, <u>Section&nbsp;8</u> of the First Amendment is hereby amended by (i)&nbsp;deleting the phrase &#147;one extended term&#148; and substituting therefor the phrase &#147;two extended terms (the &#147;<b>Second Extension Term</b>&#148; and the &#147;<b>Third Extension Term</b>&#148;, respectively)&#148;, and (ii)&nbsp;except for the instance of &#147;Second Extension Term&#148; in the first (1<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>) sentence of said <u>Section&nbsp;8</u> (which is modified by the foregoing clause (i)), deleting the phrase &#147;Second Extension Term&#148; in each instance and substituting therefor the phrase &#147;Second Extension Term or Third Extension Term, as applicable&#148;, it being acknowledged that (notwithstanding the foregoing deletion and substitution), during the Second Extension Term, Tenant shall have one (1)&nbsp;further option to extend the Lease Term for the Third Extension Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Insurance</u>.&#160; Effective as of the date of this Amendment, <u>Section&nbsp;6.1(g)</u>&nbsp;of the First Amendment is hereby amended by deleting the phrase &#147;the Extension Term&#148; and substituting therefor the phrase &#147;any extended term of this Lease&#148;, it being agreed that Landlord shall have the right to increase insurance limits or require additional types of insurance coverage, all as more particularly provided in <u>Section&nbsp;6.1(g)</u>&nbsp;of the First Amendment, effective as of the first day of the Additional Term, the Second Extension Term, the Third Extension Term or any other extended term of the Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Exterior Signage</u>.&#160; Subject to Landlord&#146;s reasonable approval as to size, design, location and method of installation, not to be unreasonably withheld, delayed or conditioned, and to applicable laws, Tenant shall have the right, prior to the first anniversary of the Expansion Premises Commencement Date, to install and thereafter maintain one sign on the exterior of the Building (the &#147;<b>Exterior</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="23423-2-MM-01_PB_7_003859_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=970272,FOLIO='7',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 03:40 2016' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Building Signage</font></b>&#148;).&#160; Tenant shall be responsible, at Tenant&#146;s expense, for obtaining all permits related to the installation of Tenant&#146;s Exterior Building Signage.&#160; The provisions of this paragraph are personal to Celldex Therapeutics,&nbsp;Inc. or a successor entity under a &#147;Merger&#148; or as a result of a transfer to a parent or subsidiary of Tenant for which Landlord&#146;s consent is not required, all as more particularly provided in <u>Section&nbsp;9.13(a)</u>&nbsp;of the 1996 Lease (as amended and restated by <u>Section&nbsp;9(a)</u>&nbsp;of the First Amendment) .&#160; Notwithstanding anything herein to the contrary, if (i)&nbsp;Tenant defaults beyond applicable notice and cure periods under the Lease, or (ii)&nbsp;Tenant subleases more than forty percent (40%) of the then rentable area of the Premises, or (iii)&nbsp;the Lease expires or otherwise terminates, Tenant&#146;s right to the Exterior Building Signage shall terminate, and Tenant shall remove the Exterior Building Signage and repair any damage caused by such removal, at Tenant&#146;s sole cost, in a commercially reasonable manner that restores the portion of the Building that was subject to the Exterior Building Signage to substantially the condition that existed prior to the installation of the Exterior Building Signage.&#160; If Tenant&#146;s Exterior Building Signage requires municipal or other governmental approval, and such approval is denied, Landlord shall not be deemed to be in default hereunder and the Lease shall continue in full force and effect, it being agreed, however, that Landlord shall use reasonable efforts (at no cost or legal obligation to Landlord) to cooperate with Tenant in obtaining such approvals, including, without limitation, executing such documentation that is required of Landlord by such municipal or governmental authority in connection therewith.&#160; If Tenant does not install Exterior Building Signage prior to the first anniversary of the Expansion Premises Commencement Date, then Tenant&#146;s rights to install Exterior Building Signage shall terminate.&#160; Landlord shall have the right to relocate the Exterior Building Signage on a temporary basis in connection with the maintenance and repair of the Building.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Right of First Refusal</u>.&#160; Commencing on the Expansion Premises Commencement Date, Tenant shall have a right of first refusal on certain space in the Building, as more particularly provided in <u>Exhibit&nbsp;C</u> attached hereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Roof Penetrations</u>.&#160; Subject to Landlord&#146;s approval, which shall not be unreasonably withheld, conditioned or delayed, Tenant shall have the right to repair and service Tenant&#146;s existing HVAC equipment on the roof of the Building and to replace such equipment in the same location and to add new equipment that is substantially similar in size and function, except as provided in the next succeeding sentence.&#160; Tenant shall not install any new HVAC equipment on the lower, front, roof of the Building (commonly called the &#147;view roof&#148;) or make any new penetrations on that portion of the roof of the Building (collectively, &#147;<b>New Lower Roof Equipment and Penetrations</b>&#148;) without Landlord&#146;s prior written consent to the location, design, materials and installation method thereof, which consent Landlord reserves the right to withhold for any reason in Landlord&#146;s sole and absolute discretion.&#160; In the event that Landlord approves any roof penetrations (whether New Lower Roof Penetration or any others), (i)&nbsp;Tenant shall be solely responsible for obtaining any and all permits and approvals required in connection</p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="23423-2-MM-03_PB_8_004034_1710"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=1014900,FOLIO='8',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-03_ZCW72302.CHC",USER="HYUNG",CD='Dec 17 06:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with installation of such penetrations and the ongoing maintenance thereof, and for any and all costs in connection with the permitting, fabrication, installation and maintenance of such penetrations, (ii)&nbsp;Tenant shall maintain all such penetrations in good condition at all times, and (iii)&nbsp;at the expiration or earlier termination of the Lease, Tenant shall remove all such penetrations, repair all damage caused by such removal, and restore the roof of the Building to its condition immediately prior to installation of all such penetrations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Landlord&#146;s Address for Notices and Payments</u>.&#160; <u>Section&nbsp;1.1</u> of the 1996 Lease is hereby amended by deleting the &#147;Address of Landlord&#148; set forth therein and substituting therefor &#147;c/o Davis Management Company, LLC, 125 High Street, 21<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>&#160;Floor, Boston, Massachusetts 02110&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">C.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Broker</u>.&#160; Tenant hereby represents and warrants that it has not directly or indirectly dealt with any broker or other party entitled to a commission or fee by virtue of this Amendment other than Jones Lang LaSalle and The Garibaldi Group (collectively, the &#147;<b>Broker</b>&#148;) and agrees to indemnify, defend and hold Landlord harmless from any and all loss, cost, damage, claim or expense arising from any claims for commissions or fees by any third parties, other than the Broker, based on dealing with Tenant in connection with the Premises or this Amendment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">D.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law/Binding Effect</u>.&#160; The Lease and this Amendment and the rights and obligations of both parties thereunder and hereunder shall be governed by the laws of the Commonwealth of Massachusetts and shall be binding upon and inure to the benefit of the Landlord and Tenant and their respective legal representatives, successors and assigns.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Understanding</u>.&#160; This Amendment contains the entire understanding between the Landlord and Tenant and supersedes any prior understandings and agreements between them respecting the subject matter of this Amendment.&#160; No modification of the Lease as amended by this Amendment shall be valid or effective unless in writing and signed by the party against whom the modification is to be enforced.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">F.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>General Provisions</u>.&#160; Except as specifically amended in this Amendment, the Original Lease is and shall remain in full force and effect and has not been amended, modified, terminated or assigned.&#160; No portion of the Premises has been assigned, sublet or licensed for use by any other occupant.&#160; In the event there is a contradiction between the Original Lease and this Amendment, this Amendment shall govern.&#160; Tenant acknowledges that Landlord&#146;s and Tenant&#146;s lease covenants are independent and that Tenant has no claim of default, setoff, counterclaim or defenses and no claim of abatement, reduction, adjustments, or concessions with respect to rent and/or other charges under the Original Lease as of the date hereof, and to the extent any of the same exist, they are hereby waived in full.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[signatures on following page]</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[remainder of this page&nbsp;intentionally left blank]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="23423-2-MM-03_PB_9_004055_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=592021,FOLIO='9',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-03_ZCW72302.CHC",USER="HYUNG",CD='Dec 17 06:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 46.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXECUTED as a sealed instrument as of the date   first set forth above.</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LANDLORD:</font></b></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DIV NEEDHAM 115 LLC, a Massachusetts limited   liability company</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 46.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Fourth Avenue Ventures Limited Partnership,   its manager</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 82.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: Cendav Investment Corp., its general partner</font></p>    </td>   </tr>
<tr>
<td width="16%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:16.84%;">
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.16%;">
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="16%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:16.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:13.34%;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="33%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Jonathan Davis</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="16%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:16.84%;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:   Jonathan Davis</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="16%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:16.84%;">
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:   President</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="16%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:16.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="16%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:16.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TENANT:</font></b></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CELLDEX   THERAPEUTICS,&nbsp;INC., a Delaware corporation</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="3" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Avery W. Catlin</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:   Avery W. Catlin</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:   SVP&nbsp;&amp; CFO</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="29" style="border:none;"></td>
<td width="65" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="235" style="border:none;"></td>
<td width="354" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=290956,FOLIO='',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-03_ZCW72302.CHC",USER="HYUNG",CD='Dec 17 06:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECRETARY&#146;S CERTIFICATE</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Anthony S. Marucci, President&nbsp;&amp; CEO of CELLDEX THERAPEUTICS,&nbsp;INC., a Delaware corporation (the &#147;Company&#148;), hereby certify that by Board Meeting on September&nbsp;9, 2015, approval was given for the Company, as tenant, to enter into a Second Amendment to Lease with DIV NEEDHAM 115 LLC, as landlord, with respect to the Company&#146;s lease in the building located at, known as and numbered 115-119 Fourth Avenue, Needham, Massachusetts, a copy of which Second Amendment to Lease is attached hereto and made a part hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I further certify that Avery W. Catlin, as SVP&nbsp;&amp; CFO of the Company has authority to execute and deliver to the landlord said Second Amendment to Lease on behalf of the Corporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Witness my hand and seal of the Corporation this 30th day of October, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Anthony S. Marucci</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:   Anthony S. Marucci</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:   President&nbsp;&amp; CFO</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=449760,FOLIO='',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-03_ZCW72302.CHC",USER="HYUNG",CD='Dec 17 06:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Expansion Premises</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="581" height="710" src="g234232mm03i001.jpg"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=485987,FOLIO='',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-03_ZCW72302.CHC",USER="HYUNG",CD='Dec 17 06:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;B</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Parking Spaces</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="593" height="798" src="g234232mm03i002.jpg"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=635410,FOLIO='',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-03_ZCW72302.CHC",USER="HYUNG",CD='Dec 17 06:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;C</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Right of First Refusal</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tenant shall have an ongoing right of first refusal (the &#147;<b>Right of First Refusal</b>&#148;) to lease certain ROFR Space (hereinafter defined), subject to the terms and conditions of this <u>Exhibit&nbsp;C</u> and the existing rights of any other tenants leasing space at the Building as of the date of this Amendment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notice Of Availability</u>.&#160; Commencing on the Expansion Premises Commencement Date and continuing until July&nbsp;31, 2018 (the &#147;<b>ROFR Period</b>&#148;), at such time as Landlord shall receive a bona fide written offer which Landlord is prepared to accept (a &#147;<b>Bona Fide Offer</b>&#148;) from a prospective third-party tenant to lease any space in the Building which is contiguous to the then Premises (such space, the &#147;<b>ROFR Space</b>&#148;), Landlord shall give Tenant written notice thereof (the &#147;<b>ROFR Notice</b>&#148;).&#160; The ROFR Notice shall set out the terms and conditions of the Bona Fide Offer in respect of the ROFR Space.&#160; Tenant shall have no Right of First Refusal during the Second Extension Term or the Third Extension Term, neither of which Extension Term shall constitute a portion of the ROFR Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Conditions to Exercise</u>.&#160; In addition to any other terms or conditions set forth herein, Tenant&#146;s exercise of its Right of First Refusal is conditioned upon Tenant&#146;s compliance with the following requirements:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant delivers to Landlord written notice exercising its right to lease the ROFR Space on the terms of the Bona Fide Offer within five (5)&nbsp;days after Tenant&#146;s receipt of the ROFR Notice, it being agreed and acknowledged by the parties hereto that in the event of any failure by Tenant to timely exercise its right to lease the ROFR Space, Landlord shall have a period of twelve (12) months after delivery of the ROFR Notice within which to fully execute and deliver a lease with the tenant which submitted the Bona Fide Offer on substantially the terms and conditions set forth in the Bona Fide Offer, failing which the Right of First Refusal shall renew and Landlord shall again notify Tenant of any Bona Fide Offer received during the ROFR Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant is not in default under the Lease beyond all applicable notice and cure periods at the time Landlord gives the ROFR Notice and at the commencement of the lease of ROFR Space by Tenant; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant must lease all of the ROFR Space on the terms and conditions of the Bona Fide Offer</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>On the date of the Bona Fide Offer, Celldex Therapeutics,&nbsp;Inc. must be occupying one hundred percent (100%) of the then Premises demised under the Lease, without any portion of the then Premises subject to a sublease or other occupancy agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Terms</u>.&#160; The following terms shall apply to and govern the lease of the ROFR Space:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=652617,FOLIO='',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-03_ZCW72302.CHC",USER="HYUNG",CD='Dec 17 06:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For any Bona Fide Offer received during the period of twenty-four (24) months immediately following the Expansion Premises Commencement Date, Annual Fixed Rent, tenant improvement allowance and tenant inducements shall be equitably and proportionately adjusted to be consistent with the terms of this Amendment (it being agreed that, for purposes of such equable and proportionate adjustment, the applicable tenant improvement allowance shall be $5.00 per rentable square foot of the ROFR Space, consistent with the portion of the Second Amendment Allowance granted by Landlord in respect of the Expansion Premises), and the term of Tenant&#146;s tenancy of the ROFR Space shall begin on the date proposed for occupancy in the Bona Fide Offer and shall expire coterminous with the expiration or earlier termination of the Lease Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For any Bona Fide Offer received after the period of twenty-four (24) months immediately following the Expansion Premises Commencement Date, Annual Fixed Rent, tenant improvement allowance, tenant inducements, and term commencement and expiration shall be as set forth in the Bona Fide Offer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The other terms and conditions, including, without limitation, the payment by Tenant of Additional Rent and other charges, shall be the same as set forth in the Lease with respect to the balance of the Premises.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Documentation</u>.&#160; Within fifteen (15) days after receipt from Landlord, Tenant shall execute and deliver to Landlord those instruments Landlord reasonably requests to evidence any lease of ROFR Space under this <u>Exhibit&nbsp;C</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u>.&#160; Notwithstanding anything to the contrary contained herein, any assignment or subletting by Tenant pursuant to the provisions of the Lease shall terminate the Right of First Refusal and the same shall be null and void and without recourse to either party hereto.&#160; In addition, the Right of First Refusal granted hereby shall expire by its own terms at such time as less than twenty-four (24) months remain in the Additional Term from the date on which the term of Tenant&#146;s tenancy of the ROFR Space would have commenced in accordance with the provisions of this <u>Exhibit&nbsp;C</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="2",CHK=117152,FOLIO='',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-MM-03_ZCW72302.CHC",USER="HYUNG",CD='Dec 17 06:14 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>3
<FILENAME>a2226904zex-10_12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.12</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EIGHTH AMENDMENT TO LEASE</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This EIGHTH AMENDMENT TO LEASE (this &#147;<b>Amendment</b>&#148;) is made as of the 1st day of November, 2015, (the &#147;<b>Effective Date</b>&#148;) by and between <b>UNIVERSITY OF MASSACHUSETTS DARTMOUTH</b>, an institution of Higher Education of the Commonwealth of Massachusetts, with an address of 285 Old Westport Rd. North Dartmouth Massachusetts 02747 (&#147;<b>Landlord</b>&#148;) and <b>CELLDEX THERAPEUTICS,&nbsp;IN</b>C. (formerly AVANT Immunotherapeutics,&nbsp;Inc.), a Delaware corporation, with an address of 119&nbsp;Fourth Avenue, Needham, Massachusetts (&#147;<b>Tenant</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RECITALS</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Tenant and&#160; the Massachusetts Development Finance Agency (&#147;<b>MDFA</b>&#148;) entered into a certain Lease dated effective December&nbsp;22, 2003 ( the &#147;<b>Lease</b>&#148;) as amended by that certain First Amendment to Lease dated as of March&nbsp;17, 2005 (the &#147;<b>First Amendment</b>&#148;), that certain Second Amendment to Lease dated as of November&nbsp;4, 2005 (the &#147;<b>Second Amendment</b>&#148;), that certain Third Amendment To Lease dated as of December&nbsp;20, 2006 (the &#147;<b>Third Amendment</b>&#148;), that certain Fourth Amendment to Lease dated as of July&nbsp;18, 2008 (the &#147;<b>Fourth Amendment</b>&#148;), that certain Fifth Amendment to Lease dated as of October&nbsp;3, 2008 (the &#147;<b>Fifth Amendment</b>&#148;) that certain Sixth Amendment to Lease dated as of August&nbsp;20, 2009 (the &#147;<b>Sixth Amendment</b>&#148;) and by that certain Seventh Amendment to Lease dated June&nbsp;22, 2010 (the &#147;<b>Seventh Amendment</b>&#148;) of certain premises consisting of approximately 23,413 rentable square feet of space (the &#147;<b>Premises</b>&#148;) in the building (the &#147;<b>Building</b>&#148;) located at 151&nbsp;Martine Street, Fall River, Massachusetts (the &#147;<b>Property</b>&#148;) in the South Coast Research&nbsp;&amp; Technology Park (the &#147;<b>Park</b>&#148;); and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="23423-2-KY-01_PB_1_035544_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=243050,FOLIO='1',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, on June&nbsp;24, 2014, MDFA conveyed all of its rights, title and interest in the Building and assigned the Lease to Landlord; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Premises is comprised of: (i)&nbsp;the original premises demised by the Lease, as amended through the Third Amendment, being 11,756 rentable square feet on the second (2nd) floor of the Building, (ii)&nbsp;the Additional Space (as defined in the First Amendment) demised by the First Amendment, being 71 rentable square feet on the first (1st) floor of the Building, (iii)&nbsp;the Expansion Premises (as defined in the Second Amendment), being 2,487 rentable square feet on the second (2nd) floor of the Building; (iv)&nbsp;the Second Expansion Premises (as defined in the Third Amendment), being 1,853 rentable square feet on the second (2nd) floor of the Building; (v)&nbsp;the Substitute Third Expansion Premises (as defined in the Fifth Amendment), being 4,864 rentable square feet of space on the second floor of the Building (referred to therein as the &#147;Third Expansion Premises&#148;); and (vi)&nbsp;the Fourth Expansion Premises (as defined in the Sixth Amendment), being 2,382 rentable square feet on the second (2nd) floor of the Building, such that the &#147;Premises Square Footage&#148; (as stated in the Seventh Amendment) is defined to be 23,413 rentable square feet; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Landlord and Tenant have agreed to enter into this Eighth Amendment to Lease to renew the term of the Lease and to amended certain additional provisions to the Lease,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, Landlord and Tenant agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.&#160; <u>Capitalized Terms</u>.&#160; Unless otherwise defined herein, all capitalized terms used in this Amendment shall have the meanings ascribed to them in the Lease, and all references in the Lease to the &#147;Lease&#148; or &#147;this Lease&#148; or &#147;herein&#148; or &#147;hereunder&#148; or similar terms or to any</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="23423-2-KY-01_PB_2_035557_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=428012,FOLIO='2',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;thereof shall, after the Effective Date, mean the Lease, or such Section&nbsp;thereof, as amended by this Amendment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.&#160; <u>Demise of Fifth Expansion Premises</u>.&#160; Commencing on the Effective Date of this Eighth Amendment (the &#147;Fifth Expansion Premises Commencement Date&#148;), Landlord does hereby lease to Tenant and Tenant does lease from Landlord the approximately 5,511 rentable square feet on the second (2</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">nd</font>) floor of the Building, as shown on the floor plan attached hereto as <u>Exhibit&nbsp;A-8</u> (the &#147;Fifth Expansion Premises&#148;) to have and to hold for the remainder of the Lease Term as set forth in the Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="54%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:54.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Space</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">8</font></b><b><font size="1" style="font-size:5.0pt;font-weight:bold;position:relative;top:-3.0pt;">th</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">&nbsp;Amendment&nbsp;(USF)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">8</font></b><b><font size="1" style="font-size:5.0pt;font-weight:bold;position:relative;top:-3.0pt;">th</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">&nbsp;Amendment&nbsp;(RSF)<br>   (RSF&nbsp;=&nbsp;USF&nbsp;x&nbsp;1.20)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:54.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;217</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,567</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,880</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;220</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,959</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,351</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:54.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hallway</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,280</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,280</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4,806</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5,511</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as otherwise expressly provided herein, Tenant&#146;s lease of the Fifth Expansion Premises shall be on all of the terms and conditions of the Lease (including, without limitation, extension rights of Tenant for Extension Terms) and the term of the Lease with respect to the Fifth Expansion Premises shall be coterminous with the Term (and, if exercised, Extension Terms) of the Lease for the Existing Premises. As of the Fifth Expansion Premises Commencement Date, all references in the Lease to (i)&nbsp;the &#147;Premises&#148; and/or premises demised by the Lease shall mean the Existing Premises and the Fifth Expansion Premises collectively as shown on <u>Exhibit&nbsp;A</u> to the Lease, <u>Exhibit&nbsp;A-1</u>, attached to the First Amendment, <u>Exhibit&nbsp;A-2</u>, attached to the Second</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="23423-2-KY-01_PB_3_035828_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=933932,FOLIO='3',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment, <u>Exhibit&nbsp;A-3</u>, attached to the Third Amendment, and on <u>Exhibit&nbsp;A-5</u>, attached to the Fifth Amendment, <u>Exhibit&nbsp;A-6</u>, attached to the Sixth Amendment, <u>Exhibit&nbsp;A-7</u>, attached to the Seventh Amendment, and <u>Exhibit&nbsp;A-8</u> attached to this Amendment; (ii)&nbsp;the &#147;Tenant&#146;s Proportionate Fraction&#148; shall mean 50.20% which is calculated by adding the Premises Square Footage as set forth in the Seventh Amendment and the Fifth Expansion Premises and dividing the Building&#146;s rentable square foot into that sum; and (iii)&nbsp;the &#147;Premises Square Footage&#148; shall mean 28,924 rentable square feet.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.&#160; <u>Section&nbsp;2.2</u>.&#160; <u>Term</u>.&#160; Section&nbsp;2.2 of the Lease shall be amended as of October&nbsp;1, 2015 to read as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Section&nbsp;2.2</font></u>. <u>Term</u>.&#160; TO HAVE AND TO HOLD for a term (the &#147;Term&#148;) beginning on the Term Commencement Date which shall be November&nbsp;1, 2015 and expiring on July&nbsp;31, 2020 (the &#147;Term Expiration Date&#148;), unless earlier terminated as provided for in Section&nbsp;2.4.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.&#160; <u>Section&nbsp;2.3</u>.&#160; <u>Renewal Term</u>.&#160; Section&nbsp;2.3 of the Lease is hereby deleted in its entirety and replaced with the following provision:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Section&nbsp;2.3</font></u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Option to Extend Term for Extension Terms</u>.&#160; Tenant shall have two (2)&nbsp;separate options to extend the Lease Term for an additional five (5)&nbsp;year period (i.e., for a total, if both such options are exercised as provided herein, of ten (10)&nbsp;successive years) beyond the Term or the first Extension Term, as the case may be (each five (5)&nbsp;year period being referred to herein as an &#147;Extension Term&#148;), provided (i)&nbsp;Tenant shall give notice to Landlord of its exercise of such option not less than nine (9)&nbsp;months prior to the expiration of the Term or the first Extension Term, as the case may be, and (ii)&nbsp;no default beyond any applicable grace period in the obligations of Tenant under this Lease shall exist at the time each such notice is given.&#160; All of the terms and provisions of this Lease, as amended, shall be applicable to each Extension Term except that Tenant shall have no option to extend the Lease Term beyond the second Extension Term. Landlord and Tenant must determine the Annual Fixed Rental Rate for each Extension Term at the time of each such notice, using an independent fair market rental value analysis for comparable buildings used for research and development, of similar age, quality, size, construction and appearance, with similar services and amenities, and in comparable locations within Massachusetts, but outside of the Greater-Boston MSA,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="23423-2-KY-01_PB_4_035852_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=712744,FOLIO='4',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">excluding therefrom any cost to renovate such space for a tenant&#146;s occupancy for advertising and lease negotiation costs, free rent or other inducements, and any other items which would normally be offered to a new tenant but which a continuing tenant would not seek. The cost of the independent analysis will be shared equally between the parties. Notwithstanding the provisions of Section&nbsp;10.13 of the Lease, at the end of the Term or either Extension Term, Tenant shall be entitled to hold over within the Premises for up to three (3)&nbsp;months, and the Annual Fixed Rental Rate shall be one hundred and twenty-five (125%) percent of the Annual Fixed Rental Rate which was payable during the last month of the Term or either Extension Term, as the case may be, and one hundred and fifty (150%) percent thereof for the period beyond three (3)&nbsp;months and up to a total of six (6)&nbsp;months.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.&#160; <u>Annual Fixed Rental Rate</u>.&#160; Section&nbsp;1.1 of the Lease is amended by deleting the provisions regarding the &#147;Annual Fixed Rental Rate&#148; and inserting, the following language:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Annual Fixed Rental Rate:</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of November&nbsp;1, 2015 and   through July&nbsp;31, 2016:&nbsp; $17.18 per   rentable square foot per annum for the Premises not including the Fifth   Expansion Premises until such time as the Fifth Expansion Premises is   suitable for Tenant&#146;s use, as evidenced by a municipal certificate of   occupancy and Tenant&#146;s ability to use same for the operation of its business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of August&nbsp;1, 2016 and   through July&nbsp;31, 2017: $17.52 per rentable square foot.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of August&nbsp;1, 2017 and   through July&nbsp;31, 2018: $17.87 per rentable square foot.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of August&nbsp;1, 2018 and   through July&nbsp;31, 2019: $18.23 per rentable square foot.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of August&nbsp;1, 2019 and   through July&nbsp;31, 2020: $18.59 per rentable square foot.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.&#160; <u>Tenant Improvement Allowance</u>.&#160; Section&nbsp;4 of the Lease is hereby amended by adding the following new provision:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Section&nbsp;4.4</font></u>.&#160; <u>Tenant Improvement Allowance</u>.&#160; If Tenant notifies Landlord in writing of its desire to accept same in lieu of construction financing from third parties, Landlord shall provide Tenant with an allowance, subject to the provisions of Section&nbsp;10.4 below, up to the aggregate amount of $55,110.00 or $10.00 per rentable square foot</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="23423-2-KY-01_PB_5_035920_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=473333,FOLIO='5',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:2.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(&#147;Tenant Improvement Allowance&#148;) which monies shall be disbursed to Tenant upon its written request and all such amounts actually advanced shall be repaid to Landlord together with the Rent over the remaining Term, in equal monthly payments, without interest.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.&#160; <u>Landlord Work</u>.&#160; Prior to the commencement of work by Tenant in the Fifth Expansion Premises, Landlord shall, at Landlord&#146;s sole cost and expense, deliver same to Tenant vacant and broom clean, and will all debris and property removed therefrom. Landlord, in conjunction with its general contractor, shall make the Fifth Expansion Premises available to Tenant at least four (4)&nbsp;weeks prior to the anticipated date of its completion, for the installation of Tenant&#146;s furniture and voice/data systems.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Landlord shall also be solely responsible to deliver same to Tenant in compliance with all fire, life safety, environmental and occupational health and safety laws, regulations and ordinances (including, but not limited to, the Americans with Disabilities Act). Landlord represents that the Fifth Expansion Premises, as well as the Building, the Premises and the public areas of the Building also comply with such laws, regulations and ordinances and, if they do not, that Landlord shall, at its sole cost and expanse, promptly cause same to so comply.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.&#160; <u>Broker</u>.&#160; Section&nbsp;1.1 of the Lease is hereby amended by amending the definition of Broker therein by deleting &#147;Jones Lange LaSalle&#148; and replacing with &#147;The Garibaldi Group,&nbsp;Inc.&#148;,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 4.5pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.&#160; <u>Section&nbsp;14.7</u>.&#160; <u>Brokerage</u>.&#160; Section&nbsp;14.7 of the Lease is hereby amended by adding the following second paragraph:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;In lieu of a Landlord contribution to commission due to the Broker for the extension of the Term, a rent credit of Eleven Thousand and Twenty Two Dollars ($11,022.00) shall be provided to the Tenant.&#160; Landlord agrees to apply this credit in two equal installments of Five Thousand Five Hundred and Eleven Dollars ($5,511.00) each.&#160; The first credit installment will be applied to the first month&#146;s rent due after the full execution of this</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="23423-2-KY-01_PB_6_040744_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=710754,FOLIO='6',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment.&#160; The second rental credit installment shall be applied to the July, 2016 rent due from Tenant.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.&#160; <u>Condensation remediation</u>. Landlord is presently treating the Building&#146;s ongoing condensation problems and agrees to continue to use reasonable efforts in the event that the present work does not cure the condensation issue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11. <u>Landlord Representation Regarding Environmental Hazards</u>. To its knowledge, Landlord represents that there are no environmental hazards or violations of any environmental laws, regulations or ordinances in or around the Building which violations might pose a present danger to health, life or safety.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12. <u>Nondisturbance of Tenancy</u>. Landlord represents that it has no financing on the Building whereby Landlord&#146;s lender would be entitled to disturb the tenancy of Tenant upon a default therein by Landlord. Landlord further represents that it shall not enter into any such financing, but rather shall negotiate with any such lender so as to permit Tenant to remain in possession of the Premises on a direct rental relationship with such lender so long as Tenant is not in default of its obligations under this Lease.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13. <u>Restoration Obligation</u>.&#160; Tenant&#146;s restoration obligations as to all but the Fifth Expansion Premises (regarding mechanical equipment installed by it) are set forth in the Lease, and Tenant acknowledges those responsibilities. In the case of the Fifth Expansion Premises, Tenant intends to migrate the controls for Landlord&#146;s existing HVAC equipment to Tenant&#146;s management system during the Term. Upon Tenant&#146;s vacation of the Fifth Expansion Premises, Tenant shall return the controls for Landlord&#146;s HVAC to Landlord&#146;s management system at Tenant&#146;s cost, which shall be Tenant&#146;s sole responsibility regarding restoration in the Fifth Expansion Premises.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="23423-2-KY-01_PB_7_040757_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=304699,FOLIO='7',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14. <u>Ratification</u>.&#160; Except as expressly modified by this Amendment, the Lease shall remain in full force and effect, and as further modified by this Amendment, is expressly ratified and confirmed by the parties hereto.&#160; This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, subject to the provisions of the Lease regarding assignment and subletting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15. <u>Governing Law; Interpretation; and Partial Invalidity</u>.&#160; This Amendment shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts.&#160; If any term of this Amendment, or the application thereof to any person or circumstances, shall to any extent be invalid or unenforceable, the remainder of this Amendment, or the application of such term to persons or circumstances other than those as to which it is invalid or unenforceable, shall not be affected thereby, and each term of this Amendment shall be valid and enforceable to the fullest extent permitted by law.&#160; The titles for the paragraphs are for convenience only and not to be considered in construing this Amendment.&#160; This Amendment contains all of the agreements of the parties with respect to the subject matter hereof, and supersedes all prior dealings between them with respect to such subject matter.&#160; No delay or omission on the part of either party to this Amendment in requiring performance by the other party or exercising any right hereunder shall operate as a waiver of any provision hereof or any rights hereunder, and no waiver, omission or delay in requiring performance or exercising any right hereunder on any one occasion shall be construed as a bar to or waiver of such performance or right on any future occasion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16. <u>Counterparts and Authority</u>.&#160; This Amendment may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same document.&#160; Landlord and Tenant each warrant to the other that the person or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="23423-2-KY-01_PB_8_040811_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=95194,FOLIO='8',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">persons executing this Amendment on its behalf has or have authority to do so and that such execution has fully obligated and bound such party to all terms and provisions of this Amendment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the undersigned executed this Amendment as of the date and year first written above.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LANDLORD:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">University Of Massachusetts   Dartmouth</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="3" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Gerald Kavanaugh</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gerald Kavanaugh</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chancellor</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TENANT:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="4" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Avery   W. Catlin</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.08%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery W. Catlin</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.08%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior Vice President and CFO</font></p>    </td>   </tr>
<tr height="0">
<td width="360" style="border:none;"></td>
<td width="29" style="border:none;"></td>
<td width="6" style="border:none;"></td>
<td width="57" style="border:none;"></td>
<td width="255" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="23423-2-KY-01_PB_9_041246_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=208342,FOLIO='9',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-01_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 05:30 2016' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="720" height="561" src="g234232ky03i001.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="3",CHK=663740,FOLIO='',FILE="DISK134:[15ZCW2.15ZCW72302]23423-2-KY-03_ZCW72302.CHC",USER="HYUNG",CD='Feb 17 07:35 2016' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>a2226904zex-21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#15ZCW72301_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kc72301_exhibit_21.1"> </A>
<A NAME="toc_kc72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;21.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kc72301_subsidiaries_of_celldex_therapeutics,_inc."> </A>
<A NAME="toc_kc72301_2"> </A></FONT> <FONT SIZE=2><B>  SUBSIDIARIES OF CELLDEX THERAPEUTICS,&nbsp;INC.    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Jurisdiction of<BR>
Organization </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ownership<BR>
Percentage </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Celldex Therapeutics Europe&nbsp;GmbH</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Switzerland</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="4",CHK=888695,FOLIO='blank',FILE='DISK133:[15ZCW1.15ZCW72301]KC72301A.;6',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="15ZCW72301_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kc72301_1">Exhibit 21.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kc72301_2">SUBSIDIARIES OF CELLDEX THERAPEUTICS, INC.</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a2226904zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#15ZCW72301_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ke72301_exhibit_23.1"> </A>
<A NAME="toc_ke72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ke72301_consent_of_independent__ke702313"> </A>
<A NAME="toc_ke72301_2"> </A></FONT> <FONT SIZE=2><B>  CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hereby consent to the incorporation by reference in the Registration Statements on Forms&nbsp;S-8 (Nos.&nbsp;333-205694,
333-182142, 333-189336, 333- 151728 and 333-117602) and on Form&nbsp;S-3 (No.&nbsp;333-192640) of Celldex Therapeutics,&nbsp;Inc. of our report dated February&nbsp;25, 2016 relating to the
financial statements and the effectiveness of internal control over financial reporting, which appears in this Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Boston,
Massachusetts<BR>
February&nbsp;25, 2016 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="5",CHK=318672,FOLIO='blank',FILE='DISK133:[15ZCW1.15ZCW72301]KE72301A.;4',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="15ZCW72301_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ke72301_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ke72301_2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>a2226904zex-31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#15ZCW72301_6">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kg72301_exhibit_31.1"> </A>
<A NAME="toc_kg72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;31.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kg72301_certification"> </A>
<A NAME="toc_kg72301_2"> </A></FONT> <FONT SIZE=2><B>  CERTIFICATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>I,
Anthony S. Marucci, certify that: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this annual report on Form&nbsp;10-K of Celldex Therapeutics,&nbsp;Inc.; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting; and </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
reporting. </FONT></P>

</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="38%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Date: February&nbsp;25, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="6",CHK=492868,FOLIO='blank',FILE='DISK133:[15ZCW1.15ZCW72301]KG72301A.;3',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="15ZCW72301_6">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg72301_1">Exhibit 31.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg72301_2">CERTIFICATION</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>a2226904zex-31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#15ZCW72301_7">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ki72301_exhibit_31.2"> </A>
<A NAME="toc_ki72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;31.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ki72301_certification"> </A>
<A NAME="toc_ki72301_2"> </A></FONT> <FONT SIZE=2><B>  CERTIFICATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>I,
Avery W. Catlin, certify that: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this annual report on Form&nbsp;10-K of Celldex Therapeutics,&nbsp;Inc.; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting; and </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
reporting. </FONT></P>

</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="38%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Date: February&nbsp;25, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Avery W. Catlin</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> Senior Vice President and<BR>
Chief Financial Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="7",CHK=572475,FOLIO='blank',FILE='DISK133:[15ZCW1.15ZCW72301]KI72301A.;3',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="15ZCW72301_7">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki72301_1">Exhibit 31.2</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki72301_2">CERTIFICATION</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="7" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>a2226904zex-32.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#15ZCW72301_8">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kk72301_exhibit_32"> </A>
<A NAME="toc_kk72301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;32    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kk72301_certification_of_chief_executi__cer05925"> </A>
<A NAME="toc_kk72301_2"> </A></FONT> <FONT SIZE=2><B>  CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND<BR>  CHIEF FINANCIAL OFFICER PURSUANT TO<BR>  18 U.S.C. SECTION&nbsp;1350, AS ADOPTED PURSUANT TO<BR>  SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT
OF&nbsp;2002    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, in his capacity as an officer of Celldex Therapeutics,&nbsp;Inc. (the "Company"), that, to his knowledge, the Annual Report of the Company on Form&nbsp;10-K for the
period ended December&nbsp;31, 2015 (the "Form&nbsp;10-K"), fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. &sect;78m
or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This written statement is
being furnished to the Securities and Exchange Commission as an exhibit to the Form&nbsp;10-K. A signed original of this statement has been provided to the Company and will be retained by the
Company and furnished to the Securities and Exchange Commission or its staff upon request. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="38%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Date: February&nbsp;25, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>/s/&nbsp;ANTHONY S. MARUCCI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> President and Chief Executive Officer</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Date: February&nbsp;25, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Avery W. Catlin</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> Senior Vice President and<BR>
Chief Financial Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
certification shall be not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange
Act. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="8",CHK=215715,FOLIO='blank',FILE='DISK133:[15ZCW1.15ZCW72301]KK72301A.;3',USER='CHE107322',CD='19-FEB-2016;21:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="15ZCW72301_8">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kk72301_1">Exhibit 32</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kk72301_2">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2226904",CP="CELLDEX THERAPEUTICS, INC.",DN="8" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>cldx-20151231.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.1.177.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2016 3:13:43 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cldx="http://www.celldextherapeutics.com/20151231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="cldx-20151231.xsd" />
  <!--Context Section-->
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_SubsidiarySaleOfStockAxis_cldx_UnderwrittenPublicOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cldx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_SubsidiarySaleOfStockAxis_cldx_UnderwrittenPublicOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cldx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PlanNameAxis_cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_CounterpartyNameAxis_cldx_GlaxoSmithKlinePlcMember_us-gaap_ProductOrServiceAxis_cldx_RotarixRotavirusVaccineMember_us-gaap_TypeOfArrangementAxis_cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:GlaxoSmithKlinePlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:RotarixRotavirusVaccineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_dei_LegalEntityAxis_cldx_BiosynCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cldx:BiosynCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_ManufacturingEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cldx:ManufacturingEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_ManufacturingEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cldx:ManufacturingEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_LaboratoryEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cldx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_ManufacturingEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cldx:ManufacturingEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_LaboratoryEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cldx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_ManufacturingEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cldx:ManufacturingEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_LaboratoryEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cldx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_3_1_2011_To_3_31_2011_cldx_DebtInstrumentLenderAxis_cldx_GeneralElectricCapitalCorporationMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cldx:DebtInstrumentLenderAxis">cldx:GeneralElectricCapitalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-03-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2010_To_12_31_2010_cldx_DebtInstrumentLenderAxis_cldx_MidCapFinancialLLCMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cldx:DebtInstrumentLenderAxis">cldx:MidCapFinancialLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-12-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_cldx_StockIssuedByTypeOfProgramAxis_cldx_ControlledEquityOfferingProgramAmendedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cldx:StockIssuedByTypeOfProgramAxis">cldx:ControlledEquityOfferingProgramAmendedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_CumulativePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CumulativePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_cldx_StatusOfMergerAndAcquisitionAxis_cldx_PriorToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_cldx_CuraGenCorporationMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cldx:StatusOfMergerAndAcquisitionAxis">cldx:PriorToAcquisitionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cldx:CuraGenCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_cldx_StatusOfMergerAndAcquisitionAxis_cldx_PriorToMergerMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cldx:StatusOfMergerAndAcquisitionAxis">cldx:PriorToMergerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cldx:CoreTechnologyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cldx:AmgenAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cldx:CoreTechnologyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cldx:AmgenAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cldx:CoreTechnologyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cldx:AmgenAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2015_To_6_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2014_To_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2014_To_6_30_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_5_31_2014_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:BristolMeyersSquibbCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:Pd1ImmuneCheckpointInhibitorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-05-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_RockefellerUniversityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">cldx:RockefellerUniversityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_BristolMeyersSquibbCompanyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">cldx:BristolMeyersSquibbCompanyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_RockefellerUniversityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">cldx:RockefellerUniversityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_BristolMeyersSquibbCompanyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">cldx:BristolMeyersSquibbCompanyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_RockefellerUniversityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">cldx:RockefellerUniversityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_BristolMeyersSquibbCompanyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">cldx:BristolMeyersSquibbCompanyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_dei_LegalEntityAxis_cldx_BiosynCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cldx:BiosynCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cldx:EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_6_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="As_Of_2_16_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <instant>2016-02-16</instant>
    </period>
  </context>
  <context id="Duration_11_1_2015_To_11_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2015-11-01</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2014_To_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2014-12-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_1_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_1_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2012_To_1_31_2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2011_To_1_31_2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cldx:StockOptionAndIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:BristolMeyersSquibbCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:Pd1ImmuneCheckpointInhibitorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:BristolMeyersSquibbCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:Pd1ImmuneCheckpointInhibitorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_RockefellerUniversityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:RockefellerUniversityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_CounterpartyNameAxis_cldx_RockefellerUniversityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:RockefellerUniversityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_CounterpartyNameAxis_cldx_RockefellerUniversityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:RockefellerUniversityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_5_1_1995_To_5_31_1995_us-gaap_CounterpartyNameAxis_cldx_CincinnatiChildrensHospitalMedicalCenterMember_us-gaap_ProductOrServiceAxis_cldx_RotarixRotavirusVaccineMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:CincinnatiChildrensHospitalMedicalCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:RotarixRotavirusVaccineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>1995-05-01</startDate>
      <endDate>1995-05-31</endDate>
    </period>
  </context>
  <context id="Duration_5_1_2005_To_5_31_2005_us-gaap_CounterpartyNameAxis_cldx_PRFAgreementMember_us-gaap_ProductOrServiceAxis_cldx_RotarixRotavirusVaccineMember_us-gaap_TypeOfArrangementAxis_cldx_RoyaltyAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:PRFAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:RotarixRotavirusVaccineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:RoyaltyAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-05-01</startDate>
      <endDate>2005-05-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_AVANTMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cldx:AVANTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_cldx_StatusOfMergerAndAcquisitionAxis_cldx_PriorToMergerMember_us-gaap_BusinessAcquisitionAxis_cldx_AVANTMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cldx:StatusOfMergerAndAcquisitionAxis">cldx:PriorToMergerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cldx:AVANTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_cldx_OwnershipChangeAxis_cldx_OwnershipChangesInJune2009AndDecember2009Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cldx:OwnershipChangeAxis">cldx:OwnershipChangesInJune2009AndDecember2009Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_cldx_OwnershipChangeAxis_cldx_OwnershipChangeInDecember2013Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="cldx:OwnershipChangeAxis">cldx:OwnershipChangeInDecember2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_12_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_CuraGenCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cldx:CuraGenCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_5_1_2013_To_5_31_2013_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_CuraGenCorporationMember_us-gaap_CounterpartyNameAxis_cldx_SeattleGeneticIncMember_us-gaap_ProductOrServiceAxis_cldx_GlembatumumabVedotinMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cldx:CuraGenCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:SeattleGeneticIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:GlembatumumabVedotinMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_CuraGenCorporationMember_us-gaap_CounterpartyNameAxis_cldx_SeattleGeneticIncMember_us-gaap_ProductOrServiceAxis_cldx_Cdx014Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cldx:CuraGenCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:SeattleGeneticIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:Cdx014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_UniversityOfSouthamptonUKMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:UniversityOfSouthamptonUKMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_RockefellerUniversityMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:RockefellerUniversityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_MedarexIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:MedarexIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_LudwigInstituteForCancerResearchMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:LudwigInstituteForCancerResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_DukeUniversityBrainTumorCancerCenterMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:DukeUniversityBrainTumorCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_AmgenIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:AmgenIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_AlterisTherapeuticsIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:AlterisTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_MedarexIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:MedarexIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cldx:LicenseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_5_1_2014_To_5_31_2014_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cldx:BristolMeyersSquibbCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cldx:Pd1ImmuneCheckpointInhibitorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cldx:USGovernmentAndMunicipalObligationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cldx:USGovernmentAndMunicipalObligationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000744218</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit16">
    <measure>cldx:segment</measure>
  </unit>
  <unit id="Unit15">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit14">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>cldx:item</measure>
  </unit>
  <unit id="Unit1">
    <measure>iso4217:USD</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <cldx:AccruedResearchAndDevelopmentContractCostsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">12696000</cldx:AccruedResearchAndDevelopmentContractCostsCurrent>
  <cldx:AccruedResearchAndDevelopmentContractCostsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">14548000</cldx:AccruedResearchAndDevelopmentContractCostsCurrent>
  <cldx:AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">0</cldx:AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">16108000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">22690000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">15940000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">23932000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">16156000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">22658000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">15907000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">23831000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">49000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">3000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">24000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">1000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">1000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">35000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">57000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">102000</cldx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">30000</cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">6000</cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">4000</cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">2000</cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">6000</cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">37000</cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">20000</cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses>
  <cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">141000</cldx:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses>
  <cldx:CollaborativeArrangementAgreementTerm contextRef="Duration_5_1_2014_To_5_31_2014_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember">P5Y</cldx:CollaborativeArrangementAgreementTerm>
  <cldx:CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_MedarexIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember">P10Y</cldx:CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_AlterisTherapeuticsIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">5000000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_AmgenIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">900000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_DukeUniversityBrainTumorCancerCenterMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">700000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_LudwigInstituteForCancerResearchMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">1000000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_MedarexIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">7000000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_RockefellerUniversityMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">3800000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_UniversityOfSouthamptonUKMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">1400000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_CuraGenCorporationMember_us-gaap_CounterpartyNameAxis_cldx_SeattleGeneticIncMember_us-gaap_ProductOrServiceAxis_cldx_Cdx014Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">9000000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:CollaborativeArrangementTotalPotentialMilestonePayments contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_CuraGenCorporationMember_us-gaap_CounterpartyNameAxis_cldx_SeattleGeneticIncMember_us-gaap_ProductOrServiceAxis_cldx_GlembatumumabVedotinMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">5000000</cldx:CollaborativeArrangementTotalPotentialMilestonePayments>
  <cldx:DebtInstrumentInterestAndPrepaymentFees contextRef="Duration_5_1_2013_To_5_31_2013_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit1" decimals="-5">700000</cldx:DebtInstrumentInterestAndPrepaymentFees>
  <cldx:DeferredIncomeFromSaleOfTaxBenefits contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">4015000</cldx:DeferredIncomeFromSaleOfTaxBenefits>
  <cldx:DeferredIncomeFromSaleOfTaxBenefits contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">12219000</cldx:DeferredIncomeFromSaleOfTaxBenefits>
  <cldx:DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">4661000</cldx:DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets>
  <cldx:DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">4661000</cldx:DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets>
  <cldx:DeferredTaxAssetsLiabilitiesGross contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">212483000</cldx:DeferredTaxAssetsLiabilitiesGross>
  <cldx:DeferredTaxAssetsLiabilitiesGross contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">269569000</cldx:DeferredTaxAssetsLiabilitiesGross>
  <cldx:DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_CuraGenCorporationMember" unitRef="Unit1" decimals="-5">0</cldx:DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized>
  <cldx:DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">3749000</cldx:DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets>
  <cldx:DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">3382000</cldx:DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets>
  <cldx:DrugCandidatesInClinicalDevelopment contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="INF">5</cldx:DrugCandidatesInClinicalDevelopment>
  <cldx:ExpectedDividendPayableInForeseeableFuture contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">0</cldx:ExpectedDividendPayableInForeseeableFuture>
  <cldx:ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">126000</cldx:ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits>
  <cldx:ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">2302000</cldx:ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits>
  <cldx:ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">155000</cldx:ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits>
  <cldx:FairValueAssetsAmountTransfersBetweenMeasurementLevels contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">0</cldx:FairValueAssetsAmountTransfersBetweenMeasurementLevels>
  <cldx:FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">0</cldx:FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels>
  <cldx:IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-35756000</cldx:IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance>
  <cldx:IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-48562000</cldx:IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance>
  <cldx:IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-57085000</cldx:IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance>
  <cldx:IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">126000</cldx:IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits>
  <cldx:IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">2302000</cldx:IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits>
  <cldx:IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">155000</cldx:IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits>
  <cldx:NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse contextRef="As_Of_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="Unit1" decimals="-5">382300000</cldx:NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse>
  <cldx:NonRefundableLicenseFee contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">700000</cldx:NonRefundableLicenseFee>
  <cldx:NonRefundableLicenseFee contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">3200000</cldx:NonRefundableLicenseFee>
  <cldx:NonRefundableLicenseFee contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit1" decimals="-5">900000</cldx:NonRefundableLicenseFee>
  <cldx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="As_Of_12_31_2015_cldx_OwnershipChangeAxis_cldx_OwnershipChangeInDecember2013Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">77000000</cldx:OperatingLossCarryforwardsAnnualLimitationAmount>
  <cldx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="As_Of_12_31_2015_cldx_OwnershipChangeAxis_cldx_OwnershipChangesInJune2009AndDecember2009Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">6000000</cldx:OperatingLossCarryforwardsAnnualLimitationAmount>
  <cldx:OperatingLossCarryforwardsNetOfExpirationsAndUtilization contextRef="As_Of_12_31_2015_cldx_StatusOfMergerAndAcquisitionAxis_cldx_PriorToMergerMember_us-gaap_BusinessAcquisitionAxis_cldx_AVANTMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">101200000</cldx:OperatingLossCarryforwardsNetOfExpirationsAndUtilization>
  <cldx:OperatingLossCarryforwardsRemotelyLikelyToBeUtilized contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_AVANTMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">60800000</cldx:OperatingLossCarryforwardsRemotelyLikelyToBeUtilized>
  <cldx:OperatingLossCarryforwardsWithLimitationsOnUse contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_AVANTMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">40400000</cldx:OperatingLossCarryforwardsWithLimitationsOnUse>
  <cldx:PatentCostsPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Patent Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Patent costs are expensed as incurred. Certain patent costs are reimbursed by the Company's product development and licensing partners. Any reimbursed patent costs are recorded as product development and licensing agreement revenues in the Company's financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</cldx:PatentCostsPolicyTextBlock>
  <cldx:PercentageOfInterestInNetRoyaltiesSold contextRef="Duration_5_1_2005_To_5_31_2005_us-gaap_CounterpartyNameAxis_cldx_PRFAgreementMember_us-gaap_ProductOrServiceAxis_cldx_RotarixRotavirusVaccineMember_us-gaap_TypeOfArrangementAxis_cldx_RoyaltyAgreementMember" unitRef="Unit13" decimals="2">0.70</cldx:PercentageOfInterestInNetRoyaltiesSold>
  <cldx:PercentageOfLicenseFeeDueOnNetRoyaltiesReceived contextRef="Duration_5_1_1995_To_5_31_1995_us-gaap_CounterpartyNameAxis_cldx_CincinnatiChildrensHospitalMedicalCenterMember_us-gaap_ProductOrServiceAxis_cldx_RotarixRotavirusVaccineMember_us-gaap_TypeOfArrangementAxis_cldx_LicenseAgreementsMember" unitRef="Unit13" decimals="INF">0.3</cldx:PercentageOfLicenseFeeDueOnNetRoyaltiesReceived>
  <cldx:PeriodForWhichBaseOfOperationsMustBeMaintained contextRef="Duration_1_1_2015_To_12_31_2015">P5Y</cldx:PeriodForWhichBaseOfOperationsMustBeMaintained>
  <cldx:PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">P5Y</cldx:PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange>
  <cldx:ReimbursementOfExternalCostsIncurredPercentage contextRef="Duration_5_1_2014_To_5_31_2014_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember" unitRef="Unit13" decimals="INF">0.5</cldx:ReimbursementOfExternalCostsIncurredPercentage>
  <cldx:RepaymentOfLongTermDebtPrincipalAmount contextRef="Duration_5_1_2013_To_5_31_2013_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit1" decimals="-5">8800000</cldx:RepaymentOfLongTermDebtPrincipalAmount>
  <cldx:RevenueFromContractsAndGrants contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">1617000</cldx:RevenueFromContractsAndGrants>
  <cldx:RevenueFromContractsAndGrants contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_CounterpartyNameAxis_cldx_RockefellerUniversityMember" unitRef="Unit1" decimals="-5">1400000</cldx:RevenueFromContractsAndGrants>
  <cldx:RevenueFromContractsAndGrants contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">2748000</cldx:RevenueFromContractsAndGrants>
  <cldx:RevenueFromContractsAndGrants contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_CounterpartyNameAxis_cldx_RockefellerUniversityMember" unitRef="Unit1" decimals="-5">2700000</cldx:RevenueFromContractsAndGrants>
  <cldx:RevenueFromContractsAndGrants contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">4038000</cldx:RevenueFromContractsAndGrants>
  <cldx:RevenueFromContractsAndGrants contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_RockefellerUniversityMember" unitRef="Unit1" decimals="-5">3400000</cldx:RevenueFromContractsAndGrants>
  <cldx:RevenueFromProductDevelopmentAndLicensingAgreements contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">160000</cldx:RevenueFromProductDevelopmentAndLicensingAgreements>
  <cldx:RevenueFromProductDevelopmentAndLicensingAgreements contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">838000</cldx:RevenueFromProductDevelopmentAndLicensingAgreements>
  <cldx:RevenueFromProductDevelopmentAndLicensingAgreements contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember" unitRef="Unit1" decimals="-5">700000</cldx:RevenueFromProductDevelopmentAndLicensingAgreements>
  <cldx:RevenueFromProductDevelopmentAndLicensingAgreements contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1442000</cldx:RevenueFromProductDevelopmentAndLicensingAgreements>
  <cldx:RevenueFromProductDevelopmentAndLicensingAgreements contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember" unitRef="Unit1" decimals="-5">1300000</cldx:RevenueFromProductDevelopmentAndLicensingAgreements>
  <cldx:ScheduleOfOtherLongTermLiabilitiesTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Rent&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;409
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;482
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net Deferred Tax Liability related to IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Income from Sale of Tax Benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,015
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,368
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,297
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21,657
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,455
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less Current Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,418
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,592
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Long-Term Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;17,239
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,863
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</cldx:ScheduleOfOtherLongTermLiabilitiesTableTextBlock>
  <cldx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit13" decimals="2">1.10</cldx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock>
  <cldx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member_us-gaap_RangeAxis_us-gaap_MaximumMember">P10Y</cldx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm>
  <cldx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">P5Y</cldx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock>
  <cldx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit13" decimals="2">0.10</cldx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock>
  <cldx:SignificantRevenueArrangementsDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(13) REVENUE&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Bristol-Myers Squibb Company (BMS)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2014, the Company entered into a clinical trial collaboration with BMS to evaluate the safety, tolerability and preliminary efficacy of varlilumab and Opdivo&amp;#xAE;, BMS's PD-1 immune checkpoint inhibitor, in a Phase 1/2 study. Under the terms of this clinical trial collaboration, BMS made a one-time payment to the Company of $5.0&amp;nbsp;million and BMS and the Company amended the terms of the Company's existing license agreement with Medarex (a subsidiary of BMS) related to the Company's CD27 program whereby certain future milestone payments were waived and future royalty rates were reduced that may have been due from the Company to Medarex. In return, BMS was granted a time-limited right of first negotiation if the Company wishes to out-license varlilumab. The companies also agreed to work exclusively with each other to explore anti-PD-1 antagonist antibody and anti-CD27 agonist antibody combination regimens. The clinical trial collaboration provides that the companies will share development costs and that the Company will be responsible for conducting the ongoing Phase 1/2 study.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has determined that its performance obligations under the BMS agreement, which primarily include performing research and development, supplying varlilumab and participating in the joint development committee, should be accounted for as a single unit of accounting and estimated that its performance period under the BMS agreement would be 5&amp;nbsp;years. Accordingly, the $5.0&amp;nbsp;million up-front payment was initially recorded as deferred revenue and is being recognized as revenue on a straight-line basis over the estimated 5-year performance period using the Contingency Adjusted Performance Model ("CAPM"). The BMS agreement also provides for BMS to reimburse the Company for 50% of the external costs incurred by the Company in connection with the clinical trial. These BMS payments are being recognized as revenue using the CAPM. The Company recorded $1.3&amp;nbsp;million and $0.7&amp;nbsp;million in revenue related to the BMS agreement during the year ended December&amp;nbsp;31, 2015 and 2014, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Rockefeller University (Rockefeller)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In September 2013, the Company entered into an agreement, as amended, with Rockefeller pursuant to which the Company performs research and development services for Rockefeller. The Company bills Rockefeller quarterly for actual time and direct costs incurred and records those amounts to revenue in the quarter the services are performed. The Company recorded $3.4&amp;nbsp;million, $2.7&amp;nbsp;million and $1.4&amp;nbsp;million in revenue related to the Rockefeller agreement during the years ended December&amp;nbsp;31, 2015, 2014 and 2013, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;GlaxoSmithKline&amp;nbsp;plc (Glaxo)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In 1997, the Company licensed its oral rotavirus strain to Glaxo and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. The Company's licensed-in the rotavirus strain that was used to develop Glaxo's Rotarix rotavirus vaccine in 1995 and owed a license fee of 30% to Cincinnati Children's Hospital Medical Center ("CCH") on net royalties received from Glaxo. In May 2005, the Company entered into an agreement whereby an affiliate of Paul Royalty Fund II,&amp;nbsp;L.P. ("PRF") purchased a 70% interest in the net royalties the Company received on worldwide sales of Rotarix. In December 2012, the Glaxo agreement expired automatically upon the expiration of the last relevant patent right covered by the Glaxo agreement. The Company's retained interests in Rotarix net royalties which were not sold to PRF are recorded as product royalty revenue and a corresponding amount that is payable to CCH is recorded as royalty expense. Product royalty revenue and royalty expense related to the Company's retained interest in Rotarix was $2.3&amp;nbsp;million for the year ended December&amp;nbsp;31, 2013.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</cldx:SignificantRevenueArrangementsDisclosureTextBlock>
  <cldx:TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse contextRef="As_Of_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit1" decimals="-5">28500000</cldx:TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse>
  <cldx:TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse contextRef="As_Of_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit1" decimals="-5">11200000</cldx:TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse>
  <cldx:ValueAtWhichTaxBenefitsSold contextRef="Duration_1_1_2011_To_1_31_2011" unitRef="Unit1" decimals="-5">500000</cldx:ValueAtWhichTaxBenefitsSold>
  <cldx:ValueAtWhichTaxBenefitsSold contextRef="Duration_1_1_2012_To_1_31_2012" unitRef="Unit1" decimals="-5">700000</cldx:ValueAtWhichTaxBenefitsSold>
  <cldx:ValueAtWhichTaxBenefitsSold contextRef="Duration_1_1_2013_To_1_31_2013" unitRef="Unit1" decimals="-5">800000</cldx:ValueAtWhichTaxBenefitsSold>
  <cldx:ValueAtWhichTaxBenefitsSold contextRef="Duration_1_1_2014_To_1_31_2014" unitRef="Unit1" decimals="-5">1000000</cldx:ValueAtWhichTaxBenefitsSold>
  <cldx:ValueAtWhichTaxBenefitsSold contextRef="Duration_12_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-5">1800000</cldx:ValueAtWhichTaxBenefitsSold>
  <cldx:ValueAtWhichTaxBenefitsSold contextRef="Duration_11_1_2015_To_11_30_2015" unitRef="Unit1" decimals="-5">9200000</cldx:ValueAtWhichTaxBenefitsSold>
  <cldx:ValueOfTaxBenefitsAgreedToBeSold contextRef="Duration_1_1_2011_To_1_31_2011" unitRef="Unit1" decimals="-5">600000</cldx:ValueOfTaxBenefitsAgreedToBeSold>
  <cldx:ValueOfTaxBenefitsAgreedToBeSold contextRef="Duration_1_1_2012_To_1_31_2012" unitRef="Unit1" decimals="-5">800000</cldx:ValueOfTaxBenefitsAgreedToBeSold>
  <cldx:ValueOfTaxBenefitsAgreedToBeSold contextRef="Duration_1_1_2013_To_1_31_2013" unitRef="Unit1" decimals="-5">800000</cldx:ValueOfTaxBenefitsAgreedToBeSold>
  <cldx:ValueOfTaxBenefitsAgreedToBeSold contextRef="Duration_1_1_2014_To_1_31_2014" unitRef="Unit1" decimals="-5">1100000</cldx:ValueOfTaxBenefitsAgreedToBeSold>
  <cldx:ValueOfTaxBenefitsAgreedToBeSold contextRef="Duration_12_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-5">1900000</cldx:ValueOfTaxBenefitsAgreedToBeSold>
  <cldx:ValueOfTaxBenefitsAgreedToBeSold contextRef="Duration_11_1_2015_To_11_30_2015" unitRef="Unit1" decimals="-5">9800000</cldx:ValueOfTaxBenefitsAgreedToBeSold>
  <dei:AmendmentFlag contextRef="Duration_1_1_2015_To_12_31_2015">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2015_To_12_31_2015">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2015_To_12_31_2015">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2015_To_12_31_2015">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2015_To_12_31_2015">2015-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2015_To_12_31_2015">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2015_To_12_31_2015">0000744218</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_2_16_2016" unitRef="Unit14" decimals="INF">98703484</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2015_To_12_31_2015">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2015_To_12_31_2015">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="As_Of_6_30_2015" unitRef="Unit1" decimals="-8">2500000000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2015_To_12_31_2015">Celldex Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="Duration_1_1_2015_To_12_31_2015">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2015_To_12_31_2015">Yes</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">427000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">970000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(8) ACCRUED EXPENSES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Accrued expenses include the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued Payroll and Employee Benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,601&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,284&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued Research and Development Contract Costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,548&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,696&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued Professional Fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;399&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;490&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other Accrued Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,768&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,826&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24,316&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,296&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">2603000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">1506000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">1366000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-95000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-350000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">19296000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">24316000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">490000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">399000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">14220000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">17059000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-5">2600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">2600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">2590000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">2307000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">672739000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">878655000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">4548000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">4548000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">6852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">6852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">12774000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">12774000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">4548000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">1908000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">2640000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">6852000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">3393000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">3459000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">12774000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">6588000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">6186000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">97000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">72000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">288000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">1013000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">1013000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1013000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit14" decimals="INF">5776544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit14" decimals="INF">5770544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit14" decimals="INF">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit14" decimals="INF">7022350</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit14" decimals="INF">7015350</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit14" decimals="INF">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="INF">8129739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit14" decimals="INF">8110239</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit14" decimals="INF">19500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">248014000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">337584000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">204985000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">294936000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">191700000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">191700000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">277612000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">277612000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">173014000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">60688000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">112326000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">218070000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">64811000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">153259000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2014_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">173023000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">173023000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2015_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">217781000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">217781000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">88000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">79000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">9000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">31000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">28000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">79000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">72000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">320000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">77000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">243000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">44580000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">89636000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">48871000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">129327000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">44604000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">89605000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">48855000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">129188000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">173023000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">60760000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="As_Of_12_31_2014_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">112263000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">217781000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_cldx_USGovernmentAndMunicipalObligationsMember" unitRef="Unit1" decimals="-3">64762000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">153019000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:BasisOfAccounting contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(1) NATURE OF BUSINESS AND OVERVIEW&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Celldex Therapeutics,&amp;nbsp;Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company currently has five drug candidates in clinical development including Rintega (also referred to as rindopepimut and CDX-110), glembatumumab vedotin (also referred to as CDX-011), varlilumab (also referred to as CDX-1127), CDX-1401 and CDX-301. The Company's latest stage drug candidate, Rintega, is a therapeutic vaccine that completed enrollment in December 2014 to a pivotal Phase&amp;nbsp;3 study in front-line glioblastoma in patients that express a specific cancer marker known as EGFRvIII. This Phase&amp;nbsp;3 study completed its first interim analysis in June 2015 and an independent Data Safety and Monitoring Board recommended that the study continue as planned. Updated results from a randomized, Phase&amp;nbsp;2 study of Rintega added to the standard of care for the treatment of recurrent glioblastoma were presented in November 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2015, the Company had cash, cash equivalents and marketable securities of $289.9&amp;nbsp;million. The Company incurred a loss of $127.2&amp;nbsp;million for the year ended December&amp;nbsp;31, 2015. Net cash used in operations for the year ended December&amp;nbsp;31, 2015 was $98.9&amp;nbsp;million. The Company believes that the cash, cash equivalents and marketable securities at December&amp;nbsp;31, 2015 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company may seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financings may be dilutive to the Company's stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company's economic potential from products under development.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccounting>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;31, 2014, the Company's wholly-owned subsidiary, Celldex Research Corporation, merged into Celldex Therapeutics,&amp;nbsp;Inc. The statements of operations and comprehensive loss, of stockholders' equity, and of cash flows, are consolidated for the years ended December&amp;nbsp;31, 2014 and 2013. These consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary prior to the merger. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one segment, which is the business of development, manufacturing and commercialization of novel therapeutics for human health care. In February 2016, the Company formed a wholly-owned subsidiary, Celldex Therapeutics Europe&amp;nbsp;GmbH, in Zug, Switzerland, to operate as Celldex' European headquarters when European operations commence, pursuant to intercompany agreements.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BusinessCombinationsPolicy contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Business Combinations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records the fair value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets such as in-process research and development (IPR&amp;amp;D), using a variety of methods including present value models. Each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of IPR&amp;amp;D assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant's assumptions regarding the probability of completing IPR&amp;amp;D projects, which would require obtaining regulatory approval for marketing of the associated drug candidate; a market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;amp;D projects; a market participant's estimates of future cash flows from potential product sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs associated with the transaction are expensed as incurred.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2012" unitRef="Unit1" decimals="-3">24897000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2013" unitRef="Unit1" decimals="-3">169402000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">28020000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">72108000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">18677000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">18677000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">59831000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">59831000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">144505000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-141382000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">44088000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company considers all highly liquid investments purchased with a maturity date of 90&amp;nbsp;days or less at the date of purchase to be cash equivalents. Cash equivalents consist principally of money market funds and debt securities.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(14) COLLABORATION AGREEMENTS&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has entered into license agreements whereby the Company has received licenses or options to license technology, specified patents or patent applications. The Company's licensing and development collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing patent prosecution costs and potential future milestone payments to third parties upon the achievement of certain developmental, regulatory and/or commercial milestones. Nonrefundable license fee expense of $0.9&amp;nbsp;million, $3.2&amp;nbsp;million and $0.7&amp;nbsp;million was recorded to research and development expense for the years ended December&amp;nbsp;31, 2015, 2014 and 2013, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Medarex,&amp;nbsp;Inc., a subsidiary of Bristol-Myers Squibb (Medarex)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company and Medarex have entered into an assignment and license agreement, as amended, that provides for the assignment of certain patent and other intellectual property rights and a license to certain Medarex technology related to the Company's APC Targeting Technology&amp;#x2122; and an anti-mannose receptor product. Under the terms of the agreement, the Company may be required to pay royalties in the low-single digits on any net product sale of a Licensed Royalty-Bearing Product or Anti-Mannose Product to Medarex until the later of (i)&amp;nbsp;the expiration of the last to expire applicable patent and (ii)&amp;nbsp;the tenth anniversary of the first commercial sale of such licensed product.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company and Medarex have also entered into a research and commercialization agreement, as amended, that provides that the Company may be required to pay Medarex milestones of up to $7.0&amp;nbsp;million upon obtaining first approval for commercial sale in a first indication of a product containing a licensed antibody and royalty payments in the low-to-mid single digits on any net product sales with respect to the development of any products containing such licensed antibodies until the later of (i)&amp;nbsp;the expiration of the last to expire applicable patent and (ii)&amp;nbsp;the tenth anniversary of the first commercial sale of such licensed product. In September 2010, the Company exercised an option under the agreement, whereby it licensed from Medarex access to the UltiMab technology to develop and commercialize human antibodies to CD27, including varlilumab. In connection with the clinical trial collaboration, the Company entered into with BMS in May 2014, certain future milestone payments were waived and future royalty rates that the Company may have owed Medarex in connection with any CD27 program were reduced.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Rockefeller University (Rockefeller)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In November 2005, the Company and Rockefeller entered into a license agreement for the exclusive worldwide rights to human DEC-205 receptor, with the right to sublicense the technology. The license grant is exclusive except that Rockefeller may use and permit other nonprofit organizations to use the human DEC-205 receptor patent rights for educational and research purposes. The Company may be required to pay Rockefeller milestones of up to $3.8&amp;nbsp;million upon obtaining first approval for commercial sale in a first indication of a product targeting the licensed receptor and royalty payments in the low-to-mid single digits on any net product sales with respect to development and commercialization of the human DEC-205 receptor.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Duke University Brain Tumor Cancer Center (Duke)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In September 2006, the Company and Duke entered into a license agreement that gave the Company access and reference to the clinical data generated by Duke and its collaborators in order for the Company to generate its own filing with the FDA relating to Rintega. The Company may be required to pay Duke milestones of up to $0.7&amp;nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of Rintega.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Ludwig Institute for Cancer Research (Ludwig)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2006, the Company and Ludwig entered into an agreement for the nonexclusive rights to certain cancer tumor targets for use in combination with the Company's APC Targeting Technology. The Company may be required to pay Ludwig milestones of up to $1.0&amp;nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of the technology licensed from Ludwig.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Alteris Therapeutics,&amp;nbsp;Inc. (Alteris)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2005, the Company completed the acquisition of the assets of Alteris, including the EGFRvIII molecule. The Company may be required to pay Alteris up to $5.0&amp;nbsp;million upon obtaining the first approval for commercial sale of a product containing EGFRvIII, including Rintega.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;University of Southampton, UK (Southampton)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In November 2008, the Company entered into a license agreement with Southampton to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers. The Company may be required to pay Southampton milestones of up to approximately $1.4&amp;nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of varlilumab.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Amgen&amp;nbsp;Inc. (Amgen)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In March 2009, the Company entered into a license agreement with Amgen to acquire the exclusive rights to CDX-301 and CD40 ligand (CD40L). CDX-301 and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. The Company may be required to pay Amgen milestones of up to $0.9&amp;nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of the technology licensed from Amgen, including CDX-301.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Seattle Genetics,&amp;nbsp;Inc. (Seattle Genetics)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In connection with the acquisition of CuraGen, the Company assumed the license agreement between CuraGen and Seattle Genetics whereby CuraGen acquired the rights to proprietary antibody-drug conjugate (ADC) technology for use with the Company's proprietary antibodies for the potential treatment of cancer. The Company may be required to pay Seattle Genetics milestones of up to $5.0&amp;nbsp;million and $9.0&amp;nbsp;million for glembatumumab vedotin and CDX-014, respectively, upon obtaining first approval for commercial sale in a first indication and royalty payments in the mid-single digits on any net product sales with respect to development and commercialization of these product candidates.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2014" unitRef="Unit1" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2015" unitRef="Unit1" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(16) COMMITMENTS AND CONTINGENCIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has facility and equipment leases that expire at various dates through 2020. Certain of these facility leases contain renewal options, early termination provisions, and provisions that escalate the base rent payments and require the Company to pay common area maintenance costs ("CAM") during the lease term. The following obligations for base rent and CAM costs under facility and other non-cancelable operating leases as of December&amp;nbsp;31, 2015 do not include the exercise of renewal terms or early termination provisions (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,021&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,242&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,698&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,754&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,524&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total minimum lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,239&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In February 2016, the Company amended the facility lease in Fall River, MA for additional space and to extend the term from 2017 to 2020. The Company's total rent and CAM expense for all facility leases was $2.9&amp;nbsp;million, $2.7&amp;nbsp;million and $2.7&amp;nbsp;million for the years ended December&amp;nbsp;31, 2015, 2014 and 2013, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember" unitRef="Unit14" decimals="INF">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2014" unitRef="Unit15" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2015" unitRef="Unit15" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="INF">297000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2015" unitRef="Unit14" decimals="INF">297000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">64359513</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">89246832</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="INF">89592779</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2014_dei_LegalEntityAxis_cldx_BiosynCorporationMember" unitRef="Unit14" decimals="INF">152172</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">89592779</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2015" unitRef="Unit14" decimals="INF">98685595</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">98685595</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="INF">89592779</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2015" unitRef="Unit14" decimals="INF">98685595</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">90000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">99000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-81627000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-118158000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-127480000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(3) COMPREHENSIVE LOSS&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The changes in accumulated other comprehensive income (loss) by component for the years ended December&amp;nbsp;31, 2015, 2014 and 2013 are summarized below. No amounts were reclassified out of accumulated other comprehensive income during the years ended December&amp;nbsp;31, 2015, 2014 and 2013.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gain (Loss) on&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Marketable&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Foreign&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Currency Items&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Balance at December&amp;nbsp;31, 2012&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;156
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,589
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,745
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other comprehensive loss before reclassifications&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(74
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(77
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amounts reclassified from other comprehensive income&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net current-period other comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(74
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(77
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Balance at December&amp;nbsp;31, 2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;82
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,586
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,668
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other comprehensive loss before reclassifications&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amounts reclassified from other comprehensive income&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net current-period other comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Balance at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,581
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,590
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other comprehensive loss before reclassifications&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(298
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(283
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amounts reclassified from other comprehensive income&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net current-period other comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(298
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(283
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Balance at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(289
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,596
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,307
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes foreign currency translation adjustments and unrealized gains and losses on marketable securities in other comprehensive loss. The statements of operations and comprehensive loss reflect total comprehensive loss for the years ended December&amp;nbsp;31, 2015, 2014 and 2013.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Concentration of Credit Risk and of Significant Customers and Suppliers&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Revenue from Rockefeller and BMS represented 62% and 24% for the year ended December&amp;nbsp;31, 2015, 75% and 20% for the year ended December&amp;nbsp;31, 2014, 35% and 0% for the year ended December&amp;nbsp;31, 2013, of total Company revenue, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company relies on contract manufacturing organizations (CMO) to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. The Company also relies on CMOs for supply of raw materials as well as filling, packaging, storage and shipping of drug product. These clinical studies would be adversely affected by a significant interruption in the supply of Rintega and glembatumumab vedotin. The Company also relies on third-party collaborators to develop companion diagnostic tests for certain of its drug candidates, including Rintega.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_BristolMeyersSquibbCompanyMember" unitRef="Unit13" decimals="2">0.00</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_RockefellerUniversityMember" unitRef="Unit13" decimals="2">0.35</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_BristolMeyersSquibbCompanyMember" unitRef="Unit13" decimals="2">0.20</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_RockefellerUniversityMember" unitRef="Unit13" decimals="2">0.75</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_BristolMeyersSquibbCompanyMember" unitRef="Unit13" decimals="2">0.24</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_cldx_RockefellerUniversityMember" unitRef="Unit13" decimals="2">0.62</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">1027000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
  <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">75000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
  <us-gaap:CostsAndExpenses contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">85553000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">126016000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">135021000</us-gaap:CostsAndExpenses>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">8410000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">8043000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">4661000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
  <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">4661000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
  <us-gaap:DeferredRentCredit contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">482000</us-gaap:DeferredRentCredit>
  <us-gaap:DeferredRentCredit contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">409000</us-gaap:DeferredRentCredit>
  <us-gaap:DeferredRevenue contextRef="As_Of_5_31_2014_us-gaap_CounterpartyNameAxis_cldx_BristolMeyersSquibbCompanyMember_us-gaap_ProductOrServiceAxis_cldx_Pd1ImmuneCheckpointInhibitorMember" unitRef="Unit1" decimals="-5">5000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">5297000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">4368000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">2078000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">1703000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">220893000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">277612000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">95577000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">180777000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1882000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">2017000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">29709000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">35895000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">85889000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">48608000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">5556000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">8393000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">202000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">219000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">217144000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">274230000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilities contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">4661000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">4661000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-5">300000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-5">300000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-5">400000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">1932000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">2388000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">2998000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(12) STOCK-BASED COMPENSATION&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has the following stock-based compensation plans: the 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"), the 2008 Stock Option and Incentive Plan (the "2008 Plan") and Celldex Research's 2005 Equity Incentive Plan (the "Celldex Research 2005 Plan"). There are no shares available for future grant under the Celldex Research 2005 Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2015, a total of 200,000 shares of common stock are reserved for issuance under the 2004 ESPP Plan. Under the 2004 ESPP Plan, each participating employee may purchase shares of common stock through payroll deductions at a purchase price equal to 85% of the lower of the fair market value of the common stock at either the beginning of the offering period or the applicable exercise date. During the years ended December&amp;nbsp;31, 2015 and 2014, the Company issued 15,755 and 10,798 shares under the 2004 ESPP Plan, respectively. At December&amp;nbsp;31, 2015, 137,571 shares were available for issuance under the 2004 ESPP Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Employee Stock Option and Incentive Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The 2008 Plan permits the granting of incentive stock options (intended to qualify as such under Section&amp;nbsp;422A of the Internal Revenue Code of 1986, as amended), non-qualified stock options, stock appreciation rights, performance share units, restricted stock and other awards of restricted stock in lieu of cash bonuses to employees, consultants and non-employee directors.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2015, the 2008 Plan allowed for a maximum of 14,350,000 shares of common stock to be issued for grants of Stock Options and other Awards made prior to June&amp;nbsp;9, 2025 and grants of Incentive Stock Options made prior to April&amp;nbsp;16, 2025. The Company's board of directors determines the term of each option, option price, and number of shares for which each option is granted and the rate at which each option vests. Options generally vest over a period not to exceed four years. The term of each option cannot exceed ten years (five years for options granted to holders of more than 10% of the voting stock of the Company) and the exercise price of stock options cannot be less than the fair market value of the common stock at the date of grant (110% of fair market value for incentive stock options granted to holders of more than 10% of the voting stock of the Company). Vesting of all employee and non-employee director stock option awards may accelerate upon a change in control as defined in the 2008 Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A summary of stock option activity for the year ended December&amp;nbsp;31, 2015 is as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Average&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Price&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Per Share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Average&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Contractual&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Term (In Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options Outstanding at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,015,350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,865,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24.75
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(700,561
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.81
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Canceled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(69,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.79
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options Outstanding at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,110,239
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13.13
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options Vested and Expected to Vest at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,065,256
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13.08
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options Exercisable at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,705,304
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Shares Available for Grant under the 2008 Plan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,790,709
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The total intrinsic value of stock options exercised during the years ended December&amp;nbsp;31, 2015, 2014 and 2013 was $14.4&amp;nbsp;million, $2.7&amp;nbsp;million and $10.0&amp;nbsp;million, respectively. The weighted average grant-date fair value of stock options granted during the years ended December&amp;nbsp;31, 2015, 2014 and 2013 was $15.25, $8.82 and $10.51, respectively. The total fair value of stock options vested during the years ended December&amp;nbsp;31, 2015, 2014 and 2013 was $10.0&amp;nbsp;million, $5.7&amp;nbsp;million and $2.4&amp;nbsp;million, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The aggregate intrinsic value of stock options outstanding at December&amp;nbsp;31, 2015 was $38.6&amp;nbsp;million. The aggregate intrinsic value of stock options vested and expected to vest at December&amp;nbsp;31, 2015 was $38.6&amp;nbsp;million. As of December&amp;nbsp;31, 2015, total compensation cost related to non-vested employee and non-employee director stock options not yet recognized was approximately $36.2&amp;nbsp;million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average period of 2.6&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Restricted Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A summary of restricted stock activity under the 2008 Plan for the year ended December&amp;nbsp;31, 2015 is as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Average&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Grant Date&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(per share)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Outstanding and unvested at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14.78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(26,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;22.60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Canceled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Outstanding and unvested at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Valuation and Expenses Information&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Stock-based compensation expense for the years ended December&amp;nbsp;31, 2015, 2014 and 2013 was recorded as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,186&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,459&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,640&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,588&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,393&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,908&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,774&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,852&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,548&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The fair values of employee stock options granted during the years ended December&amp;nbsp;31, 2015, 2014 and 2013 were valued using the Black-Scholes option- pricing model with the following assumptions:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;67&amp;nbsp;-&amp;nbsp;69%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;70&amp;nbsp;-&amp;nbsp;72%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;71&amp;nbsp;-&amp;nbsp;72%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected option term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;6.0 Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;6.0 Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;6.0 Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.8&amp;nbsp;-&amp;nbsp;2.2%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.9&amp;nbsp;-&amp;nbsp;2.2%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.2&amp;nbsp;-&amp;nbsp;2.1%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;None&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;None&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;None&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company estimates expected term based on historical exercise patterns. The Company uses its historical stock price volatility consistent with the expected term of grant as the basis for its expected volatility assumption. The risk-free interest rate is based upon the yield of U.S. Treasury securities consistent with the expected term of the option. The dividend yield assumption is based on the Company's history of zero dividend payouts and expectation that no dividends will be paid in the foreseeable future.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit15" decimals="2">-1.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit15" decimals="2">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit15" decimals="2">-1.32</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2014_To_6_30_2014" unitRef="Unit15" decimals="2">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit15" decimals="2">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2014_To_12_31_2014" unitRef="Unit15" decimals="2">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit15" decimals="2">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="2">-1.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit15" decimals="2">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit15" decimals="2">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit15" decimals="2">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Net Loss Per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Basic net loss per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common shares outstanding during the period when the effect is dilutive. The potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,110,239&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,015,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,770,544&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Restricted stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,500&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,129,739&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,022,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,776,544&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-3000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-5000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">15000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">4284000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">5601000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">36200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;As of&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Money market funds and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,677&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,677&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173,023&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173,023&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;191,700&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;191,700&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;As of&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Money market funds and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,831&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,831&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;217,781&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;217,781&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;277,612&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;277,612&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(4) FAIR VALUE MEASUREMENTS&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following tables set forth the Company's financial assets subject to fair value measurements:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;As of&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Money market funds and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,677&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,677&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173,023&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173,023&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;191,700&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;191,700&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;As of&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Money market funds and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,831&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,831&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;217,781&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;217,781&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;277,612&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;277,612&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;There have been no transfers of assets or liabilities between the fair value measurement classifications. The Company's financial instruments consist mainly of cash and cash equivalents, marketable securities, short-term accounts receivable and accounts payable. The Company values its marketable securities utilizing independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. Short-term accounts receivable and accounts payable are reflected in the accompanying financial statements at cost, which approximates fair value due to the short-term nature of these instruments.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has certain assets and liabilities that are measured at fair value in the financial statements. The Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company's assumptions about how market participants would price assets and liabilities) when measuring the fair value of its assets and liabilities. These assets and liabilities are classified into one of three levels of the following fair value hierarchy as defined by U.S.&amp;nbsp;GAAP:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Level&amp;nbsp;1: Observable inputs such as quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Level&amp;nbsp;2: Observable inputs other than Level&amp;nbsp;1 prices, such as quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;Level 3: Unobservable inputs based on the Company's assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-30962000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-43536000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-46598000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">5789000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember" unitRef="Unit1" decimals="-3">4708000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember" unitRef="Unit1" decimals="-3">1081000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">6802000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember" unitRef="Unit1" decimals="-3">5605000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="As_Of_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember" unitRef="Unit1" decimals="-3">1197000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">1000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="As_Of_12_31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember" unitRef="Unit1" decimals="-3">14500000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="As_Of_12_31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember" unitRef="Unit1" decimals="-3">1296000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="As_Of_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember" unitRef="Unit1" decimals="-3">14500000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="As_Of_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember" unitRef="Unit1" decimals="-3">1296000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_12_31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember" unitRef="Unit1" decimals="-3">9792000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_12_31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember" unitRef="Unit1" decimals="-3">215000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember" unitRef="Unit1" decimals="-3">8895000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="As_Of_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember" unitRef="Unit1" decimals="-3">99000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_AmgenAmendmentMember">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cldx_CoreTechnologyMember">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Foreign Currency Translation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Net unrealized gains and losses resulting from foreign currency translation are included in other comprehensive income (loss). At December&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014, accumulated other comprehensive income includes a net unrealized gain related to foreign currency translation of $2.6&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:GainLossOnSaleOfOtherAssets contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">400000</us-gaap:GainLossOnSaleOfOtherAssets>
  <us-gaap:GainLossOnSaleOfOtherAssets contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1000000</us-gaap:GainLossOnSaleOfOtherAssets>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">21000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-6000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">14805000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">20622000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">33837000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:Goodwill contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">8965000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">8965000</us-gaap:Goodwill>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(7) INTANGIBLE ASSETS AND GOODWILL&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Intangible assets, net of accumulated amortization, and goodwill are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="10" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Estimated&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Accumulated&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Accumulated&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="17" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Intangible Assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Indefinite&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amgen Amendment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;16&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5,605
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,895
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,708
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,792
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Core Technology&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;11&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,296
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,197
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;99
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,296
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,081
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;215
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total Intangible Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;27,596
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(6,802
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,794
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;27,596
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5,789
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21,807
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Indefinite&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,965
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,965
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,965
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,965
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The IPR&amp;amp;D intangible asset was recorded in connection with the acquisition of CuraGen and relates to the development of glembatumumab vedotin. At the date of acquisition and at December&amp;nbsp;31, 2015, glembatumumab vedotin had not yet reached technological feasibility nor did it have any alternative future use. Glembatumumab vedotin is in a randomized, Phase&amp;nbsp;2b study for the treatment of triple negative breast cancer and a Phase&amp;nbsp;2 study for the treatment of metastatic melanoma.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Amortization expense for intangible assets was $1.0&amp;nbsp;million for the years ended December&amp;nbsp;31, 2015, 2014 and 2013. The estimated future amortization expense of intangible assets for the years ending December&amp;nbsp;31, 2016, 2017, 2018, 2019 and 2020 is $1.0&amp;nbsp;million, $0.9&amp;nbsp;million, $0.9&amp;nbsp;million, $0.9&amp;nbsp;million and $0.9&amp;nbsp;million, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Goodwill&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. The Company has the option to assess qualitative factors to determine if it is more likely than not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under U.S.&amp;nbsp;GAAP. As part of its annual impairment test of the goodwill asset as of July&amp;nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed the two-step impairment test. The Company concluded that goodwill was not impaired.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
  <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Intangible Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;IPR&amp;amp;D assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible assets. These assets are capitalized on the Company's balance sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the carrying value of the related intangible asset is amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value and an impairment charge is taken in the period in which the impairment occurs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;IPR&amp;amp;D assets are tested for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. As part of the annual impairment test of the IPR&amp;amp;D assets as of July&amp;nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed a calculation of the fair value of the asset. The Company concluded that the IPR&amp;amp;D assets were not impaired.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Intangible assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a straight-line basis over their estimated useful life.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Impairment of Intangible and Long-Lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company evaluates the recoverability of its long-lived assets, including property and equipment, and intangible assets when circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(15) INCOME TAXES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The components of income tax expense attributable to continuing operations consist of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Income tax benefit (provision):&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Federal&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;46,598
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;43,536
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;30,962
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;State&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,642
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,328
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,920
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expiration of Net Operating Losses and Research&amp;nbsp;&amp;amp; Development Tax Credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(155
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,302
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(126
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;57,085
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,562
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,756
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred tax valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(57,085
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(48,562
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(35,756
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A reconciliation between the amount of reported income tax and the amount computed using the U.S. Statutory rate of 34% follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Pre-tax loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(127,197
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(118,080
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(81,550
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Loss at Statutory Rates&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(43,247
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(40,147
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(27,727
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research and Development Credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,935
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,126
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,261
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;State Taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(10,642
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,328
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,920
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,584
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;737
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expiration of Net Operating Losses and Research&amp;nbsp;&amp;amp; Development Tax Credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;155
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,302
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;126
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Change in Valuation Allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;57,085
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,562
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,756
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Income tax (benefit) provision&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future expected enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The principal components of the deferred tax assets and liabilities at December&amp;nbsp;31, 2015 and 2014, respectively, are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Gross Deferred Tax Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net Operating Loss Carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;180,777
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;95,577
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Tax Credit Carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,895
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29,709
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,608
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;85,889
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,393
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,556
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Fixed Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,017
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,882
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,703
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,078
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;202
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;277,612
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;220,893
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Gross Deferred Tax Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other Acquired Intangibles&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,382
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,749
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;IPR&amp;amp;D Intangibles&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,043
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,410
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total Deferred Tax Assets and Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,569
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;212,483
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Tax Assets Valuation Allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(274,230
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(217,144
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net Deferred Tax Asset (Liability)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The net deferred tax liability of $4.7&amp;nbsp;million at December&amp;nbsp;31, 2015 and 2014 relates to the temporary differences associated with the IPR&amp;amp;D intangible assets acquired in the CuraGen acquisition, which are not deductible for tax purposes.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2015, the Company had the following federal net operating loss ("NOL") carryforwards:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Prior to the merger of the Company and AVANT, $33.0&amp;nbsp;million was generated by the Company which expire at various dates starting in 2023 and going through 2028; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Prior to the merger of the Company and AVANT, $101.2&amp;nbsp;million, net of expirations and utilization, was generated by AVANT which expire at various dates starting in 2018 and going through 2028; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Following the merger of the Company and AVANT, $392.9&amp;nbsp;million was generated by the combined company which expire at various dates starting in 2028 and going through 2035; and &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Prior to its acquisition by the Company, $518.3&amp;nbsp;million was generated by CuraGen.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2015, the Company has an additional $17.7&amp;nbsp;million of federal and state net operating losses not reflected above, that are attributable to stock option exercises which will be recorded as an increase in additional paid in capital on the balance sheet once they are "realized" in accordance with ASC 718.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In general, an ownership change, as defined by Section&amp;nbsp;382 of the Internal Revenue Code, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50&amp;nbsp;percentage points over a three-year period. Such ownership changes can significantly limit the amount of NOLs that may be utilized in future periods. The Company currently expects that it is remote that the CuraGen NOLs may be utilized and, as such, no related asset has been recorded for such losses. The Company has not completed an analysis of losses generated by AVANT, however, the Company believes it is remote that $60.8&amp;nbsp;million of the AVANT NOLs may be utilized in future periods and there may be substantial limitations on the Company's ability to use the remaining NOLs of $40.4&amp;nbsp;million. Following the merger of the Company and AVANT, the Company experienced changes in ownership as defined by Section&amp;nbsp;382 in June 2009, December 2009 and December 2013. Further, prior to the AVANT merger, the Company as a stand alone company experienced a change in ownership in October 2007. As a result of the ownership changes in June 2009 and December 2009, there is an annual limitation amount of $6.0&amp;nbsp;million on $67.7&amp;nbsp;million of NOLs generated before that date. As a result of the ownership change in December 2013, there is an annual limitation amount of $77.0&amp;nbsp;million on $178.7&amp;nbsp;million of NOLs generated before that date. Any unused annual limitation may be carried over to later years, and the amount of the limitation may, under certain circumstances, be subject to adjustment if the fair value of the Company's net assets are determined to be below or in excess of the tax basis of such assets at the time of the ownership change, and such unrealized loss or gain is recognized during the five-year period after the ownership change.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Similar to the AVANT and CuraGen NOL carryforwards above, the Company believes that it is not more likely than not that federal and state research and development ("R&amp;amp;D") credits of $20.8&amp;nbsp;million and $14.4&amp;nbsp;million, respectively, will be utilized in the future periods. Further, the Company's ability to use the state NOLs of approximately $382.3&amp;nbsp;million and the remaining federal and state R&amp;amp;D credit carryforwards of approximately $28.5&amp;nbsp;million and $11.2&amp;nbsp;million, respectively, may be substantially limited. These state NOLs and federal and state credits expire at various dates starting in 2016 going through 2035. The Company has not yet completed a study of these credits to substantiate the amounts. Until a study is completed, no amounts are being presented as an uncertain tax position.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Subsequent ownership changes, as defined in Section&amp;nbsp;382, could further limit the amount of net operating loss carryforwards and research and development credits that can be utilized annually to offset future taxable income.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company applies the authoritative guidance on account for and disclosure of uncertainty in income tax positions which requires the Company to determine whether an income tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. For income tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced to the largest benefit that has a greater than fifty perfect likelihood of being realized upon the ultimate settlement with the relevant taxing authority. At December&amp;nbsp;31, 2015 and 2014, we had no unrecognized tax benefits. A full valuation allowance has been provided against our deferred tax assets and liabilities and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Massachusetts, New Jersey and Connecticut are the three states in which the Company primarily operates or has operated and has income tax nexus. The Company is not currently under examination by these or any other jurisdictions for any tax year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has evaluated the positive and negative evidence bearing upon the realizability of its net deferred tax assets, which are comprised principally of net operating loss carryforwards, capitalized R&amp;amp;D expenditures and R&amp;amp;D tax credit carryforwards. The Company has determined that it is more likely than not that it will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance was maintained at December&amp;nbsp;31, 2015 against the Company's net deferred tax assets.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax basis. Quarterly, the Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company's tax provision in the period of change.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records uncertain tax positions in the financial statements only if it is more likely than not that the uncertain tax position will be sustained upon examination by the taxing authorities. The Company records interest and penalties related to uncertain tax positions in income tax expense.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">35756000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">48562000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">57085000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-27727000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-40147000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-43247000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">26000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">737000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1584000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-4920000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-7328000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-10642000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">3261000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">4126000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">4935000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">445000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-62000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">543000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">7236000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">1450000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">4875000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-276000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-65000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-6000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">1317000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">6577000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">7202000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">706000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">2026000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">653000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="As_Of_12_31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="Unit1" decimals="-3">11800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="As_Of_12_31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="Unit1" decimals="-3">11800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">27596000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">27596000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">21807000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">20794000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestAndOtherIncome contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">819000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">4350000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">2344000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">927000</us-gaap:InterestExpense>
  <us-gaap:InterestExpenseLongTermDebt contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit1" decimals="-5">800000</us-gaap:InterestExpenseLongTermDebt>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">1209000</us-gaap:InterestPaid>
  <us-gaap:InterestReceivable contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-5">1400000</us-gaap:InterestReceivable>
  <us-gaap:InterestReceivable contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">1500000</us-gaap:InterestReceivable>
  <us-gaap:InvestmentsAndCash contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">289900000</us-gaap:InvestmentsAndCash>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(5) MARKETABLE SECURITIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A summary of marketable securities is shown below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortized&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,580
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;30
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,604
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing after one year through three years&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,108
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;49
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,156
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total U.S. government and municipal obligations&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;60,688
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;79
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;60,760
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;89,636
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(37
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;89,605
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing after one year through three years&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;22,690
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(35
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;22,658
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;112,326
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;112,263
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173,014
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;88
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(79
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173,023
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,871
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(20
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,855
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing after one year through three years&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,940
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(57
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,907
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;64,811
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(77
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;64,762
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,327
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(141
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,188
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing after one year through three years&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;23,932
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(102
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;23,831
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;153,259
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(243
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;153,019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;218,070
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(320
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;217,781
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The marketable securities held by the Company were high investment grade and there were no marketable securities that the Company considered to be other-than-temporarily impaired as of December&amp;nbsp;31, 2015. Marketable securities include $1.5&amp;nbsp;million and $1.4&amp;nbsp;million in accrued interest at December&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">36354000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">47479000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">248014000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">337584000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">24491000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">30240000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
  <us-gaap:LongTermDebtTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(10) TERM LOAN&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In December 2010, the Company entered into a loan and security agreement pursuant to which the Company borrowed $10.0&amp;nbsp;million under a term loan. In March 2011, the Company amended the loan agreement and borrowed an additional $5.0&amp;nbsp;million. In May 2013, the Company elected to prepay the outstanding principal under the term loan in full, pursuant to the terms of its loan agreement, as amended, and paid $8.8&amp;nbsp;million in principal and $0.7&amp;nbsp;million in interest, prepayment and final payment fees. The Company's obligations under the loan agreement had been collateralized by a first priority security interest in substantially all of its assets, other than its intellectual property. In connection with the repayment of the term loan and the termination of the loan agreement, those security interests were released. Interest expense on the term loan was $0.8&amp;nbsp;million for the year ended December&amp;nbsp;31, 2013.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:MarketableSecuritiesGainLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-11000</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:MarketableSecuritiesPolicy contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Marketable Securities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company invests its excess cash balances in marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds. The Company classifies all of its marketable securities as current assets on the balance sheets because they are available-for-sale and available to fund current operations. Marketable securities are stated at fair value with their unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the statements of operations. Realized gains and losses are determined on the specific identification method and are included in investment and other income, net.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">289599000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">1171000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">193151000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-77422000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-41011000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-50191000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-67669000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-101537000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-98887000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-81550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-81550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit1" decimals="-3">-29903000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-118080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-118080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_4_1_2014_To_6_30_2014" unitRef="Unit1" decimals="-3">-28274000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-28082000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_10_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-31821000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="-3">-30174000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-127197000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-127197000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit1" decimals="-3">-32359000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-31980000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-32684000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2014, the FASB issued a new U.S.&amp;nbsp;GAAP accounting standard that creates modifications to various other revenue accounting standards for specialized transactions and industries. The new U.S.&amp;nbsp;GAAP accounting standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB deferred the effective date of the new standard from January&amp;nbsp;1, 2017 to January&amp;nbsp;1, 2018. The amendment allows for two methods of adoption, a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. The Company will further study the implications of this standard in order to evaluate the expected impact on the financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In April 2015, the FASB issued amendments that provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The new guidance does not change the accounting for a customer's accounting for service contracts. The standard update is effective for fiscal years beginning after December&amp;nbsp;15, 2015 and interim periods within those years. Early adoption is permitted. The standard allows for adoption retrospectively or prospectively to all arrangements entered into or materially modified after the effective date. The amendment is not expected to have a material impact on our financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In August 2014, the FASB issued a new U.S.&amp;nbsp;GAAP accounting standard that provides guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new accounting standard requires management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The new accounting standard is effective for the annual period ending after December&amp;nbsp;15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not expect the adoption of this standard to have a material impact on the financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit16" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:NumberOfStatesInWhichEntityOperates contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="INF">3</us-gaap:NumberOfStatesInWhichEntityOperates>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-81442000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-122430000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-129541000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">13239000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">3021000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">1524000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">2754000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">2698000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">3242000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-5">2700000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-5">2700000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-5">2900000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">17700000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_cldx_AVANTMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">392900000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2015_cldx_OwnershipChangeAxis_cldx_OwnershipChangeInDecember2013Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">178700000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2015_cldx_OwnershipChangeAxis_cldx_OwnershipChangesInJune2009AndDecember2009Member_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">67700000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2015_cldx_StatusOfMergerAndAcquisitionAxis_cldx_PriorToMergerMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">33000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2015_cldx_StatusOfMergerAndAcquisitionAxis_cldx_PriorToAcquisitionMember_us-gaap_BusinessAcquisitionAxis_cldx_CuraGenCorporationMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" unitRef="Unit1" decimals="-5">518300000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1826000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">3768000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1722000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">1428000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-5000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-5000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">15000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">15000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">-74000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-77000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">-3000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">-73000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-78000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">-5000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">-298000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-283000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">15000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">-74000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-77000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">-3000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">-73000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-78000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">-5000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">-298000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-283000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">15000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-74000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-74000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-298000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-298000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherLiabilities contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">14455000</us-gaap:OtherLiabilities>
  <us-gaap:OtherLiabilities contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">21657000</us-gaap:OtherLiabilities>
  <us-gaap:OtherLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">2592000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">4418000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(9) OTHER LONG-TERM LIABILITIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Other long-term liabilities include the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Rent&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;409
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;482
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net Deferred Tax Liability related to IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Income from Sale of Tax Benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,015
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,368
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,297
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21,657
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,455
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less Current Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,418
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,592
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Long-Term Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;17,239
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,863
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In November 2015, December 2014, January 2014, January 2013, January 2012 and January 2011, the Company received approval from the New Jersey Economic Development Authority and agreed to sell New Jersey tax benefits of $9.8&amp;nbsp;million, $1.9&amp;nbsp;million, $1.1&amp;nbsp;million, $0.8&amp;nbsp;million, $0.8&amp;nbsp;million and $0.6&amp;nbsp;million to an independent third party for $9.2&amp;nbsp;million, $1.8&amp;nbsp;million, $1.0&amp;nbsp;million, $0.8&amp;nbsp;million, $0.7&amp;nbsp;million and $0.5&amp;nbsp;million, respectively. Under the agreement, the Company must maintain a base of operations in New Jersey for five years or the tax benefits must be paid back on a pro-rata basis based on the number of years completed. During the years ended December&amp;nbsp;31, 2015 and 2014, the Company recorded $1.0&amp;nbsp;million and $0.4&amp;nbsp;million to other income related to the sale of these tax benefits, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">11863000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">17239000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">112118000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">148314000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">206405000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">4219000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">1929000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">4876000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(17) RETIREMENT SAVINGS PLAN&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company maintains a 401(k) Plan which is available to substantially all employees. Under the terms of the 401(k) Plan, participants may elect to contribute up to 15% of their compensation, or the statutory prescribed limits. The Company may make 50% matching contributions on up to 4% of a participant's annual salary. Benefit expense for the 401(k) Plan was $0.4&amp;nbsp;million, $0.3&amp;nbsp;million and $0.3&amp;nbsp;million for the years ended December&amp;nbsp;31, 2015, 2014 and 2013, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2014" unitRef="Unit15" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2015" unitRef="Unit15" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="INF">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2015" unitRef="Unit14" decimals="INF">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_CumulativePreferredStockMember" unitRef="Unit14" decimals="INF">350000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit14" decimals="INF">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2015" unitRef="Unit14" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2015" unitRef="Unit14" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2014" unitRef="Unit1" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2015" unitRef="Unit1" />
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">3515000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">4077000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">295697000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2013_To_12_31_2013_cldx_StockIssuedByTypeOfProgramAxis_cldx_ControlledEquityOfferingProgramAmendedMember" unitRef="Unit1" decimals="-5">17100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">188840000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="Duration_12_1_2010_To_12_31_2010_cldx_DebtInstrumentLenderAxis_cldx_MidCapFinancialLLCMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit1" decimals="-5">10000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="Duration_3_1_2011_To_3_31_2011_cldx_DebtInstrumentLenderAxis_cldx_GeneralElectricCapitalCorporationMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit1" decimals="-5">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">38894000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">109232000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">161090000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">21000</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:ProceedsFromStockPlans contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">5403000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">1171000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">4311000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(6) PROPERTY AND EQUIPMENT, NET&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment include the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Laboratory Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,432
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,223
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Manufacturing Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,178
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,274
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office Furniture and Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,088
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,888
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,371
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,603
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Construction in Progress&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;451
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,767
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total Property and Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;28,520
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24,755
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less Accumulated Depreciation and Amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(17,059
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,220
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,461
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Depreciation and amortization expense related to property and equipment was $3.0&amp;nbsp;million, $2.4&amp;nbsp;million and $1.9&amp;nbsp;million for the years ended December&amp;nbsp;31, 2015, 2014 and 2013, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">24755000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_LaboratoryEquipmentMember" unitRef="Unit1" decimals="-3">4223000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_ManufacturingEquipmentMember" unitRef="Unit1" decimals="-3">2274000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit1" decimals="-3">1767000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit1" decimals="-3">1888000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2014_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit1" decimals="-3">14603000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">28520000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_LaboratoryEquipmentMember" unitRef="Unit1" decimals="-3">5432000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_ManufacturingEquipmentMember" unitRef="Unit1" decimals="-3">4178000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit1" decimals="-3">451000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit1" decimals="-3">3088000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit1" decimals="-3">15371000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">10535000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">11461000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Property and Equipment&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment is stated at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Laboratory equipment and office furniture and equipment are depreciated over five years and computer equipment is depreciated over three years. Manufacturing equipment is amortized over seven to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the non-cancelable term of the related lease, including any renewals that are reasonably assured of occurring. Property and equipment under construction is classified as construction in progress and is depreciated or amortized only after the asset is placed in service. Expenditures for maintenance and repairs are charged to expense whereas the costs of significant improvements which extend the life of the underlying asset are capitalized. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated and any resulting gain or loss is reflected in the Company's statements of operations and comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The treatment of costs to construct property and equipment depends on the nature of the costs and the stage of construction. Costs incurred in the project planning, design, construction and installation phases are capitalized as part of the cost of the asset. The Company stops capitalizing these costs when the asset is substantially complete and ready for its intended use. For manufacturing property and equipment, the Company also capitalizes the cost of validating these assets for the underlying manufacturing process. The Company completes the capitalization of validation costs when the asset is substantially complete and ready for its intended use. Costs capitalized include incremental labor and fringe benefits, and direct consultancy services.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Laboratory Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,432
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,223
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Manufacturing Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,178
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,274
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office Furniture and Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,088
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,888
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,371
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,603
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Construction in Progress&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;451
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,767
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total Property and Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;28,520
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24,755
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less Accumulated Depreciation and Amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(17,059
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,220
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,461
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_LaboratoryEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_ManufacturingEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cldx_ManufacturingEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(18) SELECTED QUARTERLY FINANCIAL DATA (Unaudited)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q1 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q2 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q3 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q4 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands, except per share amounts)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;416
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;592
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,477
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(29,903
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,274
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,082
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,821
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.32
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.36
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q1 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q2 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q3 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q4 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands, except per share amounts)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;486
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,178
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,790
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(30,174
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(32,359
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,980
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(32,684
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.32
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">472000</us-gaap:RepaymentsOfOtherLongTermDebt>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">11029000</us-gaap:RepaymentsOfSecuredDebt>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">67401000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">104381000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2014_To_12_31_2014_dei_LegalEntityAxis_cldx_BiosynCorporationMember" unitRef="Unit1" decimals="-5">2000000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">100171000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;font-size:10pt;"&gt;Research and Development Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other preclinical studies, personnel costs, depreciation, license fees and funding of outside contracted research.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Clinical trial expenses include expenses associated with clinical research organizations, or CRO, services. Contract manufacturing expenses include expenses associated with contract manufacturing organizations, or CMO, services. The invoicing from CROs and CMOs for services rendered can lag several months. The Company accrues the cost of services rendered in connection with CRO and CMO activities based on our estimate of costs incurred. The Company maintains regular communication with our CROs and CMOs to assess the reasonableness of its estimates. Differences between actual expenses and estimated expenses recorded have not been material and are adjusted for in the period in which they become known.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">-463759000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">-590956000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic drug products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. In accounting for these transactions, the Company allocates revenue to the various elements based on their relative fair value. The fair value of a revenue generating element can be based on current selling prices offered by the Company or another party for current products or the Company's best estimate of a selling price for future products. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;These collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of the Company's involvement in achieving the milestones and whether the amount of the payment is commensurate to the Company's performance. If not considered substantive, milestones are initially deferred and recognized over the period of the remaining performance obligation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Payments received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or the Company's contractual partner. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Product royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize the Company's licensed technologies and are recognized when the amount of and basis for such royalty payments are reported to the Company in accurate and appropriate form and in accordance with the related license agreement.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">4111000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit1" decimals="-3">416000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">3586000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_4_1_2014_To_6_30_2014" unitRef="Unit1" decimals="-3">592000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">1101000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_10_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">1477000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="-3">486000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">5480000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit1" decimals="-3">2178000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">1026000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1790000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">2334000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_CounterpartyNameAxis_cldx_GlaxoSmithKlinePlcMember_us-gaap_ProductOrServiceAxis_cldx_RotarixRotavirusVaccineMember_us-gaap_TypeOfArrangementAxis_cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" unitRef="Unit1" decimals="-5">2300000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyRevenue contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">2334000</us-gaap:RoyaltyRevenue>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued Payroll and Employee Benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,601&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,284&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued Research and Development Contract Costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,548&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,696&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued Professional Fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;399&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;490&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other Accrued Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,768&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,826&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24,316&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,296&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gain (Loss) on&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Marketable&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Foreign&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Currency Items&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Balance at December&amp;nbsp;31, 2012&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;156
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,589
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,745
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other comprehensive loss before reclassifications&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(74
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(77
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amounts reclassified from other comprehensive income&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net current-period other comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(74
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(77
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Balance at December&amp;nbsp;31, 2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;82
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,586
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,668
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other comprehensive loss before reclassifications&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amounts reclassified from other comprehensive income&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net current-period other comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Balance at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,581
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,590
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other comprehensive loss before reclassifications&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(298
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(283
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amounts reclassified from other comprehensive income&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net current-period other comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(298
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(283
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Balance at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(289
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,596
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,307
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,110,239&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,015,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,770,544&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Restricted stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,500&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,129,739&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,022,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,776,544&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortized&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,580
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;30
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,604
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing after one year through three years&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,108
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;49
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,156
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total U.S. government and municipal obligations&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;60,688
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;79
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;60,760
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;89,636
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(37
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;89,605
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing after one year through three years&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;22,690
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(35
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;22,658
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;112,326
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;112,263
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173,014
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;88
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(79
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173,023
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,871
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(20
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,855
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing after one year through three years&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,940
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(57
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,907
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total U.S. government and municipal obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;64,811
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(77
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;64,762
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,327
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(141
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,188
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Maturing after one year through three years&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;23,932
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(102
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;23,831
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;153,259
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(243
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;153,019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;218,070
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(320
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;217,781
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Income tax benefit (provision):&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Federal&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;46,598
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;43,536
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;30,962
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;State&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,642
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,328
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,920
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expiration of Net Operating Losses and Research&amp;nbsp;&amp;amp; Development Tax Credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(155
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,302
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(126
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;57,085
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,562
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,756
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred tax valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(57,085
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(48,562
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(35,756
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Gross Deferred Tax Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net Operating Loss Carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;180,777
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;95,577
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Tax Credit Carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,895
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;29,709
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,608
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;85,889
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,393
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,556
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Fixed Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,017
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,882
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,703
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,078
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;202
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;277,612
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;220,893
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Gross Deferred Tax Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other Acquired Intangibles&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,382
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,749
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;IPR&amp;amp;D Intangibles&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,043
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,410
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total Deferred Tax Assets and Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,569
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;212,483
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred Tax Assets Valuation Allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(274,230
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(217,144
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net Deferred Tax Asset (Liability)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Pre-tax loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(127,197
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(118,080
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(81,550
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Loss at Statutory Rates&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(43,247
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(40,147
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(27,727
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research and Development Credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,935
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,126
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,261
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;State Taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(10,642
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,328
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,920
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,584
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;737
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expiration of Net Operating Losses and Research&amp;nbsp;&amp;amp; Development Tax Credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;155
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,302
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;126
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Change in Valuation Allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;57,085
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;48,562
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,756
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Income tax (benefit) provision&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,186&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,459&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,640&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,588&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,393&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,908&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,774&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,852&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,548&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;The following obligations for base rent and CAM costs under facility and other non-cancelable operating leases as of December&amp;nbsp;31, 2015 do not include the exercise of renewal terms or early termination provisions (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,021&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,242&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,698&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,754&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,524&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total minimum lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,239&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="10" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Estimated&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Accumulated&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Accumulated&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="17" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Intangible Assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Indefinite&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amgen Amendment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;16&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5,605
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,895
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,708
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,792
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Core Technology&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;11&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,296
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,197
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;99
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,296
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,081
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;215
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total Intangible Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;27,596
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(6,802
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,794
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;27,596
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5,789
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21,807
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Indefinite&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,965
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,965
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,965
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,965
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Average&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Grant Date&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(per share)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Outstanding and unvested at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14.78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(26,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;22.60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Canceled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Outstanding and unvested at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q1 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q2 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q3 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q4 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands, except per share amounts)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;416
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;592
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,477
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(29,903
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,274
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,082
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,821
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.32
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.36
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q1 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q2 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q3 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Q4 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands, except per share amounts)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;486
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,178
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,790
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(30,174
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(32,359
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,980
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(32,684
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.32
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Average&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Price&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Per Share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Average&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Contractual&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Term (In Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options Outstanding at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,015,350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,865,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24.75
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(700,561
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.81
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Canceled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(69,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.79
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options Outstanding at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,110,239
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13.13
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options Vested and Expected to Vest at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,065,256
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13.08
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options Exercisable at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,705,304
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Shares Available for Grant under the 2008 Plan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,790,709
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;67&amp;nbsp;-&amp;nbsp;69%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;70&amp;nbsp;-&amp;nbsp;72%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;71&amp;nbsp;-&amp;nbsp;72%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected option term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;6.0 Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;6.0 Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;6.0 Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.8&amp;nbsp;-&amp;nbsp;2.2%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.9&amp;nbsp;-&amp;nbsp;2.2%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.2&amp;nbsp;-&amp;nbsp;2.1%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;None&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;None&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;None&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">4548000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">6852000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">12774000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member_us-gaap_RangeAxis_us-gaap_MaximumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">39000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">25.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">19500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">14.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">25.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">26500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">22.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="2">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="3">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="3">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="3">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="3">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="3">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" unitRef="Unit13" decimals="3">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="0">14350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" unitRef="Unit14" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember" unitRef="Unit14" decimals="INF">137571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">5790709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">4705304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">8.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">14400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">69800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">1865250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">10.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">8.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">15.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">38600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">7015350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">8110239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">13.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">38600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">8065256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">13.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">5700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit1" decimals="-5">10000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember" unitRef="Unit13" decimals="2">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">5.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">15.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit15" decimals="2">24.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and directors is recognized using the straight-line method over the term of vesting or performance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;31, 2014, the Company's wholly-owned subsidiary, Celldex Research Corporation, merged into Celldex Therapeutics,&amp;nbsp;Inc. The statements of operations and comprehensive loss, of stockholders' equity, and of cash flows, are consolidated for the years ended December&amp;nbsp;31, 2014 and 2013. These consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary prior to the merger. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one segment, which is the business of development, manufacturing and commercialization of novel therapeutics for human health care. In February 2016, the Company formed a wholly-owned subsidiary, Celldex Therapeutics Europe&amp;nbsp;GmbH, in Zug, Switzerland, to operate as Celldex' European headquarters when European operations commence, pursuant to intercompany agreements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (U.S.&amp;nbsp;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company considers all highly liquid investments purchased with a maturity date of 90&amp;nbsp;days or less at the date of purchase to be cash equivalents. Cash equivalents consist principally of money market funds and debt securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Marketable Securities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company invests its excess cash balances in marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds. The Company classifies all of its marketable securities as current assets on the balance sheets because they are available-for-sale and available to fund current operations. Marketable securities are stated at fair value with their unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the statements of operations. Realized gains and losses are determined on the specific identification method and are included in investment and other income, net.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Concentration of Credit Risk and of Significant Customers and Suppliers&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Revenue from Rockefeller and BMS represented 62% and 24% for the year ended December&amp;nbsp;31, 2015, 75% and 20% for the year ended December&amp;nbsp;31, 2014, 35% and 0% for the year ended December&amp;nbsp;31, 2013, of total Company revenue, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company relies on contract manufacturing organizations (CMO) to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. The Company also relies on CMOs for supply of raw materials as well as filling, packaging, storage and shipping of drug product. These clinical studies would be adversely affected by a significant interruption in the supply of Rintega and glembatumumab vedotin. The Company also relies on third-party collaborators to develop companion diagnostic tests for certain of its drug candidates, including Rintega.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has certain assets and liabilities that are measured at fair value in the financial statements. The Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company's assumptions about how market participants would price assets and liabilities) when measuring the fair value of its assets and liabilities. These assets and liabilities are classified into one of three levels of the following fair value hierarchy as defined by U.S.&amp;nbsp;GAAP:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Level&amp;nbsp;1: Observable inputs such as quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Level&amp;nbsp;2: Observable inputs other than Level&amp;nbsp;1 prices, such as quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Level&amp;nbsp;3: Unobservable inputs based on the Company's assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Property and Equipment&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment is stated at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Laboratory equipment and office furniture and equipment are depreciated over five years and computer equipment is depreciated over three years. Manufacturing equipment is amortized over seven to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the non-cancelable term of the related lease, including any renewals that are reasonably assured of occurring. Property and equipment under construction is classified as construction in progress and is depreciated or amortized only after the asset is placed in service. Expenditures for maintenance and repairs are charged to expense whereas the costs of significant improvements which extend the life of the underlying asset are capitalized. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated and any resulting gain or loss is reflected in the Company's statements of operations and comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The treatment of costs to construct property and equipment depends on the nature of the costs and the stage of construction. Costs incurred in the project planning, design, construction and installation phases are capitalized as part of the cost of the asset. The Company stops capitalizing these costs when the asset is substantially complete and ready for its intended use. For manufacturing property and equipment, the Company also capitalizes the cost of validating these assets for the underlying manufacturing process. The Company completes the capitalization of validation costs when the asset is substantially complete and ready for its intended use. Costs capitalized include incremental labor and fringe benefits, and direct consultancy services.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Business Combinations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records the fair value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets such as in-process research and development (IPR&amp;amp;D), using a variety of methods including present value models. Each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of IPR&amp;amp;D assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant's assumptions regarding the probability of completing IPR&amp;amp;D projects, which would require obtaining regulatory approval for marketing of the associated drug candidate; a market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;amp;D projects; a market participant's estimates of future cash flows from potential product sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs associated with the transaction are expensed as incurred.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Intangible Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;IPR&amp;amp;D assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible assets. These assets are capitalized on the Company's balance sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the carrying value of the related intangible asset is amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value and an impairment charge is taken in the period in which the impairment occurs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;IPR&amp;amp;D assets are tested for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. As part of the annual impairment test of the IPR&amp;amp;D assets as of July&amp;nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed a calculation of the fair value of the asset. The Company concluded that the IPR&amp;amp;D assets were not impaired.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Intangible assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a straight-line basis over their estimated useful life.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Goodwill&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. The Company has the option to assess qualitative factors to determine if it is more likely than not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under U.S.&amp;nbsp;GAAP. As part of its annual impairment test of the goodwill asset as of July&amp;nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed the two-step impairment test. The Company concluded that goodwill was not impaired.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Impairment of Intangible and Long-Lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company evaluates the recoverability of its long-lived assets, including property and equipment, and intangible assets when circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic drug products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. In accounting for these transactions, the Company allocates revenue to the various elements based on their relative fair value. The fair value of a revenue generating element can be based on current selling prices offered by the Company or another party for current products or the Company's best estimate of a selling price for future products. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;These collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of the Company's involvement in achieving the milestones and whether the amount of the payment is commensurate to the Company's performance. If not considered substantive, milestones are initially deferred and recognized over the period of the remaining performance obligation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Payments received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or the Company's contractual partner. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Product royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize the Company's licensed technologies and are recognized when the amount of and basis for such royalty payments are reported to the Company in accurate and appropriate form and in accordance with the related license agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other preclinical studies, personnel costs, depreciation, license fees and funding of outside contracted research.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Clinical trial expenses include expenses associated with clinical research organizations, or CRO, services. Contract manufacturing expenses include expenses associated with contract manufacturing organizations, or CMO, services. The invoicing from CROs and CMOs for services rendered can lag several months. The Company accrues the cost of services rendered in connection with CRO and CMO activities based on our estimate of costs incurred. The Company maintains regular communication with our CROs and CMOs to assess the reasonableness of its estimates. Differences between actual expenses and estimated expenses recorded have not been material and are adjusted for in the period in which they become known.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Patent Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Patent costs are expensed as incurred. Certain patent costs are reimbursed by the Company's product development and licensing partners. Any reimbursed patent costs are recorded as product development and licensing agreement revenues in the Company's financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and directors is recognized using the straight-line method over the term of vesting or performance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Foreign Currency Translation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Net unrealized gains and losses resulting from foreign currency translation are included in other comprehensive income (loss). At December&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2014, accumulated other comprehensive income includes a net unrealized gain related to foreign currency translation of $2.6&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax basis. Quarterly, the Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company's tax provision in the period of change.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records uncertain tax positions in the financial statements only if it is more likely than not that the uncertain tax position will be sustained upon examination by the taxing authorities. The Company records interest and penalties related to uncertain tax positions in income tax expense.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes foreign currency translation adjustments and unrealized gains and losses on marketable securities in other comprehensive loss. The statements of operations and comprehensive loss reflect total comprehensive loss for the years ended December&amp;nbsp;31, 2015, 2014 and 2013.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Net Loss Per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Basic net loss per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common shares outstanding during the period when the effect is dilutive. The potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,110,239&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,015,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,770,544&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Restricted stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,500&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:12pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,129,739&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,022,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,776,544&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2014, the FASB issued a new U.S.&amp;nbsp;GAAP accounting standard that creates modifications to various other revenue accounting standards for specialized transactions and industries. The new U.S.&amp;nbsp;GAAP accounting standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB deferred the effective date of the new standard from January&amp;nbsp;1, 2017 to January&amp;nbsp;1, 2018. The amendment allows for two methods of adoption, a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. The Company will further study the implications of this standard in order to evaluate the expected impact on the financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In April 2015, the FASB issued amendments that provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The new guidance does not change the accounting for a customer's accounting for service contracts. The standard update is effective for fiscal years beginning after December&amp;nbsp;15, 2015 and interim periods within those years. Early adoption is permitted. The standard allows for adoption retrospectively or prospectively to all arrangements entered into or materially modified after the effective date. The amendment is not expected to have a material impact on our financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In August 2014, the FASB issued a new U.S.&amp;nbsp;GAAP accounting standard that provides guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new accounting standard requires management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The new accounting standard is effective for the annual period ending after December&amp;nbsp;15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not expect the adoption of this standard to have a material impact on the financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-4920000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-7328000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-10642000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2012" unitRef="Unit1" decimals="-3">95774000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">156000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">2745000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">2589000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">357094000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">64000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2012_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-264129000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013" unitRef="Unit1" decimals="-3">319795000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">82000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">2668000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">2586000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">662717000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">89000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-345679000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">211660000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">9000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">2590000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">2581000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">672739000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">90000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-463759000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">290105000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="Unit1" decimals="-3">-289000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">2307000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="Unit1" decimals="-3">2596000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">878655000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">99000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-590956000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;(11) STOCKHOLDERS' EQUITY&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Common Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In December 2013, the Company filed an automatic shelf registration statement with the Securities and Exchange Commission to register for sale any combination of the types of securities described in the shelf registration statement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;During the years ended December&amp;nbsp;31, 2015 and December&amp;nbsp;31, 2013, the Company issued 8,337,500 and 21,613,483 shares of its common stock in underwritten public offerings resulting in net proceeds to the Company of $188.8&amp;nbsp;million and $278.6&amp;nbsp;million, after deducting underwriting fees and offering expenses, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;During the year ended December&amp;nbsp;31, 2014, the Company entered into an amended and restated supply agreement with Biosyn Corporation. Under the supply agreement, Biosyn will manufacture and supply keyhole limpet hemocyanin (KLH) to the Company for use in connection with the development, manufacture or commercial sale of Rintega. In connection with the supply agreement, the Company issued to Biosyn 152,172 shares of its common stock having a value of $2.0&amp;nbsp;million. The Company is recording the $2.0&amp;nbsp;million to research and development expense through August 2021, the current term of the supply agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;During the year ended December&amp;nbsp;31, 2013, Company issued 2,433,608 shares of its common stock under a controlled equity offering sales agreement with Cantor Fitzgerald&amp;nbsp;&amp;amp;&amp;nbsp;Co., as amended, resulting in net proceeds to the Company of $17.1&amp;nbsp;million, after deducting commission and offering expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Convertible Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2015, the Company had authorized 3,000,000 shares of preferred stock all of which have been designated Class&amp;nbsp;C Preferred Stock including 350,000 shares which have been designated Series&amp;nbsp;C-1&amp;nbsp;Junior Participating Cumulative Preferred Stock (the "Series&amp;nbsp;C-1 Preferred Stock").&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">840228</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">193775</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember" unitRef="Unit14" decimals="INF">10798</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">755316</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember" unitRef="Unit14" decimals="INF">15755</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">152172</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit14" decimals="INF">21613483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2013_To_12_31_2013_cldx_StockIssuedByTypeOfProgramAxis_cldx_ControlledEquityOfferingProgramAmendedMember" unitRef="Unit14" decimals="INF">2433608</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">21613483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="INF">8337500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">8337500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="INF">2433608</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_us-gaap_PlanNameAxis_cldx_StockOptionAndIncentivePlan2008Member" unitRef="Unit14" decimals="INF">700561</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">5403000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">5402000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">1171000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">1170000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">4311000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">4310000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">2000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Duration_1_1_2014_To_12_31_2014_dei_LegalEntityAxis_cldx_BiosynCorporationMember" unitRef="Unit1" decimals="-5">2000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">2000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">278563000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_SubsidiarySaleOfStockAxis_cldx_UnderwrittenPublicOfferingMember" unitRef="Unit1" decimals="-5">278600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">278541000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">188840000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_SubsidiarySaleOfStockAxis_cldx_UnderwrittenPublicOfferingMember" unitRef="Unit1" decimals="-5">188800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">188832000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">17134000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">17132000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Duration_1_1_2013_To_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="As_Of_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit1" decimals="-5">20800000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="As_Of_12_31_2015_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit1" decimals="-5">14400000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2015_To_12_31_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (U.S.&amp;nbsp;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit1" decimals="-3">-35756000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">-48562000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-57085000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2013_To_12_31_2013" unitRef="Unit14" decimals="-3">79777000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit14" decimals="-3">89399000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="-3">97051000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cldx-20151231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.1.177.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2016 3:14:16 PM-->
<!--Modified on: 2/23/2016 3:14:16 PM-->
<xsd:schema targetNamespace="http://www.celldextherapeutics.com/20151231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:cldx="http://www.celldextherapeutics.com/20151231" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
        <link:definition>00201 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossDetails" id="DisclosureComprehensiveLossDetails">
        <link:definition>40301 - Disclosure - COMPREHENSIVE LOSS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40401 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesDetails">
        <link:definition>40501 - Disclosure - MARKETABLE SECURITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40601 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" id="DisclosureIntangibleAssetsAndGoodwillDetails">
        <link:definition>40701 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetailsCalc2" id="DisclosureIntangibleAssetsAndGoodwillDetailsCalc2">
        <link:definition>40702 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40801 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" id="DisclosureOtherLongTermLiabilitiesDetails">
        <link:definition>40901 - Disclosure - OTHER LONG-TERM LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetailsCalc2" id="DisclosureOtherLongTermLiabilitiesDetailsCalc2">
        <link:definition>40902 - Disclosure - OTHER LONG-TERM LIABILITIES (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetails" id="DisclosureIncomeTaxesSummaryDetails">
        <link:definition>41501 - Disclosure - INCOME TAXES - SUMMARY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesDetailsCalc2" id="DisclosureIncomeTaxesDetailsCalc2">
        <link:definition>41502 - Disclosure - INCOME TAXES (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview" id="DisclosureNatureOfBusinessAndOverview">
        <link:definition>10101 - Disclosure - NATURE OF BUSINESS AND OVERVIEW</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLoss" id="DisclosureComprehensiveLoss">
        <link:definition>10301 - Disclosure - COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>10501 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10601 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill" id="DisclosureIntangibleAssetsAndGoodwill">
        <link:definition>10701 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10801 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" id="DisclosureOtherLongTermLiabilities">
        <link:definition>10901 - Disclosure - OTHER LONG-TERM LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureTermLoan" id="DisclosureTermLoan">
        <link:definition>11001 - Disclosure - TERM LOAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11101 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11201 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>11301 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements" id="DisclosureCollaborationAgreements">
        <link:definition>11401 - Disclosure - COLLABORATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11501 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11601 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan" id="DisclosureRetirementSavingsPlan">
        <link:definition>11701 - Disclosure - RETIREMENT SAVINGS PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited" id="DisclosureSelectedQuarterlyFinancialDataUnaudited">
        <link:definition>11801 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossTables" id="DisclosureComprehensiveLossTables">
        <link:definition>30303 - Disclosure - COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>30503 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30603 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillTables" id="DisclosureIntangibleAssetsAndGoodwillTables">
        <link:definition>30703 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30803 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables" id="DisclosureOtherLongTermLiabilitiesTables">
        <link:definition>30903 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31203 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31503 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables" id="DisclosureSelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>31803 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverviewDetails" id="DisclosureNatureOfBusinessAndOverviewDetails">
        <link:definition>40101 - Disclosure - NATURE OF BUSINESS AND OVERVIEW (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
        <link:definition>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONCENTRATION OF CREDIT RISK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationDetails">
        <link:definition>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - FOREIGN CURRENCY TRANSLATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails">
        <link:definition>40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - DILUTIVE COMMON SHARES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureTermLoanDetails" id="DisclosureTermLoanDetails">
        <link:definition>41001 - Disclosure - TERM LOAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>41101 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" id="DisclosureStockBasedCompensationSummaryOfPlansDetails">
        <link:definition>41201 - Disclosure - STOCK-BASED COMPENSATION - SUMMARY OF PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationAndExpensesInformationDetails" id="DisclosureStockBasedCompensationValuationAndExpensesInformationDetails">
        <link:definition>41202 - Disclosure - STOCK-BASED COMPENSATION - VALUATION AND EXPENSES INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
        <link:definition>41301 - Disclosure - REVENUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreementsDetails" id="DisclosureCollaborationAgreementsDetails">
        <link:definition>41401 - Disclosure - COLLABORATION AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" id="DisclosureIncomeTaxesCarryforwardsDetails">
        <link:definition>41502 - Disclosure - INCOME TAXES - CARRYFORWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlanDetails" id="DisclosureRetirementSavingsPlanDetails">
        <link:definition>41701 - Disclosure - RETIREMENT SAVINGS PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails" id="DisclosureSelectedQuarterlyFinancialDataUnauditedDetails">
        <link:definition>41801 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cldx-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cldx-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cldx-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cldx-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
  <xsd:element name="PRFAgreementMember" id="cldx_PRFAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RotarixRotavirusVaccineMember" id="cldx_RotarixRotavirusVaccineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" id="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfInterestInNetRoyaltiesSold" id="cldx_PercentageOfInterestInNetRoyaltiesSold" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionAndIncentivePlan2008Member" id="cldx_StockOptionAndIncentivePlan2008Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" id="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" id="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" id="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" id="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsMember" id="cldx_LicenseAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MedarexIncMember" id="cldx_MedarexIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RockefellerUniversityMember" id="cldx_RockefellerUniversityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DukeUniversityBrainTumorCancerCenterMember" id="cldx_DukeUniversityBrainTumorCancerCenterMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PatentCostsPolicyTextBlock" id="cldx_PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BasisOfPresentationAbstract" id="cldx_BasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GlaxoSmithKlinePlcMember" id="cldx_GlaxoSmithKlinePlcMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LaboratoryEquipmentMember" id="cldx_LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManufacturingEquipmentMember" id="cldx_ManufacturingEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CuraGenCorporationMember" id="cldx_CuraGenCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentContractCostsCurrent" id="cldx_AccruedResearchAndDevelopmentContractCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="cldx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="cldx_RevenueFromProductDevelopmentAndLicensingAgreements" name="RevenueFromProductDevelopmentAndLicensingAgreements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_RevenueFromContractsAndGrants" name="RevenueFromContractsAndGrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="SignificantRevenueArrangementsDisclosureAbstract" id="cldx_SignificantRevenueArrangementsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantRevenueArrangementsDisclosureTextBlock" id="cldx_SignificantRevenueArrangementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementDisclosureAbstract" id="cldx_CollaborativeArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" id="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmgenAmendmentMember" id="cldx_AmgenAmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CoreTechnologyMember" id="cldx_CoreTechnologyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentLenderDomain" id="cldx_DebtInstrumentLenderDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MidCapFinancialLLCMember" id="cldx_MidCapFinancialLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedByTypeOfProgramDomain" id="cldx_StockIssuedByTypeOfProgramDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ControlledEquityOfferingProgramAmendedMember" id="cldx_ControlledEquityOfferingProgramAmendedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GeneralElectricCapitalCorporationMember" id="cldx_GeneralElectricCapitalCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" id="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredIncomeFromSaleOfTaxBenefits" id="cldx_DeferredIncomeFromSaleOfTaxBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ValueOfTaxBenefitsAgreedToBeSold" id="cldx_ValueOfTaxBenefitsAgreedToBeSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PeriodForWhichBaseOfOperationsMustBeMaintained" id="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentLenderAxis" id="cldx_DebtInstrumentLenderAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedByTypeOfProgramAxis" id="cldx_StockIssuedByTypeOfProgramAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" id="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityTable" id="cldx_StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityLineItems" id="cldx_StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="USGovernmentAndMunicipalObligationsMember" id="cldx_USGovernmentAndMunicipalObligationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" id="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" id="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LudwigInstituteForCancerResearchMember" id="cldx_LudwigInstituteForCancerResearchMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AlterisTherapeuticsIncMember" id="cldx_AlterisTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UniversityOfSouthamptonUKMember" id="cldx_UniversityOfSouthamptonUKMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmgenIncMember" id="cldx_AmgenIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeattleGeneticIncMember" id="cldx_SeattleGeneticIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonRefundableLicenseFee" id="cldx_NonRefundableLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" id="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementTotalPotentialMilestonePayments" id="cldx_CollaborativeArrangementTotalPotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <element id="cldx_CollaborativeArrangementAgreementTerm" name="CollaborativeArrangementAgreementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" id="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets" id="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsLiabilitiesGross" id="cldx_DeferredTaxAssetsLiabilitiesGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" id="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AVANTMember" id="cldx_AVANTMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossAndTaxCreditCarryforwardsLineItems" id="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossCarryforwardsAnnualLimitationAmount" id="cldx_OperatingLossCarryforwardsAnnualLimitationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossCarryforwardsNetOfExpirationsAndUtilization" id="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossCarryforwardsWithLimitationsOnUse" id="cldx_OperatingLossCarryforwardsWithLimitationsOnUse" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" id="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OwnershipChangeAxis" id="cldx_OwnershipChangeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OwnershipChangeDomain" id="cldx_OwnershipChangeDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="cldx_OwnershipChangesInJune2009AndDecember2009Member" name="OwnershipChangesInJune2009AndDecember2009Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" id="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PriorToAcquisitionMember" id="cldx_PriorToAcquisitionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PriorToMergerMember" id="cldx_PriorToMergerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StatusOfMergerAndAcquisitionAxis" id="cldx_StatusOfMergerAndAcquisitionAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StatusOfMergerAndAcquisitionDomain" id="cldx_StatusOfMergerAndAcquisitionDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" id="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossAndTaxCreditCarryforwardsTable" id="cldx_OperatingLossAndTaxCreditCarryforwardsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" id="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyAgreementMember" id="cldx_RoyaltyAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CincinnatiChildrensHospitalMedicalCenterMember" id="cldx_CincinnatiChildrensHospitalMedicalCenterMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" id="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ValueAtWhichTaxBenefitsSold" id="cldx_ValueAtWhichTaxBenefitsSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FairValueAssetsAmountTransfersBetweenMeasurementLevels" id="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" id="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <element id="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" name="AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="AccumulatedOtherComprehensiveIncomeLossRollForward" id="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RepaymentOfLongTermDebtPrincipalAmount" id="cldx_RepaymentOfLongTermDebtPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentInterestAndPrepaymentFees" id="cldx_DebtInstrumentInterestAndPrepaymentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" id="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <element id="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" name="CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" id="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ExpectedDividendPayableInForeseeableFuture" id="cldx_ExpectedDividendPayableInForeseeableFuture" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <element id="cldx_ReimbursementOfExternalCostsIncurredPercentage" name="ReimbursementOfExternalCostsIncurredPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_BiosynCorporationMember" name="BiosynCorporationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="GlembatumumabVedotinMember" id="cldx_GlembatumumabVedotinMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Cdx014Member" id="cldx_Cdx014Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock" name="ScheduleOfOtherLongTermLiabilitiesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_BristolMeyersSquibbCompanyMember" name="BristolMeyersSquibbCompanyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_OwnershipChangeInDecember2013Member" name="OwnershipChangeInDecember2013Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_Pd1ImmuneCheckpointInhibitorMember" name="Pd1ImmuneCheckpointInhibitorMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_DrugCandidatesInClinicalDevelopment" name="DrugCandidatesInClinicalDevelopment" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" name="NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cldx-20151231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.1.177.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2016 3:14:16 PM-->
<!--Modified on: 2/23/2016 3:14:16 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementBalanceSheets" roleURI="http://www.celldextherapeutics.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureComprehensiveLossDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIntangibleAssetsAndGoodwillDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIntangibleAssetsAndGoodwillDetailsCalc2" roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureOtherLongTermLiabilitiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureOtherLongTermLiabilitiesDetailsCalc2" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIncomeTaxesSummaryDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIncomeTaxesDetailsCalc2" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635918372543177449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_635918372543177449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635918372543187449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635918372543177449" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635918372543187449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_635918372543187449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635918372543177449" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_635918372543187449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_635918372543187449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635918372543177449" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_635918372543187449" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635918372543187449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635918372543177449" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635918372543187449" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635918372543187449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635918372543187449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_635918372543187449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_635918372543187449" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_635918372543187449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_635918372543187449" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_635918372543187449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill_635918372543187449" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635918372543217449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_635918372543217449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635918372543217449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635918372543217449" xlink:to="us-gaap_LiabilitiesCurrent_635918372543217449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635918372543217449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635918372543217449" xlink:to="us-gaap_AccountsPayableCurrent_635918372543217449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635918372543217449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635918372543217449" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635918372543217449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_635918372543217449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635918372543217449" xlink:to="us-gaap_OtherLiabilitiesCurrent_635918372543217449" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635918372543217449" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_635918372543227449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_635918372543227449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635918372543227449" xlink:to="us-gaap_PreferredStockValue_635918372543227449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635918372543227449" xlink:to="us-gaap_CommonStockValue_635918372543227449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635918372543227449" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_635918372543227449" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635918372543227449" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635918372543227449" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635918372543227449" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635918372543227449" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_OperatingIncomeLoss_635918372543227449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_635918372543227449" xlink:to="us-gaap_Revenues_635918372543227449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_635918372543227449" xlink:to="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_635918372543227449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="cldx_RevenueFromContractsAndGrants_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_635918372543227449" xlink:to="cldx_RevenueFromContractsAndGrants_635918372543227449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_635918372543227449" xlink:to="us-gaap_RoyaltyRevenue_635918372543227449" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_635918372543227449" xlink:to="us-gaap_CostsAndExpenses_635918372543227449" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_635918372543227449" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635918372543227449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_635918372543227449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_635918372543227449" xlink:to="us-gaap_RoyaltyExpense_635918372543227449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_635918372543227449" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635918372543237449" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_635918372543227449" xlink:to="us-gaap_AmortizationOfIntangibleAssets_635918372543237449" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_InterestAndOtherIncome_635918372543237449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_InterestExpense_635918372543237449" order="3" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xlink:type="extended" xlink:title="00201 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372543237449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635918372543237449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_635918372543237449" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372543237449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_DepreciationDepletionAndAmortization_635918372543237449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_AmortizationOfIntangibleAssets_635918372543237449" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_635918372543237449" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_MarketableSecuritiesGainLoss_635918372543237449" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_635918372543237449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_635918372543237449" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_ShareBasedCompensation_635918372543247449" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_635918372543247449" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_635918372543247449" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635918372543247449" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_635918372543247449" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635918372543247449" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372543237449" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_635918372543247449" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635918372543247449" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635918372543247449" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_635918372543247449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635918372543247449" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_635918372543247449" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635918372543247449" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635918372543247449" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635918372543247449" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_635918372543247449" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635918372543247449" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635918372543247449" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635918372543247449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_635918372543247449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635918372543247449" xlink:to="us-gaap_ProceedsFromStockPlans_635918372543247449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt_635918372543257449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635918372543247449" xlink:to="us-gaap_RepaymentsOfSecuredDebt_635918372543257449" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_635918372543257449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635918372543247449" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_635918372543257449" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_635918372543337449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_635918372543337449" order="4" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossDetails" xlink:type="extended" xlink:title="40301 - Disclosure - COMPREHENSIVE LOSS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_635918372543347449" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635918372543347449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecurities_635918372543347449" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - MARKETABLE SECURITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_635918372543347449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_635918372543347449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_635918372543347449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_635918372543347449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_635918372543347449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_635918372543347449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_635918372543347449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_635918372543347449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_635918372543347449" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_635918372543357449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_635918372543357449" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xlink:type="extended" xlink:title="40701 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_635918372543357449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_635918372543357449" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_635918372543357449" order="1" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_635918372543357449" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetailsCalc2" xlink:type="extended" xlink:title="40702 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_635918372543357449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_635918372543357449" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_635918372543357449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_635918372543357449" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635918372543357449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:label="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_635918372543357449" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635918372543357449" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635918372543357449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635918372543357449" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - OTHER LONG-TERM LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent_635918372543367449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_635918372543367449" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetailsCalc2" xlink:type="extended" xlink:title="40902 - Disclosure - OTHER LONG-TERM LIABILITIES (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_DeferredRentCredit_635918372543367449" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_635918372543367449" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredIncomeFromSaleOfTaxBenefits" xlink:label="cldx_DeferredIncomeFromSaleOfTaxBenefits_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="cldx_DeferredIncomeFromSaleOfTaxBenefits_635918372543367449" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_DeferredRevenue_635918372543367449" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetails" xlink:type="extended" xlink:title="41501 - Disclosure - INCOME TAXES - SUMMARY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_635918372543367449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsLiabilitiesGross" xlink:label="cldx_DeferredTaxAssetsLiabilitiesGross_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="cldx_DeferredTaxAssetsLiabilitiesGross_635918372543367449" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_DeferredTaxAssetsLiabilitiesGross_635918372543367449" xlink:to="us-gaap_DeferredTaxAssetsGross_635918372543367449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635918372543367449" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_635918372543367449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635918372543367449" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_635918372543367449" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635918372543367449" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_635918372543367449" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635918372543367449" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_635918372543367449" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635918372543367449" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_635918372543367449" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635918372543367449" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_635918372543367449" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635918372543367449" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_635918372543367449" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_635918372543367449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_DeferredTaxAssetsLiabilitiesGross_635918372543367449" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_635918372543367449" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets" xlink:label="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_635918372543367449" xlink:to="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets_635918372543377449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" xlink:label="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_635918372543367449" xlink:to="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_635918372543377449" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_635918372543377449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_635918372543377449" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_635918372543377449" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_635918372543377449" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:label="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_635918372543377449" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_635918372543377449" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesDetailsCalc2" xlink:type="extended" xlink:title="41502 - Disclosure - INCOME TAXES (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_635918372543377449" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" xlink:label="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_635918372543377449" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_635918372543377449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_635918372543377449" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_635918372543377449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_635918372543387449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_635918372543377449" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_635918372543387449" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:label="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_635918372543387449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_635918372543377449" xlink:to="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_635918372543387449" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635918372543387449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635918372543387449" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635918372543387449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635918372543387449" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635918372543387449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635918372543387449" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_635918372543387449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_635918372543387449" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635918372543387449" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635918372543387449" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cldx-20151231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.1.177.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2016 3:14:16 PM-->
<!--Modified on: 2/23/2016 3:14:16 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DocumentAndEntityInformationAbstract" xlink:label="cldx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="cldx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents at Beginning of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts and Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts and Other Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less Current Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Portion of Long-Term Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Long-Term Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingent Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, $.01 Par Value; 3,000,000 Shares Authorized; No Shares Issued and Outstanding at December 31, 2015 and 2014</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, $.001 Par Value; 297,000,000 Shares Authorized; 98,685,595 and 89,592,779 Shares Issued and Outstanding at December 31, 2015 and 2014, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">StockholdersEquity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Par Value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par Value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares common stock issued in connection with supply agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVENUE:</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:to="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents revenue from product development and licensing agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Product Development and Licensing Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Development and Licensing Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product development and licensing agreements revenue</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="cldx_RevenueFromContractsAndGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_RevenueFromContractsAndGrants" xlink:to="cldx_RevenueFromContractsAndGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_RevenueFromContractsAndGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents revenue earned during the period arising from products sold or services provided under the terms of a contract. Also include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_RevenueFromContractsAndGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contracts and Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_RevenueFromContractsAndGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contracts and Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cldx_RevenueFromContractsAndGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contracts and grants revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Royalties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING EXPENSE:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product royalty expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense for intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Acquired Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Operating Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment and Other Income, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-tax loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Loss Per Common Share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted net loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Used in Calculating Basic and Diluted Net Loss per Share (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMPREHENSIVE LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMPREHENSIVE LOSS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive (Loss) Income:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation Adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Losses on Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Loss on Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued under Stock Option and Employee Stock Purchase Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued under Stock Option and Employee Stock Purchase Plans (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued under the plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued In Connection With Cantor Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued in Connection with Cantor Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued in Connection with Cantor Agreement (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued in Connection with Supply Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued In Connection With Supply Agreement Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued in Connection with Supply Agreement (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued in Underwritten Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from sale of stock in an underwritten public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued in Underwritten Offering (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization and Premium of Marketable Securities, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized (Gain) Loss on Sales and Maturities of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized Gain on Sales and Maturities of Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on Sale or Disposal of Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cash Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Operating Assets and Liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts and Other Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Used in Operating Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Investing Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and Maturities of Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale or Disposal of Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Used in Investing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from sale of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds from Stock Issuances</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Stock from Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Secured Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Term Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Other Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Other Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by Financing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate Changes on Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Increase (Decrease) in Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Disclosure of Cash Flow Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Paid for Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash Investing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in Progress Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued construction in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF BUSINESS AND OVERVIEW</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF BUSINESS AND OVERVIEW</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss) Note [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MARKETABLE SECURITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MARKETABLE SECURITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INTANGIBLE ASSETS AND GOODWILL</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INTANGIBLE ASSETS AND GOODWILL</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUED EXPENSES.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER LONG-TERM LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER LONG-TERM LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TERM LOAN.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TERM LOAN</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_SignificantRevenueArrangementsDisclosureAbstract" xlink:label="cldx_SignificantRevenueArrangementsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_SignificantRevenueArrangementsDisclosureAbstract" xlink:to="cldx_SignificantRevenueArrangementsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_SignificantRevenueArrangementsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVENUE.</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_SignificantRevenueArrangementsDisclosureTextBlock" xlink:label="cldx_SignificantRevenueArrangementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_SignificantRevenueArrangementsDisclosureTextBlock" xlink:to="cldx_SignificantRevenueArrangementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_SignificantRevenueArrangementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element may be used to capture the complete disclosure pertaining to an entity's significant revenue contracts and arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_SignificantRevenueArrangementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Revenue Arrangements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_SignificantRevenueArrangementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVENUE</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementDisclosureAbstract" xlink:label="cldx_CollaborativeArrangementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CollaborativeArrangementDisclosureAbstract" xlink:to="cldx_CollaborativeArrangementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COLLABORATION AGREEMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COLLABORATION AGREEMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RETIREMENT SAVINGS PLAN</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RETIREMENT SAVINGS PLAN</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk and of Significant Customers and Suppliers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible and Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PatentCostsPolicyTextBlock" xlink:label="cldx_PatentCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_PatentCostsPolicyTextBlock" xlink:to="cldx_PatentCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of changes in accumulated other comprehensive income (loss) by component</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets subject to fair value measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of intangible assets, net of accumulated amortization, and goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock" xlink:label="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock" xlink:to="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of other long-term liabilities, not separately disclosed on the balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other Long Term Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of restricted stock activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used for the fair values of employee stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of income tax expense attributable to continuing operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation between the amount of reported income tax and the amount computed using the U.S. Statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of principal components of the deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of obligations for base rent and CAM costs under facility and other non-cancelable operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of selected quarterly financial data (unaudited)</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DrugCandidatesInClinicalDevelopment" xlink:label="cldx_DrugCandidatesInClinicalDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DrugCandidatesInClinicalDevelopment" xlink:to="cldx_DrugCandidatesInClinicalDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DrugCandidatesInClinicalDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of drug candidates in clinical development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DrugCandidatesInClinicalDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Drug Candidates In Clinical Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_DrugCandidatesInClinicalDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates in clinical development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments and Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesMember" xlink:to="us-gaap_SalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer concentration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name Of Major Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BristolMeyersSquibbCompanyMember" xlink:label="cldx_BristolMeyersSquibbCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_BristolMeyersSquibbCompanyMember" xlink:to="cldx_BristolMeyersSquibbCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_BristolMeyersSquibbCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Bristol Meyers Squibb Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_BristolMeyersSquibbCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bristol Meyers Squibb Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_BristolMeyersSquibbCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk (as a percent)</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BasisOfPresentationAbstract" xlink:label="cldx_BasisOfPresentationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_BasisOfPresentationAbstract" xlink:to="cldx_BasisOfPresentationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LaboratoryEquipmentMember" xlink:label="cldx_LaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_LaboratoryEquipmentMember" xlink:to="cldx_LaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Furniture and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ManufacturingEquipmentMember" xlink:label="cldx_ManufacturingEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ManufacturingEquipmentMember" xlink:to="cldx_ManufacturingEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ManufacturingEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to manufacturing equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ManufacturingEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ManufacturingEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of CuraGen Corporation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTranslationAbstract" xlink:label="us-gaap_ForeignCurrencyTranslationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTranslationAbstract" xlink:to="us-gaap_ForeignCurrencyTranslationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTranslationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTranslationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net unrealized gain related to foreign currency translation included in accumulated other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss) [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Net Unrealized Investment Gain Loss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain (Loss) on Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="us-gaap_AccumulatedTranslationAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="us-gaap_AccumulatedTranslationAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedTranslationAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Translation Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedTranslationAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" xlink:label="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" xlink:to="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in accumulated other comprehensive income (loss) by component</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive (loss) income before reclassifications</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net current-period other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets at fair value</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels" xlink:label="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels" xlink:to="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of transfer of assets measured on a recurring basis between Level 1, Level 2 and Level 3 of the fair value hierarchy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets Amount Transfers between Measurement Levels</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred between the fair value measurement classifications</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" xlink:label="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" xlink:to="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of transfer of liabilities measured on a recurring basis between Level 1, Level 2 and Level 3 of the fair value hierarchy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Liabilities Amount Transfers between Measurement Levels</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities transferred between the fair value measurement classifications</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types of Debt and Equity Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types Of Debt And Equity Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types of Debt and Equity Securities [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_USGovernmentAndMunicipalObligationsMember" xlink:label="cldx_USGovernmentAndMunicipalObligationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_USGovernmentAndMunicipalObligationsMember" xlink:to="cldx_USGovernmentAndMunicipalObligationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_USGovernmentAndMunicipalObligationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents securities issued by US government agencies and municipal governments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_USGovernmentAndMunicipalObligationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Government And Municipal Obligations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_USGovernmentAndMunicipalObligationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. government and municipal obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Maturities, Amortized Cost Basis, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturing in one year or less</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of available-for-sale debt securities at cost, net of adjustments, maturing in the second fiscal year through the third fiscal year following the latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities, Debt Maturities after One Through Three Years, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturing after one year through three years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Debt Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Gross Unrealized Gain [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the gross unrealized gains on securities, at a point in time, for those securities which are expected to mature within one year of the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities, Debt Maturities within One Year Gross Unrealized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturing in one year or less</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the gross unrealized gains on securities, at a point in time, for those securities which are expected to mature after one year and through three years from the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities, Debt Maturities after One Through Three Years, Gross Unrealized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturing after one year through three years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xlink:label="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xlink:to="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities, Gross Unrealized Losses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the gross unrealized losses on securities, at a point in time, which are expected to mature within one year of the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities, Debt Maturities within One Year, Gross Unrealized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturing in one year or less</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the gross unrealized losses on securities, at a point in time, which are expected to mature after one year and through three years from the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities, Debt Maturities after One Through Three Years, Gross Unrealized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturing after one year through three years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturing in one year or less</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of available-for-sale debt securities at fair value maturing in the second fiscal year through the third fiscal year following the latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities, Debt Maturities after One Through Three Years, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturing after one year through three years</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" xlink:label="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" xlink:to="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of investment in debt and equity securities considered to be other-than-temporarily impaired, categorized neither as held-to-maturity nor trading.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities, Considered to be Other than Temporarily Impaired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities considered to be other-than-temporarily impaired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest included in marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in Progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less Accumulated Depreciation and Amortization</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of the carrying value of purchased amortizable finite-lived intangible assets, including disclosure of the carrying value of indefinite-lived intangible assets not subject to amortization, excluding goodwill, in total and by major class.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite Lived and Indefinite Lived Intangible Assets by Major Class [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived Intangible Assets [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AmgenAmendmentMember" xlink:label="cldx_AmgenAmendmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AmgenAmendmentMember" xlink:to="cldx_AmgenAmendmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AmgenAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to an amendment to the license agreement, Amgen Amendment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AmgenAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amgen Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AmgenAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amgen Amendment</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CoreTechnologyMember" xlink:label="cldx_CoreTechnologyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CoreTechnologyMember" xlink:to="cldx_CoreTechnologyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_CoreTechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the core technology of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CoreTechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Core Technology [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_CoreTechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Core Technology</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite Lived and Indefinite Lived Intangible Assets by Major Class [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets and Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived intangible assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-lived intangible asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Gross (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of total intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated future amortization expense of intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Payroll and Employee Benefits</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:label="cldx_AccruedResearchAndDevelopmentContractCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:to="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development contract costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Contract Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Contract Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Deferred Tax Liability related to IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredIncomeFromSaleOfTaxBenefits" xlink:label="cldx_DeferredIncomeFromSaleOfTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DeferredIncomeFromSaleOfTaxBenefits" xlink:to="cldx_DeferredIncomeFromSaleOfTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DeferredIncomeFromSaleOfTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the deferred income from the sale of tax benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DeferredIncomeFromSaleOfTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income from Sale of Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_DeferredIncomeFromSaleOfTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income from Sale of Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ValueOfTaxBenefitsAgreedToBeSold" xlink:label="cldx_ValueOfTaxBenefitsAgreedToBeSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ValueOfTaxBenefitsAgreedToBeSold" xlink:to="cldx_ValueOfTaxBenefitsAgreedToBeSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ValueOfTaxBenefitsAgreedToBeSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the value of tax benefits agreed to be sold by the entity during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ValueOfTaxBenefitsAgreedToBeSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of Tax Benefits Agreed to be Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ValueOfTaxBenefitsAgreedToBeSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount at which New Jersey tax benefit agreed to be sold</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ValueAtWhichTaxBenefitsSold" xlink:label="cldx_ValueAtWhichTaxBenefitsSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ValueAtWhichTaxBenefitsSold" xlink:to="cldx_ValueAtWhichTaxBenefitsSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ValueAtWhichTaxBenefitsSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the value at which tax benefit sold by the entity during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ValueAtWhichTaxBenefitsSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value at which Tax Benefits Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ValueAtWhichTaxBenefitsSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of sale of New Jersey tax benefit</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PeriodForWhichBaseOfOperationsMustBeMaintained" xlink:label="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained" xlink:to="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents period for which base of operations must be maintained in New Jersey.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which Base of Operations Must be Maintained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which base of operations must be maintained</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income related to sale of tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentLenderAxis" xlink:label="cldx_DebtInstrumentLenderAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DebtInstrumentLenderAxis" xlink:to="cldx_DebtInstrumentLenderAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DebtInstrumentLenderAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The information pertaining to the debt instrument by lender.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DebtInstrumentLenderAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Lender [Axis]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentLenderDomain" xlink:label="cldx_DebtInstrumentLenderDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DebtInstrumentLenderDomain" xlink:to="cldx_DebtInstrumentLenderDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DebtInstrumentLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Identification of the lender, who may be a single entity (for example, a bank, pension fund or venture capital firm) or a group of entities which participate in the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DebtInstrumentLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Lender [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_DebtInstrumentLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Lender [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_MidCapFinancialLLCMember" xlink:label="cldx_MidCapFinancialLLCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_MidCapFinancialLLCMember" xlink:to="cldx_MidCapFinancialLLCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_MidCapFinancialLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to MidCap Financial, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_MidCapFinancialLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mid Cap Financial L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_MidCapFinancialLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MidCap</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GeneralElectricCapitalCorporationMember" xlink:label="cldx_GeneralElectricCapitalCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_GeneralElectricCapitalCorporationMember" xlink:to="cldx_GeneralElectricCapitalCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_GeneralElectricCapitalCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to General Electric Capital Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_GeneralElectricCapitalCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General Electric Capital Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_GeneralElectricCapitalCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GECC</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount borrowed</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RepaymentOfLongTermDebtPrincipalAmount" xlink:label="cldx_RepaymentOfLongTermDebtPrincipalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_RepaymentOfLongTermDebtPrincipalAmount" xlink:to="cldx_RepaymentOfLongTermDebtPrincipalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_RepaymentOfLongTermDebtPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of principal repaid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_RepaymentOfLongTermDebtPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of Long Term Debt Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_RepaymentOfLongTermDebtPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of principal amount</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentInterestAndPrepaymentFees" xlink:label="cldx_DebtInstrumentInterestAndPrepaymentFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DebtInstrumentInterestAndPrepaymentFees" xlink:to="cldx_DebtInstrumentInterestAndPrepaymentFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DebtInstrumentInterestAndPrepaymentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of interest, prepayment and final payment fees paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DebtInstrumentInterestAndPrepaymentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest and Prepayment Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_DebtInstrumentInterestAndPrepaymentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of interest, prepayment and final payment fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLongTermDebt" xlink:to="us-gaap_InterestExpenseLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on the term loan</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockholdersEquityTable" xlink:label="cldx_StockholdersEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_StockholdersEquityTable" xlink:to="cldx_StockholdersEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_StockholdersEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information pertaining to changes in stockholders' equity during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_StockholdersEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity [Table]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockIssuedByTypeOfProgramAxis" xlink:label="cldx_StockIssuedByTypeOfProgramAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_StockIssuedByTypeOfProgramAxis" xlink:to="cldx_StockIssuedByTypeOfProgramAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_StockIssuedByTypeOfProgramAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A categorization of various plans or programs under which stock of the entity is issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_StockIssuedByTypeOfProgramAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued by Type of Program [Axis]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockIssuedByTypeOfProgramDomain" xlink:label="cldx_StockIssuedByTypeOfProgramDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_StockIssuedByTypeOfProgramDomain" xlink:to="cldx_StockIssuedByTypeOfProgramDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_StockIssuedByTypeOfProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A group of different programs or plans under which stock of the entity is issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_StockIssuedByTypeOfProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued By Type Of Program [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_StockIssuedByTypeOfProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued by Type of Program [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ControlledEquityOfferingProgramAmendedMember" xlink:label="cldx_ControlledEquityOfferingProgramAmendedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ControlledEquityOfferingProgramAmendedMember" xlink:to="cldx_ControlledEquityOfferingProgramAmendedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ControlledEquityOfferingProgramAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Controlled Equity Offering Program of the entity, as amended, through which shares of common stock may be publicly offered and sold through Cantor Fitzgerald and Co. ("Cantor") in privately negotiated and/or at-the-market transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ControlledEquityOfferingProgramAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Controlled Equity Offering Program Amended [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ControlledEquityOfferingProgramAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Amendment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class C Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CumulativePreferredStockMember" xlink:label="us-gaap_CumulativePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativePreferredStockMember" xlink:to="us-gaap_CumulativePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-1 Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockholdersEquityLineItems" xlink:label="cldx_StockholdersEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="cldx_StockholdersEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_StockholdersEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_StockholdersEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_StockholdersEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" xlink:label="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" xlink:to="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Celldex Research's 2005 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Celldex Research Equity Incentive Plan2005 And Cura Gen Stock Plan2007 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Celldex Research 2005 Plan</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockOptionAndIncentivePlan2008Member" xlink:label="cldx_StockOptionAndIncentivePlan2008Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_StockOptionAndIncentivePlan2008Member" xlink:to="cldx_StockOptionAndIncentivePlan2008Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_StockOptionAndIncentivePlan2008Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2008 Stock Option and Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_StockOptionAndIncentivePlan2008Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option And Incentive Plan2008 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_StockOptionAndIncentivePlan2008Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2008 Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xlink:to="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an employee, consultant or non-employee director is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the holder pays the strike value in cash to the issuing entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize recipients, in addition to other compensation and other benefits, if any.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Consultant And Non Employee Director Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price as a percentage of the lower of the fair market value of the common stock at either the beginning of the offering period or the applicable exercise date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum shares of common stock to be issued for grants (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time, from the grant date until the time at which the share-based option award expires.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation, Arrangements by Share Based Payment, Award, Options, Expiration Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms of options</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of options granted to the holders of more than 10 percent of voting stock of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements by Share Based Payment Award, Options, Expiration Term for Holders of More than Ten Percent of Voting Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms of options granted to the holders of more than 10% of the voting stock</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold percentage of voting stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation, Arrangements by Share Based Payment, Award, Options, Threshold Percentage of Voting Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage of voting stock</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise price as a percentage of the fair market for options granted to the holders of than 10 percent of voting stock of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements by Share Based Payment Award, Options, Exercise Price as Percentage of Fair Market Value for Holders of More than Ten Percent of Voting Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price as a percentage of fair market value for options granted to the holders of more than 10% of the voting stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding at beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canceled (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Vested and Expected to Vest at the end of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercisable at the end of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available for Grant (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding at beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canceled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Vested and Expected to Vest at the end of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercisable at the end of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Vested and Expected to Vest at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercisable at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total intrinsic value of stock options exercised (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant-date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of stock options vested (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of stock options outstanding (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of stock options vested and expected to vest (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total compensation cost not yet recognized (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period over which compensation cost is expected to be recognized as expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding and unvested at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding and unvested at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding and unvested at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding and unvested at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation and Expenses Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense (in dollars)</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ExpectedDividendPayableInForeseeableFuture" xlink:label="cldx_ExpectedDividendPayableInForeseeableFuture" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ExpectedDividendPayableInForeseeableFuture" xlink:to="cldx_ExpectedDividendPayableInForeseeableFuture_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ExpectedDividendPayableInForeseeableFuture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of expected dividend payable in foreseeable future.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ExpectedDividendPayableInForeseeableFuture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Dividend Payable in Foreseeable Future</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ExpectedDividendPayableInForeseeableFuture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend payable in foreseeable future</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions used for fair values of employee and director stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, minimum (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, minimum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, maximum (as a perecnt)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected option term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" xlink:label="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" xlink:to="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to collaboration arrangement for development and commercialization of product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement For Development And Commercialization Of Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration arrangement for development and commercialization of oral rotavirus strain</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LicenseAgreementsMember" xlink:label="cldx_LicenseAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_LicenseAgreementsMember" xlink:to="cldx_LicenseAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_LicenseAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to the license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_LicenseAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_LicenseAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreements</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RoyaltyAgreementMember" xlink:label="cldx_RoyaltyAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_RoyaltyAgreementMember" xlink:to="cldx_RoyaltyAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_RoyaltyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to royalty agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_RoyaltyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_RoyaltyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GlaxoSmithKlinePlcMember" xlink:label="cldx_GlaxoSmithKlinePlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_GlaxoSmithKlinePlcMember" xlink:to="cldx_GlaxoSmithKlinePlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_GlaxoSmithKlinePlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Glaxo SmithKline plc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_GlaxoSmithKlinePlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Glaxo Smith Kline Plc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_GlaxoSmithKlinePlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Glaxo</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CincinnatiChildrensHospitalMedicalCenterMember" xlink:label="cldx_CincinnatiChildrensHospitalMedicalCenterMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CincinnatiChildrensHospitalMedicalCenterMember" xlink:to="cldx_CincinnatiChildrensHospitalMedicalCenterMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_CincinnatiChildrensHospitalMedicalCenterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Cincinnati Children's Hospital Medical Center.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CincinnatiChildrensHospitalMedicalCenterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cincinnati Childrens Hospital Medical Center [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_CincinnatiChildrensHospitalMedicalCenterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cincinnati Children's Hospital Medical Center</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PRFAgreementMember" xlink:label="cldx_PRFAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_PRFAgreementMember" xlink:to="cldx_PRFAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_PRFAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to the agreement with Paul Royalty Fund II, L.P. (PRF).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_PRFAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">P R F Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_PRFAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRF</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_Pd1ImmuneCheckpointInhibitorMember" xlink:label="cldx_Pd1ImmuneCheckpointInhibitorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_Pd1ImmuneCheckpointInhibitorMember" xlink:to="cldx_Pd1ImmuneCheckpointInhibitorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_Pd1ImmuneCheckpointInhibitorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the product PD-1 immune checkpoint inhibitor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_Pd1ImmuneCheckpointInhibitorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pd1 Immune Checkpoint Inhibitor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_Pd1ImmuneCheckpointInhibitorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PD-1 Immune Checkpoint Inhibitor</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RotarixRotavirusVaccineMember" xlink:label="cldx_RotarixRotavirusVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_RotarixRotavirusVaccineMember" xlink:to="cldx_RotarixRotavirusVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_RotarixRotavirusVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information related to the product Rotarix rotavirus vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_RotarixRotavirusVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rotarix Rotavirus Vaccine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_RotarixRotavirusVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rotarix</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVENUE</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementAgreementTerm" xlink:label="cldx_CollaborativeArrangementAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CollaborativeArrangementAgreementTerm" xlink:to="cldx_CollaborativeArrangementAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_CollaborativeArrangementAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of the collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CollaborativeArrangementAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Agreement Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_CollaborativeArrangementAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the agreement</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ReimbursementOfExternalCostsIncurredPercentage" xlink:label="cldx_ReimbursementOfExternalCostsIncurredPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ReimbursementOfExternalCostsIncurredPercentage" xlink:to="cldx_ReimbursementOfExternalCostsIncurredPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ReimbursementOfExternalCostsIncurredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents percentage of reimbursement of external costs incurred by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ReimbursementOfExternalCostsIncurredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of external costs incurred percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_ReimbursementOfExternalCostsIncurredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of external costs incurred by the company (as a percent)</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" xlink:label="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" xlink:to="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of license fee payable to third party on net royalties received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of License Fee Due on Net Royalties Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of license fee payable on net royalties received</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PercentageOfInterestInNetRoyaltiesSold" xlink:label="cldx_PercentageOfInterestInNetRoyaltiesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_PercentageOfInterestInNetRoyaltiesSold" xlink:to="cldx_PercentageOfInterestInNetRoyaltiesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_PercentageOfInterestInNetRoyaltiesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of interest in net royalties sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_PercentageOfInterestInNetRoyaltiesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Interest in Net Royalties Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_PercentageOfInterestInNetRoyaltiesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of interest in net royalties sold</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_MedarexIncMember" xlink:label="cldx_MedarexIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_MedarexIncMember" xlink:to="cldx_MedarexIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_MedarexIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Medarex, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_MedarexIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medarex Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_MedarexIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medarex</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RockefellerUniversityMember" xlink:label="cldx_RockefellerUniversityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_RockefellerUniversityMember" xlink:to="cldx_RockefellerUniversityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_RockefellerUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Rockefeller University.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_RockefellerUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rockefeller University [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_RockefellerUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rockefeller</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DukeUniversityBrainTumorCancerCenterMember" xlink:label="cldx_DukeUniversityBrainTumorCancerCenterMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DukeUniversityBrainTumorCancerCenterMember" xlink:to="cldx_DukeUniversityBrainTumorCancerCenterMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DukeUniversityBrainTumorCancerCenterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Duke University Brain Tumor Cancer Center.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DukeUniversityBrainTumorCancerCenterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duke University Brain Tumor Cancer Center [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_DukeUniversityBrainTumorCancerCenterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duke</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LudwigInstituteForCancerResearchMember" xlink:label="cldx_LudwigInstituteForCancerResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_LudwigInstituteForCancerResearchMember" xlink:to="cldx_LudwigInstituteForCancerResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_LudwigInstituteForCancerResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Ludwig Institute for Cancer Research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_LudwigInstituteForCancerResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ludwig Institute For Cancer Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_LudwigInstituteForCancerResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ludwig</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AlterisTherapeuticsIncMember" xlink:label="cldx_AlterisTherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AlterisTherapeuticsIncMember" xlink:to="cldx_AlterisTherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AlterisTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Alteris Therapeutics, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AlterisTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Alteris Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AlterisTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Alteris</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_UniversityOfSouthamptonUKMember" xlink:label="cldx_UniversityOfSouthamptonUKMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_UniversityOfSouthamptonUKMember" xlink:to="cldx_UniversityOfSouthamptonUKMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_UniversityOfSouthamptonUKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to University of Southampton, UK.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_UniversityOfSouthamptonUKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">University Of Southampton U K [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_UniversityOfSouthamptonUKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Southampton</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AmgenIncMember" xlink:label="cldx_AmgenIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AmgenIncMember" xlink:to="cldx_AmgenIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AmgenIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Amgen Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AmgenIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amgen Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AmgenIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amgen</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_SeattleGeneticIncMember" xlink:label="cldx_SeattleGeneticIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_SeattleGeneticIncMember" xlink:to="cldx_SeattleGeneticIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_SeattleGeneticIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Seattle Genetics, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_SeattleGeneticIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seattle Genetic Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_SeattleGeneticIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seattle Genetics</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CuraGenCorporationMember" xlink:label="cldx_CuraGenCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CuraGenCorporationMember" xlink:to="cldx_CuraGenCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_CuraGenCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to CuraGen Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CuraGenCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cura Gen Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_CuraGenCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CuraGen</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_NonRefundableLicenseFee" xlink:label="cldx_NonRefundableLicenseFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_NonRefundableLicenseFee" xlink:to="cldx_NonRefundableLicenseFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_NonRefundableLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of nonrefundable license fee expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_NonRefundableLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Refundable License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_NonRefundableLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrefundable license fee expense</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" xlink:label="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" xlink:to="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period from the first commercial sale of licensed product for royalty payment under the collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Royalty Payment Period from First Commercial Sale of Licensed Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from the first commercial sale of licensed product for royalty payment</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementTotalPotentialMilestonePayments" xlink:label="cldx_CollaborativeArrangementTotalPotentialMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_CollaborativeArrangementTotalPotentialMilestonePayments" xlink:to="cldx_CollaborativeArrangementTotalPotentialMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_CollaborativeArrangementTotalPotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total amount of potential milestone payments to be made by the entity based on terms of the collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_CollaborativeArrangementTotalPotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Total Potential Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_CollaborativeArrangementTotalPotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment due</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit (provision):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:label="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:to="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reflects the amounts of net operating losses and research and development tax credits expired during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration of Net Operating Losses and Research and Development Tax Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration of Net Operating Losses and Research &amp; Development Tax Credits</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" xlink:label="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" xlink:to="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations before the effect of the change during the period in the valuation allowance for a specified deferred tax asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit) before Change in Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit (provision) before valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Change in Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (benefit) provision</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation between the amount of reported income tax and the amount computed using U.S. Statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss at Statutory Rates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:label="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:to="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to expiration of net operating losses and research and development tax credits under enacted tax laws during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation Expiration of Net Operating Losses and Research and Development Tax Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration of Net Operating Losses and Research &amp; Development Tax Credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal components of the deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Deferred Tax Liabilities</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets" xlink:label="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets" xlink:to="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from other acquired intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Other Acquired Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Acquired Intangibles</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" xlink:label="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" xlink:to="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from in-process research and development intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets in Process Research and Development Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPR&amp;D Intangibles</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Deferred Tax Liabilities</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsLiabilitiesGross" xlink:label="cldx_DeferredTaxAssetsLiabilitiesGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DeferredTaxAssetsLiabilitiesGross" xlink:to="cldx_DeferredTaxAssetsLiabilitiesGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DeferredTaxAssetsLiabilitiesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DeferredTaxAssetsLiabilitiesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets (Liabilities) Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cldx_DeferredTaxAssetsLiabilitiesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Deferred Tax Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Deferred Tax Asset (Liability)</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:to="cldx_OperatingLossAndTaxCreditCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss and tax credit carryforwards, including an assessment of the likelihood of utilization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss and Tax Credit Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Internal Revenue Service I R S [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State And Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AVANTMember" xlink:label="cldx_AVANTMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_AVANTMember" xlink:to="cldx_AVANTMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_AVANTMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to AVANT Immunotherapeutics, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_AVANTMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A V A N T [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_AVANTMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AVANT</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StatusOfMergerAndAcquisitionAxis" xlink:label="cldx_StatusOfMergerAndAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_StatusOfMergerAndAcquisitionAxis" xlink:to="cldx_StatusOfMergerAndAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_StatusOfMergerAndAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to status of merger and acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_StatusOfMergerAndAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Status of Merger and Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StatusOfMergerAndAcquisitionDomain" xlink:label="cldx_StatusOfMergerAndAcquisitionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_StatusOfMergerAndAcquisitionDomain" xlink:to="cldx_StatusOfMergerAndAcquisitionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_StatusOfMergerAndAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details of status of merger and acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_StatusOfMergerAndAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Status Of Merger And Acquisition [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_StatusOfMergerAndAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Status of Merger and Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PriorToMergerMember" xlink:label="cldx_PriorToMergerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_PriorToMergerMember" xlink:to="cldx_PriorToMergerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_PriorToMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details prior to merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_PriorToMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior To Merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_PriorToMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior to merger</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PriorToAcquisitionMember" xlink:label="cldx_PriorToAcquisitionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_PriorToAcquisitionMember" xlink:to="cldx_PriorToAcquisitionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_PriorToAcquisitionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details prior to acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_PriorToAcquisitionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior To Acquisition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_PriorToAcquisitionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior to acquisition</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeAxis" xlink:label="cldx_OwnershipChangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OwnershipChangeAxis" xlink:to="cldx_OwnershipChangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OwnershipChangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to transactions that result in ownership change as defined by Section 382 of the Internal Revenue Code.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OwnershipChangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership Change [Axis]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeDomain" xlink:label="cldx_OwnershipChangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OwnershipChangeDomain" xlink:to="cldx_OwnershipChangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OwnershipChangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions that result in ownership change as defined by Section 382 of the Internal Revenue Code.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OwnershipChangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership Change [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_OwnershipChangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership Change [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeInDecember2013Member" xlink:label="cldx_OwnershipChangeInDecember2013Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OwnershipChangeInDecember2013Member" xlink:to="cldx_OwnershipChangeInDecember2013Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OwnershipChangeInDecember2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to ownership change in December 2013.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OwnershipChangeInDecember2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership Change In December2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_OwnershipChangeInDecember2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership Change in December 2013</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangesInJune2009AndDecember2009Member" xlink:label="cldx_OwnershipChangesInJune2009AndDecember2009Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OwnershipChangesInJune2009AndDecember2009Member" xlink:to="cldx_OwnershipChangesInJune2009AndDecember2009Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OwnershipChangesInJune2009AndDecember2009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Details pertaining to ownership changes June 2009 and December 2009.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OwnershipChangesInJune2009AndDecember2009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership Changes In June2009 And December2009 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_OwnershipChangesInJune2009AndDecember2009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership changes in June 2009 and December 2009</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credit</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss and Tax Credit Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss and tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization" xlink:label="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization" xlink:to="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The sum of domestic, foreign and state and local operating loss carryforwards, net of expirations and utilization but before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards Net of Expirations and Utilization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL, net of expirations and utilization</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsWithLimitationsOnUse" xlink:label="cldx_OperatingLossCarryforwardsWithLimitationsOnUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OperatingLossCarryforwardsWithLimitationsOnUse" xlink:to="cldx_OperatingLossCarryforwardsWithLimitationsOnUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OperatingLossCarryforwardsWithLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the operating loss carryforwards with limitations on use.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OperatingLossCarryforwardsWithLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards with Limitations on Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_OperatingLossCarryforwardsWithLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss carryforwards with limitations on use</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" xlink:label="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" xlink:to="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amount of deferred tax assets attributable to deductible operating loss carryforwards not yet utilized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards not yet Utilized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets recorded for net operating losses not yet utilized</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" xlink:label="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" xlink:to="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the operating loss carryforwards that are remotely likely to be utilized in future periods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards Remotely Likely to be Utilized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss carryforwards remotely likely to be utilized in future periods</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="cldx_OperatingLossCarryforwardsAnnualLimitationAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:to="cldx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the annual limitation on operating loss carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards Annual Limitation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_OperatingLossCarryforwardsAnnualLimitationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual limitation</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" xlink:label="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" xlink:to="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period of recognition of unrealized gain (loss) after ownership change.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of Recognition of Unrealized Gain (loss) after Ownership Change</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of recognition of unrealized loss or gain after the ownership change</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" xlink:label="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" xlink:to="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of the net operating loss carryforward with substantial limitations on use before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss Carryforwards With Substantial Limitations On Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards with substantial limitations on use</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" xlink:label="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" xlink:to="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of the tax credit carryforward, with substantial limitations on use before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward Amount with Substantial Limitations on Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards with substantial limitations on use</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for Uncertain Tax Positions, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="us-gaap_NumberOfStatesInWhichEntityOperates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="us-gaap_NumberOfStatesInWhichEntityOperates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfStatesInWhichEntityOperates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of States in which Entity Operates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfStatesInWhichEntityOperates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of states in which the entity primarily operates or has operated and has income tax nexus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligations for base rent and CAM costs under facility and other non-cancelable operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total rent and CAM expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum contribution by participants (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer match (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of employees' gross pay subject to employer match</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit expense for the 401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosure Item Amounts [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate Of Fair Value Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BiosynCorporationMember" xlink:label="cldx_BiosynCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_BiosynCorporationMember" xlink:to="cldx_BiosynCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_BiosynCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information about Biosyn Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_BiosynCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biosyn Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_BiosynCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biosyn Corporation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_UnderwrittenPublicOfferingMember" xlink:label="cldx_UnderwrittenPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_UnderwrittenPublicOfferingMember" xlink:to="cldx_UnderwrittenPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details about an underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwritten Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwritten Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2004 ESPP Plan</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GlembatumumabVedotinMember" xlink:label="cldx_GlembatumumabVedotinMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_GlembatumumabVedotinMember" xlink:to="cldx_GlembatumumabVedotinMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_GlembatumumabVedotinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Glembatumumab product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_GlembatumumabVedotinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Glembatumumab Vedotin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_GlembatumumabVedotinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Glembatumumab Vedotin</label>
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_Cdx014Member" xlink:label="cldx_Cdx014Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cldx_Cdx014Member" xlink:to="cldx_Cdx014Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cldx_Cdx014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents CDX-014 products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cldx_Cdx014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cdx014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cldx_Cdx014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CDX-014</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cldx-20151231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.1.177.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2016 3:14:16 PM-->
<!--Modified on: 2/23/2016 3:14:16 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementBalanceSheets" roleURI="http://www.celldextherapeutics.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.celldextherapeutics.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureNatureOfBusinessAndOverview" roleURI="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureComprehensiveLoss" roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureMarketableSecurities" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIntangibleAssetsAndGoodwill" roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureAccruedExpenses" roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureOtherLongTermLiabilities" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureTermLoan" roleURI="http://www.celldextherapeutics.com/role/DisclosureTermLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockholdersEquity" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureRevenue" roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureCollaborationAgreements" roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIncomeTaxes" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureRetirementSavingsPlan" roleURI="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureComprehensiveLossTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureMarketableSecuritiesTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIntangibleAssetsAndGoodwillTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureOtherLongTermLiabilitiesTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureNatureOfBusinessAndOverviewDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverviewDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureComprehensiveLossDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIntangibleAssetsAndGoodwillDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureOtherLongTermLiabilitiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureTermLoanDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockBasedCompensationSummaryOfPlansDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockBasedCompensationValuationAndExpensesInformationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationAndExpensesInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureRevenueDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureCollaborationAgreementsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIncomeTaxesSummaryDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIncomeTaxesCarryforwardsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureRetirementSavingsPlanDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSelectedQuarterlyFinancialDataUnauditedDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DocumentAndEntityInformationAbstract" xlink:label="cldx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_635918372544087449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_635918372544087449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_635918372544087449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_635918372544087449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_635918372544097449" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_635918372544097449" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_635918372544097449" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_635918372544097449" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_635918372544097449" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers_635918372544097449" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_635918372544097449" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_635918372544097449" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat_635918372544097449" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_635918372544097449" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_635918372544097449" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_635918372544097449" order="14" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_635918372544097449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_635918372544097449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635918372544097449" xlink:to="us-gaap_AssetsCurrentAbstract_635918372544107449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635918372544107449" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635918372544107449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635918372544107449" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_635918372544107449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635918372544107449" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_635918372544107449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635918372544107449" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635918372544107449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635918372544107449" xlink:to="us-gaap_AssetsCurrent_635918372544107449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635918372544097449" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635918372544107449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635918372544097449" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_635918372544107449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_635918372544107449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635918372544097449" xlink:to="us-gaap_OtherAssetsNoncurrent_635918372544107449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635918372544097449" xlink:to="us-gaap_Goodwill_635918372544117449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635918372544097449" xlink:to="us-gaap_Assets_635918372544117449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635918372544117449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_LiabilitiesCurrentAbstract_635918372544117449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635918372544117449" xlink:to="us-gaap_AccountsPayableCurrent_635918372544117449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635918372544117449" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635918372544117449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635918372544117449" xlink:to="us-gaap_OtherLiabilitiesCurrent_635918372544117449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635918372544117449" xlink:to="us-gaap_LiabilitiesCurrent_635918372544117449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635918372544117449" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_635918372544117449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_Liabilities_635918372544117449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_CommitmentsAndContingencies_635918372544117449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_StockholdersEquityAbstract_635918372544117449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_PreferredStockValue_635918372544117449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_CommonStockValue_635918372544117449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_635918372544117449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_635918372544117449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635918372544117449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635918372544117449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_StockholdersEquity_635918372544127449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635918372544117449" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_635918372544127449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_635918372544127449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_635918372544127449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_635918372544127449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_635918372544127449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_635918372544127449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_635918372544127449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_635918372544127449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_635918372544127449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract_635918372544127449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_635918372544127449" xlink:to="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_635918372544127449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="cldx_RevenueFromContractsAndGrants_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_635918372544127449" xlink:to="cldx_RevenueFromContractsAndGrants_635918372544127449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_635918372544127449" xlink:to="us-gaap_RoyaltyRevenue_635918372544127449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_635918372544127449" xlink:to="us-gaap_Revenues_635918372544127449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_635918372544127449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635918372544127449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_635918372544127449" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635918372544127449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_635918372544127449" xlink:to="us-gaap_RoyaltyExpense_635918372544137449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_635918372544127449" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635918372544137449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_635918372544127449" xlink:to="us-gaap_AmortizationOfIntangibleAssets_635918372544137449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_635918372544127449" xlink:to="us-gaap_CostsAndExpenses_635918372544137449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_635918372544137449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome_635918372544137449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense_635918372544137449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544137449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635918372544137449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635918372544137449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_635918372544137449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6359183725441374491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_635918372544137449" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6359183725441374491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_635918372544137449" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_635918372544137449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_635918372544137449" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635918372544137449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_635918372544137449" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_635918372544137449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_635918372544137449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_635918372544137449" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_635918372544137449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_635918372544147449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635918372544147449" xlink:to="us-gaap_StatementEquityComponentsAxis_635918372544147449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635918372544147449" xlink:to="us-gaap_CommonStockMember_635918372544147449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635918372544147449" xlink:to="us-gaap_AdditionalPaidInCapitalMember_635918372544147449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635918372544147449" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_635918372544147449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635918372544147449" xlink:to="us-gaap_RetainedEarningsMember_635918372544147449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635918372544147449" xlink:to="us-gaap_EquityComponentDomain_635918372544147449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635918372544147449" xlink:to="us-gaap_StatementLineItems_635918372544147449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635918372544147449" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_StockholdersEquity_635918372544147449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_CommonStockSharesIssued_635918372544147449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_635918372544147449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_635918372544147449" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_635918372544147449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_635918372544147449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther_635918372544147449" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_635918372544147449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_635918372544147449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_635918372544147449" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_635918372544147449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_635918372544147449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_635918372544147449" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635918372544147449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_635918372544147449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_635918372544147449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_635918372544147449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_635918372544147449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544157449" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_StockholdersEquity_635918372544157449" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635918372544147449" xlink:to="us-gaap_CommonStockSharesIssued_635918372544157449" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635918372544157449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635918372544157449" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544157449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635918372544157449" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" xlink:to="us-gaap_DepreciationDepletionAndAmortization_635918372544157449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" xlink:to="us-gaap_AmortizationOfIntangibleAssets_635918372544157449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_635918372544157449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" xlink:to="us-gaap_MarketableSecuritiesGainLoss_635918372544157449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_635918372544157449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" xlink:to="us-gaap_ShareBasedCompensation_635918372544157449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_635918372544157449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635918372544157449" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635918372544157449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635918372544157449" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_635918372544157449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635918372544157449" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635918372544157449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635918372544157449" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_635918372544157449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635918372544157449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635918372544157449" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635918372544157449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635918372544157449" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_635918372544167449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635918372544157449" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372544167449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635918372544167449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_635918372544167449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_635918372544167449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635918372544167449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_635918372544167449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635918372544167449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635918372544167449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635918372544167449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_ProceedsFromStockPlans_635918372544167449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_RepaymentsOfSecuredDebt_635918372544167449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_635918372544167449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635918372544167449" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635918372544167449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_635918372544167449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_635918372544167449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_635918372544177449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_635918372544177449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635918372544177449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635918372544177449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6359183725441774491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6359183725441774491" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_635918372544177449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_635918372544177449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_635918372544177449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_635918372544177449" xlink:to="us-gaap_InterestPaid_635918372544177449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635918372544177449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635918372544177449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_635918372544177449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635918372544177449" xlink:to="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_635918372544177449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF BUSINESS AND OVERVIEW" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635475927070245870" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635475927070245870" xlink:to="us-gaap_BasisOfAccounting_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLoss" xlink:type="extended" xlink:title="10301 - Disclosure - COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - FAIR VALUE MEASUREMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" xlink:type="extended" xlink:title="10501 - Disclosure - MARKETABLE SECURITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10601 - Disclosure - PROPERTY AND EQUIPMENT, NET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill" xlink:type="extended" xlink:title="10701 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10801 - Disclosure - ACCRUED EXPENSES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" xlink:type="extended" xlink:title="10901 - Disclosure - OTHER LONG-TERM LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_635918372544187449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_635918372544187449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureTermLoan" xlink:type="extended" xlink:title="11001 - Disclosure - TERM LOAN" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_635918372544197449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_635918372544197449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11101 - Disclosure - STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_635918372544197449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_635918372544197449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11201 - Disclosure - STOCK-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635918372544197449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635918372544197449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="11301 - Disclosure - REVENUE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_SignificantRevenueArrangementsDisclosureAbstract" xlink:label="cldx_SignificantRevenueArrangementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_SignificantRevenueArrangementsDisclosureTextBlock" xlink:label="cldx_SignificantRevenueArrangementsDisclosureTextBlock_635918372544197449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_SignificantRevenueArrangementsDisclosureAbstract" xlink:to="cldx_SignificantRevenueArrangementsDisclosureTextBlock_635918372544197449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements" xlink:type="extended" xlink:title="11401 - Disclosure - COLLABORATION AGREEMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementDisclosureAbstract" xlink:label="cldx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_635918372544197449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_635918372544197449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11501 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_635918372544197449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_635918372544197449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11601 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_635918372544197449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_635918372544197449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan" xlink:type="extended" xlink:title="11701 - Disclosure - RETIREMENT SAVINGS PLAN" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_635918372544207449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" xlink:title="11801 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_635918372544207449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_635918372544207449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_635918372544207449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_635918372544207449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_635918372544207449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_635918372544207449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_635918372544207449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_635918372544207449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy_635918372544207449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_635918372544207449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_635918372544207449" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_635918372544207449" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_635918372544207449" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_635918372544207449" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PatentCostsPolicyTextBlock" xlink:label="cldx_PatentCostsPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cldx_PatentCostsPolicyTextBlock_635918372544207449" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_635918372544207449" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_635918372544207449" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_635918372544207449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_635918372544207449" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_635918372544217449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_635918372544217449" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_635918372544217449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_635918372544217449" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635918372544217449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635918372544217449" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_635549443914366014" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635918372544217449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635549443914366014" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635918372544217449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossTables" xlink:type="extended" xlink:title="30303 - Disclosure - COMPREHENSIVE LOSS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_635918372544217449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_635918372544217449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_635918372544217449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_635918372544217449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - MARKETABLE SECURITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_635918372544217449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_635918372544217449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30603 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_635918372544217449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_635918372544217449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillTables" xlink:type="extended" xlink:title="30703 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_635918372544227449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30803 - Disclosure - ACCRUED EXPENSES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635918372544227449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables" xlink:type="extended" xlink:title="30903 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock" xlink:label="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock_635918372544227449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31203 - Disclosure - STOCK-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635918372544227449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_635918372544227449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635918372544227449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635918372544227449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31503 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_635918372544227449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_635918372544227449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_635918372544227449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_635918372544227449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_635918372544227449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" xlink:title="31803 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_635918372544237449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverviewDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF BUSINESS AND OVERVIEW (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DrugCandidatesInClinicalDevelopment" xlink:label="cldx_DrugCandidatesInClinicalDevelopment_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="cldx_DrugCandidatesInClinicalDevelopment_635918372544237449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InvestmentsAndCash_635918372544237449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544237449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635918372544237449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONCENTRATION OF CREDIT RISK (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable_635918372544237449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_635918372544237449" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_635918372544237449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_635918372544237449" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_635918372544237449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_635918372544237449" xlink:to="us-gaap_SalesMember_635918372544237449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_635918372544237449" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_635918372544237449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_635918372544237449" xlink:to="us-gaap_ConcentrationRiskTypeDomain_635918372544237449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_635918372544237449" xlink:to="us-gaap_CustomerConcentrationRiskMember_635918372544237449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_635918372544237449" xlink:to="us-gaap_MajorCustomersAxis_635918372544237449" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis_635918372544237449" xlink:to="us-gaap_NameOfMajorCustomerDomain_635918372544237449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RockefellerUniversityMember" xlink:label="cldx_RockefellerUniversityMember_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain_635918372544237449" xlink:to="cldx_RockefellerUniversityMember_635918372544237449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BristolMeyersSquibbCompanyMember" xlink:label="cldx_BristolMeyersSquibbCompanyMember_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain_635918372544237449" xlink:to="cldx_BristolMeyersSquibbCompanyMember_635918372544237449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_635918372544237449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_635918372544237449" xlink:to="us-gaap_ConcentrationRiskLineItems_635918372544237449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_635918372544237449" xlink:to="us-gaap_ConcentrationRiskPercentage1_635918372544247449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BasisOfPresentationAbstract" xlink:label="cldx_BasisOfPresentationAbstract_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_635918372544237449" xlink:to="cldx_BasisOfPresentationAbstract_635918372544247449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_BasisOfPresentationAbstract_635918372544247449" xlink:to="us-gaap_NumberOfOperatingSegments_635918372544247449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PROPERTY AND EQUIPMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544247449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544247449" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635918372544247449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635918372544247449" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544247449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LaboratoryEquipmentMember" xlink:label="cldx_LaboratoryEquipmentMember_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544247449" xlink:to="cldx_LaboratoryEquipmentMember_635918372544247449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544247449" xlink:to="us-gaap_FurnitureAndFixturesMember_635918372544247449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544247449" xlink:to="us-gaap_ComputerEquipmentMember_635918372544247449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ManufacturingEquipmentMember" xlink:label="cldx_ManufacturingEquipmentMember_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544247449" xlink:to="cldx_ManufacturingEquipmentMember_635918372544247449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544247449" xlink:to="us-gaap_RangeAxis_635918372544247449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635918372544247449" xlink:to="us-gaap_RangeMember_635918372544247449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635918372544247449" xlink:to="us-gaap_MinimumMember_635918372544247449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635918372544247449" xlink:to="us-gaap_MaximumMember_635918372544247449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544247449" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544247449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_635918372544247449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544247449" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_635918372544247449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationDetails" xlink:type="extended" xlink:title="40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - FOREIGN CURRENCY TRANSLATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTranslationAbstract" xlink:label="us-gaap_ForeignCurrencyTranslationAbstract_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTranslationAbstract_635918372544257449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForeignCurrencyTranslationAbstract_635918372544257449" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_635918372544257449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - DILUTIVE COMMON SHARES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635918372544257449" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635918372544257449" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635918372544257449" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635918372544257449" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635918372544257449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635918372544257449" xlink:to="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_635918372544257449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635918372544257449" xlink:to="us-gaap_RestrictedStockMember_635918372544257449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635918372544257449" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635918372544257449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635918372544257449" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635918372544257449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossDetails" xlink:type="extended" xlink:title="40301 - Disclosure - COMPREHENSIVE LOSS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_635918372544257449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_635918372544257449" xlink:to="us-gaap_StatementEquityComponentsAxis_635918372544257449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635918372544257449" xlink:to="us-gaap_EquityComponentDomain_635918372544257449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635918372544257449" xlink:to="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_635918372544257449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="us-gaap_AccumulatedTranslationAdjustmentMember_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635918372544257449" xlink:to="us-gaap_AccumulatedTranslationAdjustmentMember_635918372544257449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635918372544257449" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_635918372544257449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_635918372544257449" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635918372544257449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" xlink:label="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_635918372544257449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_635918372544257449" xlink:to="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_635918372544257449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635918372544267449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_635918372544257449" xlink:to="us-gaap_StockholdersEquity_635918372544267449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_635918372544267449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_635918372544257449" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_635918372544267449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_635918372544267449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_635918372544257449" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_635918372544267449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6359183725442674491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward_635918372544257449" xlink:to="us-gaap_StockholdersEquity_6359183725442674491" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635918372544267449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635918372544267449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_635918372544267449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635918372544267449" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_635918372544267449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635918372544267449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_635918372544267449" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635918372544267449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_635918372544307449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_635918372544267449" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_635918372544307449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_635918372544307449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635918372544267449" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_635918372544307449" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_635918372544307449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_635918372544307449" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_635918372544307449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635918372544307449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain_635918372544307449" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635918372544307449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_635918372544307449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635918372544267449" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_635918372544307449" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635918372544307449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_635918372544307449" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635918372544307449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_635918372544307449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635918372544307449" xlink:to="us-gaap_FairValueInputsLevel2Member_635918372544307449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635918372544307449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635918372544267449" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635918372544307449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635918372544307449" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635918372544317449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635918372544307449" xlink:to="us-gaap_AvailableForSaleSecurities_635918372544317449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635918372544307449" xlink:to="us-gaap_AssetsFairValueDisclosure_635918372544317449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels" xlink:label="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635918372544307449" xlink:to="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels_635918372544317449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" xlink:label="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635918372544307449" xlink:to="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels_635918372544317449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - MARKETABLE SECURITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_635918372544317449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_635918372544317449" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_635918372544317449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_635918372544317449" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635918372544317449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_USGovernmentAndMunicipalObligationsMember" xlink:label="cldx_USGovernmentAndMunicipalObligationsMember_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635918372544317449" xlink:to="cldx_USGovernmentAndMunicipalObligationsMember_635918372544317449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635918372544317449" xlink:to="us-gaap_CorporateDebtSecuritiesMember_635918372544317449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_635918372544317449" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635918372544317449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635918372544317449" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_635918372544317449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_635918372544317449" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_635918372544317449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_635918372544317449" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_635918372544317449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_635918372544317449" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_635918372544317449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635918372544317449" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract_635918372544317449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract_635918372544317449" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_635918372544317449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_635918372544317449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract_635918372544317449" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_635918372544317449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract_635918372544317449" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_635918372544327449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xlink:label="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635918372544317449" xlink:to="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_635918372544327449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_635918372544327449" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_635918372544327449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_635918372544327449" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_635918372544327449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_635918372544327449" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_635918372544327449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635918372544317449" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_635918372544327449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_635918372544327449" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_635918372544327449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_635918372544327449" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_635918372544327449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_635918372544327449" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_635918372544327449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" xlink:label="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635918372544317449" xlink:to="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired_635918372544327449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_635918372544317449" xlink:to="us-gaap_InterestReceivable_635918372544327449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_635552010668495026" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544327449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_635552010668495026" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544327449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544327449" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635918372544337449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635918372544337449" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544337449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LaboratoryEquipmentMember" xlink:label="cldx_LaboratoryEquipmentMember_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544337449" xlink:to="cldx_LaboratoryEquipmentMember_635918372544337449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ManufacturingEquipmentMember" xlink:label="cldx_ManufacturingEquipmentMember_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544337449" xlink:to="cldx_ManufacturingEquipmentMember_635918372544337449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544337449" xlink:to="us-gaap_FurnitureAndFixturesMember_635918372544337449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544337449" xlink:to="us-gaap_LeaseholdImprovementsMember_635918372544337449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372544337449" xlink:to="us-gaap_ConstructionInProgressMember_635918372544337449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635918372544327449" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544337449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544337449" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_635918372544337449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544337449" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_635918372544337449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544337449" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635918372544337449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635918372544337449" xlink:to="us-gaap_DepreciationDepletionAndAmortization_635918372544337449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xlink:type="extended" xlink:title="40701 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_635918372544337449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_635918372544337449" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635918372544337449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635918372544337449" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_635918372544337449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_635918372544337449" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_635918372544337449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_635918372544337449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_635918372544337449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_635918372544337449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_635918372544337449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_635918372544337449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AmgenAmendmentMember" xlink:label="cldx_AmgenAmendmentMember_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_635918372544337449" xlink:to="cldx_AmgenAmendmentMember_635918372544347449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CoreTechnologyMember" xlink:label="cldx_CoreTechnologyMember_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_635918372544337449" xlink:to="cldx_CoreTechnologyMember_635918372544347449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_635918372544337449" xlink:to="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_635918372544347449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_635918372544347449" xlink:to="us-gaap_Goodwill_635918372544347449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_635918372544347449" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_635918372544347449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_635918372544347449" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_635918372544347449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_635918372544347449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_635918372544347449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_635918372544347449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_635918372544347449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_635918372544347449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_635918372544347449" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_635918372544347449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_635918372544347449" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_635918372544347449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_635918372544347449" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_635918372544347449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_635918372544347449" xlink:to="us-gaap_AmortizationOfIntangibleAssets_635918372544347449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_635918372544347449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_635918372544347449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_635918372544357449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_635918372544357449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_635918372544357449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_635918372544357449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_635918372544347449" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_635918372544357449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_635552014462283345" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_635552014462283345" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635918372544357449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AccruedResearchAndDevelopmentContractCostsCurrent" xlink:label="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_635552014462283345" xlink:to="cldx_AccruedResearchAndDevelopmentContractCostsCurrent_635918372544357449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_635552014462283345" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635918372544357449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_635552014462283345" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635918372544357449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_635552014462283345" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635918372544357449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - OTHER LONG-TERM LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_DeferredRentCredit_635918372544357449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_635918372544357449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredIncomeFromSaleOfTaxBenefits" xlink:label="cldx_DeferredIncomeFromSaleOfTaxBenefits_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="cldx_DeferredIncomeFromSaleOfTaxBenefits_635918372544357449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_DeferredRevenue_635918372544357449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_635918372544357449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilities_635918372544357449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_635918372544367449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_635918372544367449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ValueOfTaxBenefitsAgreedToBeSold" xlink:label="cldx_ValueOfTaxBenefitsAgreedToBeSold_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="cldx_ValueOfTaxBenefitsAgreedToBeSold_635918372544367449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ValueAtWhichTaxBenefitsSold" xlink:label="cldx_ValueAtWhichTaxBenefitsSold_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="cldx_ValueAtWhichTaxBenefitsSold_635918372544367449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PeriodForWhichBaseOfOperationsMustBeMaintained" xlink:label="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained_635918372544367449" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_635918372544367449" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureTermLoanDetails" xlink:type="extended" xlink:title="41001 - Disclosure - TERM LOAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_635918372544367449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentLenderAxis" xlink:label="cldx_DebtInstrumentLenderAxis_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635918372544367449" xlink:to="cldx_DebtInstrumentLenderAxis_635918372544367449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentLenderDomain" xlink:label="cldx_DebtInstrumentLenderDomain_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DebtInstrumentLenderAxis_635918372544367449" xlink:to="cldx_DebtInstrumentLenderDomain_635918372544367449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_MidCapFinancialLLCMember" xlink:label="cldx_MidCapFinancialLLCMember_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DebtInstrumentLenderDomain_635918372544367449" xlink:to="cldx_MidCapFinancialLLCMember_635918372544367449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GeneralElectricCapitalCorporationMember" xlink:label="cldx_GeneralElectricCapitalCorporationMember_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_DebtInstrumentLenderDomain_635918372544367449" xlink:to="cldx_GeneralElectricCapitalCorporationMember_635918372544367449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635918372544367449" xlink:to="us-gaap_LongtermDebtTypeAxis_635918372544367449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_635918372544367449" xlink:to="us-gaap_LongtermDebtTypeDomain_635918372544367449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_635918372544367449" xlink:to="us-gaap_SecuredDebtMember_635918372544367449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635918372544367449" xlink:to="us-gaap_DebtInstrumentLineItems_635918372544367449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635918372544367449" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_635918372544367449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RepaymentOfLongTermDebtPrincipalAmount" xlink:label="cldx_RepaymentOfLongTermDebtPrincipalAmount_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635918372544367449" xlink:to="cldx_RepaymentOfLongTermDebtPrincipalAmount_635918372544367449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentInterestAndPrepaymentFees" xlink:label="cldx_DebtInstrumentInterestAndPrepaymentFees_635918372544367449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635918372544367449" xlink:to="cldx_DebtInstrumentInterestAndPrepaymentFees_635918372544367449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635918372544367449" xlink:to="us-gaap_InterestExpenseLongTermDebt_635918372544377449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="41101 - Disclosure - STOCKHOLDERS' EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockholdersEquityTable" xlink:label="cldx_StockholdersEquityTable_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="cldx_StockholdersEquityTable_635918372544377449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockIssuedByTypeOfProgramAxis" xlink:label="cldx_StockIssuedByTypeOfProgramAxis_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityTable_635918372544377449" xlink:to="cldx_StockIssuedByTypeOfProgramAxis_635918372544377449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockIssuedByTypeOfProgramDomain" xlink:label="cldx_StockIssuedByTypeOfProgramDomain_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockIssuedByTypeOfProgramAxis_635918372544377449" xlink:to="cldx_StockIssuedByTypeOfProgramDomain_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ControlledEquityOfferingProgramAmendedMember" xlink:label="cldx_ControlledEquityOfferingProgramAmendedMember_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockIssuedByTypeOfProgramDomain_635918372544377449" xlink:to="cldx_ControlledEquityOfferingProgramAmendedMember_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityTable_635918372544377449" xlink:to="us-gaap_StatementClassOfStockAxis_635918372544377449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635918372544377449" xlink:to="us-gaap_ClassOfStockDomain_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635918372544377449" xlink:to="us-gaap_SeriesCPreferredStockMember_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CumulativePreferredStockMember" xlink:label="us-gaap_CumulativePreferredStockMember_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SeriesCPreferredStockMember_635918372544377449" xlink:to="us-gaap_CumulativePreferredStockMember_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityTable_635918372544377449" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_635918372544377449" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_635918372544377449" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_UnderwrittenPublicOfferingMember" xlink:label="cldx_UnderwrittenPublicOfferingMember_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635918372544377449" xlink:to="cldx_UnderwrittenPublicOfferingMember_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityTable_635918372544377449" xlink:to="dei_LegalEntityAxis_635918372544377449" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_635918372544377449" xlink:to="dei_EntityDomain_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BiosynCorporationMember" xlink:label="cldx_BiosynCorporationMember_635918372544377449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_635918372544377449" xlink:to="cldx_BiosynCorporationMember_635918372544377449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockholdersEquityLineItems" xlink:label="cldx_StockholdersEquityLineItems_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityTable_635918372544377449" xlink:to="cldx_StockholdersEquityLineItems_635918372544387449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityLineItems_635918372544387449" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635918372544387449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityLineItems_635918372544387449" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635918372544387449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityLineItems_635918372544387449" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_635918372544387449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityLineItems_635918372544387449" xlink:to="us-gaap_PreferredStockSharesAuthorized_635918372544387449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityLineItems_635918372544387449" xlink:to="us-gaap_CommonStockSharesIssued_635918372544387449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityLineItems_635918372544387449" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_635918372544387449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StockholdersEquityLineItems_635918372544387449" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635918372544387449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xlink:type="extended" xlink:title="41201 - Disclosure - STOCK-BASED COMPENSATION - SUMMARY OF PLANS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635918372544387449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635918372544387449" xlink:to="us-gaap_PlanNameAxis_635918372544387449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_635918372544387449" xlink:to="us-gaap_PlanNameDomain_635918372544387449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" xlink:label="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635918372544387449" xlink:to="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member_635918372544387449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockOptionAndIncentivePlan2008Member" xlink:label="cldx_StockOptionAndIncentivePlan2008Member_635918372544387449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635918372544387449" xlink:to="cldx_StockOptionAndIncentivePlan2008Member_635918372544387449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635918372544387449" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_635918372544397449" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_635918372544397449" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635918372544397449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635918372544397449" xlink:to="us-gaap_EmployeeStockMember_635918372544397449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635918372544387449" xlink:to="us-gaap_AwardTypeAxis_635918372544397449" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635918372544397449" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372544397449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372544397449" xlink:to="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_635918372544397449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372544397449" xlink:to="us-gaap_RestrictedStockMember_635918372544397449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635918372544387449" xlink:to="us-gaap_RangeAxis_635918372544397449" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635918372544397449" xlink:to="us-gaap_RangeMember_635918372544397449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635918372544397449" xlink:to="us-gaap_MaximumMember_635918372544397449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635918372544387449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_635918372544397449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_635918372544397449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_635918372544397449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635918372544397449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_635918372544397449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_635918372544397449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock_635918372544397449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock_635918372544397449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock_635918372544407449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock_635918372544407449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635918372544407449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635918372544407449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635918372544407449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_635918372544407449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6359183725444074491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6359183725444074491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_635918372544407449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635918372544407449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_635918372544407449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635918372544417449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635918372544417449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635918372544417449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635918372544417449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635918372544417449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635918372544417449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_635918372544417449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_635918372544417449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6359183725444174491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6359183725444174491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_635918372544417449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_635918372544417449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635918372544417449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635918372544407449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635918372544417449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_635918372544417449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_635918372544417449" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635918372544417449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_635918372544417449" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635918372544417449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6359183725444174491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_635918372544417449" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6359183725444174491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_635918372544427449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_635918372544417449" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_635918372544427449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635918372544427449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_635918372544417449" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635918372544427449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_635918372544427449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_635918372544427449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635918372544427449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635918372544427449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_635918372544427449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_635918372544427449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635918372544427449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635918372544427449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_635918372544427449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_635918372544427449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_635918372544437449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_635918372544437449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635918372544437449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_635918372544427449" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635918372544437449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635918372544437449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635918372544437449" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635918372544437449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635918372544437449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635918372544437449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635918372544437449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635918372544437449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635918372544437449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_635918372544437449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635918372544437449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_635918372544437449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6359183725444374491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635918372544437449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6359183725444374491" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635918372544437449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635918372544397449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635918372544437449" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_635918372544447449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635918372544437449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_635918372544447449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635918372544447449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635918372544437449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635918372544447449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_635918372544447449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635918372544437449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_635918372544447449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6359183725444474491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635918372544437449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6359183725444474491" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationAndExpensesInformationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - STOCK-BASED COMPENSATION - VALUATION AND EXPENSES INFORMATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635918372544457449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635918372544457449" xlink:to="us-gaap_IncomeStatementLocationAxis_635918372544457449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_635918372544457449" xlink:to="us-gaap_IncomeStatementLocationDomain_635918372544457449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635918372544457449" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_635918372544457449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635918372544457449" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_635918372544457449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635918372544457449" xlink:to="us-gaap_AwardTypeAxis_635918372544457449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635918372544457449" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372544457449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372544457449" xlink:to="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember_635918372544457449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635918372544457449" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635918372544457449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635918372544457449" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_635918372544457449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ExpectedDividendPayableInForeseeableFuture" xlink:label="cldx_ExpectedDividendPayableInForeseeableFuture_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635918372544457449" xlink:to="cldx_ExpectedDividendPayableInForeseeableFuture_635918372544457449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635918372544457449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635918372544457449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635918372544457449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_635918372544457449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635918372544457449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_635918372544457449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635918372544457449" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635918372544457449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635918372544457449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_635918372544457449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635918372544457449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_635918372544457449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_635918372544457449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635918372544457449" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_635918372544457449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="41301 - Disclosure - REVENUE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_SignificantRevenueArrangementsDisclosureAbstract" xlink:label="cldx_SignificantRevenueArrangementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_SignificantRevenueArrangementsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544467449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544467449" xlink:to="us-gaap_TypeOfArrangementAxis_635918372544467449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_635918372544467449" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372544467449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" xlink:label="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372544467449" xlink:to="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember_635918372544467449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LicenseAgreementsMember" xlink:label="cldx_LicenseAgreementsMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372544467449" xlink:to="cldx_LicenseAgreementsMember_635918372544467449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RoyaltyAgreementMember" xlink:label="cldx_RoyaltyAgreementMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372544467449" xlink:to="cldx_RoyaltyAgreementMember_635918372544467449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544467449" xlink:to="us-gaap_CounterpartyNameAxis_635918372544467449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_635918372544467449" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544467449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BristolMeyersSquibbCompanyMember" xlink:label="cldx_BristolMeyersSquibbCompanyMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544467449" xlink:to="cldx_BristolMeyersSquibbCompanyMember_635918372544467449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RockefellerUniversityMember" xlink:label="cldx_RockefellerUniversityMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544467449" xlink:to="cldx_RockefellerUniversityMember_635918372544467449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GlaxoSmithKlinePlcMember" xlink:label="cldx_GlaxoSmithKlinePlcMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544467449" xlink:to="cldx_GlaxoSmithKlinePlcMember_635918372544467449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CincinnatiChildrensHospitalMedicalCenterMember" xlink:label="cldx_CincinnatiChildrensHospitalMedicalCenterMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544467449" xlink:to="cldx_CincinnatiChildrensHospitalMedicalCenterMember_635918372544467449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PRFAgreementMember" xlink:label="cldx_PRFAgreementMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544467449" xlink:to="cldx_PRFAgreementMember_635918372544467449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544467449" xlink:to="us-gaap_ProductOrServiceAxis_635918372544467449" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis_635918372544467449" xlink:to="us-gaap_ProductsAndServicesDomain_635918372544467449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_Pd1ImmuneCheckpointInhibitorMember" xlink:label="cldx_Pd1ImmuneCheckpointInhibitorMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain_635918372544467449" xlink:to="cldx_Pd1ImmuneCheckpointInhibitorMember_635918372544467449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RotarixRotavirusVaccineMember" xlink:label="cldx_RotarixRotavirusVaccineMember_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain_635918372544467449" xlink:to="cldx_RotarixRotavirusVaccineMember_635918372544467449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544467449" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_635918372544467449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" xlink:to="us-gaap_DeferredRevenue_635918372544467449" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementAgreementTerm" xlink:label="cldx_CollaborativeArrangementAgreementTerm_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" xlink:to="cldx_CollaborativeArrangementAgreementTerm_635918372544477449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ReimbursementOfExternalCostsIncurredPercentage" xlink:label="cldx_ReimbursementOfExternalCostsIncurredPercentage_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" xlink:to="cldx_ReimbursementOfExternalCostsIncurredPercentage_635918372544477449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" xlink:to="cldx_RevenueFromProductDevelopmentAndLicensingAgreements_635918372544477449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="cldx_RevenueFromContractsAndGrants_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" xlink:to="cldx_RevenueFromContractsAndGrants_635918372544477449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" xlink:label="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" xlink:to="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived_635918372544477449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PercentageOfInterestInNetRoyaltiesSold" xlink:label="cldx_PercentageOfInterestInNetRoyaltiesSold_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" xlink:to="cldx_PercentageOfInterestInNetRoyaltiesSold_635918372544477449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544467449" xlink:to="us-gaap_RoyaltyExpense_635918372544477449" order="8" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreementsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - COLLABORATION AGREEMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementDisclosureAbstract" xlink:label="cldx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544477449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544477449" xlink:to="us-gaap_TypeOfArrangementAxis_635918372544477449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_635918372544477449" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372544477449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LicenseAgreementsMember" xlink:label="cldx_LicenseAgreementsMember_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372544477449" xlink:to="cldx_LicenseAgreementsMember_635918372544477449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544477449" xlink:to="us-gaap_CounterpartyNameAxis_635918372544477449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_635918372544477449" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_MedarexIncMember" xlink:label="cldx_MedarexIncMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" xlink:to="cldx_MedarexIncMember_635918372544487449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RockefellerUniversityMember" xlink:label="cldx_RockefellerUniversityMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" xlink:to="cldx_RockefellerUniversityMember_635918372544487449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DukeUniversityBrainTumorCancerCenterMember" xlink:label="cldx_DukeUniversityBrainTumorCancerCenterMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" xlink:to="cldx_DukeUniversityBrainTumorCancerCenterMember_635918372544487449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LudwigInstituteForCancerResearchMember" xlink:label="cldx_LudwigInstituteForCancerResearchMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" xlink:to="cldx_LudwigInstituteForCancerResearchMember_635918372544487449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AlterisTherapeuticsIncMember" xlink:label="cldx_AlterisTherapeuticsIncMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" xlink:to="cldx_AlterisTherapeuticsIncMember_635918372544487449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_UniversityOfSouthamptonUKMember" xlink:label="cldx_UniversityOfSouthamptonUKMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" xlink:to="cldx_UniversityOfSouthamptonUKMember_635918372544487449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AmgenIncMember" xlink:label="cldx_AmgenIncMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" xlink:to="cldx_AmgenIncMember_635918372544487449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_SeattleGeneticIncMember" xlink:label="cldx_SeattleGeneticIncMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372544477449" xlink:to="cldx_SeattleGeneticIncMember_635918372544487449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544477449" xlink:to="us-gaap_BusinessAcquisitionAxis_635918372544487449" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_635918372544487449" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_635918372544487449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CuraGenCorporationMember" xlink:label="cldx_CuraGenCorporationMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_635918372544487449" xlink:to="cldx_CuraGenCorporationMember_635918372544487449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544477449" xlink:to="us-gaap_RangeAxis_635918372544487449" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635918372544487449" xlink:to="us-gaap_RangeMember_635918372544487449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635918372544487449" xlink:to="us-gaap_MaximumMember_635918372544487449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544477449" xlink:to="us-gaap_ProductOrServiceAxis_635918372544487449" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis_635918372544487449" xlink:to="us-gaap_ProductsAndServicesDomain_635918372544487449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GlembatumumabVedotinMember" xlink:label="cldx_GlembatumumabVedotinMember_635918372544487449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain_635918372544487449" xlink:to="cldx_GlembatumumabVedotinMember_635918372544487449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_Cdx014Member" xlink:label="cldx_Cdx014Member_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain_635918372544487449" xlink:to="cldx_Cdx014Member_635918372544497449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_635918372544477449" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544497449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_NonRefundableLicenseFee" xlink:label="cldx_NonRefundableLicenseFee_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544497449" xlink:to="cldx_NonRefundableLicenseFee_635918372544497449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" xlink:label="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544497449" xlink:to="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct_635918372544497449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementTotalPotentialMilestonePayments" xlink:label="cldx_CollaborativeArrangementTotalPotentialMilestonePayments_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_635918372544497449" xlink:to="cldx_CollaborativeArrangementTotalPotentialMilestonePayments_635918372544497449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetails" xlink:type="extended" xlink:title="41501 - Disclosure - INCOME TAXES - SUMMARY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635548605205503226" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635548605205503226" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_635918372544497449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_635918372544497449" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_635918372544497449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_635918372544497449" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_635918372544497449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:label="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_635918372544497449" xlink:to="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_635918372544497449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" xlink:label="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_635918372544497449" xlink:to="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance_635918372544497449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_635918372544497449" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_635918372544497449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_635918372544497449" xlink:to="us-gaap_IncomeTaxExpenseBenefit_635918372544497449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635548605205503226" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_635918372544497449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_635918372544497449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544507449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_635918372544507449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_635918372544507449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_635918372544507449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_635918372544507449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:label="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_635918372544507449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_635918372544507449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_635918372544497449" xlink:to="us-gaap_IncomeTaxExpenseBenefit_635918372544507449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635548605205503226" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635918372544507449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_635918372544507449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_635918372544507449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_635918372544507449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_635918372544507449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_635918372544507449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_635918372544507449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_635918372544517449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_635918372544517449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxAssetsGross_635918372544517449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_635918372544517449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets" xlink:label="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_635918372544517449" xlink:to="cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets_635918372544517449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" xlink:label="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_635918372544517449" xlink:to="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets_635918372544517449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_635918372544517449" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_635918372544517449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsLiabilitiesGross" xlink:label="cldx_DeferredTaxAssetsLiabilitiesGross_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_635918372544517449" xlink:to="cldx_DeferredTaxAssetsLiabilitiesGross_635918372544517449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_635918372544517449" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_635918372544517449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_635918372544517449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635918372544507449" xlink:to="us-gaap_DeferredTaxLiabilities_635918372544517449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" xlink:type="extended" xlink:title="41502 - Disclosure - INCOME TAXES - CARRYFORWARDS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsTable_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cldx_OperatingLossAndTaxCreditCarryforwardsTable_635918372544527449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable_635918372544527449" xlink:to="us-gaap_IncomeTaxAuthorityAxis_635918372544527449" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_635918372544527449" xlink:to="us-gaap_IncomeTaxAuthorityDomain_635918372544527449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_635918372544527449" xlink:to="us-gaap_InternalRevenueServiceIRSMember_635918372544527449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_635918372544527449" xlink:to="us-gaap_StateAndLocalJurisdictionMember_635918372544527449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable_635918372544527449" xlink:to="us-gaap_BusinessAcquisitionAxis_635918372544527449" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_635918372544527449" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_635918372544527449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CuraGenCorporationMember" xlink:label="cldx_CuraGenCorporationMember_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_635918372544527449" xlink:to="cldx_CuraGenCorporationMember_635918372544527449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AVANTMember" xlink:label="cldx_AVANTMember_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_635918372544527449" xlink:to="cldx_AVANTMember_635918372544527449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StatusOfMergerAndAcquisitionAxis" xlink:label="cldx_StatusOfMergerAndAcquisitionAxis_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable_635918372544527449" xlink:to="cldx_StatusOfMergerAndAcquisitionAxis_635918372544527449" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StatusOfMergerAndAcquisitionDomain" xlink:label="cldx_StatusOfMergerAndAcquisitionDomain_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StatusOfMergerAndAcquisitionAxis_635918372544527449" xlink:to="cldx_StatusOfMergerAndAcquisitionDomain_635918372544527449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PriorToMergerMember" xlink:label="cldx_PriorToMergerMember_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StatusOfMergerAndAcquisitionDomain_635918372544527449" xlink:to="cldx_PriorToMergerMember_635918372544527449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PriorToAcquisitionMember" xlink:label="cldx_PriorToAcquisitionMember_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_StatusOfMergerAndAcquisitionDomain_635918372544527449" xlink:to="cldx_PriorToAcquisitionMember_635918372544527449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeAxis" xlink:label="cldx_OwnershipChangeAxis_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable_635918372544527449" xlink:to="cldx_OwnershipChangeAxis_635918372544527449" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeDomain" xlink:label="cldx_OwnershipChangeDomain_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OwnershipChangeAxis_635918372544527449" xlink:to="cldx_OwnershipChangeDomain_635918372544527449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeInDecember2013Member" xlink:label="cldx_OwnershipChangeInDecember2013Member_635918372544527449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OwnershipChangeDomain_635918372544527449" xlink:to="cldx_OwnershipChangeInDecember2013Member_635918372544527449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangesInJune2009AndDecember2009Member" xlink:label="cldx_OwnershipChangesInJune2009AndDecember2009Member_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OwnershipChangeDomain_635918372544527449" xlink:to="cldx_OwnershipChangesInJune2009AndDecember2009Member_635918372544537449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable_635918372544527449" xlink:to="us-gaap_TaxCreditCarryforwardAxis_635918372544537449" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_635918372544537449" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_635918372544537449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_635918372544537449" xlink:to="us-gaap_ResearchMember_635918372544537449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable_635918372544527449" xlink:to="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="us-gaap_OperatingLossCarryforwards_635918372544537449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization" xlink:label="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization_635918372544537449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsWithLimitationsOnUse" xlink:label="cldx_OperatingLossCarryforwardsWithLimitationsOnUse_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="cldx_OperatingLossCarryforwardsWithLimitationsOnUse_635918372544537449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" xlink:label="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized_635918372544537449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" xlink:label="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized_635918372544537449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="cldx_OperatingLossCarryforwardsAnnualLimitationAmount_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="cldx_OperatingLossCarryforwardsAnnualLimitationAmount_635918372544537449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" xlink:label="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange_635918372544537449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange_635918372544537449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="us-gaap_TaxCreditCarryforwardAmount_635918372544547449" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" xlink:label="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse_635918372544547449" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" xlink:label="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse_635918372544547449" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_635918372544547449" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="us-gaap_UnrecognizedTaxBenefits_635918372544547449" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="us-gaap_NumberOfStatesInWhichEntityOperates_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems_635918372544537449" xlink:to="us-gaap_NumberOfStatesInWhichEntityOperates_635918372544547449" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635554454506376748" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635554454506376748" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635918372544547449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635918372544547449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635918372544547449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635918372544547449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_635918372544557449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635918372544557449" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635918372544557449" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635918372544547449" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_635918372544557449" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlanDetails" xlink:type="extended" xlink:title="41701 - Disclosure - RETIREMENT SAVINGS PLAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_635918372544557449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_635918372544557449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_635918372544557449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_635918372544557449" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" xlink:title="41801 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_Revenues_635918372544557449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635918372544557449" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635918372544557449" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635918372544557449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>cldx-20151231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.1.177.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2016 3:14:16 PM-->
<!--Modified on: 2/23/2016 3:14:16 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.celldextherapeutics.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureComprehensiveLossDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIntangibleAssetsAndGoodwillDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureTermLoanDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockBasedCompensationSummaryOfPlansDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureStockBasedCompensationValuationAndExpensesInformationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationAndExpensesInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureRevenueDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureCollaborationAgreementsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cldx-20151231.xsd#DisclosureIncomeTaxesCarryforwardsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635918372543527449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_635918372543527449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONCENTRATION OF CREDIT RISK (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_635918372543567449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_635918372543567449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_635918372543567449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_635918372543567449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_635918372543577449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain_635918372543577449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RockefellerUniversityMember" xlink:label="cldx_RockefellerUniversityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="cldx_RockefellerUniversityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BristolMeyersSquibbCompanyMember" xlink:label="cldx_BristolMeyersSquibbCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="cldx_BristolMeyersSquibbCompanyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BasisOfPresentationAbstract" xlink:label="cldx_BasisOfPresentationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="cldx_BasisOfPresentationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cldx_BasisOfPresentationAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PROPERTY AND EQUIPMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372543587449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_635918372543587449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LaboratoryEquipmentMember" xlink:label="cldx_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cldx_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ManufacturingEquipmentMember" xlink:label="cldx_ManufacturingEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cldx_ManufacturingEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635918372543587449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_635918372543587449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - DILUTIVE COMMON SHARES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635918372543597449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635918372543597449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossDetails" xlink:type="extended" xlink:title="40301 - Disclosure - COMPREHENSIVE LOSS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="us-gaap_AccumulatedTranslationAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedTranslationAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" xlink:label="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cldx_AccumulatedOtherComprehensiveIncomeLossRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635918372543607449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635918372543607449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_635918372543607449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_635918372543607449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635918372543607449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635918372543607449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels" xlink:label="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" xlink:label="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - MARKETABLE SECURITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635918372543617449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_635918372543617449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_USGovernmentAndMunicipalObligationsMember" xlink:label="cldx_USGovernmentAndMunicipalObligationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cldx_USGovernmentAndMunicipalObligationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xlink:label="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" xlink:label="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LaboratoryEquipmentMember" xlink:label="cldx_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cldx_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ManufacturingEquipmentMember" xlink:label="cldx_ManufacturingEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cldx_ManufacturingEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xlink:type="extended" xlink:title="40701 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_635918372543647449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_635918372543647449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_635918372543657449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_635918372543657449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AmgenAmendmentMember" xlink:label="cldx_AmgenAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cldx_AmgenAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CoreTechnologyMember" xlink:label="cldx_CoreTechnologyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cldx_CoreTechnologyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureTermLoanDetails" xlink:type="extended" xlink:title="41001 - Disclosure - TERM LOAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentLenderAxis" xlink:label="cldx_DebtInstrumentLenderAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="cldx_DebtInstrumentLenderAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentLenderDomain" xlink:label="cldx_DebtInstrumentLenderDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cldx_DebtInstrumentLenderAxis" xlink:to="cldx_DebtInstrumentLenderDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentLenderDomain" xlink:label="cldx_DebtInstrumentLenderDomain_635918372543677449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cldx_DebtInstrumentLenderAxis" xlink:to="cldx_DebtInstrumentLenderDomain_635918372543677449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_MidCapFinancialLLCMember" xlink:label="cldx_MidCapFinancialLLCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cldx_DebtInstrumentLenderDomain" xlink:to="cldx_MidCapFinancialLLCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GeneralElectricCapitalCorporationMember" xlink:label="cldx_GeneralElectricCapitalCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_DebtInstrumentLenderDomain" xlink:to="cldx_GeneralElectricCapitalCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_635918372543687449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_635918372543687449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RepaymentOfLongTermDebtPrincipalAmount" xlink:label="cldx_RepaymentOfLongTermDebtPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cldx_RepaymentOfLongTermDebtPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DebtInstrumentInterestAndPrepaymentFees" xlink:label="cldx_DebtInstrumentInterestAndPrepaymentFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cldx_DebtInstrumentInterestAndPrepaymentFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="41101 - Disclosure - STOCKHOLDERS' EQUITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockholdersEquityTable" xlink:label="cldx_StockholdersEquityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cldx_StockholdersEquityTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_635918372543687449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_635918372543687449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BiosynCorporationMember" xlink:label="cldx_BiosynCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="cldx_BiosynCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockIssuedByTypeOfProgramAxis" xlink:label="cldx_StockIssuedByTypeOfProgramAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cldx_StockholdersEquityTable" xlink:to="cldx_StockIssuedByTypeOfProgramAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockIssuedByTypeOfProgramDomain" xlink:label="cldx_StockIssuedByTypeOfProgramDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cldx_StockIssuedByTypeOfProgramAxis" xlink:to="cldx_StockIssuedByTypeOfProgramDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockIssuedByTypeOfProgramDomain" xlink:label="cldx_StockIssuedByTypeOfProgramDomain_635918372543697449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cldx_StockIssuedByTypeOfProgramAxis" xlink:to="cldx_StockIssuedByTypeOfProgramDomain_635918372543697449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ControlledEquityOfferingProgramAmendedMember" xlink:label="cldx_ControlledEquityOfferingProgramAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cldx_StockIssuedByTypeOfProgramDomain" xlink:to="cldx_ControlledEquityOfferingProgramAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cldx_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635918372543697449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635918372543697449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_UnderwrittenPublicOfferingMember" xlink:label="cldx_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cldx_UnderwrittenPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="cldx_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635918372543697449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_635918372543697449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CumulativePreferredStockMember" xlink:label="us-gaap_CumulativePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_CumulativePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockholdersEquityLineItems" xlink:label="cldx_StockholdersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="cldx_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cldx_StockholdersEquityLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xlink:type="extended" xlink:title="41201 - Disclosure - STOCK-BASED COMPENSATION - SUMMARY OF PLANS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635918372543717449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_635918372543717449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" xlink:label="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StockOptionAndIncentivePlan2008Member" xlink:label="cldx_StockOptionAndIncentivePlan2008Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="cldx_StockOptionAndIncentivePlan2008Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372543727449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635918372543727449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" xlink:label="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationAndExpensesInformationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - STOCK-BASED COMPENSATION - VALUATION AND EXPENSES INFORMATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635918372543887449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_635918372543887449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" xlink:label="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ExpectedDividendPayableInForeseeableFuture" xlink:label="cldx_ExpectedDividendPayableInForeseeableFuture" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="cldx_ExpectedDividendPayableInForeseeableFuture" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="41301 - Disclosure - REVENUE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372543907449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_635918372543907449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" xlink:label="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LicenseAgreementsMember" xlink:label="cldx_LicenseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cldx_LicenseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RoyaltyAgreementMember" xlink:label="cldx_RoyaltyAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cldx_RoyaltyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372543907449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635918372543907449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_BristolMeyersSquibbCompanyMember" xlink:label="cldx_BristolMeyersSquibbCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_BristolMeyersSquibbCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RockefellerUniversityMember" xlink:label="cldx_RockefellerUniversityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_RockefellerUniversityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GlaxoSmithKlinePlcMember" xlink:label="cldx_GlaxoSmithKlinePlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_GlaxoSmithKlinePlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CincinnatiChildrensHospitalMedicalCenterMember" xlink:label="cldx_CincinnatiChildrensHospitalMedicalCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_CincinnatiChildrensHospitalMedicalCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PRFAgreementMember" xlink:label="cldx_PRFAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_PRFAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_635918372543917449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_635918372543917449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_Pd1ImmuneCheckpointInhibitorMember" xlink:label="cldx_Pd1ImmuneCheckpointInhibitorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="cldx_Pd1ImmuneCheckpointInhibitorMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RotarixRotavirusVaccineMember" xlink:label="cldx_RotarixRotavirusVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="cldx_RotarixRotavirusVaccineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementAgreementTerm" xlink:label="cldx_CollaborativeArrangementAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_CollaborativeArrangementAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_ReimbursementOfExternalCostsIncurredPercentage" xlink:label="cldx_ReimbursementOfExternalCostsIncurredPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_ReimbursementOfExternalCostsIncurredPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromProductDevelopmentAndLicensingAgreements" xlink:label="cldx_RevenueFromProductDevelopmentAndLicensingAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_RevenueFromProductDevelopmentAndLicensingAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RevenueFromContractsAndGrants" xlink:label="cldx_RevenueFromContractsAndGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_RevenueFromContractsAndGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" xlink:label="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PercentageOfInterestInNetRoyaltiesSold" xlink:label="cldx_PercentageOfInterestInNetRoyaltiesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_PercentageOfInterestInNetRoyaltiesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreementsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - COLLABORATION AGREEMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LicenseAgreementsMember" xlink:label="cldx_LicenseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cldx_LicenseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_MedarexIncMember" xlink:label="cldx_MedarexIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_MedarexIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_RockefellerUniversityMember" xlink:label="cldx_RockefellerUniversityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_RockefellerUniversityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DukeUniversityBrainTumorCancerCenterMember" xlink:label="cldx_DukeUniversityBrainTumorCancerCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_DukeUniversityBrainTumorCancerCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_LudwigInstituteForCancerResearchMember" xlink:label="cldx_LudwigInstituteForCancerResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_LudwigInstituteForCancerResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AlterisTherapeuticsIncMember" xlink:label="cldx_AlterisTherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_AlterisTherapeuticsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_UniversityOfSouthamptonUKMember" xlink:label="cldx_UniversityOfSouthamptonUKMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_UniversityOfSouthamptonUKMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AmgenIncMember" xlink:label="cldx_AmgenIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_AmgenIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_SeattleGeneticIncMember" xlink:label="cldx_SeattleGeneticIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cldx_SeattleGeneticIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_635918372543937449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_635918372543937449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CuraGenCorporationMember" xlink:label="cldx_CuraGenCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="cldx_CuraGenCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_GlembatumumabVedotinMember" xlink:label="cldx_GlembatumumabVedotinMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="cldx_GlembatumumabVedotinMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_Cdx014Member" xlink:label="cldx_Cdx014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="cldx_Cdx014Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_NonRefundableLicenseFee" xlink:label="cldx_NonRefundableLicenseFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_NonRefundableLicenseFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" xlink:label="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CollaborativeArrangementTotalPotentialMilestonePayments" xlink:label="cldx_CollaborativeArrangementTotalPotentialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cldx_CollaborativeArrangementTotalPotentialMilestonePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" xlink:type="extended" xlink:title="41502 - Disclosure - INCOME TAXES - CARRYFORWARDS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_635918372543957449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_635918372543957449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_CuraGenCorporationMember" xlink:label="cldx_CuraGenCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="cldx_CuraGenCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_AVANTMember" xlink:label="cldx_AVANTMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="cldx_AVANTMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StatusOfMergerAndAcquisitionAxis" xlink:label="cldx_StatusOfMergerAndAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:to="cldx_StatusOfMergerAndAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StatusOfMergerAndAcquisitionDomain" xlink:label="cldx_StatusOfMergerAndAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cldx_StatusOfMergerAndAcquisitionAxis" xlink:to="cldx_StatusOfMergerAndAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_StatusOfMergerAndAcquisitionDomain" xlink:label="cldx_StatusOfMergerAndAcquisitionDomain_635918372543967449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cldx_StatusOfMergerAndAcquisitionAxis" xlink:to="cldx_StatusOfMergerAndAcquisitionDomain_635918372543967449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PriorToMergerMember" xlink:label="cldx_PriorToMergerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cldx_StatusOfMergerAndAcquisitionDomain" xlink:to="cldx_PriorToMergerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PriorToAcquisitionMember" xlink:label="cldx_PriorToAcquisitionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_StatusOfMergerAndAcquisitionDomain" xlink:to="cldx_PriorToAcquisitionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeAxis" xlink:label="cldx_OwnershipChangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:to="cldx_OwnershipChangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeDomain" xlink:label="cldx_OwnershipChangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cldx_OwnershipChangeAxis" xlink:to="cldx_OwnershipChangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeDomain" xlink:label="cldx_OwnershipChangeDomain_635918372543967449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="cldx_OwnershipChangeAxis" xlink:to="cldx_OwnershipChangeDomain_635918372543967449" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangeInDecember2013Member" xlink:label="cldx_OwnershipChangeInDecember2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cldx_OwnershipChangeDomain" xlink:to="cldx_OwnershipChangeInDecember2013Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OwnershipChangesInJune2009AndDecember2009Member" xlink:label="cldx_OwnershipChangesInJune2009AndDecember2009Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_OwnershipChangeDomain" xlink:to="cldx_OwnershipChangesInJune2009AndDecember2009Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_635918372543977449" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_635918372543977449" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:label="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_OperatingLossAndTaxCreditCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization" xlink:label="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsWithLimitationsOnUse" xlink:label="cldx_OperatingLossCarryforwardsWithLimitationsOnUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_OperatingLossCarryforwardsWithLimitationsOnUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" xlink:label="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" xlink:label="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="cldx_OperatingLossCarryforwardsAnnualLimitationAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_OperatingLossCarryforwardsAnnualLimitationAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" xlink:label="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" xlink:label="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cldx-20151231.xsd#cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" xlink:label="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="us-gaap_NumberOfStatesInWhichEntityOperates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="cldx_OperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_NumberOfStatesInWhichEntityOperates" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g234232mm03i001.jpg
<DESCRIPTION>G234232MM03I001.JPG
<TEXT>
begin 644 g234232mm03i001.jpg
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MI9'B+"TF)5AU!(7('. W3C@YIKZ]9VEV\KC4C&X4%3I]P50C/(^3OD#%1_\
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M0O*)7V)LVN5)+<8)'/T-._X2RZ/3PMKQ_P" 0?\ QVD;Q=<JI8^%M?P!GB.
MG\A+3(/&9F<B3PWXA@P,YDLP<_\ ?+&II?&,%O$TL^E:S'$@W.[6+84=R<<X
M%)-XVTU;D0VL-_?_ ")(SV5H\R(K*&7)48Y4@@>AJ2/Q/I]XL9DLM71@=P63
M2KD;2/<)C]:E?Q191L5-OJAQQ\NEW1'Z1TUO%NGJI8V^K@#DDZ1=@?\ HNKV
MDZO9ZW8QWFGS":WDSM< CD'!!! (.1T-7:*****8"_G,"%\O QZYYS_3]:PO
M$$I'B#PQ$!PU]*V?I;3#^M=!129K \?.$\!:X2H;_0I!@^ZXS1X5@$4^NR*?
M]=J<CD#L0B+_ .RY_&N@I&) XZT#.!GKWQ7D'QLBDN-0L5$@$<<#/LPGS,2<
M$[B.!CWQDUW&OR1-\-+N2YE;R_[.+,8V$9?]WG:,@@;NF,'KC%>60WB0JFH6
MEQIFGWBPLAA8+;F4%57*ADDA;<JC)3:#UXR170>!;&VU?5/-@5DM9;*0R-:1
MFW1)<F+Y@N8RV#(49=IQG(],/5M8\+W>GZ4VC00+=PS"-EU<(S; & \QFW H
M#U"\] ,'%;V@3:2^E>*M\NAL1$RQ-91+'$=T/(0'GT!]2*FUJQ\'/HNB_98-
M%::YO[;<L$BG"F1/.( /(P,'/0=:NZ1I?ANV^(]VEK:Z;$D-C#+;%"OWMTF]
MEY[# )'H*Q3<ZG?^*=8;3CYL23>=#/97AAN)T;<OR DQRJIB88([=:NS^)+R
M_P!.N;&^M5U984)#0YM[N!PA&9K<'=G)ZIQWXZ#2\+>&=*U?PQ+'<R2M=O+*
M)3%>2!XR)'5.-WRD*.F,9!X-<_J7AF:VG?1YO-AOP&;2[PW#B/4!MYBD&X!9
M!V(QG^<UFWB3QMJ4%K'=7MC;V@$5]>Q":U='7[T:@3,CMD\L5X_(5TSZN?!\
M%U8V-OJ^MO#_ *1<2W5R"L"E,\RO@ 87..V3]*Y_3KVZ\3>,],GO(-;T^RU*
MUDF-NVI/Y$NU4P8PA! YYSP<CCK70:-HT^I?VT9-=UB%#=R6T:1W /DJCJ05
M+ MN.""<]&/'2N;O_M>E^$=!UB3Q-JL,FH>29WEG4HFZ!Y,?<)QD8 Y^\>#P
M*>_BW6KUX+EY+G1M)P%L;^YC7RKIL':UQGE5;;P5P!N[Y%2ZOXCUV>[L$M=3
MGTJ[GO(;.[LI8H&%N7(&Y"RDN& 8J0<'!Z$8/0W^J:Q!?1:'92PR2V]F+NZU
M"Y3<=I+* L2%=S$J>^!^-4_#MCXC\0>'K34;WQ1-;-.HGCCM[:'Y5/W=QP=Q
MQ@D<#)([57&H>(-)BU8R2:9J<>ER+)<0?9Q;DIM\SS$;<0&YR0PZKD&M74%U
MK6IMNE2:/;Z?/'')))/$TUQ@C(S'PO;C)[&J6HZ!XHL[07EOK]I=S6<9:*WF
MTR-$X'.U@<IP,"K/A_Q7J<PTEM3@MWL]4B#6]U &0A]N[8\9)(Z'D$CZ5TU]
M%&EI<S_91<,8R6C" F7:"0OO[?6O-YO&-[/J5N?M.GZ;)Y)#M%8&XN+;G)AD
M1F60 84Y"8)(';)DM=?UN_\ $EKIDESI^KV;R*SE[ Q21KM.6:-CD 'C('8Y
M(Z'0F@U&*VUTWEUHUS'IT1,J2:4-DV(@X9OWG! )'4\'H*V=-\(Z?<0P7NM:
M5HLFHJ=WFVEMM0],=<DXP.3^&*Y*^U/1+[6+G0_#&A>'[J%5S<>8HB%TZ@GR
MHF5<%QUR3ZX]:Z33-"\*>(]*A:#38U2"+[,;=LQRP<Y,4B@Y!!)R#GDD\YR:
M>MZMJMK>)H5WH>GMI]RXBLW>^>)9<'*KN"':X !P<9/W2U<HU]X8AEOX-=\.
MIIFH6T9(B%W=,2=H&UG1, %4!!!8$=.]7/#-O8:O)]M3PF8=(MI?,-])JTYB
M;8NWS%C=1O\ E&,D#T/<4^[70))H;6Q\,ZQ<0WB&.VS>S0K<(IR1'&7R$PY.
M2%4!CZ\LCT6QNK]=+_X0N^AN3$9MEQJ>%FB5@"I;+9 +C'?T/6NOTJXD\:Z%
M>6&J:/+I]B0(LI<AA-AB&52N" -@!Z9R1VK+\4:5X=\)6#2_9[QI[V]CGM[>
MUD*N;A0?F3LI()SV.<8Z5S<+VTLS1KX>\11-9CSYU2_02QALL7920V6&<YQF
MM*RDM-$U9+Z'0/$XN+Z)HXVS!(\O&=V V=P&>2?YUF76@:1J<PTN32O&4TUG
M#LW/':@F,R,05+]!NW8*X/8]*FLAIEG-'XK@L_%N?M F9I+*"0NK*Q9RV,^6
M5)&0> >.V-3P_P"*-+\/PB'3?#GB-6U"4W"F:T#-(F5!VA"3M52-O&,8YYR=
M#QWH%B1)JU]<7ZV[>7YRVEN'*! Y#MQNV@,V>HY'%84<V@1:Q#>/J&JQW]U<
MEY ^FR(;B-E*X/R@8 =B&'(#=\"NN\.>"5T'4X[LWSSK;V9LK>/R4C"QE]YS
MC[S9 YX[\<UB>(I3%XMO(]H*W-UHT9R,\?:)#_-:]$7[HIU%9OB/_D6M3_Z]
M)?\ T US?P_V#4M<$1!C LMI&<$?98\=:[,A0^XXR.*<6 &2:0G*G'-8_A@*
M;.[E3/[R_N\@@#!69T[=?N]ZVJ******YWQ "?$_A<@' NYR?;_1Y*Z*BFLB
MOC<H."#S[<BN<^(CJGP^UHLV ;9ES[G@?SJ?PK,DZ:LT;;@-2G4G'<$ _J#6
M]117D7Q<NX;+Q3I<USEH?LQ6:,'!EB\Q3(H.1U4,/?.,\UK:O::_IVBM=W=]
M_9UI$F'9]8,FW=@ -NM6+<G'!YSU-<PVJW=VT<,NKK=H2/+8ZI"B8.0 !):C
M'((S[8K7MY_$CZ!_:%I+=-ID2-()8=5M2H5,@XQ:9(&#QZY[US%Y-$EJ;A8-
M$DW.5!^TZ:Q)P#T-J.Q&3[BI8($$\D.H0:3:R1GYAYFCL O')_=@CKZ?X5<G
MLV5H[=X;:2- K*NW25V!^F%= 1DD=ADU9TS2H8G$O]GEIF.8Q''I1!RN, JR
MGG)X^A[T6FEWEIJ+R:;X>CCN[1E!$"6<DD+G^]MDRO'J*MZE;:KKFTZUH^I2
MRPG*.-,MV('. &$H//<=.F?6IM+_ +0T)Y+C3-#U""6X1%D_XE"%G50QSQ<8
M#?7U'!JY/JUYK]A'#JMM.$9M^R?PQ=DHP^Z<I*<'/.0>^..:=9:AK.F1)9:1
M]CCM5'RA_#FH1\]3GD]3SDG)K(U"34]0U07-]IVBR/$I62X-CJ-M(4(QC>(^
M!U')-5(HK2%8C:6UC;-$K+"T.IZFAB#==H\O SQD>W-.LVFMA<QQWFQ;EQ)(
MR:K?(Q8<D@^1P3QDXR<"KJI;7%K9V-Y!8W=G9E&AMKC4I_+&U<+D?9>< ]S[
M'TK7G\1M<:2UG-INBSV31B/R#?3G*] #FW]JXV[^SW<RR7NIPPRV:A;<3:S&
MLRA7WJ QM=_!"D;R#[FM)O%-J\%LUS%I\M]:QB..^'B(+.5//S.B#(_V2",]
M16+I_B6]L;8VMIJ%S';_ -Q=<L1LYSA=R<#GMCOQBM2#6-.$/E:A"VHJ[[Y5
MN?$5GB8]BX60;L  8;(P.GI-JFIZ=J^LIJ\,]W87P1(0;/5M/  ],F4D]_EX
M!Q^5R6_N]1TP69U?6)(7SF2*XTT.XZ$%A-R,G&/PJSI&I:;I4RW4MIJ=[-;D
MPV\LVHV3F-0H!142954Y!' )/KV&T_CR*YMY8X]%U<!E*[U-M@$\=?-QD9''
MN/45R']A3VND0VWV36IK;R CI=6-I+&H#?+MW2Y7U.&P=V>#TV-(L#IWV2:Y
MCUF>6S#_ &:)+8!(&90K9578GZ;L#)^M1W$6L36%_974VHR?;3)Y[IHC G=%
MY7\,N,!0,>XSS4NH2ZWJ.F&VDUC5+&)DV2>3X?D+DY/W=K,5&"!CKP>>:5X+
M0^#[?1(H[L30%=MV?#]Y\K Y$B*!N#C@Y+<G/8XJ"&?5K.\BOK:5TOO+6.\D
M.C7ICO-HP&=!&/F]&!]NG%=/JFI:3JVE/9ZG9:E-'*H#A=+NC@]<@B/((/0U
MQ\^G1ZI=1VNIW>I7%E NR29-)O1=7,><B*;$>T@8!W=3CH,G/1W?B?PFVBRZ
M*PO(+1X# 84TZY3:A&,#]WQP:YZ\U"XBN=+NK#6[6\FT\2)$UY9SQ,8W !5]
MJ,&/RCD!.G?FHW\:W-MXEM]1U*[\/B9;62U2(3W,0P[(VX[H2<9CQ^/M6SX2
M\7:=IEL^GZIJ>AP!9&>)K>]W!B[NS!@P4J03WZY[59\4^-+$Z.)_#VK:)/J"
M2*8Q-=0@A<X;&YUP<>XX-<-=!_$=Z]]J444EW>KLC6SU6V18/D7AG!W,N &V
MY(&3W/.^WBC5#?:9,^@JJZ8K[MNIVS%]R%!CYOH3U[_4Z%AXJN9_%5Q<RZ%<
M^4T*6\;PW$$APK.68_.,#YEZ9Z&N870=?M/"F\IXR-]Y8MQ;K?QO%NV?>V8)
M$>>,=<=ZZ+^U[J._T*^C\-:YY5C;3VTD*VR[P6$6T@;L8^0]^W2B^\2>(K[0
M-5T^]\/WJW<\$T=O-:6[%.054,&P0>^1D<CZ4E]J+V^O>&KE-+U>>/3+::*X
M\K3YC\SQH!MRHR,J16_X2\2:GK]UJ']H:/<:9;PB+[.)XG5WSNW [@ 2,#IZ
MBN<\1L!XT93M_>7VD!2V>JR3,<8[X4]>QKTE?NBG45C^+9##X/UF5>J6,[#\
M(V-87@598-0\1-+&^8Y;>,@#^)+= 5'N./\ )KL D<ZAVCY9<88<@'J*=)&D
ML9CD161A@JPR"*38RN2&^0@#;@8!]?Y?E6/X3/\ Q*I_^PA??^E4M;E%%%%%
M%8'B);T:II$NG-:23QO)_HUQ*8O-4K@E6"L?ESD\=#ZXJ&35_%22,J>&;&51
M_&NJ\'\X@:;_ &SXL_Z%6T_\&P_^-4#7_$R9\[PB6.<#R-2B;\]P7U_3\Z&M
MW&O^(]+DTJ7PK-;1W+(KRS7L#(B[U+$A6)/ /04NDSZQX:EU."7P_=WD$VHS
MW,4]K-$VY)&W#Y696!&<'CMUK2_X2NZ_Z%77_P#OB#_X[1_PE=U_T*NO_P#?
M$'_QVIE\2SLBD^'M84L0"#''E>3R</VZ\>HK@_&OAC7?%FHWM_I]FUM%!8B)
M$N\&2=MTC,J+\P'#<9P<[<$<X[8>*4EB"RZ%K.TX.UK(G\^W6N+N]$L;J&YM
M&M-9MK2[OVNY?^)1*S;><1@IG #.YY!R&-=#X8OK#0?"UKH]Q#J4_E*R,1HU
MWMDR23D&/J<DG\:YQM LKO7#JU^^I2SS3R^<ATB\\L0-$8PJY3 (SG)_3'-"
M7P1<?8+:*WD?SX[8K<-]CG5996D5V! @/R!1QC!X Z5/J>FQ0WFH1QO8+YQF
MV^=:W,4B>9)YBOQ&<.@.%//W5_#GH]+NX3;M"=,5;8% BK,!+E77<1Y.,_,2
M#QUY'IU_@&ZL_#-]JS7UWYB3K;)#,()2S+''MVL-O4=,]^3771_$#PN\[0_V
MO;)*I */E6R>V"!S5F?QGX>M>;C5;:+/_/0[?Y_0U$OCOPP^W;KNF<YQFY0?
MS/%68/%>@7<\<%MK.F332':D<=W&S,?0 ')-3VVLZ;J0:.TN[2[R"&2*59.,
M@'(!Z#(S]:T 1CM37>.&)G<JB*"S$G  ZDFE7;M& !Z"EX]J8T$,@8/%&P?&
MX%0<XZ9J$Z;8[@QL[;<!@'RER ?P]A36L=/FDE5[2V9W&7#1J2V<]?7.#2G3
M+#RRALK;9C;M\I<8].E TS3UP196HP21^Z7OU[=Z8-,TZ;YGT^UR5Q\T*YQZ
M=*:^A:7),TK:?9F1AM+&!,D'C&<>U11>&M$@C$<>DZ<J#D*ML@&?RI__  C^
MC?\ 0*T__P !D_PI'\.Z*RE6TK3\'J#;)S^E5_\ A#?#?_0OZ0?^W*+_  I'
M\&^''Q_Q(],7:0RE+5%(((Y! ]A33X+T!GW_ -G0[L]B<?EG%1#P%X>$GF?8
M!D<X\Z3;TQRN[!ZGM36\ Z*6!"7:*&)V)>S*N#VP'X&0#QW JJ?A?X;-T9OL
M]SRN&3[7+AO<G=G/XTZ3X9^'G!(CO$?G]X+Z;</S?M_2FCX<:<KJRZGK8VJ%
M &H2<8_'TP/P%<KXTBB\'7&GP6O]MWGG JC#6G@V$MPHX.<G/Y4Y]3>Z%Y#>
MW?B6*.,">/<UNQG19%B=DQ$<;2PXXW=>I)J)M0L9;W3[":Y\6P_;)_)MYFAL
ME$AW["=P7<P!Y/7C![C-&ZU;2H;*2\&IWUQ$)I8!(FE6+!W0@;<E,Y(*L/8^
MO%;^K:'!HFF6U[J&JRQI.Z1A?[*LLJS#(#9C '3%9[V^G7$,4@N;R8/$UPD7
M]@6TA948(6"K'G[S#GI58?V$VF)=Q'3W0N5VGPW&6"J 7<X!^558$GH,CIFM
M"WT[0)KEHX;_ $/,8=C+_P (_&(@$ +XDQM^4$9YXJS8>'--U'0Y=5C;2H+*
M)69VF\/1)P@Y;!ZC //UJK9V.B7,44MG=:>ZW$QME,?A?J^%;:WR\<,#S@8Y
M['&G8>'(=?\ /ELY-*Q%*8W$NB3P%6 '!'G)SWZ=ZJ-!_9^I:9IK06226VOP
M,9;6-D$@:WD(RK,QR/\ >/X5Z;134)9<L,'TS61XP7?X,UM2P4-83C<>@_=M
M5?PMIT=F^LB,_P"LOR<C.0%CC4#.<D?+W]370*, "H[@2&%A"5$A!VEAD ]L
M^U.*G;C/>L/PE-(WA:WFV^9))-*7YQG,S9/\S6]2T44445C:A;^=XJTA]V/)
M@N7QCK_JUQ_X]6P3@9HI:88\RA]S< C&>/\ /%/HI@DS*R8/ !Z''/OT[4^B
MFA0&)'4]:=32BE@Q'(Z>U.HHI"0*3>-X7G)&>G'YT%<YY-#QK(,,,CT-02:?
M:RL6E@B=FQDL@.<=/Y"H6T73"P9K"U+ Y!,*Y!SGT]2?SJJ_A'P].Q>30],=
MO5K.,G_T&H_^$)\.&9I&T33&)S\ILXL#./\ 9]N_J:E3PCX>B.8]"TM#G/RV
M<8_I2CPGH 8,-%TT$=_LD?\ A4;^#/#S0F(:-81JW7RH%C/YJ ::W@K0'QG3
M8N!C@L/Y&A?!>A(?DL O^[(X_K3D\':)&X=++:XZ,)7!_G4@\+Z4!@02 ?\
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MN;FXG\Y"\4\L:(4'7GRS@\#L?I6#H%J+[7=":VD^Q74FFQS7,MM#"I9B)@6
MVE""V>0.E=J="U7<V/$^J;<C:!#:\#C.?W7)Z^E-_L/6Q@+XFN, ]7M("2/?
M"C^7_P!=W]BZY_T,LG_@%%4D>EZPBJ&ULNPSEGM$Y].!BI/[/UC_ *#$?_@(
M/_BJA.DZK)<EY[^RE@W.1&]AD\KA>=_8\GCD<<=:KZCX;N=1TVZT^1K!([BQ
M\@SI:C?YIR'<+G@8Z#.0>_%;FGV4.FV$-G:QB."! D:#L ,4^2SMY;F.XDAC
M:>($1R%060'&0#U&<#/TJ1E#(58!E(P0>]>:V7@672[9+3_A$]*O_(=BET^H
M-&[@DD$CRS@XP.O;WIUUHATFQ,LG@C3$AC*KMCU5R?F8#@>7ZFBPL[>^N[NT
M'@I1<V;(EPJWX*H64,,$D9X([5I#P_Y5TSQ^$5#EMQE74 "21R<YS[5CRW_A
MZ35KJPGTN\BU.WB9I$&K&)!MQP7\U< [QV_O<<5N>!&TK0/#-II<NK6AOB^9
MT^UH[&9B"5&#SDD<=>:[-0 H Z5Y]'X;O;2_U(3VWB:YCEO99X6L=32"((YW
M8"^>O.XM_".M1WEO!8>2+RV\90O.YCB3^U][2,%+$ +.><*?Y=2!46EZUIFI
M01/8P>,YTCW,K;I6Y4D,-Q;YB"V,9/Z"I6U>P@D>)U\6),I:1HVE8R(N2"^P
ML3LSGG&WCVK$O?%\TMPT^A:S)%"J*?)U(2,PD!QSM;A3N0'.>2*QKGQCK5O)
M)'=^(VCVE69TM)"OW<#E6XSM./7!/?-:.A?$32&LX!JOB37!>X9Y2BKY><G@
M#:>,8QG^=:DWC;P_#.[-XRU_(QD1QP2*.<C&(B/\X-3CQQI3;\>*_$F457(_
ML^'.TC(/_'OT(YY[56O_ !Y!)ILCZ%XFU.YO(G7>EU9($5,_,6*0<<!L=_8U
MF+\1-9A5GGU,%,9!\EQUQ@9^R\#D>O;US6MX>\<RZK+<_;=:DMX88Q^\AB$F
M'+D -F!=O;COSR.VB?%>GN"T?CV(*H&[-I&<'USM[FDC\7:?DC_A/;=R1@ V
MB=?; JFOBK:Y/_"Q],9<Y"OI8Z?@XK.U+XD:I::D+?3_ !'HU[ (0YG^R>5A
MB6&W!DYZ ]>_2IA\0=>" '6= )=MH;,.0?IY_ ]SQ6EI_C?5[NS667Q%X-MG
M)8&*9CO7#$<[9B.<9X)'/!-6H_%NH>8HE\6^"0F?F*EB0/IYP_G3U\3ZM(0(
MO$O@QRQ^3!?D=.GFGOBKKZQKI6/9J_A=6"D.27()QP0-XP,_6N<F^(7B:VOY
M8FL[&XBC<H'MXLJX!QD,9A_*J\WQ2\3VEJT]QH5EL1"SE9CD8]L_CU.*Z4Z_
MXHP/+/A25ST1+^3)_-:N0:KXO6/$^@Z8[YZIJ3(/R,9_G4O]J^*C_P R[I__
M (-3_P#&J?%J?B9I )= LD3N4U/<?R,0KF8OB]%-$CKHM[M< A@CD8/T0Y_"
MIQ\58&>WC739O.N)5B1'+QY9C@?,Z!?UKHO[7UW:#_PCDF>X^V1?XU!+K_B"
M-PJ^$[B7CJE]!_5A4T>NZN8U,OA74E<_>59[5@/H?-&?RIEWXGO;5%\SPOK1
MWL$&S[.^"?7;*2!QU/%8G@?QC?ZD&MM<M+B.^ENYXU*P@11[.2F<Y^7!'?MS
M7>4M%%%1 RF212JB/:-C!N2><\8^G/N>..<3QQ(8? 6MELL?L4J]<=5(_K6E
MHO\ R [#_KWC_P#013=*WG[86#;3<OLR<\<#CTYS^M:%%%%%%9.A?ZW5/^OY
M_P#T%:U-XW[/XL9Q2XS2T45YEX26)?$WAY< ?\4_:S(F2<%O.W$9_P![^5>F
MTR*59EW*& R1\RE3P<=#09%5U4G!8X&>YZ_TI]%%%%%%%8'C4X\., &):ZM5
M 5MIR;B,#G\?QZ4>'0KZUXDG&=YOTB.>.%MXC_-FYK?K/O\ 0])U'Y]0TVRN
M=N6S/ CX]3R*X[^R=#UGQ580>']*TZ.UTV87-Y=VULB?.N?+B5@O/S89L'@
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MAK3O%.F_8=4A\R(,'4@X9&'<'M7-VVO:GX+N8=/\3YNM,<[+;5D4_(!P%G[
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M(]B^)M3$:[4%W+M7<&P-YP,C@_6OJO1>-#L/^O>/_P!!%6U#"1LJ-O8YY/\
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M!R"#T(J2F22B,J&!^8[1@9YIQ&>M<9K7@I[2^.M^%72RU??ND7 6*Z3=N*.
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M1=QQOXGTXR ;DM[ADR>AW1#^1-<WIK>)H/#7VJTNM'%M%&[HDMI*7VC)P2)
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MFI=V,NX,,-&>'B;NK#L0?\XK20,%PS%CGJ:=7%_%S_DFNKG_ *X_^CDK5T5
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MZC")(6.X<D,C#HRD="*YFTU^]\&W,>F^*YFFLF.+;5S]ULYQ'*,?*PP?FZ$
M9QS7;JP90P.0>0:8\;M*CK*RJN<H,8;Z\9_(U)5/4]+M-7LGM+Z%9K=R"R,3
M@X((Z>XKR;QSH5]X3TA+&"X6XT&YOH3 DK#S;9P1\N>KKA2!W 4#MFO3=%*G
M5M>"K@B^4,?4_9H/Z8K7;E3]*XJ Z-8>++Z1+_4Y;N.7SYK..T>2-&= @8;8
MRV-J@<,1P:9X>DCN= \216DES<WGVB;SFG0QR22-$NWY&Y48VJ 1_":\0M?#
MVL>&[VQUC5]&O([&VN(I9?,B*Y4,#CGUZ<U[EX0^)^D>+M4_L^T@O()_+,@$
MR+M.,9 ()]3U]/PKL?./G>7Y3[<9W\;<^G7.?PKF->@6;XC^$W;.88KYUQZ[
M(UY_!C5KQZS1^!M8="586SD$?2M;2A(-*M/-9VD,*;F<Y8G:,Y/<U<HHHHK"
M\9HTGA>X2-2SM)"%51DD^:G K<'04M%%%<]XMD53HD9SF75857 SR S?R4UD
M_"O#:'J,BJPC>^.PD=<0Q*<'OAE(^H-=O129'3O2.2%)49/IFG4444R1-Z@;
MBN"#D4^F32K!"\CG"H-Q/H*X/Q!>/)J6O7EM*Z+%X8,T.5VD%C*<X(!!^1>#
MTK6UB!;KX:RV[':LMBB$CJ,J!5[PI"T>E3%PP=KZ\8J22!FYDZ>W_P"OO6W2
M4M(?NG'7%>1^(K:.'X=>/(X 0O\ ;.\@DDY)MV;K[DUZS;Q^3;Q1Y!V(%X&.
M@JMJND66MV$EEJ,"3VTF-T;=#CD=.17,KJ%]X(E:/6II+W0V;$%\06DMAV27
MCYAV#]?7K77Q3Q3PI+#(CQR*&1E8$,#T(/<5)117.Z]X;DN+L:MHLJ6>KQX)
M?!V72@?ZN4 C</0]5[5+H7B>+59GLKRWDT[5(4#R64[#?MZ;E(X=<\9'XXK<
M!!Z4M%96MZ%;ZS"A<M%=09:VN8^)('/\2G\L@\$<&J.G^(I;*>+3/$0CMK\@
M+%< XANS_L$]&]4/KQFNB!!Z'-+17/\ B3PNFKNNH64K6>LV\96VNXS@CJ=C
MC^)"3R#ZG%,T+Q/YLZ:3KBK9:TBX:-OE2YP.7A)^\IYXZC!R.,UT0(/2EK!\
M1^&(M:"7,$SV>J6X/V6]A'SQGT/]Y3W4\')J+0/$4LMU_9&MP_9-7C3)!/[N
MY ',D1[CU'45T5+5:_L+;4[.2UO8(YX)1ADD7(-<:L]_\/)=EVT]_P"&!@+.
M<O+8#H V.6C&.H&1[\5VEK=PWMM'/;R+)%(H9'4Y# U*[%4+!2Q ^Z.II&C5
MV5B!N7H<<BN%^+2A])T2-N4EUFW1QGJ,/6]X:F2?4_$CIG U/9SZK;0*?U!K
M?IGE1B0R;%WD;2V.<>F?Q-,BM(()998H8T>9MTC*@!=L 9)[G  _"N%^-3,G
MP^FVN5#31JR@X##.>?R%>?? F-)/'%P64%H["1E/H=\8_D3^=>\(1"[KL"H6
MR#GJ6)S^O\ZY_4(9V^(6A.622-+>\<;5QL3$"\G)R=Q/(QU QQDW/&:-+X3U
M!(WY:)E*]G!&-I]CGL1]:T=*01Z9;1AD8)"@!2/RU/RCHA^Z/;M5RBBBBL?Q
M5"UQH+PQMM>2>!%;T)F09K7'04M%%%<UXOB,U[X:55+$:NC8 !Z0S$G]*S?A
M-:RV_@^261T9+F]GDB"K@JH?9@^IRC'Z$5V]%,8 9;O389&D4LR,G)&&QG@X
MSQZ]:JZKK>G:*D;:E>16PE;;'YAQO;T'J:30=5_MO0K/4A"\ NHEE$;]5!Y'
MU^M:%%%%(0",'I7#>(K:>[USQ+!;(9))O#8B1 .6<M.% ^O--U3Q"E]X4-M:
M:3K=O.PC40-IDY**&7(+!".@(ZU?T;Q):Z7HQ34DU)9(Y9GDD.E704[I6(8'
M8>N0<9[U83Q_H1\PM/=C8V,&PGS^6S/_ .JKL7BC39L^7]M/)'_'A.,X../D
MY&>,BK.G:W8ZK++%9S,\D*H[HT3H0KYVG# <'!Q]*O'H:\=\4WJ/\.O&,T1W
M0W>M#RGY 8?N.1ZCY3^1KV(=!2TR:&.>)XID5XW!5E89# \$$5R,VE7OA&Z>
M]T.&2YTDKF;2H^60YY>')]/X.!UQS71Z5JUGK-FMS8SK+&25..JD=58=01W!
MYJ]116-KWAV#6$65':UU"$'[/?1<20GV]5/=3P16?I/B6>VU!='\2B"UU%C^
MXE0D0W@/=">C=BA.?3(-=0#D9%+1534--M=4LY+6\B66*0<@]0>Q![$=01R#
M7/1:O>^%KV.S\03"73IG*VVIMP5)/RQS=@>P?@''//-=3%(LT2R1G*. P.,<
M4^BLG7O#]MKEKM<>5=IDV]T@Q);OV92,'TXS@]#61HFN7FE:A%H/B1A]K;Y;
M2] Q'? #G_=<=U/7MFNL!!&12UFZYH-EX@LA;WJ/\C!XI8W*21..C*PY!K$L
MM>NO#=W%I?BNXB\N0?Z+J?W8Y?\ 8D[+)W]"/<8KK P/2EIDD:2HR2*&1A@J
M1D$>AKBKC1]3\&W<E_X=B-WI+'=/I"_>0]WA///?9QGG'48Z?0]<L?$.EQ7^
MG3"6"7H<8(/<$=B*T:X3XJHTECX=1!EFUVV 'J</6KX.4K=^)"1@/K$C+[CR
MXA_0UTU(3@9- .:\Y^.38\"QCS=F;R,;<9W_ "MQ[>OX5P_P&_Y':\_[!S_^
MC(Z]WN%*1R/%S*1\N<L-W;C/^%8,Z!?B/9+R<Z5<=?\ KM#4OB5(/^$<N(CN
MEPT<#'.Y@&=1W//4=3SCDUOH@1 !G &.3FG44445D>)Y6ATJ%EQDWUFO/O<Q
MC^M:PZ4M%%%<GXRNC#K'AQ6 ,:74URV.I,=O(0!]<FF?"R0R^ +%BI4^9/P?
M>9S_ %KKZ*2BN&^)9%S;V]A/-=6MM+%,QG3/E22!?DB8#.[/)Q_L\9K4T[Q+
MIFD:!H\>K75OIL\UG$P@GDV%?E&1\WH>.:Z16#HK*001D$4ZBDI$#!0&.3W-
M<#K,DJZAX^=9&4Q:+%MQQ@^7.0<]<@Y_.N,M['Q7IGA?2]1M=?U'^R[F&-IF
MC7S3;*0<X0G.  O((ZGIWZW2_#WB#5[6.[LOB-+<VL@^5XK%.?QW<'U%23^$
M/'"JT5KXR'DDL<RVZE^2?XMN1QCC/%51H/Q05U$?B;33$ .&1=V<>ODG//?O
M[59TG0/&^GZG<ZC-<:+<WEQ"D+22RR8PK$@[4C49^8_H.*NRW'CIK2>WN=,T
MB<NA7S+:Z>, $8XW G/4_E7+7G@WQ9<:#;Z1-##<6%HXD2W>X0+)M8X5F #$
M,"2>ASCIU'HGA?7QKMBQF3R+^#Y;NT.0T#GH"" >1R#T/:MNBD(!ZUS&K^&[
MNVOSJ_AB>*TO6)-Q;R9\B[]W Z-_M#GUJ]H'B6VUL/ 5:VU& ?Z193$"2(\9
M..Z\\,.#6U116;K>@V/B#3WL]0B#Q-RI'#1MV93V(]:P(=9U#PA<QV7B25KK
M36PD&K!<;3T"SC^$] 'Z'(SCG'8T45#=VD%]:R6]U#'-#(NUXY%#*P]P:Y0Q
MWO@F5?(9[OP[N"M$>9-/!/WE/5X^>1R5'/0&NHLKZVU"V2>SGBGB=0RO&X8,
M/7(^A_*K-%4-8T:RUW3I;'48%FMY!\RMZ]B#V(]17-0ZMJ'@N\2R\0SR7FCN
M=MOJKXW1'LD_\@_<D9[X[-6#*&'((R,4M5=1TVTU:RDM+ZWCN+>3&Z.1<@XY
M'ZUROVJ[\"3)'J%S/=^'6&U+J1=TEB1T60J,LAZ!L<'@GD&NP@GCN8$FA=7B
MD4,CJ<A@>00:DI" >HKE-7\,75CJ4NN^&)1;WIR]S9M_J;W@\,/X7YX;\ZO^
M'O%5KK\)C\N2SU",?O[&X^6:(^NWJ5Y&#[CITKF?BK-/'IGAQ1Y8NSK%O(N[
M+(&"MUZ$C)'I6K\.;N;4="N+^Y55EO+IIV"*0JEE7@9)/'3\*ZZDZTD<:1($
MC544= HP*\T^/7_(DV?_ &$$_P#1<E<O\ H2=?U.;C"VH7W&7'_Q->YNI;&#
MC!KG7>?_ (6+!'M1H5TUV9\X*DR*%'O]UO\ (&;/B]BGARX9"0^^+;@9R?,7
M ZCO6M;(T=O&C,[%5 RY!8_4CO4M%%%%8_B="^DPA5W'[?9G'TN8SFM<?=%+
M1117'^.(GDU/17496);QF/H/LSK_ #(JQ\.+7['X&L(=V[!E;.,?>E=OZUU%
M(2!U-+17F7Q9_<:CI$Z2")F61))%DPX08. N]=Q/.,8P1RP%5?&6B:I?V&B?
M\(KHRW%K]C2,-NVA$.,+@R<''\1!(SD-GFO4K:(06L4055"(%"KT&!T%2'@&
MD0N5_>* <G@'/&>/TIU)D9QWKSSQ#)]GE^($TBL(GTJ",-CC<8YAC\V'YUTO
M@V&(^ ]$B95V2:=!N4C@YC&>/?)K O/"5WX2NI=7\'!FB+!KC2,XCF'?8?X6
MP?0]./0]%X9\4V7B6R+P'RKJ'Y+FTDXEMWZ%6!YZ@C..<?6MRBBBL'7/#,>H
M7"ZC8R?8]8B7;%>*">,YV.H(#J?0^O&#3=$\1M<7ATO5H%L=509\HL"LZC_E
MI&>Z\'CJ.];X.>12TS<?-*[3@ '=V/7_  K%\0>&(=8=+NWGDL=4A_U-["H+
MH/[I!^\I[@U4T+Q/,=1_L/7X4M-84$IL_P!3=J/XXB?89*GD?GCIP0>E+145
MS;17EN\%Q&LD4@*NC#(8>A%<?*MWX$D5X4N+WP\QPT07?)IX )W+W:(=P>5'
M//0]=9WEO?VT=Q:S1S0RC<DD;;E8>QJ>BFN@D0JP!!Z@URUWHUWX:F>_\-PF
M6V=@USI8P%(S\SP] K^WW6Y[\UNZ3J]MK-BMS:OP3M9&&'C8=48=F'<5>HJ&
MZMHKVUDMYT62&4;71U!#*>H(/J*XJ;[?\/)_,B6:^\,L273EGTY1_=[LG/\
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M\ G!QZ&O4@<@&EHHII0%@W.0<\$UYUXM8'2O'P"(N(H 2I!+?NUY..AYQSV
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M/9:G;)<6[G)1L]?4$<@^XKF/MNH^"+F./5KF74-#<8_M&;F>V;LLN/OJ>H;
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M.,L"<$'M],U1^(6K6][\*=0O[8B6&>&,IG@_,ZCD'H1GI[5Y%\'=G_"R-.W
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M:YJNEQM;VWB62QGQ-'MUDG.><[C;D\YSC/6K5II7B"SAD$%OXK1I%V$?VKD
M$]B;?*GW S1]A\4CRP(?%C"(DJ?[9)SSGG_1OF'US3YI?%-N-TL'BM=PVCR[
MH3=P3PML/3K_ /7S$NM^)[>X#1P^-7XQN-DC+Z=&B_I6)XAU+5-2ACM=3N=<
MA$!BE6"_58F?,H7.T(NX#UR>2/2OH( #H*6BH+NT@OK62WNH8YH95VNDB@AA
MZ$5RLB7_ (*PUOYU]H(8M*CNSS6*?['=XP/X>H'J*ZC3[^WU.QAO+.59;>9
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MO$/A<:A<Q:II<@LM9M\F.X PLH_N2@?>0_F.WO%H'BK[3>MHVM0K8ZY$-S0
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M?(!SZ=.E;K[%S(^T;0<L>P[\U!#J5E<R>7!>6\K_ -U)58_D#7!:1\0-3O\
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M]:L+1_!7B6]^RA;NRGC$4A)W(SW&7(_%C@^@%>US.8H\*=JA"=[<A<>O.?\
M]5>4:]'#>:3>>,(1/'-/J4*6DR2M&3 I1,XZ?,0_)!X/I6OX<TFT\+>+-,:)
M7$.L:;M$DDC.WGH0Y&6_O*W ']SI72?$&4P^ -;8$C-JZY!['@_SK@?#>BVN
MD_$;2+6U$@BCLUN%#R9.^2&0-C(SC&/E[8SZU<TC42OQ3:'<!=SWEPDP9HF"
MQ*LI0(.74D+&QP<'/0<TO@32+E==TG44BN&M)()7RPEV19 V@,TK*V03T4=*
MI?$F)9_BIH,3$A7>Q4XZ\S3"O8",T 8&*9-!'<Q-%-&LD;##(X!!'H0:Y&?0
M]1\*7*77A=#/IF2USI;OTR<EH,_=/7Y<@'VK;T#Q)9>(K1KBS9U*,8Y895VR
M1,/X67L:UJ6BBBBJ]]?6^FV4MW>3)!!$-SR.<!14&C:BVK:>EX;::W24L8UE
M&&9,G:V.HR,'!YYJ_111111111115'5='LM;L)+/48%G@DZJ>H/8@]01ZBN5
M-]J'@!RFH^=>^&]P$=WDR368]) !ED'9ADCOVKM(9XKB))89%DCD4,CJ<A@>
M00>XJ2BJFI:79ZO92V>H6Z3V\JE71_Z'J#[CD5R(NK_X>&./4)I;[PV<(ETR
MYELB6 59.<NG/#8R.GIGM(+F&YACE@D62.10Z,IR&!&00:EHJEJNDV>M6$MG
M?P+-!(,%6_0CT(]:YN"_U3PA.EMK<CWND.RQ6^I,098<\ 7'3C_IH/3+=:X[
MXK,%\322,#Q8VXZ<85YY"?KB,X]\=N1Z[;1>1;1Q;W?8H7<YRS8[D]S4M%%%
M%)7.^$_^/[Q+_P!A9O\ T1#4NNMC5=#^?&;\_*<$X$$W(_,?TY(K='04M%%%
M%<Y]J,GQ+%J1_J=),JGTWR@'_P!%C]*Z.BBBBO-?&T&Z?4A*\CPW%W!#(O)P
MAMY, ?W1N8'MW]0*]*JD--TW^TI+H65K]M<*9)A$OF,!PN6Z]N/I2PZ386\T
MLT5I"LLTOG.^T$L^ -V?7@5;/2O)--TO4/$'@?5XM/"/>R:C "9&"@JJ0R<Y
MXX+$]*T;JZU3Q'J5W87SS7D,+E)+'1SMA5AGY)KF3;G@X95'X=JCUK6_[6\!
MW:7&FP:>ME?26H@68.@:&-G&"%4#YEQTP,9Z5H>(;M[N_/A>WT>:[AL[>"Y^
MTP7*)/#SA616&"PV_P!X9!(K,_M;7?%/AO5]!$<&IW"CRGGWBUECR?NRPL.#
MP1E20?P-;5G!9M\4I8XX$$D%@0C$?=VB(#'_  &4C\36MIG@RSTJ_FO(;J^E
MN)P1(\\Y=F_$\\9XJ[HWAO2]"MH(K&R@C:",1K*(U\PC&,EL9)/>O.?%\Q?X
MN:7YR K'=6<<;;,Y_P!8W7!'!<'\1]1ZW3&#[U*D;<_-GTQV_'%/IKH'7!SU
M!X.*Y_6?"BW<QU#29O[.U=1\MS&/EDZ_+(G1P<GJ,CJ*AT+Q8TFIKH6O1BUU
MP+G:@)AN !DM&W?CG!Y&#Z5U%%%%%<]XON=+DTY])U:TO;J*]0CR[6UDE.%(
M.?D!P0<&E\(W6J3V,T6KQR[H)2D,\B!&N(\#:S+U#=0> ..*Z"BBBBBBBBD)
MP,TR&>.X3?"ZNG(W*<C@X-,DO88;R&UD8B:<,8Q@X;;C//3O4],EB2:-DD17
M5A@JPR"*XV31]1\&W7VGP\OVC13\]SIK,2T([M 2?Q*$X].O'4:3JMIK6GQ7
MNGS":"095A^H([$="#TJTD@D+ !AM.#E2.P/'KU[4^F21I+&R2*KHP(*L,@C
MTKAY]&O_  5J']H:(DEWHI+/<:8A^>$G&YXLGD<?<_+J,=;I&K6FMZ;!?:?,
M)K>9=R./U'L1T(J]14<]O%=0/#/&LD3J59&&00>H->/ZEX4M)?$'B:R5KF2+
M3M/C>VCDN&(B#!R0.Y4!GP#GJ:]B7.T9IU%%%%(>AK \*2>;+KK[55?[4D4$
M8RV(XP2<>X(YYP!VQ4'B>.>76]!5$G>#[3)YBQ;1SY3;3DC((Y.01P&QDD ]
M,.@I:****YT0D?$@S?+M.E;/NC/$N>O<<].W/K7144445Y/XS9?MNM,Y.Z/5
MX6CY  (T\GG/;K6</B;KA#'^V=)^[D#R4R3SP?WN!VYI[?$G6?,8PZQI3_+U
M,,2$\@8YG]2?PR:=;_$+Q8VXQ3>'YR1N4/=6X.WJ20+GC &<?7I5RS^(?B6X
MF",- ; WE89X&R!C(W?:L \\9^M1Z'JLMIX-OK32KR*+5;^_@BA$GRO%YD4"
ME]N2>!DY&0.O.*]-T?2K30]+AL;)%2&)<#'5CW8^I)Y)KR^_,<GA77X1(GF_
MV[J#;"PS@)*<X[_3OTKK=*DCN/BEJ\L4B2(NFP(60Y .YN_2G>,;7^RIK;Q+
M8;4NK1TCNL+S/;LX#*?IG<#VQ7+Z[XK/AOXA7&HVEJFH>9$T'EI(P."L#%LJ
MK<#;@_459M/BS>NX#>&KEE!^=E>5B/P\@5H+\46<-C0+]2 <;X9L$_A&:X?7
M9IO%/CNRN+61K"XGN8EB+*V8GC#%6VNJD_PGICG':O0] \7SP:@NC^*[4:?J
M[$)'./\ 478QD%'Z \GY3^')P.S!!Z$4M,C=GW;D9,' SCGWI]9>K>'=-UJW
M>._M8Y"3N$@&)$8="K#D'W%<^FIZIX-G$.MF;4-&)VQ:DJ?/;+S@3@=0 !^\
M[YY]NML[R&^MTGMI%EA<91UY##U%3T5GZYJ%UIFFM<6-A)?W 9%6W1MI;+ $
MYP<8!)_"J?B9]7_L5GT8%;L.A8*%+;,_/MW C=C.,@_2E\(S:C/X=MGUAB]Z
M=XD8Q&,L [!3M*J1\H'51]!6W1111111117%:EH^J^&=0FU?PYYMU:33-/?Z
M:QWE\G<SPYY#\L=N<'/3H*Z/1-=L?$%@MW83!U)VLC</&W=67J""#6E12$9&
M*Y+5_"USIUS+J_A(K;Z@WS2V;-BVNL?WEZ!_1ACOGKFM30?$]GKGG0J'M;ZV
M;9<6=QA98CUZ9Y4YX8<&MFEI",UQ>J>&=1TO5;C6?"J1K<2-F>R>0B*[]6QC
MY'SWS@]\5T&@^(;37K9G@WPSQ'9/:SC;+"WHR]OY&M6BO--6<IKWCJ6)R'6T
MLHR0>S!L@_A7I2C I:**88E,OF8^;&,^U(),RE!@XZD'H>.#^=//2L?PS$T=
MK?,VW$FH7#+@<X\PCGWR#^&*HZ^)CXO\.F)D"AY]P,@!_P!7V7(+<9X[9![5
MTPZ"EHHHHK#CE#>.[B'/S)IT;D>QD<#_ -!-;E%%%-D+B-C& 7Q\H8X!/N>:
M\H\=W'V6/7&C9TG?4F)9<\*NFJ!SV^9U_.N8&D0QV#_;]-DOXAY:3ZBVKR+'
M!YI!C5UV'D;E)P& R,U=DTS3(+5(_/GTZTME427+3S2M<X#DM"BN%$>8GPQS
MD$$ =#<U"RTR+3]-E\-ZSJ"Q:G<O#,U]J,L" (CYC/3#$X )SSC@YK.GGMM.
MC5-!U"[FEGM;II5N)C+-#)&I 7@[=K9...<#KTK>^'_@C2M<\-QZA*U]%=)<
MS>6T5T\9BPQ ( /!Q75I\.[.&:62'5=>C:4DOLU*09//.<Y/7/.:A/PNTGS)
MY$O-6C>X):4I>'+DC!RQ!8Y&<Y/<U';_  FT6S>1K.\U:V,C!G\BZ\L$C..%
M Z9./3)J?4/AY'>:9=V@UW7/](5@?-O"ZDD=P1R.F17$6W@#P_;7;Z1XD:^T
MZX9BUNXG1K:;/>.1DR'^495N>F,YKH+CX(^'[ZX>>:^U8NYR3YT?_P ;IK?
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M015BBLW6M!L-?L6M=0B+IG<C@X>-NS*>H(KSG3[-A)XDANKB2[E&LZ9;/<.
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M9.#]1G%=_111112'@&N)U#4-9E^)%I8(-0.BO$5N%_LP-;DE3C,QYYR<] "
M,')PD^GW_@)[B]T2%KS0F8R3::O^LMB?O/#ZKW*<8[=>.IT?6K'7=.BOM-N%
MGMY1PP&"#W!'8CTJ_12$9&*Y'Q%X1G;4H]<\-R1V>KQ<.&XBND[JX Z^A_\
MK$7?"_BV+7EFMKF%['5;4[;BSEX93_>7^\I['_ZV>BIH0!B0.3UIU8_B#P[!
MKD<,GF2VU[;-YEM=0MM>-OY%3W4\&LW2_$UQ9:LF@^)%2&^* V]V@Q#>#OM_
MNN.Z_EP16%X?3R8K\J0?.\6S$Y ./GQQZ?='ZUZ,1FJ.M6T5YHM[:W$HB@FM
MY(Y)"1A592">>. >]>;QZ=I^L7+67@[3I[E4^675;V[N/LZ8/\ W?O#\O;CZ
M@FM*30;'PUX:UVU6^N+^]:"*2Y6X)*IEF"%%_A&=V.3C:,YQST_@L!?#%N!T
MWRD<@\>8V.1WK8NBJP%FC,@!!VJ,D\]JKZL[QZ+=O&%)6!S\P!'W3V/!^E9/
MP])_X0'1=RE3]E3@_3K3KIXU\<VVY/G-A(N\-R,R1X&/0[3SGL!R2*Z$=!2T
M444A.!6)H#!]7\1L,?\ (14<?]>MO6Y24UU<[-C!0#\P(SD8/3TYQ3J&Z5XG
MXAMT<>&([=C,9=7_ .6A+#<;B0%?8 \8'_UZ]4UCPU;:R(I)'E@O( 1#>6[;
M)H_Q'4'NIR#Z5GV^OW>A7:V7BEX0LC;;?4(D*0R<#Y9,DA'/)QG![=,5U .0
M".AI:0@'K6'JWAI+J^75=.F^PZM&FU;A5W+(O]R1>C+^1'8BF:3XC:6];2M9
M@6TU1 " &)BN!_>B8@9'JO4=.>M;XZ"EHJCJNCV6MV$EEJ$"36\G56['L0>H
M([$<BN;GU/4_!"K_ &H9M4T4,$%XH+7%LO8S#^-1_?'/J"<5UMO<Q7<*36\B
M21.-RNC!E8>H(ZU+12$ ]:Y_7/"D6H7\>K6$[V&KP+M2ZC&0Z_W)%Z.OMU]#
M5?2_%,UMJ4>C>)4CMM2=?W,L9/DW?)'R$]&X^Z?7C-=3111117/ZSK<WAJ;[
M5?XETIV^>4$*]KP>2/XU..@^;/0-D 6]!U.?5[9[V2)8K68[K5<Y<Q]F;!P"
M>3CL" ><UJT5D^(]2T[3M+?^U+MK:&<-%OC+;^0<E=O((&3D=.O%<OI7@SP_
MH_BK2]5LPTQN%9;>=IS)NDV$YSG#90,<_P"S]*[ZBBBBBF/(J%0Q +' YZFG
M  4$9KD=7\*75EJ,VL^%;D6FH2MON+5^;>\(_O#^%O\ :'OGJ36AX9\5V^OQ
MO"\<EIJ4!VW-E.-LD1QGIW4]0:WZ*0C-8/B/PI!KQAN89GL=4M<_9KV(9>/V
M(Z,OL?TJCH7BZ9-070O$L2VFL!?W<@/[F\'3=&?7U7J/SQU@.1FEHK.UO0[#
MQ!ISV6I6ZS0,=V#P58=&4CD'W%>?^%Y/+T"-OWTW_%3L-SL'=LOC<QZ$\Y)^
MM>H Y&:K:E8QZEIUS9SD^3<1/$^WKM88./P-<1JVD_#?1%?^T+33%E4X,*9>
M3_OA26_3BL2P&G76G^)9-%T:YTJUDM;3R4E0IYX,DGSA.>^0#DY '3OWW@H8
M\*VG0AC(P(.009&(/Y$5N.P4#=W.!536#_Q([X_].TG_ *":R/A[G_A -%R1
M_P >J=![4MU+%_PG=M&9"DB6+N><;P9% &._.3SR#C'5JZ(=!2T444AZ&N<\
M)_\ (0\2_P#86;_T1#7244V21(8V>5U1%&2S'  ^M.IK_=->-WP$T_@@1*@W
M:FDH5%P //D;GW]3W.3]/9JKWUC;:G92VE["D]O*-KQN,AA7+%-0\%D-OGU'
M00P79L:2XL@2.1CF2-?^^@,=<5U5G>07]K'<6TJ2Q2C<CHV0PJ>BJ.JZ/9ZU
M:&WOH1(FX,IZ,C#HRGJ&'8BL&VU34/"]REIXAF%S82-MM]3V[=O. DPZ _[8
MX/?%=4KJZAD964C((.<TZBFNBR(R, 588(/<5Q]WH>H>&)A>>%H_-L=V;G22
MV$*_WH/[C=21T/L>O0Z)K=IKVGK=V;';G:\;C:\;#JKKU!'I6C29'K2U3U72
M;+6[![+4K:.XMG^\CC/XCT/N*Y1;O4? .R*_:?4?#^0J79&Z:R'I)_?0?WNH
MZ>E=C:W4-Y;1W%O*DL4JAT=&R&4]"#4U%-8D8P">:02HSM&'4R*H9DSR <X)
M'O@_D:RX?#EFFJR:C+)/=7#/OC\^4ND!V[?W:]%X'4#/O4=CX8MM+U62[TZ>
M:WAFW--9JV86<_QA?X6X[<'TK;I,C.,C-<QXX-LEC97%T)XXXKG_ (_;;'F6
MF58;^01M[,#G(/0]LSP3#HD]Q&MEK46IR6.]X(8HQ'';!R=Q5?4Y(SD@ X
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M2Q_:4OK!;A4(WH'N8MI/?IG%6/ >[_A"-)\Q=K_9EW+MVX/ICM]*Z&J6L_\
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M+_L3*"3^0_&O5Z**Y'XD '1-/#' .J6N3C./W@K0\#J%\$:( NW_ $&'MC^
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M'OS7):9XW?P]KKG3="UJ+1) &DL'MC^X8Y+-%SP"2/EX')Z<5T__  N'3?\
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M&Z#/0^O6NPAF2>))(W5T=0RLIR"#T(/I4E%<U\1-@\!:RSQ1R@6KX$@! )&
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MZ30O$>G^(;4RZ?-N9#MEB<;9(FYX=>JG@]?2M6N7^);JGP\UDN0 8,9)QR2
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MJ9<?*') S[XI89"ZX<*) !O56R%/UX_E4E%%%%%%%%,DD2&-I)75$4$LS'
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MN'C\MI(U<IG.TD9QG J?:/048'I1@>E8TOB$Q7NL0?8I6&FP+-N5U_?94MM
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+111111111117_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g861164.jpg
<DESCRIPTION>G861164.JPG
<TEXT>
begin 644 g861164.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$S,SI;,35:0U<Q+C$U6D-7
M-S(S,#$N3U544%5473(S-#(S7S%?0T5,3$1%6%]+7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@!2@'O 0$1 /_$ !\  0 !! ,! 0$
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MR%E#'T'E&0UQS7 X[+IC'HX]3)Q3V<L]#&&QX<4:Q[5%@-MMQ+>2??SIA1
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M/;>QXZ;8+K T.9&<&=$]S/%48Q]G*5X^GN#9$M3+WJ/9<%#,,A-<-QVL;5D
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M0<!/+2C(32\R4R5PR Z87D%IRL,8+L'L\<?;UZR3-2*$)L1.G"+U(Y:P=A_
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M4UARRQ60J16'NS*0U."A&J%H<7!.7SPS0#A%\-$0W#17@(0'K 0A9>PAZ?\
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MZO/3E6A<%HW6A<(;A;N'*$.OK /.(=0_Y#Z*<JWKZPZMQ'K#J !$!$?1L("
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MYX?U1YP+-[>5SNU:2E5R 9M(6JU;=L)AGA\*B$?+M($+>;,+->)P1:<;>-P
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ME*4I0! 0W 0$/2'6%*4I2E*4IN&^V_7Y]OV[>FE*4I2E*4$0#SCMY@Z_2([
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MPG&*[*DB\;,AJ8>SEM%\ND?A#HJ!W>+2[[[%"NT]Z=3++[;2[;!7'A;: 7
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MO+.2F-)RJ]:>6LL3IY+\D/3=[=_WJ<D/3=[=_P!ZG)#TW>W?]ZG)#TW>W?\
M>IR0]-WMW_>IR0]-WMW_ 'J<D/3=[=_WJ<D/3=[=_P!ZG)#TW>W?]ZHYZH\$
M*M0^-X[ T4D(BYK'G;3-F*]R5-Q[L6I38!U#8SS<L8K4Q*Y#>4?)DD!.CR9P
M$Z\IK4N93D<E6E)+TATC.0'7UW=8B/\ :N#SB(^8+J<D/3=[=_WJ<D/3=[=_
MWJ<D/3=[=_WJ<D/3=[=_WJ<D/3=[=_WJ<D/3=[=_WJ<D/3=[=_WJ<D/3=[=_
MWJI=8 @'7=U767==UP_V;@NVVY7[=MJC9I&P$KTRX/:\1+I,FERAOR!G*:B^
M)6LYG)-*R_G;)68DS>" ]:X&VF,2:>DL1ZD55UK@>VFN!9*4M58E)DM2E*4I
M5MS&6,\%BLAF+_<MM9HRSKWIQM;&QP>G0Y,WI[S[TS4RM*=8[/+JJ&VU*V-#
M4C5N3HO.3H4"50K4%%7Z_P"*<47 #]',IGR:'YMQ3E/$.4<.X:E&G3*,#;8_
MG-;D/42>VI]/['%V)LE;]#9*5F*YR R+/#9.S&5I3MDD43I?$"8I);VN_I7Q
M"=/\*TX2#4Y(/'HJ%0O+08)G\<;8I\/SS'V7",OHL&.\*F;,Q.;BU,RA@R(X
MHFYT?;G\Z)WM:UND34_N;$[LZY?[.;]=N"L!3UW@,W/DYY\)BN/)[F.3L;2@
M61#!$"RUD53BO&DQRN[KGEL4-3/,)DV/Q"(F.-\I>6N/QF2S>1-+-"F59(+)
MF ("&X?O#^ @.PA_(0$/15:4I2@B  (CY@#<?X!4'Y=KVQ1 M1D"T\3&$9JC
MQ64)[=A^ 9T<<=7E:?91G$(L[S.S"S?.[7BYWMFZF/,#XH0N"F)$0!Q=F5WB
M;?-E,O;%["F]/!NNW!.H&:M$,@BB3663>,Y-F^')8]M3>AB6=X3AG(:+%N49
M9B=:E>G%U=F:(3-V8DIHR%EC"^0,4AC\VB"&0PAX12$ST8-K8PSD'3YEW4LP
MI<AVXYPG(\^Q6;I%\ ?4\X)>--DKD\,R<F;X&78HDBDU$^Q![(;D9Z-&Y+"4
MP'GHD5EXA9GC$63HQFS%&,<RPH5]T-RUCV%9-B=SJEM0N@QF>QILE;"+DBL/
M56(UXM3LD%8EL4J+4ZCG";3S0L R[(E*4I2HW:E=2;;ILB:22'8FSCFQT7?"
MZLB!X @1$\FP,$;;OA64R@]$Z/T58TK+'D5Z7G[54@)>7MR<6N/1)HD<D<T+
M0='EZXI>DIOB<"R RR23S3'DST]PC5D]SJ+1<\6#%.FC(TD21.'YGRM9(5D>
M>8W&79\O>2/@=M:7Z<(44,R ^.$32L4$DSDWR6<-2N-FS4S&]*"L),5E&581
MFVH%J4WQM:3"3,?8_F,%@TC,\<5-Q#6H>TCYD6,\IE;P6J$R%6*UQO0E7I 5
MXDPIKRQ5FK/DDTX$P?-F,LC(L>+\QP"W+^-E,)9,WX8:9>B@CME7$[E\*.AJ
MZ-M4F>(ZC<6::(H//D:.4QA\.AMC"^(7(R;E*4I2O$DLB:8C'GR4OQYR9ECK
M2XO;JH3HESFI*;VM(:M5WIFUK3+7-R4\P3>"9O;4:MP7*!+2(4JA4<43?KVC
M'%%P"ZQW.BR:0O.^&9_I^D&$XU,L'Y;QG;'\PO+EJ9>0C6FT(,P,LADL?EUN
M<Y58KBL+*;Y5:M:Y*UO;+/TD+6L3Q8BOF8<0[ $"TU9;U02LJ>MT1P+/7W%N
M9H>BBI4DR-CC(T9EK9#GV)R-CB[N],EAJ!<]L;J$B0R9;#%L4?&67-\D5QYV
M0KS_ '-4>N'&^D=WA)>3X!FYRA,FD<%C<KR[!L;G2?%F'3\FS=%CF!+\J2,'
M9 N;V^13)P1,VT199HY,(+&]TE3<Q,SJTN"^9P"%P;@.X;B'\[1&T0Z_0("'
M_IU56E*4H([ (CY@ZQJ#^2=>^)L2Z@,?8(G4,S.SM^3,AQS"\9SP..[SM/IF
M=9BTK'J)885SDMX^&BYG(D:3P=O=$\058^*?U">'N,W0S"XYB(]3$NNW!.9\
MDM6.8@JD1=LR,S85B6<O#>UH8'FXS3A-6['F<@Q6ZDOBQV>2\=RYS(;U1[TQ
M1XB4MY#C)X$;*XFUN#XGOW ^JC%&H:*92FD+4O[-'L.Y>RQA2=+,@,1\&,:I
MAA5V%FGIYR-\.*5)&%M5V'7DNSJ4W >B3FN%R<E&)1QG;TNZG,5ZP,.-&>,*
MKGATQQ()1DN*L3J^,JF/K'51BW),KQ:_.9#4NN\/(:'"0PYT5L)K@2C7+64U
M N5-Z Y3<D)D)2E*4J/^H;4 DT_15$_EXJS1FZ0.RU0E9<:8$A:.;Y"=R&Y$
M8YO;HG0/#_$X\A:F-N+ ]8L>Y,U>&K%#;'V(MXE#TRLCA%I3Q6-(YV.\?Y5B
MC_+I]!)OIV6ZN'=YB45N$W%NF=H?6V,/V8\IM$B<8Z]1MB89"M7-+A&V]O?L
M@G'1:=JFN'N3= Y8M:I//6IW&+'J&Q5IG47R-3D',N*LDYD@SD@CZI3!7&%8
MJ<H(URL_QU$PMG/="5&2(F:E:&R]Q67HG,E>KM1I#DIJGS83J@C>0\Y3+"D4
MQWF!S1P;X;1/6:[(03;@,R41DYM0R2#-F1A?/^$II'W=P.8GAC3,@W(7IF?V
M\Y0!C.L&V3-*4I2K+R-*7*$0*8R]FALER(\1J-O#TU0*'6-U\JF;DW(3E*"+
MQ[X87-;.6[OBNPEM0GN[DWM28Y1:I<EJ5$4>=9^?==A;-N=$;-J%>=)N>85G
M7&^N_21K2S<7E1DQ*SF94AN*VZ98PNPMIWC<%RKD!>\M^FS$DAODL2NEUT7<
M\E3\EQ?&\L)?.U3,T=G+&DG4:_<.K7J@;,8R9ZR?J_XB-FJ+'V(425&EF;#B
MHO4_IZ6QRV3I7-U(;&.0K,0X//R<_LJUV3+&99(0BJI,5*B3F:RX]>>D7/\
M-IEQ,HQB_'[I,2>)[I?TL8-QS.DR/=DQ/*L;/>3<?Y._2HH./1*XA&H_C?*:
M3+L5<U 7IW]R8IE$T!)DTN8&"1?H*3%<R043RKK^:+++"^_KOO NRTL+[_\
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M.O4_(V2U20LF&98.S0H>8/@4_&CL2LN-DRB?0>?O>3L@\MM+.@LAC*N-2FY
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MQ:72:'S6=-!C?D>3J,^L1294_1+(:6-/DADSHK4M4+V[TI2E*" "&P@ @/G
M>L!_E7$+;0 0"VT 'S@   #_ !  Z_YU4;;1#DC;:-H>8! -@_EYJ#;:(@(V
M@(V_V1$ $0_AZ/Y56E*4I2N/(LWY7)MY6^^_)#??T[[;[U4  !$0  $?.(
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MV[\D #?K'8 #<?2.U5  #J   .OJ#J\X[C_F/6/[Z4I2E*H-MMW]JT+MO-N
M#M_G5.3;U!R;=K1WM#8/U1](=74/[PJNP"("(!N'F'8-P_@/G"@6VV[\FT W
M'<=@ -Q]([><?WC5:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*MU'+XHXR5ZAJ"31];+HXVLK
MQ((LD>6U3(V)HD9CD5'G1Y8R5-[HUMK\:S.Y;*N7)$Z5U,:G*Q :HN0J@*N*
ME=(QQ0$JBD)JU(4M.M"\E(8H)L5&V#>)8&%)[[[3C"Q, 2POLLNM&\!L >4
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MU(>R+$CP6?<VJ"E5V.%VLG"C3FN<X:>I2Q,YN/L;Q;(4BFBZ4Q<N+H3I//\
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...ZY,CO))$;!N>E*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g234232mm03i002.jpg
<DESCRIPTION>G234232MM03I002.JPG
<TEXT>
begin 644 g234232mm03i002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ,> E$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBJ=[<S
M0RP16\,<CRDCYY"@&!GJ : +E%4#-J8_Y<[3_P "F_\ C='FZI_SYV?_ (%-
M_P#&Z +]%4/-U3_GSLO_  +?_P"-T>;JG_/G9_\ @4W_ ,;H OT50\[5/^?.
MS_\  IO_ (W2^;JG_/I9_P#@4W_QN@"]169)>:C%+%&UG:;I20,738X&?^>?
MM4OFZE_SZ6G_ (%-_P#&Z +U%4O-U+_GTM/_  *;_P"-TGFZE_SZ6O\ X%-_
M\;H O451,VI#_ESM3_V]-_\ $4GGZG_SY6O_ (%'_P"(H OT5G^?J7_/C;_^
M!1_^(H^T:E_SXV_X71_^(H T**S_ +1J7_/A!_X$G_XBC[3J7_/A#_X$_P#V
M- &A15 7.H][&+\+C_[&@7-__P ^,?\ X$?_ &- %^BJ/VF__P"?!/\ O^/\
M*0W=^/\ F' _2<?X4 7Z*S_ME]_T#&_[_)1]LO?^@8_X3)_C0!H450^V7O\
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M^L?^NC?^@-5R@ HHHH 2EHHH 2BEHH **** "BBB@ I*6B@!,44M% "44M%
M"4M%% "44M% "#K10*6@ I*6B@!*,4M% !28I:* $Q1BEHH 2BEHH *2EHH
M3%%+10 4E+10 E4HP/[:N3W^SQ?^A25>JE'_ ,AFY_ZX1?\ H4E '-7]Q.UI
M>6J.1 R2D)L R3(_.>IZKTZ>_;:@NC>:M$QCV",3(ISG> 8^>E85RC@2-(66
M,AEB#9VL1(<X(R._0X/?G%2S:>=3O9$@G,4X:9D9<H%=3'U"MWR<^HZ@XH&;
MEA*D^HWTD9RI$?48_A--\+<^%=*(Z&TB(^FT5E>"P\7]JV\\DS3Q7 #K,067
MY1W[@\D'OU]AJ^%?^12T?_KRA_\ 0!0(U:"0 2> *6H[@[;:4CJ$)_2@#$\5
M/(VE1-:7+0N905EC&[^$GIT/KSQ7/2PR3:K8BXEG,@M++Y_*#9?S&)#*Q+#.
M,\'C&3G%9H^;0IHFMK_RY7@'$OG"3(D)\H<JI..1&>-V!@BKUW;?;-9T:4QN
MK_9[,E=S1C_6!B,/\O&,D ;OE [\ ST,5G^(2%\.:FS=!:2D_P#?!K0K+\4Y
M_P"$3UC'7[%-_P"@&@0NI@CPY*IZ^2!^/%6?^8J<=H1G_OK_ .M4.K<:))]%
M_F*EW*NJ/E@,PKU/?<U $=N0N@JW;[/G\-M%X,:$ZGJ8<?CC%-B_Y%Q<?\^O
M_LM27V/[*8]MJ_S% #]1_P"/5<=3+%_Z,6B[QYMI_P!=O_96I=0_X]D_Z[1?
M^C%HN_\ 7V?_ %V/_H#4 )/SJ-J/9S^@_P :)/\ D*P?]<9/_0DHE_Y"EMZ>
M7)_-:)/^0I;_ /7&3_T)* %C_P"0G/\ ]<8_YO1;#-U=G_IH!_XXM+'_ ,A.
M?_KC'_-Z+7_CXO/^NH_] 6@!MK_Q\7O'_+8?^BTJ@>/#>H?[UU_Z,>K]K_Q\
MWO\ UV'_ *+2J!X\.7YQT>Y/_D1Z -D4M(*6@ HHHH *HW'.KV?M'*?_ $&K
MU49_^0U:?]<9?YI0!S>M037.MZA%;"<RO8KM7<&YWK\RJ6 &/PY!^IPEU2_T
MB?4MIFB%K%%&JQA6VL1&/NXQ@8.<$\9QCK6SXF>>+4=1=7E@7[ BI.C>60QE
M4<.2 ,9'<#GMFLXPZ==VU[;07\\4D,, E^US[8E!5=F K9#=P<9)[\# ,ZG0
MK1;?5]4F-W!--.RLT:/EHP,@9';C'^16]7,>&G!U_6@UT)7,H*Q>86\H9(/R
M[CMR1GHN??MMWUQ*KQVUKM^T39(9AD(HZL1WZ@8]2/>@1///';1-+-(D<:]6
M=L ?C5:RU..[N+BW!030GE5<,"IY5L^X[?\ UB8M(@:!K^)YYI]MSPTS[CS&
MAX[ 9)X  JJJ7%M=:A>V\LDB"<&2W;D, B@E.X;CIT/IDYH T+KG4;+ZN?\
MQVKM49'674+)T(*LCL".XP/\:NCI0 M%%% !1110 4444 %%%% !124M !11
M10 4444 %%%% !1110 4E+24  ZTM(*6@ HHHH **** "BBB@ HHHH ****
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MY\)S-_TYD_\ CE85AIHUC[3;SR/"HNIG&Q@W1E."&7CDYQS^N*W+PX\(3?\
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MX[$>WO715D6?AZUL#;&U1$\I][MMR7.S9U[#'8<<5KT %%%% !5*;_D-6O\
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M&D= @9B05(\SC''WBIYZ53UZ>XU.;1[H1W"B9(S,;=U^SGY\[7828(XX&#Z
MFIM*-O'/K$?G6_V>*W2:);*5K=.KMR V58D'([TW7;6*VUC3_+F,RQPQ*'D1
M9F8-*<$':3GW+ ?4YH ] J"^YL+C_KDW\JGJ&]_X\9_^N;?RH YZYN[IM'N(
M"FVW%B<.R8W'RL\'//?MVK1U.]GLM2MV@T^YO=T,F1 T8*\IUWLOZ5@7**99
MGR PT=AMW=1LZXQU'3KWK3\67*VL2.T[P#8?F1L-]]#@'(]#GD<9H +'6[U;
M3 \/:FPW-R'M\?>/_36JYUB\_P"$<*?V#J07[)C?NM\?<Z_ZS-;^G?\ 'EUR
M-[_^A&JS?\BJV/\ GS_]DH I:AK5XUE(#X?U-1QR6M\=?^NM+>:S>,D7_$@U
M-<2H>6@]1Q_K:UM3_P"0=-]!_.EOO]5%_P!=H_\ T(4 9%SK%X;BS)T'4AME
M) +0<_(_'^LI9=9NS?P$Z#J0(1P!N@Y^[_TTK5N_^/FR_P"NQ_\ 1;T3?\A&
MV_W7_P#9: ,HZS=_V@&_L+4L^5C&8,]?^NE+%K%T+V=O["U+)5.,P9_B_P"F
ME:O_ #$A_P!<3_Z$*(O^0C<?[B?^S4 9%MK-T+B[(T+4SNE&1F#CY%Z_O*RI
M+^XD>6,BXMTE@NBT$@'!W2<DKD9X_O>M=7:_\?5[_P!=1_Z M<U>V4DMU/=I
M I6**[1IM_*Y+_+C/(/';L.?0 Z\=*6D'2EH **** "J-QQK%F?6*4?JA_I5
MZLW4[=+F^L4<R %GYCE:,_=/=2#VH RY]":_UK4EN;2,6EQ"$\UG+A\[<Y0M
M@?=[ ?X]!;PF"VBB+LY1 N]NK8'4U5_L:V_YZWO_ (&S?_%T?V+;?\];W_P.
MF_\ BZ &:=I7V#4+RY#QG[4VY@L9#9R<9)8YP#CH*TZH?V-;?\]+W_P-F_\
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MZ/\ "E_LIO\ H(7W_?Q?\* -"BJ']FR#IJ-Y^:?_ !-+_9TO;4KP?]^__B:
M+U%9_P#9D_\ T%;[_P A?_$4?V9/_P!!6^_*+_XB@#0HK/\ [-G_ .@K>_E%
M_P#$4O\ 9\__ $%+W_OF+_XB@"_15 Z=<'_F*WOX"+_XBF_V7/\ ]!:__P#(
M7_Q% &C16?\ V9/_ -!6^_\ (7_Q%)_9D_\ T%K[\HO_ (B@#0'6EK.&F3_]
M!:^_*+_XBC^S)_\ H+7WY1?_ !% &C16?_9EQ_T%K[\HO_B*/[-N/^@K>_\
M?,7_ ,10!H450_LZX_Z"M[^47_Q%']G7'_05O?\ OF+_ .(H OT5DS6=U'-
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MMI89K^Y82JZ,WEP[L.26 ;9D<L?SJ3_A'2+E;A-0N$E5BVY8H1DD8)/R<]:
M,J2037.F2^6F=UN1@;U4?/T)_G5KP\':6U/(1;4=2YW'/_?(_G5MO#K/*)6U
M&X+@J5)BAX(S@CY..II+7PZ]F%\G4[A65=@?R8=VWTSLS0!MT5F_V;>?]!BZ
M_P"_4/\ \11_9MY_T&+O_OU#_P#$4 1>([?S=,^6!Y7$D9&R,N1AAS@,I./K
M^!Z5QVHVQ%QI16%3)Y"1HCF6)C^\;=A6..G4%LCT(Q7;?V;>?]!F[_[]P_\
MQ%5;GPRMY,LUS>/+*HPLCV\)=1G( ;9D<T ;=17?_'G-_P!<V_E53^SKS_H+
MW/\ WZB_^)I'TR[D1D;5;G##!_=Q=/\ OF@#,N--C_L":_W-YQTTIT'W?+Z=
M/7FK6NS"WGBED>$1+$^X2PF3.60# !'K3WT.9]/:R;5;KR6B\H@1Q9VXQUV^
ME1W?AV2^9#<ZI=.$Z#RX@.H/]WV% $FGIJ/V3Y;BUQO?K W]X_[=5F34?^$9
M;]_:[/LG3R&SC9_OU<BTBZACV)K%WC)/^JA[G)_@]Z:=$N3:&V_M>Z\HQ^7C
MRXNF,?W* #4DU'[#*3/:8QVA;U_WJ6\34?*CW3VG^M3I"W]X?[5+-I%U/$T;
MZO=;6Z@1Q?\ Q%+)I-W*JA]7N2%8,/W474<C^&@!ERNH_:++=/:9\XX_<MP?
M+?\ VJ69=0^WV^9K4G:^,0M[?[5.;2KIWC9M6N28VW+^ZBZX(_N^A-*VEW32
MI)_:L^Y 0/W<??&?X?:@!FW4/[1 \ZUSY1_Y8M_>'^U1$NH_VA<8FM<[$_Y9
M-ZM_M4[^R[WSO-_M67=C;_J8^GY4+I=ZLC2#59=[  GR4QQG';WH ;;+J'VF
M\Q-:Y\T9_=-_<7_:KGKO<M])YJ6[2/#=9D" ,,&3(!/('(XSSSZ&NB32[U'=
MAJLF9&W-^Y3DX ]/05GZAH$D-E=W'VW?(L4C;VMXRW(8L <9 .3^= '2#I2T
MU?NBG4 %%%% "53N_P#D(6'^^_\ Z :NU2N_^0C8?[[_ /H!H NT444 %%%%
M !1110 4444 %%%% !5/4(P1;RX^:&=&7\3L/Z,:N56U %M/GP"6$;%<>H&1
M^M %FBD4AE!!R#T(I: "BBB@ HI#2T %%%% !124M #4;>H.TJ2,X/44ZBB@
M HHHH *I:E?BP6!BH82RB,DN%VYSS[].E7:RM=5V2S,<;.RW*-PF[:/7_P"O
M[T :@ZTM(.II: "BBB@ HHHH JWWRI#(/O),F/Q.T_HQI+&/RA/%YIDVS.?F
MZKN.['X;N/;%.U $Z?/@98(2/J!D?K2Q'_2I-J (RJ^\?Q$Y'\@* $M2H:>-
M01LE/4]20&/_ *%2W15?)D89V2+CG')^7_V:A21?2*6&THI"YYSDY./RI+]9
MFL9OLQ F"$QDG W#IGVS0!"-^-1\L@/O^4GH#Y:8J\*S@T;VVI,Q)C8DDKZ>
M4O2M$4 +1110 4444 %%%% !1110 4444 %(S!5+,0 .I-+5+6,?V3<\9Q&3
MTS_G^G6@"X"" 0<@TM5=-Q_9EKA0N8E.%Z=*M4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !535?^01>Y_YX/\ ^@FK=5-5_P"01>?]<'_]!- %E/N#
MZ4ZFI]T?2G4 %%%% !5*[_Y"%A_OO_Z :NU2N_\ D(6/^^__ * : +M%%% !
M1110 4444 %%%% !1110 4A&12T4 5M/_P"/" 'JJ!3]1P:LU5L?E66,]4E?
M/XG</T85:H **** $)J);E6N6@&=Z*&/'&"2!S^!J#4[<W, 56PRL&"ERH;V
M..:RDTI)K[=$ES!\A$BS2,Z$Y&WC<01RW0BKC%-:L1T.:6LNVL)K>Y0JEM&@
MSN,(*[^.,KT_'-:8J6ABT444@"BBB@ HHHH *R=>\SR[/RW=2;E,[6VYZ\=1
MU_R#6M63KT;R1VGEQNY6ZC8[5)P,\GCI]?Z4 :HZTM)2T %%%% !15#4]1;3
M_LI$1D$]PD)Q_#N[]*O4 ##(P>E9VGNKK9MYF2(6C(]64J#^((-:-9L:K;RN
MJ1ED2[)&,DKO7)/_ 'TY_ F@"Q.B+J-M.0Q<AH1@\8(W'(_X!5KL:@N=P1&0
MA2)%SGTS@_I4_:@#*L2?LE\L"X9',:AN>5C5?YBM45EQJ1#JZSD[/-;Y@.=I
MC4_U_2M04 +1110 4444 %%%% !1110 4444 %4M80/H]VK%@#"WW6*GIV(Y
MJ[574@ATZX,D*S*(V8QMT; SCH: $TM0NE6@ P!"G7Z"K=06;B2R@94"*T:D
M*/X>.E3T %%%% !1110 44AZ5C:9JIEU"]M[JZMV*W!CA11M8<9VGGDXY^E
M&U1110 444F: %HHHH **** "JFJ_P#((O?^N#_^@FK=5-6_Y ][_P!<'_\
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M0&2<#&0.1V''!/3MT (Z:BBB@ JIJW_('O?^N#_^@FK=5-6_Y ][_P!<'_\
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M.,#H<C^8!N:K<Q0II7GA9&DNHT0NV#N(/(QU-;0K AAN)7S=7 CB,Z- K8;
MY..V#R.&SC'Y;XH$+5+47$/V>9AE4G4'_@7R?S85=JMJ*>9I\XQD["5^HY'Z
MT +:X"2)NW%9&SQTR=P'Y$4RQ5(C<1(& 69CR>[?,?U8TZ YFFPHVMM=6'\6
M1C^G\J5<K>N"PVF-2JYYSDY/ZB@"C<\+=N$WLEPNU3T):-5Y]OFK5%9ET,V>
MJX?9U.[T_=+S6F#0 M%%% !1110 4444 %%%53?QC4!:8??C.=O'3/7\#^7T
MH M44F<TM !534]ITVX5I4BWH4#NV "1@9/U-6ZI:O$DVF2I(DCH<96- S'D
M= >M $NGD'3K8JZ.IB7#HV5;@<@]Q5BJU@"NGVZMNW")00XPW3N/6K- !111
M0!6U %M/N  23&V !GL:YJU>:*:V7YMT<-HIB92X4$D%L'C(_O#\?2NFOB5L
M9RO41L1\Q7L>XZ5S8F:.:T$B1R'%H))'!9BQW#^+OG!S@'DT ;FLN(]&N6:*
M.4!/N/T8]AVKG)'AN[]K>X+ONNY4AB#E"P\LAE)ST^;@C)QCCTZ75EWZ/=#R
M3-F)AY:YRW'08(.?H17.-;QF>:2&\2Y<W<N+20F/>2A!C!SCCDYQ^5 S5T-I
MH+B6P9#'%!;PLD9D#E,[@1GJ?N]3[X)JQXDLI+_0;J" XE*93@GD<C@<]JR8
M;M=)D$T=HP>[>*$1[E"*OSD;6_BXR<>I[#FNI(!H$>7Z7J$$EK<:=F.V65(U
M#R8&PHQR7 YSP<GID>@)'5ZMHBRWEHMG$4WK<[G )0,Z8RPZ'G'7TXJKXA\$
MB[=[O2R(KC&?*SM5F'0@CH<<>G.>V*QK/2O$%CA734'C48^S*%:/C' (E7(.
M[N!T- R77C-;I:6#)%+%91K$[ER TC8.T,.0< $8.[GWR=_P5;,FERW+(4%S
M*64'&<#@=L]NY)JG9^&]0U)@-8$5I9H6VV=H=JL22,DCU&3Z_-UZ@]=%$D$2
M11(J1H JJHP !T % A]%%% !5/5O^0/>_P#7!_\ T$U<JGJ__(&OO^O>3_T$
MT 6E^Z*=2#H*6@ HHHH *HW?_(2L/7<__H)J]5*[_P"0E8_[S_\ H)H NT44
M4 4M6L7U&Q:WCF$1+*VXIN!P0<$9&1Q4=K]JL6M[>ZFBFC*^6KK&4.X#OECG
M(!].GO4EO'>KJMW)//$]FRH((E3#(1G<6/?.1^73UM2('7D XY&1G!H ?14-
MM<)=0B2/.,D$$8*D<$'W%34 %%%% !2&EHH :O QZ4ZF_P 7UIU #)D$L3QM
MT<%3^-5]+DDDTVW\[_7*@63G/SCAOU!JT:K67R^?'_<E;G_>^;_V:@"U1110
M!F:SIHOEB?R8YVB)_=2GY'!X((P>?0_TS5#3UN()(+6>TNU"2%HI) '"KC&T
M,"Q]>6Q70FBK4VERBL<U=:E%/?\ V>YGMK:5F,?DS$,'7L'0XS[%3W[UNV$7
MD6<4?F+)M& RC QZ#VJ26WBG&)8T<>C*#2Q0QP($B140=%48 _"DY)JR >1D
M&N8N=-NO#][+J6DHTMG(=US8I^KQCIN]N_Y5U%(>E.$W'T%*-RIINI6VJV,=
MW9R!X9!P>GU!'K5O-<SJUI-X?-QK&D[/+"F2[M&.$D '++V5\#Z'O4D.NQZM
M+H]SI]T5MKAG\R/9DDA<[6X^4BB45\4=@BWL]SHZ*0=*6H*"J.IVL=TMOYB.
MQBF21=N."#U^G-7JR->9@=/"RF+-VF6W 9Z\>^>F!0!KUQNO0SOJ5THB<1R3
M6XW*F 1AN6;'(!'KZ9]*[*N>U)+\7D[0//L$D;HJAL'Y2".O3O\ X=:!HSUL
MH)V:2V;,44UPUSYI3$3,G0A3TY!Y!-,@LX;+3C)Y:7-B+%81)!+CS/GX 88]
M?0?A3Q87P@4I;R?-)<-*FX@8(XXW<Y//YG@TEO921:9Y<[VL1-DHDMYY-NS#
M\;N^,<9SU]10!<74M\BK:E(,WT<<CJ!B0;>^?90N?;MVZ6N233I/[0C=)DN-
MM[&S>6=_EJ Q^;N#\W?/\ZZT4 Q:0]*6D- C-L6$;VREN6A\HK@GYD.#S^)^
MM6Y2JW<)*<LK*&STZ''XX_2J\>5;:$W>5<G/'(W G/\ X_\ SJS<95HFWA0K
MC(/\6<C'YD4 0;"ZZ@H56)8@*PR#^[7K4]HP:UB(!4;!\I.<>U5S@1ZB7)"[
MCDCJ!Y:U/:ON\U#(KO'(0V/X<_, ?^ D4 6**** "BBB@ HHHH *P[]88]5G
M<W<,=R]N?+5U(8*!U!!Y )[#//TK<KFM<^SB]NV+2+.+8X+!3&>,X]?SX]^M
M &[8'-A ?,$N47YP<[N.N>]6*I:1QI-KG )C!P !^G%7: "J6L%UTB[*,RL(
MF^9<Y''48Y_*KM5=2C$VG7$;&,!HV&9#A1QW]J ,K1+JY;59H)Y'>,V\4B!Q
M@@[0#C)R<YY]#]:WC6!HTN-:FMS:6ZM' @^U(5W2C:OXX_P%;YZ&@"L+^$WI
MM=Q\X<XVG' !//3N/SJU65'!=KKTDS<VK+M'S#.<+V_/]?:M6@"O>OLL9WVJ
MVV-CM;H>.]<W%/'-+;F.1'=ELR8H^$1<L0003[]>, 5TEZ2+*8CKY;8S]*YF
M%!)<6H1XXL)9D^8VW=]_@<?,<8'^% S:\1%5\-:@7?8OV=\MQP,>_%<[$EM#
MJ*?9C=.@O)ML>8SO98VR$YSC)[\@\=#73ZN\J:1<>00)"N%)91C)QU;C\ZP8
MI)VU)PMO'"$GG#R+:Y(&S()('.<@\'GI0!7M;1X#&-0L99%*VT<>TLFV0(V6
M)STR??K7:5Q5G<RP:2'3[9F);3YE<;'SP<*.>AY'?C KMJ!!3)9%AB>1_NH"
MQ^@I]4M5F6.PE1L_O4=!CUV,?Z4 7!S2UGZ->R7MI(\NPLD\D>4Z$*Y Q^ '
M_P!;I6A0 4444 %4]7_Y U]_U[R?^@FKE4]7_P"0-??]>\G_ *": +8Z4M(*
M6@ HHHH *QM=^W?;-*_L\0[_ +2/-,N>(OX\?[6,XS6S5*[_ .0A8?[[_P#H
M!H NU2U<WPTR8Z6L+7F/W8F.%S[U=K(US4Y=.:Q$,4T@EN523RH]^U,'<2.O
MY9/ZT :PZ"L_5IU:W>QBEA%W<HRQ1N^"W')QUX&:M6UW%=H6A+$*=I#*5(/T
M//<5'+I=G-J4.H26Z&[@4K'-CY@#U'N.3^= %?2VNH4AMKV*-9?*!+QN6#E<
M GD#U%:5,)0SXX\P+^(!/_UJDH **** "BBB@!I^\*=32?F [TZ@ JM%\NH7
M"]F5)/Q.1_[**LU5;Y=3C/9XF!/K@KC^9H M4444 %%%% !1110 444BL&&0
M<B@#.UV94TF[0,OFM!(40GDX'7'H,BN$MK2%=1M-2TV)_P"UH9=CHTNZ.Z/E
M_,"3]TX)P?SKM-?TZ"ZC^U7,WDQ003+(P0$[67GGJ!QT[_A7/:#FWU&"".)A
M:W%P7A+_ "[5$0/"Y&<C'/(_+)J,N5W!JZ.ITC6K76(6:WWI)&=LL,B[7C;T
M(K1K"U719GNQJ6DRK;ZBJ[26&4F7^ZX_D>HJQHNMQZK;D,C07<7RSVS_ 'XF
M]_;T/>G**MS1V_(A-WM(U:R-??8+'()5KN,'&??'2M&>ZBMHFDGD6-%QEF.
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M!H;IDN-:MT4G:]FIQMP&Q_$,\^@P2>H_'I*YG3%B&OVLD<<2M)8*3L4@ 9&
M,@$#K@?7-=-0#"J.M%?[%O S;0T+J#D#D@@<GBKU4M7N&M=-EF1BK+C! SCD
M#I0(S-"2W_M%Y8IF>1X$!1D/R *O\0^4]>PK?/2N5T[4$BUB]NKN;;%';HY
MY W*N2%!)'('7';@]:Z>*5)X4DC;<CJ&4^H- %**-/[8E8RJS@9\OSBQ48 ^
MYCY>AY'6M&LB(7*^(Y@8V6V:+<&"C#M\HZCG(]\>V>VO0!6U#)L+@+U,;8Y
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MQ^(&170T Q:S=?"MHMR&3S!M^YG&3D8['O[5I5AZD[W5U>6+21K$ULC*'8
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MEH **** "J5W_P A"Q_WG_\ 035VJ-W_ ,A*Q'N__H- %B R;I1(. WR'U7
M_KFN9N[Z\TNTU1]2LW,$LQ\J175OE8[0,9S]T \ UO:I?+IL"7,A40JV)."6
MP>!M ZG../KBLFUU.=VO!J6GW$ENTY:!Q%YBF/@ XQQTSWZT ;$45G=*=JP2
M@8Y4 X/4?T-+=7JV13SE81,RIY@YPQ. ".PYZU#I;V+2W"V*(I1@)-BX!.T$
M$>H[?4&G:OI,>L6@@EFGA4.'W0/M;C/&?3GI0!0LM:@OM0D1[B&)H;@K&C,
MSKMQCW)89^F.];U9EHB#4YHFN+B>:&-3F0*%4-G@;0.?EYSZCUK3H **** "
MBBB@!K' IU(PR#0* &3PI<0M'(,JWH<$>X/8UGZC;KJ&FWEC=1R% @Y4\R#J
M"#C&<CI_0UJ56N8A+)%MDV2HV]?<=",>F#_*@#EEO)CX@TQFD4PE8V4$\_/&
MRMT ZD+UST/3MK>%=%ET&QN[61LHUY--$?,9CL9LC.>AY_KWJ+2);--*M;BX
MB03>9]G#.@WJ?,("_GCBM\'B@;'44F?:@MCK0(6BL^\U[2]/S]LU&T@(ZB29
M5/ZFL<_$+1Y&VV*7]^WI:V4K@_CMQ^M/E;Z =#>0"YLYH3C]XA7GIR*H>&MP
MT2)6D$K*\BE]@3<0[ \#W%55U[5;M-UGX;NU1NC7<\</_CH+,/Q%5X+7Q0MO
MY5O_ &/9(79\GS)V&XECT"#.2:.4#IZ,US+Z'J\Z;+[Q5.@/)%I;Q0_JVX_K
M6?-X,\/(RR:I=ZCJ&X_>NKR1U/UQA?SHLEU Z+4?$FE:2N;W4+6(_P!UI5!_
M(FN>G^)%JUPIL()[JV&27AA>3=P>FT<<XZYZU=B7P]I++'I^CP!R<*;:U#\^
M[*#C\2*(M/TG6+R91%'/*/G=B2RC)SM., X/;)]:- %M/%6I7@#0^&M09"H*
MDLB Y_WROZ ]:GFO?%%PF+32].M21]ZZNV<C_@*+@_\ ?57+^Z^PK'YM[96L
M7(W2G9^ !//YBL!-5@77)K5M6FG)#2.;>)V",H4;1]Y><D[>>F>]%_(+$EWI
MGBU[.9Y?$EG!((V\M+>R !?'&6<GC/M5F+0+2\B62ZU?6+M70-C[6Z+CW$6T
M5+I[W#S230:=?!\;4:]>.)&&1_"F2/Q7\JN6QO#I46V2UMWB!1RZM*HVD@]U
M].M%V%C(BT7PI&^^/3+>[D!ZNOVA_K\Q)K2M+F(6ZMI>GA4D4,ICAV#GOSM_
MG0\DZS!YM<MHTV\1)&@4\=<DD^_7\ZRK2PLYYKG#:Q=LY>-H@[I"$W<*N=J
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ME?().3\I&.:T[.8SVR.RE6QAE/\ "PX(_.@">BBB@ HHHH 2H5N(O/,"M^\
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M<],YP/PK4U)F.D7+(_EMY+$,6QM..N<C'YBN6G:[D262\295:UFC>>51CJP
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MIZO_ ,@:^_Z]Y/\ T$T 6UZ"EI!TI: "BBB@ JE>?\?]A_UT;_T!JNU3N_\
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M(,  #:,?E0!#I/F_V/;>><R;/F._?G\><_G7*7!A^P2RS6L5Q&\=S),S,-[
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M8_Y M]_U[R?^@F@"V.E+2"EH **** "J5W_Q_P!C_OO_ .@&KM4[O_C^L?\
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M85F'#$#^'C&/Q)SGIW!'/RPHGVJ9BZQ^7-OD:W<K&PE#8(^8$9)&,Y/IUJ]
M8(M3M;>$,@^W.S,92P)$7;'3.[[I[Y[U#<%+87CQO=I<?9I&:*559<F3[V#P
M>2>V,'J.<W+:2>"\C+*L*W&H-G./WB^4<=.AR!_WS0,U8-BZY=CR\.T<;%]R
MG(^88QU'3Z?K3+M$?7[ M@LD<K(.01]T$^_7I6;J^P:E,9+N>'YH,^2#G;\P
M"MG@@MZ<_3K6C/#(WB*TF*LT2V\B@JHPI)3.XGUP, 8Z'K0!JT444""J6L_\
M@2_Q_P ^\G_H)J[5+6.=$OO^O>3_ -!- %P=*6D'2EH **** "J=W_Q_6/\
MUT;_ - -7*IW?_']8_\ 71O_ $!J +E%%% !1110 4444 17$"7,#PRC*.""
M,X_7M2?:8@CL9$ CSO)/W<=<^E1WJW3>1]E:-0)09M_>/G('OTK/?0;9[B]@
MFA,UEJ"'ST=L@,#^?(/KQM% %6VMM2T_4=4U%Q:W%K<LLR!'8.J*N.FT@G'N
M.@KHD8.@93D$9!J(O%;+%"65 2(XP3UXZ?D*=;[/)41XVK\H [8XQ^E $M%%
M% !6-JSK;ZE93. 4,JJ<]LYC'ZRC\JV:R?$%OYUA(ZJ69$9ACJ"!N!_[Z5:
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MHVN$,9A#+#L^8'/)W8QC\:P&ME33XQ9B-P\4\8DN<*$)9% +*N >,XQR1^-
M&O8S%K74-_V=2A8,=B\MCDOM)S[].AXJSI\4BW,S2+:#;&B$PJ0V[&6SG^'E
M<>U9^GX:UU1;HRR0L"<A<@IM(^7DYX'H.HXJ308;=)LP,3MM85' Y&.O0'L.
MO/6@"G+#(\@ABB@%V]H[1O;R&)1\Q*;>,\]\'MR",5+IW[JWUIKE%*>:^1(Q
MD4CGJ 6XYY'Z=JK2SC[(+6SVQ1RQ3?O/+51&V[ !8D ')Z8Y(Z^MJPVR:=K
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M >V>2,UJ6%L88-5#MY[MDE9(W88()"E3G(P<87CT SBKDFA12L&>><N 1N+
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M(8R]U/ )5: K#")/,W<\C:>!@^G6EL"UI>&SEO8Y3Y0,<7EA& '4\=>HZ=*
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MZX@?'*!,XQ@X'  KU$CBM74="3=/:2)2YMSCK93),+D:C>232_+YL,3$,/0
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M<8/.#Z57)*+N*YQ7@3P+J&D^)[JXO[!I;6T!$!>/_7%B!E0Y7&%R>?YUZ/\
MV3(DV8HE5%R/ED$._DD?<7/ ..H^E8,-WK>H75U9MK5PDT938T%BD22;LX*L
MV_(P-WT]ZSY-*NKZ.W>^@U:ZB^T&*]2[OV41Q@GY]J;1]T!L8YWBMZK=67--
M_P!?.Q*TV.FO)K&U#'4-0TN'!(Q=2&7'_?;C^54;?Q-X=CF,"ZZK_:LQ1Q6T
M6U0QX^4HN<^GS'K63;^'H-.U:2*ST&S*/&KJTD)5X#GYL2MD%0,#(R<DD>E/
M\/:?>:_<-J>M3)J(TJ1H[$Q+MCEDSDN, 9P=J@X ^7-2J4+.3>@G-WL=#/<:
M>^H2S_9+NY!B(F1XF4#;@CB3 Z,>/?WJ>Q3^SF$&F:.EMYH+%99@G ]E#X'.
M.W6I;N%;=]/CF9C&9\NX4G>YR0".P+<^G '0U>^RR,9W\P+-+\JL!G8HZ8'K
MR3]37.:&5-?WUU%=VLUGQ(A6WD@#.IDY!!./E ..3COZ<K<:!(LR2VLBD^?Y
MA##;@;BW4=><#IT ]R=;SK:PMU5G1$12 "W.%&3[G %+8W]OJ=E%=V<@DMYA
MN1\$9'T- BD^1>MC$]W_ ,LP0=D"GC)/8]?<].G3,TY9;K6X)VE3* M*C$;M
MYC52H!'48R1D=16F[/<74UK9+Y48.9[D==QZJOJV,9)X''7LECHL<,6GL';=
M:*P'R_?)').><]\]>30!D:4<P>)OWGDC^U&^<9X^2+TYKI[DL(E*L%.]>2<<
M;AD5RNE86W\3[H_.']JO\F3S\D7IS747A7R5W9QYB=#WW#'ZU=3XA+8YZQBM
MK_5'C$R1SLTDCQ&(><$$GS*6[*20>F<,,'H:WK(R>?>"1U8"?Y "#M&Q>#[Y
MS^=<IH5Q:0^)I[AY;:+>\UNJJ6W2.SH>_?CG'J.M=1IYC-SJ'E[\BX^?<>_E
MIT]L8_6H&7Z**1B%!)( '<T (SA%+,0%'))[51^?4B,@I:=<'AI?J.R_J?IU
MC5O[4F(90;)0"ASQ,?7_ '?3U]QBM"25(8B\C!449)/0"@!6*0QDDJJJ.IX
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M 4444 %4KK_D(6/^\_\ Z":NU2N_^0A8_P"\_P#Z": +M%%% !1110 4444
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M81QW#23'9=Q!C*B,88RS$-'NPXQ\O7()_&FQZJ+5!?72%HC;1_O_ "RF]BQ
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M>JLJ!'\T8C(!PC8 !5L=<XZ\4 7?#Z2Q:- DZ;'7(V\\#<<=>>E:597AHL=
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M=0" #^-:HJJ--LS&5-K 5)W$&,<GIGZ\"F-I[H0;6ZFA(/*L?,1O8AN1^!%
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MB;'^VSX_7'YT#+%WIJOJUDFWS8R':7SF,G VXP&) Y(Z5K(B0H$C554< *,
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M.!2H^20P&,?C3@Q*'$?([],T ,L0!JA"C'[CI_P*K5Q!&M[;3!%$C2;6;')
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M<C]?I3DN[4$YN[89' \T?XT 651GC4JS8!R,GD$T&+<IQDD=,#&..U5#=6B
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MW/7.SW]N!ZU?O;[4$A7.G*,2H!ND5]WS #'3!/8GIC.*O_V9;'/^NY_Z;O\
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MKW%VEM) CK(3.^Q2D98 X)Y(' XZGBK%,< J0>XQ0!%;7'GRW"@J5B?8,>N
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M;A@^E "T444 %%%% !1110 4444 %%%% !1110 45'<3+;6\DTF=D:EFP,G
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M)SSSV&*N!I@O*H3]2*99[75Y5!'FN6Y[XX!'L0 :LUF,:I)4%A@^F<TZBB@
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M,3:NTF?EMX=H /4N>OU&S]34<@;SE#MR3DCTIUC?VUK#?2/)O*.S%$!=@JJ
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M@GT.\>U R6>")(+/3E.^2YG5) !@.J,6D/XL6/X^E;]Y:RSJI@N7MY%Y! #
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MK!0QXQS^74]:@\SD%@">>!G!^O\ A0!9<AMQ4XS_ 'CQ^)ZU$D;P BTE:W8
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MD8!S_*@!EQY#^$[X1Q2)%YQ5ESN+?. <<=QZ_CFI]2E5K;2%+KYKL'$0(_>
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MZ]NHTC[-Y=S]EC*8G?S,X^9^,G_/I7*PW1U#0Y+G49O.>6RD$D80!BHDP2&
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MU+Y)D$DDDF9)>3E>H(^Z/U%9:Q[7M9889(FD>T8;C\F,,2/N_>^]GJ3D=,T
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M"" >QXXZ\5T&EH?)U8L02UQ+T;.!CC/)QU_^M0(U; YL+<_],U_D*L57T_\
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MGT__ %T"-33O^0;;?]<D_D*LU6T[_D&VO_7)/Y"K- !1110 52G_ .0O:?\
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MI_3/!!YH ?;R312I#(PDFDS)+C[L:] !^/'O@GVJ&+78FOVMIXV@#$"WF?\
MU=QD=%;IGVZGJ,C..;N+^YT">>+5XB--FD5MT>^5PH7D9Y++QD]" 2 ,8K<2
M:"^A^T($F$ZF&WA/3;T)([>_H !C- &[15:"YC8O&ISY.%9L<9] ?7_&K%
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MR7WAMWOD<8^E/^PQVUA/# C8D#$C=RS$<\GUI='@DM=(M89O]8D8#?7OW/\
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MKDUF:?+=?\(@ZVJN]W )8$16&=T;L@ +#'\/<5MVWF?9HO.(,NT;R!CG'/%
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MMBK'58Y9I4,AAD7;N!8CS,@\=L$=^_Y;-8>D6L4%ZARPD"S )'CRPIE]N,\
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M)"D 9.>C>N*N&SMS L/DIY:,&5<< @Y!_/F@#G]7NP;:>.W"(ALYGVO@+D.
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M5?HH H?V/;_\]+S_ ,#9O_BJ/['M_P#GI>?^!DW_ ,55^B@"C_9%O_STO/\
MP,F_^*I/['M_^>EY_P"!LW_Q57Z* (X84MX4BC&$C4*H] .!4E%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g234232ky03i001.gif
<DESCRIPTION>G234232KY03I001.GIF
<TEXT>
begin 644 g234232ky03i001.gif
M1TE&.#=AT (Q G<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M8V-J:FIE965Q<7%B8F)D9&1K:VMG9V=N;FYF9F9H:&B+BXN3DY.8F)B7EY>
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M1["ZT5&&W94,-^RP7NB9I9Y9?_XC,8][]:BGD'WQJ9 X[D0#!@@AB# ""24
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M.=AT#U(7(#AJ#/\"@) !&.G1G\AXI@,*%L^!#UC0GB]FI&\JIY[ZJ2(!#NW
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MSN %$J#6-S -XX ,/O#)"XX7FQ  %+ ([I "$$X!GL#7%' $R6 $&X .AH
M6? "$& *W+ &(@ !28 /<^ $(=  M:#BX]WBY6W-,+[9,D[C>%Z5-@[?:C'?
MIRU^W8 %$=  /C *Z+ .?O]  Q)  4[@"O,0#XI@ B&0 TUN%M+@!120!7XP
M 3!@#'SM";O0 !3 ![C0-?*@"0,P!$KP (% #9ZP! *P >\ "'(P Q2 "' .
M#NE "BGD#*I1PU_!"^\0@72>V7:>Y\@NG7N.X\$0#Z&P"M70! > !O0 #F=
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M1#JZC&5>]YJE6OX'D/C;97#$0CVX",<Y_B $9QS#!P_8 0(<$(=ZP.$!#]B
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M$1"%7<B!H63']0H'0J@M*N2*>:S'?+3*J[21?>S'?PS(@:P*<V $"M.""(@
M-6 '1["!!NB"&:  (ZE($P"!=<!(W3/!"*  (/A(&:( 2FL'+'  $= ! > #
M?T (6Y"!E\2'/4  4*C)(?,&$6@ A>D^2I" (="$$!""<;0Y.X %%A!,*:
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M!F5(!W&P3BL0!5$ K]4@T6< !F0XM'(H!3,@!%^@AX30!U,P!!6$!F*(!W#
MA5CH!W#(!EK8A69XAF%P!W!H!C/"A0TKAU!(!52P!_]K2(1&N 17T =P2(=9
MV(_^HTU/8()V( ?5K$H.Y=,^50L/G<W:],JJP+&$& <OF,/^")M"Y99SZ)6%
M&,6G1 ,S44U*.!<_Q=1,#8MSZ(<YH(+LNHLFT 7](U1&#9=<= -3557_6*]S
M> 0V"*=*O51-I=5:O0IT\(<+ 9?O^(<FZ 52I8I5W3-#6]5BS8SUB@=;<(-Y
MD]4KM-5GY5!OI(<T6(+.4"Q?!=:9,]9MY5:ZNHISD(=ER 1Y\(IYM%1GA=9T
M;4UP*(=]Z(,E@!=>Q=;(*M5NM==M+<UY^ 5-**EF5==_Q51SZ <[8 )0O=9?
MI==@O=>%7=7U(@=&8 ,OZ8K_<OB$2IA5@,58#0T'?]B#(9!-IC""44W8L "'
M:CBTA(B'7RB%+RU4:B &'!N';E"&8IB'NR@+@UB&*1C4K"B'0IB$B\W8H+W*
MUOK8I0C9; 6+:GB"$TJA5B '6\@!(E"R0OT"&MB#(MN6<,"$@MD!.+ '7B6+
MJ=B&+[",B?59H!7:M$5%HJ6*HQU9L,"%J&,!$;"!UUL'7F@ ()A3'$L"$OB$
M! L'+$  )6B!%L &L(6N?QC;LN6*GOU9=%7;R$TYMFT*MS4+V6L 3[B'1%@!
M"H@%V]/;PCH>6YB&<1 ';7@&:B %7* &BT &6\ 'XQ$&<P"'5%@\=V &6W '
MXPD._XO@76.8W80(W!' !"R@@+\51; 06[+-K:5P7+25W.CE/,H%69&]7!-P
M $0P"#2@ $=H/[V-!T(0, $#@W>0!S9X 2:P 0<@!' 0AB!H@#D0,"*8!GVY
M@4W$@@98 P%C@HB0!0=02R!0 L)$B,#E-R6X@9Y(WJ]87L;="G:@A$B84NFE
M8/^CWF #AR8P,ZDDBVK0 0<0A'Y8!N.5!?/36UN8@1_8@RE @![(!WP 31VH
M P$0 6\@!1>X3B:@@/4 AQ*@@5B8" I0 3Z@@!\8P22( "^0@G>SUH,@! H@
MRS5HLP7V"CB%!R H!\C]AWFPA$[(X@H&8Y6[8(EQ EH(%?^SZ <@:( I0 (8
M$( C6(=HR-M@6(4B^ -^2#\*Z 9_<((9< 5_2($?OF$*B()G:  3P 5P@($?
M#F)*$ :;<P1P@$5NB(6H:^(?N0,> P%DX(= T#6S$(=V2 <=N >OX&(OUN(P
M5N7>&F-P*.,S+HM2P&$)B  (F(!/8 <YUEMRN(=NL(4KL+D]=@(7$ 5%%F0<
MI@)I:  8* 5C!F+C101E[EYQ6 $0" =9IH F#H<T0+@-\(%B&(04^$VS, =V
M: <?4*FL..4O7N5V-K%6?F4.'@O,Y0),P 1=J%E=#H9V$ 0'" $5@  ]YF-B
M=N9!?@-EI@%:<.8@CF9(=H89L&;_;&[B?I ! ? #))B 0B !'"B&5+:*<T@'
M?T@"=)!G=>YB=G;GE*ZOPI*#,"A:B6F"6H!ELI"]["U@7YAC7@B!"<"$5F!+
M82;H18Z%0:X$:=9>H69H:78$6;"!B,;A)GX&$@ !<2@&(^ Q&,@\LA"'=PB&
M.T!:JX#@1T!1E29KYT('?K"#3_61?[B6K_:*FM;>1VN%.0:$"5@!?5 %'!#H
M82YFH1YD/5!F&XB%A89FI69JI\YFA(AJ&+"'>W # 6B 3#.+<$B'74#-MP5K
M2A!KCR[KSCXKREZ'.? ";:"*+K@%M^X*N"Y@9:#K"3 !1J #"=AK8G:'0!YJ
M'%X".;Z!_UP@; IHZ.X5!1"P@51@A!U([(.X!AS $T&X@Q^@@$N@XE,A#D)(
MMJX(Z['V[.Q&+:K2!S)PJ](^;<SV"@^VZ4<[A#DFA1UP@/;A,: 6A6 8@1]6
M!AZ@@-Q.DE;H;43HA@ATA'E@ P?8 1QP@.,V""1J@ C(@0D8\!@ E\F>[NKF
MBNOF;.VF<'\2!WG(!SN ,/!&;:X0!UG @GE#B-\0A"ZIADD8!&&H!EU@AW"8
MAE(XAW% !$+X1$1H WP0AU#PA#=-A"IP!G%@!2OH!W%HADQXTWO0!$=8A!8@
M<(.8ASQ8H3R8A$FX@BMU<$B@;O&F"@FO\"X7+'98AS_ @L@S[?\.WPJ#P%HT
M%]9'4X@W& )2" 0<8 &#?;2(4O,))T!V (0LMV[-QFXO!_2S E21R> --@N&
MY8\_4($64 $?V(1S4:^R2+8S( 0S7PHN#_1,;RDM(V,S+FF21?3,X(9>(/5F
MT#56E71PH(-*MU"MP'1-A_5_XG17]O1##W5NG6Q59_4^W^Q8]_5^FO5XMO5;
M-]9<7_58C7!*"(0___5F]Z3- @/@4@HRENE/5UYB+W9)%X<QJ'0M]Y%TH(1!
M8%9G)_=-F@IZD ,_\ <.U_*<N@=U4 =O50K,Z)ESZ ^OL7=L7[*/3H=+T 1K
MMPHX#?=Q+_>"YZ%PP(<_D$%VOR%I>(3_,L"#.*@%%.VOAB@'6U #4R@'?N %
M8F!9A1 '2\ $LS.(>% &-C*%*=:,?@ %8E#YS!"'7GYYQ(6I?O]WY0!W<<=S
M@^?YC2$'?.@#)'BKIBAS\;:'.!"RO20%Q&T(?$!4+*"&0)" *6@&AA@' ?"Z
M@TC,\14P&*@%$<^,5JB!)>A$_BB'5M@"652(4;1Y@"?4G"?XGI=[P9&'?8@#
M))#VI2CZ@#>&%HB +2"$&$" /HAWN6J(LS2"27B'-20!5K!Z$42(>^!>"H@#
M/3!N+FA=S6B% )"#Y>./$,&WKY7WJ@!I?W?[8(7[G9_[U7>5=E@'.[@";)">
MO:\*5'F %M %_W<HA+RU!GD8!#, _E9HLT/@!%$P!#6(!9@Y!3 P!6UP @J8
M $Z(!V[P!#50@TP(CG& _(.(A_:C@&I0!UR8@;*[A4PP!F2(-6BP?C4HA7GC
M!C#XU78H!.LW?X.0!T>P_F@ AWHPR ,%!V  "#5J9NG[9_ @PG/I+FD:A_ A
MQ'_N,CE"!RXBQHP:-W+LZ/$CR) B1Y(L:?(DRI0J5[)LZ?(ES)@BS87K9X<'
MMHL(@=P2=PXBN'#F C4 <0H<M2B%Y%U"T"!'A V.D(UH(*%'U%ON+C5(U&@
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MPAM$@"" 0"C0@15DPPIL5UR@@VB\ 5UN@#GH0A&X 1NT0S@H@Q240B3\0"D
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MO''BVL5#EXY<OFOX[K%S5V[</''AQIDCM\^>.7?BSB96O#CB5\>/'8>;)TE
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M,Z!4\-&*051B#4>*B#HVT8W%Q(,-6$@#-MI1B4> XAS<D,4@\H&3=<!"$-
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M' H!Y& 5!*Q!7XGB%8@ #,I &I3!%W P=\!A%"9@"BXA&SA!";2 ! (A#U#
M"(X@H-H!#*!@"*@ %.#  +,@'2S!"(#@!3"#'"1!!Z1 ![B!&9K@"N!A%&
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MH0R<@!-(X!F\X13:X LV 05VX1": !-$P!=(00?H( 5BP1'4H1:*P!:XH!/
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M(,"745 B @TVF!  !!+@D(,-)_PP@@TV"# ""32$(  -(]P90@@X1,""%YQ
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M8,,,(.$)$-0!@%AP01&P  0^I $-EJ!#$K;P B0L00<R6 ,GD@>%)V0B"9]
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M\D<K:KF+$CE'7\*Q"ARD@!;I0,>6V5&/<=A#'3HJ P:LH(YY$%<@(+L1)VY
M@33L R5_- =$QL&.>'2,'> 81U<==HZ$P<P>:Y#_  6^P%6OO@6L-WS1.;@1
MA"#X@0E6Z'2GAP#J(51A"47@@A"\$.HA4.&"6,!"$9A A5@OH=6M7D*L8[V%
M5 _!TY].M6KT .Q@Z^$.<R@V9?0@AS#083:TP<-RT""&:$?;.]2&]AJT8XE,
MN(>@:F##)<J "3948@UMJ$0A:A &/_/L&F  &EIZ"^]XRYNW@0&'/=:ACN(N
M!1Q_9(<[QF$.?'AC$*EHQX)X-(\R%. *8C#")?*!DBS^!27 R(082& %24I
M#($P!3L 1HZ9B",=U,##%;   PK P11M0$0L5M&'1=#""6PX!0F.P H]=,(1
M?=C%)O:0"E5P 0:1V$0Q_SIQAU+X(A%JV$ :>H&)/XAB%TA Q1[ND(LZT $5
M;Q #-O; B5.0@0_($$,G4B&'5'##$G- Q1K $ M%U  "58@$*@HQA$, H@_/
M$,065M&*/+""#>E<!0H@80^!/&3+6&S\2FB&DGZ,XA?UB&T11T(.A 0ZT7#
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M"130!/L ,_'0$BWA%UKA#N=@"3G@#5*8#M&0#7J5#0-)D ,I#7'E#--0D-$
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MS2 *R0 *N] $@7 ,>FL%P\,-I!  8I $.@ (3I "O1 *I0 *I\ /?E8/8-
M*# )WT ))@0*9J &KI (93  +B (NH &B1 +6$ (K\ *.C ';8#_"H;@!)?0
M#)I@"5> !NMP"GMP"+)P!YX "Y>P"IX0O8* ![KP"& @"UM !;@@"'_P#*]0
M!(Y@!EB "I*P![:@"GP0#&70 '1P"5FP"IOP!X?P"DM0";*0!IX@"'/P#;F
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M!GZP#'$P!MS <\R@"7VP"BE0!I!P D>0#;10!M$, ZO0"$0="$Z "KSP!RD
M"T9+(E81#G*0 7JPOH0TL'9A,VP  0,0 P' _P("  $1(/41L $!T ,]T 1'
ML 32  YMO1,:X0DG\.$X80_DH -U< =(P 1K#VN\-FI+ /=+L 5SOP5(X#W>
MPVM6($)QS_=]#_=T/_=]S_9KW_=%8/B&/_A,0 2+O_A3X/B.?P11(/E1D 25
M7_F33_E.8 2;;P1/X/F>S_FAS_E/X 4I, AC9.9HC@YKSOH\$0[I0 E$H HU
M@ LB$ 5$T 1(, E$D 9%70*I( I@T KPT C4X :+4@EG@ %.H @\@ TK< 29
M0  @, ,*H 9P\ QJ, %44 U^8 :YX ET?@M.P G3L 9SOP>3@ OTL.I$$Q7V
MX W%@!#.0 M6,  )X/\ 44 (P^ 35@,5(@$0T.H(X'7/W3EP\=RM,0")'#B(
MX,:!:S?(Q!$B&PA\N3$$GBH*+5QL>+ C0*UPX<:1$W?NG+8K$'BTND=&T"AJ
M>21UVB.K2XM0TZ0X\^3EV2<)J*ZA@37HBZ9#2J(0JD.O69AL;R"U(X-E&YDJ
MW J]B;8DU2T6>9[-L:(-#1YC089PXW/D&ITF^"YE&=7NE)]"8W#!Z:+LDHYC
M@<"\NX:IFA!F_R1/IES9\N7+$35'# >N#08PZ#:/CHC9M&ET[,PH.-#DB^LO
M1F0;Z0*DBPP_@?S4&R?/,CERGDYXHPPNG(YL+<<M7R[.N7/FRUVZ'/?<^O/_
MZ-FU3Z>NW?LX[N>R7_^^W1QPX-6OKV?OW-:;>+Y/4P;F1]<X=//U[^??W_]_
M  ,\#9QS6%&""2>P\<224HBXQ!Y!E!@"A2^<0*(/:,8A! \LCM CGV>^* 0;
M-:Q!@@I'P*"CDB9D$6*,(BSQP@\O= GF$5G6Z(>,-:K!H@<5IHCC!5<V$_#(
MXC0+IYQ[LD$FE2% B"  +<[ !IUQYF$GO<V *T>6'+# IAYXZ/&G&S0*@,0<
MS<Y9DI0I<J&GB@.Z,,$*?VYI8(49C'#%#!ZR.:>E<LY!AYQH>#  C6( .<,;
M:00I(Q0P-/DF!2AJ88(26=)0QAHN2 AE"$P2,6(3_U N*<0+.W(9=9!9A""E
M%"%NR>0(7/!PPI9,_%@F#SUR6<.'1#SI@I=!_M@FE2D0::2+2D(IP85"!$D$
MACF8R8404K#IPQ5B^&CE&$Q.228(4,!!4C_2(JI.$ JH8,>ZSMI==[)RXE'#
M !YT^2899HC!9F!LOO%F'41(X$&.=K)4ES+@A"-N,G+F@0&;?\:)9^-X"IV.
M''9"#GD>DN>)QYSPIDM-9)9;'KED+5GF>..6839YYO#0*6?G<M#S&3B=.2[4
MNO':$Z><<6BI(J7^ZKLOOWNCEGIJJOE;$AYDOLF&'7OVV0<4?LCQ9YAO2J$'
MFV*@L<>=4GSY9IU\]&%'E/]9@DEFGV&>P8875M9Y)I592*FEEU1R84669HXA
MA1%M@,F&L5B.H88;-^2H%Z*J_=M,G'BL8>,+'$*XP8Y=OMEG8RP'#4><R\$1
M9YQT\*%B #[HN$,,/L@PXH!%$-*LG'#J@>22>@898 D6[J#G%P2BH**-=OJ8
M96=SWA$'Y"7#"( ,-=2HA0XJ]O"%C41"40,"%\A@@Y<N2A%F#A,0*,.48> @
M!!(U2&DBC&<NF>,12<0A%9S@@B\\H09E:,(.OD##&GI!ATY@8PQ_R(4:UF"+
M-KQA&86@ RDL08=?8((3?*" "D*0@PA(80U<L$(?A/ $,U#A"G:H@0]TU0-?
MA"/_<TEJ5\\4H8 DR(,[XFC7P^[5L3548 K:.(<YP&,==*!#'+PH0B/2D(YP
MH,,<E8G8<"!&#A]L8W5*"D\1PY&RZ1"QB&MD8QLA<IV4Q%&.JZ.7DN0(QSG*
MD1WF&,415M*T._3B=3LD9"$-V9]PR&,>X)B'.^;!DG0,RASR8(<\Y"&.@Y3C
MD:(Y%.SNP8DY;,(2PV#'+C QA#M( A-H0,,NYG"&,JQ"#%3P0R[2@ 1A0&21
M$R''./Q!A&",XSSC."0YD,8.U351A^B@ASG"\8Y7%&$&&%A!&U01C9/I\'4H
M4Y>ZG#B9<\P#'6I(  (,X  *'" $-## ),Y1F4A*0PQ2_UA%+UQ@AAOP 1^F
M^,$:3%&,>F@A%?B0ASO<L;IXJ"L/&_@"+ZB!!CNP(8%FZ 06.J&%&[CB&$L8
MA2JH,($>], /^L $)AI1B6[00@2V>(420O$**U"#$5N@VQ.*L0D]3,,/E##&
M&\3P#"]@(1:$N(,^&&&'9+BA!+:@0Q!($0D[ $,,&PB! G)P@ .D8 (.B$ +
M$&"#'P1@ S)P0 AB8 -2Z/"0$D%'/OPACGZ<XACJP$1KYC&.:(#"%_"HQS2L
M(0QG;I&(]R)0.3"1 !2,@APH&Y1QP!./<&#B#*@@PSP&18[*6)82._@&9:I3
M@F"HQ(VC=>. -&/:T@3(2/=RD_\MF-"2_D ##+8@AUH/>5O<'C(<[#!%&MB
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M9< &B,"#SH '-_ "*L"%:0 '5-"&=U #)C0.?30':6@#'$-*JBD'<_ %$'"
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M0,GH#)54$GJ@A4](A&"XATWXA$:HAG$ AEWX!$:H!H1H!VU8!T;XA$"H!G.
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MA0=0 UG@TEZFC%_^A&"F##?1@6)6(W! 9B@@@R-8@C.8 2W0@DOH!#-@'7>
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M: <PB'$-:6R4*.9XQS@*00,SP* .\*#%#^1PASGD8QSX4 4KJE&-4T#C&=K
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M&C!"+BQ!+6!#$C2#*>B #+C!)>@"'?0!-%0!&'P#'O! *=#!%U0,'4@#+,S
M+B !%'B1#*!!+,3  LP '3!#)R@!,_""% Q#+C2!+?R"$>@"-' !$(C1EQD$
M.-C1LLB)OHP#.B"B..Q"_P0$049,1VRL&&%<W!7M@QK@ 0O8@37$@!1H V3,
MQS],1"7P 2J003JXPW3DQ$[TQ$\$13&(B@[*I$< A2UP0;3 13K@P0R4 @S.
MY$\"Y4J1PSI<PA@ PU*<#)3! B)0P0],0*,501V\ 36@@32L@RXH0RNH@QY
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M*R" (W!@S:S#+C3"(0S"(1@#*TC"* 2B.\3!!52!.R3$4WA##>S  ,A "U#
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M!-"!).0 $%0!'S@ '6R#&QB!+ 3""-P"7]7,'<:#(YE#.\Q#F8D*T=P#&KS
M"#R#/30(.\!"' 2!" A"/] #/+S#.PP#K-6!""B "]S"/>0#/:P#/,""#OC
M&*1"-KP#& A )1A"'K3"+$0"'R0")71"-9Q!+:S"%&Q!"@!!*A0#GP)#&ZP
M'$P!)QR"'O0! NB +,#"%41"*U3!(%0"%C2"-\R"%.S &(!"+H3!+"B"%Q"#
M($S?+$!!.ML!*=0"%83"*"S!$&"!_PT( *H2@RE  2OHPA[,@BU0P2(,@QA\
M0C+0P1@<PVDM 6: W3F,@A=H@B^LP\",'='<11#_0SAT30CYA=#(B3QH0QP4
M01J(P0_00CS,D2M(0!/H@SZT0REHPB><@C^,W3RT]%-0&"+"$ K_ SF, S3
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MZBZL%%Q#IF@$H$0$.CC(.\!!'R1"#/@#.?3""ER"=" ,>A3$.(!"$+0 "XQ
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M3*)H(0 >.!D%CQZF$$(+ 68(AA1.D)G"G6@V_VF'C6?BR489)5B)YAIUYHB
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MDR%2 (.-,]A@0XV.U?\P V0SV/#D#3<TT2P"'.*P)),B9OAD#4PT(2&,,&)
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M1>HA"98 &$9M/TO7=">'0AB'(;AI "WB&A!A"&I@ )2 "0CT 4+A& BA%$I
M"Y:A!(12!O)!#.JO#-(A%TB@!?@ 'O! 'F#!"KK!$/)!$?@ &EH!'G8A!%+A
M&6JA"@J "=! #K+ "KB!#V"!$*\!%TK!#B8@!T9 %/+!#>0 %,;A'MBA&\IA
M'.(A$R0 %^0-?61A6 @A#>A@"(! $H[A?EG1<BY'G>3-H@APG\S/_,"!'?(!
M%X  "&P@$"XA"6ZA#+8@"0P!#1;!&M  $U8A#-[@$4)A"7! !4J #?B@$UY!
M#FK!$*#@A/7@$'3_80JLK@LHH1GV !-800YF(1%\8!$Z 04H01'V@!G<,198
MP0D2017&P!4Z(0R4H<82816<8!5JP>N.80A*(1:$0 U&P0\N@1G:P!)R 0FH
M@!6,0 V: 0SL(!GB0 Q:(0_$H!0@X0]:81&H !8D 04D(1?D0'?!P ^6 0^(
MCA#X@!C&H ]4 0VX0!2V  Y&;@EL01*<0!*V)1EZ00X$X16H( T<(0EJ@1:(
M@!>& 0OD0!6FH!%&(0X.CPPZ(1?H0 V(80_&P!O((!-(@0]F816F  W.H E\
M01'B0!1VX0MF@1&>@!#4X Z:P13HP!0V8194@04:X!+8(0#CP4)DPQ-&_\ ;
M J4<:L 9+ H<<';0PB$?;$ .?J$.F& ?BG8)%L$>H@$)TB -@D 4&D$%,&$4
MD@ *U. =L%8U6;,$E,$>D@ 1[, '6&$6?*"2'_,=FF$5>*$)R, ;=, 3_,$;
MQ( 1H* $<,$,8N 1BN5O _<.I*%PF\$*3"$:,J%581(1ZB%U:U!R92$;R@ *
M>.$2@L$8>"$8XFT3P&! 0J0>IB /UB&=3E>JI_I&*,0_[8$<P($<>&,?1,$.
M4H  0B #F$ 6E( %Q$D9ZB 67" +1.$!,&$21@ 84* 6["@=Q* !(, /U$$.
MTH$1L( >W" :7N$/B&$0]F$0"* (CF )LB &9O^@ ;)@!@[ #$Z@$  A"4K!
M!V# !0) !F[ %MXA!G"@%M"A'08-')X!!CQAHO"A$&2@"]8 %II  (!@$4RB
M;S0$T.#)?-1A$6A@"U2@"OP@%G8A?V"!1*.!%9# &1ZA#I@!$#!A#V;@!R;@
M!\1@&_H@$&K5#I;!"M3 &*H $:H!#,9@&)B@!93!#R A&<9 %ZK!#Q;!%XK
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MA,)4212!-8]49)L!R]VD RM\C6@1*DV_<OK>E9%FCU@J%Q1RI,G5QI8Z:<7
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M_. (=Q$Z_#$,0?CA!0((@!5XH EZ:*(=E B$/-" CVL 8AA[\.@64J"%9<S
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MF+ #)U $/A #8( "5Z '*B #2_ %;< %7M '2& #6V $YE=[>D %*S %4R
M2O $ Q $6Z "7/ (G+ /\0!K('$PXY )*2 ,4BAKVY1P7-@BV.8-71A1_$!L
M6X4BAF %X9!JM7$/3. #Q! .]B!P83B'=%B'=M@_[H &-F #.I "F@ (P4 (
MEV /^M .E] (XD -XQ ,EG /W8 .GA *0U #RE #1\ -CQ ,DN "]Z ,OR $
M*C !.6 #%* ':" "L^ #"* #9T -J# 'Z4 BG5 )[% -^H (?6 -_G -<S (
M8S "/6 ">* %$B  _PT !7>@ C=P"'QP"N8 =F#',.)@#A4B&V?G$?(@!A>@
M">_!"V^B"4,0 ']P=^& !@- "^= #%]@!FG0!V_@!RJ@ C]P!YCP!GF !2P@
M"_V @X!P!V<P!V+P!G,@"680!;I #=5P""VP!DN01R&0 %X0"D^  *&@#9&
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M#TH0!GW:F[.!G3B;LSH[%>RP"R! !2<@ ,B "NW4!-% !NI0"8% #UX #,$
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M %TP<HK@#O:S" <@!_90#FEQ %SP!%Q #?'P=>GP"01@"/53#OXP!F# "-P
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M@& :BYP?JJY@BGWL0QVOVH07MA$.9(!@#'H PY"+?.1Y*)G)3O:.+93@B&^
M8@AV $26M]SE+PL"";!X!A>F4 PY"V()LE##/M!QB$Q0PPW&F'.=[RR($!"B
M$F3_N$8>"BUH0I]Q8(A&)T9J!ST0@G4(/#7!D$G3 "<@!G)HA\5#K?' (7M8
M!WN -+E+AAHP _:*IR1J!WBHAWA JBV*0/(*$D?0 #)(DK@K0?&0IW< AGQ(
MAPLL#S<@ $"0JDAS!VZHAGZ IP)[*0JYAV? @CI0AWY@AU8@!6@0!7[@!0/0
M 5S ATF8@-<*!#N0!#N  $-@!3Y8!U- A"^( !3PA#?0@4@(A$= ATU0@WG@
M!GE A%Z(!V"0!C@  C:0@ BP VG8!R'P@GN@L1:\O.]0CQA"A_:QAVT(OBZ@
M@CLX@BAX@U6P!G]@!B"P F/H @E  ".H!B58@W( D#10_X%N^)"GDI":*H0)
M6A)!)(]SZ(0)2 7T8L7Q2 <T2 )I.,!9E"EU  ,MN(?X8469,@<LB &K"T1!
M+ =X  (E* 9%:\%,.0=3J $*:(!1  =JR(,W  9)P(-\B(<J,  WR(4A6(<)
M<RY.V39$<D%V< %KP#WYF0=*V($BF(,YJ 13N"4_N(-.X(,(R 0B\(-PT 8J
M8(1BP(%0,(4[.)9"N %L\(XY>(3OB 4_@ 7MX[)P> 4M* 4W:(- 0($E0(;R
M6P)OD(-,\ 0;V -JH(-OB#\[RX1@< $T^ 0B4(8OV+]!8X%2L+P^ 4!G5!-]
MD((HZ ;^0L!P4$ I (9_L+=9%/\/\5H3A!&'#-Q 4V&/#'JB!&G!&B('1R"
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M%I  &9@%/4  *>@",V@&:G CU\P2$GJ0_R '?B@E(2@#+G "/3 #4RA'K87
M=[ '.UB!7L '<D+101F'.>@['I$'V*L1FW&%]X'H<X"$ $@%#EI/8H[8<-"'
M/+@"_2WI\K"AXGH"'H"'0V7*>&C/8*AL->FT4/@#)[ !$" !,$B#.: #.<"#
M/=B#.E"!!1""-B"#>H"3'X0J<] $&+ 3%T2'%\#1"PH'>#!N>-@G%LV-)4H/
MYNXB?#CN>G!N%H[GJ;*I>\9G_++G#EJ$*J#;^7F'*L ";?"G4VP[@<HA3$B
M*(@&I<RBCX;*B:[_:/B6GP[:2@Y8@W3 (1:D;_,(Z9$6M_XN#_3PASH  W]0
M!WTP!69PAC<X!1[P@U!H@ $X !F8 Q2  ACP U^0 580!4O@ACKPAF= !'.@
M@R:P!"J8@!:H)EMP Q@8 T](@1F@@24 @1T !&*@![Q+M?/,DG^J-W4 AEZX
M!"Z @BB0@SR(A.-HCQG*.;@[ABP0A&E5$N\8(;]^AR5YSIZJD4R0@$" 8OE-
M[,7NVQ)T;*;$D,B>;&1&K<M&A\S>[#*/0,]>1M#N3G-HATAP@ =  #R(A$N
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M2ZS/$3-L@!,"A?9 H/B'/'1#&^[ !2F*L09F#*,9R9! &[JQ#&=\ 6_R.,8
MO,([K(,_R$$[I$,^H ,?+ ,]+(,.(($F! $,($$H\(,\])8YV$JA7$NL((8]
M !LXH((5F, ," $B$(,Z7(1]Z,1+% H]O,$$T  KR <(JHE&C,DXD ,Y: ,1
MY( *.,$SN(,TZ( $I  .S( *F(#/G( (*$$!H$%(F<2&\$U&D$,EA, JM-S0
MJ4,9'$$V9!P F8,]Y($3D$\&FDA&C,-R)4$)<,.3M4BN0($6>,..:4@\F,,I
MH "3[1ZP45V4_Q5$!E4#3YP#.7R!,H#@5N&"1NS#+M #+ R#/1 "+1A#,PB$
M+BBB0&##&J0!)Y*!&_0".' #+_2"#_3"()!,.K@#(:1!)=R",1A#*(##.!P#
M-JB#(W B*\A#(RC#/* ")SX"-W1#(\0#. C#(@Q$-.0B,K:"/(R#,WQ"&GC"
M.JR#(H #.ZQ".XB#-TB"*21".Q #)PY"/M0#)Z:!(ZA#*+R!&0Q",ZA#(_A!
MI93%.-B"$\!"%W1 "!2""ZS +N###NA *DB!"?""/Z"  QS!8Y1#1EE?."A#
M#6A"0HG?B"5"!T@!-7B1^/V#&E  'LR#3$571)U#/+A!%:S#/8P#)O_H@3.4
M02AL@1,@0P!<0B/HBQUH01S, BGT "R4@A\00Q_H S.L@3K\@3'80R3X0 .L
M !TDPSYD2TH=Q6Q9F$ <1SS<DCBDP000 BI(@T).'5*@239( 0$H@5$!G70!
MCT 0HBX @0*P0"#8 SI,0! X@1$8@1,\P1$X 1:P01T8@!X<BK9)"(1D%#BX
M R3,@"M(E-Z\PQA,03;PWM"%0SO401)0@QB&WX:<PZ&$0SKH  I,5<^1"CCD
M Q0H@4VEBCN40S/H0 >HP?.\85N\!)4)HE2$PQWP@YM B-217$;)ATML&824
M"(0L5SP4)T5!B#D8@PYTPSE(I5?<8; 1SYO_Q$1Q2ATY$,\]W2%&#)LLRH31
M!4KZC4DXD /#;6=:9D1%4 I&%.>@%*=V3E0Y$*(X ((?,!M4F ,K2,$LI,$&
MI$$P-($2& ,]R$ :] ,;N("_N4 $,$&R701D7ALQQ( 9Z$.M^=)$5B0U@*'X
MB8$#D,'PB%\HH0,@/ $R[ ,Z^%$UK$$OW( 5" ,(0 (DO, ^%((--( F'(,,
MK,(L3,$V,,$U$ ,AF ,F*,(E/$ ,T$$NJ$-4GM]7GD,HG<,[<(,R! (MM$,Y
M4%D^R(-\_.%A."DN$,  #,+NA28(H65,F ,ZP$( V  BH(,H?($\I(,\Q&DZ
MS(,^V,,\B $&7,$V_XS*%-H'L'5#%B3 '?3#;@J9,KQ "ZQ".0P=0B$"#+@;
M.FS<1;R*N*#""8R (<B6WIS#+MC  #R".P!0.TQ"$=R ! 2". 341Y:%;(H
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MX,((PE %*BQA"4? 0A&F((()/.$P?,U=5=@1CWQTXPTT8 0P3-$+4HA"%*1
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MX!C. 1["P1JVP E0@!  AX)"K3+BP3VZPRRJXB&\#@R*@!3RX1.$@!N&00<
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MVJ#_">R@"KS U?0 ";S "E(M"89 #YC@")*@"H 3.)%@"XBS.(L3"9! "H3
M"H*S"FR3"XJ "9!@"*B3.NM #[!3#^I@.[F3.\&@.JG3"L13/,.@/,OS#OP@
M/=5S/=>3#]SS/?\@/O]@#NB3/NW@/N]3#NA@/^D@#=)@!2*!=T0E%K[@$>9@
M 'X #5;@#[KA'/#AS=*D'@Z! ;@@&[H$'8YA"MA %<; $28$+#*E ;]!#] 3
M/?V $NR!T+Q!,"ZD$T" %59!!>"@&KQ!ILZ!$!P ]#1AN+AB.CHE';2C'6L"
M)XB/%([ %["!%UX %^2A'23! Y"@']1A1:@!#I2 #R1A_W'"01](1C6,KT,\
M(QS2P3/JP0Z" !3:(1%, !1*S ;< !_2+QTN00>X@!'D@4MSS2=BSL/J00UB
M !)X@0=D82Y\00=BDG>03,XFS\_.P43,  1F( JF( 3LH!LZH0LVH1,:H1A4
M@ 1@X?TB)_8,YQU"@0L.( *<@!>:(1_F01[2Q*)4@O#*H1(NP 9< 7"\0O7$
M81_4X "6(!D&:&/\00@V0"[-(J<(I\+P4B\%T\/\$C";534,YSZ:,5969!Q&
MK1ZHP OZ 4/2H8!6Q" S4R8VLS,_TR9"<S1+<W=.\W2V,/C<@C4Y@F"J 12V
MX1M^@1:4P1A,H1:"81J8(16& ?\;3$$6;@$;$!8;BH$8)+%A(Q%TCL$;BB%A
ML2$8F@$.CV$8''9S.)9CB>$1A\$;OF%D1U:.3/884#9E579E659E%9$1&]%E
M[6@?F$8JQJ$5@F 2Z, &$* 5H, $> $=-N@P&J8>#.$#1$ 4M$'UR@$>_.,>
MU.$N&BE3\L$?J$$3OV$:KC8;*&C4H,HZVJ$;*@$(,( %7B +*F$>[D$4-@$?
MCB$6/%,CVL$?NJ$<Y$$ZA-1.PN8:B&%"Z@$7&A0=$,$!J" ?ZD'UDB$+M, %
M(H 1/"-+ &6HP(&"SD$>]L$)S<$>:&$;IB,8.L$7 D$/#* ),,$0WJ$?O, $
MA. *:"'_0Z@"'12,+XL!!0*A':8!"WQA(%!!"0YU)I$U(VA&'/RA%JB  G8
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MMN 5C $;#&D:''L:G $4H>$4G($.GJ 5C*$6]  !1J ,LJ$6;F 2&*<=_*
M5D$?Z*$=],'_"Z#@&:[!%%Q  DVA"D !&)YA"@:@!EY!&JR!&*K!&2(;&(!!
MLH7;L;<A",! '="!'JP@#J A1'Y@!58A'[#!&7A!!3A!F^?@#*8A&HHA&K*A
M%*7!%*,!LJV!&XC!"BC  9#'&8*!#&B@%+;"$4( $_R!'E!;&/3@%+9!!YB
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M"%WP"[%@!;]P#7/ "*< !HUP"'[ "OLP";4@"C<P">!A";?0!(+ #$-@",D
M G6P!<-D"XO0"=_@!C5P"YE0!==0"R/  JO@#K/!#C_$*_-@C7SD.?6@#U/$
M*U^C9P7X(B]R#JIP FJ0<RJ&(_'@#2QP H6@#5=  #*@#/5Q.^Q!3\7P  L
M!-, 9;)S#ITP  B@"?:@4-" !0H  5G_X ^D)#NBY#EK$  !8 ;U$ \X,H[M
M" 0;T !V4 \"Y0]2,)@XX LD= [ML _O( \ %49>)$K;2'-&MH#>Z(#GJ($
M1H(5>(Z[R7/I" X<R(XF0@ZS( :S8 (H8%: 5$K,MT($IFY"%&92Q"M3IIL4
MN![R44CDYG(:(@[<!" K!&5-(A_=EAPO\@_DF5Q79$D$N!_F8 \%=@[ON1X-
MYC@H0W'LH$+OP [:*9_PF9L819W$PU; )V?*%42?)$5AIF[<240H P[(P9Y
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M(_/0!DCP"C5P!?[ 'FRE9R34#UTU#O5A#O)P#FC5#AG%1UIY2N<D;^0V#_1
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M"ZI0"UJRJ=_J"[: "Z. "LM@K:Y*"\R@#N/ #['0"_/<"Y1JSW"""J:0#*A
M"J!P"K^P#*;0#**@"J @#B,T#MNP"JZ*)Z PSJ/P#/.0#N[0#*A@"\ *JJ#Z
M"\T0"MPZL+MJ"J1P"LF0#NR1#MN@S];JS\V0#*(0"HZZ#MTY#2R-"B,=K\V
MTS@-"LV@##L=KN *"I>:#-T@I^/@#MB "KK@"_"*#,A@"Z0@#/80-?7 TJ(P
M"LF "] P#,MP#,-P#!R-#,^ #*$ #=NP#<)P"L4P#,JPJ]+ 3>#0#I@ QRL
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MYO]0#4YP!5'P!#30 C,0!$U0 R*P C>@[NJ> NT^=6J>%$G #$)4#W!P TE
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MFI<8B"BI&!"@RA@MN'BA@D[::2>,/GSY)(LK&KQ""QXBY,$'*$I0@@@:*$
MA"?\,/\DB2'P^<<<7DPP8YU1WG!EEQ:T8$("./H9I08M2$E$AP%H<&"%&E!
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MPQ".'('L1A(>D ,>6&,<_%JD50QSE<0L$J",M-8Y%2R8!T,XH LV\(*S%F&
M8EAK[/C*$:C!E9&ZP![LO,HS+D&-<SB&&I9PQCB&,(,;R& ')YA!%G0AM'S^
M<S#\M+"#$6SAM%#%#Y<8L&+D$0<]Q..]'[7*.-CQCB)HH []^(<^J,$$]$CA
M$TSF\F.LDD%QI(,<PH "'N!AC"G0H Q50$ 0]L"&7-S*%USP S2VV^4NAP,-
M./@$(GS0"Y))X@-#X$=4PB$*%4B!"#@01305"=+WLD,<_#B562JF1Q18 QB
M,($=/$$"#<S $O_ >H<0D%")8##3J'@&Z1EPT(8QL  ZL4#"'MH1#G8\AAWG
M.,8-'M"*%5B"&$C0Q#7Z4(5=$-L;>"C#-%@Q7QJX( @LF,0U+I$(9]@!$-7
M Q*248DPH&(78 B%*\RP!!M$ 13?N$(T3L&%11 B"Z(H!0J&D(VO@G25^Y78
M?=EQ! P,8!?Q(,4(]F'-08IC&"+PP"  AE]&)BN0]1@%%'XP 1U8(QS[JE:/
M/?YQD(=<Y"-?UCPZ_.%S\D/$)&[OMMA1CPP>0Q.0<$8W*J$)1. #QR#6,81[
MWF,>]S/(XOA#)A*FF'@40@Z6)"HXSU$/>9#! %,5QSOF$8I'-$(:[JC_)JNQ
MXB6$M0MCY#!%$>;@"1_P !W+*($D\+%K1[IK6U[G\ED\X8(&0& 4Z7!')SP
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M P\#,94;L:YKN3LK)M'[J!S[,7]BP8\+NJXIJCVP!(-*#'1H!#K8M1(4&G.
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M*&$%6=C"'SAA#7I$XY*>C"93^<&-:DPCJ=1@*E6C*4RF>C(;M<Q&-)_)#7Z
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M$H3")=! ";Q"-[3!)&R"%53!,UQ!"W##+$1"-9 !%_P"+<#!,B2""YB #+S
M&!2!'#!#+'S"'IP )CCB7E2A.*@#<;C!"/@"77RAI9 $79"#((3 '!1"$N2
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MP3J@ 0P@ A.@@3Q8@AX$P@N4PC* 0 JHPB-X03YP0A\4@S4 01 <E#7TY33
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M+N$YI(,D_, AF,-\"@H[R,,QG$$0&  "Z, :D$(VI ,[S(,4DB%6C$,Z*%V
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M_4+S_>;O^I)O__8#"AA &M2#D,RCH A&.7A##!C %BC#$G3".H!")F2"$=
M HS (U2#&_"!+?1!)9C"$J !+E@"&Q@#+4A! +1 $8P"&5S!"9" %I3R":1"
M+( !*AC"'3!#+?3!*SS" 5#"/%#%#P.G( 1  U0".A #)-!!##A #C0!)#S#
M.XQH1Q0E%19)TCS=WL(@7<Q#.BB,-D/S3P/_=5"3L1FCL1HG*QN[,5:6PR!P
M 2PX=2\4@PX P1Z\0!B, @Z(P1L, "0  R5T 1]4 0OTPB(T0*%5P12T @S
M03OLP1/LP1[4@#8TP B, 1=$ #5X A.P@AKL 3<,PA*(@S'H@"(P 1=<@QBT
M0"O\P3.PS!G0@@AH@R 4 B<, "%(@@L4 B."(5;"RQ0T@CM4+^=>P1_@Q?K"
MRS&#;U(S\_FFKT^39_N^;_S"BS63,3;KKQAS<PD4P!C40Z]6(4G81C_D@08D
M@2I<0C&T A.,@!)P01@, 2LTPR68 2^H@2. @AA8@C$XPABX0B.40 [0@ 2T
MP"!XPBWH0 ^<@!/(_X$LD,(><$(F%$$LQ,(;K,*IB  4,(/VWB03DD,S0 $&
MX,$J+ $)0  ,+($@6,,]Q*'"O#'>_G:9>*$RWFUL%#%M"_6%8WB&UR]1I_$:
MM_$R.Z4YN ((@ $8Y,$Q1'4D[(,=N$ RZ(!D]X [#,,+C  /Q, #S,$B>($P
M[ ,S!$$GP  JF,,)I, 4A $+T$(3B$$].,(.9(,*!$$<:($-M,)?!_9@AT$A
MA(,FC$ GW,(]D,(9L 03'((@6$(F#$!ZZ $>J,.#;@,D* *MPC$X"($AE$-H
M[\,2_,'+F3;W>F]J@[@8-W-K0S-L4_-L_[1MNS9YYO8"R$$_C(,^, =WQ/]#
M.N@#/FA#,###)D# #1B7'SB  T3!+Q2#)K0",E0!)&##&2A"*3Q!)M1#*O""
M,H#!2B, '60! :C &0P!"43  5!!-[C"%&@P$D #(R1!*^ "%@A",EQ!);0Y
M2(_#.NS!$M\ !/2 %Z"".HBN^CIHNN;J.SA#9WST"U(%N_#%HFOXNK-[NY?Q
M&7?X47_X&Q,G*@BP/^S#.40U(X0#',Q (O  (P!"#XC#+VP "O2!"(2 (2S"
M(J G,&3!),! 6#0 !6R !,P *;! )H3#*YA -C3 Q5/ "T2#E0NV(H !)(2#
M/J0!"Z  *I"")-AA'DB"( A")0R ..R#'/!L$U;_@OR$@KKS!1:L@F  \SBH
M@^Q]C(6'I9\CLS+3^QB# S/H@"',@[H_IZ'+]OPF.O[>=ACW+S^(  'L03>0
M S\D6-KG@TM50S&8PB[00BG,  7(@ _8P F(@"W4@QA(02(T@1!< R5003%0
MP1GPPR[P0 Z$P #< 1@DPC:0P41!P C$0!"$@!R 0ABHP81<0S!802HL@Q#,
M@3\D@PKH0"_8[G&^87!& R\(P0A 0 0 P2XH8OO\0SNR)(U$/=N.9#C,0R+$
M 93HA8FB7%#"Q?QBO;LK__)#LSC8 QYX 3=X[39<@6H_K[WO0_;?@S#<2[_/
M@"/PP"90 L%'@\SZVR5L_\,B@,$V[$,R!$$@3/PY7 $B--TDT$, S#$OC$ V
MZ$ ;],,Q $2E=X.,.",50Q$82.%0/8/GA0JI3_[$Y9$D:(V; ?RVU<&C#ES(
M<.%"_C-Y$F5*<>>PT!H'+B7*D.)>7@LAAYPY<C%1AONW#LN"._3"Q0/GDV=2
MI4ME?H,Q2QQ3J5-1BAM9SM('/?1@1J7Z=:D>&Z->@C7+TRHY;C$6P*$G3EQ(
MN>?HUB5'CU".'SXX<1+Q:9H93H?J^#E$!TTR,X&N81+0@\<F4)]V";/DB4^>
M2:LV.6)R $@P4'M6==JRJQ::7<?H,!)30-.[<^3BH0M7+IJJ-#Q"S.A"*!0_
M=/_B:)^-"6X<NWEA6#RC.4^N7./3J5>W?AU[=NU*X]8C$R5;RF(ZXID-=RI+
M'O62D$F)%:Z1"%-<]E12(LX=HBQ+I$ YM>@'*<#( @Y3IAA&G#:PR.,*+_SQ
MP91P0%&"FTYB@*(+/M2IA84ONE""%CT, 0<3&;K@(9)DU* F'#P<,403-@0X
MXL-4S(E..JK"02>)5<9!2JEPS@''&P7\0,<<=Y;R"2BAB#(*R.V2 L<IJ*1D
MRJK;LMJJJRO#&JLL+Y-*:ZVVWHHK.KC4#(<<>*@(00M2Y'GC#6'.F*,4.^PP
MAA--K*'E"&8 24&!$]H0!Y8EOBDB#&8H^:(?4;QHQ0[_"E(PII!>4BG"$%]\
M $X..(@9@@ BI,E)''3L6::(' [8 (5#BGG'J'',.<<KZ\ I9YQ"MJB'G7C8
MP1$F,8T]%MEDE1T3'._ $X\\\_B!A5I7FL%G%'[":6<7>TZ!)9M31IHG&5A<
M88:<2N:@5A9KM&%&GG#VR87::,[!I9UPWG&EG7EHN221>L"YIQ!">C%&'5JZ
M 4<83]X 9!YXELE7&6NNN682 0YQHQ5]B"V)JG/D">*0>')-2D@J"[BC''/D
M6?*GH(8JZJAE_Z'RJ9.3S1(KK;CZ1V=DQ2*KV&7)9,LMN#Z6:Z1[$FEAADI*
M<>,91N9X10@N8H'DDF1T*6*%_SW2"*0!&Y+8!1!5,NEC%4KJJ"/&3EP!9 @!
M^%!D%3Y4.2:-3IHYXXY0,LE$C!24*:<>8UHI(X@#3&#"$E+:$5:><:P:YYSK
MPAFG''2.N<8<>X(EUN;233\==2R;_2X\E,8K#ZR19(].]MIMKUT?,A*YG??>
M2:*]=ARS' G'<"9I(<NEBY:*G'9XZ"2=<92:Z25L!-@#R7)@;G)F*&W&V4J;
M>=[RYZ"/'3I,H]DL,VDT<SPI'';(T28,"2:811@[_%!F"S>$X<43LG "#09@
M A?@@AI;>$ .[. -,[ A&X-P@S$P08)&'&((QVA% ;0 "CCP8A)&B(4_'K$(
M:/3!$O^]<,,5T" *02@A!#]001$@80U_L(,FX[#-/XK"#LV-8Q[VV ;FW&&.
M8>$H=4E4XA*/U1W600MV7[$=\'QG.W300A15U.+OF!8\*A*/=LB@Q>R6)L5S
M=&$1-YH>7*0'#1S$(2>9"U+,G$2S*"$+?.8SUOA\UB6;H6]Y.UL?TLZ$Q)2H
M@QS[B(0 !M"*3?"@%YY( CVFP8=)/($$6[B"&)KP!%=  P8-8,(HG#",38T"
M'E8X01G D EO)"$'--C"Y[00AG:,0@B6:$07^ &(0G1B!"((P0($,($SX(,=
MYX@'7>2AS)/43'/D$(<T[E$.<L2/=$S4YC:Y:18G/LMUT8K_G1=%LL7:E:,<
MYO1=\<A93C(RC1S7!./'OL(Y+0 BBMR!23,:( 9>Z=$D+^$&%RBP!WJ,PV0W
M4MY"@5<.<91'>>%HAA)V<<2ET04<-!G)/\;Q(X8N#3_H*$<A*H"'>DB3BQ\E
M5ES@(B2X#$EY=P#30BTW#G>  Z;OXXDA3[*2>/"C!@DXP\O0(161O8,,!RA!
M([9Q"TDTXQ-&B  "P%"*28C!&FM 0A->\(4["" +V+@$$V;1"2ZH@A ]8(0K
MYG *1Q1 ![L80RR2(0@@/,!2WSC$&F81A@A 0 EI:$0V<F(.<P T.SSMYF(9
MVUA].JMU)\%&"=*16*;-(Q_PL,<\_U7ZT99%1Q[RN,<^W+&CSF935TKHA#FD
M$I=_\-.?EEM*7(#!! GL 1[)R>AIE3<.<M@#B#=;FD0I:M&/"8FU;)(F.%S&
M6[F@ U?DD(0!U%#9Y3J7N7&9S6<SZKZ/R91H# U'\J*S%,4B)Z/44$$!AOJ/
MHDYOO+/)10@HT(M<O$$1=3C! %S AF=DP@^]F$0-/=&&9C@"!EE(!1^RL8LM
MY*(6F9B"$.:PC&6<H0DIH,(A3K&&0!@"!"Q8 R180 (2T  %>DA&.;J[)CR6
MU[$QEC%COQE9DTRVLMAA6C< $84ML($HV(TH*T;!-$U @@U3< 4]#G$/(>M8
MM:Q5W6O[^?_/I9PC'-WP0@;\((UXJ$.X0DY3.>BAG# 3B[@57>C-V.2.>:P$
MR\8][>;,@0X2&P(Z117R894)#G+89D=RQA%X7Q+1'-I*L<>!L4G\+ YSX ,%
M"VCO>U'F/FT080-3^,(-KF"'-=@A%L6X1"2.D8DR_,(-EX@D)RRA@B2,8@][
MT$4C[!"-1=0 $)\  RHNL0,Z'&(.AO#',+; @SG@0 (ZT$,BK+&/<IS#HXL6
M4Z)G7&UKFZ[&*<&Q97<E"!U48A%9:$-*%RH/[\KC'<(;0AOD(HX?P&$0;1 %
M*'#PC"=?!QQ1;NT^JRQ;I;R$'U*8P!'8$(IV[%;,3+N&(GA!"J[_#'>B:HYH
M..IABEW\0A^.QNF3KYD.,ZQ@$$K2,W9_%,]R *,:V<"R0I=&Z(6>0Q^9K0?+
M038E:1,G'/2@MP(F_15V3 (""$B!%F81C"9@PAIH^ ,_?&$%5JS!"[CH@A6V
M$0HM@,$,5W!%)$JPBU-P00=,N$,ROL$%(,# "*:(AR#HX(0(N" '2E %/=1A
M#LY=TW34OO;>^>ZE;*-DVSH.B3LXL09VA(,1<!"'-0QAB%DXHUF]<#SDJ>&*
M. A"'O%0AB'<T ;*-P(-@D@"+=J] UG(A13U[@<BQ*"(;X"#&HUHO3S240I#
M ,-]4%XM4S87%U <X WQ,,<=4T(2:E"A_PY3@$ :#GO8-='.N\@I='3<00D;
MI* )OU">.*S^"D%'IW._"$(.B& ,CJ(7N_^X9BA<$( H7",<-U*3TE1*$VCO
MHPPZF$(Q=+)27('##T+ %WA%>>SA%9@@"NY &[IHMG*OIVRJ$H!  A" #>IA
M-JC"SXKA"R2 !NR@&M@ $$ !$/9 %=J "5C!##0A%M2@#4"!#=9 $VY@#+YA
M$_B %B"A#Q@A#EY %KYA"%I!%D: #X)A%D2  B8 !H: $Z9!'=C!5CS**DI'
M[_J."JN0.O[N)(H!!>R!V^*A$WS #'K!AM8!#<  $X2 ">2A$Z; #?R ";I!
M#I" $_S +<2 "?\^ 1.XP!D^80G:P!).(!;:K0<X01=(+1=.0!06H0HX@1*D
M0!KLH XX(0G@@!OJP N8(:?P+1QTH!/D2"GH@AS H102P W<(127XB7HX0\2
M01)PH 0V015^P11FL11P@15T011P81E0X1=4@19<0110811,H11(X1=\(1=P
M00DZX IL0!-\ 1I]X1AUH1=0@10PH0;8 !6B$1ISP1N]L12:00P@(PL.0118
MX1=Z0176415Z@1N_T1M] 17F$15$X1G4 1!^X F:8!>0H1=(X1@"\AB^(1@*
M,AB8@102DA1*X10:\A28 2)!H1FD8 !"8!-*811RX1=(011$(2-M813_OL$.
M>F 03F$9A@$EA^$8AL$:FL$4CH$/>B ')$ 9S"$>@($9M"$>=G(G#<LG=>(<
MW,$9+) N;B4=[* !(L !UD >P($+0V8<9B$$!. ,-($,M$$-) $?*($,GH$0
MR" 6FJ ,^ $-^  :.($ ^L 5-.$9TD *H $5WN .;B (1*$=O*$(1B +1@ "
M0F .0J$)C^)WK) P"Y,PL= DM/ I\4TDN,$2EF %*(H44( 38*$,9F 7WD 9
MY"$:SJ 9J. 9V$$=9* 7VJ 5V"$=3, 3ZD 7YD$>P" 09R("CN (<F 2<.$$
M7($*&H$=W"$%'*$&>H$=ZB$&I($,5"$4=6HZ_\:+!P)!>JYL-L"!%!*@#4PQ
MD%+BV>H!"_"@&DJ!"R9@!&A  ,9S/ > !68@!%R !&Y@!P9  FJ@!5+@!E0
M!E1 !F9@!C9 "<A& E+ /U,@/D\ !U3 !0:@ 7!@!61 017T!AJT0>WS!U!@
M%>C@/@5@!G; !#+4!'!@067 01M4!OXS!5Z@!4H@ *B@%I3@!&8 !G" !5[T
M14] 1D\@!4# 1D&@!EY 1U\ !&9 !5 ,!=R@"FX@!6)@!F1 !5; !5I !4[
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M6& '8'0]3\ $9L $&H //H$%0L &PG8$>F  VK9M(P!NX;8':*!KUS8 [E8
M;-8&,F$7A, -*DO*I@(NT,$2%* &8F$3RD 6(($/6.$3_D 0,($2F.$3^D 4
M(N$.6B$1 L -4F$2:F$0JN#V)H$(>*$-<B  1D )T" 6\&%S1"JGKO-59Y=V
ME2A69U7PP$$=""$6KJD57F 44L /,O,%KF$-1*$<_XHA#G:A"(HA'. !!UK!
M#9RU!4:A#E2AH]RC]%9!=KKU6P&A'.[A!C9!!'!A'+*A!IPA#=95VI;379V3
M*4!1.JG3.I<$VKRA$1AA%F#!&-9A'^H!@.L!'^CA&'"A&I#A&;"A&79A&92A
M%5S!%U1!%AZ8%WAA%QC!$%)A%ER!@UUA%5CA%5+A@<UE%AB!%ZB%6BI8A5VA
M%E3A$0X!$5BA%F[A@6G!AFEA%3K8%5"X6EC!AUG!%1X!$Q;!$#I!$EI!$7;!
M$1"!B9G8$9YXB0]!B@^!$:#8$0:!$Q*A$>CF!>J@$WC!$0YA%EZ!6O(7$1(!
M%A#!$1CA%0Y!$00!C@W!%?\2X15J 1"@5 9$3!(@@1$V80T: 9 !>1(&>9 #
M81  (1,:X1$(61(D 0U*( M0( 42P2@\42JZB_T<0 @6@1H2P0ZF@1%$0!$J
M00Z0@1+ 8%_J0!AZP0N(0 &(H!IP@0H09HN[0 :65@DL 13N84<Z2IG0H7UK
M5YB'V6A6!YRR< NY;1XZX0@R81*D8 F<80B\0 ^T@ _HP0RBX!* 0 N0@0SL
M8!+FH B<80R<504&@0VJH! J@09.;R9& !6Z]P1Z@1.D0!/00 BF80^0H!"H
M  R& 0O85SF-@SGA%SI#<5[GH5Z38DCJK!VD:2>08_[@HAQ,<3;2XIHZIYQH
MPN[_<@@=.JJC7NI'+.=6R &D3_JDAP2'EFN\;.?04-IRYL\<T@$?TB'0\,,<
MYL&EU<16?C*>3$X?YL$=VD$:0F$:YH$=T %):FH>=,*D?RLGH.ND:8(<SN$>
ME*$4Y#$?TL$=V '=ZJ(H?U)8W,$>TD'X# L=W&$?D$$93"%;W,%6ON*EZ$$3
M.!"J\, 08.'R' $->D$3QJ 7*N$.:L$5Z, 7S$ #F$ 9VH 10 $-BO8\>V 7
M0J',TLF7?2LY$TZS-YNSE8>8/]LX:JR\</>T9.)CQ $8V  )D& (B $=3&&?
MR0 8SD$8X("U0>$<DL$.D* *B$$=9,$8Q@L0LD$8T  )_RPA%KB!:>* *$:B
M'Y@ &N#!$GA;&,SA&XR["MP%$:3AWIYIS'Q $1#K'^1W.@F!'=1H>GAH*HJF
MI68BHT@B)023W&KNS!BJIXZBNQF-=D0"X;J(LXZ+:2P'X7I">.2[=O0;:$AB
MON=LI69B<S8* Q'*'(R!#QQ@"1!A&#3A#6*!#-9@&=J@#;:A$"CA&]B@"$SA
M$2BA!%J %E!A$8P  B  !_:@%H# 'VQC):0'PCN;QWN<LT$;R.7:F+-AM).Y
MOM?,NS]F'.Z!'_BA'T*"'.J!'SP&I]3!R4.B'/"AR9%#'EC,*7%*'_@!.G $
M'W!$&X"Y';8<S+<\*&.WM$U;+O_&P1YX@!'@E:'E-0',&[VW \F3O(S\W+[C
M._W@W,?[7+]52M +W;._ AQP7!$$H FFH1,*(1G>H!,:0UW?8 RN(1#*H!E8
MX1*@@0T00 B<8 (B( L\P13VX1SLP!.@RR=TB- 5G=9KG5V#'-=-0K2E@[0[
M:]9M'=CSN[YW1 D@)G[Q7,]E5U<6'=!1Z\B9O=D1_=>#/=$_JMJ#7=EYHBP,
MZQEX( +BP U,H0KLX!H^@0^,00[N@!C0  M.(1<JH1L"X048H  (( \:(11N
MY![:019N(!>8BR0"]]FQG> U.]</'BV&O,B?\LT/O> ?/M !?22  !"4Y*#G
M-]FOQ-#_!UZG&C[:K7W:@?W:-Q[B^S04T8$=^$$.C 35ZN 4S$ *?J$1Y( 9
M&($*EB$5_& 0)N$&(& &^B 3L$$=[&$VV*$=UB$&Z$ ?AH^C0A[B.UL<[ $>
M:F,?Z"$>[@$>W('V@.A&Y&$?%+H>X$'LX:$ILQWA@7S72Z+7I=WAG][MVU=X
MS"$*#&$GH-,V2$$!.*&IQ=LX2-[0/;[M?=WI:WWDH9WC:5V*@'DDR"$7/G;9
MM,$5^@ 5.($-2N$3W( (=< $9& "LB 3<B$?[B$Y.VI;V$$2F. 7A*71>Z*(
MR$$>G"$;RJ$=LB$?;&,>^L$?A@\:G.%\J:$;AB,GY-P=Q"'E_]4A&_2!XO+!
M5NQ!&*0!NG("'K@!F&N?'-+M>;FAJAVJ&_(A_NQ!'5X"'P!!$F!A$#!A%G:A
M$%[!'TCA%OP!%8)!&BA!$6B!%,R@%9YN$?[=[,_^L^."'N( ())D T<0W#]O
M,$9!^]:L83-EWR)&?$:QHD6)WYXM<ZC,HL=CWD*&Q/A-9,AAPE*J3$FLF,N7
M,+?)E.FL9DU@T7)&T]:MIT^?^?@)'3I4&[6CU.#16TJOWC,HI\RQ^T>UJM5S
MY]"%(T7@TSQSYZR*'4NVK-FS:-.J7<NVK=NW<./*'0LN7AT")9:1LC*'%!ID
MMC29:A6$PH,)85K9 T=NG%6#Z<9I._]C21TZ<.:LBO.G;YZM3'[*D!'"Z98\
M:KQJJ=LE14VJ5WCL#*JESQL_?,^ .6-39TXA>:!6>?Z3YU*P:=)$\6GC39HD
M8=NJI>,6",PN9\=:C0ES#!\[;]/6%>-R"$F*6Y!>B(%&3A"@8IE6H4+1"[T?
MF4 8L2(XM[___P &**!8XH!#3QP":;:,"2 $X0(,$$+HPH031FAAA!2ZL,*%
M'$:X0H8@N@#"B"368.*))\:@XHHLEN"BBSSH(*,.2FAAHQ99!*$C%$!TX>./
M/QHAI)!,(&$D$D)(H:045"BQP3?CD',65EIQY158 V:IY99<=NDE6>&$XTH$
M/=!10P\(A#'_S"Q)C&$%"PB (,4@Z[ASSCCCA/,8./* M0P;4([#CCEAFA./
M.>CXHTDRJ8@1A1C)R&%,/IR\0H\1)*3"A!V$V+(*%G^DH@XQ.DPQC"4SK*%"
M-8L4D@X;=QPS2B1Q&#/)'G*TX<@6G4 R"S)6=*%&+(X00<0F>1!112^QR"**
M,"*\,886:<SRQ!&8U+.)'[#0(9\@:1P2R!2!O%,'$H/P]^6Z[+8[8($')EA5
M..ZT,@LBB^2;[R:*]-OO(  ''+ @_BHBR";Z"H+(P@PW7+#!@D1,<,$25QSQ
M()MDK/'&@73<<20@A]S)R+U.8K(DCS2B<B.10.+RRR]_4LC,A4A"_W(GDE#R
M23[VB#-E5EMU]558[A9M]-%(QV7..-TLT<$)4-RP !*HK#"! SFL0$@^@Y*#
MSM(&635.@>>$TP\=;61#C3KZI&./.O7<\XXK>EB#CC,\7F,%*O=,DDH^.I30
MC1M1?.'(/+6$$4TYRW AP2;-&-%+ ([4088]<A"!##1M',$-&$RXP<D26F1"
MB"!BH%$&$+? 48$;[3330!?+\()*,-M,\4P\E>#S"Q%I!&-/&5!XT<<90Z0R
M2"9DV.&,-JHLD@<U82=M_?7NPHM@-F*'HX\XY42&9Y3SE&_^^>B?'\^=>(:?
MSOOPPX^^._33S\[]]]MSS_[WM.-_._:0A_\ !TC <AC0@/' 'SOBP4 &*I =
M\ZB?.Q[X0')8T(+S(& \T$$.=KP#+50*VI6(AKT2FO"$6LJ3.6!! !\4@00C
M $$7(L"")B"B&O0PASC(<8ZPB4-/5<$*. 15CT]H@0I=F,,>_J!$/%3A$<A
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M!Z8P!W8P"TS0"J.0#M< !9Q0!X60"NRP"KOP"8"@!MS@"IY $, P!=E0![U
M"&J0!NY@"ZS0"76 #Y,RM4A6M=E*%AT;#E@+LEY[N9B;N=<&MO\IMNRZ!)8
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MYE[742 $B*!C[@ "CQ"@.MWG?R[:@4[H]G[_[[2D)X<>!HH^+\O  \ID%:@
M 84P#R" !YE0!\#@#V  !(XF#"3@"@#%")*0#8@ !-4 !X^@#?#0#8+@"_F
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MYY8=(#GD!A24N*$791H!QYL=> EGG$-\X$$'/:QA8P8>O%#ECAITV$&,8:!
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M>-B'?$ J\!BX#_]E'.XB*I5)-6WPRW(82)L*M$C @62X' 'U4:\,AW[8 SV
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M01G#0)L$I+W5I97=3_L7?Z"#I^4(=C@%&M"!%)B!5P+>5[*!$/@! 0@ ! B
M'F !$P#>'/B! 8#>$ A>X+6!'[!>Z]V![,W>X.V!Z_5>ZX7>\!6 \1W?[_W>
M\$5?Z!6 ")" ]D6  <B!^,V!]J5? 4#?"$" _$4 &>"" K@5N(R:QE"9U[75
MV35@KJO=V^U5CC"'4 B"4R"%4>B%":;@"M:%6\"%6J@%6:@%5<B%7*A@#,:%
M$;Z%"EXA5$!A7QCA%?^NX!;N!558X1C&!5N0A1JNX57 81RVX1IFA1[N85<
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M*V%>TL.>P%"/?7MYH0KAXQ[)%; U-E1?3'PF'QLZ21S+N)P\Q)&0F(Q#7F8
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M)>.X!SK.88]]D ,<YHB')!^+#WO((Q["& $IR!$O<9"A!M,0Y"+!JMK5LC9
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M\0,M%"$)]R7,*DH T2$$ @S3^(4(7@:?>PAC'T#" A2 ,0\B." :+C $+%Q
MC30H0QF[6(&2/W/_X 0O&+SBE;)YL2SJ44O8PN_]LDK>L0<TW*,=CP#T*,K!
MBQWD@PY5N 0]&@$"?;1C$XG@L4I>,0EM>(,*N;!"&IZ@@\K"IQE 0 :0BA
M303"!!N(!@1H8 ().&,))SC!#AZ0:<]LNLF=;C *NB$[T9*ZW>Y6+7MY\80'
MI<<?47 3.- 1#11X 0\U0$ V6L""19QC$3%(R2[ ,*U@*^$/3?@"-J)Q!1WD
M0W+ON(5@V2../^ !"U$8! Z(,0-+X,((>Y!1* X!@W%WIMQ4-@B4PS$&$53\
M'-U]-\YS3DD!)D(*A$U/.M2 !W>P8Q;)J (@A-$)&WR#"F68PS$><7!P_^S"
M#6,+-A=,D0LAE (<0H#$]? Q"V# K!!8T ,\7( +$_!A#5P@A)'!@626<V;3
MIV#WDQDL<YK+[N8Z_SO@+\ASGY=#A<N0PB <L8-;>"$4>B-!*CHA#S&0:P:J
MN,4>3 &A8!^!%[LH@B^\SHCK&8,)OP 2(HK1"UG,0PS[ $,8PD"':#A")<"0
MPSZ6/("[GWOO-?=[X(,O_/ -_N?L><<AA  %2JPC$(731A^0T0IP!&,1WUA"
M$;Z@!VFP!Q0\N$$=/K$.<&!B&=<KAS'F]IZYE4-2_J#).M;Q#G$8&ASSD ;>
M6XY@W@]1[S/__? %H "*3O$5WGNP S!4@SN,@_\[J,0YX$,\S,TXO,,X= ,T
M& ,_1(]*L,,U>(,V4*" M=A\&9#N\5_>>=K_]=T KB +,DWQA9?@D- *C: !
MR>!NL15\W%9FA(,H[%[^P5Q,.$8:^  __$-1M" 2)N&L1$,>N(% "<0Y'$(2
MG(/OD%!7>(572!)TA1<+C0,:[=4+Y05:*<5:V2!AH$/[M=];L8,\R ,[8"$[
MV-8_-)8XG$-0<%%=R5=>V!![K)5 A,5>U-<$1$6G"2$1&B%^**$B+N*7B ,3
M.N%=G((7V&$YI!4:#1<ZA$523 53()<G'E=:O9 YY-5,X%4HED.3S(-0D(,[
MR(,]I /1?44:EH,LIB'_.MRB5.35+<Z$%Z)1.9"#%U;B)38#"91";)V@(1;A
M$3(B,S8C@3AB$SZA0 !#$H ",6"#,62C,6Q#-71C-5B#,TR#.#I#,6"#.6Z#
M.(IC-00#,;2C.[9C,,1C/!:#-F:C/,:C,T"#/NXC,/2C/R:@,)Q"*(0"*1@#
M+I "(G2"(B#".[U"*CSD0[:"+$RD+-2"*ESD1=Z"1FJD+G2D+BA3,NG"1MX"
M*OR"2?[",L@""QAC(8K7(2ZC,\:D3"+((THC.!B#"N1!&-P!&/0D&%@!%00E
M%6R!%2#!%@Q!'FQ!%0Q![ V!4PY!%5 !$TPE$RR!52X!%2"!5B)!%?AD3PIE
M_U""01Z,91Y I16,91A8@5I6@15P ?8E@14$%0^\@ B(  ]H018H@0[LI0[P
M@%_^I1($9F"N%%YF@1;P)6)^@1;P@ YDP1=D 61F0104@0(H@SSH8&\%H4LJ
M8R+.I&=^9F5 (R02Q#(\P31< S X@VJN)FLZPS5L@S, @S!@PS5,0S[NXS18
M@S?N9C5,PS^F)FNFHSC^ICE>@VKJ9C<:PS54 S0 0S!@@S5PHS5XPS 0 ST2
MPS!DYS $0S%T9S$0@S"$9WB^HST.PS,T WJBYS8(PS-\@S$(@S?$IS<4PR90
M0#(DST)813CP@1;HPX-P%6@&J(!FA&A*XS\PPA3H9_\-QA<--F@,Z05=)5"$
MBM%W#<8HA  H&.A!Z"=_+L?T#"B(ANA$%&A!($*"PF"#IN@)O</"]8,TO(A*
MM$,T1,,^U(,T1 ,U.$9@] ,[),F,9IR*^@PIY$"&,@2':H&' JB(+BF3CD9-
MENB)IL<X<,,R+(,W,)L\[(,YA$.5+D,Y*H.7SD.*Q@,(O@<UB$$EE,,WV $<
M4,*/@,,L8 $9K($C9(); D-@'$,>#(,VX($=M,&=!2E\#&F1YF=X=>A_-JFB
M+JJ]/"E!F*B"JL0\-$(,Q, 5N D[P,(=0,,X;$$,!$$DU $*Q( ?^$.*8H,9
M1 -\ (,=5$$^U($:'(,E;(+_2O"!*S##&;Q"-%0!'_AG.$B""IC"D*;!-RR<
MH+X'H6KH:!PJDB8JHSYKB)+HHT8I8<@#(6R!+KA!",0?']  ,H1#*-!!&W3#
M$1R"+C!#\C0H,/S!*?C,*"P!-7"!-8 #*:Q!2GS#.81"'-R7$P2#8/ #'X@"
M*2! #%!!X1PKLA*ILA9$5X3#'C1KDT"KQ JH.$A#-!9$SQF?2EBKF^2##"2#
M*$R!':1".>S#'K ".'A!&K#!(!B:2#@@/30@?+QKO!(#O;Z!'6:5$D#"/>Q"
M;@R$,;R *;A#,I "VBG01H"#+PQ ,]B/0C2L'$ L9DXLU2IBQ5XL062L 6XL
M(;@)_SK( 2ZHP0CH0 MH@SJ4 <HR@2>0P28(ULO""!R @KO"JQ@80350D3C(
M QY0@3300S%< 2-,1A01 PR8PBDL 2DPP?AA3]+F@@ T+4- K=16+>4ZX]6.
MYD!H;7JX R?TP3JHI"KLE!M\02'(@R"@K"9 0SW@@Z2\+3$,09K!!S*<P3Z
M0A.<0!>\0CV(&0N8P!R$PA1\@V55(CA(PC$  Q6<@!+  ])&CN-"[D)(KH=.
M;>56;P!>KH%J;F' P@N  1/403?8@3.X0Q:Q0RWT CCPP1_T01D$SMN" QWY
M3#HP+SA,0RM @SKD@SN4@B'L@C+8 RHT8#G8@V/T@V!1 _\K (.W6,_S.FU"
M2"^]6:\$(R'V8BSAJ5 _'$(BZ((_Q(,SJ,0]!(,XT /SEL(F+$(JK,S['A!T
MS8,]M)#]Z4,0P4]'@$,#&ZECS,'D3C /"V %#Y0A1$$X2!+"RI!#O$\)D0,[
MV&$@FL-/S,4G B)PX>!(A*%>C,,H[, R%$U^.@:B1FP/AW'P_;! @,,J1(%5
M,+$5KS$;L_$4]U4;0R@-UQ #1<07G0+'+*PG>?$.B[$?YQP9_P,YZ (7B,6#
M1#$B)_(GQO%>*#)=G$-><>)27")RX2$*,;)?_94X^,($B((>#Q0?3^\?C_*[
M!?(_6(,?P,.,"B<KM[(KOS(KMZ;_+ <G+ LG-&0#+N,R->SR+G.#+_MR/O"#
M,/,#//B#,?L#/M"#,B\S,S<S,]<#-$>S-.,#+?1 ,KCM_'CQ%8@R*7>SJ 5R
M. C#"P""'C!!$7A!'E0!%M0!%0@!%G"!$,1S/&,!/;\S%]3S/=^,/N\S/]>S
M/]<SSA2!%?A!$2!!']"!'Z0!'6"!'2@T'3ST'H1!':1!&L"!&%ST19?!&6ST
M&6#T1;^!&82T2(LT&Y2T29\T(:1T2FL"2[,T)^S! BR#O'1Q./P!%-S#7.R/
M-^]T>H%S-FB!*0""&."!'T ")LC!(I@!'Y#!03_T0W,8A_5!'\0!'*3!&) !
M'&0U'* !_U=W=5?#@5,_-$6/]1O$ 1I0@B/ @1G0@BQL0BVTPAP8@BY@I"JL
M B%X0BRXPBW@ E_S=2W\]5_30BP,-F$3-D5.)"T =BT<MBS\DF,7=BRT@AE0
M #*T;C;7-!#@M.?P-&>C5R"/@S500=[6 SWLPSRD P3J S_H@SI(<SVH VRW
M=CWHPSO -FV_ V[GMF[GMFO'-FS? VW+ SJP=EC(T3EH0V-9X3U08%6<$1I!
M3AV7\?N8@R[\@#)T)IDXQA]D=DYWMG=[ML5B[AS20A*$PU2D$1/# RA, SN@
M(CXL0SW4X2AN(EQT8AQW$27/!57,Q5H%Q1+'X7:PT)9F8@R^\?^$9H>!L] M
M($ S )]<:#=W;_9W3WA7F3(C+,%<W 4V< $,G  ;](,1W, +A( BD,,KA$%N
MID!=:<(*S$"Z!2E0^((NH(,]-((SA,$[W\(R6($7U,$HV 4XM*&0SP.1$SE2
M: 4:IB$6>@4[-'F3+WDMME\\./D2A\(-/,,]O-QH>'&$ZS2%?WDEF7(G3($[
MV,/F@8,[/((00(,I' (P7 $QF,,C. (^_$$)0 (JX, HB@,:^,(W;((C7Z)>
M>!8=2<4Y$+D0Q, IO ()3(,GV"4R"($+,($1$,):G3GC3@85%SB#^DPXD (-
M+$,Z*.EZ_-P==#F8ISH_%6A\( (6'/K_O>3;*,P!("0"-B0#&:0$.]#8'8RE
M,J@X.+2#'_!!(+A"IB\8.&C#'RB#;T61. S!$Q1",FB!-LQ#)KR!.*@!$Z2"
M(AQ"A9KA2QR7)9=1("8X7MQ"!("" WM74("#'@!!.W2WJL_[SM5D?#""%Q!6
MA$@1*D2"':Q!+)A!2LP#/LC"#8  ""S#"AR9%VP!'M2>EP,A..C#,=P#S'2"
M&0P"$'##.[1=/,AJ&2R!)60<:-CPXZX[S+7[N\>[A-.[RV.2O:L'ONO[0+##
M)L@!-J "YWB!J4+")HP!0S^!(\Q 2@S#'"R#.HC@0["'-:0K86R<+,Q"#0@
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M[-##";\JCR9P@.DB&&P,041%%1UIL<45533DFG[H6<<;;/A9!Q]Z\.EQGWZ
M#%+((?'Q)II^O-E%FU)NN8675%Z),A5>J.3%%5=8805+5EIIQ15<<+E%%56:
M)/.67M#L)9<UU_2%E%+@+&445.A$Q90X2SD%%%!".<7//T6YI812[C%JLCJF
M2.>V#QEMU-%'(8U44ID4 DL-=TXRQQL3?!AAA!] _2$$&DBEP88!4$4U!158
M5:&%5UN 0=998:WU_U485L@U5UM/Z+7740<(8  !:)B!A@%HZ&&%$@8X5085
M$ C !A%ZO2&' 68H 08!')A !A),.':$&E0(X0<61L"!!AEF..%3"":0( 49
M!MBAAP<:$( $&5+( !3SJ,,)447SFM3@@Q%.6.&%FZHTC$M/.F>8*'R1)19:
M,*:E%ELXMJ666$ &N<N1268%EI-AX9+DE5$^>>6-.XX%EUA:6<6556RQ^>-?
M3&&E%EER\667)I\QQ11>#'&%E&^,P:416;8!)9=4.%'$E%!HF>454K;YYIIM
MMIGF%$-H><600!(!991#)(D%&V=H(4$9=PP5.-%%&<Y;[[WY[CL\AR$.R?^=
M5J*0JZ+B$.^(.;N8HT\E=""'G#=ST)DH(;\F\JIR<@ZBS9US(!=GMGG8J0B=
M<VYB!R)QT&%'=8;6RR\< \6QQZMRWF$GLG/D*2<4$I8II^YP!L;;[^.13U[Y
MY1L6QU),0YIG%RC"(6>>AQR*7/OM(\?>^^^][\C[DDIBO2V)-HI\HI(@CR>>
M<LQY"!WWRSDG' 1%=P<=T<NAWR'?\C..<_QC'.7(GCSB,1'KE0,5+$ &.]HS
M(;L1;!S,L^ %,9A!O0$.>B!!!RP*-Y>3W",6@  $*-#1C$JL$!CA>$<NG&$/
M1X0#']50B#"*@8YH[&,NQ0B'/'!1B4F@@B[IR,;_7.#!0V*LT!4\_ <XV+,7
MU/7%)^P1('[L1Q>0W ] IQ.A"+=(CG@(D""WB0Q=/)*7!.HB ,N0AX1J D74
M_:,*=UN/!O&81SWN\4+D0<U,P,$(*; .,2 )!0Q>@ (4&&,2*D!!#*P@#E&D
M@!?$4$(WCE&$4.3#"4U0Q1\DX8YQ3,$>DJA!#&+0!5. 1!=:.,8Y4M&*=3Q!
MD5FPA4]",I7V1/ _NQ1*!$&2"P&\A"ARC$D="189/BZ3F<UTIE;\"#"9)&*0
M.#F)*?RPCG"TH1"?.(,VA,&#=GA""62PQA5*D8@3P,(1:"C#+)* @F28HPO+
ML ,IU(&-6$P#)(VH 1!._W$(7A2"$M5+11"&<9(,@4.8Q"103XYI1V4^DZ(5
MM>A%@1+-FE!S,M?T0S[ (8DW?"((9]C"#?)AA4S0X11R ,0>[H (*ZPB%8M
M0A\B48PNG((3X-B'&I:0B'Z"81%G  0OP@!2<(0B"\M0*(88.DQV%!.B=)0H
M1K&:5:WF4:,TX:@U0X)-D*9BI'Y@QBQ ( P1X&$*;\ &#_B@BCXH@1]E8,,>
M8(&)(0 T#-2XARB$X(>/-&(,[R $%'A!"6^ !!5/2&@NH=K0J3[4?E9-YE8Q
MFUG-[JVK,_EJ(<%ABB:XS0Z-^(0GP!$/+8"!#=& !1_P080^X&,,<] ''? @
M!/]8% ,(0 !&'MSP#% $0;#@(.PX2B$#7C0C#Z9(AA@@T8]10/9"477H+ZM:
M!2GPY(Z;]>YWP<LHGW3#"H28K&>K&4%G4 $*<;##-&8Q")# (0W4"(<['/&.
M3:QR%ZN(ARF$9HUS6 (,YFBI$=)PAU7,116_ $<VRB *=@2""T8X@S/N 0OJ
MBL>ZYPV*,>FX7:],-+PE-O&)M>.3=5A!$Q[^QU<C&(YXS.-]LS.'!VTS%[Z8
M8QP%JB(991,/*):#QO73L4_>T^-ST(8WL]MP>#I,U<IJE[LD1O&5L9QEK:B8
MQ2Z&<1P%!" MAIG,=B$S?18J62D?4\3=U?*;X1QGIG#_N<4;32^8!63F,^<Y
M0'O.3V2ENN805UG.A3;TH6E"9R_?>41AUK.?Z?/H/:<YT,7T"SB6P(1Y* 2.
MB/;TITVL:#N+0\A)(7,Q(8WF1@]HU:R>CZJA HYH[* 9-Y8,.L#!!23HCCV@
M]O6OORMJKPZRU$@Y-8&>"L@PUT32O(QT@%K]9ZB@8QD!" ;H;IWK72N$E\#V
M]K<I*FSTDKK;0WF/^]"-[DX#<B+2GL_L>@P.=T"0EW,YAW1@_>J0Q.,>XQ!A
MM,N]%-\A !OGB$>V=<WK@(.;X0W/H+BG2>R% T4>K[#$Q3%^\6X0:!2U=O8^
M8&$-*))A$^[^QUQ$\0;VN(,?_Q92M@<1,00??J35YZB'-([1C&WT QU,"4<W
M?O ,DV<4UPGGML.1GG0,0OS%$D\*/)K  S+LH0LHH$(08C , J'!$Q",HS!\
ML MPC*,!3* Y3>;2!R.P)Q1_P(>S0R*,%Y" #EX!)DC&,8PQ,($'*VA"'4[A
M<VX,X!A/)$I>*NB%*L3CZ$IW_./[IN(PU'DFX9"%%\1!CG4+!>IF('4Q0,$/
M883"'F3F.KWI<P]:8&/L90?M29;1")"D8@3:(+,9(H")+P #[N"0AQDH8 5<
M_,(1.\"#/(8^%'$ HP7/L/50#B*3*0S!-KV&_/6QCS#)4WX^R C#[*Q,E,Z_
M'B3W"/\&\K=X?G!P?1['<#\T3)):8*BC]4RX!S9J$0ACG 0>HO#I)6S %KI!
M0+@!"++ & 2 #>P!S^I!"&H %7JL'?8@":XA^81B'*XA!I)A'B8N^OYA^JIO
MXK)O!$D00[;/P\#A%[P@+T20)L;//D(A!@PA))8A!@YA_?S@#7!@!U. #]X!
M'.K!$W2A]:1@%VI@!WX !LX@&D"B#IP@'%XA!QQ@!)S '^P#&5# #>K!"YB
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MD#[T 0FZH!<:%12(( N0 0W_PQM<H!1\M2+Y@,=Z3%"153\)]8F<H06$P1X
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MF  )JL )HL#ZJ:#[O?_[L?^_"JH "99 );&@")8@_=-_"\9_":1@"*B "Y;
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JQ"VN<8^+W.0J=[G,;:YSGPO=Z$IWNM2MKG6OB]WL:G>[W.VN=S4;$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803701968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 16, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Celldex Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000744218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,703,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803958032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 72,108<span></span>
</td>
<td class="nump">$ 28,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">217,781<span></span>
</td>
<td class="nump">173,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts and Other Receivables</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and Other Current Assets</a></td>
<td class="nump">4,077<span></span>
</td>
<td class="nump">3,515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">294,936<span></span>
</td>
<td class="nump">204,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, Net</a></td>
<td class="nump">11,461<span></span>
</td>
<td class="nump">10,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">20,794<span></span>
</td>
<td class="nump">21,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,965<span></span>
</td>
<td class="nump">8,965<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">337,584<span></span>
</td>
<td class="nump">248,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Expenses</a></td>
<td class="nump">24,316<span></span>
</td>
<td class="nump">19,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current Portion of Long-Term Liabilities</a></td>
<td class="nump">4,418<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">30,240<span></span>
</td>
<td class="nump">24,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Long-Term Liabilities</a></td>
<td class="nump">17,239<span></span>
</td>
<td class="nump">11,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">$ 47,479<span></span>
</td>
<td class="nump">$ 36,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingent Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Preferred Stock, $.01 Par Value; 3,000,000 Shares Authorized; No Shares Issued and Outstanding at December 31, 2015 and 2014</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $.001 Par Value; 297,000,000 Shares Authorized; 98,685,595 and 89,592,779 Shares Issued and Outstanding at December 31, 2015 and 2014, respectively</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional Paid-In Capital</a></td>
<td class="nump">878,655<span></span>
</td>
<td class="nump">672,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income</a></td>
<td class="nump">2,307<span></span>
</td>
<td class="nump">2,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(590,956)<span></span>
</td>
<td class="num">(463,759)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">290,105<span></span>
</td>
<td class="nump">211,660<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 337,584<span></span>
</td>
<td class="nump">$ 248,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790923584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible Preferred Stock, Par Value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible Preferred Stock, Shares Authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par Value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">297,000,000<span></span>
</td>
<td class="nump">297,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">98,685,595<span></span>
</td>
<td class="nump">89,592,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="nump">98,685,595<span></span>
</td>
<td class="nump">89,592,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803852000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RevenueFromProductDevelopmentAndLicensingAgreements', window );">Product Development and Licensing Agreements</a></td>
<td class="nump">$ 1,442<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RevenueFromContractsAndGrants', window );">Contracts and Grants</a></td>
<td class="nump">4,038<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Product Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="nump">5,480<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
<td class="nump">4,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">100,171<span></span>
</td>
<td class="nump">104,381<span></span>
</td>
<td class="nump">67,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">33,837<span></span>
</td>
<td class="nump">20,622<span></span>
</td>
<td class="nump">14,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Acquired Intangible Assets</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Operating Expense</a></td>
<td class="nump">135,021<span></span>
</td>
<td class="nump">126,016<span></span>
</td>
<td class="nump">85,553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(129,541)<span></span>
</td>
<td class="num">(122,430)<span></span>
</td>
<td class="num">(81,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Investment and Other Income, Net</a></td>
<td class="nump">2,344<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(927)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
<td class="num">$ (127,197)<span></span>
</td>
<td class="num">$ (118,080)<span></span>
</td>
<td class="num">$ (81,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted Net Loss Per Common Share (in dollars per share)</a></td>
<td class="num">$ (1.31)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares Used in Calculating Basic and Diluted Net Loss per Share (in shares)</a></td>
<td class="nump">97,051<span></span>
</td>
<td class="nump">89,399<span></span>
</td>
<td class="nump">79,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>COMPREHENSIVE LOSS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
<td class="num">$ (127,197)<span></span>
</td>
<td class="num">$ (118,080)<span></span>
</td>
<td class="num">$ (81,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other Comprehensive (Loss) Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized Loss on Marketable Securities</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (127,480)<span></span>
</td>
<td class="num">$ (118,158)<span></span>
</td>
<td class="num">$ (81,627)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_RevenueFromContractsAndGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents revenue earned during the period arising from products sold or services provided under the terms of a contract. Also include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_RevenueFromContractsAndGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_RevenueFromProductDevelopmentAndLicensingAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents revenue from product development and licensing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_RevenueFromProductDevelopmentAndLicensingAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804686912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 357,094<span></span>
</td>
<td class="nump">$ 2,745<span></span>
</td>
<td class="num">$ (264,129)<span></span>
</td>
<td class="nump">$ 95,774<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2012</a></td>
<td class="nump">64,359,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans (in shares)</a></td>
<td class="nump">840,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares Issued in Connection with Cantor Agreement</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">17,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares Issued in Connection with Cantor Agreement (in shares)</a></td>
<td class="nump">2,433,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares Issued in Underwritten Offering</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">278,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares Issued in Underwritten Offering (in shares)</a></td>
<td class="nump">21,613,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,613,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized Losses on Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,550)<span></span>
</td>
<td class="num">(81,550)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">662,717<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="num">(345,679)<span></span>
</td>
<td class="nump">319,795<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2013</a></td>
<td class="nump">89,246,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans (in shares)</a></td>
<td class="nump">193,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares Issued in Connection with Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares Issued in Connection with Supply Agreement (in shares)</a></td>
<td class="nump">152,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized Losses on Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,080)<span></span>
</td>
<td class="num">(118,080)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">672,739<span></span>
</td>
<td class="nump">2,590<span></span>
</td>
<td class="num">(463,759)<span></span>
</td>
<td class="nump">$ 211,660<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="nump">89,592,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,592,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares Issued under Stock Option and Employee Stock Purchase Plans (in shares)</a></td>
<td class="nump">755,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares Issued in Underwritten Offering</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">188,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares Issued in Underwritten Offering (in shares)</a></td>
<td class="nump">8,337,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,337,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized Losses on Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,197)<span></span>
</td>
<td class="num">(127,197)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 878,655<span></span>
</td>
<td class="nump">$ 2,307<span></span>
</td>
<td class="num">$ (590,956)<span></span>
</td>
<td class="nump">$ 290,105<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="nump">98,685,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,685,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6801859312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
<td class="num">$ (127,197)<span></span>
</td>
<td class="num">$ (118,080)<span></span>
</td>
<td class="num">$ (81,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">2,998<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="nump">1,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization and Premium of Marketable Securities, Net</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(1,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Realized Gain on Sales and Maturities of Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on Sale or Disposal of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-Based Compensation Expense</a></td>
<td class="nump">12,774<span></span>
</td>
<td class="nump">6,852<span></span>
</td>
<td class="nump">4,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-Cash Expense</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Operating Assets and Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts and Other Receivables</a></td>
<td class="num">(543)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and Other Current Assets</a></td>
<td class="num">(653)<span></span>
</td>
<td class="num">(2,026)<span></span>
</td>
<td class="num">(706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other Assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="nump">4,875<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="nump">7,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other Liabilities</a></td>
<td class="nump">7,202<span></span>
</td>
<td class="nump">6,577<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(98,887)<span></span>
</td>
<td class="num">(101,537)<span></span>
</td>
<td class="num">(67,669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and Maturities of Marketable Securities</a></td>
<td class="nump">161,090<span></span>
</td>
<td class="nump">109,232<span></span>
</td>
<td class="nump">38,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of Marketable Securities</a></td>
<td class="num">(206,405)<span></span>
</td>
<td class="num">(148,314)<span></span>
</td>
<td class="num">(112,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of Property and Equipment</a></td>
<td class="num">(4,876)<span></span>
</td>
<td class="num">(1,929)<span></span>
</td>
<td class="num">(4,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale or Disposal of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(50,191)<span></span>
</td>
<td class="num">(41,011)<span></span>
</td>
<td class="num">(77,422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net Proceeds from Stock Issuances</a></td>
<td class="nump">188,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Issuance of Stock from Employee Benefit Plans</a></td>
<td class="nump">4,311<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">5,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Payments of Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Payments of Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(472)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">193,151<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">289,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations', window );">Effect of Exchange Rate Changes on Cash and Cash Equivalents</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net Increase (Decrease) in Cash and Cash Equivalents</a></td>
<td class="nump">44,088<span></span>
</td>
<td class="num">(141,382)<span></span>
</td>
<td class="nump">144,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">28,020<span></span>
</td>
<td class="nump">169,402<span></span>
</td>
<td class="nump">24,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">72,108<span></span>
</td>
<td class="nump">28,020<span></span>
</td>
<td class="nump">169,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash Paid for Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid', window );">Accrued construction in progress</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for construction in progress expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(c)-(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow attributable to repayments of borrowings not otherwise defined in the taxonomy (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794172704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND OVERVIEW<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF BUSINESS AND OVERVIEW</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">NATURE OF BUSINESS AND OVERVIEW</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(1) NATURE OF BUSINESS AND OVERVIEW</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex Therapeutics,&nbsp;Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company currently has five drug candidates in clinical development including Rintega (also referred to as rindopepimut and CDX-110), glembatumumab vedotin (also referred to as CDX-011), varlilumab (also referred to as CDX-1127), CDX-1401 and CDX-301. The Company's latest stage drug candidate, Rintega, is a therapeutic vaccine that completed enrollment in December 2014 to a pivotal Phase&nbsp;3 study in front-line glioblastoma in patients that express a specific cancer marker known as EGFRvIII. This Phase&nbsp;3 study completed its first interim analysis in June 2015 and an independent Data Safety and Monitoring Board recommended that the study continue as planned. Updated results from a randomized, Phase&nbsp;2 study of Rintega added to the standard of care for the treatment of recurrent glioblastoma were presented in November 2015.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2015, the Company had cash, cash equivalents and marketable securities of $289.9&nbsp;million. The Company incurred a loss of $127.2&nbsp;million for the year ended December&nbsp;31, 2015. Net cash used in operations for the year ended December&nbsp;31, 2015 was $98.9&nbsp;million. The Company believes that the cash, cash equivalents and marketable securities at December&nbsp;31, 2015 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company may seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financings may be dilutive to the Company's stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company's economic potential from products under development.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6630231088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Basis of Presentation</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;31, 2014, the Company's wholly-owned subsidiary, Celldex Research Corporation, merged into Celldex Therapeutics,&nbsp;Inc. The statements of operations and comprehensive loss, of stockholders' equity, and of cash flows, are consolidated for the years ended December&nbsp;31, 2014 and 2013. These consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary prior to the merger. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one segment, which is the business of development, manufacturing and commercialization of novel therapeutics for human health care. In February 2016, the Company formed a wholly-owned subsidiary, Celldex Therapeutics Europe&nbsp;GmbH, in Zug, Switzerland, to operate as Celldex' European headquarters when European operations commence, pursuant to intercompany agreements.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (U.S.&nbsp;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments purchased with a maturity date of 90&nbsp;days or less at the date of purchase to be cash equivalents. Cash equivalents consist principally of money market funds and debt securities.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Marketable Securities</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company invests its excess cash balances in marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds. The Company classifies all of its marketable securities as current assets on the balance sheets because they are available-for-sale and available to fund current operations. Marketable securities are stated at fair value with their unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the statements of operations. Realized gains and losses are determined on the specific identification method and are included in investment and other income, net.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Concentration of Credit Risk and of Significant Customers and Suppliers</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue from Rockefeller and BMS represented 62% and 24% for the year ended December&nbsp;31, 2015, 75% and 20% for the year ended December&nbsp;31, 2014, 35% and 0% for the year ended December&nbsp;31, 2013, of total Company revenue, respectively.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company relies on contract manufacturing organizations (CMO) to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. The Company also relies on CMOs for supply of raw materials as well as filling, packaging, storage and shipping of drug product. These clinical studies would be adversely affected by a significant interruption in the supply of Rintega and glembatumumab vedotin. The Company also relies on third-party collaborators to develop companion diagnostic tests for certain of its drug candidates, including Rintega.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Fair Value Measurements</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has certain assets and liabilities that are measured at fair value in the financial statements. The Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company's assumptions about how market participants would price assets and liabilities) when measuring the fair value of its assets and liabilities. These assets and liabilities are classified into one of three levels of the following fair value hierarchy as defined by U.S.&nbsp;GAAP:</font>
		</p>
		<p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1: Observable inputs such as quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2: Observable inputs other than Level&nbsp;1 prices, such as quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3: Unobservable inputs based on the Company's assessment of the assumptions that market participants would use in pricing the asset or liability.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Property and Equipment</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment is stated at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Laboratory equipment and office furniture and equipment are depreciated over five years and computer equipment is depreciated over three years. Manufacturing equipment is amortized over seven to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the non-cancelable term of the related lease, including any renewals that are reasonably assured of occurring. Property and equipment under construction is classified as construction in progress and is depreciated or amortized only after the asset is placed in service. Expenditures for maintenance and repairs are charged to expense whereas the costs of significant improvements which extend the life of the underlying asset are capitalized. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated and any resulting gain or loss is reflected in the Company's statements of operations and comprehensive loss.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The treatment of costs to construct property and equipment depends on the nature of the costs and the stage of construction. Costs incurred in the project planning, design, construction and installation phases are capitalized as part of the cost of the asset. The Company stops capitalizing these costs when the asset is substantially complete and ready for its intended use. For manufacturing property and equipment, the Company also capitalizes the cost of validating these assets for the underlying manufacturing process. The Company completes the capitalization of validation costs when the asset is substantially complete and ready for its intended use. Costs capitalized include incremental labor and fringe benefits, and direct consultancy services.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Business Combinations</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records the fair value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets such as in-process research and development (IPR&amp;D), using a variety of methods including present value models. Each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of IPR&amp;D assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant's assumptions regarding the probability of completing IPR&amp;D projects, which would require obtaining regulatory approval for marketing of the associated drug candidate; a market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;D projects; a market participant's estimates of future cash flows from potential product sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs associated with the transaction are expensed as incurred.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Intangible Assets</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible assets. These assets are capitalized on the Company's balance sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the carrying value of the related intangible asset is amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value and an impairment charge is taken in the period in which the impairment occurs.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D assets are tested for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. As part of the annual impairment test of the IPR&amp;D assets as of July&nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed a calculation of the fair value of the asset. The Company concluded that the IPR&amp;D assets were not impaired.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a straight-line basis over their estimated useful life.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Goodwill</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. The Company has the option to assess qualitative factors to determine if it is more likely than not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under U.S.&nbsp;GAAP. As part of its annual impairment test of the goodwill asset as of July&nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed the two-step impairment test. The Company concluded that goodwill was not impaired.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Impairment of Intangible and Long-Lived Assets</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluates the recoverability of its long-lived assets, including property and equipment, and intangible assets when circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Revenue Recognition</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic drug products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. In accounting for these transactions, the Company allocates revenue to the various elements based on their relative fair value. The fair value of a revenue generating element can be based on current selling prices offered by the Company or another party for current products or the Company's best estimate of a selling price for future products. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of the Company's involvement in achieving the milestones and whether the amount of the payment is commensurate to the Company's performance. If not considered substantive, milestones are initially deferred and recognized over the period of the remaining performance obligation.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or the Company's contractual partner. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize the Company's licensed technologies and are recognized when the amount of and basis for such royalty payments are reported to the Company in accurate and appropriate form and in accordance with the related license agreement.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Research and Development Expenses</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other preclinical studies, personnel costs, depreciation, license fees and funding of outside contracted research.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trial expenses include expenses associated with clinical research organizations, or CRO, services. Contract manufacturing expenses include expenses associated with contract manufacturing organizations, or CMO, services. The invoicing from CROs and CMOs for services rendered can lag several months. The Company accrues the cost of services rendered in connection with CRO and CMO activities based on our estimate of costs incurred. The Company maintains regular communication with our CROs and CMOs to assess the reasonableness of its estimates. Differences between actual expenses and estimated expenses recorded have not been material and are adjusted for in the period in which they become known.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Patent Costs</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent costs are expensed as incurred. Certain patent costs are reimbursed by the Company's product development and licensing partners. Any reimbursed patent costs are recorded as product development and licensing agreement revenues in the Company's financial statements.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Stock-Based Compensation</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and directors is recognized using the straight-line method over the term of vesting or performance.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Foreign Currency Translation</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net unrealized gains and losses resulting from foreign currency translation are included in other comprehensive income (loss). At December&nbsp;31, 2015 and December&nbsp;31, 2014, accumulated other comprehensive income includes a net unrealized gain related to foreign currency translation of $2.6&nbsp;million.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Income Taxes</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax basis. Quarterly, the Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company's tax provision in the period of change.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records uncertain tax positions in the financial statements only if it is more likely than not that the uncertain tax position will be sustained upon examination by the taxing authorities. The Company records interest and penalties related to uncertain tax positions in income tax expense.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Comprehensive Loss</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes foreign currency translation adjustments and unrealized gains and losses on marketable securities in other comprehensive loss. The statements of operations and comprehensive loss reflect total comprehensive loss for the years ended December&nbsp;31, 2015, 2014 and 2013.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Net Loss Per Share</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common shares outstanding during the period when the effect is dilutive. The potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Stock options</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,110,239&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,015,350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,770,544&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Restricted stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,500&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,000&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,000&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,129,739&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,022,350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,776,544&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, the FASB issued a new U.S.&nbsp;GAAP accounting standard that creates modifications to various other revenue accounting standards for specialized transactions and industries. The new U.S.&nbsp;GAAP accounting standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB deferred the effective date of the new standard from January&nbsp;1, 2017 to January&nbsp;1, 2018. The amendment allows for two methods of adoption, a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. The Company will further study the implications of this standard in order to evaluate the expected impact on the financial statements.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2015, the FASB issued amendments that provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The new guidance does not change the accounting for a customer's accounting for service contracts. The standard update is effective for fiscal years beginning after December&nbsp;15, 2015 and interim periods within those years. Early adoption is permitted. The standard allows for adoption retrospectively or prospectively to all arrangements entered into or materially modified after the effective date. The amendment is not expected to have a material impact on our financial statements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2014, the FASB issued a new U.S.&nbsp;GAAP accounting standard that provides guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new accounting standard requires management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The new accounting standard is effective for the annual period ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not expect the adoption of this standard to have a material impact on the financial statements.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794181280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">COMPREHENSIVE LOSS</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(3) COMPREHENSIVE LOSS</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The changes in accumulated other comprehensive income (loss) by component for the years ended December&nbsp;31, 2015, 2014 and 2013 are summarized below. No amounts were reclassified out of accumulated other comprehensive income during the years ended December&nbsp;31, 2015, 2014 and 2013.</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gain (Loss) on</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Marketable</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Foreign</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Currency Items</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Balance at December&nbsp;31, 2012</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,589
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,745
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other comprehensive loss before reclassifications</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(74
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(77
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Amounts reclassified from other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net current-period other comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(74
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(77
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Balance at December&nbsp;31, 2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,586
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,668
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other comprehensive loss before reclassifications</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(73
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(78
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Amounts reclassified from other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net current-period other comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(73
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(78
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Balance at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,581
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,590
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other comprehensive loss before reclassifications</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(298
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(283
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Amounts reclassified from other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net current-period other comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(298
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(283
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Balance at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(289
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,596
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,307
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e716-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e709-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reclassification Adjustments<br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788908640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(4) FAIR VALUE MEASUREMENTS</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables set forth the Company's financial assets subject to fair value measurements:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">As of</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Money market funds and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,677&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,677&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173,023&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173,023&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>191,700&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>191,700&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">As of</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Money market funds and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,831&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,831&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217,781&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217,781&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>277,612&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>277,612&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have been no transfers of assets or liabilities between the fair value measurement classifications. The Company's financial instruments consist mainly of cash and cash equivalents, marketable securities, short-term accounts receivable and accounts payable. The Company values its marketable securities utilizing independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. Short-term accounts receivable and accounts payable are reflected in the accompanying financial statements at cost, which approximates fair value due to the short-term nature of these instruments.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794216528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>MARKETABLE SECURITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(5) MARKETABLE SECURITIES</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of marketable securities is shown below:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortized</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gains</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Losses</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">U.S. government and municipal obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing in one year or less</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,580
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,604
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,108
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,156
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total U.S. government and municipal obligations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,688
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,760
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing in one year or less</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,636
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(37
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,605
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,690
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(35
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,658
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>112,326
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(72
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>112,263
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173,014
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(79
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173,023
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">U.S. government and municipal obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing in one year or less</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,871
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(20
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,855
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,940
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(57
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,907
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total U.S. government and municipal obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64,811
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(77
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64,762
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing in one year or less</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,327
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(141
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,188
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,932
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(102
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,831
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,259
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(243
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,019
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>218,070
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217,781
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The marketable securities held by the Company were high investment grade and there were no marketable securities that the Company considered to be other-than-temporarily impaired as of December&nbsp;31, 2015. Marketable securities include $1.5&nbsp;million and $1.4&nbsp;million in accrued interest at December&nbsp;31, 2015 and December&nbsp;31, 2014, respectively.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Debt Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Equity Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794051024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(6) PROPERTY AND EQUIPMENT, NET</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment include the following:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Laboratory Equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,432
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,223
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Manufacturing Equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,178
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,274
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Office Furniture and Equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,088
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,888
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Leasehold Improvements</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,371
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,603
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Construction in Progress</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>451
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,767
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total Property and Equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,520
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,755
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Less Accumulated Depreciation and Amortization</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17,059
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,220
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,461
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization expense related to property and equipment was $3.0&nbsp;million, $2.4&nbsp;million and $1.9&nbsp;million for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6779925936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS AND GOODWILL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(7) INTANGIBLE ASSETS AND GOODWILL</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net of accumulated amortization, and goodwill are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="10" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Estimated</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Life</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Accumulated</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortization</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Net</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Accumulated</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortization</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Net</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="17" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Intangible Assets:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">IPR&amp;D</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Indefinite</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Amgen Amendment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">16&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,605
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,895
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,708
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,792
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Core Technology</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">11&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,296
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,197
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,296
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,081
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>215
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total Intangible Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,596
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,802
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,794
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,596
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,789
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,807
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Goodwill</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Indefinite</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,965
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,965
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,965
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,965
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The IPR&amp;D intangible asset was recorded in connection with the acquisition of CuraGen and relates to the development of glembatumumab vedotin. At the date of acquisition and at December&nbsp;31, 2015, glembatumumab vedotin had not yet reached technological feasibility nor did it have any alternative future use. Glembatumumab vedotin is in a randomized, Phase&nbsp;2b study for the treatment of triple negative breast cancer and a Phase&nbsp;2 study for the treatment of metastatic melanoma.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense for intangible assets was $1.0&nbsp;million for the years ended December&nbsp;31, 2015, 2014 and 2013. The estimated future amortization expense of intangible assets for the years ending December&nbsp;31, 2016, 2017, 2018, 2019 and 2020 is $1.0&nbsp;million, $0.9&nbsp;million, $0.9&nbsp;million, $0.9&nbsp;million and $0.9&nbsp;million, respectively.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794217216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(8) ACCRUED EXPENSES</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses include the following:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Accrued Payroll and Employee Benefits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,601&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,284&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Accrued Research and Development Contract Costs</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,548&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,696&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Accrued Professional Fees</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>399&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>490&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other Accrued Expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,768&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,826&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,316&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,296&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6779925936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER LONG-TERM LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>OTHER LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER LONG-TERM LIABILITIES</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(9) OTHER LONG-TERM LIABILITIES</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities include the following:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Rent</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>409
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>482
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net Deferred Tax Liability related to IPR&amp;D</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Income from Sale of Tax Benefits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,219
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,015
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,368
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,657
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,455
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Less Current Portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,418
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,592
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Long-Term Portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,239
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,863
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2015, December 2014, January 2014, January 2013, January 2012 and January 2011, the Company received approval from the New Jersey Economic Development Authority and agreed to sell New Jersey tax benefits of $9.8&nbsp;million, $1.9&nbsp;million, $1.1&nbsp;million, $0.8&nbsp;million, $0.8&nbsp;million and $0.6&nbsp;million to an independent third party for $9.2&nbsp;million, $1.8&nbsp;million, $1.0&nbsp;million, $0.8&nbsp;million, $0.7&nbsp;million and $0.5&nbsp;million, respectively. Under the agreement, the Company must maintain a base of operations in New Jersey for five years or the tax benefits must be paid back on a pro-rata basis based on the number of years completed. During the years ended December&nbsp;31, 2015 and 2014, the Company recorded $1.0&nbsp;million and $0.4&nbsp;million to other income related to the sale of these tax benefits, respectively.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794209568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TERM LOAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>TERM LOAN.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">TERM LOAN</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(10) TERM LOAN</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2010, the Company entered into a loan and security agreement pursuant to which the Company borrowed $10.0&nbsp;million under a term loan. In March 2011, the Company amended the loan agreement and borrowed an additional $5.0&nbsp;million. In May 2013, the Company elected to prepay the outstanding principal under the term loan in full, pursuant to the terms of its loan agreement, as amended, and paid $8.8&nbsp;million in principal and $0.7&nbsp;million in interest, prepayment and final payment fees. The Company's obligations under the loan agreement had been collateralized by a first priority security interest in substantially all of its assets, other than its intellectual property. In connection with the repayment of the term loan and the termination of the loan agreement, those security interests were released. Interest expense on the term loan was $0.8&nbsp;million for the year ended December&nbsp;31, 2013.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780878000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(11) STOCKHOLDERS' EQUITY</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Common Stock</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2013, the Company filed an automatic shelf registration statement with the Securities and Exchange Commission to register for sale any combination of the types of securities described in the shelf registration statement.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2015 and December&nbsp;31, 2013, the Company issued 8,337,500 and 21,613,483 shares of its common stock in underwritten public offerings resulting in net proceeds to the Company of $188.8&nbsp;million and $278.6&nbsp;million, after deducting underwriting fees and offering expenses, respectively.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended December&nbsp;31, 2014, the Company entered into an amended and restated supply agreement with Biosyn Corporation. Under the supply agreement, Biosyn will manufacture and supply keyhole limpet hemocyanin (KLH) to the Company for use in connection with the development, manufacture or commercial sale of Rintega. In connection with the supply agreement, the Company issued to Biosyn 152,172 shares of its common stock having a value of $2.0&nbsp;million. The Company is recording the $2.0&nbsp;million to research and development expense through August 2021, the current term of the supply agreement.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended December&nbsp;31, 2013, Company issued 2,433,608 shares of its common stock under a controlled equity offering sales agreement with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., as amended, resulting in net proceeds to the Company of $17.1&nbsp;million, after deducting commission and offering expenses.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Convertible Preferred Stock</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2015, the Company had authorized 3,000,000 shares of preferred stock all of which have been designated Class&nbsp;C Preferred Stock including 350,000 shares which have been designated Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock (the "Series&nbsp;C-1 Preferred Stock").</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6785430192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(12) STOCK-BASED COMPENSATION</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has the following stock-based compensation plans: the 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"), the 2008 Stock Option and Incentive Plan (the "2008 Plan") and Celldex Research's 2005 Equity Incentive Plan (the "Celldex Research 2005 Plan"). There are no shares available for future grant under the Celldex Research 2005 Plan.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Employee Stock Purchase Plan</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2015, a total of 200,000 shares of common stock are reserved for issuance under the 2004 ESPP Plan. Under the 2004 ESPP Plan, each participating employee may purchase shares of common stock through payroll deductions at a purchase price equal to 85% of the lower of the fair market value of the common stock at either the beginning of the offering period or the applicable exercise date. During the years ended December&nbsp;31, 2015 and 2014, the Company issued 15,755 and 10,798 shares under the 2004 ESPP Plan, respectively. At December&nbsp;31, 2015, 137,571 shares were available for issuance under the 2004 ESPP Plan.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Employee Stock Option and Incentive Plan</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan permits the granting of incentive stock options (intended to qualify as such under Section&nbsp;422A of the Internal Revenue Code of 1986, as amended), non-qualified stock options, stock appreciation rights, performance share units, restricted stock and other awards of restricted stock in lieu of cash bonuses to employees, consultants and non-employee directors.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2015, the 2008 Plan allowed for a maximum of 14,350,000 shares of common stock to be issued for grants of Stock Options and other Awards made prior to June&nbsp;9, 2025 and grants of Incentive Stock Options made prior to April&nbsp;16, 2025. The Company's board of directors determines the term of each option, option price, and number of shares for which each option is granted and the rate at which each option vests. Options generally vest over a period not to exceed four years. The term of each option cannot exceed ten years (five years for options granted to holders of more than 10% of the voting stock of the Company) and the exercise price of stock options cannot be less than the fair market value of the common stock at the date of grant (110% of fair market value for incentive stock options granted to holders of more than 10% of the voting stock of the Company). Vesting of all employee and non-employee director stock option awards may accelerate upon a change in control as defined in the 2008 Plan.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of stock option activity for the year ended December&nbsp;31, 2015 is as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Average</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Exercise</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Price</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Per Share</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Average</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Remaining</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Contractual</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Term (In Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Options Outstanding at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,015,350
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.6
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,865,250
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24.75
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(700,561
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.81
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Canceled</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(69,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.79
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Options Outstanding at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,110,239
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.13
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Options Vested and Expected to Vest at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,065,256
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.08
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Options Exercisable at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,705,304
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.53
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Shares Available for Grant under the 2008 Plan</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,790,709
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The total intrinsic value of stock options exercised during the years ended December&nbsp;31, 2015, 2014 and 2013 was $14.4&nbsp;million, $2.7&nbsp;million and $10.0&nbsp;million, respectively. The weighted average grant-date fair value of stock options granted during the years ended December&nbsp;31, 2015, 2014 and 2013 was $15.25, $8.82 and $10.51, respectively. The total fair value of stock options vested during the years ended December&nbsp;31, 2015, 2014 and 2013 was $10.0&nbsp;million, $5.7&nbsp;million and $2.4&nbsp;million, respectively.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate intrinsic value of stock options outstanding at December&nbsp;31, 2015 was $38.6&nbsp;million. The aggregate intrinsic value of stock options vested and expected to vest at December&nbsp;31, 2015 was $38.6&nbsp;million. As of December&nbsp;31, 2015, total compensation cost related to non-vested employee and non-employee director stock options not yet recognized was approximately $36.2&nbsp;million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average period of 2.6&nbsp;years.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Restricted Stock</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of restricted stock activity under the 2008 Plan for the year ended December&nbsp;31, 2015 is as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Average</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Grant Date</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(per share)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Outstanding and unvested at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.78
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.41
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(26,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22.60
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Canceled</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Outstanding and unvested at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.41
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Valuation and Expenses Information</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense for the years ended December&nbsp;31, 2015, 2014 and 2013 was recorded as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,186&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,459&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,640&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,588&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,393&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,908&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,774&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,852&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,548&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair values of employee stock options granted during the years ended December&nbsp;31, 2015, 2014 and 2013 were valued using the Black-Scholes option- pricing model with the following assumptions:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2013</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expected stock price volatility</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">67&nbsp;-&nbsp;69%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">70&nbsp;-&nbsp;72%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">71&nbsp;-&nbsp;72%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expected option term</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">6.0 Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">6.0 Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">6.0 Years</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.8&nbsp;-&nbsp;2.2%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.9&nbsp;-&nbsp;2.2%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.2&nbsp;-&nbsp;2.1%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">None</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">None</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">None</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company estimates expected term based on historical exercise patterns. The Company uses its historical stock price volatility consistent with the expected term of grant as the basis for its expected volatility assumption. The risk-free interest rate is based upon the yield of U.S. Treasury securities consistent with the expected term of the option. The dividend yield assumption is based on the Company's history of zero dividend payouts and expectation that no dividends will be paid in the foreseeable future.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6767981024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_SignificantRevenueArrangementsDisclosureAbstract', window );"><strong>REVENUE.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_SignificantRevenueArrangementsDisclosureTextBlock', window );">REVENUE</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(13) REVENUE</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Bristol-Myers Squibb Company (BMS)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, the Company entered into a clinical trial collaboration with BMS to evaluate the safety, tolerability and preliminary efficacy of varlilumab and Opdivo&#xAE;, BMS's PD-1 immune checkpoint inhibitor, in a Phase 1/2 study. Under the terms of this clinical trial collaboration, BMS made a one-time payment to the Company of $5.0&nbsp;million and BMS and the Company amended the terms of the Company's existing license agreement with Medarex (a subsidiary of BMS) related to the Company's CD27 program whereby certain future milestone payments were waived and future royalty rates were reduced that may have been due from the Company to Medarex. In return, BMS was granted a time-limited right of first negotiation if the Company wishes to out-license varlilumab. The companies also agreed to work exclusively with each other to explore anti-PD-1 antagonist antibody and anti-CD27 agonist antibody combination regimens. The clinical trial collaboration provides that the companies will share development costs and that the Company will be responsible for conducting the ongoing Phase 1/2 study.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has determined that its performance obligations under the BMS agreement, which primarily include performing research and development, supplying varlilumab and participating in the joint development committee, should be accounted for as a single unit of accounting and estimated that its performance period under the BMS agreement would be 5&nbsp;years. Accordingly, the $5.0&nbsp;million up-front payment was initially recorded as deferred revenue and is being recognized as revenue on a straight-line basis over the estimated 5-year performance period using the Contingency Adjusted Performance Model ("CAPM"). The BMS agreement also provides for BMS to reimburse the Company for 50% of the external costs incurred by the Company in connection with the clinical trial. These BMS payments are being recognized as revenue using the CAPM. The Company recorded $1.3&nbsp;million and $0.7&nbsp;million in revenue related to the BMS agreement during the year ended December&nbsp;31, 2015 and 2014, respectively.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Rockefeller University (Rockefeller)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2013, the Company entered into an agreement, as amended, with Rockefeller pursuant to which the Company performs research and development services for Rockefeller. The Company bills Rockefeller quarterly for actual time and direct costs incurred and records those amounts to revenue in the quarter the services are performed. The Company recorded $3.4&nbsp;million, $2.7&nbsp;million and $1.4&nbsp;million in revenue related to the Rockefeller agreement during the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">GlaxoSmithKline&nbsp;plc (Glaxo)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1997, the Company licensed its oral rotavirus strain to Glaxo and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. The Company's licensed-in the rotavirus strain that was used to develop Glaxo's Rotarix rotavirus vaccine in 1995 and owed a license fee of 30% to Cincinnati Children's Hospital Medical Center ("CCH") on net royalties received from Glaxo. In May 2005, the Company entered into an agreement whereby an affiliate of Paul Royalty Fund II,&nbsp;L.P. ("PRF") purchased a 70% interest in the net royalties the Company received on worldwide sales of Rotarix. In December 2012, the Glaxo agreement expired automatically upon the expiration of the last relevant patent right covered by the Glaxo agreement. The Company's retained interests in Rotarix net royalties which were not sold to PRF are recorded as product royalty revenue and a corresponding amount that is payable to CCH is recorded as royalty expense. Product royalty revenue and royalty expense related to the Company's retained interest in Rotarix was $2.3&nbsp;million for the year ended December&nbsp;31, 2013.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_SignificantRevenueArrangementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_SignificantRevenueArrangementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_SignificantRevenueArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element may be used to capture the complete disclosure pertaining to an entity's significant revenue contracts and arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_SignificantRevenueArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794169408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementDisclosureAbstract', window );"><strong>COLLABORATION AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(14) COLLABORATION AGREEMENTS</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has entered into license agreements whereby the Company has received licenses or options to license technology, specified patents or patent applications. The Company's licensing and development collaboration agreements generally provide for royalty payments equal to specified percentages of product sales, annual license maintenance fees, continuing patent prosecution costs and potential future milestone payments to third parties upon the achievement of certain developmental, regulatory and/or commercial milestones. Nonrefundable license fee expense of $0.9&nbsp;million, $3.2&nbsp;million and $0.7&nbsp;million was recorded to research and development expense for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Medarex,&nbsp;Inc., a subsidiary of Bristol-Myers Squibb (Medarex)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and Medarex have entered into an assignment and license agreement, as amended, that provides for the assignment of certain patent and other intellectual property rights and a license to certain Medarex technology related to the Company's APC Targeting Technology&#x2122; and an anti-mannose receptor product. Under the terms of the agreement, the Company may be required to pay royalties in the low-single digits on any net product sale of a Licensed Royalty-Bearing Product or Anti-Mannose Product to Medarex until the later of (i)&nbsp;the expiration of the last to expire applicable patent and (ii)&nbsp;the tenth anniversary of the first commercial sale of such licensed product.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and Medarex have also entered into a research and commercialization agreement, as amended, that provides that the Company may be required to pay Medarex milestones of up to $7.0&nbsp;million upon obtaining first approval for commercial sale in a first indication of a product containing a licensed antibody and royalty payments in the low-to-mid single digits on any net product sales with respect to the development of any products containing such licensed antibodies until the later of (i)&nbsp;the expiration of the last to expire applicable patent and (ii)&nbsp;the tenth anniversary of the first commercial sale of such licensed product. In September 2010, the Company exercised an option under the agreement, whereby it licensed from Medarex access to the UltiMab technology to develop and commercialize human antibodies to CD27, including varlilumab. In connection with the clinical trial collaboration, the Company entered into with BMS in May 2014, certain future milestone payments were waived and future royalty rates that the Company may have owed Medarex in connection with any CD27 program were reduced.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Rockefeller University (Rockefeller)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2005, the Company and Rockefeller entered into a license agreement for the exclusive worldwide rights to human DEC-205 receptor, with the right to sublicense the technology. The license grant is exclusive except that Rockefeller may use and permit other nonprofit organizations to use the human DEC-205 receptor patent rights for educational and research purposes. The Company may be required to pay Rockefeller milestones of up to $3.8&nbsp;million upon obtaining first approval for commercial sale in a first indication of a product targeting the licensed receptor and royalty payments in the low-to-mid single digits on any net product sales with respect to development and commercialization of the human DEC-205 receptor.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Duke University Brain Tumor Cancer Center (Duke)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2006, the Company and Duke entered into a license agreement that gave the Company access and reference to the clinical data generated by Duke and its collaborators in order for the Company to generate its own filing with the FDA relating to Rintega. The Company may be required to pay Duke milestones of up to $0.7&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of Rintega.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Ludwig Institute for Cancer Research (Ludwig)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2006, the Company and Ludwig entered into an agreement for the nonexclusive rights to certain cancer tumor targets for use in combination with the Company's APC Targeting Technology. The Company may be required to pay Ludwig milestones of up to $1.0&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of the technology licensed from Ludwig.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Alteris Therapeutics,&nbsp;Inc. (Alteris)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2005, the Company completed the acquisition of the assets of Alteris, including the EGFRvIII molecule. The Company may be required to pay Alteris up to $5.0&nbsp;million upon obtaining the first approval for commercial sale of a product containing EGFRvIII, including Rintega.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">University of Southampton, UK (Southampton)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2008, the Company entered into a license agreement with Southampton to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers. The Company may be required to pay Southampton milestones of up to approximately $1.4&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of varlilumab.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Amgen&nbsp;Inc. (Amgen)</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2009, the Company entered into a license agreement with Amgen to acquire the exclusive rights to CDX-301 and CD40 ligand (CD40L). CDX-301 and CD40L are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. The Company may be required to pay Amgen milestones of up to $0.9&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in the low-single digits on any net product sales with respect to development and commercialization of the technology licensed from Amgen, including CDX-301.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Seattle Genetics,&nbsp;Inc. (Seattle Genetics)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the acquisition of CuraGen, the Company assumed the license agreement between CuraGen and Seattle Genetics whereby CuraGen acquired the rights to proprietary antibody-drug conjugate (ADC) technology for use with the Company's proprietary antibodies for the potential treatment of cancer. The Company may be required to pay Seattle Genetics milestones of up to $5.0&nbsp;million and $9.0&nbsp;million for glembatumumab vedotin and CDX-014, respectively, upon obtaining first approval for commercial sale in a first indication and royalty payments in the mid-single digits on any net product sales with respect to development and commercialization of these product candidates.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774439712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(15) INCOME TAXES</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of income tax expense attributable to continuing operations consist of the following:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Income tax benefit (provision):</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Federal</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,598
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,536
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,962
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">State</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,642
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,328
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,920
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expiration of Net Operating Losses and Research&nbsp;&amp; Development Tax Credits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(155
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,302
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(126
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,085
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,562
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,756
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred tax valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(57,085
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(48,562
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(35,756
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A reconciliation between the amount of reported income tax and the amount computed using the U.S. Statutory rate of 34% follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Pre-tax loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(127,197
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(118,080
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(81,550
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Loss at Statutory Rates</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(43,247
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(40,147
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,727
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Research and Development Credits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,935
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,126
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,261
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">State Taxes</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,642
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,328
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,920
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,584
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>737
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expiration of Net Operating Losses and Research&nbsp;&amp; Development Tax Credits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>155
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,302
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>126
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Change in Valuation Allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,085
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,562
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,756
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Income tax (benefit) provision</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future expected enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The principal components of the deferred tax assets and liabilities at December&nbsp;31, 2015 and 2014, respectively, are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Gross Deferred Tax Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net Operating Loss Carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>180,777
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,577
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Tax Credit Carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,895
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,709
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,608
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,889
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Stock-based Compensation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,393
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,556
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Fixed Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,017
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,882
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,703
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,078
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Accrued Expenses and Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>219
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>202
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>277,612
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,893
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Gross Deferred Tax Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other Acquired Intangibles</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,382
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,749
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">IPR&amp;D Intangibles</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,043
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,410
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total Deferred Tax Assets and Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,569
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>212,483
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Tax Assets Valuation Allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(274,230
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(217,144
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net Deferred Tax Asset (Liability)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The net deferred tax liability of $4.7&nbsp;million at December&nbsp;31, 2015 and 2014 relates to the temporary differences associated with the IPR&amp;D intangible assets acquired in the CuraGen acquisition, which are not deductible for tax purposes.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2015, the Company had the following federal net operating loss ("NOL") carryforwards:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Prior to the merger of the Company and AVANT, $33.0&nbsp;million was generated by the Company which expire at various dates starting in 2023 and going through 2028; </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Prior to the merger of the Company and AVANT, $101.2&nbsp;million, net of expirations and utilization, was generated by AVANT which expire at various dates starting in 2018 and going through 2028; </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Following the merger of the Company and AVANT, $392.9&nbsp;million was generated by the combined company which expire at various dates starting in 2028 and going through 2035; and </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Prior to its acquisition by the Company, $518.3&nbsp;million was generated by CuraGen.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2015, the Company has an additional $17.7&nbsp;million of federal and state net operating losses not reflected above, that are attributable to stock option exercises which will be recorded as an increase in additional paid in capital on the balance sheet once they are "realized" in accordance with ASC 718.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, an ownership change, as defined by Section&nbsp;382 of the Internal Revenue Code, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50&nbsp;percentage points over a three-year period. Such ownership changes can significantly limit the amount of NOLs that may be utilized in future periods. The Company currently expects that it is remote that the CuraGen NOLs may be utilized and, as such, no related asset has been recorded for such losses. The Company has not completed an analysis of losses generated by AVANT, however, the Company believes it is remote that $60.8&nbsp;million of the AVANT NOLs may be utilized in future periods and there may be substantial limitations on the Company's ability to use the remaining NOLs of $40.4&nbsp;million. Following the merger of the Company and AVANT, the Company experienced changes in ownership as defined by Section&nbsp;382 in June 2009, December 2009 and December 2013. Further, prior to the AVANT merger, the Company as a stand alone company experienced a change in ownership in October 2007. As a result of the ownership changes in June 2009 and December 2009, there is an annual limitation amount of $6.0&nbsp;million on $67.7&nbsp;million of NOLs generated before that date. As a result of the ownership change in December 2013, there is an annual limitation amount of $77.0&nbsp;million on $178.7&nbsp;million of NOLs generated before that date. Any unused annual limitation may be carried over to later years, and the amount of the limitation may, under certain circumstances, be subject to adjustment if the fair value of the Company's net assets are determined to be below or in excess of the tax basis of such assets at the time of the ownership change, and such unrealized loss or gain is recognized during the five-year period after the ownership change.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similar to the AVANT and CuraGen NOL carryforwards above, the Company believes that it is not more likely than not that federal and state research and development ("R&amp;D") credits of $20.8&nbsp;million and $14.4&nbsp;million, respectively, will be utilized in the future periods. Further, the Company's ability to use the state NOLs of approximately $382.3&nbsp;million and the remaining federal and state R&amp;D credit carryforwards of approximately $28.5&nbsp;million and $11.2&nbsp;million, respectively, may be substantially limited. These state NOLs and federal and state credits expire at various dates starting in 2016 going through 2035. The Company has not yet completed a study of these credits to substantiate the amounts. Until a study is completed, no amounts are being presented as an uncertain tax position.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent ownership changes, as defined in Section&nbsp;382, could further limit the amount of net operating loss carryforwards and research and development credits that can be utilized annually to offset future taxable income.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company applies the authoritative guidance on account for and disclosure of uncertainty in income tax positions which requires the Company to determine whether an income tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. For income tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced to the largest benefit that has a greater than fifty perfect likelihood of being realized upon the ultimate settlement with the relevant taxing authority. At December&nbsp;31, 2015 and 2014, we had no unrecognized tax benefits. A full valuation allowance has been provided against our deferred tax assets and liabilities and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Massachusetts, New Jersey and Connecticut are the three states in which the Company primarily operates or has operated and has income tax nexus. The Company is not currently under examination by these or any other jurisdictions for any tax year.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has evaluated the positive and negative evidence bearing upon the realizability of its net deferred tax assets, which are comprised principally of net operating loss carryforwards, capitalized R&amp;D expenditures and R&amp;D tax credit carryforwards. The Company has determined that it is more likely than not that it will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance was maintained at December&nbsp;31, 2015 against the Company's net deferred tax assets.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780971600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(16) COMMITMENTS AND CONTINGENCIES</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has facility and equipment leases that expire at various dates through 2020. Certain of these facility leases contain renewal options, early termination provisions, and provisions that escalate the base rent payments and require the Company to pay common area maintenance costs ("CAM") during the lease term. The following obligations for base rent and CAM costs under facility and other non-cancelable operating leases as of December&nbsp;31, 2015 do not include the exercise of renewal terms or early termination provisions (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,021&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,242&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2018</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,698&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2019</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,754&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2020</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,524&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Thereafter</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total minimum lease payments</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,239&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2016, the Company amended the facility lease in Fall River, MA for additional space and to extend the term from 2017 to 2020. The Company's total rent and CAM expense for all facility leases was $2.9&nbsp;million, $2.7&nbsp;million and $2.7&nbsp;million for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794217216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT SAVINGS PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>RETIREMENT SAVINGS PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">RETIREMENT SAVINGS PLAN</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(17) RETIREMENT SAVINGS PLAN</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains a 401(k) Plan which is available to substantially all employees. Under the terms of the 401(k) Plan, participants may elect to contribute up to 15% of their compensation, or the statutory prescribed limits. The Company may make 50% matching contributions on up to 4% of a participant's annual salary. Benefit expense for the 401(k) Plan was $0.4&nbsp;million, $0.3&nbsp;million and $0.3&nbsp;million for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49170332&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794217904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">(18) SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014 </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q1 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q2 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q3 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q4 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>416
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>592
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,101
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,477
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29,903
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,274
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,082
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,821
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Basic and diluted net loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.32
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.31
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.36
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015 </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q1 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q2 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q3 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q4 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>486
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,178
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,790
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(30,174
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(32,359
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,980
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(32,684
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Basic and diluted net loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.32
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803846080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;31, 2014, the Company's wholly-owned subsidiary, Celldex Research Corporation, merged into Celldex Therapeutics,&nbsp;Inc. The statements of operations and comprehensive loss, of stockholders' equity, and of cash flows, are consolidated for the years ended December&nbsp;31, 2014 and 2013. These consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiary prior to the merger. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one segment, which is the business of development, manufacturing and commercialization of novel therapeutics for human health care. In February 2016, the Company formed a wholly-owned subsidiary, Celldex Therapeutics Europe&nbsp;GmbH, in Zug, Switzerland, to operate as Celldex' European headquarters when European operations commence, pursuant to intercompany agreements.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (U.S.&nbsp;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments purchased with a maturity date of 90&nbsp;days or less at the date of purchase to be cash equivalents. Cash equivalents consist principally of money market funds and debt securities.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Marketable Securities</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company invests its excess cash balances in marketable securities including municipal bond securities, U.S. government agency securities, and high-grade corporate bonds. The Company classifies all of its marketable securities as current assets on the balance sheets because they are available-for-sale and available to fund current operations. Marketable securities are stated at fair value with their unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is transferred from other comprehensive income (loss) to the statements of operations. Realized gains and losses are determined on the specific identification method and are included in investment and other income, net.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and of Significant Customers and Suppliers</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Concentration of Credit Risk and of Significant Customers and Suppliers</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue from Rockefeller and BMS represented 62% and 24% for the year ended December&nbsp;31, 2015, 75% and 20% for the year ended December&nbsp;31, 2014, 35% and 0% for the year ended December&nbsp;31, 2013, of total Company revenue, respectively.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company relies on contract manufacturing organizations (CMO) to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. The Company also relies on CMOs for supply of raw materials as well as filling, packaging, storage and shipping of drug product. These clinical studies would be adversely affected by a significant interruption in the supply of Rintega and glembatumumab vedotin. The Company also relies on third-party collaborators to develop companion diagnostic tests for certain of its drug candidates, including Rintega.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Fair Value Measurements</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has certain assets and liabilities that are measured at fair value in the financial statements. The Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company's assumptions about how market participants would price assets and liabilities) when measuring the fair value of its assets and liabilities. These assets and liabilities are classified into one of three levels of the following fair value hierarchy as defined by U.S.&nbsp;GAAP:</font>
		</p>
		<p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1: Observable inputs such as quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2: Observable inputs other than Level&nbsp;1 prices, such as quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</font>
		</p>
		<p style="margin:12pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times;">Level 3: Unobservable inputs based on the Company's assessment of the assumptions that market participants would use in pricing the asset or liability.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Property and Equipment</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment is stated at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Laboratory equipment and office furniture and equipment are depreciated over five years and computer equipment is depreciated over three years. Manufacturing equipment is amortized over seven to ten years. Leasehold improvements are amortized over the shorter of the estimated useful life or the non-cancelable term of the related lease, including any renewals that are reasonably assured of occurring. Property and equipment under construction is classified as construction in progress and is depreciated or amortized only after the asset is placed in service. Expenditures for maintenance and repairs are charged to expense whereas the costs of significant improvements which extend the life of the underlying asset are capitalized. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated and any resulting gain or loss is reflected in the Company's statements of operations and comprehensive loss.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The treatment of costs to construct property and equipment depends on the nature of the costs and the stage of construction. Costs incurred in the project planning, design, construction and installation phases are capitalized as part of the cost of the asset. The Company stops capitalizing these costs when the asset is substantially complete and ready for its intended use. For manufacturing property and equipment, the Company also capitalizes the cost of validating these assets for the underlying manufacturing process. The Company completes the capitalization of validation costs when the asset is substantially complete and ready for its intended use. Costs capitalized include incremental labor and fringe benefits, and direct consultancy services.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Business Combinations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records the fair value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets such as in-process research and development (IPR&amp;D), using a variety of methods including present value models. Each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of IPR&amp;D assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant's assumptions regarding the probability of completing IPR&amp;D projects, which would require obtaining regulatory approval for marketing of the associated drug candidate; a market participant's estimates regarding the timing of and the expected costs to complete IPR&amp;D projects; a market participant's estimates of future cash flows from potential product sales; and the appropriate discount rates for a market participant. Transaction costs and restructuring costs associated with the transaction are expensed as incurred.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Intangible Assets</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D assets acquired in a business combination initially are recorded at fair value and accounted for as indefinite-lived intangible assets. These assets are capitalized on the Company's balance sheets until either the project underlying them is completed or the assets become impaired. If a project is completed, the carrying value of the related intangible asset is amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value and an impairment charge is taken in the period in which the impairment occurs.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D assets are tested for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. As part of the annual impairment test of the IPR&amp;D assets as of July&nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed a calculation of the fair value of the asset. The Company concluded that the IPR&amp;D assets were not impaired.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets acquired in a business combination with a finite life are recorded at fair value and amortized over the greater of economic consumption or on a straight-line basis over their estimated useful life.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Goodwill</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis during the third quarter, or earlier if impairment indicators are present. The Company has the option to assess qualitative factors to determine if it is more likely than not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under U.S.&nbsp;GAAP. As part of its annual impairment test of the goodwill asset as of July&nbsp;1, 2015, the Company bypassed the optional qualitative assessment and performed the two-step impairment test. The Company concluded that goodwill was not impaired.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Intangible and Long-Lived Assets</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Impairment of Intangible and Long-Lived Assets</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluates the recoverability of its long-lived assets, including property and equipment, and intangible assets when circumstances indicate that an event of impairment may have occurred. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Revenue Recognition</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller's price to the buyer is fixed or determinable; and collectability is reasonably assured.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has entered into and in the future may enter into biopharmaceutical product development agreements with collaborative partners for the research and development of therapeutic drug products. The terms of the agreements may include nonrefundable signing and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. In accounting for these transactions, the Company allocates revenue to the various elements based on their relative fair value. The fair value of a revenue generating element can be based on current selling prices offered by the Company or another party for current products or the Company's best estimate of a selling price for future products. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of the Company's involvement in achieving the milestones and whether the amount of the payment is commensurate to the Company's performance. If not considered substantive, milestones are initially deferred and recognized over the period of the remaining performance obligation.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments received to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Revenue from contracts and grants is recognized as the services are performed and recorded as effort is expended on the contracted work and billed to the government or the Company's contractual partner. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product royalty revenue consists of payments received from licensees for a portion of sales proceeds from products that utilize the Company's licensed technologies and are recognized when the amount of and basis for such royalty payments are reported to the Company in accurate and appropriate form and in accordance with the related license agreement.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;font-size:10pt;">Research and Development Expenses</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs, including internal and contract research costs, are expensed as incurred. Research and development expenses consist mainly of clinical trial costs, manufacturing of clinical material, toxicology and other preclinical studies, personnel costs, depreciation, license fees and funding of outside contracted research.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trial expenses include expenses associated with clinical research organizations, or CRO, services. Contract manufacturing expenses include expenses associated with contract manufacturing organizations, or CMO, services. The invoicing from CROs and CMOs for services rendered can lag several months. The Company accrues the cost of services rendered in connection with CRO and CMO activities based on our estimate of costs incurred. The Company maintains regular communication with our CROs and CMOs to assess the reasonableness of its estimates. Differences between actual expenses and estimated expenses recorded have not been material and are adjusted for in the period in which they become known.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Patent Costs</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent costs are expensed as incurred. Certain patent costs are reimbursed by the Company's product development and licensing partners. Any reimbursed patent costs are recorded as product development and licensing agreement revenues in the Company's financial statements.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Stock-Based Compensation</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair values of the stock-based awards expected to vest at the grant date and is adjusted, if necessary, to reflect actual forfeitures. Compensation expense for all stock-based awards to employees and directors is recognized using the straight-line method over the term of vesting or performance.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Foreign Currency Translation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net unrealized gains and losses resulting from foreign currency translation are included in other comprehensive income (loss). At December&nbsp;31, 2015 and December&nbsp;31, 2014, accumulated other comprehensive income includes a net unrealized gain related to foreign currency translation of $2.6&nbsp;million.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Income Taxes</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax basis. Quarterly, the Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company's tax provision in the period of change.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records uncertain tax positions in the financial statements only if it is more likely than not that the uncertain tax position will be sustained upon examination by the taxing authorities. The Company records interest and penalties related to uncertain tax positions in income tax expense.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Comprehensive Loss</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes foreign currency translation adjustments and unrealized gains and losses on marketable securities in other comprehensive loss. The statements of operations and comprehensive loss reflect total comprehensive loss for the years ended December&nbsp;31, 2015, 2014 and 2013.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Net Loss Per Share</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per common share is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common shares outstanding during the period when the effect is dilutive. The potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Stock options</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,110,239&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,015,350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,770,544&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Restricted stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,500&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,000&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,000&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,129,739&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,022,350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,776,544&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt 12pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, the FASB issued a new U.S.&nbsp;GAAP accounting standard that creates modifications to various other revenue accounting standards for specialized transactions and industries. The new U.S.&nbsp;GAAP accounting standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB deferred the effective date of the new standard from January&nbsp;1, 2017 to January&nbsp;1, 2018. The amendment allows for two methods of adoption, a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. The Company will further study the implications of this standard in order to evaluate the expected impact on the financial statements.</font>
		</p>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2015, the FASB issued amendments that provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The new guidance does not change the accounting for a customer's accounting for service contracts. The standard update is effective for fiscal years beginning after December&nbsp;15, 2015 and interim periods within those years. Early adoption is permitted. The standard allows for adoption retrospectively or prospectively to all arrangements entered into or materially modified after the effective date. The amendment is not expected to have a material impact on our financial statements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2014, the FASB issued a new U.S.&nbsp;GAAP accounting standard that provides guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new accounting standard requires management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The new accounting standard is effective for the annual period ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not expect the adoption of this standard to have a material impact on the financial statements.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6381980&amp;loc=d3e87707-122711<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62652-112803<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section M<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 2, 12<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788674704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Stock options</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,110,239&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,015,350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,770,544&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Restricted stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,500&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,000&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,000&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,129,739&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,022,350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,776,544&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788928160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of changes in accumulated other comprehensive income (loss) by component</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gain (Loss) on</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Marketable</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Foreign</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Currency Items</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Balance at December&nbsp;31, 2012</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,589
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,745
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other comprehensive loss before reclassifications</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(74
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(77
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Amounts reclassified from other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net current-period other comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(74
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(77
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Balance at December&nbsp;31, 2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,586
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,668
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other comprehensive loss before reclassifications</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(73
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(78
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Amounts reclassified from other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net current-period other comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(73
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(78
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Balance at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,581
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,590
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other comprehensive loss before reclassifications</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(298
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(283
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Amounts reclassified from other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net current-period other comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(298
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(283
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Balance at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(289
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,596
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-weight:bold;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,307
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794238272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial assets subject to fair value measurements</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">As of</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Money market funds and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,677&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,677&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173,023&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173,023&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>191,700&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>191,700&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">As of</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Money market funds and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,831&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,831&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217,781&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217,781&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>277,612&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>277,612&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6771968560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>MARKETABLE SECURITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of marketable securities</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortized</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gains</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Losses</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">U.S. government and municipal obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing in one year or less</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,580
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,604
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,108
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,156
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total U.S. government and municipal obligations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,688
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,760
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing in one year or less</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,636
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(37
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,605
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,690
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(35
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,658
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>112,326
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(72
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>112,263
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173,014
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(79
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173,023
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">U.S. government and municipal obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing in one year or less</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,871
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(20
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,855
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,940
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(57
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,907
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total U.S. government and municipal obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64,811
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(77
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64,762
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing in one year or less</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,327
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(141
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,188
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 40pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Maturing after one year through three years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,932
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(102
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,831
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,259
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(243
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153,019
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>218,070
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217,781
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790515680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Laboratory Equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,432
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,223
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Manufacturing Equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,178
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,274
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Office Furniture and Equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,088
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,888
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Leasehold Improvements</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,371
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,603
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Construction in Progress</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>451
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,767
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total Property and Equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,520
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,755
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Less Accumulated Depreciation and Amortization</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17,059
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,220
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,461
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788928160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS AND GOODWILL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets, net of accumulated amortization, and goodwill</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="10" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Estimated</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Life</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Accumulated</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortization</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Net</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Accumulated</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortization</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Net</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="17" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Intangible Assets:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">IPR&amp;D</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Indefinite</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Amgen Amendment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">16&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,605
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,895
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,708
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,792
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Core Technology</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">11&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,296
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,197
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,296
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,081
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>215
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total Intangible Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,596
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,802
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,794
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,596
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,789
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,807
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Goodwill</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Indefinite</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,965
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,965
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,965
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,965
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788673696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Accrued Payroll and Employee Benefits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,601&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,284&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Accrued Research and Development Contract Costs</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,548&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,696&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Accrued Professional Fees</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>399&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>490&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other Accrued Expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,768&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,826&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,316&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,296&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788906544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER LONG-TERM LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>OTHER LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock', window );">Schedule of other long-term liabilities</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Rent</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>409
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>482
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net Deferred Tax Liability related to IPR&amp;D</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Income from Sale of Tax Benefits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,219
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,015
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,368
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,657
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,455
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Less Current Portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,418
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,592
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Long-Term Portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,239
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,863
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other long-term liabilities, not separately disclosed on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ScheduleOfOtherLongTermLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6624674992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Average</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Exercise</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Price</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Per Share</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Average</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Remaining</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Contractual</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Term (In Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Options Outstanding at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,015,350
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.6
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,865,250
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24.75
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(700,561
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.81
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Canceled</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(69,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.79
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Options Outstanding at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,110,239
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.13
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Options Vested and Expected to Vest at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,065,256
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.08
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Options Exercisable at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,705,304
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.53
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Shares Available for Grant under the 2008 Plan</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,790,709
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of restricted stock activity</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Average</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Grant Date</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(per share)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Outstanding and unvested at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.78
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.41
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(26,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22.60
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Canceled</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Outstanding and unvested at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.41
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,186&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,459&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,640&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,588&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,393&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,908&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,774&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,852&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,548&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used for the fair values of employee stock options granted</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2013</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expected stock price volatility</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">67&nbsp;-&nbsp;69%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">70&nbsp;-&nbsp;72%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">71&nbsp;-&nbsp;72%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expected option term</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">6.0 Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">6.0 Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">6.0 Years</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.8&nbsp;-&nbsp;2.2%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.9&nbsp;-&nbsp;2.2%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.2&nbsp;-&nbsp;2.1%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">None</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">None</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">None</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6622451328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense attributable to continuing operations</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Income tax benefit (provision):</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Federal</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,598
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,536
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,962
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">State</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,642
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,328
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,920
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expiration of Net Operating Losses and Research&nbsp;&amp; Development Tax Credits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(155
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,302
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(126
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,085
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,562
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,756
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred tax valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(57,085
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(48,562
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(35,756
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation between the amount of reported income tax and the amount computed using the U.S. Statutory rate</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Pre-tax loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(127,197
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(118,080
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(81,550
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Loss at Statutory Rates</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(43,247
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(40,147
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,727
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Research and Development Credits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,935
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,126
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,261
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">State Taxes</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,642
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,328
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,920
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,584
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>737
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Expiration of Net Operating Losses and Research&nbsp;&amp; Development Tax Credits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>155
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,302
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>126
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Change in Valuation Allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,085
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,562
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,756
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Income tax (benefit) provision</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of principal components of the deferred tax assets and liabilities</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Gross Deferred Tax Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net Operating Loss Carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>180,777
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,577
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Tax Credit Carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,895
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,709
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,608
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,889
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Stock-based Compensation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,393
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,556
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Fixed Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,017
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,882
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,703
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,078
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Accrued Expenses and Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>219
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>202
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>277,612
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,893
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Gross Deferred Tax Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Other Acquired Intangibles</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,382
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,749
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">IPR&amp;D Intangibles</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,043
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,410
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total Deferred Tax Assets and Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,569
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>212,483
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Deferred Tax Assets Valuation Allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(274,230
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(217,144
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net Deferred Tax Asset (Liability)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6604862208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of obligations for base rent and CAM costs under facility and other non-cancelable operating leases</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">The following obligations for base rent and CAM costs under facility and other non-cancelable operating leases as of December&nbsp;31, 2015 do not include the exercise of renewal terms or early termination provisions (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,021&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,242&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2018</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,698&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2019</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,754&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2020</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,524&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Thereafter</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total minimum lease payments</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,239&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6622081952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of selected quarterly financial data (unaudited)</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014 </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q1 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q2 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q3 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q4 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>416
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>592
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,101
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,477
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29,903
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,274
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,082
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,821
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Basic and diluted net loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.32
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.31
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.36
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015 </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q1 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q2 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q3 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Q4 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Total revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>486
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,178
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,790
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(30,174
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(32,359
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,980
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(32,684
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Basic and diluted net loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.32
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791126208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND OVERVIEW (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF BUSINESS AND OVERVIEW</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DrugCandidatesInClinicalDevelopment', window );">Number of drug candidates in clinical development | item</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 289,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
<td class="num">$ (32,684)<span></span>
</td>
<td class="num">$ (31,980)<span></span>
</td>
<td class="num">$ (32,359)<span></span>
</td>
<td class="num">$ (30,174)<span></span>
</td>
<td class="num">$ (31,821)<span></span>
</td>
<td class="num">$ (28,082)<span></span>
</td>
<td class="num">$ (28,274)<span></span>
</td>
<td class="num">$ (29,903)<span></span>
</td>
<td class="num">(127,197)<span></span>
</td>
<td class="num">$ (118,080)<span></span>
</td>
<td class="num">$ (81,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (98,887)<span></span>
</td>
<td class="num">$ (101,537)<span></span>
</td>
<td class="num">$ (67,669)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DrugCandidatesInClinicalDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of drug candidates in clinical development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DrugCandidatesInClinicalDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804519216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONCENTRATION OF CREDIT RISK (Details) - segment<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Revenue | Customer concentration | Rockefeller</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Revenue | Customer concentration | BMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=cldx_RockefellerUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=cldx_RockefellerUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=cldx_BristolMeyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=cldx_BristolMeyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791757552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PROPERTY AND EQUIPMENT (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_ManufacturingEquipmentMember', window );">Manufacturing Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_ManufacturingEquipmentMember', window );">Manufacturing Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780487680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - FOREIGN CURRENCY TRANSLATION (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Net unrealized gain related to foreign currency translation included in accumulated other comprehensive income</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32022-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791652848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - DILUTIVE COMMON SHARES (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive</a></td>
<td class="nump">8,129,739<span></span>
</td>
<td class="nump">7,022,350<span></span>
</td>
<td class="nump">5,776,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive</a></td>
<td class="nump">8,110,239<span></span>
</td>
<td class="nump">7,015,350<span></span>
</td>
<td class="nump">5,770,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive</a></td>
<td class="nump">19,500<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791943632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPREHENSIVE LOSS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AccumulatedOtherComprehensiveIncomeLossRollForward', window );"><strong>Changes in accumulated other comprehensive income (loss) by component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">$ 211,660<span></span>
</td>
<td class="nump">$ 319,795<span></span>
</td>
<td class="nump">$ 95,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">290,105<span></span>
</td>
<td class="nump">211,660<span></span>
</td>
<td class="nump">319,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gain (Loss) on Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AccumulatedOtherComprehensiveIncomeLossRollForward', window );"><strong>Changes in accumulated other comprehensive income (loss) by component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current-period other comprehensive income</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">(289)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AccumulatedOtherComprehensiveIncomeLossRollForward', window );"><strong>Changes in accumulated other comprehensive income (loss) by component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">2,581<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current-period other comprehensive income</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">2,581<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AccumulatedOtherComprehensiveIncomeLossRollForward', window );"><strong>Changes in accumulated other comprehensive income (loss) by component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current-period other comprehensive income</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">$ 2,307<span></span>
</td>
<td class="nump">$ 2,590<span></span>
</td>
<td class="nump">$ 2,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AccumulatedOtherComprehensiveIncomeLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AccumulatedOtherComprehensiveIncomeLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791743120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels', window );">Assets transferred between the fair value measurement classifications</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels', window );">Liabilities transferred between the fair value measurement classifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds and cash equivalents</a></td>
<td class="nump">59,831<span></span>
</td>
<td class="nump">$ 18,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">217,781<span></span>
</td>
<td class="nump">173,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets at fair value</a></td>
<td class="nump">277,612<span></span>
</td>
<td class="nump">191,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds and cash equivalents</a></td>
<td class="nump">59,831<span></span>
</td>
<td class="nump">18,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">217,781<span></span>
</td>
<td class="nump">173,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets at fair value</a></td>
<td class="nump">$ 277,612<span></span>
</td>
<td class="nump">$ 191,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of transfer of assets measured on a recurring basis between Level 1, Level 2 and Level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_FairValueAssetsAmountTransfersBetweenMeasurementLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of transfer of liabilities measured on a recurring basis between Level 1, Level 2 and Level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6801829632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 218,070<span></span>
</td>
<td class="nump">$ 173,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract', window );"><strong>Gross Unrealized Gains</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">217,781<span></span>
</td>
<td class="nump">173,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired', window );">Marketable securities considered to be other-than-temporarily impaired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest included in marketable securities</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cldx_USGovernmentAndMunicipalObligationsMember', window );">U.S. government and municipal obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing in one year or less</a></td>
<td class="nump">48,871<span></span>
</td>
<td class="nump">44,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost', window );">Maturing after one year through three years</a></td>
<td class="nump">15,940<span></span>
</td>
<td class="nump">16,108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">64,811<span></span>
</td>
<td class="nump">60,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract', window );"><strong>Gross Unrealized Gains</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain', window );">Maturing in one year or less</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain', window );">Maturing after one year through three years</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses', window );">Maturing in one year or less</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses', window );">Maturing after one year through three years</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">48,855<span></span>
</td>
<td class="nump">44,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue', window );">Maturing after one year through three years</a></td>
<td class="nump">15,907<span></span>
</td>
<td class="nump">16,156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">64,762<span></span>
</td>
<td class="nump">60,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing in one year or less</a></td>
<td class="nump">129,327<span></span>
</td>
<td class="nump">89,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost', window );">Maturing after one year through three years</a></td>
<td class="nump">23,932<span></span>
</td>
<td class="nump">22,690<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">153,259<span></span>
</td>
<td class="nump">112,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract', window );"><strong>Gross Unrealized Gains</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain', window );">Maturing in one year or less</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain', window );">Maturing after one year through three years</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses', window );">Maturing in one year or less</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses', window );">Maturing after one year through three years</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">129,188<span></span>
</td>
<td class="nump">89,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue', window );">Maturing after one year through three years</a></td>
<td class="nump">23,831<span></span>
</td>
<td class="nump">22,658<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 153,019<span></span>
</td>
<td class="nump">$ 112,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of investment in debt and equity securities considered to be other-than-temporarily impaired, categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of available-for-sale debt securities at cost, net of adjustments, maturing in the second fiscal year through the third fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of available-for-sale debt securities at fair value maturing in the second fiscal year through the third fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the gross unrealized gains on securities, at a point in time, for those securities which are expected to mature after one year and through three years from the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the gross unrealized losses on securities, at a point in time, which are expected to mature after one year and through three years from the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the gross unrealized gains on securities, at a point in time, for those securities which are expected to mature within one year of the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the gross unrealized losses on securities, at a point in time, which are expected to mature within one year of the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cldx_USGovernmentAndMunicipalObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=cldx_USGovernmentAndMunicipalObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803621744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 28,520<span></span>
</td>
<td class="nump">$ 24,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less Accumulated Depreciation and Amortization</a></td>
<td class="num">(17,059)<span></span>
</td>
<td class="num">(14,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, Net</a></td>
<td class="nump">11,461<span></span>
</td>
<td class="nump">10,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,998<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="nump">$ 1,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">5,432<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_ManufacturingEquipmentMember', window );">Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">4,178<span></span>
</td>
<td class="nump">2,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">3,088<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">15,371<span></span>
</td>
<td class="nump">14,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 1,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cldx_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792358560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets and Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 8,965<span></span>
</td>
<td class="nump">$ 8,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,802)<span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost of total intangible assets</a></td>
<td class="nump">27,596<span></span>
</td>
<td class="nump">27,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">20,794<span></span>
</td>
<td class="nump">21,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated future amortization expense of intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2016</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2017</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2018</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2019</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2020</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cldx_AmgenAmendmentMember', window );">Amgen Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,605)<span></span>
</td>
<td class="num">(4,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 8,895<span></span>
</td>
<td class="nump">9,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cldx_CoreTechnologyMember', window );">Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 1,296<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cldx_AmgenAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cldx_AmgenAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cldx_CoreTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cldx_CoreTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790612000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued Payroll and Employee Benefits</a></td>
<td class="nump">$ 5,601<span></span>
</td>
<td class="nump">$ 4,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_AccruedResearchAndDevelopmentContractCostsCurrent', window );">Accrued Research and Development Contract Costs</a></td>
<td class="nump">14,548<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued Professional Fees</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Expenses</a></td>
<td class="nump">3,768<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Expenses</a></td>
<td class="nump">$ 24,316<span></span>
</td>
<td class="nump">$ 19,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_AccruedResearchAndDevelopmentContractCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development contract costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_AccruedResearchAndDevelopmentContractCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792467200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER LONG-TERM LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Jan. 31, 2013</div></th>
<th class="th"><div>Jan. 31, 2012</div></th>
<th class="th"><div>Jan. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>OTHER LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Net Deferred Tax Liability related to IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DeferredIncomeFromSaleOfTaxBenefits', window );">Deferred Income from Sale of Tax Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,219<span></span>
</td>
<td class="nump">4,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">5,297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,657<span></span>
</td>
<td class="nump">14,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Less Current Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,418)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Long-Term Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,239<span></span>
</td>
<td class="nump">11,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ValueOfTaxBenefitsAgreedToBeSold', window );">Amount at which New Jersey tax benefit agreed to be sold</a></td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ValueAtWhichTaxBenefitsSold', window );">Amount of sale of New Jersey tax benefit</a></td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_PeriodForWhichBaseOfOperationsMustBeMaintained', window );">Period for which base of operations must be maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Other income related to sale of tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DeferredIncomeFromSaleOfTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred income from the sale of tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DeferredIncomeFromSaleOfTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_PeriodForWhichBaseOfOperationsMustBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period for which base of operations must be maintained in New Jersey.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_PeriodForWhichBaseOfOperationsMustBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ValueAtWhichTaxBenefitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value at which tax benefit sold by the entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ValueAtWhichTaxBenefitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ValueOfTaxBenefitsAgreedToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of tax benefits agreed to be sold by the entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ValueOfTaxBenefitsAgreedToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount, as of the balance sheet date, of liabilities not separately disclosed in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791692960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TERM LOAN (Details) - Term Loan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May. 31, 2013</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RepaymentOfLongTermDebtPrincipalAmount', window );">Repayment of principal amount</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DebtInstrumentInterestAndPrepaymentFees', window );">Amount of interest, prepayment and final payment fees</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense on the term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DebtInstrumentLenderAxis=cldx_MidCapFinancialLLCMember', window );">MidCap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DebtInstrumentLenderAxis=cldx_GeneralElectricCapitalCorporationMember', window );">GECC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DebtInstrumentInterestAndPrepaymentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of interest, prepayment and final payment fees paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DebtInstrumentInterestAndPrepaymentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_RepaymentOfLongTermDebtPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of principal repaid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_RepaymentOfLongTermDebtPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DebtInstrumentLenderAxis=cldx_MidCapFinancialLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DebtInstrumentLenderAxis=cldx_MidCapFinancialLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DebtInstrumentLenderAxis=cldx_GeneralElectricCapitalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DebtInstrumentLenderAxis=cldx_GeneralElectricCapitalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804657216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="nump">8,337,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,613,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="nump">$ 188,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from sale of stock in an underwritten public offering</a></td>
<td class="nump">$ 188,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares common stock issued in connection with supply agreement</a></td>
<td class="nump">98,685,595<span></span>
</td>
<td class="nump">89,592,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares Issued in Connection with Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development expense</a></td>
<td class="nump">$ 100,171<span></span>
</td>
<td class="nump">$ 104,381<span></span>
</td>
<td class="nump">67,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cldx_BiosynCorporationMember', window );">Biosyn Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares common stock issued in connection with supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares Issued in Connection with Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cldx_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from sale of stock in an underwritten public offering</a></td>
<td class="nump">$ 188,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Class C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CumulativePreferredStockMember', window );">Series C-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_StockIssuedByTypeOfProgramAxis=cldx_ControlledEquityOfferingProgramAmendedMember', window );">Cantor Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cldx_BiosynCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cldx_BiosynCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cldx_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cldx_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CumulativePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CumulativePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_StockIssuedByTypeOfProgramAxis=cldx_ControlledEquityOfferingProgramAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_StockIssuedByTypeOfProgramAxis=cldx_ControlledEquityOfferingProgramAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804813856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - SUMMARY OF PLANS (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2004 ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percentage of the lower of the fair market value of the common stock at either the beginning of the offering period or the applicable exercise date</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under the plan</a></td>
<td class="nump">15,755<span></span>
</td>
<td class="nump">10,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant (in shares)</a></td>
<td class="nump">137,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member', window );">Celldex Research 2005 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cldx_StockOptionAndIncentivePlan2008Member', window );">2008 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares of common stock to be issued for grants (in shares)</a></td>
<td class="nump">14,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock', window );">Terms of options granted to the holders of more than 10% of the voting stock</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock', window );">Threshold percentage of voting stock</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock', window );">Exercise price as a percentage of fair market value for options granted to the holders of more than 10% of the voting stock</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cldx_StockOptionAndIncentivePlan2008Member', window );">2008 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm', window );">Terms of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cldx_StockOptionAndIncentivePlan2008Member', window );">2008 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning of the period (in shares)</a></td>
<td class="nump">7,015,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,865,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(700,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(69,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at the end of the period (in shares)</a></td>
<td class="nump">8,110,239<span></span>
</td>
<td class="nump">7,015,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Vested and Expected to Vest at the end of the period (in shares)</a></td>
<td class="nump">8,065,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at the end of the period (in shares)</a></td>
<td class="nump">4,705,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant (in shares)</a></td>
<td class="nump">5,790,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding at beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 9.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">24.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share)</a></td>
<td class="nump">15.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">13.13<span></span>
</td>
<td class="nump">$ 9.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options Vested and Expected to Vest at the end of the period (in dollars per share)</a></td>
<td class="nump">13.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 8.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding at the beginning of the period</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding at the end of the period</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Vested and Expected to Vest at the end of the period</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable at the end of the period</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Additional information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised (in dollars)</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 15.25<span></span>
</td>
<td class="nump">$ 8.82<span></span>
</td>
<td class="nump">$ 10.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested (in dollars)</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock options outstanding (in dollars)</a></td>
<td class="nump">38.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of stock options vested and expected to vest (in dollars)</a></td>
<td class="nump">38.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total compensation cost not yet recognized (in dollars)</a></td>
<td class="nump">$ 36.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which compensation cost is expected to be recognized as expense</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cldx_StockOptionAndIncentivePlan2008Member', window );">2008 Plan | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at the beginning of the period (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(26,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at the end of the period (in shares)</a></td>
<td class="nump">19,500<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value (per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 14.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">25.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">22.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 25.41<span></span>
</td>
<td class="nump">$ 14.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise price as a percentage of the fair market for options granted to the holders of than 10 percent of voting stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time, from the grant date until the time at which the share-based option award expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of options granted to the holders of more than 10 percent of voting stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTermForHoldersOfMoreThanTenPercentOfVotingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of voting stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsThresholdPercentageOfVotingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cldx_CelldexResearchEquityIncentivePlan2005AndCuraGenStockPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cldx_StockOptionAndIncentivePlan2008Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cldx_StockOptionAndIncentivePlan2008Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790714416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - VALUATION AND EXPENSES INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Valuation and Expenses Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense (in dollars)</a></td>
<td class="nump">$ 12,774<span></span>
</td>
<td class="nump">$ 6,852<span></span>
</td>
<td class="nump">$ 4,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ExpectedDividendPayableInForeseeableFuture', window );">Expected dividend payable in foreseeable future</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used for fair values of employee and director stock options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum (as a percent)</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum (as a percent)</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (as a percent)</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (as a percent)</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Valuation and Expenses Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense (in dollars)</a></td>
<td class="nump">$ 6,186<span></span>
</td>
<td class="nump">$ 3,459<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Valuation and Expenses Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense (in dollars)</a></td>
<td class="nump">$ 6,588<span></span>
</td>
<td class="nump">$ 3,393<span></span>
</td>
<td class="nump">$ 1,908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ExpectedDividendPayableInForeseeableFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of expected dividend payable in foreseeable future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ExpectedDividendPayableInForeseeableFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cldx_EmployeeConsultantAndNonEmployeeDirectorStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804810304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May. 31, 2014</div></th>
<th class="th"><div>May. 31, 2005</div></th>
<th class="th"><div>May. 31, 1995</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,368<span></span>
</td>
<td class="nump">$ 5,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RevenueFromProductDevelopmentAndLicensingAgreements', window );">Product development and licensing agreements revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RevenueFromContractsAndGrants', window );">Contracts and grants revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Product royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cldx_BristolMeyersSquibbCompanyMember', window );">BMS | PD-1 Immune Checkpoint Inhibitor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementAgreementTerm', window );">Term of the agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ReimbursementOfExternalCostsIncurredPercentage', window );">Reimbursement of external costs incurred by the company (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RevenueFromProductDevelopmentAndLicensingAgreements', window );">Product development and licensing agreements revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cldx_RockefellerUniversityMember', window );">Rockefeller</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_RevenueFromContractsAndGrants', window );">Contracts and grants revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember', window );">Collaboration arrangement for development and commercialization of oral rotavirus strain | Glaxo | Rotarix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Product royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">License agreements | Cincinnati Children's Hospital Medical Center | Rotarix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived', window );">Percentage of license fee payable on net royalties received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_RoyaltyAgreementMember', window );">Royalty Agreement | PRF | Rotarix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_PercentageOfInterestInNetRoyaltiesSold', window );">Percentage of interest in net royalties sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_CollaborativeArrangementAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of the collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_CollaborativeArrangementAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_PercentageOfInterestInNetRoyaltiesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of interest in net royalties sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_PercentageOfInterestInNetRoyaltiesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of license fee payable to third party on net royalties received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ReimbursementOfExternalCostsIncurredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of reimbursement of external costs incurred by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ReimbursementOfExternalCostsIncurredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_RevenueFromContractsAndGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents revenue earned during the period arising from products sold or services provided under the terms of a contract. Also include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_RevenueFromContractsAndGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_RevenueFromProductDevelopmentAndLicensingAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents revenue from product development and licensing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_RevenueFromProductDevelopmentAndLicensingAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_BristolMeyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_BristolMeyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cldx_Pd1ImmuneCheckpointInhibitorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cldx_Pd1ImmuneCheckpointInhibitorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_RockefellerUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_RockefellerUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_GlaxoSmithKlinePlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_GlaxoSmithKlinePlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cldx_RotarixRotavirusVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cldx_RotarixRotavirusVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_CincinnatiChildrensHospitalMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_CincinnatiChildrensHospitalMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cldx_RoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cldx_RoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_PRFAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_PRFAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791358480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS (Details) - License agreements - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_NonRefundableLicenseFee', window );">Nonrefundable license fee expense</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Medarex | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct', window );">Period from the first commercial sale of licensed product for royalty payment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Rockefeller | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Duke | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Ludwig | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Alteris | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Southampton | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Amgen | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Seattle Genetics | CuraGen | Maximum | Glembatumumab Vedotin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember', window );">Seattle Genetics | CuraGen | Maximum | CDX-014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments', window );">Milestone payment due</a></td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period from the first commercial sale of licensed product for royalty payment under the collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_CollaborativeArrangementRoyaltyPaymentPeriodFromFirstCommercialSaleOfLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_CollaborativeArrangementTotalPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total amount of potential milestone payments to be made by the entity based on terms of the collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_CollaborativeArrangementTotalPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_NonRefundableLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of nonrefundable license fee expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_NonRefundableLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_MedarexIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_MedarexIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_RockefellerUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_RockefellerUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_DukeUniversityBrainTumorCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_DukeUniversityBrainTumorCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_LudwigInstituteForCancerResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_LudwigInstituteForCancerResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_AlterisTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_AlterisTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_UniversityOfSouthamptonUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_UniversityOfSouthamptonUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cldx_SeattleGeneticIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cldx_SeattleGeneticIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cldx_CuraGenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cldx_CuraGenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cldx_GlembatumumabVedotinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cldx_GlembatumumabVedotinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cldx_Cdx014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cldx_Cdx014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792787824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - SUMMARY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Income tax benefit (provision):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,598<span></span>
</td>
<td class="nump">$ 43,536<span></span>
</td>
<td class="nump">$ 30,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,642<span></span>
</td>
<td class="nump">7,328<span></span>
</td>
<td class="nump">4,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits', window );">Expiration of Net Operating Losses and Research &amp; Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="num">(2,302)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance', window );">Income tax benefit (provision) before valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,085<span></span>
</td>
<td class="nump">48,562<span></span>
</td>
<td class="nump">35,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (57,085)<span></span>
</td>
<td class="num">(48,562)<span></span>
</td>
<td class="num">(35,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation between the amount of reported income tax and the amount computed using U.S. Statutory rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Statutory rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Pre-tax loss</a></td>
<td class="num">$ (32,684)<span></span>
</td>
<td class="num">$ (31,980)<span></span>
</td>
<td class="num">$ (32,359)<span></span>
</td>
<td class="num">$ (30,174)<span></span>
</td>
<td class="num">$ (31,821)<span></span>
</td>
<td class="num">$ (28,082)<span></span>
</td>
<td class="num">$ (28,274)<span></span>
</td>
<td class="num">$ (29,903)<span></span>
</td>
<td class="num">$ (127,197)<span></span>
</td>
<td class="num">(118,080)<span></span>
</td>
<td class="num">(81,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Loss at Statutory Rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,247)<span></span>
</td>
<td class="num">(40,147)<span></span>
</td>
<td class="num">(27,727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and Development Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,935)<span></span>
</td>
<td class="num">(4,126)<span></span>
</td>
<td class="num">(3,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,642)<span></span>
</td>
<td class="num">(7,328)<span></span>
</td>
<td class="num">(4,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits', window );">Expiration of Net Operating Losses and Research &amp; Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,085<span></span>
</td>
<td class="nump">48,562<span></span>
</td>
<td class="nump">$ 35,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Gross Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss Carryforwards</a></td>
<td class="nump">180,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,777<span></span>
</td>
<td class="nump">95,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax Credit Carryforwards</a></td>
<td class="nump">35,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,895<span></span>
</td>
<td class="nump">29,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Deferred Expenses</a></td>
<td class="nump">48,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,608<span></span>
</td>
<td class="nump">85,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based Compensation</a></td>
<td class="nump">8,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,393<span></span>
</td>
<td class="nump">5,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Revenue</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">2,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Accrued Expenses and Other</a></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross Deferred Tax Assets</a></td>
<td class="nump">277,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,612<span></span>
</td>
<td class="nump">220,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Gross Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets', window );">Other Acquired Intangibles</a></td>
<td class="num">(3,382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,382)<span></span>
</td>
<td class="num">(3,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets', window );">IPR&amp;D Intangibles</a></td>
<td class="num">(4,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,661)<span></span>
</td>
<td class="num">(4,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross Deferred Tax Liabilities</a></td>
<td class="num">(8,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,043)<span></span>
</td>
<td class="num">(8,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DeferredTaxAssetsLiabilitiesGross', window );">Total Deferred Tax Assets and Liabilities</a></td>
<td class="nump">269,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,569<span></span>
</td>
<td class="nump">212,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets Valuation Allowance</a></td>
<td class="num">(274,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(274,230)<span></span>
</td>
<td class="num">(217,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net Deferred Tax Asset (Liability)</a></td>
<td class="num">$ (4,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,661)<span></span>
</td>
<td class="num">$ (4,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from in-process research and development intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from other acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the amounts of net operating losses and research and development tax credits expired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations before the effect of the change during the period in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to expiration of net operating losses and research and development tax credits under enacted tax laws during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph b(2)<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from other provisions, reserves, allowances, and accruals not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 1<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)-(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6804744256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - CARRYFORWARDS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which the entity primarily operates or has operated and has income tax nexus | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cldx_CuraGenCorporationMember', window );">CuraGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized', window );">Assets recorded for net operating losses not yet utilized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange', window );">Period of recognition of unrealized loss or gain after the ownership change</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | R&amp;D credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse', window );">Tax credit carryforwards with substantial limitations on use</a></td>
<td class="nump">28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Ownership Change in December 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">178,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Annual limitation</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Ownership changes in June 2009 and December 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">67,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Annual limitation</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Prior to merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | CuraGen | Prior to acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">518,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | AVANT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">392,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossCarryforwardsWithLimitationsOnUse', window );">Loss carryforwards with limitations on use</a></td>
<td class="nump">40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized', window );">Loss carryforwards remotely likely to be utilized in future periods</a></td>
<td class="nump">60,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | AVANT | Prior to merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization', window );">NOL, net of expirations and utilization</a></td>
<td class="nump">101,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse', window );">Net operating loss carryforwards with substantial limitations on use</a></td>
<td class="nump">382,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | R&amp;D credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse', window );">Tax credit carryforwards with substantial limitations on use</a></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of deferred tax assets attributable to deductible operating loss carryforwards not yet utilized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_DeferredTaxAssetsOperatingLossCarryforwardsNotYetUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the net operating loss carryforward with substantial limitations on use before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_NetOperatingLossCarryforwardsWithSubstantialLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_OperatingLossAndTaxCreditCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_OperatingLossAndTaxCreditCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_OperatingLossCarryforwardsAnnualLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the annual limitation on operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_OperatingLossCarryforwardsAnnualLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of domestic, foreign and state and local operating loss carryforwards, net of expirations and utilization but before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_OperatingLossCarryforwardsNetOfExpirationsAndUtilization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the operating loss carryforwards that are remotely likely to be utilized in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_OperatingLossCarryforwardsRemotelyLikelyToBeUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_OperatingLossCarryforwardsWithLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the operating loss carryforwards with limitations on use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_OperatingLossCarryforwardsWithLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period of recognition of unrealized gain (loss) after ownership change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_PeriodOfRecognitionOfUnrealizedGainLossAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, with substantial limitations on use before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_TaxCreditCarryforwardAmountWithSubstantialLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of the amount recognized for uncertain tax positions as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cldx_CuraGenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cldx_CuraGenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_OwnershipChangeAxis=cldx_OwnershipChangeInDecember2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_OwnershipChangeAxis=cldx_OwnershipChangeInDecember2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_OwnershipChangeAxis=cldx_OwnershipChangesInJune2009AndDecember2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_OwnershipChangeAxis=cldx_OwnershipChangesInJune2009AndDecember2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_StatusOfMergerAndAcquisitionAxis=cldx_PriorToMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_StatusOfMergerAndAcquisitionAxis=cldx_PriorToMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cldx_StatusOfMergerAndAcquisitionAxis=cldx_PriorToAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cldx_StatusOfMergerAndAcquisitionAxis=cldx_PriorToAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cldx_AVANTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cldx_AVANTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791999104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Obligations for base rent and CAM costs under facility and other non-cancelable operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016</a></td>
<td class="nump">$ 3,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2017</a></td>
<td class="nump">3,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2018</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2019</a></td>
<td class="nump">2,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2020</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">13,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Total rent and CAM expense</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6769739360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT SAVINGS PLAN (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>RETIREMENT SAVINGS PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum contribution by participants (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer match (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum percentage of employees' gross pay subject to employer match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Benefit expense for the 401(k) Plan</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost recognized during the period for defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793475424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 2,178<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">$ 1,101<span></span>
</td>
<td class="nump">$ 592<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 5,480<span></span>
</td>
<td class="nump">$ 3,586<span></span>
</td>
<td class="nump">$ 4,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss</a></td>
<td class="num">$ (32,684)<span></span>
</td>
<td class="num">$ (31,980)<span></span>
</td>
<td class="num">$ (32,359)<span></span>
</td>
<td class="num">$ (30,174)<span></span>
</td>
<td class="num">$ (31,821)<span></span>
</td>
<td class="num">$ (28,082)<span></span>
</td>
<td class="num">$ (28,274)<span></span>
</td>
<td class="num">$ (29,903)<span></span>
</td>
<td class="num">$ (127,197)<span></span>
</td>
<td class="num">$ (118,080)<span></span>
</td>
<td class="num">$ (81,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;"]S='EL97,N>&ULS5=M;YLP$/XKEE--K30%2)2T70%IJA1ITE9-:C[L6V7
M$$M^8<9DI+]^-B9 D-(F7;>1+S[.=\\]OCLXQR_4CN+'#<8*5(SR(H ;I?)/
MCE/$&\Q0,14YYGHG%9(AI1]EYA2YQ"@IC!.CSLQUEPY#A,/0YR5;,56 6)1<
M!7#1JH#UOQ<)#N#3Y8>?I5!W%\"NDX^3B3MUGZ[NACN7S=85!!;G2Q) ;[F
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M?&\<N5HDA2IG)^JF_P8<"W"L2TX4TYC-F:\8P90$"Q;2F =^1*@_(6X 0#8
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MRI^&:=.-V]WR;K[L#.WEXZ^&^_\=NW\!4$L#!!0    ( -915TA,@(B*+P(
M )$'   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC97+CILP%(9?!?$
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MY_.Z_PUVE[KQQ;O)(BC27\,Q*_OC=?C'B-&,-Y"C@;P90/RI@1H-U(>!_M1
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M,5>+!%6-TVUD_BP58*;F ?5#BA[0&ZV,0HNX83 I8BFQ:HI!FUO1C&RVD+Z
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M5T63YDN<(INJ7%\O=M5SUW_U\7MS/HP_7W3U\?U_"]=_<,S^ U!+ P04
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M#?]G-A34/A[OPMF.(S4:'KOI@\R_M/@'4$L#!!0    ( -915TAEF*S[GP$
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MSK]L['^-Z,!+2:ZN*6G]_UD,!;4+QV_^;*:1F@R'_>6#++^T^ -02P,$%
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MT/AX_!S.=AJIR?#87S_(\DO+/U!+ P04    " #645=(W%A?[9\!  "Q P
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MH?,O&_O?(#KP4I*K:THZ_W\60T+CPO&;/YMII";#87_Y(,LO+?\!4$L#!!0
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M]K]&=."E)%?7E+3^_\R&A-J%XZT_FW&D1L-A=_D@\R\M?@-02P,$%     @
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MLN<'=FGUF[C]X/<SS"WA3K3*_2:[B]*B>X2D2<<^AVO3N^MM>++$>Q@=@/<
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M_B4)7?54@6GCZ%A2X:#CH*Z\RW0^L/@FG^%ET?,6GKEIA;;D@LZ_;.Q_@^C
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M 6P!W*51^)0HROS)'2\+@R,Q4VM['EYPMV>^$55PQKKCG1=JO?=<LNRNH.=
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M_FS&D1H-A]WE@\R_-/\/4$L#!!0    ( -915T@:[/*@QP$  . $   9
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MQ@2OKB 'U?A.TZB4@_!]O8HNS?Q _!7^@A=Y3QMXIJKIA$87:6PC^.M:2VG
MIA+?V5-M[7.S+!C4QDTS.U=3!TX+(_O;>[(\:L5?4$L#!!0    ( -915TBV
MQEMUN@$  'L$   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;'54W6ZD
M(!1^%>(#%(<9W>[$,>ETTW0O-FEZL7O-Z%%)^7$!Q^[;+Z!CC:4W H?OYQSD
M4(Q*OYD.P*)WP:4Y)9VU_1%C4W4@J+E3/4BWTR@MJ'5+W6+3:Z!U( F.29KF
M6% FD[((L1==%FJPG$EXT<@,0E#][PQ<C:=DE]P"KZSMK _@LL +KV8"I&%*
M(@W-*7G8'<^Y1P3 ;P:C6<V1S_VBU)M?_*Q/2>I3  Z5]0K4#5=X!,Z]D#/^
M.VM^6'KB>GY3?PK5NNPOU,"CXG]8;3N7;)J@&AHZ</NJQF>82\B\8*6X"5]4
M#<8J<:,D2-#W:60RC..T<Y_.M#B!S 2R(>#)**3Y@UI:%EJ-2$]'VU/_!W='
MX@ZB\L%0=]ASB1H7O98D^U[@JQ>:,><)0U:8W8+ 3GVQ(#&+,_E$)W'Z/IKA
M/M#W:_?[+_P/48%#$#BL_?-T4V(,\X5)%C7)(@)D8Q+#[.,F>=0DCP@<-B8Q
M3+8QP:O;(4"WH0D,JM0@0\NMHDN?/9!PNS[@9='3%GY1W3)IT$59=T?#36J4
MLN!22>]<P9U["98%A\;ZZ3<WUU-S3 NK^ENK+^]-^1]02P,$%     @ UE%7
M2%V2V:&A 0  L0,  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL;5/!
MCML@$/T5Q <L#LEFH\BQM-FJ:@^55GMHS\0>VVB!<0''V[\O8,?KIKX ,\Q[
M\V88\@'MNVL!//G0RK@3;;WOCHRYL@4MW -V8,)-C58+'TS;,-=9$%4":<5X
MENV9%M+0(D^^5UODV'LE#;Q:XGJMA?US!H7#B6[HS?$FF]9'!RMR-N,JJ<$X
MB898J$_T>7,\[V)$"O@I87"+,XG:+XCOT?A>G6@6)8""TD<&$;8KO(!2D2@D
M_CUQ?J:,P.7YQOXU51O47X2#%U2_9.7;(#:CI():],J_X? -IA(>(V&)RJ65
ME+WSJ&\02K3X&'=ITCZ,-X=L@JT#^ 3@=P V)DHROP@OBMSB0.S8VD[$%]P<
M>6A$&9VI[G07A+K@O19\O\_9-1)-,><QAB]B-G,$"^QS"KZ6XLS_@_-U^'95
MX3;!M\OLA^TZP6Z58)<(=O^4^'17XEK,X2X)6_14@VW2Z#A28F_2H"Z\\W0^
M\_0FG^%%WHD&?@C;2./(!7UXV=3_&M%#D)(]/%+2AO\S&PIJ'X]/X6S'D1H-
MC]WM@\R_M/@+4$L#!!0    ( -915TBVH2AUHP$  +$#   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;&U3P8[;(!#]%<0'+ Y)-FGD6-IL5;6'2JL]
MM&=BCVVTP+B X^W?%[#CM;:^ #/,>_-F&/(![9MK 3QYU\JX,VV][TZ,N;(%
M+=P#=F#"38U6"Q],VS#761!5 FG%>)8],BVDH46>?"^VR+'W2AIXL<3U6@O[
M]P(*AS/=T+OC53:MCPY6Y&S&55*#<1(-L5"?Z=/F=-G%B!3P2\+@%F<2M5\1
MWZ+QHSK3+$H !:6/#")L-W@&I2)12/QGXOQ(&8'+\YW]6ZHVJ+\*!\^H?LO*
MMT%L1DD%M>B5?\7A.TPE["-AB<JEE92]\ZCO$$JT>!]W:=(^C#?[XP1;!_ )
MP&? ,4O"QT1)YE?A19%;'(@=6]N)^(*;$P^-**,SU9WN@E 7O+>"/W[)V2T2
M33&7,88O8C9S! OL<PJ^EN+"_X/S=?AV5>$VP;?+[,?#.L%NE6"7"';+_(?L
M4XEK,9^+9(N>:K!-&AU'2NQ-&M2%=Y[.)Y[>Y".\R#O1P$]A&VD<N:(/+YOZ
M7R-Z"%*RASTE;?@_LZ&@]O%X"&<[CM1H>.SN'V3^I<4_4$L#!!0    ( -91
M5TBEN.G3S@(  +L*   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(V6
M77.B,!2&_PK#?0L)WPXR4^R7UIWI]&+W.M6H3(&X)-;NO]\D($H\V^5&(#SO
M.2\Y)R;ID34??$>IL+ZJLN93>R?$?N(X?+6C%>&W;$]K^6;#FHH(^=AL';YO
M*%EK454ZV'5#IR)%;6>I'GMMLI0=1%G4]+6Q^*&J2/,GIR4[3FUDGP;>BNU.
MJ $G2YU>MRXJ6O."U59#-U/[#DV6D2(T\+.@1WYQ;RGO[XQ]J(?Y>FJ[R@(M
MZ4JH"$1>/NF,EJ4*)!/_[F*>4RKAY?TI^J/^6NG^G7 Z8^6O8BUVTJQK6VNZ
M(8=2O+'C,^T^(5 !5ZSD^M=:';A@U4EB6Q7Y:J]%K:_']DT0=3)8@#L![@4X
M^%;@=0+O+$#?"OQ.X(\5!)T@&"L(.T$X5A!U@FBL(.X$\5A!T@F2L0)5\[9R
M[MA*H+[8:'264[D1-B1.VUBZ+>^)(%G:L*/5M$MI3]2*11.IDL'5J&YT_5)V
M)I>CGQF.<.I\JD@=D[<,'C#>D%E<,Z@G'&FA]X%!'SD&<OC#'#.("8;,/<2$
M0^8!8J(A\P@Q\9!Y@IADR#P#3.P.F3G$(&-^1\S/RPC/2R@7ABOEP1WCZ0C>
M9:7]!([@PQ%\'<$?>##Z*6^94#.U9HQ*+[XC!BX"V$4 N#!F-&^9^"('CI/$
M-0JX^"\V\!/"?L(K/['QR7EXE>?&PZ'I>@9A*#';[AZ,Y@5&!S] F(O,YGL$
MD\;8Z.,G ),+(C;^<IY![*KCYQ F)][\<PJO6N4&X0@EQJ)_ <(A)-T9,[<$
MN!@%P3_J'<'UCH#^,WL\NDZ4Q'%L^@8PY*+ ,[@EP(51&)JKU[G8/2K:;/6A
MB%LK=JB%6OD7H_VYZPZKW<<8S]%DCH#QA3RGM;O5.7R6[LF6_B#-MJBY]<Z$
MW/7TQK1A3%#IWKV5RVPG3Y+]0TDW0MU&\KYI#U?M@V#[TU&Q/Z]F?P%02P,$
M%     @ UE%72*:\V$0A @  TP8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&ULC57+CILP%/T5Q >,>05(1)"&1%6[J#2:1;MVB -H;$QM)TS_OK8A
MA)#;:#;8OC[GW(?Q==9S\2%K0I3SR6@KMVZM5+=!2)8U85B^\(ZT>N?$!<-*
M+T6%9"<(/EH2HRCPO!@QW+1NGEG;F\@S?E:T:<F;<.29,2S^%H3R?NOZ[M7P
MWE2U,@:49VCB'1M&6MGPUA'DM'5?_<W>]PS$(GXUI)>SN6."/W#^818_CEO7
M,S$02DIE)+ >+F1'*#5*VO.?4?3FTQ#G\ZOZ-YNN#O^ )=EQ^KLYJEI'Z[G.
MD9SPF:IWWG\G8PXK(UAR*NW7*<]2<7:EN [#G\/8M';LAYW4&VDP(1@)P43P
MXZ>$<"2$-T+TE!"-A&A!0$,JMA![K'">"=X[8CB]#IN?Q-]$NM2E,=K*VCU=
M"JFMESQ(XPQ=C-"(*09,,,/X$P)I]<E% +DH@@=Z<.]@]X@(O7O(_A&2>' 0
M(9AG:/GA/(?U?P0B4""R M%=H9)%H09,;#'MLT*M0!<KP$4*"\2@0/R09)"N
M88$$%$@>(U@O3J* ,/[B0"',XM#W$":$@TW!8%- (((%UJ# ^NOE,KT#NCW>
M%PH&@E:+BH&@Q47<@Z!D$3&:77U&1&5[J'1*?FZ5N4$SZ]2G7P/3.A;VPO1O
MVU)N,GG6X8K\Q*)J6ND<N-*-R;:/$^>*Z!B]%_T7U_J%F1:4G)29)GHNAIX[
M+!3OKD_(]([E_P!02P,$%     @ UE%72/^55<<> @  H@<  !D   !X;"]W
M;W)K<VAE971S+W-H965T-# N>&ULE57!;J,P$/T5Q <4;!)((H*4=+7:/:Q4
M];![=L@DH-J8M9W0_?NU34)I.TCT$MO#>V_F.;8G[Z1ZT16 "5X%;_0VK(QI
M-U&DRPH$TP^RA<9^.4DEF+%+=8YTJX =/4GPB,9Q&@E6-V&1^]B3*G)Y,;QN
MX$D%^B($4__VP&6W#4EX#SS7Y\JX0%3DT< [U@(:7<LF4'#:ACNRV9/,03SB
M=PV='LT#5_Q!RA>W^'G<AK&K 3B4QDDP.USA$3AW2C;SWYOH6TY'',_OZM^]
M75O^@6EXE/Q/?325K38.@R.<V(6;9]G]@)N'I1,L)=?^-R@OVDAQIX2!8*_]
M6#=^[/HOV>I&PPGT1J #@:2^\#Z1+_,;,ZS(E>P"U>]MR]Q?2#;4;D3I@MZW
M_V8+U39Z+>AZE4=7)W3#['L,'6'(@(BL^I""8BGV]!.=XO0$K3#Q],6["M>X
MP (56'B!9"20Q#$NL$0%EI\J2&+R88\PS(3-%$V2(@()+I"A ME\FRM48#7#
M)H:9L+E&DZP1@04NX&X3=F+C^4;)Q*$G,ZRBH.5$'O3D[PA%)-()"?STD^0+
M;O'S3Q9SW&*@;"(/?DT(=@=6$Q+X)2#I%]SBUX!D<]QBH(^/2C1Z0P6HLV\5
M.BCEI?&=:10=VM&.^C?X#5[D+3O#+Z;.=:.#@S3V)??O[4E* [:6^,%N6V4;
MYK#@<#)NFMFYZEM(OS"RO7?$H2T7_P%02P,$%     @ UE%72 [2G/^7 0
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MBL-LM7;@];+%)4:=?SU3(*!U8;OT>Y-^J!0XW1^?Q_1&JV]02P,$%     @
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M=W7=N3ZF^=3'W+MB>_U1NETW?$W[[\UT3CO]Z.K3Q['S]>Q[]1]02P,$%
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MZV%3BITR2Z[733=K=ALECY?1>9C?L_]02P,$%     @ UE%72*>E3>Z# P
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MQNO K1,).4FDDHBQ)6'F$5@I&7\YX$2W9L)H)  TX]/(B:9]ITS$;$0)8X\
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MMV4[>FKD"S]_9^,:8BVXX8TPO][F)"1O+R&^U]+WX5AWYG@>[F3A& 8'X#$
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MO91*:.WH06L_ZD-7]Y")O:ION;XOFV-(\Z#DZ7JJZHYV\W]02P,$%     @
MUE%72-M7_-SR @  ;@T  !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&UL
ME5?!;J,P$/T5Q <$/ :25 2I:;3:/:Q4];![=A,G006<8J?I_OW:AE "XXI<
M I@W;^8-?K&=7D3])H^<*^^S+"JY\H]*G1Z"0&Z/O&1R)DZ\TF_VHBZ9TH_U
M(9"GFK.=#2J+ ,(P"4J65WZ6VK'G.DO%615YQ9]K3Y[+DM7_UKP0EY5/_.O
M2WXX*C,09&G0Q>WRDE<R%Y57\_W*?R0/&PH&8A%_<GZ1O7O/%/\JQ)MY^+5;
M^:&I@1=\JPP%TY</_L2+PC#IS.\MZ5=.$]B_O[+_L')U^:],\B=1_,UWZJBK
M#7UOQ_?L7*@7<?G)6PVQ(=R*0MI?;WN62I37$-\KV6=SS2M[O31O%F$;A@=
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M3AY?J[HX?(1,)X?L3_^Y.W:?[_U_#!O"Z  8 N 4<!J'#A!#@/@,B+X,B(:
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M>+00EP-DG67#M$83:$5PL9082P+ETE$Y^Q[,X^U V+9$0RT'R.Z?3(PN[XK
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MU^?I"031$RB\CH5KSZ!BJ? 617$<(H/7<:!>.JYGU^CI"P31%RCL+X*\^8T
M/TI>D2#7W'EH%ZJ8!BC:=?J>45,] NY?!\B,K,4P+ G#TE&LKV]V]M[FD)?/
MW>O(:O)8O![K=A\^.WIZY7D-[7L?='S)+^\Y<3SAE^O^A>:G_&+^DCWG?V7E
M\^Y831Z*NBX.W2NAIZ*H\R9[]JWQRVV>;4X_]OE3W7[5S?>R?ZW9_ZB+EX^W
MM*=7Q8O_ 5!+ P04    " #645=(KTKA59(#   <$@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6R5F-UNHS 0A5\%\0 %CPV8*HG49K7:O5BIZL7N
M-4V<!!5P%DC3??OEKRG!QU6X"6!FYG@</H_MQ5F7K]5!J=IYS[.B6KJ'NC[>
M>UZU.:@\J>[T417-FYTN\Z1N'LN]5QU+E6P[ISSSR/=#+T_2PETMNK:G<K70
MISI+"_54.M4ISY/RWZ/*]'GI,O>CX3G='^JVP5LMO(O?-LU54:6Z<$JU6[H/
M['XMPM:DL_B=JG,UNG?:SK]H_=H^_-PN7;_M@\K4IFY#),WE3:U5EK61&N6_
M0]!/S=9Q?/\1_7N7;M/]EZ12:YW]2;?UH>FM[SI;M4M.6?VLSS_4D$/0!MSH
MK.I^G<VIJG7^X>(Z>?+>7].BNY[[-](?W+ ##0YT<:#@2P<^./!/AS[3OF==
M7M^2.EDM2GUVRO[/.";M?\[N>3-RF[:Q&ZCN79-9U;2^K8)0+KRW-M!@\]C;
MT,B&72R\)OI%@I#$(QGN%(EKB36RD5B$PSQX%X!?Y1'C  (&$%T ,0X0^9.!
MZ&UD9U/T Q%%OH]E B@3 !DVD>EMPI&,12*$$B&0H(E$:&0RR77]E<55)R+8
MB0AT@D\Z$1EY<BPAH80$$@('B&& ^/9OIIT*$#T^Z$,PQ<>_=2B9A5%FJ@@+
M@@PR^,!H1JZ8,,9!KN$T5].(^V31P2 R1&)D"8$A8\&,;#%$#%%D3(PF).1+
MVX3 ,"D,H1)/E4Q62 96)0P, \1(6PB,#)O!#&%F"#$SG6D'H_!JJI76N98P
M. 3 D=/9=C :2[63NDT)\T4$E"S?/6&^:$8)(XP.W5+$!J-QOJ&]BA$FC$ =
M,T?6+&2A?6 QAP0XE)8R01@PBF8,+":'4*TQ!E::]8S;\\6 40SRM50UC@'C
M_NWY<@P.!^ 8^7(3G(!);DN88W(X(B>PA+"L_6:0PS$Y_!9RN$D.CRFV)HS1
MX0B=:1WE)CK"%U8ES Y'[$13I1! :JUA'"/&00V3MO4[1HS+&7\B9H<C=J:5
M=#"ZJBP^(UO" C,F0!$3EOE>8,8$F[%EP>P(P$YL;%K(_&HE63$5F#$!5G^Q
M90TJ+#LL,2-AS(Y VZ?IJDR8[#!A94=@=@1:_TV_)6&N_QCXE+S19CQ7Y;X[
MI*B<C3X5W9G(J/5R$/) W6;^TWRU."9[]2LI]VE1.2^ZKG7>;=QW6M>JZ8U_
MU^1]4,GV\I"I7=W>1LU]V1]>] ^U/GZ<Q5P.A%;_ 5!+ P04    " #645=(
MDB5!TST"   L!P  &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R%5<V.
MFS 0?A7$ RS&_$<$:9.H:@^55GMHSPYQ EK U';"]NUK&\(2,[N]Q/;P_<PX
M]C@?&'\3%:72>6^;3FS=2LI^XWFBK&A+Q!/K::>^G!EOB51+?O%$SRDY&5+;
M>!BAV&M)W;E%;F(OO,C9539U1U^X(ZYM2_C?'6W8L'5]]QYXK2^5U &OR+V9
M=ZI;VHF:=0ZGYZW[[&\./M(0@_A5TT$LYHY._LC8FU[\.&U=I'.@#2VEEB!J
MN-$];1JMI)S_3*(?GIJXG-_5OYER5?I'(NB>-;_KDZQ4MLAU3O1,KHU\9<-W
M.M40:<&2-<+\.N552-;>*:[3DO=QK#LS#N.7%$TTF( G IX)?OPE(9@(P0<A
M_)(03H30(GAC*68C#D22(N=L</CX[_5$'Q)_$ZJM+G70[*SYIK9"J.BMB#*<
M>S<M-&%V(P8O,/Z,\)3Z;($ABQU>T2V#_1H1H$?(80U)$)Q$ -89&'[P4&<
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M!6XM</L*O%K@]17XM<#O*PAJ0=!7$-:"L*] >UXY1VX2[VM)8S;MG>5J-V5
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ME2 QU@()N7$TN/JXJ9#;#%(C7*WTPFTY\=(CTTDY;T+_2NJT',810#V9]IA
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MJ@%R K4>(2TPBZ%@9-:M"OT#C'+AI;2ZU!-N5J&Z'JX9)6-NRM<!1;&8Y=W
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MY$8QCZ 3(*N<VY=\/*T-6\H-]I@*%-P15 !A=/+HKD28>+VW-[!%4 S:I<&
M'983VOG=]^_>Z-L+6 BB?7'+N67ZTGW?D,=<^9HKQ-A@Y$F+K<I8%8B1S:*C
MCR;B("P%(XU@"%H/4=GZ;&%#>&_+@C&G%)Y:W]6?$[08#57FD-:VEUR%;B\H
M)U3.?,K%IA<DI  YMFZLX)124(F0*;XO@+KPG*:'6DU]H,#P2"6F-/=%D27O
M<7A[!QJ8E\I &(KP6_0;X'QN]IWL';15^%M"J$!\+8M!9]'2:Z>:8DT79%LF
M<UYR\HC#L.7!V<AD0>X(09WJ@+HW49 T,')&O69,V";R,,;ZU-MV7@Q8CD8
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M"?0"<RD'"3]+J) DE+[_FLWG-O&),:U[2W)UK'9X^)>M_9U=SJP]?+V38+
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M"3T8+]B.0)1(]<VI/Q*2(]GI%KZ"!\*Y?K@5\F\.57\@I 9[-HKLRZ*EY(F
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M\8*-VKTI#$CP,"0<CHL44ZC4IOSO8XKPU*Q43BDZJY!'J%&Y):AM^PY%9O!
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M&O.Z;X@<&T#%9DET(+UF)M2Y>LY^'XY)K@H'>DQA=4I3<<&;QE\_8 06$VS
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MIUBJ^Y?*JB\,KY?O(R 72BUED82%K0D?4+ZB0T0S=Z895&3E [V _#6"AF*
M&D+7E2_TBQQYAU:9_S-;FQ'M+W?X.E8/?63K@\^%VL:+EO@0:(LM!R/[SK)<
M5&8GOJCK%KZ>>;E9B=;ZR4F)GBM,:* <!':SF8;\I"Z^C:M*JEJJ&\8(FNT9
M1A0??MPDY3FM14O&_.YM=I^3%&:E,TZN]-(<8B-M38*G6-LY4NHHFJU@U\KB
MZR?V5&%]SB*9(-:VH%6T::*07CE]C-0)<BH">RR634N]1;H5B,LA\6)<=U8;
MBM.OD-%%@B[YKE71$5R52&)K^B8L.D?_X)UN12 .2U&&Y$ZC#&@MU4HWZD4<
ME$5]"$9-S.D/"SA0412.V^<Y/CF1P"X)5F:'#^=^*)L)A<6;6H7HP$ZGX\74
MC\T)Q*&(Z(W^07:=6OB$8."V\)D]*[WCI9 \'0Q%(CZ8,S#9K^(LX0DR*6*(
M+P.#+V?YF 5.J22.Y;Q654N%/J)&@X#3?BK+"6:6D,CI (L\Y#0;D"*6WF(2
M6?UUI<0EW)CB,\JQJ85T+T/;3LP@J2J$S2#ZAQZ,MNO 43 )VD2V'B6C'F3=
M(R8#<PV0-S/K9$9U,VX=_Z8E-3F<DA6>H72+T7UHJN7#PM-]*K> >\Q=<^TS
M;)%:V7IC#=X>#R#;_%(>8-L7,\?WXP#>M%JC67KB[1"?Q-5K#WD@52AJNDLT
M!X"1G)3%_=8)7?8=,LF+WO9T/$/4M5Q,5.BQE><VQ198V B5H"XM7Z((6IR,
M=&H/U<'0O8!- $&B#9-IP$W+5;,9B^"6'&8ZXX8"^+S!Y\H\CJT:!89<448$
MS281B=89JJS:)#XL)T:8$& :+%(I6\I$I3R6$IN/MHH':8:J#V/FMR*Z26ZV
M?A$JD3>VO-E*$CY^AMD0)7QATR)%;!DIHLV8E087IK-(?,$E9_O% M$CCP26
M TH4=$6A:><5?J1SBHUAK.C0%H=G\X&4U$5:>RF9)6>Y5A4F[$N=P+Q&M074
M8,Q&8NYHZ(.LFJ;XL(NGKM L S__Q%8\BIL@-.K<U5"Y73QG),O=$0(C!F$8
M4@-*_DDLCU1_3]%::,*.Y*#Z53K:V!64>T.%9.B!V[R<@VPW2\<4_JQT*P_$
M6=7E1!E 5:-ZS(B=(M:!M9EUFB-X6TRLM1<C((:T>!T_3ADR!JW"JQI)JK_$
MD[N"G5P4$Q^B?V$-3AE4/X"G]NQZ_5AU+-((;9E P<'V,;!AQUU)8*]:E]65
M9GC@YQBY)XGMBM#$5X+ 4W_/)G%@ S(N,1WBS&N#XV""%HF,U,//T"-%5X4*
M7FH*'2V*W(1,2GPW,185[BV;6GNZ;MVVL+)@XTZB34WGA%.9L>],S"NIZ?.H
MI2W)T/2E+]NNH >1 B:K**M@6S8AJ'CP)%Y]3':%.UU=V.8TH#F47;<<_D&A
M'-*$K:'GERQ"?1:%!,WN4[\_'9+C*-RP-$\0)+R*20X\"%F\F96/V.,8&XW4
M526WK#'@<+)QF&W+31*K()N\/KPNQ+)UVDRZ;W@<[#S$+N- [_L"DO1LDVDD
MJ-4:M1$,J 5R3/GO<'6AK&>"T$ =SNL'[5S696/-K4PEH@SJAQJHMJ)3B.MC
M.45/[5\7$TE8T;["B"?;[;.\*\*SU+^U@!L.[5\+K\2ZO M45DY4??@(O)ND
MD79)5)$'&<+A^$Z@Z>++J'NG$%IC[;%IZ6S(L@MMKWE1VZVAP)@T5.\J,7J[
M=V'XH"V^;,.])<3(<7Q; +Z]S:EC#DNL!UT-64'9'2+AM!RGQSM Q?7JUMD1
M=<9>U%YS=HT,0F5V!S](@;XY^U?$F&6ZPN-85AP"#%?S-+/ *"JH/V 8YFVJ
MILL7YG82+BR!8CZFC'-I'=>V@*X#H+(;Q0$!\1U/6Z*1M\+&)MM:WUY777*)
M,.;JU,' :3>D/(BUMU(N"PO.?$N2PR*;&(.N8:\T58$C:JV;+85B2W[8H&6?
MOIPGS1X]VB%2E2T&9%#M@EN13!W_/ JJ*!]5ZE'9ETD7%?&J#3VJS6]!Q92(
M*-R!NV]@MU_\@@_E[]<MKP/W$D.;LL I0:^61N3Y3LMVTMF336XR@>G(9#A4
M,RAM6G-TNA=HJQXSL:B8>?<E'W/9%W=O85! *["T3](]@L[8YG7P0%^7&A<
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MX^+_3QDW7BI-!!/4\T^LD]7213.=<LCP>R2Y2#C[;\Q]"5A*9$PR&!E:5[)
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M@#13),J@XH<$Q20N>I/:%#,6-8!06"!J/Q_X-@I:LY,R+=:U5YRFS]V4J2W
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M @  7W)E;',O+G)E;'-02P$"% ,4    " #645=(*^YVFQ,"  !Q)   &@
M            @ $F P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #645=(=<X+/Z(#  "B#@  $               @ %Q!0  9&]C
M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -915TC$UQMI/0$  &D#   1
M          "  4$)  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -91
M5TB97)PC$ 8  )PG   3              "  :T*  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ UE%72/G*4R]A @  0@P   T
M ( ![A   'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #645=(>.U_W2 %   .
M$P  #P              @ %Z$P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ UE%72 *I&/B$ @  >@D  !@              ( !QQ@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -915TAKE<1#JP,  /L0   8
M              "  8$;  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #645=(3("(BB\"  "1!P  &               @ %B'P  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ UE%72)=')TW2 P
M6!$  !@              ( !QR$  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( -915TCJX8XB\00  %L9   8              "  <\E
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #645=(IZZC
M!?8$  #L&   &               @ 'V*@  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ UE%72$.4O:>@ 0  L0,  !@
M ( !(C   'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -91
M5TAWM\O,G@$  +$#   8              "  ?@Q  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #645=(._3#?I\!  "Q P  &
M        @ ',,P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ UE%72- U!G2? 0  L0,  !D              ( !H34  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #645=(99BL^Y\!  "Q P
M&0              @ %W-P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( -915TB9;<$ G@$  +$#   9              "  4TY  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ UE%72*<DA;"?
M 0  L0,  !D              ( !(CL  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #645=(B@]%'9\!  "Q P  &0
M@ 'X/   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -91
M5TC\[XR_H $  +$#   9              "  <X^  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ UE%72$M<6<.@ 0  L0,  !D
M         ( !I4   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #645=(NXMVJI\!  "Q P  &0              @ %\0@  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -915TBF<MXZG@$  +$#
M   9              "  5)$  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ UE%72!MA_VF@ 0  L ,  !D              ( !)T8
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #645=(O[(
MXJ !  "Q P  &0              @ '^1P  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( -915TA;19><G0$  +$#   9
M  "  =5)  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MUE%72-Q87^V? 0  L0,  !D              ( !J4L  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #645=(H)?(HY\!  "Q P  &0
M            @ %_30  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( -915TB.UJ\MH $  +$#   9              "  55/  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ UE%72(D8A(VK @
M5PL  !D              ( !+%$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #645=(-K/QQJ$!  "Q P  &0              @ $.
M5   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -915TB2
M2H\QH $  +$#   9              "  >95  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ UE%72)PW3N>C 0  L0,  !D
M     ( !O5<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -915T@(TE0PHP$  +$#   9              "
M ?]@  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ UE%7
M2!KL\J#' 0  X 0  !D              ( !V6(  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #645=(ML9;=;H!  ![!   &0
M        @ '79   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( -915TA=DMFAH0$  +$#   9              "  <AF  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ UE%72+:A*'6C 0  L0,
M !D              ( !H&@  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #645=(I;CIT\X"  "["@  &0              @ %Z:@
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -915TBFO-A$
M(0(  -,&   9              "  7]M  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ UE%72/^55<<> @  H@<  !D
M ( !UV\  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #6
M45=(#M*<_Y<!  "O P  &0              @ $L<@  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -915TAM5GJG/@(  #D'   9
M          "  ?IS  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ UE%72&P6$F9* P  6 \  !D              ( !;W8  'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #645=(DSR$UTL"  !7
M"   &0              @ 'P>0  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( -915TBEFU8$5@0   <7   9              "  7)\
M  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ UE%72):8
MB_GD @  RPL  !D              ( !_X   'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    " #645=(IZ5-[H,#   6$   &0
M    @ $:A   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M -915TA[C-;7_@$  -X%   9              "  =2'  !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ UE%72#G]U>,_ P  "PX  !D
M             ( !"8H  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " #645=($B?)C4D"  "8!P  &0              @ %_C0  >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -915TB B4221@,
M !P.   9              "  ?^/  !X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ UE%72.H$M6U;!0  P!P  !D              ( !
M?),  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #645=(
MR"L2-^4"   [#   &0              @ $.F0  >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( -915TCJ7I8A,0,  .8-   9
M      "  2J<  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ UE%72-M7_-SR @  ;@T  !D              ( !DI\  'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #645=(W=+I17L%   V'@
M&0              @ &[H@  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( -915TBO2N%5D@,  !P2   9              "  6VH  !X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ UE%72)(E0=,]
M @  + <  !D              ( !-JP  'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " #645=("7S?F0,"  #H!0  &0
M@ &JK@  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( -91
M5TA0B+G7$ ,  )X,   9              "  >2P  !X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ UE%72!5F.O@+=@  "^$! !0
M         ( !*[0  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%!@    !% $4
*U1(  &@J 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>177</ContextCount>
  <ElementCount>313</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF BUSINESS AND OVERVIEW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview</Role>
      <ShortName>NATURE OF BUSINESS AND OVERVIEW</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureComprehensiveLoss</Role>
      <ShortName>COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - OTHER LONG-TERM LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities</Role>
      <ShortName>OTHER LONG-TERM LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - TERM LOAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureTermLoan</Role>
      <ShortName>TERM LOAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureRevenue</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements</Role>
      <ShortName>COLLABORATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11701 - Disclosure - RETIREMENT SAVINGS PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan</Role>
      <ShortName>RETIREMENT SAVINGS PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11801 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30303 - Disclosure - COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossTables</Role>
      <ShortName>COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureComprehensiveLoss</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30403 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30503 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30603 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30703 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30803 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30903 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables</Role>
      <ShortName>OTHER LONG-TERM LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31203 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31503 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31803 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40101 - Disclosure - NATURE OF BUSINESS AND OVERVIEW (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverviewDetails</Role>
      <ShortName>NATURE OF BUSINESS AND OVERVIEW (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONCENTRATION OF CREDIT RISK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONCENTRATION OF CREDIT RISK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - FOREIGN CURRENCY TRANSLATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - FOREIGN CURRENCY TRANSLATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - DILUTIVE COMMON SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveCommonSharesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - DILUTIVE COMMON SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40301 - Disclosure - COMPREHENSIVE LOSS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossDetails</Role>
      <ShortName>COMPREHENSIVE LOSS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureComprehensiveLossTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40401 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40501 - Disclosure - MARKETABLE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40601 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40701 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40801 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40901 - Disclosure - OTHER LONG-TERM LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails</Role>
      <ShortName>OTHER LONG-TERM LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - TERM LOAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureTermLoanDetails</Role>
      <ShortName>TERM LOAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureTermLoan</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41101 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41201 - Disclosure - STOCK-BASED COMPENSATION - SUMMARY OF PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - SUMMARY OF PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41202 - Disclosure - STOCK-BASED COMPENSATION - VALUATION AND EXPENSES INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationAndExpensesInformationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - VALUATION AND EXPENSES INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41301 - Disclosure - REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureRevenueDetails</Role>
      <ShortName>REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureRevenue</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41401 - Disclosure - COLLABORATION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreementsDetails</Role>
      <ShortName>COLLABORATION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41501 - Disclosure - INCOME TAXES - SUMMARY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetails</Role>
      <ShortName>INCOME TAXES - SUMMARY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41502 - Disclosure - INCOME TAXES - CARRYFORWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails</Role>
      <ShortName>INCOME TAXES - CARRYFORWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41701 - Disclosure - RETIREMENT SAVINGS PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlanDetails</Role>
      <ShortName>RETIREMENT SAVINGS PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cldx-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41801 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.celldextherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cldx-20151231.xml</File>
    <File>cldx-20151231.xsd</File>
    <File>cldx-20151231_cal.xml</File>
    <File>cldx-20151231_def.xml</File>
    <File>cldx-20151231_lab.xml</File>
    <File>cldx-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001047469-16-010308-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001047469-16-010308-xbrl.zip
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M"F\A=ZI-H\<L#C7"(/G8!VD8?>T1D>,X:E#A+[63X@A?D)^-$"$W6 _^C;\
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M8>NML*%/O?Y\'NX-12MVHQ,A5O)$BJ:9+FCF+%I2+FB95]FF.XG@.0#?\36
M#KH#@;'G"S_P]:1FZ#2&^]3>Z5+D.+3CN#-]=[[;"!&=FH:;BI,@Z!B%+*,
M*1H_A*?8^,J-ZSY8!Q@8D:BP?Y@E.S+TY3-E*]E\R,-,JR]M<^R_3ZL?#S(G
MQJL:D4/P".<V'G;D+3X1+"Q$'F'*(TR,HD;'2>G5L>&.G]AN"ZZW[X:8QN<N
ML$!T;)71<VUN!C9?R8(C*89&6UO!:$?S1 L-=][T7$1GG/X#ZDAC\3<@].@&
M$!CV8 3B%(SO_S3>Q;X@HYF>>V@NF&:;%74K!Q_#-#Y-.&-2\(7A#D(],\A&
M*]SVP!"]O@O]K1,-<Y7*CQ\\".+$S7!NX(5]\FHC^#AULSI2962O*ND9Z(!N
MM9K/;C4V_WH ;N"\!X.QJ=X2OR2SUV9_JX848/.GF]B\@C*^MW=\QG$41H<'
M78:'7E:+!IX]A(LF^.'K^Y.I E_5=CQE^FI+:Q .EZ-N-YR2%V&ZL [AU8%5
MX=JV/AY,^8NP%I/;MA<=CNGXTK6C7]"(7&?5R4#-])PQ^'3J2R[<QL)H7 $2
M#S2B8TT/P,,\<N;[@/H7#DC/BLTG"VSB>'+F<V8M^DW$XI>!9%_XQ')?M+4_
M-O$=<T@M[K_@,3'AJTJ7)\$?KH ."T7'" S7.I2[TON0N<]42IQ>W3[6VZ]=
MYX^@@[-[[\X_7[Z/&T4T&S!C^#^COOBYR:,DOQDG**\6WDPR.M,]S1QWJ!2\
MTUF_('FSCT..SBY62ZSQS+G"3KQ=3UC;]G8>'XVJAL=.'VJ"^^K9ZI-I[KV>
MT+L:,$%>I;Q"5V&B[K]ZXLP1]J<C7P;\:,T-S1^VT<Z,G4RKMT.9^SO+W*]C
MYO[M[<V32M97=PA<WGU[NOGVY>K;Y<T5I>_/2-]O,U.?78(^#_L.[0%M=?K^
M\.AVE=SD#\?75ICZH@^$+1?+18C3P_GPH9<<UAS6%<Y!@<]U^ NX^##7OV!P
M&'D.5'9G-$^NLN \_:M* AA^#BGR3&9'9\NTF,H;Q43YJ#?0ZWFC@4=L#0[[
MQ/#D7!A'L+$$?)U<_^[H\OSVZ+UAC8XXMO5( BC4?>[P<."QLU*Q"QL1HWK"
M\]NP4IUU-0;V,*7A6'7GX1FX^E@UJ#E$C:EN>L%1V):K3C0.CSD.QUDZ[4N?
M#*_1#I-GY4*TC7>J'P41 X'>^[,-(U+4Y^.NMD_'E3UFZU =NM*.<_9'X/FB
M/=!?A1_.U&EQQ\+BF K5[V[?W+9B7/1$3_1$3_1$3YEZFAQ +N@XI[K<5;OJ
M^&P=OC<V^H#/?;PFP.G@LU&IAY-]PSY]'1+7?H%X(IZ()^+IT'B:?F'V("\V
M9_0B++][5BK&IY?TA2VXBA;R\NFH>*17U?K,C#ZKT=^G(U,M(!Y%];54MNRQ
M2J+M>_PL>OBH&S*:Q1-L"\\F?]25G16G(!P?]?DRJGS\K5$I7<S"$VD532W7
M]]W>T3B/+/#=CRUF_NQ(%X;O2*(KSXR_7%Y>75U?Q\46KWG>H#B2JK&]E:N-
MYYCPZ/DY<\@CN#[XUC[QVR<^"P(E0FF(TB\[!V?N8BSR-;(S/>VDIK4_'AF.
M^R)9_].1_COT83$7U[9=YI^A<YF:0*\4BN722!U([IM;A_XL=^FYK]5_<N:Y
M&[LSN\WPRZ!N$DJ[0FD?+KQ<+6_5A1^, NS!A><R^&Y26)DNYT0HI3H*+Q?J
MITV*PC/JPG,9A9]2?)DNYT0HI3H*+Q<:M2I%X1EUX7F,PLM%BB_3Y9P(I51'
MX:5"K;Q=%WXP"D!1> +8XT$8G+5]+BG*3)>+(I2VB-*46]\W;']YQ:U9Z0=N
MWSCEN)N8M0-D$[C?C'8L!#JI#5.J(BTM7J1?2P\>29T?YKO],V!"'<9F_.7S
M*?[7B'Y4>6!S?]5UJ]\]UQ:6\9>B^L^P@-[P../]PQ.BL?V.+Z?R3*0;SH6
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MV))<.2F=5B8CD>4$)$SRF@LLY4IS,M3?.<EK+L.43T_?3++P3-O%I.J[=CR
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MQ/@^YY>"P1DH*JY<"E/TU>2[P2-)]MC Z$=RG$.-WY5NT,$J!A(\!O2HELY
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M7!], JLSW8X#*F(I>EF_+]U7T8,F[ %07S\ISU!D!UX$\J%I5=+""9PV%WX
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M"4ZJJI*'?90,)3BIRJC7$;K^2+T@B87\?66$B/P]\O>@/E!?!84(Z@/U@?I
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M?0C41M!Z^\BO0@H>.L.,J-25^L/>9DY\N^$_V%4H^N["QJ7(:AR=Z(!2H9-
MSZQ6ZW#M*;BDG\,,8 ;&#.Q:HW[ 7&C!90U#@"%,_8%]P'&R@DMZ,S,XF8Y
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M:XWZ 4?%(':@=+K&<9AI;I41.L8,]H#]U9#[MX*Y/OL/]V+3F[CTO.">^XY
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M_SN'&,>MC-B1O]D#]I>.$\:9V3AZ(_O/T5"$Z(H5BZB 4J$[K+:%:0<PC1-
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M+NL<0Q@8 @RAN+(N:0A3TAE;0!+3?LLM1$S[Q;1?4!^HKX)"!/6!^D!]6/&
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M#HMXTN-C*5Y.+UZ9@DA&]7-56#:K8;5>&>D;-[DLQ=7)$'KLX6S(R.WW/;'
MYO6F+CME[?.N4K;%OS=F\I]S&2K?YPPIH+,Q.CH2J!XVZ^<F'S5'"HX/A><1
MIZGLVU<\<;6+3I=8 "IDM>TJB\#,AK:/*XLOH:OB/Q.2CD1X*T(5^62C&Q7
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MUK>SN(;5M9>"M6.W)>.[&VN[[D;=*IQ^;1F%6';'NE@*0PK9EIQHL(B -#.
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M<H:=GD#AL1&F6;$G>R_FTT-C.SE:^:30*7Q2R/CMA <Q9Q'//D!,0C8I+K_
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MS,)[8GY/?NJ.K(5:6@642D1I)PO"[!(VL5B)U5$?N'WC5 _W DH@(=P+*-4
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MY)=W8R/A_4\? TI5H53]W,H7]B$6U0$-=*>!5>+Z:K Y4*HO,U[8 RS J6S
MWZA/=^7=V%^X_F(%E$I$";LJPKV $D@($C;7O8 22 CWJN-82D/'LH D)D0T
MVXB8$($)$9 ^2)^&1H3T0?H@?9 ^#8T(Z8/T0?HP#5;U47'L+US;Y#904GQ^
M$R; @@;:TP 38/=M<Z"D)C,P ;9YH7Y#NUI $OFZ9AL1^3KDZR!]D#X-C0CI
M@_1!^B!]&AH1T@?I@_0U;92V4=\NRU\VVG:X6YW':_.YB#XHW>]W_Z@<K=6"
M["-17^(.Q'5S@0J'=D&8>A)&[*O:T]T?T,R -<]D3=OLZ^X/V[!F#UT-=/70
M:4:^4!LC(E^(?"&D#]*GH1$A?9 ^2!^D3T,C0OH@?9"^IHT2 W]X,AIQ;8R(
M1AR-.*0/TJ>A$2%]D#Y('Z1/0R-"^B!]D+XJ4S?9J7/I\]G-^?RFZ5_+F6ST
M! J/S2N:%7NR7&1Q7)B\E14XH[/YVYO\-*,GG;<6:CF]/RL4%?EMRY)7L ?@
MW?+%Q=M9\>2/W]/XU97C3%Z?N==\F/K\='3DNNDX]9V$#^5&R,?%U=Y.Y-YG
MG\,X/A=V/"<E>.^'[H]WO_["V!_W/"Q(O*'GIPG=>\;=-/(2C\<?;UT_'?+A
MIR@<B\>GB=Q'^73TT8D"HDW\C4=GUTXT?SYS"1,Z^<Y';UL?TDA>?V'1/^)K
MAHOS\,*R+]K96>M=#M&LNEO M8V9EYS9LK.O2#;R:/LY'EU@L;U XJ<<_#$>
M/MX0_)W&B3>ZRW[*3Z@X";51WI"'5Y$SN:Z>RCC"$8YPA",<Z7>T'$L^TG"N
M-+GK-M7%CV'%?0L!$IT7.D*LW9M_2EN(M-8LXK-O0)U0)]0)=4*=4"<5Z[1Z
MP_V=\4+Z(<L]6F8Q4R$3:LSEOI_7Y6W+;,GS.)L7)<_S7*;+19=\ELO,L\AN
MZ/O.).:OIP=OLA>Q@7D@WK4XR6H9PL7>^2ZG9M7CNT3YR\IWJH_$8;M)/F^Q
M<VWF!9O U=\]6O.G]Y=2SINC1WY,SD_P#5IJC],TVHC_X4[$/I+V#N]?B0;$
MJ(P82R,Q=51JQ1&&?^Y4N&T(]_Z,6.(*88W&#<[? ".2\W?@_'!^79V_#>=O
M3%C>]!50Y=UGB9@@%$[$E* *=Z+49NTLH%052@_)3WD+RPT,RS(-NWTXKS6<
M %11'Z7JJ=(WJ%=LM+LFJ***$P E-:G2-?I]T^AV.J"*5HN7JMQ+^,[C)/+<
MA _I/NHP5$?##3\)JI^? J6J4*I>TJU#HVN6&_K  X!2[7E"O0301!T' $IJ
MTJ0'FFC7.VCH1^Y $BNE--N(6"EE4WMBI11('ZA28R-"^B!]D#Y(GX9&A/1!
M^B!]3=O:0*'IG_8NK?'4.F>E.K4V,Q& 4E4H59^2'QB6?6CT,154'2< 2FI2
MI6^8MHVIH"HY 5!2DRIB*F@/4T$QV-N,'AN01-JOV49$V@]I/T@?I$]#(T+Z
M('V0/DB?AD:$]$'Z('U-&^P%_O!D-.+:&!&-.!IQ2!^D3T,C0OH@?9 ^2)^&
M1H3T0?H@?56F;K)3[&.O^#[V.]IZ_L&M[6\<SQ=.\"F,SAR_\([OW T#U_,]
M^>AS<0TVLK__JX]UB+W>!QZ+'OX8$;&1/8YPA",<X0A'=3A:#B8?:3A7FMQU
MFVJ%-PI&G5 GU EU0IU0)]2IFCJMWG!_@J&04LD2JI99S+[(+"%SN>_G=7G;
M,EOR/,XF>\GS/$&;;7,W2]#FJ7$W]'UG$O/7TX,WV8O8P#P0[UJ<.;8,X6+&
MH69;/N_@8TOY2W'[OFH^P<5FAP^CAYT^53#BT3B,$OIMN&+#RXC]OH9";OKB
MXS!.P#JP3DO6_1F%\>H>I24S[J\@X@30'KC^I^.5MB5KH_T$9&^ $34C^V>J
M+0?;P78]V?[)\:*J*?=OQT\Y&%<9X[+S\K[AJR"GHCC"\,^=M@B6M4Z3T&@H
M7YP$++D.T]@)AO%+.&-CQ%+MU:W+2EU_X"X?7_)H;I2V93#;M#HEN;;.RRT"
M)551VLFW&_K!!I2 $B@(YP)*C4 )%(1S 250L'ZPU0^E/:0S-OL(>Y;.L)5*
M9\B[OSC1#YY-BHQGW\M6YZP;?M5>/V<%2JJBI'M[ ><"2J!@'6$#2D )%(1S
M :5&H 0*:N)<>TA<;#D/HZU>XN*O@[,#=A7>\"@84XF8$PS9. T\UYLX/@LO
M"22YE%>%R0QM,F] 2564=&]#X%Q "12L(VQ "2B!@G NH-0(E$!!39QK#\F,
M+6=A=-1+9GQQDC2BNC O8.(#W3ON1"R,F,_O^5X="3BD*9^%TC\J!^>>DLSK
M9=W;/K18$/Z,G,G;5O;_UK2LA07=1G[H)*_%M_"SOTY7T^]TC.[ A+E!"I!B
M1HHV" %"@!!S0KSHE5<;Q<W[$KZOM^]3A-0S.S!WK;JZ6X[;J]S5=48)C^:]
MW>2::GYU+?[/LY_B@IFJV\H"&2'DS>J"4O6-B-4S+', NX,=ZJ.TAQ#K$#8'
M,]1':0\=;ZN\VBANYPH[WB"!TB00P5.WC R4-G;?0P\<^ZYC!_O](KF_Y<$U
M-"(KOT5JJ#UW,N.K$0;6CS6@2@.,".F#]$'Z('T:&A'2!^F#]$'Z-#0BI _2
M!^DK5?IJD[56>;V7\S!Q?+;^JB^-FCNFS11+S5#28=YQSS1Z@S*FC-7/W" %
M2)&1HE_&3+'ZF1J$ "'R"6+]\FJCN'DKG" &WU?1]RE"ZO?PJ>X6#4)M>M@-
MS7  2:3)FVU$I,F1)H?T0?HT-"*D#]('Z8/T:6A$2!^D#]('Z=/0B) ^2!^D
MKVGSPIJW#]AQ&$W"R$DX&_++9"^;F&OS^3U04A4E;+< YP)*H&#]8 -*0 D4
MA',!I4:@! IJXEQ[2%YL^5&;RHNA8]\OY9E=/Y1TF#L].#1Z[1)W=:F1N4$*
MQ5&JGAT@!HB!UJ+PE5D;GYG!^35U?A$JF5V8NU9]7FP UIA%7+1)#0&EJE"J
MOA&Q;:-W6,:WRK [4*H].]HP.8BA/DK[Z'B7T?' !F!@09U8((*G+G9/K5</
M')\LX.,/?/>FC1'QW1N^>X/T0?HT-"*D#]('Z8/T:6A$2!^D#]('Z=/0B) ^
M2!^DKVD+O6SYK92""[UD&X"Y^U_N19OICIJAI,,<8,NRC;:-ST+ "K!BS@IL
MQ@4^@ ^%V5I]N[SJ*&[?"F=KP?E5='X1(MF],F;RUL_>F*55RWP#D$32NME&
M1-(:26M('Z1/0R-"^B!]D#Y(GX9&A/1!^B!]D#X-C0CI@_1!^IHV2VO+U;UL
M56=I45E_\,2Y]#DVY%)V[+U^*%4X_+BW-2*L?MLPK0[L#5: %?.U2[%J"@@!
M0A2G:)4Q:1$+:L'Y:^#\,D:RL=CB%DW"'CJ[2#8@;8.,M39&1,8:&6M('Z1/
M0R-"^B!]D#Y(GX9&A/1!^B!]D#X-C0CI@_1!^IHV10OXPY/1B&MC1#3B:,0A
M?9 ^#8T(Z8/T0?H@?1H:$=('Z8/T0?HT-"*D#]('Z4/6>N'#XOFL?14^+):_
M_,R\XC+TA]GC/G"7CR]Y-'?OMF4PV[2ZRKOY?F#<VQ=D0*E$E';2"ND'&U "
M2J @G LH-0(E4!#.!91 P?K!5C^4]I#.:-XZ:5^P0IKZE 9*):*D>WL!YP)*
MH& =80-*0 D4A',!I4:@! IJXEQ[2%QL.0^CK5[BXJ^#LP-V%=[P*!A3B9@3
M#-DX#3S7FS@^"R\))"?QPJ#"9(8VF3>@I"I*NK<A<"Z@! K6$3:@!)1 03@7
M4&H$2J"@)LZUAV3&EK,P.NHE,[XX21I179@7,/'AV!UW(A9&S.<Q)F,HQNSZ
MH:3#5BR=@3'H6S W2 %2S$D!2X,/X,-\LSK;+*\ZBMOW)9Q?;^<7$5*W"W/7
MJJN[Y;B]REU=9Y3P:-[;3:ZIYE?7XO\\^RDNF*F\(V2$E J<@-(S4*J^$;&Z
MQF&GC" *=@=*M6>'74:'&S8'2K5GQHMNO[SJ*&[H"GO>8('2+!#1DUDB$9IO
M]]ITP1NZA"20Q#K$S38BUB'>U)Y8AQC2!ZK4V(B0/D@?I _2IZ$1(7V0/D@?
MI$]#(T+Z('V0OE*E;P]9ZRV_D5)PP9?S,'%\IN"R+]K,?]0,)1TF!?<ZQL#"
M9U,@!4A1F,8U@*E!"!!B/GNK7\:D%7PW!>>O@?-3B-3OV3#WYBW"'KJ_2#\@
MD8,<MC9&1 X;.6Q('Z1/0R-"^B!]D#Y(GX9&A/1!^B!]D#X-C0CI@_1!^IHV
M:6LS_%6>M'4<1I,P<A+.AOPRV<L6X]I\&P^45$4)FR' N8 2*%@_V( 24 (%
MX5Q J1$H@8*:.-<>DA?8E:L<G]5FFJAF*.DP=]JR#XVV7>+' S6R-U@!5N3?
ME\'2X /X,/^\S.J4^ FRX@9^">_7V_M%C&0-\,EQO7J[6P[5J]S;Q<9<#:4)
M4*H*I3WT*=K&8;N,C@7L#I1JSXXRNA<P.5"J/3%>6&:)C8;BEJZPZPT:*$T#
MBIX&;302.G3!&_JU I#$)V_--B(^><,G;Y ^2)^&1H3T0?H@?9 ^#8T(Z8/T
M0?H@?1H:$=('Z8/T-6V-EZ9NS.7N?Z47;>8[:H:2%K. NVW#[A["WF %6#%C
M11N6!A_ A_ET+;M3(B44-W"%T[7@_2IZOXB13 LQTA9MPAXZO$@X('6#K+4V
M1D36&EEK2!^D3T,C0OH@?9 ^2)^&1H3T0?H@?9 ^#8T(Z8/T0?J:-DUK,_QG
MT[1L5:=I45E_\,2Y]#DVXU)V\+U^*%4X_)B#4_WPHVT-#+-OPMY@!5@QGZ*%
M95- "!"B,$>K;9?81BANX KG:,'[5?1^V^H;_0':A"W:A-KT=AN:;0"22%DW
MVXA(62-E#>F#]&EH1$@?I _2!^G3T(B0/D@?I _2IZ$1(7V0/D@?YF@U&'\@
MB4:\V49$(XY&'-('Z=/0B) ^2!^D#]*GH1$A?9 ^2!^D3T,C0OH@?9"^*K/6
MV:GX.G9V<SZO??K7<J:8/X'"8[/)9\6>+!=9'!<F[6<%SNAL_O8F/\WH2>>M
MA5I.[\\*145^V[+D%>P!>+=\<?%V5CSYX_<T?G7E.)/79^XU'Z8^/QT=W3B>
M+XST*8S.')^?S3YD_L[=,' ]WW,2+PS.Q37G) 7O_=#]\>[77QC[8_5IQ^%X
M0LH4)/'IZ"1PPS$_=VX_WDYX$//W/. C+UE\$*-W"('YSD=O6Q_22+[KPJ)_
M;-/J7IR'%Y9]T<[.6N]R,&85VP*8;0RZY+:6G7VHOI'OVL_QW0)?[06Z/N7*
MCS'N<<G_.XT3;W27_92?4'$2:HV\(0^O(F=R73UI<80C'.$(1SC2[V@Y:GRD
MX5QI<M=MJHOK[8C[%@(D.B]T>5B[-U^MIQ!IK5G$9]^ .J%.J!/JA#K5OTZK
M-]S?<2UTU;.,G&46>_79(FPN]_V\+F];9DN>Q]E$27F>9_A<+KJOLPQ?GEMU
M0]]W)C%_/3UXD[V(#<P#\:[%69?+$"[V9'<Y5[,>:S3(7WYF283+T!]NM6A#
M>> 4$AN9%VP"5W_W:,V?WE]*Q&Z.'ODQ.3_!-VBI/7K1:"/^ASL1^TC:.V0?
MN,O'ESR:V[5M&2!&9<18&I^HHU(KCC#\<Z?";4.X]V=$,>($YX?SZ^K\'3@_
MG%]7YV_#^1&6-P9A^&?U^91&(_GB)&#)=9C&3C",7\(7&Z.5.]O.?;9YRWQA
M9&4V;\DF)K+$N667V9Q$]F(2A3=>[(7!R]<EN?/.H-TG=*4W0$"I6I1V,KE?
M/]B $E "!>%<0*D1*(&"FCC7'OI/FWTBJ/+FEY_XD$>.7YU[:K-;C68HZ;"'
M4Z=G= \',#=( 5+,2=$VNNT>S U2@!3SS5]-X[!GP]RUBNZW'!U1,+H_2YR$
MH^NIEF(#I6>@5+UT6Z;1ZY0AW; [4*H]._I&VRZC!PRS Z7:DZ-C'):RQ;TV
M9D=*?P?8?[R=>-G::RP<T6L3=CKAXH?@BGT.XYC*X@1#]IW'W(G<ZX*IQ)'X
MEWW@-]P/)V.J$#MW;MEQQ(=>$B.KH9;0 26EDT OK&ZWO/HH;NF7H %HD-'
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M 4RP^T;?!A.4#>:;]ZWK=QYS)W*OF1,,V0=^P_UP,J:BL>.(#[T$W[\JIDU
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M,7N-I ](U@')FC"_CM V ,FEF#T[Q29M:F_2MLX>:P_MS_:OU(D2'OEWG[S
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M@5)5*%4OWB_:)H7Y6%X-3  3;*/=/003P 3MF6 9AX,R0GHP 4RH%Q-LHS=
M=*1L/[9Y0[=8:+"V,@64E,Y38J%!\  \  _  _!@R@,LN D>@ =H#S;LXF:G
MSUEH<#>U?:*JC_GPK-B3Y2(O><S">@^_39=_R#ZFFBY$,:OE]/ZL4%3DMRU+
M7O'0"@1;OKAX.RN>_/%[&K^Z<IS)ZS/WF@]3GY^._I4Z4<(C_^Z3%SB!ZSG^
M23 22R0F7AB<"^N=$Z7>^Z'[X]VOOS#VQ^HCSD1_F[KF?'@<CB<\B.6]9PG=
M<CH1A_&1FW@W7G*W^#SJKP>"K]_YZ&WK0QK)VRXL^D=\G75Q'EY8]D4[.VN]
MRX&856H+4+8QYI++;K4VIOT<ORT(W>R^M=SX,;9A84P<X0A'.,(1CNIPM!PQ
M/M)PKC2YZS;5"B\0ASJA3J@3ZH0ZH4ZH4S5U6KWA_@2#OHNRUB-[+W\I+DU1
M33H?"WD\C![6 U/!B#*!7=;'48U&#N[? "/^C[R #U=,>!FQW]>(#S9][]$-
MCYRKU9F:);_VXRV/7"^N_+W?(L^M_J4\8F<ESH=M-#&@;@TPHF;J]IV/'2\@
M:U;]XF/Z,7+<)'7\JE]]SJ,Q$\L5_H<[$18DQ(*$]?JJ)9\DPT[3)$Z<0%2+
M.0G[P%T^ON31W#1MRQ +%W=*<G#,3@1*39S#V3=,JVNTNUB'!P3!VE1S7AP>
MM,OX>K=^Q@8E%$>I>F[T#K"28;WZ!<U;M>W/R GN2UQ@P8V]:A)0>@9*U2NW
M90QZ7<,N)=J'Z9N)4H71_MYX87<.^EU8&YQH'DHK5 %LS70N##?L /OI_(<*
M.Q;:]'N!4G-30B_ZIFET>U9Y=5+<VF4-K#>""CH,&'0/!B5Z?XV,C=:A82CI
MWH/0QKDP,+$#[(^=P.4^1B948S%04CH#^Z)W: Q,;!T )F@Z!&%U#_HE[B%3
M(VNC=6@82KIW(+1QKMIT(.Y;VW$3N'?S 4K6J"Q];_)_;FW3?*^^EVJ/Y/X^
M3=30B*Q\_6ZH/7?2"#?"P/JQ!DCJC&1-F%]':($DD%0-2= =3JI4%[UYLP2?
MNRA!MSIGUV:P&BA5A5+U8R$#P[),PVZ7,1X"TS<3)1WF&%KM ZO$#==J9&UP
M0G&4JB='[Z /HV]N]#UT#- Q0Q<78W?:&!%C=PU/Z6'LKD;2!R3K@&1-F%]'
M:($DD%0-2= =3HHNNJKX TETT9MM1'31&]YRHXM>(^D#DG5 LB;,KR.T0!)(
MJH8DZ XG;4 7O0[3:__-XX0/F1,,V<?;"7?%21+*GU69;KNA\^\1W!IU /1$
MJ?J94P/#E+L"E+&K"TS?3)2T6)*G?6 .8&UP0GV4JB='.=-MM3'Z'CH*S?T.
M+U^UW[GTN2H= VWFC0.EJE"J7N,[1M_L&FT3.Z&"( IV#/;W?>I!%Y_A@1(U
M0*EZ;G0/0(UZ]0N:-X!P=NU$]+ZC&\?S9:=@%$9,[AC,J.(\8LDUI_Z .6#?
M?"= 2D,MZ0)*2B=^ND;_T*2. 18K!T$:B!(6*X=S 250L'ZPU0^EI<Y.=BH"
M]N688_K7<JK]1)T?J^&LV)/E(B\%5%F!LT\;S-_>Y*?9IPITWEJHY?3^K%!4
MY+<M2U[!'H!WRQ<7;V?%DS]^3^-75XXS>7WF7O-AZO/3D>Q<O7=B/CP.QQ,>
MQ(X8A#E+0O='/AYSY";>C9?<G0M3GA.9W_OTQW>__L+8'X\][YMS-Z8.Y-%/
M)QH6G_=OQT_E2X[B.!UGORT^F[D$"9U\YZ.WK0]I)*^^L.@?,>IS<1Y>6/9%
M.SMKO<L1FM5V"[2VL?*2+UMVUJ'>R*'MYSATH8,PNV\M_WZ,AH]/E?T[C1-O
M=)?]E)]0<1(>O?*&/+RB;LAU]4S&$8YPA",<X4B_H^50\I&&<Z7)7;>I+HX+
MB/L6 B0Z+_1Q6+LW'U4H1%IK%O'9-Z!.J!/JA#JA3O6OT^H-]W=<"UWU+ 5G
MF<5>O<P],9?[?EZ7MRVS)<_C;-!=GN<I/9>+[NLLI9<O/N&&ON],8OYZ>O F
M>Q$;F ?B78LC^,L0+O9D=SGN7X]DHOSE9Y9$N S]844YV"T2U)D7; )7?_=H
MS9_>7_J6M4ST]KBD2Z,-]Q_N1.PCZ>UPQ7"7$?M]#5G<],V53Z!OM!U!P)H:
M3D$"=D! $! $W!\!V]L,<.,KOTTF%\S6_HC%F#";1)[+V4WH.XGG>\E=69S6
M>!+Z/E#:B3#M"K=>?X[<J_EA[_ WY7&$M]7.V_KFO=[6M^%M\+;=>YNU$V_;
M0VC3O ^59J%-*&>U,7*-<77>K,T\TSU/8MX_YWL')A.=J5AYV.!<<"XX%YQK
M.^="WF4'T'_WXA^O1A'G3$[4%JNN1D["E8^V-6-Y$_HDUL'@WDZ)?8 ^,/RM
M#'\[A+_!WRKT-_L!?[.0==E?UF7HW7A4IB&[\[B_.L:H6F"N&?&;T'WY&@85
M!LSP*_B50HC!KYKO5TL!27:*)1SJLH3#YDLN+"WG<.^B$(\NR]!>6):AW6)I
MX&57_D4'5HL-N>N-'3]^VWK5;KWK=#L#TS0+U;GWE5L7J[-0K,Y3Q>H-NG85
MQ5I>Q.*)8EEVO]_94;F.HL@)KKCPD_=W][N._(_8EXF$[QM1-1Q:SZG-15Z
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MX<"844TVVI*U)2&,;/U5E&&H*!P\A8F8N%F-8)92)2G-$Y(J,F>ZL(A5^,)
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MO__C.'\Q[R#13B+_0PP[UCDP\D1\<6_/8&E@8WXK(C$*LE-F?VCL4^'PHDQ
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MWHA1D,C$LBJAIRY(=>J\#[+?QR)U0[\R!?RO^.HTWFL1(HY50&O)36"PUUE
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M(<;=7?CI+W^^':;AK_\/4$L#!!0    ( -915TB$0$(IA14  +/J   1
M8VQD>"TR,#$U,3(S,2YX<V3M75N3XCB6?M^(_0^>?-F>B,T+F57571E=/6'
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MGF/B<EG.K+K?G*7?=%R&X7TK8 Q4P=6((>J%,A_5>_*+S>M#QT3YKI6.86I
MI+3&I@G:Z#<%)J/^L!L9@G5/.D-/:A,'2G@19H9+AW/$,H],.;[ O-[S[JC>
MT]:[XQ&/0'+[!CK,\+-JUN>N')S]D-$+]E]+,97F0M3(')T5D352,PGE:!7,
MD:B!.XE;=3.?\EV/F9-N"58YN"7R*G9G7KZ7LIY&3X,YW[D1[O"GFZA5[("I
M4IV@8%EYO2*I]F?W"KY5),HKZ,?"97H?-+=>K:8=D9R3@?S>6SF6V:DZ-2JG
M2=K)/$Q02BU'K40*3PWCX=&P%F)L!9/C*V)V%HYYY'(@\T[W!%Q5T_P&4^47
MU6S78)XDI21SWI30RF$LGF!2(WB>6%F6%E2.6X[RL8DG_Z^PY__C]YN:>*J(
MZT4??2#Z=.61Q=+AMW6*9W-QMRN_&?9Z?>OK/T'<F[>%LR;AY4MN#17=9;^%
MH@^OBT#,2I22N/X4"A%^<(*]VW7EKY3;DXD%6)05:P^^*DH%':6L5+M]JXI"
M@6)65BA@P<YYY/GU=O^NU^C)[IVPXD98$,UEOD)3[X7.N> XO%FZZUJBS'S.
M?LAXS>^MO6[<7S<^W$ 5UO4N49WDQ;>%ZN(PML-U4$6D%QQGU"*5A_^XWC(?
MV!3)ZYO+H7)"2.(7,A>IA&#A?VVN9.;5>.#5*-,<Z9=V%ZS FH%_^7WQ;TKO
MB)9U@E3&6^SXWOK)];:H1'VB*]9%A3Y=#<S.Q@SLX<4$LU"9X5/3/]->AK-9
M>)'YH^TN$*&ZCQ=\+89:!Q//)W[ Z_S$W&#YZ4K<O_T(FLCB2D'PEB'+_W3E
M,W[*!R7<&N7S5/AW2 MS$G'MD?B.';#HO)9,"4R8CAAYX_^\$!9XS\BR",4)
M87+H*B?7 #.^QP+-L#'M$HL[S3H8MP-LT#[V37>%'#YUF]C"Y&6=]1S"5I8S
MDAT$7X:L!T@^18YW#M%U"AHT]GQ]I^Y#U\F26,90-4&%N]181JY176RJ 4BX
M"0ASR2^)/ER0OG)]6017$VYAE3%$9Z$'JKG:T@S02ER3P#T:H;">]K8DX5=X
M5"_>(J<N.6R[4,JU9(4;KXJ-U7'9YS# 9DQ[+L.C.8+G-!HRQO39Y4%QT;/.
MUZZE*O%_ ((1*/@>CVO&9Z8SM73^MPZ?]O);,U2[_//V9Z@U\?  E$RL>G$Q
M>8YQF*DJ,HU_6%\_2P7/"5N!01"I#MLH06(YRJ2HW +4PS;@]P8K9D*(Y*O*
MU=Z$[H"GV'$P&U-8[YE'_%6*@BNAJIQ,[> [WE:SR:!"HV#ALA:WX5@+<RTN
M(6(9ILI)/$ ^_-%R/3\\@68UPF]^T]F=BV1$.Q+YZ^<_6(6%.9' 9#:(^4+5
MZ$,QL:14\?4>GL$$^&.!>G+0FSM<$'_^NP,6XL!)3AK9))7K=MTPWNNRU6:?
M=7(BSZ:IG#P]1(,I%!KPCI(MDIRL<E*U@.0)TY;+EE%T/B%1-DGEI(FRW4T8
M[8A9<[!5V_@%.Z[ @&<&\B^*22[<P1V?*@[@C4\@"Y=B'['5J:?%27@%'%12
M)+L<I@K+;@!,F36+D?_8Z7,MX%8-"3<"=9B[&##7#BP_AA]($BJ-4,OX";.1
MGG,0ZUZ=C^H,,H&S^L'"H5Y:I.7^[JYQ^[77'0I7;J$&6W=O<<@'F!^I39-*
M=&&-D&(E;K?J1[+&#;#801K)85*>M6H:1U$)TC3& WB/5"1/L^!M=Z*]Q&LL
M1;H,4]4P[O#P,^YRC[OPW48!Z?#)_B$_S54/_2_8-0Z*#KN+-<*Q!1W0,+;_
M.%]Q)T0PP?H9U8;%#%,5'MBI*EWZZ\HI/RWNU\'6G+J..TN:Z>FO*R=%&T]\
M'10:)C20+C0Z9FU1K[B"(B&JG$0]8K?0<K,5J]MM)8V&3)+*22-\A+KG@:K<
M7'$N;EV[,X86"93R22LGG=!Q8++'=I@59$RGF,]44;W%)(#ME+%5AJUR4H-U
MAQER-+Y[D!$+NB+QD2.S"0MS5$[6@U>Q+J%B#?).L23&"JN:OM#&T'<9KS[?
MZLT5_R%R8.B.T%L34)\2W]N9B0M0'V45G-$L%J&1G;H* \\>N4V\%^G/)_TQ
M0A;;U0#D'9=]F1-KSF-)QM2 ,@2?UPL\OXE[,"Y]^&]_/T<IQA\?/TW3"]0W
MXN6H#B')8?JI31;<-Q!*^I>ON7O"Y1%66,2\6&A.*/0+)K.Y#]/P"_3/&38Q
M7VE OK73(D .WP^09L7_U5^NVH2?S(7>M_PR*:IKTB6KG+9^2ZFJAM-X^.1"
M'Z.14[(74&*1)7*,B4-FT9R\KZ>5X*F<IJ:^(")*@16(*Q7;\\#Y'-[C1X6)
MO]2ICYE!\6@.%9O-^;84_ TCYJD+E_GD7WQ@>SN>_A,7?,Z5W\:38MI-PKU;
M5,HOQ)\3"F)RT:""GC>F#".'R_<DK+1R<!0H[[Q.XTW+G,MQ?G3_.4$KERS[
MLEJ\S%RP)R^_I0-:)[G,'UQ"Q<)<IQB&H8BG'-B;$G],1UO/DE4;V8<U=.G2
M+ZK1S[#0;VY\.>4B'RNT$@M\LMVTQ=)Q5QB#I>$%#B<&%:_OTO7S-F'8\D'\
M[>[]A()X1!F54QB[@?U*9MRXYQ_FP(?[\]9;.I+;CPHR5$Y2U8%.2[Q1+)L\
M;8NIG*QR4FUW6!K3H1OX<[18^BX=_YXT:_(H*R>;B"&F8K3WHG(U'V+D^P[F
M'G_H0&DB9%)43A:8V$P\#:C-2]JFJ,5DR:3X2_=Z92X*1VQP"%/25I$'*_+M
M,G?1(<SS^5F4/)< .:'[/I+<CK9#%=@*<5SQ1[F.S[/!.$O0D>LC9^#R[=(@
M3X\XV(.I!T>">P6:*K>$BNXK3*C+60)NMLF%J6WR]MPGEBBSI7N&=$?9T7KK
MYC D$ULNM8A#1-';##1CVL=^%#&AL\BPI!E;3*&<\#SS>!<ZWR<N9CY;1QBA
M\K&KD,052:KU9T!8,M*:$I\LQ5W1\2=MF[#N,1F%L9C>$EFTU>@3!XBM4UA)
M+.QYZ?V^6/\XL*B+Z2SJL]H?)?7/^-/**6P[,QL@L9G!=DZ?2POME.:L6KAG
M1X"=2JL #W*Z9$&BC*8%/V$\2_9"K)<R\K,EX\O@=+LN<LC'/DQO_XK:N4#C
MY!5Q^8W$7;A;\#V#CCU<J&G2&2^_04R\ #W<677)=_@_W\P3(KZS#^8P]HMI
MG%>*F3<GR]:<J^1[.TI2WU9W&\E>=1-;4C/>_^!U+V%8[543E)+_"2CFYUP)
M;<02RS7_<[UPITI?@"W5V#I-.YS7]@H=#,:4VT6S\'P]8[H;]A0+O_#N[S9+
M8H?;@:54T&<Q &HV<H5EXY%4AW\V2>64OZBJ/<QF*3GYJ6\K)\,05LR '[HA
MJ@G#,-;PB<U[>:35G7=E=4_)"\@GKAR0J?9#J#YSY6C(JX2$0T^B8!U3R,7H
M$X4,K_TMAJ6XJKOM,,O)V7'9;DKQUB,>F1=BIRYWAJ<DEYRLS,J-JBAJD'T4
M9!9!Y21I$6H12H&L-2>.S6#*_>QZ(BVF!_W80D[&V3)E&2LG^2G]W3_:L7U&
M/[;82Z+Z(I<BED:2EF>215415V.1+*OUYIG02QHN<>*VQ"DHT4WLOV(,BB?B
MJ=-A'@9@N9-9=6 !E[)*;N2+>>&/:*5#2JE(;SIB(S/?M$1LS,(T+!'4"0^V
MXT<?(T:<E;Y8(A[CR=^"5ZJL2]]P9UG!@A^UCVTA*$]\87C.K827Z(H7/N&:
MH'AT0LUK]YR<TLQ5\ZV;>!D&VXUIUZ4S'GGFNP+!I*0B/2+A42_*4)$Q53I5
M;GUX,2RK [:6M8-Q=N:<A.-R&F$37H]NAXN6VR8&@P.'?AX]=HN<X[BOX1'Q
MR0!]V1*JH:8DMW2$]]2LU:PP*6K_P.?WW-@(3P43^T*CQS_O>B-/4]3%>B@3
MD65)X,GUOV$_)?)P1!F7H@CQ<</O+&J3%UA^*<^PY!_2*;]JV\-8+-:!#[K+
MKIE0F*DBLU&NFF-BLI@$S,/A,J.]P?Q*^9D*'M^48/$SYV(G+6_/YRK)E3Z>
M#CCK]Y2C)]$83>)ZJ[0C!Z/#/S-?7^QT\01_39 /JM4"39ZQS0]D3CG^,YOH
M&%%/XP&QW^X:[Y+^C9W'?W$M$QV+XV '? ^J4%[7RES,?A(^QMBA99&#NSR?
MK"N6/_SLO,.-$<]WG1Y>@<4XA(5Z,N%J/:*KO7&73W<A S#1!&-^$,0KV((^
MIH-@XA!K?8C/;A,4H+O4)MB+<.IT&S)N/$@CS1FDE]H0 [NA+Q8!!04>6]^7
M+N'FSIR CN.RW78H1'FIS=!FP:R%J$UL,/9!FV@YA')_=,SQNFZ'8J02MPDT
M')YA=A*OR;%R[SN>$SNAI'&Z*-/DN#(NQ\$4WLX77AOVV[\!4$L#!!0    (
M -915T@]I.X8UA(  .,K 0 5    8VQD>"TR,#$U,3(S,5]C86PN>&UL[5U;
M<^(X%G[?JOT/WLS+;M62A%PZW5W=,^6 Z::6VP*9R].48P1HQMBL;"=A?OU*
MOH"-+5NR#98A+YT&I&-]YWPZ/CJZ??GI;:5++P!9T#2^7C0OKR\D8&CF#!J+
MKQ>.U5 M#<*+GW[\^]^^_*/1D%H(J#:82<\;J0\0@KHNM4RT-I%J8P%2H^$7
M_/5QW)-FIN:L@&%+FE_K%=K+;;U'!&<+($D?+IN7S8>'R^M=[4?5PJ6Q/%?,
MS65S^TOP?-/X+-U<W=Q>W5PW/TBWGYMWG_'?47];L(\AS&%F21T:?WXF_SSC
M1TIO%OQL:4NP4GNFYB+Z>K&T[?7GJZO7U]?+MV>D7YIH@45=WUYM:U%+D$^-
MH%B#?-5HWC1NFY=OUNQ"PHHW+/?9# \)BN,61DJ_W@9EFU>_]GL3M_$-:%BV
M:FB[6K&G^/6:GSY]NG)_W1;%CX<I#=J*QMJ3I"_(U,$8S"57QF=[LP9?+RRX
M6NODV>YW2P3F7R\T??:&-="\;]YX^'^8V-B0A!V/JDX$3I8 V-:%1"0^C;N1
M)FA UV?@S5X"I*Z!8T/-NM3,U14I>T43Y.)A4NU5:5BV_[&&\^$:>+W"DHU9
MRURM$5@"PX(OH&=:A8#R/*4*+;1,8X;; '![#,O4X8QT6?9&MU1=NRFBGW*>
M7S5_6JJU[.CF:VE4"0D\(K8VM#3=M!P$8HIN UN%>AY\+$(KP=A1(?I9U1W0
M!RKY[*J^#)SI@BO!VE?1G[@!SSJ8 ,U!T(:@%*BI<BM!.D(F]ACV!GL+Y7\.
M7!/E#X!=!M@LT97@[1KX';^ V *R9>&7*6[<-].<O>*PK0S,+.(%Q9WWW93C
M&95H0-8TY("9\K8F+]!2NC--9"7XAJ2U/=-83 %:]:#Z#/72_%:F;!$1%R<T
MVP,JZL^XO6"JO@%KXJQ6*MJ4X[ZH4JM&6:*7HLBL*G)<0=L->=R W;"AL0"&
M5E+'91'/C5O#^G)T=Y31P[_Y6,F32QC:AG2)ZP(\W)EMOX4V><3U=?/Z6FI(
M6Q'X_X]R3QZT%&GR75&F$PY,+B*,23>UR+-UDB4Q4=20OCA7U%RUGEUYCM58
MJ.J:)&'NKX!N6\$WKLD;UTT_+?*#__7OWLLQD*RKST!W\U&1'Z\J:UC+00@K
M-;5]?IG?/]S>?VI^O'VXN;^[;3X\W-U]"K4\1!,914&H2 ODX__&F!.UE5_B
MRB(>B4AK0&SWH/X<F:NX^OR'F3P--]$,H*\7S0O)L7![S#5YEJI?2*\ +I:V
M^TL59B&#6])Y\1\21[^HNMN=[9:*T 9W9W?L1#$74]VH-CX*8\8T8\4-G!^J
MJ(:77["#)H/%CHDF:G3,^&SO/F7T6#XIIT&&,D#[M+@1CA::9CK>"]T-4,=
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MFJ'7@,^E1]6"&J6?<$NI9,SLT<%8[)I*&RS'2XK7SW-:+C)L9L0I:IP^!B_
M<*A3/<'/XMF.5?%)3CH%4_EVBB^7)]\$K>A@4"-DSAS-;N-O=--=$X*=;0]J
MQ-$:"WF!@.>.]VR45XQXMDRUR,Z I0*NPM!DPP)2-6\K&5*S31JO<#+&8X0F
MZ@!Y;&Y4W=[X@&C>,U*HMJ;C@"/JT+9E6B[3@KV-U'14M)AX)LO_VF/"EMG=
M&I7%*1; >B);(D+^WL="#5Y2ZHAG6B8#)84SO"B%C44]_Y)AU$BAT[%B-BQ1
M7X7?@(%]DHXQR[,5-*!E$P_U M+MF%$KJH';^AHV#TY1WZ+RRD0V_,O5U'"^
MO_J9E@].K70R=LX!4]1<+VX\0,"R@_TF7JA!,6]R8?',6D*NAP.JJ+XZ@)#N
MF_=*G;0Q"_GAQE$3\R6=EL:6LF_NI>Q;PT%;&4P4DI\?3(:];EN>X@^<F7SI
MGZ05TLV_Q$[I)\S<9<QZIM:HHJ=7,BLAGJ=@L&38*Y2!5]3A%6U.NF,BW###
M6\.I;:9(-2Q5<ZUDS-Q/OLUF?SB6[6]9=#4X(B$/_L&V$7QV;$]5(S5K#>6Q
MVE![-E:O+5'C&)IFG@P$5!W^!6;?<3<EVS!5:)"^/#1VIR3(")()@C;^:"Q&
M $%SEN'=#_6XDV7H013#/BP^]C*)\(&M+.'57<:*B)8\^2YU>L-?!%_ZD'Q(
MC6=*3 3, 0NT@?>7%CAQB:@HDB*M&R'S!6)C/FZ>< C>-;:9>!E[WA=O&X1[
M()F#O]M%XO3 JH!0 ?U&#B;L!5YEZX,E#EOC]F%GM*GL1?8>IA_*_.<5W+<!
M?@5KT-4'_K\._&@PG):DD(>EZIDR)K=J1(V;SR*#?Q1JY,_WBS>MH^'WLFNA
M""9R[&IPY-@(@15T5E;7> '>B))*EES"SI5$Y2DK<S*IJI4;29<$!*-!"H?2
MJIPI4[A5PK*G8!?]WE2T=&"7%< #AN$\<DC:]H0TV@H"ILIGRI<"RO&9\R'5
MD^RH<UO11N^EBH![_1A)/P'#2@MQDPM'T=^="S4XE.%3X4&XB"7ZN@3/=O#*
M]%^73)%L0KTSI40^O?CL^"@:._;S35TCY?!<ZA((#AEGRIKB.O(9]$FXH#4.
MS3^*M^T?RY!X)"\SEUB$O9.JJ+*"7-UU#>CE8MEIDH].297?Z<.KG( N]-RN
M.'39.RV/I"1C!ZUQO]G2A+W3J:BR GH)EQ/.ZC)Y*$65\,ZC7!H*R"-<[IBB
M/2];6?+D.*-0\2AVH,GQ(OI@F:"J?'(< ]8 F%EDOS!)8V$=]E6;9#\WPWE2
M1I3")VXYXE'H !2(\ZP</8DZ18[?V.[TR=24-=P+DZ\OIC&(I>ZYLB:W;H3=
M;1R#1+V]A94O5 'OI,FC((Z=.=6^LMR9%W)*"7Q)7V217?%<F9)/,2R;*RN?
M_Z0HL ,-U=!*CIX9A8K'L@-%ST7TP;*21ZCHN6M9#KF7>#C//L(ULYYX%#F
MB=,=$;M>A(V&PVZ5M)Z\>)E>3MO"[SS(4H:HRT#'8.W'7\.Y&Z.3\TF?Z4>X
M)I:.(KX_%_/S:$/8,#4,PKOYP3064X!6C#2(U7DG Z-.A%VGJ<SG0+.'<^5-
M6ZK& HQ5&PR-Y."+(QHM*C:BQ%L1UN\5C4</HA&^X<XQ-DJ2%42Z:6'_&#N)
MHDV.R=;9-DO>7=^Z9U'LQ+F'4<0/EO"%"GZR1(&#]=FJBK0;F[3L$<Q-!,9
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M^?7-Y=N+-RWDF*Z%G<6O;P+OS/!,C-_\]W_]\S_]\B]G9ZT.08:/K-;#NC5
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M$(%YZ;6"F/0B?(+E(=$'+)=L'49M/TK=ZY+U;A3BK;RD, 3'209!W%FV$I(
M3*V[@%!>4@.&4G.'7]@G^7&^K *$#5]&B%3( @ 3\_\$/B+R*91:&L*F,"=
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M(>R),TC8SI:1D*2#W0/#">;4D [8!58%CLO+0]ALYF&ZG"H :]5=0"@[J9%
M";K#+^R3_*:(K *$'5]&E%3( @!3'U&KBSU90W<5Q'V*DDI)<9+6@'!@G1,H
M*5T D&(;0Y\$)AM#SZ%$+J@DI5V^DE6!X*C/B96<, !@">DZVCVJ&FI]"->K
MU,GBWZE*,\V;>J5*2%=XBI@5ZDTET*:)%/ TRJ#YK6+'OK?HD2 3AW=OZ6<;
MA6QWK$V8?/B]D#R1@[NTYD';0?(#U=)X $UXA$,=(I% R*N MJ'RS?N0+FC
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MZ-CM;/57QW4\R@S#81D>AJZS_?X6$V32QF); O$.J$!C("P C;-HM[<JP",
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M54+>H9J=13 S:J-$W"G@\BI B/*N"D8>_=H!VR\(H_DF<N4.H=L C9PA\J/
M"HR\"3(1)>_P_9=\34!X5E0KJ)DY4BG,VYLKO<1@IJZ=BJZL9J6@?JH95!DC
MH-T!V@1'R;,7'1:J%,W/]>Q>#FD&<><E1C1E^4YU9[L#\^[X#DQGU.^W;T:3
M36KYKY-N=] =SJ:OEV)>+\6\7HIYO13S>BGFIXV#UW1=04\<_&M4]FM4]FM4
M-J2H;,$R.$"60=!+SY%$)AZ7@;#PY8^[.J;G->SVI,)N;X,?:-_3#:&#F@4K
MEW0,QT0D+0 T2VT(!U'Y@<E"J18;++">\8(]5H?]P$=WVYZW#YU(3#+%FA!.
MD_+CHTJE#FS:-AT@]F8Q1XA42<C+0SCGR8^#G#8=W-_/RM%\Z@;^TE@]^JYS
M_[L8@-0J$ YI\F.02IZ62;!:($<N]@<E(!R:%!#T VIT\'2*#-^W$7L,B4XD
M*7.%12&<8N3GLI L !NUF\###O*\MOE7@+V(L^)=M[#TSW8%0,@(H)"RCU1H
MI7MNA7I ]MHI0IL&U %1IPQ9,J3^&M:%@3)AY!*J)=0Q( 9=R3LN>=P<!TJN
M%@K+0G"H* O=/DI12 ^ .31A"[A$=\5^KT%;B1(+5Z*M8J1# 4K^I&N\!!"=
M<R1>1PP&-!<VF6^E3#XH V%%XDA&G,L'(P; YR9>G14E@7Z].OMZ=;;,J[/"
M%!ET^AI^0">R\? -6:Z/)1:4K#2$%4O]HI^,$OWW<ZR7B\MW$D,U\3N$TR=U
MQB;'#BW,\_7VY.OMR5)O3PIF.!WV!,T#QV+CV@>W\R:[L"B$>:\U5EQ(>6T7
M)#?!SIO7 *+'%MFEDSM,/'^?,'9JV/L["]9F;>0NY%KZ@7#J7<OURV)LJTVJ
M9JYOV&/7IQ_IZ ;81I[O.FA#!O?"5^ZF()RXUR(;J9P!<7&A1ZE?H9GQ@KR.
M0<AZ[A+VY$C&FPOO+ZX.;R[TAIW1H-N:M?_1G;*+#.W)Y/O=:/)'>W);P>T%
MP808T6TOQ<E9]%V/@4_I[A!D83]!.^^>0?;J=5B3.S3;@;\,A4OB<1 5KO_^
M0%ZLXM:<B#H -O_QT*2N!'%Q()X$N=3)00%TR%82+,F3IO>PCM2*0\4E#P1Z
M4=Z$S<WLC5.@-YE*G=RIM2 XD=($,PE;"D$ H)KZAH]8K@/:A?T_ <&>A4WA
M2:ER+0C;TRQ0I1($ *KFAO]<E6]2O ;UO ;UO(9^5!KZ(8K#_=8>SB1!N/&?
M(:B%[/Q,D* E[)9JG\ ;S0>(+!"ABZ%\B5>L4W^<9Y&%7I'(JN'@+N#*M6I>
MOC,)FQ((.I=P73 D=TT?8&P*=4'#)59+>B3F09VYT4@DB9EYQ>I4LQE%;9_+
MB$>(1L;&1I3*74[9.C5O019SJ-'!Y]&S@XBWQ(^=I2 Z55RL_B#5PJJ62U<%
M?!:OY(*"$'2H1%9$#-6I*8NQ%*X^S,WFRK3>0>\]YQ:9X1I%BUZ+UVFE:K5K
M1:E8B0#@TZ+]>/U@%%[/^9_ 05<7%Y_I.K@?T<5G95#2FZA=I^8"*)TN "XT
MKN:2I5\3EZ\_;+L,?Z>$0*API28.2JT%Q-N9*HRI0 %[OU4+7$F=^Q&&&:$#
M0BZA %"59F81%8+@X584QV1F+OU95M16[+X@XCM?$]5'=!<A=6]B9%%N37W%
M)D%D@C#!7)-5J-]VS ^Y"GWZ#7YAYT,4/MWQB*.S+T;<O8]M_'?X9^HTS=16
MG='6Y<_<3*37B/ ?V%_V\0K[T<A&SOU15O9<+=09'ZT933[!VC'</F_%HG \
M#_F>1-Y<_SOR(Q'COY)1H+$Z<YR5@FP!VFN<J!.T<GUDK_OX!_UWYMX@&;[Y
MVJDS=9KF22LCNT94VXX3&/9^-6FO6&ZM;(B*VJ@S1YMF-$4D5_%R#7:MT7R"
M3'<1\70TOW<(,D)9^DHY$Q([]Q$Y<!9R#QF+-%=G=KA2\"U$/;0;SWRW"&\Z
M*]6H\\F;LC8U4@*U3U5F=$MMN&GPX/E&>(U-Q0(NUEZUSJ$+#;.U&/W:X98(
M6PZPB[16+=0Z?%!%J(>V+O>Q\4 -/7]]YY)[EE7:9^F_C9>Q&\7!>!WV%*EP
MD5:O7BWLFOQ0ZN1"PYG9#:$9\7>XL[M!#H7AZ-)W:NEJ42S9#95*'330A@'C
MQV@>WAGR>LX?2VPNNW1E\=<1&Y (0*6:U8)9LA<J$Z6Y+MW_<AYQ%D=7T?_K
M_P%02P,$%     @ UE%72/-WT:3LB0  P!\) !4   !C;&1X+3(P,34Q,C,Q
M7VQA8BYX;6SLO7MSY+B1+_K_C;C? ==[[W%/A-0S/=Y=[WAWSXF25.K1L:22
M)75['1TW-B@2)='#(FOX4*O\Z0\2X .LX@,D02)9/;&Q'K4$Y(O('X!$(O$?
M_^MMXY%7&D9NX/_G[SZ\_^%WA/IVX+C^\W_^+HE.K<AVW=_]K__Y?_]?__'_
MG)Z2\Y!:,77(TX[<T#!T/8^<!^$V"*V8$2"GIVG#_SJ[OR9.8"<;ZL?$3GM]
M=>.7O-]9Z#K/E)!_??_A_8<__O']#T7O,RMBK1D]3N;']Q_ROV3\ _]/Y,?O
M?_S#]S_^\.%?R1_^].&?_\3^>W>3-[QA*JS=UI:>Z__R)_B?)\:2O$7NGR+[
MA6ZLZ\#F&OWG[U[B>/NG[[__^O7K^[>GT'L?A,^,U ]_^#[O5=L"_G6:-3N%
M7YU^^/'T#Q_>OT7.[P@SO!]QW@I,LN9,PE+KKW_(VG[X_K]NKA^X\*>N'\66
M;Q>]#KBD_3[\]--/W_._YDT9>[=!H)PTLQXA_Q$&'KVG:\)I_"G>;>E__BYR
M-UL/>//?O81T74W/"\/OH?_W/GV&CPH6^@DL].%?P4+_E/[ZVGJBWN\(M/QT
M?U4KVD\E6FDGKI.2>;^?3)_'(+:\7DK)/3MK)D8Z=+YF/Y44I&\Q]1WJ9"H"
MSP;27"0^9CAEH!W8)8(>>$\0EDUF>\X;,\F'?_GPHW"!?X+?_/=%"A(+WUGZ
ML1OOKOQU$&ZX]RV>HCBT[#@CQ,47E%3[=303* -,%F%9(RNT,R'8CRT&2EM\
M;P?,4;;QJ9=^,MY]'0:;;BH(,8(.G?[;>^HQ1#+=2XJ'- J2T*:=QH:L;]=O
MELO.>L(<1/W33P\=E/F?&1-B^0X1;(C$YS^$>)V&;LJ5<UQ;T1-GRR;'9\O:
MPKSR+]]3+XZRW_!!?OK#AQ3I_RG]]7\_Q,R)0;)'ZZG D]0^M8V0#N!FI6"T
M5K= .#1;!.T[#G-RY LG^/\C&'D,^ND5^S%J,X'<<"XC\$"YRE&8MYK#2#P4
M5L-H!**$4ST8DEHTB]EN@EX;4F^HDT74?O\<O'[O4!?\ZY_A!W"K?Y;<BOWJ
MO\7$<D^?79BV_/C6VNQ#>D,SI"[5IA@X5%T;A.[4*FK?T9:N*@JJ!,A.._3.
MV6 /+>^*+=S?_DQWM:H?MD,_^&I4*X^^O4:HAU^=K /'7TJ6<+J$$9YJ!&9+
M[$=&MD+IO3\C'F]5BF3#3/X;TM%5*>+@?1-0FWHDW='0#=BFT+E@\WB#IOOM
M9C"V*E7;'V2E1LA'6[6L@X>=(,MV[ X!PE.-P 5C[H  EY[U7*'U_M\1C[A*
M5;*15OHCTA%6+6/?D953(T!NJO%TGH0A:.!&MN7]C5IA/:@U-$4\RMH4S 9<
M73ND8Z]5W+[#,"5,!&4"I"<'.;%@_"OUO#_[P5?_@5I1X%/G*HH2&E88HZT]
MXN&II&IY*U'3&.E 59-YX-8"R)_^ O1)QH (#M,.V<^!E_BQ%>XN78^&^V'+
MIG;HAVB-:N6AN=<(]9"LDW7@4,S)$D%WXC"+0.][N@W"V/6?(="8U(_#VN;H
MAV.SHGNQE\JVJ =GB\A#(S'I')^3)X+^M&.5^\<Y6U8\!V%]0'"_%?J16:E6
M>4"6FJ >A]62#AQ^G"C)J$X[Z.Z2)\^U+[W VD_3J&N#?L!5J%0>;E(#U(.M
M2LZ!0TV0))SFQ#-QL-D$_D,<V+\\O%C,6*LDAEPT2%6LA_WF3NB'HHK2>W-S
M0P_4@U5)\*'S-.=!.),3(M@0B<_48>\BVG#)?E.UK*QOB7CLMJBW'_S>:X9T
ME+9).S@ +@>(.&DSHU'$X=7&8[GM;$9DA8K58U)J.(M1626OKG&9GL]H&9D:
M4ME6ZTO7MWS;95H'D=N0+MRQ*])1W,< E0EP#?T0CO%>XO<.U:]N'U;75Q>+
MQ^4%.5M<+V[/E^3AY^7R\<'<B%]$$8VCEK%]T CY**Y62AZOY1:(1V:-H+U/
M+3DY\B4C:"A'4[=6#P\(G"@-TRGYTF';6;A4C8J'GK77$+V#U<D[S,].\M M
M#H?3K66FG:#^)W,.>&Y%+PO?@?\L?TW<5\MC8D6+^-P*PQW;>7^VO*3N3HQJ
M7^0.VLD$LL,J=43LP-WD[SW4&7E^YXO_(#$Z(59,,EZ$,QO%Q;=97ER3FQNV
M!9@"DD^"=;J?&]$2;,D>QLAM<4:?7=^'<3&N15KAW[ M#*[,7BW7@_MQET'X
MP(1YH'82LFT=C2[H4US\*YW)ZF;/SE203Q8]S5):YW4C@7@"Z:M)[[5AQN]T
M'82G$>-("B8G!)B6?I'R-;1PG-@X-U;X"XV!H62#<527ZQU@4/W2<L/J!<2$
M>&G;00)3@^^LXA<:WE.;,A1G1HAN:=R"DHI]L6-C%Q.4$%&E(V8<["1_;_1+
MN?"% N=#)$8GA+$R#7D([& . >Y"NK5<9_FVI7Y$,QN4X@<U=E/KB=S[.Z@O
M^[Y"-\2>WT7ZON,]Y4%2)M*PWXN5F7'Z*4U0J%X.H"$)8*N$$/$[<JO+SL4Y
M]8[!29RM=66M525>N R-*]V%P9:&\>Z.:<-+4?V:N%LX6F9KAUKL:>R"W-%4
M%"Y/E?7M$;NADMC]9P9!_(1P\J*X6,: KXE-S8H3*#V9MFVPA$7;Z<#JRH^9
M-B[;<0C89,(LWVPO@6S5CT'@?'6].F,I=D4.7ET,((.82C_$8-9)_+XCOF"2
M+_$9'_(NYT0R5M^903>#5C #<-@_^W3 )^WN;AE*-&Y\ZMHBA[9&%64LJVR(
M&+R:Y>T[;,NQB(*P&6@:7T=SOM>RL)C/XJ%I@3"#18 VQ,\(F7&5T=68.@S7
M&#3![Q5E)0XC;H@]8D_ 83$VDZ$U33$UTS/%M6L]N1X_9&?;<7ZO\B7P'(8(
ML(&.=RVIUAVZ(_>IKH:0O4ZU+V*_[*Q"WV$O,<KC-/'.>/;V=/I?+<ZNKJ\>
MKY8/9'%[01X>5^=__GEU?;&\?_@]6?[ET]7CWU# @=I=B\8.\W%YA5L7]:WG
MX=:Z;R9(I/%<PAA1WTQ%B87!ZQA9;LN=M8-L%K6TL8/&R!VT6<FJQ+!R2\2.
MV2+PX)2GE"Z2/*^1M33JAF%"G4/8J3=(;7O\SMBLZIX_5C?&[9(M,@\8KT"9
M5$V9QAQS9%W3-"]3>W1C^DU\P**,//6MD>-.BYH'QRRSPIPVB8<=0XR/-]6/
M=DZIZ36-HGS[<0?%.P^?")SP0&D$#?>4@XN.UX'_?/I(PXW\B3%%#92W9_CQ
M1PUZ9H4Z8[CA9$N;MJE_!.7*Z:\H7&X?;-12+.HZ('?!=F6;5@'SR;AH%EKC
M6@!%[L6HVJI,D%IT?:7A4V!,VT+/FJ6/D45 .S+CQYP*=6KF>\2H4B6EAAG>
M^,2N:49',9-#26,WWE!Q'?8\\.'Y >K;]7[4W .Y7RFH6RJ=5-\<L=^I2-U[
M.UC0%I5@9.KO#16_,:$ODI5XYYR9.6?)=,N+F64FS(BY'S+IWV>9+XLX#MVG
M1!1DB0-R9Z$X29_8# :/TN\8+<J6XR+KIZF.875+Y"[;H-Y>>87]9HB=M$G:
M ;4#!,WL>0E.]D0\FS=.53F%S>,8FK(IE'&.^06B ZW_W_<_?  0$NK_._G#
MR0\__ #_GSVWL4CBER!T_T&=?R>W0?9;8251>*%XCP-*]%U0FVZ>V*;\#Q].
M"/@@;P3/&)A==*=OE306+CULAMS;ZQ3;7U/+;1#[>:VH0U:3Q0,R*#Q\9!V9
M/Y<=^L>?_MCDTC_]V\F__MN_G/S+3\)/_^TG]N./)W_\XT]#//V$L)Y;:L?N
M*_4&/W V(%_'<?B+ Y9W9[G.E7]N;=W8\J1/4/.1E#HBQP9UY4NI/*V]$.-'
M!^%[)X3D+ CP(*Y/4BXGI>>J#"7Z3&Z TZO< $;S\I)-XD%2 H^^,WVW(7VA
M?L0 Z,JW@PV]#B*XG;U:/UIO=<;K3 4[ O0SRUYF7Q<2F+&AIR8#,L<R?EEM
M,IDC$2S).V#ZG;C1'ZP)XVPL11"A><Q!RCV-+=>GSM(*H=YX),E[0=>N[=;%
M^Y0Z(@<.=>5EK&COA1@>.@C?=\AG+$C&@[R3O2!E8ZATRP3Z5RB+*8ZO'!G%
M[[_URC7'ZQ'[9X.P.@+3@J2Y=T9&4._,8AWM,=].:7TQ9&9:M>8DC*"/2$VH
M.B-!D=M3>3NZQCH*W9#CIJKB7:H!(,949='UWOXWGD\TCK('249<95R>73Y>
MNK/"5<A?:G5XL/B.ACSHJW0VU= 9N9=W,T+]J6E=3\0>WU$!;6>K<!X1A$3P
M$B<3\'R7.&,P5I]^"E,T'K[FQS3DG>L3)_ \*XP(6UR1")@;+.=8MHXX"BJ.
MC91,6M%I5L!0IW0](.SWF T0U JN#0 .3AXQ.+UVM1N=?1H3=,XQ&?';1T+Q
M2"ANU2IN%M;$ 7<'6^4=9@AG967;H$RTGAF,[0FM&\)&S![I!5^:U%6!KFK5
MS7JOE)/2P6CE7C/TXPJUVYQ9ZC(SCZZ27+=;2SSP^+9.Q54<O,$(1I(U.P8H
MU'HB]_8.ZM=D><XP+M%%>CUYD@@C$F:,@#/^(-E",?C0W&,^3J\2=FAH/@\G
M'V'G+8]K)-$&1 H;]-S&_75]Z[EY;/W.NJ;IG#Q5VR;S<-".>A]#*?=B+&W3
M5 4^MXH8V#BY78K)&'-7LSO<CCAJ\5PBTJIJJIPM-.;Q6^**"T#LZS)8].%2
M#_O35S=^(5&RW7H[8CV'E&XJJ@L9G'3:PT(M7>8V_;0$A)K:SVDBTAL1J9J-
MC >")M<91]A')/SS/>^F_2&*^M;(';=%S?*3J)5-$;MKF\2]1^WJ]F)Y^["$
M]U,6C\N;Y>WC UE=DM7=\G[Q>+6Z%8^KG*]N[NZ7/[.65Y^7Y'KU\&#R_L@K
M]1.VY6L>QQ7-D _@.L7*-T'*;1 /V5I1^]_R$ 2-EW31K]GR\_+VT[)7[1;;
M<]ZXJWSX,744^$TFXR4;87=AX"1V?,%^XP7\*>\%V[:Y-MP'\Y\7V1ISOTK:
M #)('6VH8< 1^](P[*A.8"<@AP5[#$T?>GA>[XL;$>IQ:B2D6Z88KTX6"ED(
M?#6R%=(0IQ"'I_]ZF4#%+FFDJFU5(&?,9O>R;5*NY&+/-CEC4G">%BJ-V<>X
M21IB#,:-HN)#F?>-,Q=!T4&8,N&FP,?0:I]U*CO,9'ZI5[9J)CEL/:,YHT'X
ML68':H5PY==)0AC \0LE(EQ+K-#E8UJ>/B(2!9X#Y](1#5_9L(_@+Z^NPR@D
MOD-#3H#!V2:"8@$61.2X0N_)PHL"XOJVESBTG3EGZ@?^*9-8/*I%HF0#-#>!
M3W?$^FJ%P#0.F <2IA"4+F3_L*TPW)$@88Y)H,"/NW9MLDW"+<,28DG2NCYY
M!@.CF/9&^.RE"2ZGS^%*<# [D8V@\61*=IB:1E>3C^%!DXVF:$*PL[QXEZI>
MM^';;X1T FI6JA1'*+7 '$6H%K0WN@ARY+YZW$T4/]"K4[:Z$V2-UG#.(B,M
M@9,9>-">(E4Q.,Q>LR_BT)B;V4";IAO$-9.-'EW:;DEKUJ4&P*8\&([XZB![
MO[$E'-_0'#D4M"E:/@RN;HL8*EI%[K_>B]*U7D;:>.!^-%W3X[+;CV3Y7W=P
MGF:P#/L]VR>SX?W"])0B2ZG*M>#4W >YBRJI7)["&SH@=E8UN?M/]H(Z=UHY
M@)HR,+4(,*&SJ?PS0U^85G_AR??A+3"UWP@[+E4J5;$/GP'R5 LZ=,\:IOOQ
MFO$WZ7Y<FY,)<N9\Z2/U:6AY#$(6SL;U75CD0,'X9N=J[X7<VQ35EMVOI0MB
M?U25O.\@3NGSB:+,P>QJP)S>!HNP;^!-TG_P<[C5^LJ/F6IPVW@11?3@ %6Y
M$W)O5E.Z5%&]L0=B7U84O'=U8(D\'$06#(C@,,[=F2!RP6V:G'E*Q=,5!ED'
M(7$+"UCC6:"],ORTWWUA_YJX4)I@F@&@L-G!-O#-14\5 U;X8;M.L:8H*6)H
MKA557U34S'&$=L7$L<1J2V&UY#_7K1*G<[%<E.*-C1I;5+=$[F@-ZLF^5M$,
ML;LU2=L[-I\/R=+#,&;<;EP%@9S)>V9LQ4,C2&+E[\X(%6L,4=L8N=LU*UF^
M9%;5$K'SM0C<=WAF9,5#A_Q!HNHGB*99=(^FY2LCFF=6RWKR)ZC,NV5S].^P
MU4P<L2&ZM]=D!JZG*XJ5^]PHL;J?A$(^?88R6BK.-I5>TWD5<^EB"E^\6JX'
MN=Z/@73'/'V;X,R*7+O&/MVI(/?*GF:1O;8C"<1>W5>3OMX!+QV6UK@D9PI7
M#.0*!2G?$\(Y&PL 3FVANY">QM8;\2H6RM,L/TR,B:IMP33;G:/25B&@B47?
MZ>;![%7#K(XFUPN25UPOB6N+T[7W0C[/*:HMSVLM71#/8ZJ2]QW%^:N=>9G8
M=%X2:4J"BQFX'EOU S5)YM+<&-F4#:P5*\E.!7736<9)+>,SR\#$S97/"JEU
ML,QTH/A7ZCZ_,)$7S([6,[U--D\T7*VYG:224&I8V9L8<@@=9B096?M10@RX
M Q7JZW(96Y+R)8(Q')T>UC-# ]&&C)5:Y%,D[F2?6YX-+S!#&+X!U+?9#-=4
MU'/2ZH[[;]%G[]"WWN=1Z8D<@CJHOU?RL:T;8G#I(GW_LG)M]>*FP08SNAJ\
M_,//'2JT!O#)-+^#K)C 7\1QZ#XEL=BAWC$D:JT-J8\Z<F#0;,;2@;P>TH@!
M1K>&O<_%^1E<29!R>)0?S,'JA@ET0E*1B"P3A$V%5,;O+F*V:AIM%@(A1+_+
M(&2+1/\\"9DI[-UC:/F1Q<MMLP4A_Y?'DP07SM\3<8BK8-&.WVDL&6:*I*-^
M$A6\'46 &:+RN'88$;M3P4DF.9%$YYLO27A22-\%]'$A/<XO5?T9#LQN\(BB
MSIZ?_)!:'KSI\W/@08C@H^7Z,+A6_@.UD]"%6CH+44SN@A=ZN^,UWC*K=OQ\
M&MC-%.MU&5H%UH?RFB&":U-Y1+ N9"2ID 2DS%:.<,:1BTI268D0E@AI9=S&
MA<O&[2\9%]@R"S)[WECA+U3,9X44I@Z+YF(Z9<.A"-%V#WKAGT,4U%4,Q2)&
M<A6I^U\P4HQW3+GD;;^--)5!S&;+Y ^XK-9R,M#RU\2-=RW!5]6^R!V\DPED
M5U?JB-CIN\G?_S3B]F%U?76Q>#QXT^?A<77^YY]7UQ?+^X??D^5?/ET]_@V!
M*P@#@)<&/FP4%V]NW46]MCYS&?I-*E<.^:H.<QCJC7+W3A?C1$E!E7P!N@=Q
M^0F3(,MJ7@0;MHRMRYNJ:8M\[#:J6$ISK&J(>*PVRZMKC)(O@K"APR/#2AIY
MKO2&0B)0_8+SH!UR#ZQ5K>8U4M$(L>?5RSI@J9_?<"%?!%%CI6;'5,Y@+2K'
M<2&T;WEWENM<^>?6UF6;NT9G:^N#W/&45"X5HFKJ@-@AU>3N78TGITZ /+F"
MI$G.P+"K3JKV::&V02>V[60#V:K4J8O,-CMTA_[8G;NK*4J.KMH9L]-WUJ&W
M)Q2<2,.1D6$P0&8.DW7D8[:6ITYVT:<1$6H;(W?_9B7+)>.K6B)V[!:!^Y<0
M%V1)?FO/K,..I*;LG1=T[=JNT1(N=DB96!=4_/?*/XP@WP>>=QF$\+Q@C:6Z
M4T'NO#W-4BX1TXD$8G?OJTG_4BR"#WF7<?P.[D')3']/T@C1%V!,4LZ&< *Q
M?4P>PC!IKJ(HH8Z<7O'9\A*ZW&R]8$<I;W/'OL<+T^&.6:,VZ-^/%G*0&62B
M\F%.#T*( 6>8/KVO7?+8GF"[GR#&69^0C'D:!\S8$^!O!GL,F4K<4$UM)5XY
M%B99;?,DZ29C&4V4J+284*G69/7GQGVIS1.<5,VD $]MI.8'4,H:C0%1@GDS
M1AFJ3&7,7(-AJNDN_509KH:MY\K6X\_15TQVQN&;3W@\UM5CHLSZS1.2#U57
M71OR3O.#V0K9]2 $'* $OD_%1:^_NO$+.;=\-I#)XCFD=+3'^P:M\L8PA%LR
MQ%<50QA' *%!#P@H=YPG!E0HK[P"FRD*5 D_YKJ*<T+E_EHMT-7_<509:@)&
M\>O+('R@X:MKU[Z$TY7&/!&BV22J*X8# O/#C18]]*R6X2FP*"6-"C/&U;X>
M/AZ2[=;;H5\^#,2,>B+S!(T6HR@O,8X -MH4T;+TJ-B [#M.NAY!!2JCV:8K
MJN!?E-S2K_PO?18C<M]YXDFU"507'WG'^:%'C?QC[E<8-]$B>H\*+'2;8A\C
M/D&@\FOHQC'UR6J]IL :6>Q6LPW@[O4V#&Q*G8B (Y+(\BA<QX[X0'$ATBTB
MN)EAMLF3Y]JL2;5]C(.E^*P]T?*P\SSALL8(RLNN&0-FG0+3("8JP-1N"B7$
M1'_RI<\@Z?6G%"N%65 L)*4:9X]!S5T2;@S0PX$<;^I'O#S:/?TU<2,WINE:
M7!CNGMK!L\^I\!FHQNP3L$6.QU,9OGRU:UR>B.> R53O?],J%Q#JV>S?-W/S
MBU?I9'+*!26RI"<DEY6DPJ83$)'$-75-#;G]A5'/#HR*H,;(:GUN12^77O U
M4J^R4]4%.22J*%Q34^>@/6(H4A)[0 6=B^7MPT'YG//%P\_D\GKUUX.W#"9]
M=104O@N#5]>ASMD.GA^Y\O,7P!=V[+[R@G7G@<]^D;#?I7\,_+:AKXTX<B?1
M:\2]ITLU4$;L>)H5'!)* 3E()@AYVI%WZ5,\WY%<'%+(<T(*B4@ADO&R_D@L
MRJW)<52$IJI,:+"P?VGM PL7WW8]6GIM\S%0M&,+"H[$"CDFCFG@VOV3)CZ(
M\7)4=37MDW*QR.'[T?!J=#><-0ZH\S,Y+SS,?IO/:MF;<LA ^()N0VJ[?.9A
M/WLT?7I@L8'G!?[!?U_S412[(@?)+@:004^E'V(0ZR1^7P^1F9R0G V__"$S
M,@,JDYM@&KT5HOMF-+<DZH2^02C)8"64A6V'0F])K-7ZPHWL((&JIKYS%]*-
MFVRB*_^5ID!?-S_U)88<'(<9::^J4@]*B %TH$(#2I@(MN2=S/@[2#G(>7-W
MR[B?$(F_7L3Y29C)I\]04J5Q 6?(6C+D2$8!:U4^"<&KZ9L#I4*F0J3L]8P:
MR[9T00XP*@K+,-+4'C%8*(G=OWA3^MC).R#Y7?[FR8/E40$%-U:</<-3-_#-
M+,&FL0M_E&BH0:8# >FY'";P:LWVM&S/&._@;C$OOK[=U+]4J=P9.3!T,X(,
M$6H]$8-%1P7ZNL?>4UUL*MX&$3\Y!I_(F/++^#')V9I:0$QIE!0J2!"F5K$\
M,,DBBJC))P_Y4?S9?AY W6EJ76/D?M^L9.F8N[(E8K]N$7A8AL9AVHNA3,J1
ME(0,P8HT%+(T'D<H;VCH4YQM:M*]1MV.2*$?<E]55KT4"&CKA-B#U677LF&%
M+3WCD>_KR;N4S3AIP>VG,*.K?QOXI_RTQ+A;'U:6S ]NTK2\EB/G3@20.WIW
M8S278ZWKC=CU>RBAN<AH<7"8O[!@^%1V0IN<O[!^<,F_=(#*%^1\0W_M6D^N
M9_HP]= @"SN/;_)J(??4INXKA!KJXGE=:<P..A1,THP>#01F!2 J>FC&D(PE
M]QGQ/H'$U=3>?EK3=+.!2?!@JZJMY3H7=$W#D#KIFBBSB4 _99,J$IL=G'0Q
M4C.NJ%":%<!T4D@STJ2\LX6\Y&S5831S6#.)E3)S%&8X3T)XFMMX5+%B$0?R
M%8ESW6"FIO/L8*7)""V;FXJ>LX*-1@5T;VJX+^POZ?& PRBV:,)!#)N5.VL'
M:R%("+/M,&$V*W97G9=P+<1F!PQ=C*2VCVFB-"O@Z*306#N;E+G(M13LY>@
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M,&U G;!E>\X;!Z,//Z90!+^1Z[[<TU?J)W01AO DD;B-V!8+[4L#*<P,,@F
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ML6*V97]*1)IK'+ .</,]@=L.D 9G^N%':='-[W+F-ZV8$>^MF [*VN]%<C;
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MOU"&H&NXB<0G#;8J@B40CR4$:3(#&Z%NSAOB#A[G/WGFPD@FV'/!$R)HDR]
M?6Q'O A@U:FJ;]YZ;LY85K/1'473.3KDGN2]:WT[$--;N[95NEO(69RP74S
M-BH[V*]8)&)^ZN4QP'>PRZ%OUF;KT1/VUR?+_^6$0#HZT%DGO@,7$%]9:R@^
M:UM;%TIHK]UP\QW\P2+/89!L@2$G"+<8Q9YI:X6Q:[M;N$>9WEW<0P4$6*#)
M^GMHD(.!(#]QV>*)E3UITW8 ^-VXSKFUO71]R[==R[N^/K^AFR>Z7\ZJK2UF
MX&M3,8>]NH;80:]5;@VAOOK%B.!.<O9LM%Z?3PP\HUF $28E[<@U^[]S\D70
M-X$[8^K*"&O$EH]LDQ]:WA+NYX>N?2YFMO,@W 8BQE</->I=,2-/1P/D0*38
M#SLN=55C5)A*A2&9-"05ATCR3(Q:4]E'1763B#:9'9;GY^8"CA!<@M@2+.X>
M&;.*6$]+4Z10IZ*@''.L:H<XZ-@H;M^A6(XTGA @/""R,<X(K0R"M#:>V2@]
M#($TMYS12-6T&\W(BJ"X&*E&MMT3Z'GHDP.VW'J\\H':24@=D*ERO=S4#KDO
MUJHFN^%!(\0>6"]K[^,I05'XGIDUVGC*/8*S70>6P;? ]Z)XKD^O8KJI6YC5
MMT;N:2UJUA\)YTT1>UV;Q+IBSE^ -.&T#;G@6)HB<,2[,+ I=2*X^WL510F4
ME%RM0>$:6S1V0.Z.[<K*'EG?&K%3*@C=.WDP)2UN<&?$X8 ,R)OQS!'53=/-
MGX(P#+[V2X*L"=#>TZVU R19K6'Q^YBNJ>]"UX=C14]PK@K9*/=$ZH@]U,^C
MLVK=L =G.VJAZ?:,E5^=V&:,X&*,Y>Y=G)DX$CN=,02;+-F,/.;[ZIP7$<P,
MQ&%-6*$8!E:EVMKR>JY\ICR-XH7OW(69!%#7L\H2ZETQXUM' ]2D_]3VPXYP
M7=70#G%NRO*$C?)\S$.UZ+4+166SWZR9$,0X!$YEK8/<EHP5MTS!K++F[N1I
M/>/98=%GF)C;GF6&2.NHRO-#S8JXN0=2W.R@KKQ#:VB.>(NF(G7O;,G,J_.'
MH,KA=3.[M$DTIH(XW/L!-.<J>SUC*S5+FX<XL']Y"3R'*;S\-6&S1=4%EI:F
M2%U01<%\J5+3#OO2I$WLWI.K&]E>$$$>,9]8ZI)A[!=&GT*Z#(DD47Y/*!=&
M+EM@I%C!6/:1Z1)!>(2;/9P+!(&H<[:#4\35^BX,GD-K4W>_I[4'>E]M5;?L
MLK7-9^&Y[=+W7A42-LSH<Q!F[R@R-WZUF <F;(O :$9P(V K&$8DX5GAXC(
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M9+M(N P+BF=J,/U3:T59-0NA+\^.*?^*$?+A1AB__.7Z*<7TRA:\VL<9,<O
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M5U&=QC8'FE\>:FZTS.J49M (:PN/Z>5&CR\TM+8TB5T[:HPNM;3'#&$JJN;
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M+$EE%^"']_83/%1FT "-TZ[^@852@_E!@K-&-=Y.(H-Q W&"<^1]-N6>Y<K
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M4MC=O,,<DU*N$(<O+W:$I&EOD1PX2]=;Q^HLR;+(5EM'VU-'=&VNUZ$> #_
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MZ8VCVX3&2/VKA!0\V--:\+4AZ192>1<9[B1Q-**<::BDZH.[2G7E;[OYF((
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MQ&R)6='K9<SX_#O1[F+L3/%\ZJ'I,KJ8Q!Q[R]B,<J:B\ON9=01NNU$HNJK
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MX>=*;9PP:S@ D;ZO(AUM P^ZB_$2I[E?.=$9[GCYZ'C C-C_Q81.A.02??G
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M,C,Q7V-A;"YX;6Q02P$"% ,4    " #645=(PK9T:G$L   \\@( %0
M        @ $G@0$ 8VQD>"TR,#$U,3(S,5]D968N>&UL4$L! A0#%     @
MUE%72/-WT:3LB0  P!\) !4              ( !RZT! &-L9'@M,C Q-3$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( -915TBH@,B\@U   .7^!0 5
M      "  >HW @!C;&1X+3(P,34Q,C,Q7W!R92YX;6Q02P4&      8 !@"*
) 0  H(@"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
